<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:dikbD2R="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:ns1="ncit:"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:poc="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0e5e5e67-ca92-422f-b7ea-369e47ef03b1">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:2006afca-51ff-4d90-bb98-e8653d41fb3a</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N57326080ba534031ad912f6323ad9950"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:424b3cae-bb89-441f-9e53-ee832c015503"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8AD21D6C-B585-4986-9335-FAD5A45407B9">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Warfarin-ab047628-67d0-4a64-8d77-36b054969b44.html </ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:F9D4CB21-4899-4A2F-B0CD-7E645C1D09AE</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:6B63AAA7-56D3-4CE3-85CF-8ADE045F53A7</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e1430434f70e501434f711b6e0000"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8D869AC5-11A1-47C6-B72D-5D0285ABE2A1"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-02-20 13:49:40 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N2f219c1775194c5e961979f2621e856a"/>
    <pav:createdOn>2014-02-09 21:25:30 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:263840C3-C8D5-40AC-A465-5111FD082080">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <ao:exact>Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered. </ao:exact>
    <ao:prefix>   7.14 Carbamazepine   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-02 14:32:16 -0500</pav:createdOn>
    <domeo:uuid>263840C3-C8D5-40AC-A465-5111FD082080</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:263840C3-C8D5-40AC-A465-5111FD082080"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8da725d2-10ca-4098-a390-68bf5b85f8e6">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:f7c4993f-1635-4d38-bad5-1cdeaa4ea413"/>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:69db2418-ff53-48cd-8746-73b384d1053e</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="Nb50e6f8283ca4a70a4db523fc5e6c58a"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF">
    <pav:createdOn>2015-10-26 15:39:34 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:473D0896-0D53-4D70-8D36-6C39BAEF5E24"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A9D5B64D-ACC6-48E2-97F3-1BFCF4042ABF"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:08FD5455-C61E-46AA-BB91-9EE24D2C0BF5"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:4542AA2A-08CE-4CD4-BB7A-30435925C4CA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:6A79EDC8-2A07-4FC3-9988-642EA225CB1D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7A937F4C-96F9-4410-B00E-BA0518627421"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AB452058-2FA0-4AAE-9550-A00439838E36"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:57697AFD-0A84-4932-840E-039887A1AB7A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8551B156-C941-41DD-B228-B433B74B1B86"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6CED04B2-3B40-43F9-85A7-7F7B118E1020"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6CFE257C-BF0A-4225-A0D7-D25F385C84A9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2EC0D6D4-F4E1-47C8-9484-38C09E81707D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AEAFC682-DC51-4E8A-A59D-77FBCCE46E6F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E5643869-6E9F-447C-AEE2-4328CCFF875D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4D74F517-FC1B-4651-9D7A-8655A123B08B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EC37D59A-A1D5-46A3-A339-64FD1259E0D0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C312DCF4-7BE7-409F-ACFA-A1E3C8AB0CAB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5059B838-6797-461A-A9C9-602802BF8629"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C42FCFD8-0A10-4301-B999-03B395377674"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:05CA5393-1520-485B-8CFC-97D8A0DC8B1C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0BF8B7F3-A1F8-46D4-B993-E10F99513C98"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:73BDD15E-B6A8-472C-BEED-B2C113AC3572"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A9F88591-2F38-463B-9F26-D5DD24E843E7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FC31EB53-9A4E-43B6-9687-DDD11F8CA71B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C4EFB0BB-D0A9-403F-9C34-A63EE321C695"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D79272CF-C733-4559-A232-9D174813C454"/>
    <pav:previousVersion>urn:domeoserver:annotationset:CFF7F432-2FDE-4310-BB4D-C8BB2A099304</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:9B808F3F-443A-4D13-B5FF-6F8FDF5C5836"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3860D410-0829-4E39-A0C2-B42464272E52"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4D6EE8BE-79FA-42D9-93F1-2F1DA66E4A12"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5A2BABFE-1C7D-4040-8DC8-35A60F10ACF9"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/224b124c-872b-4fe4-8a11-4ad818fe9dd7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0D97811C-104D-424F-B7B5-69C0B3D4AB93"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F86C9668-0BB6-411C-BB37-CD5E367DCC1F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1EF7F49C-0E10-4BA2-B520-445A84319A11"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EFB0E4E2-8161-4326-A245-D59ED64BB363"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DB9B67A7-9AA1-4C75-AF75-9F525F42A852"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A2753BAA-6626-4C65-9789-F05F3DDDFE82"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BD591909-A4FA-4901-BC4B-41EBEF7946E5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A4D70620-2D9B-432D-8F66-97CC591BA87F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DF041D0D-4D3D-40C7-9D72-DB37F5BC9AFF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9EFB92F4-975E-4F86-9948-F021DBFAE845"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FB88A8EB-F03C-4ED6-8C15-27BB85F94920"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:608AC101-BC3B-4B0F-97DD-A1EE6CA20CB3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9C59480D-EBE0-40CC-9354-66AD95191331"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5D4579D5-300F-4A64-914F-5AB7F7055F84"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1288E615-D85A-45AD-9A15-8E220A79FD43"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:66C06BB6-10D8-4C4F-93A1-352AF9CB1F95"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E60CD6BC-68A2-4AB0-B95D-7DE55D4670C0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:57229497-C009-4B65-A612-416CA524262D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5DE193BF-0F87-477B-B636-ABB34FBA2C89"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E37EA565-D7DD-4EFB-BFEB-50EF8130F62B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B3E6AC78-3F92-4397-88CF-7524C52CF120"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FE72B2A4-A8DB-4125-A4EC-54C56B37DD3A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6B691E86-E215-4DD2-AB5A-49A04ADABA9F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E5FF6B35-2CDF-4450-831C-126721FE893B"/>
    <pav:lastSavedOn>2015-11-05 16:21:18 -0500</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:6824DF76-BDE1-43ED-A937-21F6EF6C4AE6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9803516-9F11-42EF-BAFB-32FB6A010A78"/>
    <permissions:permissions rdf:nodeID="N64c8dc28b1a44ad6b77b922897dd51f3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3CCD34C2-F743-43D0-BD8C-7ECCCD371E17"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EB75A44A-E683-49BF-A717-FEF4808EB2E4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:66713D6C-E17E-4C19-B978-B9FEB0BA8D62"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:766F06F7-705E-4801-B50C-C716F350B9DA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:42CEAF50-2AFE-41CE-9C71-5882C69D2A21"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:DDB09D95-8435-46BD-BE86-4F8DEEBA5E66"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3087234F-2B79-4EA5-B4A1-77DDE8D85249"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:26940A54-443A-4CC6-9627-1891284DBE46"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9AC2E427-C645-477F-A4A1-AF548A1D6900"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E39F3498-8BD1-4604-BAF4-6E8AB33E1FD8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A80025D9-244D-47CF-A16A-810A6FA92A8D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:8643186B-738E-462F-8AB6-4B58B2F3D1F9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A734DFA3-4B42-40B6-A58F-00BD63342A8C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:56A74F63-26A2-4CC3-B26E-8C681A965BAE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6424BAC9-05E2-4B40-B6AE-6E98318239CE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C7804B5F-7695-4935-B702-077D589B2F8B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:344BDBE4-D00E-4219-8F90-A1550269DB93"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:312E826B-20AF-4BDE-A339-26DEE6333413"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:415CF7CD-2512-40CF-93F7-CE9B6EC6C933"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">29</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:BEEA7C5B-9654-4244-9C6C-8D96EEC7842C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ACDCE7CC-F73E-4E9A-9E3A-91B1277D97BA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F35B5C59-2605-4012-90C0-CB0C838A711F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3644D385-D4A0-41A1-AE04-CADF7E05C850"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:DB4012A4-8440-40AA-92FF-784FDC2F95DF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d98b9db8-bb1d-42e2-aaec-a43209aa0ca3">
    <domeo:belongsToSet>urn:domeoclient:uuid:7748cb6a-f169-47fd-828b-3d35b03c40f1</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:a8fa50aa-4823-4449-808e-ca058f6e3f9e"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 11:30:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 11:30:25 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:fe4a772d-5ce4-412f-99af-e7a4cd586dc2</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N62403b66935244df81b02bb203ef513a"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6BDB144B-BEBE-41B7-9CBB-B402D8C7AC84">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>dDOSAGE AND ADMINISTRATION .   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6BDB144B-BEBE-41B7-9CBB-B402D8C7AC84"/>
    <domeo:uuid>6BDB144B-BEBE-41B7-9CBB-B402D8C7AC84</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-28 16:36:29 -0400</pav:createdOn>
    <ao:exact>Drugs Metabolized by P450 3A4–In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/77443745-9e96-4d51-99bd-4aa1d4debee0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8118454F-FECB-4563-AEFA-575878F61E80">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:997FCEC3-A266-4A61-A642-6D267C9C6E63">
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:6426edbd-e01c-45ce-9151-eac311cb230b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-27 14:23:19 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-27 14:21:07 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:9CC336FC-B343-4718-A7DA-E000ADCBE2BA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8f0ea9cb-160e-4cce-9a62-fea291449a57">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:prefix> CMI with phenobarbital increases plasma concentrations of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8f0ea9cb-160e-4cce-9a62-fea291449a57"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-26 15:40:42 -0400</pav:createdOn>
    <ao:exact>phenobarbital</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:134682C9-0DBD-4749-9801-00B84C5475FE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:134682C9-0DBD-4749-9801-00B84C5475FE"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>134682C9-0DBD-4749-9801-00B84C5475FE</domeo:uuid>
    <pav:createdOn>2015-11-02 13:25:52 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ss this question are limited.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <ao:exact>CYP3A4 and CYP 2C19 inhibitors: Since CYP3A4 and CYP 2C19 are the primary enzymes involved in the metabolism of citalopram, it is expected that potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, and macrolide antibiotics) and potent inhibitors of CYP2C19 (e.g., omeprazole) might decrease the clearance of citalopram. However, coadministration of citalopram and the potent CYP3A4 inhibitor ketoconazole did not significantly affect the pharmacokinetics of citalopram. Celexa 20 mg/day is the maximum recommended dose in patients taking concomitant cimetidine or another CYP2C19 inhibitor, because of the risk of QT prolongation (see WARNINGS and DOSAGE AND ADMINISTRATION).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FDE74EB4-3679-48DA-8C40-5A05900D845B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B7AFB92A-6B48-45B0-BBFD-BC3E46B0F6B2"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/46747E2F-0D7F-4D6E-8DC2-D949CDDE63A3"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5D5AF78-FE2A-4685-AB34-3FE17035070F">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:exact>
    <ao:prefix>, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine .  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-27 14:26:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D5D5AF78-FE2A-4685-AB34-3FE17035070F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E1D6C6EE-88E8-4378-94F7-A48C80B19F82">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DD213A82-BA39-45B5-8675-A7E880E75033"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2280FAFA-BEA2-4B8E-B7F1-2DBC7D343EA0">
    <domeo:uuid>2280FAFA-BEA2-4B8E-B7F1-2DBC7D343EA0</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <pav:createdOn>2015-10-28 16:31:09 -0400</pav:createdOn>
    <ao:exact>n a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-administration to steady state was associated with a mean increase in pimozide AUC and Cmax of about 40%, but was not associated with any changes in EKG. Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline and pimozide should be contraindicated (see </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2280FAFA-BEA2-4B8E-B7F1-2DBC7D343EA0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>I</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f6c7872b-d9c6-4e9a-a8e5-9f973e7ab81b">
    <rdfs:label>digoxin</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4732e899-4ed8-4d7e-b5ed-26d55bf192f6">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ac8c5505-0c3a-42c0-9143-5dcc800968fa"/>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ac809895-3ed6-4b43-ad44-65f777a8b6d5"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:caa0c76f-96ca-4959-b0e7-f4267d3ba603">
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:75b873eb-3b7d-4683-b123-18c27d67a5c7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0ae11964-a857-4ba9-b83e-ec2e653fa866</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="Nf1d2053fc52c4e4d901ee21b1c2bd318"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F3CB7C2-BE04-48F6-A831-60BE526797C1">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with 5- and 8-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine. </ao:exact>
    <domeo:uuid>2F3CB7C2-BE04-48F6-A831-60BE526797C1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2F3CB7C2-BE04-48F6-A831-60BE526797C1"/>
    <ao:prefix>    Tacrine   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-27 15:38:33 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3AA83FB6-6FE2-45EE-8771-63A50012CFE6">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/610F9D4F-70F5-410C-BEDC-ED9D38092078"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B9B1E3FF-6F08-485E-AFC8-CC76921390F9"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:babe1c0f-27a4-4c12-9215-b76c75745278">
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f319c72f-30e8-4c28-a811-eb6b9e67c8ec"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a24638b8-ca6f-40ca-8582-b90c172f43d4"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99599146-6845-4B4F-986C-6A1CF2C84691">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:body rdf:nodeID="N89b4b8d5898146d1ab7cace2a8bb59e7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-10-27 15:33:40 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:83258F28-2323-4A34-8E0C-B5B3A85840AE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F17B0155-6940-42DC-9A9B-A9CADC77949E">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:4B838713-7978-47A4-8388-9F4804CACE74"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdOn>2015-10-27 14:25:31 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87dd2aa7-737b-4670-acac-935fb7d7547c">
    <domeo:belongsToSet>urn:domeoclient:uuid:216744d1-4f9b-41a9-aeac-ff03ccaee95c</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:74921e69-ac02-474c-9b11-a940aa5b784c</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:b9e65f94-db35-4316-ac44-31abb9eb8e11"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nbc7173fcdb51450d8fdd4456ae6e072e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2C670E10-FD19-4267-9C5F-C4D31BC43253">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>2</dikbD2R:cl>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>Increase</dikbD2R:clDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/34BD3DB9-5249-442C-8A9A-E3E536702D1B"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D51BFAD4-356D-482E-9711-4B9CBE65B766"/>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <dikbD2R:clType>Fold</dikbD2R:clType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA246F73-4ACE-44D8-9EAE-7DE41B03D2E3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-05 15:28:24 -0500</pav:createdOn>
    <ao:suffix>(e.g., </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FA246F73-4ACE-44D8-9EAE-7DE41B03D2E3"/>
    <ao:exact>antidepressants </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:0D56CBB6-C44E-44FD-8A32-E7EFF20B9DA9">
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:72BA2EF1-7A2F-47C8-9C8A-ED18DD950825"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:74A86F48-D8CB-4360-BDC7-210BFE619D2F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/a31e3265-4b55-4cce-87ad-ccdd04955d3e"/>
    <pav:createdOn>2015-10-26 15:40:15 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-28 14:38:28 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:449a25ec-0231-4763-aa53-0abbb586174a</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4fdca1cc-8a4d-4451-b292-964852284e82</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C0F2638-5394-46EA-BC83-C1799ADA2BEE"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N3a68377c7d4c44d78eb67751bff42646"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:12A7ED1B-846C-494F-B1CD-DA9984CFD9DA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/926C0CA5-E021-4A57-A07C-0A8797724BEA"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3390169D-640C-48A1-9899-D6D25BEFEC61"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/425AE49E-984D-4EBD-BF94-B2FC79BBE063">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>levothyroxine</rdfs:label>
    <dikbD2R:dose>0.15</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ce406fc0-e044-43be-ac4a-24f5f011c5aa">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:4d211731-d3b4-42d4-a6f5-b8318076b467</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:c19b3f11-dfa6-4eed-a773-c0aaab12aca2"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Ncbb152e26da14b6aae06fbc2d5443a51"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-14 11:31:14 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:8ec7f7e5-7386-4eab-8245-ea5d0cc4207a</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-14 11:31:14 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:90E77CD4-EB99-4A2F-B1DD-B6F0F6456D4D">
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmax>2</dikbD2R:cmax>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8308F0B0-CAB5-4632-971F-2B697F113C03"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptDuration>22</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4FB730C3-5350-46D6-96A0-A2AE3788CCA4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E42BA8F8-37D0-44F0-A473-B7C3920CEC7F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <ao:exact>Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see WARNINGS AND PRECAUTIONS (5.12)]. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E42BA8F8-37D0-44F0-A473-B7C3920CEC7F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E42BA8F8-37D0-44F0-A473-B7C3920CEC7F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-29 09:30:20 -0400</pav:createdOn>
    <ao:prefix>   7.2 Inhibitors of CYP2D6   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D21F7444-0694-40EE-BEBB-19138C9D3A3F">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:c4a875d9-0edd-42b9-a1d2-af1fdfc9491f</pav:lineageUri>
    <rdfs:label>NER Sets</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-10-26 15:41:08 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-11-02 14:27:27 -0500</pav:lastSavedOn>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/2c1fb7bf-9548-42d9-af4f-4646a00f3732"/>
    <pav:previousVersion>urn:domeoclient:uuid:1720310e-1798-4e2f-a80b-260a991e7515</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:3AC99F8D-E316-4138-856D-AF3DD84F5D89"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <permissions:permissions rdf:nodeID="N6764f215529945b889db310b104a5e3d"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FBB2D93A-4125-4710-9BB8-1E2593082591">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cmax>6</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AE9B1057-1982-4DA4-83BD-046A6D0DDF27"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A0EB2950-7505-4EC5-9796-6E82906B9CBD"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:auc>6</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/88F8ED64-25D2-457F-BBF7-01D5B02DFF94">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:638d38cc-b86c-4caa-82c9-cd55abbb2d1d">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N5ec1faf6688e4d3f90aae0d6301361ff"/>
    <pav:createdOn>2015-09-14 11:32:07 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:ddf891c0-c921-46ef-9dbb-d90790bf35af</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-14 11:32:07 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:568fb98f-defd-45b4-ba2c-28d6c684a89d"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:1bfff068-5ff1-499a-a76e-cae4a4b56e20</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D55E50B1-2373-4502-8F9B-738483B8825E">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:755177f1-0e54-45c0-a48e-503e9eff1f45</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:c55bb44f-5c27-4ab1-9c3e-e54b8f749a2a</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-10-27 14:15:20 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7d3b3fc4-7754-47da-9c4f-64e4fa9b0c27"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nf712b56bdaa24a56884c8c2854d247f8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:52C8BA72-3C4B-429D-92B1-89F1B16729B8">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:6bcae986-4c46-4a0b-8d58-8f7a83b89ebf</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:a268bcae-58ad-4487-b259-0e421726bda2"/>
    <pav:previousVersion>urn:domeoclient:uuid:bd7ca3d3-363c-4817-8ed7-c636b0a12978</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-10-29 11:36:33 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N0dd49bfbfc7b4e5d86363aeeaf847d6e"/>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8172188e-20d2-488a-9448-55d8b5327838">
    <pav:lineageUri>urn:domeoserver:annotationset:6edfdb29-d5d7-48a6-8511-8c05d6833471</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N63b060470c5e4100b54b058df3f1c1fd"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:d256acd9-f09d-4421-b2ec-09fe46d412e6"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E4C23D6-E976-4A8B-8E85-4FD7B240DEA9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>(600 mg/day for 10 days) at steady state and a single 30-mg dose of </ao:suffix>
    <ao:prefix>No relevant clinical effects or significant changes in pharmacokinetics have been observed in healthy male subjects on concurrent treatment with subtherapeutic levels of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>lithium </ao:exact>
    <domeo:uuid>1E4C23D6-E976-4A8B-8E85-4FD7B240DEA9</domeo:uuid>
    <pav:createdOn>2015-10-29 10:47:32 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1E4C23D6-E976-4A8B-8E85-4FD7B240DEA9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8b0687e8-b41f-4dd5-b451-4128c9d99e01">
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>16e3fd5b-5aa0-458b-8775-33a3cbfd7e97</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5AA4A5DE-9329-4D0B-AAB7-8AE4ED41086E">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>600</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ritonavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1835049a-eb90-431e-ac38-197f12190eb1">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluoxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BBFC1C65-66D0-4A3B-9FCC-473D39C12D1B">
    <rdfs:label>CMI</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05CA5393-1520-485B-8CFC-97D8A0DC8B1C">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <ao:body rdf:nodeID="N3308fcbfbbf942ebb3560c0b8337221a"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:25AE618C-1355-4395-B7C5-0C02149C971A"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:4CEE8D0E-B023-48E0-A038-A0024F43A84E</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-05 16:15:30 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">26</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-05 16:15:31 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15bffb41-cd0a-4e36-bcad-4d7eb157bb44">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:d9db95c6-1104-427c-8504-bdd04bc2dafb</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Ndceb556106c64968866aefb393b66ab4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:391cd575-ca0b-41da-bcc0-612d6ee43ef3"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:fd9b5244-196b-419d-8911-e84e3a482bbf">
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f29879d0-467a-4432-a31a-b37fb7c7d9df"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3637aedf-f9b9-4efa-aab9-beb485d37117"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A3B462E7-B917-45CC-B2EC-A1210E0157DF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>antiarrhythmics</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2eaa27ec-4db5-4aeb-b152-6e7c9c3705f7">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Ncbe39700b731458c83dc97c852d267e4"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:daeca897-be1b-494d-9695-334eb7006e10"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:b5f48a95-5e65-4e12-a982-59a20b3ac9be</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:fc105bb8-3fb2-4ec9-9255-e8c1e34bb8c6</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99a98311-d32a-4914-a5f4-1b171e4865d0">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N295380945fd0404ebad96d5447a9fb42"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoclient:uuid:b015f077-7d1b-4f84-8d5e-5b65ee148da5</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:22FF7872-7D7B-4663-A4F9-F5180305E827"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C0B2C907-F897-4896-BA9E-FB49739DCA69</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:9efe1893-a4f0-420f-91b2-f43de3da156a</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-28 15:25:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:96E0C7A5-10FA-4F95-BF86-28FB3B2D7161">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:6062acac-55d4-4126-b816-4b7fc655e2e5</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:fdbca9a5-9ad5-42a4-84f6-1b8a9e8fc847</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N0fc38d3caf4547efa6f0afde5b7b2c5a"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0ab910aa-966d-465b-93ca-21f97867a457"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-29 11:36:33 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D7C8F33-3F77-4103-A6A8-BC8795CCBCD3">
    <ao:exact>Drugs Metabolized by CYP3A4 — In an in vivo interaction study involving coadministration of fluoxetine with single doses of terfenadine (a CYP3A4 substrate), no increase in plasma terfenadine concentrations occurred with concomitant fluoxetine. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>2D7C8F33-3F77-4103-A6A8-BC8795CCBCD3</domeo:uuid>
    <pav:createdOn>2015-11-02 16:12:38 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2D7C8F33-3F77-4103-A6A8-BC8795CCBCD3"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:22792633-0A0D-4820-9A3E-4433C813EC8A">
    <pav:createdOn>2015-10-29 10:34:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>  Cimetidine  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <domeo:uuid>22792633-0A0D-4820-9A3E-4433C813EC8A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In healthy male patients (n=12), when cimetidine, a weak inhibitor of CYP1A2, CYP2D6, and CYP3A4, given at 800 mg b.i.d. at steady state was coadministered with mirtazapine (30 mg daily) at steady state, the Area Under the Curve (AUC) of mirtazapine increased more than 50%. Mirtazapine did not cause relevant changes in the pharmacokinetics of cimetidine. The mirtazapine dose may have to be decreased when concomitant treatment with cimetidine is started, or increased when cimetidine treatment is discontinued.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:22792633-0A0D-4820-9A3E-4433C813EC8A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a8fa50aa-4823-4449-808e-ca058f6e3f9e">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>1e24d653-f4f7-4b89-9a7e-7bf53d457acb</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63cd69eb-9f18-4dc8-a80f-2fc6ed845170"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ED3048D5-BFFB-4654-BAD7-5C8E7260A311">
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F25B20CF-E40D-44C5-A17F-C8B7A6CEB492"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2154613A-DE7F-4BFB-A173-C3CE6239EB7F"/>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4dc6c242-e6bb-428d-9bfb-42a11322f817">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ee53199a-d11b-460b-b8ca-50d1a8859253"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c536d7b6-4ffc-403f-ac8c-715de5c51808">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:86fec734-86b8-41ea-9d50-3262c80bd6cc"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8aa0af45-7ecd-4eb3-84d7-8191e8353e12">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
    <rdfs:label>flecainide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72653064-46F0-4D6B-B5DB-F798E5DA211C">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N14229f1dad194606aa660d024d576973"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:96FF54D7-9899-4A14-98A3-7880D30E249D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-27 15:22:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EEBD589-980F-4087-9AA6-844C0AE51C83">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7EEBD589-980F-4087-9AA6-844C0AE51C83"/>
    <ao:prefix>Elevated serum levels of </ao:prefix>
    <ao:exact>clozapine </ao:exact>
    <pav:createdOn>2015-10-27 15:21:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>7EEBD589-980F-4087-9AA6-844C0AE51C83</domeo:uuid>
    <ao:suffix>have been reported in patients taking fluvoxamine maleate and clozapine. Since clozapine-related seizures and orthostatic hypotension appear to be dose related, the risk of these adverse events may be higher when fluvoxamine and clozapine are coadministe</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D3D9CE0D-95AB-422E-B21C-7B575372FD42">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>Celexa</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B21E8999-5A2F-41A8-A668-2B095576B5F9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <ao:body rdf:nodeID="Ned8a07a0b88c43178ca40c775b291dff"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-27 15:33:27 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:B7FE72EF-2550-431C-95D0-360F034A90C4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bc24890a-8fb3-4404-ba59-6868f5573431">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-30 12:41:52 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N902c67cc5c5d4d24b9700d3cdb64411e"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:187BB272-AB9E-4D45-899D-5CB7C8321076</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:7a7f8f83-3aad-4e6c-aae9-086c7625f3e1</pav:lineageUri>
    <pav:lastSavedOn>2015-10-29 10:29:25 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:4E3E1944-C5DE-44AE-9FFA-57DF08EEBE0C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36E380A4-D4FC-4A19-8633-71825303E8D2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:D375F768-12E1-4181-AAF8-6B3901E3969C</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <ao:body rdf:nodeID="N6e7196470e744d19a13b718ebb396bfa"/>
    <pav:createdOn>2015-11-05 10:37:42 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:B277CC13-768B-4004-BF78-723D147C8501"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d3161b66-53c4-43bb-9d97-caf52979ed83">
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0a650de3-78ca-46b2-968d-35ee13d11aa6"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7f8bde98-7275-4a2c-a670-e67c1ac1b0d8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:4995AB8A-EB6D-4671-9103-EA13C6AABF91">
    <pav:previousVersion>urn:domeoclient:uuid:9a9aa196-3fbf-4882-9d60-d6ee8108d254</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:87ef6c97-0630-429e-99e5-b7b9f2a0ecf8"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:892a79af-d113-4fc2-a25f-941d0df65593</pav:lineageUri>
    <pav:lastSavedOn>2015-11-02 14:33:30 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N0c247fed8eb04fcfabd9c65e3c0a095f"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6e79e785-0a04-4d19-b6f6-47e53976ec3b">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N02e3495cf15e43f681f03e521e919e6c"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-29 10:29:25 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:bca49c54-d98d-49b3-899d-5fe9c0c1df4b</pav:lineageUri>
    <pav:createdOn>2015-09-30 12:41:52 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D1A77A1-50DE-4D2E-A95F-972818B92A1E</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:08448F7B-D11F-45B3-8826-2026F21BF1EE"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7382F3FA-040F-4782-AE65-7B5062737C2B">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>escitalopram</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>20</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N41ae9824e70b4339aa392e823f4d908f">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC007E85-5B0A-4100-A5C4-5502104C8066">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AC007E85-5B0A-4100-A5C4-5502104C8066"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-04 14:13:38 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:prefix>(TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AC007E85-5B0A-4100-A5C4-5502104C8066</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:45e00331-2a3c-48a9-9082-4986d7b1fefe">
    <ao:item rdf:resource="urn:domeoclient:uuid:2ccc5293-4aca-452e-a2ed-4e25b5863670"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:b58beea5-c373-46c9-baf9-07449c7ac3c7</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N1a05a0ef24b245fd8396e9cf91ab54d3"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-10-14 12:07:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2CC0744-CB78-4E44-9966-146A058F3C6D">
    <ao:context rdf:resource="urn:domeoclient:uuid:0DA68951-B82C-4701-A781-ACEC78A94503"/>
    <pav:createdOn>2015-11-06 15:37:02 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-06 15:37:50 -0500</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:27387736-AEB3-4AB1-866E-8ED6BF3888BC</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA">
    <ao:item rdf:resource="urn:domeoclient:uuid:1CBC52AB-2630-4311-A3B2-FF9304FA9A5A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5F7E40A5-EB73-4336-8F25-862E0BE2544B"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:CF0BEAA2-8D19-4721-84FC-193CDA5000A0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E7D2F705-12C8-4309-89D6-397AB84891A5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FE0339C1-03DF-4BA8-B0AF-BA7ED7EA24FC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:48E7CC6E-29ED-4979-A040-C521F1CBBAFA"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Nfe8c37df06134c0484daed6f1548ee51"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E41CCAB4-350E-4E95-83AF-8EAA72D51C91"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F654BDDB-235C-4284-9515-25EC3E182501"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1C32CC6A-5196-4913-84F7-7FAC36BD2F6A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:121CEF2D-2F3C-4D73-B93C-6FD4D2B21CF7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:47BB2BB9-37E2-47ED-8A73-EAA48EE1CA15"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:96003E4F-1304-4028-BF04-20D3BFE7C71F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9DB621FD-6FEE-49B3-B2B3-C459589B1F5C"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:previousVersion>urn:domeoserver:annotationset:0D552EAE-9617-4040-9F7B-2871702C8529</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:CB90BDF7-4F93-4A3F-BED4-D370D59F9F20"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:B5CAAAD5-F0F8-4495-93CA-75E4FA8279CC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:21ab3694-0521-45a0-aac4-063bbf59cd54</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA174FDA-075C-4A3F-BE05-648A1F4A71B3"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:createdOn>2015-10-26 15:38:33 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5CD80665-523A-46BE-9FBC-8D4B2192FA37"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/6f262eb6-0bd7-4228-a2c6-8a63166bf314"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5AB58091-AC2C-401B-85A0-EA5266CABF70"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6f5b9d39-bb4d-494c-90f7-ebdad0289141">
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:7220d6f7-4364-4484-8751-8c2356d40233</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Ncc980231575c461d9c64498768000335"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:c6c1e53d-5fc7-4785-beee-f177867bf196"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:3a1e4d38-e337-4da5-a1fc-dad5159bad78</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N19c20ee5784d451d89c8326b7f00abba">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5705ED86-C877-4657-9A9F-3CC2B6600329">
    <dikbD2R:t12Type>Percent</dikbD2R:t12Type>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C16B858F-2ED4-4D72-9186-5824945540E9"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BA7C9D31-CBDC-48B2-A42B-0A592E676B26"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>Decrease</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>25</dikbD2R:auc>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12>38</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f4d5b966-3835-45a4-bf04-cdea69aa3d12">
    <permissions:permissions rdf:nodeID="Ne701be22eacc44c88197835ce2289b4a"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:8b44f40d-5eaf-44dc-9102-9e10badc0f76</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:c859c12d-8c32-4a7d-8a9d-3949b5970949"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/612702FD-A9D4-4852-AE07-4D0351FEB979">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8501d432-8163-451f-b0b2-86f04a812b3b">
    <dikbD2R:dose>5</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>procyclidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:51D2FCCF-39C7-41CB-B64F-17E20095455E">
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E85641CB-10AA-4EFD-AAEF-11A1CCD2DB43"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F2ADB11E-7655-4106-841A-C0468A78118A"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D07DB5F-34BF-4840-9F23-4139B1C6A05C">
    <ao:suffix>, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. An increased plasma concentration of pimozide causes QT prolongation and has been associated with torsades de pointes-type ve</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact>ketoconazole</ao:exact>
    <ao:prefix>is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that </ao:prefix>
    <pav:createdOn>2015-10-27 14:23:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7D07DB5F-34BF-4840-9F23-4139B1C6A05C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C89BE45B-6DDD-40A2-962A-59CABF7AA9C7">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A8A997D3-AD14-4712-A1D1-32036CC40162">
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>10</dikbD2R:objectDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C798082B-6017-4D26-9646-83FAA75450BB"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B314B36F-5452-4F63-BFCB-FA17BD1F66DB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:31A9C144-668C-4A87-B041-12809B461F68">
    <ao:item rdf:resource="urn:domeoclient:uuid:a88ad973-8e54-4b60-85f9-76b2db05031e"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-02 14:22:34 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:80967190-2bfc-4236-8d24-e3733dcf3f3b</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:9c3dc0b1-1c4d-493b-8a36-8485a56577d1</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N9637eac75df5456080cd0cdc9c8807b4"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:51554DF2-DDF2-4251-8173-54A9DA6EB60F">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/48BBC616-F47F-476F-94DA-5FFDF84C3B40"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CEC5548E-5026-40AF-878A-42713C83EBE5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07a675d5-5c2d-499e-bc3f-8ef5e743a8e3">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N2bd81a0bcbaa4ca99c76b4a588e7ea8a"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:b74e2f88-22ff-45d5-adf8-2e2603816c18"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:d35be9d6-fc0e-4185-8378-c3300dd92b81</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CF4BEBD5-99E4-4580-8D38-FD1D1F3F393E">
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3E74B343-A86E-4FEE-B9E7-2313AF593C2C"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/105A0F92-D7CB-4505-8607-757457B6899B"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:auc>7-20</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AE9B1057-1982-4DA4-83BD-046A6D0DDF27">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>duloxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5c3dee37-f2b6-49ac-8607-347751f0d946">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a8df9a1a-f528-49dc-bc66-dc68eef7a342"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9fb72584-f1bf-41b3-b487-67935b39aee4"/>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CF7C69D5-7BB8-4CA8-9AD3-117FF9A65B78">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>citalopram</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/30514888-2B3A-4703-A890-1191D9210E04">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>levomilnacipran</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8D9122CA-5371-485E-9356-3C3274919690">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EC91E328-6717-4DC4-A626-501948A85F29"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C2833A45-07DF-495E-B888-B41AAAA8AA6F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdOn>2015-10-27 15:28:29 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A39EFA50-ADE0-4CD9-889C-A3899ED085D1"/>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3db8290c-8561-437e-920b-98793428a995">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N91d85a4cab8e4d10981e3c26ce7f243d"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:29a153ba-9210-42a0-a383-6421247e28fa"/>
    <pav:lineageUri>urn:domeoserver:annotationset:511b0159-8fbb-4567-9850-50526244836e</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:43606530-1B05-47AD-8316-BEA446BB0050">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FDA9A854-8492-46B4-84A6-0940A4CE35FF"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B0A650FC-AF06-473C-9DD1-FFCC354C3CC1"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants>24</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6FB6F12D-2ACC-415F-B387-F2925BF1A33B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>6</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7520d508-6673-470e-8698-c67ad1519b73">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N0eb6bf99df3744558965130dab64fead"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-08-20 10:29:59 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:d3a4f8ee-b5a0-44d9-9b41-22ce43864e7b</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:03281665-e00c-45cf-ba5d-ae64e6a865d9</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 10:29:59 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:abf3261a-125e-4d13-93d4-9c091bdf2559"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E536FE66-FAD0-488D-B7C0-39E59CBD9678">
    <ao:item rdf:resource="urn:domeoclient:uuid:92FA08EC-8F77-4381-A0D0-783B6EFFC898"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:F5910395-E670-41B4-A50F-A4A5034D7CF6"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:FF03119B-C10F-4EBC-9066-5E530D1EC804"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:D0065C4F-ED7F-43E0-9AF5-6A0941357243"/>
    <pav:lineageUri>urn:domeoserver:annotationset:e5208d0d-d470-424b-a0e0-4a4b5da16c0e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-26 15:40:40 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:0BD1C4FF-5749-4CB8-9588-7BE67B1E525D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:06622E87-E360-445F-B0CB-BE8262FABD89"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2AEF6EFE-861B-4DE5-A749-12E2401F48B8"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8E922CAF-C62B-4286-B19A-C3993646558A</pav:previousVersion>
    <pav:lastSavedOn>2015-10-29 10:48:14 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/3313aa37-ebb5-4291-9897-937890e2dd3b"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3C105085-6A08-4692-BFB3-86F0EB8E5221"/>
    <permissions:permissions rdf:nodeID="N7717c842092e40bda884fff9a456423f"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3c14989e-e92c-4b72-a598-0aee4ac2ee51">
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1225b190-04ff-40da-83f8-bd8bdde53e80"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/28fd3e88-85ff-452c-9d78-fdf289fd103a"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:dcfd172a-fe2d-447e-a47e-8ade5dcb207b">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:e9001232-e48e-444f-b992-dc8d94aec5cf"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:ff4d4305-d210-4fd8-8788-e5ad55f5ad28</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N46ffe93af80c441fa5d9d2ae7e998c3b"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d35c2fa6-90ad-4c9d-90c2-83e00233d7aa">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:D97FB6D6-3D79-48FB-99F4-A0276B7CF996"/>
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EBC5B786-4892-4544-85FB-2E855ECB0199</domeo:belongsToSet>
    <ao:body rdf:nodeID="N33ed56507b6244ca96f68f122404a953"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:a2a5d0ed-1287-4d8d-95b1-da59cbdade49</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-16 15:31:12 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B14001E8-4F68-4FC8-AC34-6F1A8A1AE85C">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B56751B4-AF9C-4DBF-A5E2-C85185834522"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>28</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5AE0D453-B766-4124-B840-2034C7C7B5EC"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3C12AAD-425A-4D90-A370-476976CF22EE">
    <pav:createdOn>2015-11-05 10:36:41 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:6B0A6BDB-747E-4636-BAF2-2DABD0FBF8E4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1E5D6005-CEEA-4512-93E7-6AD0AC87663C"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1070f69c-4312-43c3-976f-19b5273730fc">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e9259a46-2244-4ccf-9964-aefe6b085941"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ee4038e6-5312-4b9c-9cff-181a64ee5948"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/83B55ADC-0E96-4293-ABFD-179ACB5D2077">
    <dikbD2R:dose>50</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5831e197-040a-4893-a0d8-bd9de0e57ed8">
    <ao:item rdf:resource="urn:domeoclient:uuid:4595d2b7-e304-48dd-823e-5733f189ccc1"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N39ca4e41fcb749dcac946a5bf5ec095a"/>
    <pav:lastSavedOn>2015-09-29 11:41:50 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-29 11:41:50 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:682620e6-f078-4490-b426-f082cdb1264d</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6046ff91-fde2-4f97-9602-33a29a65bd4e">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/73e0d409-a485-4465-8c9e-57adccee4a9a">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>digoxin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7da5ee9e-f83a-490f-9547-cb9c9679ecb0">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:e1a7276e-b078-4625-9913-4c49fa21673b"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N58b9e38ba3cf425bb01f00407e658ac5"/>
    <pav:lineageUri>urn:domeoserver:annotation:a379d046-8a01-4770-97f6-6d02162e5133</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:13bfd14f-c780-49f2-aeeb-1656e979a49d</domeo:belongsToSet>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:bb03298a-1efc-4e4d-aa18-d3bf593fe9b7">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0d2c99f4-473f-4dd4-a770-e8ca2b77a858"/>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8c5f0ce9-3b5f-4f7e-afcf-52a8b7dde825"/>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D8056D38-6718-4AED-87A8-4EB5DC6338EF">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-28 15:25:57 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoclient:uuid:122ec269-0f49-4a69-9258-781c28cde8cb</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:cbdc73f9-4a55-433b-801c-6820b1d7f6c0</pav:lineageUri>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:1d272e64-b3a1-471e-8bec-4a398c3393e6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N8e57484f664747cb96bc9cb0acbb9354"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/78D16F31-5EE9-493C-8F78-68759658B14F">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2845582A-54E7-48D8-B314-7E1539F0CA1F">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>, respectively. The exposures of hydroxybupropion were decreased.   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Prasugrel: In healthy subjects, prasugrel increased bupropion Cmax and AUC values by 14% and 18%, respectively, and decreased Cmax and AUC values of hydroxybupropion by 32% and 24%, respectively.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 15:49:43 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2845582A-54E7-48D8-B314-7E1539F0CA1F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:F782750E-AA75-484A-B1C7-696C3491621D">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N44d00d4b81fa425da02189e0560f162f"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:0eeb4ad9-9b7d-4f32-a2f9-2e284246f12f</pav:previousVersion>
    <pav:lastSavedOn>2015-10-28 15:23:31 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:f2f08985-d9b9-40fe-934d-75814128946d"/>
    <pav:lineageUri>urn:domeoserver:annotationset:89f6b805-c508-48d9-a94e-93967b45d101</pav:lineageUri>
    <pav:createdOn>2015-10-09 13:18:59 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:89D701E6-757D-40AC-8868-90907A1298F9">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N59212061205e4e41ada9d453294a3f18"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2015-09-16 15:31:12 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:f5c41af5-a1da-4df3-9244-8c8e8faed15d"/>
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:e17028e2-e644-42e6-a320-1db28fdd6dc5</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:4973a4dc-6768-4c10-8664-51ec100f51f8</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:168F2DF5-17B3-472A-B69B-45BD4A9B2076">
    <ao:prefix>Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic type drugs.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs. Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine. Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen. Discontinuation of cimetidine in well controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.</ao:exact>
    <domeo:uuid>168F2DF5-17B3-472A-B69B-45BD4A9B2076</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-29 11:11:53 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:168F2DF5-17B3-472A-B69B-45BD4A9B2076"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:525194d7-24d7-48ed-b4f8-10ba39a6a4e3">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ab762727-95ba-4ba4-897e-84db4834082c"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/91956349-ef7e-475f-8c61-72ed80aa4c9e"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A5E72FC8-7711-4048-8268-94FBC922E11C">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B5AB9A73-5222-4C33-9092-E09514AD7770"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptDuration>11</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EC9EAD2C-5617-4FEC-8FF8-F60E4DBD2413"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c4fcd40d-23e5-4b17-b235-288f3494df35">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/43b506b5-57fa-43c4-b591-838c17ba700c"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e40df49a-0ec4-422e-8060-ca175ce73456"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/67D0F870-A48B-4EDE-95AC-EA7ADBEA5274">
    <rdfs:label>quinidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:C6F4FDC1-8820-48F1-AC68-629C968A965D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 14:17:34 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:9041d0b2-fde1-4222-a6b2-ba1b41613c4c"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:78b1b022-efb0-41a6-bbf3-ecdbcc555afb</pav:previousVersion>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N072b325bc1a940e0bf6f0bce5f38af26"/>
    <pav:lineageUri>urn:domeoserver:annotationset:452a0dc9-8647-4fad-ac32-c21701ef99ae</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f9219569-80bc-43de-aea9-6eeb95c5405d">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:914834f9-7b6b-493a-b5c0-3172b1a4b0f2"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:32E5C2F2-8FFF-4355-9A4A-D2791D308EF1">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B7605E3C-245C-40B9-B3B9-DB42DDE0BACE"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>9</dikbD2R:preciptDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1A65E25D-9757-47F6-9655-59083C9A3124"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3101FF80-E3B3-4B2B-B800-B478744873D4">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0d62acf7-6f15-4585-b6b3-8bf0427d94cb">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:189EF30F-86D5-4DBC-BBBB-57E7B9584324</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N1b985d7b6c384a93acbde5a0c1a381da"/>
    <pav:lineageUri>urn:domeoserver:annotation:47d4d1d7-8d57-4b32-ab59-1361d752fcc0</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-29 10:48:41 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:EAE3C703-C91D-4A1A-A489-73B4CB6B09D8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B15BA85B-19D4-42FD-A00B-A74D35AE722A">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:28B8819C-FACB-470B-B82D-9B499A63B4B6"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72852bd1-938e-42fd-82fc-d0ed3051fcb2">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N9ec2790d7ac54db4b7448e0d8cb4b056"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D946C533-B69B-42B6-B679-B6ADF9769A1A"/>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:f13b1277-bb04-43c5-b017-67f88d001556</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-02 13:56:21 -0500</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B613EFD6-04C9-4350-98BA-6C3385DDF2EA</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e987ce6f-4579-45b4-9065-834f79fa8294">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:34ce721a-b2b1-44e3-858a-7a6cfbe633e8"/>
    <domeo:uuid>3582b8b3-cb46-43b5-938c-23ea1a50aad1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9e738bbc-6091-42f5-8ac2-68c5c3c4aaaa">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N7a441d78703848a1af141b0962fa87cb"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CECA99DA-8FA8-4891-A150-E815F325EA3A</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:5FC7ACB8-10D2-488A-8882-3559BD635CE1"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:8a995e06-60ba-4541-9672-db4ce7763282</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4bcaa1c3-4507-49c6-8b20-ba63d5b64fff">
    <permissions:permissions rdf:nodeID="N483afa2556fe4024bbb937503a391f04"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:01cf036a-54c9-425e-aff8-289bb6f08f3e</pav:lineageUri>
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5622b045-28f2-4a28-985b-a734a92e22e2"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:83D76B22-B626-4E0A-89D6-BE781064F3DC">
    <ao:item rdf:resource="urn:domeoclient:uuid:F210FD11-A089-4263-89B1-25BD3EF2F28F"/>
    <pav:createdOn>2015-10-26 15:40:42 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>urn:domeoclient:uuid:e6b8a03f-fc38-4860-8ce5-216a4589c809</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:096d956d-6c40-4fa4-b6ba-b25f42a50d5b</pav:lineageUri>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N689d8f8b718540e398509b7cab3931d2"/>
    <pav:lastSavedOn>2015-10-29 11:26:06 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/0a7b8978-94ca-4057-807e-48d4646f1be1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6d9fd086-1348-4ef3-9f33-0b8ee5ee97eb">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N2b8ecde475d140179d86f9b6ffdc8d9a"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:2402aa21-3e6a-4617-80ab-68f5acf65a56"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:6df2b348-9133-44ff-8883-4b57f56ff579</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8b2e6641-8e64-44cd-a239-fd56f6fd3d07">
    <ao:context rdf:resource="urn:domeoclient:uuid:d95d96b3-1b7f-4428-9629-6379f0038692"/>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:76850941-3af6-41a5-a2ed-25223d9c3b09</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:b07ac358-5acd-49fa-84f7-095d1f9cc764</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N61914bd2f437481ea5c2a9fa8b7ab9f6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:74785AAE-1127-425F-A8ED-83190C7E022C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A7AE82BF-B99F-4549-AF3C-3506B47DB5BA"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CF8E8B63-CBC6-4D5F-A9D3-C3F1488586F8"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:dbc81dd2-96e0-4072-bb5a-eccc1b66e935">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:c1483618-10e4-4e5c-86ba-c162c53a6216"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:aa53822d-06cf-4afb-a959-c5eadfccb77a">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:0FF0A8F1-628D-4598-AAEA-3A7F10AA518E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-29 10:35:24 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N3506dc73837f4aa585b647f57c923ec2"/>
    <pav:lineageUri>urn:domeoserver:annotation:c41ccc6f-9d13-4014-bc62-a0cc4c7aaf94</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:30AE0552-A927-4E46-90ED-CD6BC60720E5</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:cdcb4550-818f-4e21-8b4a-99607c9fca93">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/cfca7b9f-402c-4a09-b5cb-c46981030fc7"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/c975267b-9c1c-4559-b181-cffb551cb3ad"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b64a0753-272c-4b43-ad9e-0c670a4de269">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>dextromethorphan</rdfs:label>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6adab0a1e66b489fa05b199b51a9dd08">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:610BE8DE-3A23-4126-BF22-C9802248CEC2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:610BE8DE-3A23-4126-BF22-C9802248CEC2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (</ao:suffix>
    <pav:createdOn>2015-10-29 11:29:39 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:exact>TCA </ao:exact>
    <domeo:uuid>610BE8DE-3A23-4126-BF22-C9802248CEC2</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09776643-eea6-4a3b-a146-a688d5091f35">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>54d094d7-b453-47d2-bb46-cfcb8953b2b3</domeo:uuid>
    <ao:prefix>yclic Antidepressants (TCAs)   </ao:prefix>
    <ao:exact>Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced. </ao:exact>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3e9bcb64-6f70-4084-85f7-17e9f3b83e87">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:2495865a-0dce-4d74-8a01-06206dd80418"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:67a1b4a2-850c-48c9-b301-13bb1f8f3cf6</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:33f99c4f-8af7-4e45-b51e-69a24113b8f3</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nb486aa6de834440cb54a4b822aaed2bc"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CC2580C2-D65B-4693-BAD0-A138C53EE2FC">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>tamoxifen</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C18603DF-B344-4BF7-B514-7A84CCD042C5">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>risperidone</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3E6AC78-3F92-4397-88CF-7524C52CF120">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-05 15:26:12 -0500</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-05 15:27:20 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Ncf32040173e84b7ea394641cc6949052"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B170CAAA-860E-44B8-A1BD-171CE3E86595</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:60E6AF24-633B-4B2D-AB30-F8D39266FFF9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42CEAF50-2AFE-41CE-9C71-5882C69D2A21">
    <pav:lastSavedOn>2015-11-05 15:25:55 -0500</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1EE88710-0B98-407A-B6EB-CAF24A7B0439</pav:previousVersion>
    <pav:createdOn>2015-11-05 15:24:32 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:56BC2FA2-8F69-4C15-8175-D383A04D506E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:74B5DF46-170D-48DA-9F73-90F0895A77D9">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>10</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/18887DA6-4A05-4BB8-8864-CB0B883338B6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6EBF6209-A8F3-4532-8FE7-B5304E77BF97"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:635a7090-85cd-4916-a005-f60c3e248012">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:baab44e2-0ef4-4d03-bc67-918924327145"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:a6f5cfd8-9a80-4157-9471-7d429648b87a</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nc68e6fa66f83446a98c46d6c3799db78"/>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4fe28337-f7e5-4585-bbf3-f32d24cd2a91">
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1f567f03-c77f-43bb-bf1d-5353f675580a"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/30f38d08-0321-4172-ad4d-0959ae9c6813"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12></dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fcb60ea5-63e9-48a4-8ec6-cc9a813c9807">
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:0afbb7f5-57f8-4bf6-8daf-ec3a19de73cf</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N0e7e60a1e3ae4ea282aeeec47cd16e29"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:cbc149c6-cfb6-4199-ab22-607776fc0e60"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:7D8503CE-4A92-4F09-89E3-8F59A55247BE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:4da3045b-781b-4b23-a68e-4439ffc837e2"/>
    <pav:previousVersion>urn:domeoclient:uuid:ddf9f5fe-0a5b-488c-b630-f436baa21001</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:a19d9343-039b-4b21-8cc0-301585041ce2</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N595885f17f124697bff6d4bd2cf47e60"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 10:49:25 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6991e6a3-29d3-448e-95dd-682bf9fbdc3c">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-25 10:05:58 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AFA8CC09-93EE-45C1-97FF-36A9DE513EBA</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nb6e18290048b40f2b3cce19d391e00d3"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A9B7372E-3C69-48CE-810B-2D623912A656"/>
    <pav:lastSavedOn>2015-10-29 09:45:11 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:fcd7357a-26f2-46e8-8690-45b11a373a73</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6351F1D0-8091-47FF-9C3E-F0AD612A8179">
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5A1B37FD-3B9D-444E-BDF9-388BAB48887F"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmax>2 to 10</dikbD2R:cmax>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2D010F3C-304F-490C-BEE3-BF7E867EC5EF"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:873D3CFB-0F82-4177-8E17-11CF268DB883">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N2624a815236a4ce898ad3239fe41a528"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-10-27 15:31:15 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-27 15:31:16 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:E5B1DB9A-30E0-4F29-B4CF-644F8520E116</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7D74D48F-FE26-442A-9CD1-BE6D3AAB0CD0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a4de8a69-aeba-4cb8-a243-cdf491e30382">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:hasSource>
    <domeo:uuid>cec221d6-6d63-42e6-aa8f-c8d988a9e2e6</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:062595f6-59e2-49e7-988d-2011bf9abab9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:87BE57B5-2BAD-4490-939D-9A43FEFEF37B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:08B5EA17-3190-479E-859A-95B04924B522"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CCB3039E-BFB1-4214-96F5-B83479DFB787">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>propafenone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3482EC00-F34E-4A86-9427-08C44E43DAC4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3482EC00-F34E-4A86-9427-08C44E43DAC4"/>
    <ao:exact>TCA </ao:exact>
    <domeo:uuid>3482EC00-F34E-4A86-9427-08C44E43DAC4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (m</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <pav:createdOn>2015-11-05 10:36:30 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:86DCADF4-8760-4542-8980-77F72E0F44F6">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:a2e65c35-2d92-4b21-a9aa-0b2ffa99c377</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-28 17:22:12 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-24 15:38:09 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f1c7e613-a179-4038-8850-6a0a37369faa</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:ba48ba0c-7ffe-484b-a8a9-fc87211f7494"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="Nf662a8d6686e44429496fa17c9bf9a3f"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9B4B8432-3C36-4730-8632-45BC14A5B023">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4F885F18-A22B-4E57-806B-38A9FE31D96F"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DD34A168-80AF-45E5-9E93-ACB3257B5CB0">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9B7003CB-BB99-4A92-A8D6-7E0E9FF488E7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bd882a7c-3cdf-4966-bac9-f2170eb6535f">
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:d4c5b460-30ac-4f01-95b7-c30a9f741af6</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:555B1075-C935-454E-9F61-0D1D762CE9F7</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:6BDB144B-BEBE-41B7-9CBB-B402D8C7AC84"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nd5a79912a47b4fb98c23c80c33d0d2b5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-16 15:31:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A1FCBE3B-2E25-4D35-B1D7-9811D3F113AF">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/406476A8-071B-4A70-A095-F35D3C11B4CC"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B904ADD5-BC92-492F-8D2B-B5D8F9C19A80"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2AD2635B-9C45-4B85-AFEF-FAA086B0A351">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>6</dikbD2R:numOfParticipants>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BE7DDE94-24BC-4324-9856-F896DC577B26"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D89E6669-526A-41B2-AD15-B08DC587227F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b1c973c4-c699-4d2b-af34-25571732d51d">
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/13b46c48-1551-4f30-aca0-e4a6a0606766"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/84ad187e-7fdd-42bb-8964-df89e8465523"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>1.3</dikbD2R:auc>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8ED5E692-F32D-42E9-A802-F0941D286A1A">
    <domeo:belongsToSet>urn:domeoserver:annotationset:09FE9163-3F21-491C-94F0-EBB12BEF6F16</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:829E94D5-16C6-4C3E-99A4-1F1AC0162A39</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-29 11:29:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:610BE8DE-3A23-4126-BF22-C9802248CEC2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c2554a22-a850-4127-a501-5c45c9e5faef">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6046ff91-fde2-4f97-9602-33a29a65bd4e"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ed207b06-cfd8-4ee5-8e75-33e82defe23f"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2bb96f9b-fe8f-4c41-89df-f7d5718c57da">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2015-10-26 15:36:05 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:994b3987-a688-488a-83ec-76243da34598</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6252181e-2778-4810-b740-fe9ddbcd08f0"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-26 15:36:05 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2402aa21-3e6a-4617-80ab-68f5acf65a56">
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:6d9fd086-1348-4ef3-9f33-0b8ee5ee97eb</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:33c3871d-f58e-4717-bd54-9cc8db773681"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N03c9830a683040078f2c54fb507eca7f"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:c52514e5-fd16-4224-8a9e-fa8b01107be8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A3CFFDA4-057D-4098-993F-84B80DCC85B2">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9F47AC04-1EB8-4851-A741-3F51527D4017"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0C138572-0533-4877-9861-BD4CE935C3FF"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9005E612-DEFD-4B7F-8FA7-F593C5D62654">
    <domeo:uuid>9005E612-DEFD-4B7F-8FA7-F593C5D62654</domeo:uuid>
    <ao:exact>Ketoconazole    Seven-day treatment with ketoconazole (200 mg per day), a potent inhibitor of CYP3A4, did not affect the steady-state pharmacokinetics of selegiline in subjects who received EMSAM 6 mg per 24 hours for 7 days and no differences in the pharmacokinetics of ketoconazole were observed [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 14:12:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9005E612-DEFD-4B7F-8FA7-F593C5D62654"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CD6A0ECF-BD80-499C-AE72-8CB5A55A2F46">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdfs:label>selegiline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34ce721a-b2b1-44e3-858a-7a6cfbe633e8">
    <ao:prefix> Immune-Modulating Therapies   </ao:prefix>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>4b4a9d5e-a79d-4ceb-b7c6-63ffa99ebfcd</domeo:uuid>
    <ao:exact>Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8065299d-136d-428b-bb7b-b274b88a87f5">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>imipramine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B35F575C-C858-4647-A75D-FFDF26747A6B">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptDuration>11</dikbD2R:preciptDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5B0C656D-DC3B-453A-9B1B-3048733D55CD"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/89DD806C-4753-49A5-9436-5CD201BABD13"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6e1bf271-6425-4eda-b438-479632c1dc01">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>a0ff7b51-8305-4681-b4e4-6798c9c9871e</domeo:uuid>
    <ao:exact>There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following repeated doses of teriflunomide and a single dose of 0.25 mg repaglinide, suggesting that teriflunomide is an inhibitor of CYP2C8 in vivo. The magnitude of interaction could be higher at the recommended repaglinide dose [see Drug Interactions (7)].</ao:exact>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <ao:prefix>er Drugs    CYP2C8 Substrates  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2471FCCA-2C5F-450F-AFFD-210CAF332992">
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1E42F6B1-6D16-46D4-9D9C-6C8C2FA0E227"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <pav:createdOn>2015-11-04 14:18:35 -0500</pav:createdOn>
    <ao:body rdf:nodeID="N978d28361c034d41b40fe3ca313ea5de"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f50a8cfd-0afa-4395-8a23-47a8d03b3380">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N5564150b746b4820a785d02b5b9f9bb9"/>
    <pav:createdOn>2015-09-14 10:25:07 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-28 14:38:28 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4FFBE488-8351-432D-91F9-4EE04E021A00</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:f76af48e-d8b3-433a-8842-2302f09c14ea</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4CED261-084C-41BF-8E10-C9F684AD3940"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8eab6ae3-5bd1-4845-8b79-9eece52cf228">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9db617cc-4cc4-4a22-8fd3-f94334b441f7"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N260470b89225488b839d8b67886c6117">
    <domeo:sets rdf:resource="urn:pddi:uuid:F3EB56B6-EC97-4D62-AC33-69410D3C3670"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ned8a07a0b88c43178ca40c775b291dff">
    <domeo:sets rdf:resource="urn:pddi:uuid:54BA2B86-CE76-4B15-9303-B5AFCC143189"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:CBA0B0B2-92E5-4B9D-AB23-DB1E1723AB92">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:47b7806e-93c8-4fff-b03b-13f2573490dd</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:d10d8722-e0ad-4a5c-ae3a-9941092a678b"/>
    <pav:lastSavedOn>2015-11-02 14:27:26 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:38f47611-b30f-4637-b6f5-0f5230d59bc7</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N272f4d29c8ab4504b374d0a7bc143dee"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DDB09D95-8435-46BD-BE86-4F8DEEBA5E66">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdOn>2015-11-05 15:31:22 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:79417F6C-DA72-4057-938A-8615D296B733"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Ne379fea10d634edeba3f16ca8813eade"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:31F40E8C-65EA-4FEF-B949-615B81F92506">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E646185A-9C81-4B34-8A0A-B763F591CBD5"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D62A9890-1032-4015-8785-729A247627D5">
    <rdfs:label>imipramine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F49C4F1-8C35-4B06-967C-710EA6BE82E9">
    <ao:prefix>with potent CYP3A4 inhibitors, HIV protease inhibitors , </ao:prefix>
    <ao:exact>azole antifungals</ao:exact>
    <ao:suffix>, </ao:suffix>
    <domeo:uuid>7F49C4F1-8C35-4B06-967C-710EA6BE82E9</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F49C4F1-8C35-4B06-967C-710EA6BE82E9"/>
    <pav:createdOn>2015-10-29 10:39:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4BE1ACE-0602-403B-964A-242B96EBDDAF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Levothyroxine    In healthy subjects who had received EMSAM 6 mg per 24 hours for 10 days, single dose administration with levothyroxine (150 mcg) did not alter the pharmacokinetics of either selegiline or levothyroxine [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>D4BE1ACE-0602-403B-964A-242B96EBDDAF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-27 14:13:17 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4BE1ACE-0602-403B-964A-242B96EBDDAF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4542AA2A-08CE-4CD4-BB7A-30435925C4CA">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoclient:uuid:a80a885a-21a8-41f6-8e6f-1f2c43009aaa</pav:previousVersion>
    <ao:body rdf:nodeID="N0da9c05411544c54a1a1e6e8347952c6"/>
    <pav:createdOn>2015-11-05 15:21:27 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-11-05 15:24:24 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:22E3D5BF-8FEF-4BD9-BE43-5D35A4DE0120"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6a07c639-4fda-455c-b5ff-960c32b06834">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:33e06587-43de-473f-912b-ab91453c5405</domeo:belongsToSet>
    <ao:body rdf:nodeID="N3cdfb965e69c4ee58b4863dfd2fbae19"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:1b43bda6-818c-4649-b43d-a554b505b5b2"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:908898b9-f58c-446f-a943-9d2c3518ffae</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C963BD83-FC2E-4C9F-BC3B-03ED3156CD41">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C963BD83-FC2E-4C9F-BC3B-03ED3156CD41"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>C963BD83-FC2E-4C9F-BC3B-03ED3156CD41</domeo:uuid>
    <ao:exact>Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <pav:createdOn>2015-10-27 13:24:55 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433">
    <ao:item rdf:resource="urn:domeoclient:uuid:B8AE83D3-0280-4B36-9E78-089494988065"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A9A9EB19-D8D7-495B-B220-E480F358A6B4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EB9584DB-2B31-43F8-948B-D1E99BE0ED29"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:021AEAFE-0B52-4478-910C-30BB5578CF2E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8DDBD5CA-FB6B-4D4D-BDBD-F19852E3D3E6"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:9EC5E026-38F9-4C27-A73A-EDABAF308CA2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F84CF2A5-400B-49CC-8DE4-63DCB5246C8C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:79144D90-8F25-410E-B7D9-583DD5E71DA9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2471FCCA-2C5F-450F-AFFD-210CAF332992"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:9CFA0214-E245-462A-B431-39BDC3A7B02A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1422CE8D-F3C4-40DD-B50E-E19B70A9C645"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:56CE6883-91AB-4795-B3FF-4FEF027B21CA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:906F3FA6-8000-486A-B628-F0F7EEA2E6F5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9715997F-2002-4E04-A15D-A06859A12C8B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A3504868-B1EB-4829-BD98-37C2A863F17F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8757D17B-8E07-4FB2-B697-37BBB1429A7F"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CFC9B2CF-3F31-4A14-94C9-37420FD3E25F"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0D5ADBDB-7146-43C2-8DB6-71FA9248929D</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:7543B431-8ECB-455C-A470-42B5D47CA644"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1232A1FB-E79C-4412-9A8E-E1A5CA0D8714"/>
    <pav:createdOn>2015-10-26 15:38:26 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:annotatesResource>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:878D979D-590C-494B-9A86-F9A71357DC10"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:78C8A78D-BC0B-41EC-B63D-B9866D87DF36"/>
    <permissions:permissions rdf:nodeID="N45074c9cb3404948a004a5bf5492fcc7"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/cd23061b-83ce-4129-83e5-bc28e53b6ede"/>
    <pav:lastSavedOn>2015-11-04 14:21:12 -0500</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:6686CF4E-F395-4A00-9B7C-24E29A14028A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:81A9031B-88B8-436E-B2E2-9A08647FAD62"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C6B7529D-3CA2-42D4-8C8B-E0D23C3DD1D9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:629AB3EE-7925-4673-A859-BE58ACD16E71">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-10-27 14:16:44 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:629AB3EE-7925-4673-A859-BE58ACD16E71"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Pseudoephedrine    EMSAM 6 mg per 24 hours for 10 days, co-administered with pseudoephedrine (60 mg, 3 times a day) did not affect the pharmacokinetics of pseudoephedrine. There were no clinically significant changes in blood pressure during pseudoephedrine administration alone, or in combination with EMSAM [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <domeo:uuid>629AB3EE-7925-4673-A859-BE58ACD16E71</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:454a4298-5ee3-47bd-9bcf-01f8db203d24">
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Ne2a7751ad83b41798f9ebd0abda6464f"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:de99662d-88b8-4cce-b7a2-8da3680c567e</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:6427fe63-8aa3-42c4-b8f4-3a5cf619af33</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:1c6e122b-aa6a-4657-be4c-815acb4666e2"/>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:62A5F1A2-FEBD-438B-9D5A-2E6D98358166">
    <pav:previousVersion>urn:domeoclient:uuid:4e02827a-68f0-4386-9103-e240c7d4c4da</pav:previousVersion>
    <permissions:permissions rdf:nodeID="Ndfe9d6b1d2e84bf5a60dab6ce527b12c"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-24 15:38:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2015-10-28 17:20:53 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:7a84140d-0985-4ee7-a95a-bb06e3f813bc"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:6d01c11b-ed99-443e-93f9-998dc4ebe79f</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ECA0147D-A883-4690-B967-2814E7616BE9">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7626439D-6862-44C2-A493-3F7DC61F0170"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>31</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/30A4DA43-F737-46B5-AC51-E4D39AEB3B72"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>16</dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:bad6d0b8-6028-41d0-867a-a665f030262d">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:cdab081c-2536-49df-9581-5f0639e22882"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N00e7ae5447ba4bdf9e6f997073226ef2">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d9ad2e5a-6eb0-48a8-b9b2-4caaf6488bee">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>nsporter 3 (OAT3) substrates   </ao:prefix>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <domeo:uuid>1b242b86-0c9a-43aa-b2dd-e65807db20a3</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:3901971F-C222-471B-A82C-004E188A07CA">
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N01c6b55f7b7840838f8633df88752cb3"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:a6b5f493-b8ae-409d-8b16-ec6fb8164929</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:b1137d71-70f4-4a68-af08-55209a1dfb87"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-09-24 15:47:22 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:65DE1162-8FDF-4113-A0E9-5C70855CDFE7</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-29 09:30:25 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f32795c4-d05c-459b-8767-05c7f83a782e">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:b62571cf-cc53-4b66-82ff-14271a96513a"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:257b60d6-6ea9-47ce-9632-3b3d4cd03686</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Ncdde6d3c28eb470284ff8329b76f1af2"/>
    <pav:lineageUri>urn:domeoserver:annotation:9c5539ae-3c8a-4eca-bb75-722bb8eba2f4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6D49F60B-A05B-4BD7-A809-51FC2F326469">
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-27 14:25:26 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:B9F75EAB-A75D-4664-A915-3EC4552F4132"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ad13a882-c1d3-44b4-8e1d-50f85ad3be9f">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8830e691-36fb-4c4d-8d27-b7482920ee0c"/>
    <dikbD2R:auc>55</dikbD2R:auc>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0afd341f-828b-4020-8886-b1d5dbba6ae3"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6d64278b-00ce-4b9a-b318-3b31b2d476f7">
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
    <domeo:uuid>761c76ed-85fb-4b41-be46-ccd9b43eb34b</domeo:uuid>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:9B2A10FB-A843-483F-ADE7-0BBF5CE7A00A">
    <pav:previousVersion>urn:domeoserver:annotationset:904F73B2-54B0-4B45-9979-B95BE2418BE7</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:cd4b1fdb-c7de-461f-87d9-d0e844e9fdbb</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-10-29 10:48:13 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4cbc767f-9c50-4043-b361-69cc86d1da58"/>
    <permissions:permissions rdf:nodeID="N2d3e2d6829104446a01ac7e434e8d68d"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF0BEAA2-8D19-4721-84FC-193CDA5000A0">
    <ao:body rdf:nodeID="N9204a0cd176d4745b1587a56f6f01d73"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3D1806BB-FE81-49F6-AB8F-3E00071D634F"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-04 14:10:24 -0500</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:9f66b4af-6083-4081-b81c-bd2656e0280a</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:21ab3694-0521-45a0-aac4-063bbf59cd54</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-04 14:10:24 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44646423-61e2-40e5-90cd-8bd6645b0311">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:f639e5bd-9ebd-4806-9d30-c2a70cb606fe</pav:lineageUri>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Ne93322c661ae46a6aae9b8c81ce4ae6e"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:86de9401-7ab3-4acb-b90e-5d14dddfb9af"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:0480ffda-e35d-478f-a6ea-7cbd43129679</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:498307F9-9F27-4AA4-A5F2-0CDEFE98C185">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>498307F9-9F27-4AA4-A5F2-0CDEFE98C185</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>AIDs, Aspirin, and Warfarin)   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are co-administered with warfarin. Concomitant administration of warfarin (2 to 9 mg once daily) under steady state conditions with duloxetine 60 or 120 mg once daily for up to 14 days in healthy subjects (n=15) did not significantly change INR from baseline (mean INR changes ranged from 0.05 to +0.07). The total warfarin (protein bound plus free drug) pharmacokinetics (AUCτ,ss, Cmax,ss or tmax,ss) for both R- and S-warfarin were not altered by duloxetine. Because of the potential effect of duloxetine on platelets, patients receiving warfarin therapy should be carefully monitored when duloxetine is initiated or discontinued [see WARNINGS AND PRECAUTIONS (5.5)]. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:498307F9-9F27-4AA4-A5F2-0CDEFE98C185"/>
    <pav:createdOn>2015-10-29 09:30:05 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DF926A4B-CD53-4A10-A541-15C8C71AD1A1">
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E4BB4DEF-0D75-4F18-A457-0725077929FD"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmax>38</dikbD2R:cmax>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F4DF85CF-6385-415D-BBC2-3A90824C5845"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>85</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0E69B322-8A4B-4DE9-B274-E5D5CEC877D7">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/54B987B8-831B-4EEC-AA4D-9A1D6801708F"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A641BAC9-3C21-4625-B587-6449FBFD51D2"/>
    <dikbD2R:preciptDuration>8</dikbD2R:preciptDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectDuration>21</dikbD2R:objectDuration>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmax>39</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:auc>43</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ace8823f-9600-451d-8810-5bc17e3898ff">
    <ao:prefix>see Drug Interactions (7) ] .  </ao:prefix>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).</ao:exact>
    <domeo:uuid>8233aa4b-3be6-4057-b503-ff480d3472fb</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/152FF263-6CA7-447E-AD60-F819C3B36F4E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B613EFD6-04C9-4350-98BA-6C3385DDF2EA">
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:e6e4e960-a193-4c1e-8a99-0e747f2e6107</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:72852bd1-938e-42fd-82fc-d0ed3051fcb2"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:6f36c711-ac6a-4b74-bbe2-b1abb6d1e55a</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N9e0a51312049404e896eda603f8c39ac"/>
    <pav:lastSavedOn>2015-11-02 13:56:21 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A38C9832-E37C-497A-8410-123D736CEBF8">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ED469DA0-660F-4DA0-B689-AF741C45CF8F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26c22ae9-8b56-47b1-9fe8-dad7802e72f7">
    <pav:lastSavedOn>2015-08-20 11:17:13 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4bd89788-6e1c-4fb9-a21d-586338a8c2d9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:cc4881c3-0158-4f78-9669-ecd668543b0f</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 11:17:13 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N2f02e557b83d4de295ac617f530477c2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3de6cb16-92ce-49e2-b57e-474c82c00b31">
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:a8defcb3-3817-44e8-809b-8cd4dd24fd9f</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:6a9da872-1768-4766-9c43-3f133009420d</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N354826b58c2e4326877565f703e04570"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:d7ebf644-59c8-4910-9b1c-734f99863ce6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D272258B-AF8E-464E-B6FD-60953E36BB61">
    <ao:exact>Fluvoxamine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-10-27 14:22:20 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>is a potent inhibitor of CYP1A2 and tizanidine is a CYP1A2 substrate. The effect of fluvoxamine (100 mg daily for 4 days) on the pharmacokinetics and pharmacodynamics of a single 4 mg dose of tizanidine has been studied in ten healthy male subjects. Tiza</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D272258B-AF8E-464E-B6FD-60953E36BB61"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:88986DD6-354F-4EFF-8F9C-F86E4612349E">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4C80BE51-7CFC-43DC-B631-77858E0C5FD1"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0E2BE91C-77AC-4D82-BE84-077C18551974"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>10</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:FA6E3D16-2F6D-4EFC-B607-E400E4D673DB">
    <rdfs:label>NER Sets</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-10-26 15:38:58 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:F05C56D7-4CD4-42F6-A8FE-779097F20087"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-10-27 09:16:54 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:81de54ca-ce00-472d-81f0-a1da870cf9e3</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:50710251-c1a7-4ab0-9343-d3c82dd20bfa</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/7b5176af-defd-4d7e-af90-32b9fdf0c797"/>
    <permissions:permissions rdf:nodeID="Ncea2d4dace4143bda54c2b0a9a99069d"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D5DD1E34-940F-4606-8DA9-E72F658D29B9">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:bf38e6cc-243c-48b3-ad3e-84cc000009e3"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-28 15:26:32 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:72144331-5246-4df1-b88b-a6f0c83b5fcb</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:97dc7b28-09a4-4a6c-8dd4-16dbd5786fc0</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N99b159222610472ab8d253906b608c15"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C7AD6DC1-3160-45B1-AB05-72F7BC8BE3AC">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AF81C836-72F6-4534-AF05-F76926D461AB"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/262AA3E4-378D-462F-9325-EF6516AACE0A"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4090A61-420C-4451-8E06-1D335F7E7D76">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Ketoconazole    Seven-day treatment with ketoconazole (200 mg per day), a potent inhibitor of CYP3A4, did not affect the steady-state pharmacokinetics of selegiline in subjects who received EMSAM 6 mg per 24 hours for 7 days and no differences in the pharmacokinetics of ketoconazole were observed [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <pav:createdOn>2015-10-27 14:12:48 -0400</pav:createdOn>
    <domeo:uuid>F4090A61-420C-4451-8E06-1D335F7E7D76</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F4090A61-420C-4451-8E06-1D335F7E7D76"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b88e2107-7294-49e5-bc4d-fdbc185edaab">
    <rdfs:label>ritonavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CE013527-AFE7-452A-BED1-B877E1B5BB53">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B87CCB4D-9591-41EB-9B0E-35AFB8C2A6C6"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:auc>95</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AFEA092F-A14C-4CD1-BB29-86D0231890B9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BB683AC0-8B9D-425E-B8AC-8420C9115DDF">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EEFEB881-A5E0-4B31-B687-86A0B7E22F71"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:0FC91DA4-6ED1-411B-9877-77E98B69CB2E">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N4a96e95c39a9410f8dc1543dcef0d1ed"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:52efb2e9-9018-4de5-9351-4a3a5c1f523e"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:db8cca5a-1f79-49fe-b38c-2dcc7d141bf2</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:88ed68cd-a39f-4fca-9465-eaff65e06869</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:021AEAFE-0B52-4478-910C-30BB5578CF2E">
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A72D1BE3-A365-4956-8523-775DBA27592A"/>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-04 14:17:35 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/88B3779D-F888-4CED-8B26-F1734F8D457B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:992e1f09-7e0b-47d5-a4c9-94e09c6eb442">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:cf091acb-c26b-4d0e-a3ca-64d4b84ff90e"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/92ff139f-ebf2-41c8-a3b8-60ce94ee3d43">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <rdfs:label>lorazepam</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>50</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D2C0DCED-F203-4E56-8095-93413ED156CD">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N5e6e3ad7d40d439e827fd855e6c4def4"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-10-29 11:09:04 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3e579c4-0682-4544-945f-a38cd229445f</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:fc8d2d6a-5089-472c-9680-14b0687c4ab6"/>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:ec33fcaf-a17b-4fba-ad67-64a23059e791</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5c962074-6934-4690-8232-84ea412d2b25">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:313ef7f4-70cc-4328-b572-9320b6736ccf</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N83e6a36d201b42f39a29fbd5984f44c3"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A904ED53-6540-41CF-A820-BE05493B3448"/>
    <pav:lastSavedOn>2015-10-28 15:23:30 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-14 11:03:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE30BA3A-EC97-4FF5-AD74-D796A845417B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CB51C0E9-51E7-4453-A999-418ECC4D4271">
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C4D7B940-55CD-4FF2-9F07-2AC3E28AF9C5"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0D3E37EB-5715-4D3B-8839-B544C0318C25"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:703f6d49-f622-4114-b7ae-3038d70cc2f4">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/cda6160b-7a52-417f-a8a9-78de32ccfce8"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2de13a78-5394-4708-b9d9-330402d73860"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:auc></dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4DA5AC1A-6B23-4C8E-B169-F07C285ACB2A">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:905DAE6E-BEF6-4FFC-9532-867CF5C95BA3"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:db0e1f27-51bf-4c3a-81fa-a570c5d8a9d0">
    <pav:lastSavedOn>2015-11-03 12:56:19 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CC25777F-B8E5-46FF-A194-D243F2B44210</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:7897771e-8a7d-4ac4-9858-7cba40f5f8fb</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:69ADAD32-DA3A-4C4D-843F-342B189EFE89"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N7ab6aab85c3b4b398f84438a88823955"/>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9EFB92F4-975E-4F86-9948-F021DBFAE845">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">23</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:2A1CA4C2-69FD-4899-A78A-8E053D6C80C5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:751FBB26-E5EB-4878-A2EA-2B9845EC5906</pav:previousVersion>
    <pav:lastSavedOn>2015-11-05 16:07:34 -0500</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdOn>2015-11-05 16:06:46 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E37EA565-D7DD-4EFB-BFEB-50EF8130F62B">
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:830D5D6B-C940-441B-A31A-9B0C4421863B</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-05 15:28:35 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:83262D58-1DEB-46D2-9ACE-E2E2411339F7"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdOn>2015-11-05 15:28:32 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5EB72BDF-FA05-4439-8879-E53DAC77CBB3">
    <pav:createdOn>2015-11-06 15:46:55 -0500</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-06 15:56:02 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:7D07AE07-E7AB-4DBE-940F-5C3753A85D3A</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:FE74DB2C-6DCB-41AC-AC68-5F4BAED43826"/>
    <ao:body rdf:nodeID="N8a9402c368c84e92bfb898e579e4a163"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09438C0B-85B9-412C-AD28-3D09EF0E7ACA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Interaction With Carbamazepine  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:09438C0B-85B9-412C-AD28-3D09EF0E7ACA"/>
    <ao:exact>The coadministration of carbamazepine 200 mg BID with nefazodone 200 mg BID, at steady state for both drugs, resulted in almost 95% reductions in AUCs for nefazodone and hydroxynefazodone, likely resulting in insufficient plasma nefazodone and hydroxynefazodone concentrations for achieving an antidepressant effect for nefazodone. Consequently, it is recommended that nefazodone not be used in combination with carbamazepine (see CONTRAINDICATIONS and PRECAUTIONS).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>09438C0B-85B9-412C-AD28-3D09EF0E7ACA</domeo:uuid>
    <pav:createdOn>2015-11-06 15:44:45 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fb350350-0137-457b-ae9c-c95d3ce0ed46">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:ccc0ed5e-fb0e-4d9c-ba6c-f2ded1050c0e</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:a6f1e57a-796d-4d50-846e-2c28539f7b8b"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nb1b3e580850741689e1922fa655cecdc"/>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:a96702ae-a3f2-494b-bd27-5146edf90452</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C670D2A-ED8B-4504-8A4E-4F270B3AA666">
    <ao:prefix> is reported to reduce hepatic metabolism of certain </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3C670D2A-ED8B-4504-8A4E-4F270B3AA666</domeo:uuid>
    <ao:exact>tricyclic antidepressants</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, thereby delaying elimination and increasing steady-state concentrations of these drugs. Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3C670D2A-ED8B-4504-8A4E-4F270B3AA666"/>
    <pav:createdOn>2015-10-29 11:11:37 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6CED04B2-3B40-43F9-85A7-7F7B118E1020">
    <pav:createdOn>2015-11-05 16:04:09 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BCBBFA9D-EEC8-42EE-B456-ADAEDC906CF0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-05 16:05:45 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">22</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:4F598533-EB1E-421C-AADA-97962DA8B220</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DB75D1B8-BD87-485C-99C3-4AFE5D221AEA">
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B7150E40-97A7-4D99-BCB4-48BCF3DB490E"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cl>35</dikbD2R:cl>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ECEB36F8-4F28-49AD-81C8-67E8B7F65193"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF03119B-C10F-4EBC-9066-5E530D1EC804">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-29 10:40:38 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:1E320F65-4CEC-42FF-AD4B-2FD2CA437883"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-29 10:41:13 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:e5208d0d-d470-424b-a0e0-4a4b5da16c0e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Nf6a2401529d546aa8ea0dccf7b5fc44c"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E536FE66-FAD0-488D-B7C0-39E59CBD9678</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:9540ed61-ff6a-4399-86bc-04d7b87b26df</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:1D62F0FD-B317-469D-8729-9DB0ADF6D587">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N9d2530731bb5482c8be75450df59553f"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7014615f-a989-431a-bafe-bda154de4fb1"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:874a54d2-a175-4fda-af08-5729cbe9319a</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
    <pav:previousVersion>urn:domeoclient:uuid:2fdaa522-bd39-435a-8746-8f62ddd08c2a</pav:previousVersion>
    <pav:createdOn>2015-10-09 13:32:08 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-28 16:46:43 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:31F0D165-0794-445D-8066-39BDFE176116">
    <ao:item rdf:resource="urn:domeoclient:uuid:94b8748c-175b-4f25-b1b7-704cf6034cd6"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:27439b41-21ab-4498-90a7-d17a6773631f</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:00200feb-365e-433a-8c27-7c739ebcea84</pav:previousVersion>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Ne823657d4b914ea7b067f31f6bcc3b44"/>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b7a75c7a-0f92-407c-8af7-00ea1796b873">
    <domeo:uuid>3878f25b-2bb8-4dac-89e2-68ec3118f33d</domeo:uuid>
    <ao:exact>Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes.</ao:exact>
    <pav:createdOn>2015-08-20 10:29:59 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10375a83-5d58-478d-8b53-d21699603367">
    <ao:exact>There was an increase in mean ethinylestradiol Cmax and AUC0–24 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC0–24 (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide [see Drug Interactions (7)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <ao:prefix>(7) ] .   Oral Contraceptives  </ao:prefix>
    <domeo:uuid>f0f8fc14-ba45-4e84-a0fc-c6bf69a44ee0</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2c82c4b8-1419-474f-93f7-d90bc18455a7">
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1b719f83-4360-4200-829e-80ab0390c854"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/435bb8ee-22ab-4b1c-8151-d2798b4b94d4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c20c8019-d6f5-4d1b-9d08-696fc3405464">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:24e474b9-768b-4b59-99f3-88d632e635df"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0FF0A8F1-628D-4598-AAEA-3A7F10AA518E">
    <ao:exact>In healthy male patients (n=24), carbamazepine (400 mg b.i.d.) increased mirtazapine (15 mg b.i.d.) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 60%.    When phenytoin, carbamazepine, or another inducer of hepatic metabolism (such as rifampicin) is added to mirtazapine therapy, the mirtazapine dose may have to be increased. If treatment with such a medicinal product is discontinued, it may be necessary to reduce the mirtazapine dose.</ao:exact>
    <domeo:uuid>0FF0A8F1-628D-4598-AAEA-3A7F10AA518E</domeo:uuid>
    <ao:prefix>  Carbamazepine  </ao:prefix>
    <pav:createdOn>2015-10-29 10:34:14 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0FF0A8F1-628D-4598-AAEA-3A7F10AA518E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1EB799F8-3FCA-4858-BCD1-94F69D4E37C8">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C9784705-7323-40F4-A671-8C59F2C2E8B3"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BAB2886E-1076-448F-AB1D-DF31180FC269"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>24</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e9818f5e-9bbd-41ec-98cc-7daad01aec97">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d9251d83-cbcb-45b5-abe5-4b415b738b14"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5fe21ecc-56d5-4754-a5cd-7fad59e956c5">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:5a9358d5-fa2d-4348-bc88-3229c434cd1c</pav:lineageUri>
    <pav:createdOn>2015-08-20 11:32:27 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:0826dacf-9806-4cdf-85b1-e61256b81be8"/>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N4afa184f0b994f64a3c26449f2699822"/>
    <pav:lastSavedOn>2015-08-20 11:32:27 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:74B6C9D1-3EE0-4CD7-A3D7-D4CA1732386F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N871c41f606b24559be65d4bee00deb32"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-27 14:13:55 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:d7725cfd-900b-4965-a02e-4c01df9fe12a</pav:lineageUri>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:165d91e3-8a76-4562-b2f9-b66d53316f3e"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>urn:domeoserver:annotationset:EC5D0CF7-A01C-486B-8C77-2C9E8F01EB7E</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd695f83a1dac40ebb759b308dcb60bce">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ab047d4-d254-4885-91ec-df0fcc1a22f3">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N30493caa12e946f6961d9ede5f168c08"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:870efd42-c0e4-4bbb-901d-46ad988e85a8</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:ca960edd-b53c-44d5-bba5-4795cb80b9a8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:bbf41883-bfd8-4244-833c-3ec91a16e806"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b191020a-fd09-45cd-a698-c126461230a3">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:8a42c678-10fe-4aef-a024-493695f78fe4"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:6874e1b3-0789-4c5d-abaf-7356de826a66</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Nc78546dc81de40b9923d2f73996718e6"/>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/286e3056-d44a-4d61-8531-78bc83f29d2f">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29a153ba-9210-42a0-a383-6421247e28fa">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:3db8290c-8561-437e-920b-98793428a995</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N25df53743540483493c94712d6445c37"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:e987ce6f-4579-45b4-9065-834f79fa8294"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:1549f966-a931-4fa6-99e6-bb99dfc8fee2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N871c41f606b24559be65d4bee00deb32">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:905c58e5-3722-40e4-b31a-b39167600429">
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/40cce96c-7f63-49f9-8bc0-52b7552284f9"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/314968b4-f1e7-4367-bc08-aaeadfba1eed"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16bb992b-d01a-4812-a4ad-4fb7faa04c59">
    <domeo:uuid>ae67518f-5502-4413-afb1-8b1fa3e766e9</domeo:uuid>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:08b11b32-6119-4306-a70c-a1b1a7e5a570">
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>1.7</dikbD2R:cmax>
    <dikbD2R:auc>2.4</dikbD2R:auc>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/bfbdd8a4-ebef-47f2-8f51-7c8914730eca"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/cae3fc36-8a22-412e-a360-864098cf8258"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C54E6622-AA86-4D40-A887-092EA65F0BC2">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F150CE21-F727-434D-B914-C86D3F1D1E74"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E5CDA3E2-B50C-46D0-B521-358756C618CB">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:69b3a8c2-2106-4b01-92d8-e5285ad6da2c</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:1470d07c-375e-4080-bb71-2a0c3804de10"/>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="Ne7e6095a2d5c449092b53ea00366004d"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-02 14:48:13 -0500</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:1cbd1377-944b-4b5b-bc99-84b592c01041</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:48f140e0-21bc-4490-8bc8-1d129166ebe7">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d3161b66-53c4-43bb-9d97-caf52979ed83"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:25277176-7CB9-438A-BD6D-E351F32825E7">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:4c5ca0cb-3dbb-425f-8296-47643cb679ab</pav:previousVersion>
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:4d86ea2d-7fc3-4586-8c48-280af5523b26</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:27bb3a19-c554-43a5-b824-2f2490ef5a90"/>
    <permissions:permissions rdf:nodeID="N83ac88a9f6514cd8a793f5aae6787457"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AC8BA089-5DA6-48A8-A88A-2C36A10CBF4E">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8E66559D-1344-4165-875A-990BD8968C67"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1695E16A-CCD8-4D1F-86A4-AF7C1BAC36A8">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6623B1D7-FECC-4EBE-B01C-2AA1E4F528C8"/>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/88B3779D-F888-4CED-8B26-F1734F8D457B"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:363E28C3-53DA-47DF-B559-C09024DF0B0F">
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N4118820bb7ef43de82b1ff667b7367d2"/>
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-27 14:26:18 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C8C69CF3-92B5-4335-8221-AA495100DE39"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5E869193-267D-447D-BA12-D914DE0E9BB7">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4AD05388-C1D0-472C-A129-60F73FF73E80"/>
    <dikbD2R:cl>32</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5FB81420-6ABA-4A37-BA68-CBB96D7C3C1C"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>IV</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D3D3E35D-45AD-4DC0-BECB-AAB713508F71">
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1F973256-10FE-4D92-88DD-E736959600A8"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cl>10</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9D7E039B-4D66-4366-B79F-EEEDC4561511"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>21</dikbD2R:auc>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C58292CD-9C7E-48D2-9400-4A40A04E2506">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 14:28:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C58292CD-9C7E-48D2-9400-4A40A04E2506"/>
    <ao:exact>When fluvoxamine maleate (100 mg q.d.) and alprazolam (1 mg q.i.d.) were coadministered to steady state, plasma concentrations and other pharmacokinetic parameters (AUC, Cmax, T½) of alprazolam were approximately twice those observed when alprazolam was administered alone; oral clearance was reduced by about 50%. The elevated plasma alprazolam concentrations resulted in decreased psychomotor performance and memory. This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is coadministered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100 mg to 300 mg. If alprazolam is coadministered with fluvoxamine maleate tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended. No dosage adjustment is required for fluvoxamine maleate tablets. </ao:exact>
    <ao:prefix>   Alprazolam  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3d5bf9ae-1c0e-43e6-890b-585e9b48a857">
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N9f93c4a9afad4d04b0565200aaedc455"/>
    <pav:lineageUri>urn:domeoserver:annotation:a0cf8f28-0718-415b-8215-908d3bb1b87b</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:183e162d-172e-4e51-89e9-be54836b04e2</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:c397f117-3ce0-422f-8772-b02afa3e8958"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/28a4164c-b385-4cd9-9579-52dee3a3d025">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>phenothiazines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:23b7ef5e-6ef2-4b6d-a10b-72d563a454db">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/c35dbfb9-2e51-4dfa-9f42-c5c2217782b5"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/32eb83b6-00ce-4efe-a5d7-1f5654551e88"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6fd9a3e6-0e65-4886-9154-6a1be77a73a5">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:1b5fc232-c084-4970-833a-b171cd706975"/>
    <pav:lineageUri>urn:domeoserver:annotation:94b44b1a-4a3d-40a8-8289-7b7a0a3eeb48</pav:lineageUri>
    <ao:body rdf:nodeID="Nc5c454eda46a490788066cf3a88eea6a"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:33607660-b714-4ca7-b211-e74448060e1a</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne962070e479c447788fb99ff2e13f9cc">
    <domeo:sets rdf:resource="urn:pddi:uuid:3E3217F7-B3C8-43E2-ADA0-8C60C55F248A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:bf1d4d4d-7e1a-4484-8b53-5d78a39546c8">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ab4bebbb-9ce9-4ccd-8588-e00abe2bcb89"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a4b4b310-c7aa-4dd8-8981-be90134b4ecb"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmax>62</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:auc>151</dikbD2R:auc>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a3af321c-f0eb-42d7-ad44-d271b7e73879">
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e2c0acef-a7a2-4e2e-80a2-ef32efa7d2b5"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/24086ed6-fb76-40de-b816-eecb754fafe7"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ba9a793a-8751-4a7e-b37e-c92df7aabc6d">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7489C129-C473-4D4B-AF73-E7D8D313FA14">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/74B3A68B-C237-4EAC-942B-630953D80997"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FF41495F-3930-422C-BCE2-E56C300FCF0D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:062595f6-59e2-49e7-988d-2011bf9abab9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The metabolism of saquinavir is mediated primarily by CYP3A. Additionally, saquinavir is a substrate for P-glycoprotein (P-gp). Therefore, drugs that affect CYP3A and/or P-gp may modify the pharmacokinetics of saquinavir. Coadministration with drugs that are potent inducers of CYP3A (e.g., phenobarbital, phenytoin, carbamazepine) may result in decreased plasma concentrations of saquinavir and reduced therapeutic effect.</ao:exact>
    <domeo:uuid>3b2a2ea2-c2bd-447c-8a79-6c701f9a7ff7</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-13 11:13:09 -0400</pav:createdOn>
    <ao:prefix>ther Drugs to Affect INVIRASE  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:202B0EFA-3862-41F0-9B1F-F6DE88CDE6AB">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F5D8EC3B-5C90-4232-8825-4103A22D50E8"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cd023039-00ce-400d-9146-f58ffd941877">
    <domeo:belongsToSet>urn:domeoserver:annotationset:B5FEDBD6-FDAF-4372-97D2-D0933C5B217A</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:FF0DB672-0993-4DF9-BB33-C00CC5BBA8AC"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Neecdc3cdde124f2ca04360e5b927044d"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:0adcdb4e-f894-4c8c-b00d-0f8edc65209a</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-29 11:26:06 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68ab60dc-4a3d-4902-a852-e861f212a928">
    <pav:createdOn>2015-10-14 12:10:56 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:d0a51890-240c-4745-a74e-4b71fe324de3</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:9b95720d-0d36-4464-a020-7cfbcd2d64ca"/>
    <permissions:permissions rdf:nodeID="N29d32061b29f45fa957cbf1918e0ee45"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf0707eb79db94d738db324cf42e48aee">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:766F06F7-705E-4801-B50C-C716F350B9DA">
    <pav:previousVersion>urn:domeoserver:annotationset:751FBB26-E5EB-4878-A2EA-2B9845EC5906</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-05 16:06:31 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N039915a3407745cc94e2422d826c600c"/>
    <pav:lastSavedOn>2015-11-05 16:07:34 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:11D4B1CD-61DD-4CA4-9DCF-F0548507CA91"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">23</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:257b60d6-6ea9-47ce-9632-3b3d4cd03686">
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:e8943c4b-50fc-4cc5-bc35-6321ae6f8eae</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:f32795c4-d05c-459b-8767-05c7f83a782e"/>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Nf7df831bd5d54f8cba8857953b70e0f3"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne9a42d3b71064889b5087517eb4fd0a7">
    <domeo:sets rdf:resource="urn:pddi:uuid:4F1D2562-84E1-43CB-8C24-82A6BD1FF26E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33607660-b714-4ca7-b211-e74448060e1a">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:ae884c53-9ce8-4a67-89d9-53d1ccb252ca</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6fd9a3e6-0e65-4886-9154-6a1be77a73a5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N9304f1b3cbdb41b0ab823ef85338b5d6"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:cdb6d72e-1c0e-4075-b2ab-3d94eb2671fe">
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/c893fcc9-7b8e-4bb5-8e92-7b3efda86157"/>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b6fed66e-512e-4a14-8479-1c6e65d88a54"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B494B604-15CA-4998-98A2-CAECAD140675">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D3D3E35D-45AD-4DC0-BECB-AAB713508F71"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:df1ba755-a0c8-4541-83e9-13625b8ed9ce">
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/854d7ea8-6d10-46cb-bd32-c757a1f4d867"/>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/537355bf-9900-4d44-a6c3-7197ef87fff1"/>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12></dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B38F81C8-AC6B-461C-878E-E8523FC3F803">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>B38F81C8-AC6B-461C-878E-E8523FC3F803</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>    Alprazolam   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended. No dosage adjustment is required for nefazodone.</ao:exact>
    <pav:createdOn>2015-11-06 15:38:24 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B38F81C8-AC6B-461C-878E-E8523FC3F803"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:df8d82f7-d09e-4227-a792-ba593d70e7e5">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:9b84cfa0-f89e-4785-a173-ed743e90dc75"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="Na276de35f00f48a08a8a71d15781feb1"/>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:79770b00-668e-40b8-a28c-711b74721860</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0D0B84AF-AB09-428C-8667-3A081C2450D1">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/478C9609-29BA-46CC-B2AA-BE6514A5F624"/>
    <dikbD2R:objectDuration>10</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7F6E8B26-0798-4591-A35A-FD286D21BC5B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7ef6d86d-8e4f-4200-bdaf-9f612108f830">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:d251fb19-577c-4ea2-aad9-6236765c7020"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N93f362b5b9454f7d9d5b8b642b238b0d"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:46f9a1c0-0d43-4558-a3e3-7947863fd127</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-14 11:03:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:ad2e2f34-5481-4a9a-89a0-bf56f1a4f3fd</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-14 11:03:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:cf129d37-0488-41b3-b230-8d0d985bca11">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3d1161bc-7cd5-4906-9b4b-56609c467a54"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5703E553-0680-4625-A085-39A6E0C36327">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:043496E3-8479-4B04-A488-DED34CB30620"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B2C50C89-17EA-4718-96C1-A1FF90A718BF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:66cef0a6-6063-4fce-8f3a-8a33aeae2159">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d46a91e3-87fb-4c9c-8c07-6fa432c03d1c"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FE9F12A1-D547-405E-BA48-ABEF1169B998">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>6</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:241974ac-88f0-4dca-b2bb-7e0e518218f8">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a8358570-c250-4b5f-8854-0a089e90f6ce"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/591e49d1-3e58-43fd-895b-0462e962e599"/>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4e7f3830-c3b2-43fb-87a4-c71659910983">
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:15205c46-00e6-4b20-91e1-7b604903fdf2"/>
    <permissions:permissions rdf:nodeID="Nfd00bfcb24b34f92973257d2d02a0351"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:8e86cc16-81d9-4bcc-8b82-b5d711722588</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/40cce96c-7f63-49f9-8bc0-52b7552284f9">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>pioglitazone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2D761C04-2758-42B7-B1E1-7D47C91191D3">
    <rdfs:label>temazepam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4a4e316b-04d9-4897-b407-b1d6a4aa4bf2">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/26a2a894-6644-423e-8475-82a148eac3ef"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2d0f38d4-3457-41ff-b228-5424937bfb9b"/>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:24F2C0F8-FD20-4342-ABBE-3799C1E2D587">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> by approximately 55% and 34%, respectively. The AUC of </ao:prefix>
    <ao:suffix>was unchanged, whereas C</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:exact>hydroxybupropion </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 16:13:25 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:24F2C0F8-FD20-4342-ABBE-3799C1E2D587"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:95706406-F367-4FD6-AF3A-C95786CB2CBB">
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>UNK</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3DB7DDA8-408A-4B48-A14D-7853029A9B62"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>8</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/294ABC2F-243F-49ED-9DEC-165CBB938C4E"/>
    <dikbD2R:cl>65</dikbD2R:cl>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D285DCED-B51D-474F-B761-69F917B7B95F">
    <ao:item rdf:resource="urn:domeoclient:uuid:37b83851-9377-4599-833c-c782bead232c"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2015-09-25 10:05:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-10-29 09:45:11 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:c2566599-9301-4011-99ff-2212b312148d</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Na9e97fc893c940a58bcfc6834c5f61d7"/>
    <pav:previousVersion>urn:domeoclient:uuid:1718bc8b-7f69-44ec-9f31-6b6a1c6f3251</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F9C6704F-2CAF-4609-9BDF-A4D3412C59C1">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5AA4A5DE-9329-4D0B-AAB7-8AE4ED41086E"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7382F3FA-040F-4782-AE65-7B5062737C2B"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4C511CB4-33BA-4123-AA4B-CF65005565E9">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5F235CB3-EA79-4FFB-849C-9E8629488B0D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f1364b2c-1d29-4704-9ba5-a42fd1b39af7">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9f8b1153-a08e-47ae-9593-8ca4369d626c"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/11b52f45-96ef-49d4-8eb3-36d05bc11bdb"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:DD1433CC-419D-4B6B-BC28-4A752A9B1714">
    <pav:lastSavedOn>2015-10-28 14:38:28 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-14 10:25:07 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N2e301c2554734f9bb9b295708e6868ac"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:564b498f-0f39-4b78-b2dd-79ea1f2a7702</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4f4bcb93-680b-4d13-b13b-9062e968a16e"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:a30b5659-9617-4681-8e4b-958599c257d2</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:376344B6-F6C8-49EF-A853-3DD9408625EF">
    <permissions:permissions rdf:nodeID="Na6c21559b8cc4d2985710a421e8f5dd7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:2b1cbd1c-078e-47c8-a63b-138050ae8d5e</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:6f94aaa2-32f6-4197-8622-58a1f3b94087</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5177fb23-de92-452e-95da-08c6ffba0ae1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42CDF3D8-206B-4339-A4F1-E3270243FB5B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 15:42:03 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by CYP2B6. Therefore, the potential exists for drug interactions between WELLBUTRIN XL and drugs that are inhibitors or inducers of CYP2B6. In addition, in vitro studies suggest that paroxetine, sertraline, norfluoxetine, fluvoxamine, and nelfinavir, inhibit the hydroxylation of bupropion.</ao:exact>
    <ao:prefix>Potential for Other Drugs to Affect WELLBUTRIN XL    </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:42CDF3D8-206B-4339-A4F1-E3270243FB5B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b4c1b7c7-ce79-41dd-84a5-33883b2edf98">
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/d5a63b73-f6d0-47ab-9fbe-4e1c02650364"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/c78ba8c8-6549-48b4-82c6-faf239bce66d"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:da032a0b-8fbb-4be0-879a-38b2186c3c8e">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>b4e10bb0-3893-4fdf-9236-62dd039617df</domeo:uuid>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2B2E7199-99B9-4D32-AB5D-82F58B49A785">
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/93E316EB-615C-4FEE-B0CD-16B2E615FF3A"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmax>50</dikbD2R:cmax>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>82</dikbD2R:auc>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D6604E90-A752-455D-866E-C857E492EA2A"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4f851737-ac84-430b-bed7-95616cbc3228">
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:fc7ced73-1f59-41ab-9811-02974b62acf0</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:82f90ada-99b2-4d0b-ba9b-7bf6d0decc19"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N69b5d1ec41bb4b60aa763b62231d0398"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/487b81df-8dd5-4717-a6a1-92bb8fdf5393">
    <rdfs:label>carbamazepine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b5f48a95-5e65-4e12-a982-59a20b3ac9be">
    <ao:item rdf:resource="urn:domeoclient:uuid:2eaa27ec-4db5-4aeb-b152-6e7c9c3705f7"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nd68ace3364c34b84b7d6716e81369961"/>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1d798a85-df6e-4023-995b-cebe1fa377f3</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:910a6a92-9cf3-4e81-b723-58e6ea716f9f">
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9ea604e6-e20d-4437-88b5-9182da6c77b4"/>
    <pav:lineageUri>urn:domeoserver:annotationset:de7c8fad-1a9c-4865-b2c8-18adecc834f4</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N2981718a7b5143b09405f06337c06c06"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:584c1bb8-4995-4d6b-aecc-acde9a1825d3">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4f6bb99c-9324-494f-8b73-04d939bb21d5"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2659C5FA-AF80-461E-95E8-F25661252ADE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F068D28E-EC58-493C-B53C-9C6F1C17BCAC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e67c3eb4-b749-419f-89c2-a22b408af8ec">
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9c25d43b-002a-4b60-8e1e-ff4017084189"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e79980d7-47b5-47f8-8c29-bff1264cd1c9"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A0C16A5E-F5CE-4CE5-AC78-BE8D72CD75EF">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7AB8AE53-31E4-42BD-BDB1-B0F1162CA000"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/410BBE7D-B70B-40BC-A97E-5AD7DECBF53B"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>6</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65AACA18-300B-456E-955E-CBD7FB1F9A12">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-27 14:25:31 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:94232E79-3674-4468-B130-EB1D12A847A9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D8A6394B-01B3-43A1-9780-07287688E420">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:939C6A70-88A3-41E0-B347-184B5F87D9ED"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12353fec-0819-4a58-93e8-8c1f8ab850dd">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <domeo:uuid>00ce6cdf-4c27-4d0d-bc61-bdcf42b0f815</domeo:uuid>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:237d2d40-40a7-4c9e-9c3d-e28fe1555f43">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:18c86de9-724e-42b8-991e-f98dcff255ac</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Ne33766a25c5d43939ce229cfc8cd0228"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:066340e2-1581-4fa3-af9e-052965e1836c"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:cda0afee-59dc-42c2-bc9c-cc6aec3962aa</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:41625D29-6F4B-4A7E-99A2-D244302C1BF8">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-29 09:10:04 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:e9a81ed8-0f9f-4549-bdb8-c35a76903a2d"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:c6713094-ed57-4154-b557-9358b07c4f28</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N4fdb0b8893a74b38874d96f70126457d"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:4ac15bf5-d934-46fd-8fd1-71bb1de62aee</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9a08aff7-01cd-462f-af7b-35c7f18dd810">
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8795ba1b-c5be-4b78-a2d9-e9e8575bf0a8"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4ce6c94d-b81e-4b93-9601-87445b6b8889"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a7552df6-4b8d-41c3-a267-281f2e4cf031">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:6e472ca1-6e6c-4dda-b889-fbcbfb5b55dc</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6c86458a-def9-4c7d-8118-996ee2bbbd0e"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:6a1d4126-6472-4af0-b5e0-8307e6d61666</domeo:belongsToSet>
    <ao:body rdf:nodeID="N160a748bcdd840a4ab8c65c66d2a8066"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69c6c642-bd3a-4118-89b4-734f39df2215">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:b2e96e76-d0ed-49f6-abc6-bd3f41f28444"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:0fdd8015-8567-485e-85a9-853b25f8b9d8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:e88acfc7-2df9-4018-978d-3f37b180180b</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Ndbe8a9b0a5304a93a1c482910c13d1bb"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78663589-F9AD-496D-907B-E70693832F7B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C397F3D7-D462-4F97-8A7F-D50A88A55469</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 09:45:11 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:B0FB8F84-7AFC-421E-B290-63237F9AE29A</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:B3EE42BF-EB88-4CA4-8F5D-EA836AFCAEA1"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-29 09:44:52 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Na732a57e80384b158e4410f8f4b36459"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a519a3a5-8070-47e8-bd49-9d06442cc06d">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/c9e476b2-c06a-4e73-9591-c5f08ad5e899"/>
    <dikbD2R:auc>4</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/06d54b86-deff-4e00-939c-a079d6651171"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:af044f4a-fe8a-4d74-be0e-9274fe7e61f0">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:3b96c039-200a-49dd-ab0b-542a335c370a</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:4358ef34-271a-4444-925d-2be09ba568c2"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:4f01712a-e7cc-4c96-b3c3-9e805381593f</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N2f231972897345ef96448bb49cd718f0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E9CEF418-2F94-436C-B0D1-F12774A00594">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1EB799F8-3FCA-4858-BCD1-94F69D4E37C8"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:424b3cae-bb89-441f-9e53-ee832c015503">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:d905d7c3-b264-443c-8076-46f094aeb113"/>
    <ao:body rdf:nodeID="Nbb8b3376cc4e4eb880a013c070f63aa6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:0e5e5e67-ca92-422f-b7ea-369e47ef03b1</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:cdbee72d-27c2-4556-b2e2-fff5d9dacf97</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f988e802-61db-47f9-b5e3-f3afd5989f1e">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N386f9f937a6543d38e27bb638d7077b2"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-08-20 11:17:13 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:6d4555b2-cc68-423d-9485-1744eaf1c0ec</domeo:belongsToSet>
    <pav:createdOn>2015-08-20 11:17:13 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:76f7167b-97bd-44f2-8786-cf8b650ae385"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:5b6c655e-75ab-49bd-9837-8faf1810015f</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E7E47972-9A4A-4957-85B5-77E51BA7242F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CD5F5269-6E50-460B-916C-F4EE02AEDCB0"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>31</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/59144EDD-22D5-41E9-AE18-482F804EAF63"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70450371-5A3D-445A-A7E1-2E1F5E0B5EE9">
    <ao:exact>Alprazolam    In subjects who had received EMSAM 6 mg per 24 hours for 7 days, co-administration with alprazolam (15 mg per day), a CYP3A4 and CYP3A5 substrate, did not affect the pharmacokinetics of alprazolam or selegiline [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <domeo:uuid>70450371-5A3D-445A-A7E1-2E1F5E0B5EE9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-27 13:24:09 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:70450371-5A3D-445A-A7E1-2E1F5E0B5EE9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:452197d9-9703-4fc1-9b34-49bf39291fa7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:DC14BEEA-BCA1-4540-93E6-982BB400369B</domeo:belongsToSet>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:e1541e6c-d450-4c99-ba3e-8dced430d066</pav:lineageUri>
    <ao:body rdf:nodeID="N23da738550324245b419e15be2e5df4c"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CD0227C5-C430-47AC-9EEA-A01EC48EDADE"/>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ffabb2e0-e86b-4909-b1d2-fade666dccb7">
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>1.54</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/498c06fd-f756-4339-8883-6d8792b31ccc"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmax>1.58</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/31833f6b-cfc9-43e2-8378-748266586508"/>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ee4038e6-5312-4b9c-9cff-181a64ee5948">
    <rdfs:label>ketoconazole</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:794AF275-38FD-4082-BA1D-CB9029261F0A">
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ABF0CC7E-AB36-42A4-8E12-6EB76AAEEF26"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>57</dikbD2R:cmax>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:auc>57</dikbD2R:auc>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A30AC5C4-04EA-45C7-8434-43F16C34D5AE"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E73D6B7D-A3A8-4817-A2C4-32DE510299C5">
    <pav:createdOn>2014-02-19 12:38:23 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E73D6B7D-A3A8-4817-A2C4-32DE510299C5</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <ao:suffix>(</ao:suffix>
    <ao:exact>Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E73D6B7D-A3A8-4817-A2C4-32DE510299C5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DE83202F-90D8-4503-9E34-F2007C1B2722">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>phenothiazines</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C2D8DB93-B0CA-4578-8D63-9A85C6FEC43C">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DD84EF36-17DE-4FCB-B447-52BDFC787EE3"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9E7D01D2-6379-4CCD-A5DF-4416922C8755">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E7C844E5-2FA8-4494-A242-004123173C26"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:098F35D9-F94C-45FA-B857-9BDA3662BFEC">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C1B78A95-0376-43E1-B24E-91F166401E47"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b4bcb545-b9aa-412b-b772-55699651ec75">
    <permissions:permissions rdf:nodeID="N053c9d97e7b340939507e39fed098f00"/>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:58e23aa1-bdc6-4413-867b-c59977b3c0a7</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1846d100-f88c-48f4-b448-53ac47422ed5"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b4e8d318-358e-46d5-9d70-2cd68f48bf69">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:1128a740-23e9-4a84-8d26-e73c85015028"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N58c1ef5a3636478baa23edc13e501a9e"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:81501c45-8114-4793-8735-9f22f702a988</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96fddaed-47e8-4075-bfaa-a31655a9851e">
    <domeo:uuid>75b7e3e8-570b-4d5d-ade7-bab5c9eb9e80</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28929f5f-f73d-432a-861d-66ff4bf69938"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5dbe1418-f39e-4a38-947b-6280ea8e1fbd">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3da5a544-4864-4be0-a1cc-1e586c48e75a"/>
    <dikbD2R:auc>1.41</dikbD2R:auc>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/bede2bda-c515-489b-858c-33a5616d2053"/>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:cmax>1.33</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01abc207-86df-4cfc-9c65-e56ca9ee51f4">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:9471B72F-5B68-49FC-A139-7D70D90BA0D1</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:e077a204-88d5-4110-9b24-3c95153dad15</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-29 10:48:14 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:2CB047FB-3614-4E9C-B521-6D1717B92E98"/>
    <ao:body rdf:nodeID="N17bfa2b91e0d4bfeb4780b9c9bd9d0a8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8EE66C33-C850-4A44-B471-B426996500DD">
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7487DC0A-C307-4A1A-9564-8601F8F17047"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6ABC1A3F-1658-49EB-A538-AD58A2E168E1"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0A695369-965B-4E1E-A972-1BA89AF625BC">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A08A7985-6DF1-4E33-9678-662D96CD2447"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1EF44FB4-771B-416F-AD61-759B3603A20B"/>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A02C3322-A287-432C-9065-C5ED1C54E42E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>CYP3A4 substrates (Figure 2).  </ao:prefix>
    <ao:exact>Clinical studies have shown that desvenlafaxine (100 mg daily) does not have a clinically relevant effect on tamoxifen and aripiprazole, compounds that are metabolized by a combination of both CYP2D6 and CYP3A4 enzymes (Figure 2).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>A02C3322-A287-432C-9065-C5ED1C54E42E</domeo:uuid>
    <pav:createdOn>2015-10-28 17:17:47 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A02C3322-A287-432C-9065-C5ED1C54E42E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7d75d730-59d6-4220-a92f-21d1c77f2cc4">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>lithium</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2b9411d8-433e-45c5-aa92-d202b86010f5">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7f8b6f90-796b-42c9-bf4c-3fd14f71173d"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e8c95c09-f673-4c0d-a38f-5c1c9d179877"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e087f9bd-f775-47f9-8a1d-e2cf284a4791">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:da8dbb94-9b72-4b8b-ab61-b4b2efc16e24</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N0fe3894aa6fb448e9f166b95d7e36e52"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:a1404cab-4738-4e83-83aa-2f57311b85e0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0cffe297-6116-434a-8f1f-e0879a939d90">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:90cc9434-2300-406e-8edc-348fcd0a1a59"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <domeo:uuid>98d7af8b-879f-40f8-83fe-134da4dd0399</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69ADAD32-DA3A-4C4D-843F-342B189EFE89">
    <domeo:uuid>69ADAD32-DA3A-4C4D-843F-342B189EFE89</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69ADAD32-DA3A-4C4D-843F-342B189EFE89"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
    <pav:createdOn>2015-11-03 12:47:13 -0500</pav:createdOn>
    <ao:exact>Tricyclic Antidepressants (TCAs) — In 2 studies, previously stable plasma levels of imipramine and desipramine have increased greater than 2- to 10-fold when fluoxetine has been administered in combination. This influence may persist for 3 weeks or longer after fluoxetine is discontinued. Thus, the dose of TCAs may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47EAD704-8F7F-4017-B0ED-49D8D6DC6D6B">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-28 16:39:54 -0400</pav:createdOn>
    <ao:prefix>450 2D6 under PRECAUTIONS ).   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:47EAD704-8F7F-4017-B0ED-49D8D6DC6D6B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <domeo:uuid>47EAD704-8F7F-4017-B0ED-49D8D6DC6D6B</domeo:uuid>
    <ao:exact>Hypoglycemic Drugs–In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose. Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of this decrease in tolbutamide clearance is unknown.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E571972A-4EC7-4480-8000-4A9FEDF958A7">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:61bbf6cb-ae90-4232-85aa-9ebf7600cabd"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:f7d244cb-3d2d-4776-9a18-bf14d9a519d2</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:b2d2de35-2525-4504-b3c5-75e1ac8270ad</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N1ef1cc8585d742eeac5ff9e23ab1ff7f"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 15:38:36 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7220d6f7-4364-4484-8751-8c2356d40233">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:6f5b9d39-bb4d-494c-90f7-ebdad0289141"/>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N99f72856379f4e0393576aa01c0ccadf"/>
    <pav:lineageUri>urn:domeoserver:annotationset:e324d830-cb13-4f0c-aa86-b797f308c1e0</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:929BF940-1099-4796-BBA3-341FACCD0F42">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <ao:exact>CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen (600 mg loading dose followed by 150 mg once daily) in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established in clinical outcome trials.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-02-09 21:23:27 -0500</pav:createdOn>
    <domeo:uuid>929BF940-1099-4796-BBA3-341FACCD0F42</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:929BF940-1099-4796-BBA3-341FACCD0F42"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5ded21bc-9e1c-4d40-920d-e787a1e874c4">
    <domeo:belongsToSet>urn:domeoclient:uuid:81ad4b82-319a-485b-b356-fa43c79d4508</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:9cd8353b-ead7-4551-bd65-d6d2f7ce999c"/>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:f540b04d-727b-4585-ac47-f32805aaa723</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N4c7a6a2f992a437080c1c767a6a61c61"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57697AFD-0A84-4932-840E-039887A1AB7A">
    <ao:body rdf:nodeID="Nb44c22559bbe4639af53769dc05534b2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:4CEE8D0E-B023-48E0-A038-A0024F43A84E</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-05 16:14:19 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">26</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:85744EE4-C6E3-43CF-9D87-A3EA114378E5"/>
    <pav:lastSavedOn>2015-11-05 16:15:31 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2884C04C-5C92-40CB-AD40-01680FAB45E5">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-02 13:31:42 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <ao:exact>Cimetidine - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of 400 mg twice a day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively. </ao:exact>
    <domeo:uuid>2884C04C-5C92-40CB-AD40-01680FAB45E5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2884C04C-5C92-40CB-AD40-01680FAB45E5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8c5f0ce9-3b5f-4f7e-afcf-52a8b7dde825">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a57ec363-3a62-4f8e-a163-112d32ab3435">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N6f283a64a7604eb98788ab2619b08065"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:05ae53d8-3ae9-4b5c-8864-5155016fc649</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:42314dc7-6074-42ae-b2f2-81cd65a08eb0"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b0f01395-ff79-4dbc-892b-da3586b50d6b">
    <pav:createdOn>2015-09-14 11:31:14 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9b3a315f-8d8e-42d1-805e-2623ce8e1f1d</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N4e67b9e8e6b146b0a2c4a1b072cb0866"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:439d3a3b-8d9a-4445-a7a4-8694e6d0c126"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-14 11:31:14 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:aa05604c-eb94-49a3-b5d7-2b25f10b3682">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:0999323d-a069-4f7b-a45c-818952500a50</pav:lineageUri>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:66a6209e-7f39-4b94-b85b-6f3182974c8e"/>
    <permissions:permissions rdf:nodeID="N626a2e74155b469096609834316af225"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03281665-e00c-45cf-ba5d-ae64e6a865d9">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N031fd98d293444e493a94b0f6d7631a1"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-08-20 10:29:59 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 10:29:59 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:2247bc9f-34e8-4912-af58-21fd82cc2498</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7520d508-6673-470e-8698-c67ad1519b73"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a4ef75e1-9591-4dcc-9846-8f184b9abb46">
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7559f5e2-70fd-4459-a178-29bf077a7bcb"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/73e0d409-a485-4465-8c9e-57adccee4a9a"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:auc>15</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D4144D4B-58CC-487F-A4EB-E611D622A2C5">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:9265a506-96bc-44ca-a73a-7775e90caa50</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2015-11-02 14:00:45 -0500</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N0bda6c60c50f47329667a3cce1be1846"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:15875549-3fb4-439a-8ffd-7d31c3f3d7b2</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:7bdad30e-d65f-4e9b-b295-a929e28682ef"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13bfd14f-c780-49f2-aeeb-1656e979a49d">
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7da5ee9e-f83a-490f-9547-cb9c9679ecb0"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N0f1e581569ff42f4910a65669fb25c0b"/>
    <pav:lineageUri>urn:domeoserver:annotationset:e2507f20-282a-4743-a924-1995059ee1cb</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e08f2f59-a3c3-4b4c-a310-75f6166843d1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:9742da2b-f247-49b8-8b73-08fd5cc25b9f"/>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="Nbfe1a2f67bd4438b99850c906864f121"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:ec6d810f-36d8-4b4e-a683-ab9296d53b73</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7477443b-a5f7-4bcb-bd49-c15ee62f98e6">
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/eeb4116d-9623-48ae-8564-a4da24422f50"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/acfe51aa-53c0-4ba7-b40e-8e0805c0ff11"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:clType></dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncaeceac612664fc49a65b7c2dd835d23">
    <domeo:sets rdf:resource="urn:pddi:uuid:7CA3C576-3612-49BE-B189-E2A43C383F9E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e3093c1b-7b23-4281-8b8e-e79247762353">
    <pav:createdOn>2015-09-03 15:43:15 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N104508a713364bfb8b3a73cbafb96556"/>
    <pav:lineageUri>urn:domeoserver:annotation:e9cadfbb-d4df-4a01-9014-66b497fd6080</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:041c7855-95f8-4ddc-8053-533a5e692709</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-03 15:43:15 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:660ec989-e444-444a-ad55-0e1c1a28b457"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f8b46576-0492-4941-ac45-c6e0967e9aab">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5c3dee37-f2b6-49ac-8607-347751f0d946"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/92BF7FDA-437A-4910-B4EC-198C6FA1B794">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7119f066-0a03-40ab-bb6b-017cf28601e3">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N813a54ce62c541858b26b58b2b245e3f"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:97671749-5d9a-4b07-827e-ae2b78a53a9e</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:db18ff10-4429-47bf-ba51-83fe2ae8990c"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:c2d9be80-437d-4cbe-9216-8219619ee444</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9726cd10-4858-4848-b747-96f5f0600a56">
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nc3cc2943cbf942599f424b54ab96e636"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:065b4177-e994-4959-aeb6-e3304a914dbf</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:955e8807-d714-4998-807e-78bfe31e1606"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:35D69913-BB90-494A-B3C2-EA35074CA04C">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="Ne071d34994d04e8ca00bf0952ec4a111"/>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:ef3804e6-3241-4217-a5f3-cede28dc925e</pav:lineageUri>
    <pav:lastSavedOn>2015-11-02 13:32:32 -0500</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:f71bb8a5-f38a-4ee1-9eea-46d7f7755ac8"/>
    <pav:previousVersion>urn:domeoclient:uuid:7d73009f-05ab-49df-adeb-6fcef3befbc1</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb06990c8fdbb467da91363ae45750b4e">
    <domeo:sets rdf:resource="urn:pddi:uuid:9672191B-D72F-4881-9C96-E6E2BB06B380"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:08B5EA17-3190-479E-859A-95B04924B522">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/545887A4-8F7B-46C3-ACFB-ABDD4706EA9F"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7FDE70D7-14B5-4E50-B4AA-A68B51265ABA"/>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>32</dikbD2R:cmax>
    <dikbD2R:auc>24</dikbD2R:auc>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cdedaa7f-d2bd-4668-a964-637ee626cdec">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:172B4563-4648-4E3C-9ADA-0C2A2E655F90"/>
    <ao:body rdf:nodeID="Nb06990c8fdbb467da91363ae45750b4e"/>
    <pav:lineageUri>urn:domeoserver:annotation:38e72091-7173-4925-a8a9-40f5c4beb1e4</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E89F899-B5BE-4081-A778-6C6EF96E93B4</domeo:belongsToSet>
    <pav:createdOn>2015-09-24 15:38:09 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-28 17:22:11 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:09759DBC-4657-4886-A32E-B55461E2187A">
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:5C6572E5-5022-40D7-90F8-843E207FABBF</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N05a000c1c57344fcbd7be0a0fc623905"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:7acfec2a-60c1-455f-b7b6-7a841c172bc3"/>
    <pav:lineageUri>urn:domeoserver:annotationset:41c056a7-09aa-4b5f-b20d-ffa35b22ea9a</pav:lineageUri>
    <pav:lastSavedOn>2015-10-27 13:28:11 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6623B1D7-FECC-4EBE-B01C-2AA1E4F528C8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>warfarin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0f5b0fd1-f6b8-4aab-bf1e-88ee1dee66d5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:f2609359-5f09-46a1-b4e3-ec8fb37a350f"/>
    <pav:lineageUri>urn:domeoserver:annotationset:45231057-878b-47ab-9e76-ecd34fdbc008</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N31d8f16ba591450ab0399c7fd1891fc4"/>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d523bed0-a3e8-49f6-8c56-9cfe2c143cd9">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.</ao:exact>
    <ao:prefix> be an inhibitor of P450 2D6.  </ao:prefix>
    <domeo:uuid>5e5ef1a3-5a0f-4cd5-ac08-c23fb7b3389f</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2264F182-4C37-40CE-9E84-3AC83C4F4642">
    <pav:createdOn>2015-11-04 14:17:20 -0500</pav:createdOn>
    <domeo:uuid>2264F182-4C37-40CE-9E84-3AC83C4F4642</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (m</ao:suffix>
    <ao:prefix>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of </ao:prefix>
    <ao:exact>TCA </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2264F182-4C37-40CE-9E84-3AC83C4F4642"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nce597b5be967400bba26d8f3ea71353b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/08251c19-284c-411f-a606-95b56c9f31ce">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Lithium</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:600DC4DF-8428-4EC0-B9DA-53C93F607E9D">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5705ED86-C877-4657-9A9F-3CC2B6600329"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D4DA3A63-3518-4147-B784-30125038917D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>erythrohydrobupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f3c72c10-fc44-41e5-9545-4696a4a2bf62">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-09-30 12:41:52 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:770fcf28-72b6-473c-82a2-503dc5995759"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:242c7aae-1986-4c7d-8481-82f5c0a79a1d</pav:lineageUri>
    <permissions:permissions rdf:nodeID="Nba0f047c9b3c4688aa03568ded0093ce"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-30 12:41:52 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9e5c0d1c-d7e7-4dc7-baa9-ca866612bbeb">
    <ao:body rdf:nodeID="N5be64ad9bda4478e938a8b254c32ec53"/>
    <pav:lastSavedOn>2015-10-27 15:40:46 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:367C2452-773F-4F99-BD33-55370E01A2AD</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:6ff85699-d8fb-4a8c-9ab1-48154819cf9f</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:8862F260-44F9-4907-B1EB-6D3E0EBF6698"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/717DA49B-EA1A-466E-965A-EBDD2FC6CCBC">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>phenytoin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F7E40A5-EB73-4336-8F25-862E0BE2544B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:59794496-BAE7-4461-9DFB-327908370E7E</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:createdOn>2015-11-04 14:11:21 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:46A3F825-D3C6-437F-9311-635F5C1E0D6F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d123a3ef-b6ae-459f-959c-96bcf6287519">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:46be170d-6277-4c65-8847-a0ee4ce7a1bb</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N64ff6bc308d94f67bbf8862c9755fc61"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:f90149dc-c758-46f3-8700-d6c167270a16"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:735951cc-134f-4d32-b09e-9c50fa3c961f</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b2583a58-f0a5-4c95-b767-75cf4dfe819f">
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:45c8ad2f-86fb-4273-b169-f567d8fa2d5f"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:d9e6c955-262b-4ee2-8ac1-62ecc538f260</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:84dbf186-fb7d-4b0b-8cfe-858601caa434</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Nde8d6393ac6b49dc91bb2abd773d77c6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3E8A080-87D0-4805-9E6E-BF93250883A3">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-28 16:28:35 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:03390AC1-85E8-4A41-94DA-5A6229862117"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:8ef31bd1-f7e0-4603-8d36-48793058314d</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B19016AA-1639-420A-B594-59F3CC8DF372</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoclient:uuid:10ec79e9-3622-4501-88c4-e9e3893d7182</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2EFD3C06-AD9D-4B20-983D-F9E7BF78C62C">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2E7E6846-B3ED-4D77-8AFD-9CBF1690E31F"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:525baee6-0e6f-45ce-a15b-84dc5b76febb">
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b1929c2e-85cd-480f-b52b-7ae54d9b3a8b"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/db0c596c-d59f-4bfb-9d87-a0017bb988f1"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5605df64-91b6-4fba-a401-9504d56416b3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>CMI</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:68B82816-11A0-4F71-A29C-EB26E27431E6">
    <pav:previousVersion>urn:domeoclient:uuid:6fb772a3-d396-4fc3-a10b-b79a0d6b0979</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c9552be6-7d78-443f-9886-3c01628ffe6e</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N6a060f374dce4594bcd1d293840dcb1c"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:4622e5eb-5521-4783-b58f-ff8e603f7006"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:eb979a0a-3185-44fc-9881-c6050b92e754">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>de509b3d-21dd-4483-a4ba-df98e5db3c0d</domeo:uuid>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)]</ao:exact>
    <ao:prefix>AUBAGIO on CYP1A2 substrates   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9ea604e6-e20d-4437-88b5-9182da6c77b4">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:910a6a92-9cf3-4e81-b723-58e6ea716f9f</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:31af2b2a-1a95-4970-99d3-ed918a6ef76b</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5aab3708-a0dd-40f2-b69b-8500e270918b"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N987b69631d3a46e4b95b56cd740335f3"/>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:54621CFD-3C2E-437C-80B7-494435CD8704">
    <pav:lastSavedOn>2015-11-02 13:32:33 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1547d986-86d2-4de6-a05f-eac86f075e82</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:18ce2f6c-8703-4d6f-90ec-c9ccea256cee"/>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:ad2cd699-2e56-40cb-8f24-fe7e5debdf3e</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N902a8c0aefab43cfb89add4ab5034760"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N34046dd519564dc5ae29cfe4e05b3583">
    <domeo:sets rdf:resource="urn:pddi:uuid:1B50D262-6912-4222-AC3F-A2A941FC809F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B5AF7BA9-ED99-473A-A4A6-3C92A9FA2DCD">
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2BF414AA-94F7-4EBB-B325-1ABB968AA088">
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>carbamazepine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F58B04C5-3A70-4F3E-98E8-D59B7266A4A3">
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:B4C99E3F-34EF-4E44-90DF-C6552C4F6FD5"/>
    <pav:lineageUri>urn:domeoserver:annotation:0111B8F4-F848-4372-9E3A-C6DCA6745851</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-29 11:28:47 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:09FE9163-3F21-491C-94F0-EBB12BEF6F16</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D6225BB5-4839-4138-A0EC-0B9D3FF414CA">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4F520324-073F-4FDD-8659-E3CC0835058B"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1B8C178E-7D58-4C51-BDA2-E50BCEEEC9C6">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>warfarin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1A6DC028-1017-415F-82CA-F8BDF155D596">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>16</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ramelteon</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6ED9986C-92AE-4FCF-B344-7A60A67656F4">
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/57F6F661-08CF-42DB-979F-C1A7EEA14A88"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D92B9C92-3F95-4EEA-88C5-CF605AC5F11A"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:43407a0b-4ca1-4a6d-b8eb-8a1c4c7063c7">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:62c026ba-9838-4fe3-abe0-183c15d23a76"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0393E4D6-5304-41D2-A25C-DACC2797FAF1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0393E4D6-5304-41D2-A25C-DACC2797FAF1"/>
    <pav:createdOn>2015-11-04 14:16:40 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Cimetidine </ao:exact>
    <ao:suffix>is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs. Clinically significant effects have been reported with the tricyclic antidepressants wh</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <domeo:uuid>0393E4D6-5304-41D2-A25C-DACC2797FAF1</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8ea672f10585420bb8031bfc76d8a132">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2175D38D-CD24-4E11-B943-723D1E0F0CAD">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>maprotiline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:fb7020ff-8ea2-487c-83d4-2ae5e67eabf8">
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e77fa0f8-efde-475f-8cb1-5c7a486b502d"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/af6c0260-816e-4466-b557-69cfc9858e27"/>
    <dikbD2R:t12></dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:17446e00-973e-4de1-9989-bf8a562942a8">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b88e2107-7294-49e5-bc4d-fdbc185edaab"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0a38cb0a-85d5-452c-8382-bc4a1ced5ade"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:auc></dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2c708c1e-cb8c-4d93-9c88-7959626ff352">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/add85373-a8a0-4fc1-a2e0-1f672655a4f4"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8fbf2351-d973-4d57-bade-cf029a716559"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>1.54</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>1.43</dikbD2R:cmax>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:173F3E1B-30B8-4F52-ABA4-E3A7D2154165">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2462766A-D934-4140-8C3D-CE07F4607397"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E8D47830-2805-4776-8255-1907F39942D2">
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptDuration>8</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/42D5DED1-4A50-4235-9C3D-D2123B489DFF"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmax>16</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cl>16</dikbD2R:cl>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/40BC6619-23DD-4A7D-B03F-A2D37167EA14"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4F1D2562-84E1-43CB-8C24-82A6BD1FF26E">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EE6EBD70-2EC7-44FD-8C18-7C0A9FF26D11"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:cb3a2b17-fb65-4132-8dea-340415f0e7f8">
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8aa0af45-7ecd-4eb3-84d7-8191e8353e12"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ea0e1478-fdd1-42a1-bc55-89e9d51c34ef"/>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6fb13d58-36d3-4b9e-868b-9fd33563bc16">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1173d7c1-d785-4b40-be33-5461a8c83e88"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:1389b841-3efe-48fd-9664-ed76f8a7548b</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nbabd42f0692d452ba95aec8e8d230c00"/>
    <pav:lineageUri>urn:domeoserver:annotation:2e47b340-7c66-4df6-8f61-0722b0103d5a</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5EEB9DFF-5401-4185-A505-E183EF0C46F3">
    <ao:prefix>with other drugs metabolized by CYP2D6 has not been formally studied.   </ao:prefix>
    <ao:exact>Citalopram: Although citalopram is not primarily metabolized by CYP2D6, in one study bupropion increased the Cmax and AUC of citalopram by 30% and 40%, respectively. </ao:exact>
    <pav:createdOn>2015-11-05 16:18:29 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5EEB9DFF-5401-4185-A505-E183EF0C46F3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:291FC4FD-BDE1-418B-A2E7-0D40C3C80056">
    <pav:lineageUri>urn:domeoserver:annotationset:b36c9fbc-b41a-4b1a-b60b-0862d0029319</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:550B712D-2D8B-435B-AB94-9CFF944910AA</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-10-27 14:13:55 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nc703ddcf0a1d40e192a3051b80d68d69"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9c3938ba-6227-49fb-bf02-154979bf8945"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N272f4d29c8ab4504b374d0a7bc143dee">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:589E8E19-029C-4213-A0A9-D85714D83449">
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5A96DB80-3720-434E-BB84-E5C1259F8E30"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>31</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B5D43310-BC0F-457C-A969-72FBAF39F48D"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/57727E7C-91AD-44ED-9312-A65638E9FAE1">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdfs:label>desipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FFB8E54C-978E-4FA9-906C-3E4F31503BFE">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:AF5E7138-652C-43B1-B901-2485B3ED9DD7">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:e8870973-cbc8-43be-813b-62f2cb600399"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:a74e5089-6da8-4ab8-abd7-ddd6d3b64d38</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>urn:domeoclient:uuid:69164857-ca70-4fa8-a66c-f0642e18540e</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N9556fc22f69748538b85183633850df1"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 13:28:11 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D146098-2EAF-4A7C-82ED-06C39413E92D">
    <ao:exact>Haloperidol – When a single oral 5 mg dose of haloperidol was coadministered with nefazodone (200 mg BID) at steady state, haloperidol apparent clearance decreased by 35% with no significant increase in peak haloperidol plasma concentrations or time of peak. This change is of unknown clinical significance. Pharmacodynamic effects of haloperidol were generally not altered significantly. There were no changes in the pharmacokinetic parameters for nefazodone. Dosage adjustment of haloperidol may be necessary when coadministered with nefazodone.</ao:exact>
    <domeo:uuid>9D146098-2EAF-4A7C-82ED-06C39413E92D</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-06 15:54:47 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9D146098-2EAF-4A7C-82ED-06C39413E92D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Monoamine Oxidase Inhibitors – See WARNINGS .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d7f6f33e-808d-4e62-a88c-2fd79dbed552">
    <pav:lineageUri>urn:domeoserver:annotationset:6681cf97-ab33-4f36-b296-1a74a21df931</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:14a183fe-fa54-4111-94d2-92007999254c"/>
    <pav:lastSavedOn>2015-09-29 11:41:50 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-09-29 11:41:50 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N88a729a62030460b8c95a98c991d7a7b"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f3d6c982-d2e2-41e0-8efa-6e06a5f29283">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N2a97a09042c64e47bf3c89cb73d39b8b"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:5d7d605f-90bf-4ee3-b8d3-46fd4816aadf</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:dd3eb8b9-c22b-4046-8bfa-fb1c0ffa5cd7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:10387F9A-9BD6-4D83-8F90-B7496B827EB5">
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-10-27 14:17:34 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:a6010a17-6d8a-4f4c-963f-0c60e41740d9</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="Ne58317e9b7414b5a9637a30a586b124c"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:dbf859d2-8eca-48e6-96b9-c612be78bc1f"/>
    <pav:previousVersion>urn:domeoclient:uuid:99a3020c-dd27-4913-9eab-2a03aa651dde</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:39e90d3a-f87a-42f0-813b-e20db40826ed">
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1d091652-cbab-466a-bfce-26f155cdfdb6"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/64825377-af06-4be7-9331-ba4ae3bb707d"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b1126b28-f5ef-48a7-91fc-44e5215aa5fc">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:b1c973c4-c699-4d2b-af34-25571732d51d"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:fc97c714-0a10-42d7-aa73-ece5d87c4723">
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/706cbff6-f390-42f8-bced-260da4c97b0d"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/71673b97-4f3c-424a-bebf-db379bf0ae96"/>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4CED261-084C-41BF-8E10-C9F684AD3940">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4CED261-084C-41BF-8E10-C9F684AD3940"/>
    <pav:createdOn>2015-10-28 14:30:25 -0400</pav:createdOn>
    <ao:exact>In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions)</ao:exact>
    <ao:prefix>).  Drug-Drug Interactions    </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D4CED261-084C-41BF-8E10-C9F684AD3940</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C5716382-9548-43C7-AF5F-2BFE4C11A6DF">
    <dikbD2R:auc>40</dikbD2R:auc>
    <dikbD2R:cmax>30</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6F4AA0E2-D571-430C-A8CE-BD0532E742B3"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/44F4E8E4-CBB2-4020-865C-E8D64A64311A"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29F4CEA2-667F-4AFC-86C5-D1C19703B418">
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
    <pav:createdOn>2015-10-27 11:46:58 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:29F4CEA2-667F-4AFC-86C5-D1C19703B418"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>29F4CEA2-667F-4AFC-86C5-D1C19703B418</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c4c4054a-68df-4add-abe5-86cdc8389c92">
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:31750d8f-32cc-4143-944c-f77b870865bc</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N0956377d3c7249de988fb31e10fb6375"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:de69f687-e05b-451f-a50a-e9f36fceef06"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD591909-A4FA-4901-BC4B-41EBEF7946E5">
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:2B45C7F0-046E-423D-ACCE-4C8269DE7FBD</pav:previousVersion>
    <ao:body rdf:nodeID="Nf4ca8328550142d2b1cac7dc2e8179f0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdOn>2015-11-05 15:55:34 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:57F17CF9-9308-4760-851C-F357958B8144"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">19</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-05 15:55:58 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB616F1B-E294-49C1-902B-38E8CCE7CC39">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:prefix>  Ketoconazole  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-29 10:41:13 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EB616F1B-E294-49C1-902B-38E8CCE7CC39"/>
    <ao:exact>In healthy, male, Caucasian patients (n=24), coadministration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30-mg dose of mirtazapine by approximately 40% and 50%, respectively.    Caution should be exercised when coadministering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, or nefazodone.</ao:exact>
    <domeo:uuid>EB616F1B-E294-49C1-902B-38E8CCE7CC39</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:27bb3a19-c554-43a5-b824-2f2490ef5a90">
    <pav:lineageUri>urn:domeoserver:annotation:6786b409-13ad-4726-bcde-92ccaef24f9e</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:93696DFA-114A-4C7F-9D8C-E2A9CE191ECB"/>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N469c940447af46fb9100cacd84a9a990"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:25277176-7CB9-438A-BD6D-E351F32825E7</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3b96c039-200a-49dd-ab0b-542a335c370a">
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N4dfad2ba22804d9bb2ab91baf78449f1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:74d2cc68-6924-43cc-ab5b-34342e1c7d7a</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:af044f4a-fe8a-4d74-be0e-9274fe7e61f0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2462766A-D934-4140-8C3D-CE07F4607397">
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FEB21963-21A2-42AB-8567-8ED1E3743C52"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CB6E5200-8E6D-41C4-8721-F3D75AA71617"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a5437e98-6ada-4edd-816e-cd8eaf2a7922">
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f43f5739-998d-4762-87ed-c34faedc1353"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/921f6520-0468-403a-8b48-e8c0f66ecd1a"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmax></dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71762762-972b-4c03-91e4-59cd4ac1bda8">
    <ao:exact>Repeated doses of teriflunomide decreased mean Cmax and AUC of caffeine by 18% and 55%, respectively, suggesting that teriflunomide may be a weak inducer of CYP1A2 in vivo.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>2f5c47f7-8281-40f0-9769-9ac3549c7406</domeo:uuid>
    <ao:prefix>s (7) ] .   CYP1A2 Substrates  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1a4308f1-a43c-4734-ad4f-8f9f8df487a7">
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2c646e75-e2b3-4ba5-8a3e-3df826f456f0"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/d258ea10-1fe6-4f77-9636-4201f8a108d9"/>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F1D1F48A-5A61-447F-9979-13D0F5998480">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>desvenlafaxine</rdfs:label>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/441B4064-F7BC-4292-B897-71AC507C5B45">
    <rdfs:label>phenytoin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:552DC9F9-BC80-42C4-A20E-76CD50328768">
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DB7993C6-2489-40B0-93AB-B366A0720C09"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C000DF83-03A0-43E4-A485-F936DE9054E4"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E51BF9BD-A111-4938-9E6A-2702C8889B87">
    <ao:exact>Imipramine and Other Tricyclic Antidepressants (TCAs) - In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown. Nevertheless, caution is indicated in the coadministration of TCAs with Celexa.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-02 14:00:43 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E51BF9BD-A111-4938-9E6A-2702C8889B87"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E51BF9BD-A111-4938-9E6A-2702C8889B87</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:831BDB6A-28AF-4C5B-9157-A7E24E24DC11">
    <pav:lineageUri>urn:domeoserver:annotationset:f877e84b-4b43-4279-8ffb-f30a41d526b1</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Nb19fc3419c99464cbbf9d7d0ffd5b222"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:745fecc5-f8ed-475e-9368-9b1f012ee3cf"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>urn:domeoclient:uuid:718058a8-a688-41eb-ac23-8db8ad82fdff</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-10-29 11:36:34 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7491d451-dddc-47ef-ba1c-7124681a15b0">
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <domeo:uuid>4b2af607-49d2-401b-afcf-057a6a0da8a6</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13A98AE2-A525-4243-99D6-071A32594D31">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-27 14:23:30 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-27 14:25:13 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:140D5529-FD9F-4AF8-BA0C-9429231AADBA</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:7D07DB5F-34BF-4840-9F23-4139B1C6A05C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:5B2950F2-8CF2-41F1-8F38-65247766F227">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-11-02 13:32:33 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:57f0fe6b-ead0-464c-88ab-f4d3578385f8</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:faea14ef-5d20-475c-91b3-005b03d0aa6a</pav:lineageUri>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N08717813da984e3c99144b2016814a54"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:d254abbb-5939-4f17-8250-44e68d2804e9"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5e23a293-9958-4e8c-b04e-87ee5b2a6faa">
    <permissions:permissions rdf:nodeID="Nc600044f88ed45079c0146df77a9ce36"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1cf675c1-6cf0-44b6-9b1e-585afdd4bc5b"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-20 11:32:27 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:ba2e0dfc-80f4-4cf3-8037-a989b57e91d9</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-08-20 11:32:27 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74E53D1E-D490-4F1E-8104-B98B4132ADE4">
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-11-06 15:42:45 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6014DB9D-8992-4573-BDCE-4A7D344B778D"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-06 15:43:14 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N1afaec78210944a595fa809bca04d417"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:8EE4F288-19C8-4519-85CB-791C9E9709D8</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:F56270D9-805E-4042-AECF-43B8EF01F8B5">
    <pav:createdOn>2015-10-09 13:32:08 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N1a619cac6c2c414692d81ad53a8124ba"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:20851f35-7304-4a77-8899-13a4aaca5a5a</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6889d9dc-e32a-492e-8f48-4b26ab621711"/>
    <pav:previousVersion>urn:domeoclient:uuid:0297b914-2394-44f7-ac67-e5c41b21d542</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4e37c20f-f55a-43de-9373-903bf7c34705">
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/164b68d7-1779-4c96-8064-368dc9c29860"/>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/95ea3119-40c1-413e-9f19-7296cb3daddc"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d1f4afd3-c3a0-4041-ab9e-613a83049322">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:772af0f4-6c30-4526-baf5-40a181be8d52"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EA885D76-4BD2-4B6C-BA56-3FD9FDF04AF0">
    <rdfs:label>sertraline</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:570DFBC9-829C-4A5E-90C6-00F9BA888882">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C121A421-8DBC-41A4-9B5B-4F136D2305C9"/>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>32</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2F0536B7-B5D5-4DB5-8CF0-744D6EA90763"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cafa5971-bfe1-4d84-b5aa-61c0c37d4142">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:003b5253-2e58-4f48-980e-c85b8280d99a</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N554abdc4cd5c4409977eeb962f133569"/>
    <pav:lineageUri>urn:domeoserver:annotation:a0c6a4c9-775e-4a0f-ab47-7dcf4dc079f6</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:a4f5eb61-abfd-40ed-bb0c-6f30d6a9b611"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:43A5EEF2-A478-45AB-8F51-693594396CBD">
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0DDC0503-0E10-47CD-9C67-774F67A74350"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FFD9031A-454A-45E8-B895-04EA75ECEFC2"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12>2</dikbD2R:t12>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>2</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/26a2a894-6644-423e-8475-82a148eac3ef">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>abiraterone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:580bea3e-4ab8-48a5-8dbb-c3f8d4f85dbd">
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ad387288-5f50-4e3d-8c08-e4d020d78d83"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f80789e5-efff-448b-842c-02a82bdb4423"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:auc></dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f25b8b83-c2e9-4559-b69b-835d8d0353ce">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7ad0eef3-2cf2-4a42-9157-08d5191bc419"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c985d708-0ea5-4fb0-8a90-b45076f46e88">
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5349d9ba-9d80-4373-8982-8084819456b2"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ef0428b2-5a44-424f-a383-da4fdf81c546"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4f4bcb93-680b-4d13-b13b-9062e968a16e">
    <pav:createdOn>2015-09-14 10:25:07 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C4027282-757F-4F4A-965C-0CD4E3374FBD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DD1433CC-419D-4B6B-BC28-4A752A9B1714</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:78b9e4a2-c7f4-48b9-8437-461cb4cfef65</pav:lineageUri>
    <ao:body rdf:nodeID="N0621e9b3272e429cbc13553e54db2fa4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-28 14:38:28 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b6790782-15b7-4bb1-8880-581c3153d020">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:158b70f0-4ac7-4986-92cd-ad3404c5b5ee</pav:lineageUri>
    <ao:body rdf:nodeID="N58d5be46f7564a1686e17afec56a592d"/>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:0a35250c-054c-41aa-9b98-1d944dcd7347</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:f4588c66-7648-42b1-a7ab-23e0ccf4f7e2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A116E1A7-A0EB-4A62-BEA7-68CF500A9BF7">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>mirtazapine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EFA37061-987D-4F2D-9653-EA3F999481E9">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D2C4E45D-CB3F-48CA-84DD-6EC6554304FA"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a6d02742-82bd-4497-be46-4e50e03ea8ab">
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e740dc3d-d8a9-4d2c-9e90-1bc396adb9ed"/>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/212ff18e-8660-4823-b55e-414f6a337d58"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912">
    <ao:item rdf:resource="urn:domeoclient:uuid:225847C4-68BD-4417-BE91-CE55BF7E78E7"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/fe7ef7e3-4a4f-4310-b009-6f845fbd94a7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EF87ADCC-927E-4772-8DCF-81F31A76091E"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B1586ABF-DA16-476C-A029-6D283F1EB7DB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A4FF1CE8-CD65-4C89-A734-19251BD03557"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:B223767F-DB13-4A0A-9C2D-62B081E21D2B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B97125FC-7478-43ED-A9DB-23F5DD137E27"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5B958EDE-4B07-480E-8919-8195B58C0EB6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:72653064-46F0-4D6B-B5DB-F798E5DA211C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:694B43E7-F271-407C-8B6C-F4CB0C8F5E94"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6CE00BC9-DCCA-412D-B793-3D9050678C0D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:65AACA18-300B-456E-955E-CBD7FB1F9A12"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:363E28C3-53DA-47DF-B559-C09024DF0B0F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E926BAC0-480E-42D1-A370-D339FE2F94F1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:62C562F0-3A35-43B3-BE41-518CE3B75265"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:F6127250-435C-4F5A-BEEE-41801DE0FC7B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:84735175-44EB-4BFE-B714-0C099CA2BB4B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:99599146-6845-4B4F-986C-6A1CF2C84691"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:997FCEC3-A266-4A61-A642-6D267C9C6E63"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8E9CA7EB-4A14-4686-9DDE-CF7FEFC189A7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B21E8999-5A2F-41A8-A668-2B095576B5F9"/>
    <permissions:permissions rdf:nodeID="N88c1b52b5ca5496d9c25101144216c20"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C2833A45-07DF-495E-B888-B41AAAA8AA6F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9FCEA670-FDB7-45A7-A6D2-1117F83CD763"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:53814A73-9DAC-4898-AE43-8E28A903859A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0BBD3B06-87A7-4FDC-9628-A01095DBD083"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C58BC222-8C6F-41CD-BA41-244967C7201F"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>urn:domeoserver:annotationset:67845551-E218-4DCC-91FA-807FDB092B5F</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:F17B0155-6940-42DC-9A9B-A9CADC77949E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A3F5FAB0-91AD-4BF9-AF2C-5FDF2A7F257E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DBDBDF71-0B3E-49B2-9397-6C608A61AFE2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1AF94052-E330-4051-8005-E54DB2E43846"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:592DFA35-F147-4508-9404-B15EDE7C828B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B8564B00-C52C-46C0-A39F-FBD996191442"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B286D1A0-FEE2-400F-A626-9EB497D649EB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0469DA73-556A-46EF-84C8-BD8CAFE4D9CC"/>
    <pav:lastSavedOn>2015-10-27 15:38:04 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:FBDA916D-82F6-4FE0-ADF7-A37807AE87E6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:052A6B6C-2961-4268-B3BF-A668E7BF8EC4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F716C59B-3BBD-45DF-A5A1-839E52FCF68E"/>
    <pav:createdOn>2015-10-26 15:39:09 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:6C81AD14-8F85-443B-8E85-57A5D1A07D70"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6D49F60B-A05B-4BD7-A809-51FC2F326469"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2AD242D5-C64B-4051-8107-A3C1B72B9E54"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5EA2D7C7-2D3D-4E59-8661-2333A395A5DF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A54C1212-DD2C-4552-9AB2-B56185D59A18"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9B605897-8200-4C13-953F-30416867B42C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1A032EDE-54D3-4848-B61A-7717F80F3883"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:56F908E4-D00F-4A85-8963-635BA1958420"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:244CD2F1-584D-4BEC-BDFF-77883BE78446"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4138D86D-7673-4E65-BB61-B7556BAB77B2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9BD7FC77-ACA5-4CE9-8093-25EC1F3869AC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2629B00B-C687-48AE-A969-B1BF9A47FD12"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA71FD8A-2323-4BBA-88FC-F3B78D523339"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:3A5DE28E-2CA7-4820-AFB5-811A76EB966D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:13A98AE2-A525-4243-99D6-071A32594D31"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F3B78AB4-5439-495D-9E60-E60DCBCBE345"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D04845BF-A522-4128-ADFE-03C7500CDDBA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:873D3CFB-0F82-4177-8E17-11CF268DB883"/>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:51F8EEFA-A73A-460A-A289-86D68C779290"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D0E1A3C-C4B4-4B7A-AA4D-F4AF2FB07A20"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:44C6879D-DCFD-4556-AC6A-3D341BE774C2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D2F83D44-363B-4535-BB38-C3AB8DB27127"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C23749C8-CD2A-4D5D-84FC-3B79948EA8AE">
    <pav:createdOn>2015-10-28 16:31:52 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:10ec79e9-3622-4501-88c4-e9e3893d7182</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N6064a994201b42f1ab972995283d6f01"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:8ef31bd1-f7e0-4603-8d36-48793058314d</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:142D170C-7C70-46F7-91E6-F859F3C5486F"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B19016AA-1639-420A-B594-59F3CC8DF372</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d15fb319-49db-4775-8f78-635514434724">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1eb5b851-8707-42c5-b6c3-ed440120f6a7"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1b82084e-9346-4112-8d17-aa85763cad38">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:9c3586d3-4294-41da-8aec-1ab9af86ff0b"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:76b35fbc-c6f9-4f03-b385-d6a42f7c9eab</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N1b600a5daf514abc83059c5921db1746"/>
    <pav:lineageUri>urn:domeoserver:annotation:e0bfbbfe-0b93-4935-af9a-8575432e26a3</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CD5F5269-6E50-460B-916C-F4EE02AEDCB0">
    <rdfs:label>ritonavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fb8b0b2b-98ef-4a08-b53a-06a872764fb2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>1dd40698-e088-41a4-b67a-1f4f04ab4d81</domeo:uuid>
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/62be5ad6-591d-4bfb-9e45-8333befbaddf">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>phenothiazines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8ACA7EAD-7AB2-422D-9421-8E9FBCCD2DEC">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>quinidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4febf6d4-0759-40af-9534-f18a16c7eb8d">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4e37c20f-f55a-43de-9373-903bf7c34705"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1CB379D5-79F4-4179-AA0D-1701504B2A62">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E60D729F-84D5-4421-9FBE-ADF7CADD806E"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:aa9bb773-bea1-4778-a885-6d558f96f33e">
    <ao:body rdf:nodeID="Ne4ffb4b383c84f4d87cfaa8b9ae2b968"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1DC876DC-F1E0-423B-A480-AC459B0CBE9C</domeo:belongsToSet>
    <pav:createdOn>2015-09-24 15:28:55 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E2578664-1D75-48A3-AFA7-3836F25D953C"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:837cbbec-59bf-4d4f-bc66-3798567578f3</pav:lineageUri>
    <pav:lastSavedOn>2015-10-28 17:17:46 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8564B00-C52C-46C0-A39F-FBD996191442">
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:140D5529-FD9F-4AF8-BA0C-9429231AADBA</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2015-10-27 14:23:29 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-27 14:25:13 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:93528B14-0ADC-4837-8A60-81F9A3A181E2"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E11191D4-8147-4A58-8A12-EE7E6B99A5F8">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A3CFFDA4-057D-4098-993F-84B80DCC85B2"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4027282-757F-4F4A-965C-0CD4E3374FBD">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C4027282-757F-4F4A-965C-0CD4E3374FBD"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>C4027282-757F-4F4A-965C-0CD4E3374FBD</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-28 14:31:16 -0400</pav:createdOn>
    <ao:prefix>).  Drug-Drug Interactions    </ao:prefix>
    <ao:exact>In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:36F6DE1B-9AA6-494D-8935-7F4B68EC3061">
    <pav:previousVersion>urn:domeoclient:uuid:353c4b7e-277c-4cb3-a68b-640d37c8a0bd</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <permissions:permissions rdf:nodeID="Nd1a8233e234f41148e935e750ace8c1b"/>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c3b3aabd-fb5c-467e-806a-e098b82a3454</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8eaacc16-bab5-4b46-912f-8889c54b0adc"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9b3b333f-6948-4090-9996-5ddb144fdd06">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="Nae870788c3ec48c4b7f3612f45399291"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:48a55bd3-f979-44b0-b4f8-683e12aa0315</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:db1c2961-ffcd-4d04-9652-aa5d00dd98fb"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/94c636d5-3d66-4b0b-8405-3698ff617604">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoprofen</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8C1FCFF-D626-4F30-AADF-9546F374EB44">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E8C1FCFF-D626-4F30-AADF-9546F374EB44"/>
    <pav:createdOn>2015-10-28 15:24:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme. In most patients (&gt;90%), this CYP2D6 isozyme is saturated early during dosing with paroxetine. In 1 study, daily dosing of paroxetine (20 mg once daily) under steady-state conditions increased single dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. </ao:exact>
    <domeo:uuid>E8C1FCFF-D626-4F30-AADF-9546F374EB44</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Concomitant use of</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2F4217F4-3B1D-47C6-8A45-8A9552D57D65">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:47B79AF8-3797-4198-BD35-A3EF9EE9BE7A"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3E3217F7-B3C8-43E2-ADA0-8C60C55F248A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0A946F22-D8F8-493C-B29D-C4EFBADA668E"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9742da2b-f247-49b8-8b73-08fd5cc25b9f">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5bad3adf-9caf-4d6d-abf2-c12d985c08d0"/>
    <ao:body rdf:nodeID="N218cd82e65f14238a03349daec473c24"/>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:3ee8a0b9-b12e-4b34-b917-f4f9d71645bf</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:e08f2f59-a3c3-4b4c-a310-75f6166843d1</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e6ca4c27-ac31-48bf-9529-ab1c8a45c149">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d08bc5a8-e096-4eeb-b90c-32944522639c"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e9b628c8-4be0-44fd-b7fc-0837aa9533a6">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:a65b1502-21c8-4ccd-8b9b-c5752da1719a"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:133AAB4C-75DA-45B9-B12F-E9695F11D97B">
    <ao:item rdf:resource="urn:domeoclient:uuid:75121eba-b283-4645-b5df-f8224e169a5a"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="Ndd2db3e276b8417496e42122b43873dd"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:cc366b26-f745-4f83-afcf-84802664c29f</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:24ffe2c4-7822-4e8b-b521-b813f810a5e2</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-10-29 11:26:06 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d810a411-8c08-4a20-9a9d-332a0dbcb250">
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/95c78963-6986-4f03-82be-bf5bbcc9a3ae"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a55fcc9d-1eae-4cd6-88dc-8afa3291dd01"/>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:544e9b08-6a79-4d3f-adaf-808db77cb9cf">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ae5ebd88-e5d8-4712-9e87-93de42d0fed4"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8bad76c4-78a1-441a-906c-55ce6233a34e"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6ed80242-eb61-4dfa-aa6e-fc185ad808cc">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <rdfs:label>phenytoin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9d32ef53-af08-40cf-a035-176f8174db52">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary</ao:exact>
    <ao:suffix>)</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>c9dfdeb6-2e94-4dfb-9709-38c3dbcc8236</domeo:uuid>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f898a49c-9757-462a-af1d-1a9bf8c394d3">
    <permissions:permissions rdf:nodeID="N1dab71a4847a48f8bc256022d441f1c5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:d491232d-c505-464e-a382-a57f342e5396</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:e843d464-cb31-491e-93d1-b8b51097c0c2"/>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6DA2E84E-AB19-4725-8587-594694E37E5B">
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C781641D-BF17-4E60-B476-E59765D2E327"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>TID</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0605D3E8-5910-432E-ABFA-3ADA636D3736"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <foafx:build>050</foafx:build>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:version>2.1alpha</foafx:version>
    <foafx:homepage></foafx:homepage>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:44E0EBB0-041E-4CF4-9A06-CA1AF1A850DE">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/06C3D4BE-D638-4476-B823-ADD0020C5254"/>
    <dikbD2R:cmax>35</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2A080FCF-3F46-416D-AF77-BAEC6DF7AB70"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:auc>35</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7acfec2a-60c1-455f-b7b6-7a841c172bc3">
    <pav:previousVersion>urn:domeoclient:uuid:e8ac92b1-64fe-4c4a-acef-d7a5c414822f</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:41c056a7-09aa-4b5f-b20d-ffa35b22ea9a</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 13:28:11 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:09759DBC-4657-4886-A32E-B55461E2187A</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:70450371-5A3D-445A-A7E1-2E1F5E0B5EE9"/>
    <ao:body rdf:nodeID="N6ca015e765e84d8da58b0658b0fcf278"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51345ed7-4a77-421a-9c54-6238824e84d7">
    <ao:context rdf:resource="urn:domeoclient:uuid:A5D7D1AA-39CA-4E48-A91F-50B42EFA386D"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:4256471f-e001-4304-8322-e1eb4e575660</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N5e68407625854efea6e82dbffa00218f"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-14 11:00:37 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:712D9618-25B7-4CF7-8F1F-7A34EB1CBA5C</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-28 15:23:30 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9B7372E-3C69-48CE-810B-2D623912A656">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>ketoconazole (see Figure 1 ).  </ao:prefix>
    <pav:createdOn>2015-10-29 09:43:42 -0400</pav:createdOn>
    <ao:exact>No dose adjustment of FETZIMA is needed when co-administered with a CYP3A4 inducer or substrate. In vivo studies showed no clinically meaningful change in levomilnacipran exposure when co-administered with the CYP3A4 inducer carbamazepine or the CYP3A4 substrate alprazolam (see Figure 1). </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A9B7372E-3C69-48CE-810B-2D623912A656"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:hasSource>
    <domeo:uuid>A9B7372E-3C69-48CE-810B-2D623912A656</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:255b8bae-4139-4afb-93e7-759c024d4dd3">
    <domeo:uuid>191e483a-63e0-46ba-aa03-1825b0e96044</domeo:uuid>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E85641CB-10AA-4EFD-AAEF-11A1CCD2DB43">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>bupropion</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5c7e8cea-a396-43f2-a53e-4c65fd358518">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>d7a382ec-8f2c-4a1a-ba25-1a48905abb5c</domeo:uuid>
    <ao:prefix>yclic Antidepressants (TCAs)   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced. </ao:exact>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2269E5AC-C285-48E9-AE9C-C536F5421114">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B5AA4C70-0C5C-422C-9191-BB1B1825A2E0"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e75aab40-f419-4d24-8e66-c728da39c5af">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-29 11:41:50 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:b032d5f3-a425-4836-aea7-447845cd2cf1</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-29 11:41:50 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Na43fc9b358b24bd3a8c6da9a11e70c54"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:a272c89c-4ae6-4871-bf19-a443042f6023"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:e5e3aefd-43e8-4404-a1a0-b4782eac7c74</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E27FAE9-EDF7-4B3B-B054-36E694B88D89">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E27FAE9-EDF7-4B3B-B054-36E694B88D89"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-02 14:48:05 -0500</pav:createdOn>
    <ao:prefix>   7.20 Metoprolol   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>3E27FAE9-EDF7-4B3B-B054-36E694B88D89</domeo:uuid>
    <ao:exact>Administration of 20 mg/day Lexapro for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg). Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of Lexapro and metoprolol had no clinically significant effects on blood pressure or heart rate. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E59CB2D6-D1A1-4771-AE33-9048BE8E4CEC">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:2B05CAB9-B97B-452D-A22E-D8E84D97D603">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:d217f685-3bcb-413f-98bb-e6b9bb2c7dd9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:cdc72504-752c-433c-9fb7-3fb268f71dcd</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-11-02 14:35:22 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:fec451ac-bb39-4940-b0bd-4676e4a4bd0d</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N9478da06eb134f7a8f7d785eb7cd2957"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a8ad0339-4e3f-4626-837e-efbd98802192">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:17446e00-973e-4de1-9989-bf8a562942a8"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6A4322F0-9674-49E3-8475-647A19CCF969">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D11DF95F-4CCE-4E68-AF92-AE915C8DCDA2"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5adb13de-b0ce-446f-ad49-16fe6b902e5c">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>atazanavir</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/343047</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB75A44A-E683-49BF-A717-FEF4808EB2E4">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-05 16:11:19 -0500</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:6A2852CE-D29C-4BED-A012-2BB24F2DA21C</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C791A172-C783-423B-990F-54562331192F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">25</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N7c837b03719745a080bb1eddc6acce3d"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-05 16:13:14 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7E21CA9A-17C6-434C-977F-C0BFE96BDCD5">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>25</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/22532B6F-28E6-4A9D-B21B-848E8CE21C87"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>17</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2F9EC50F-66B4-42B9-8595-2B6CE61728AA"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:eda2e093-7e07-41c3-a40b-6e0b8ca3dae6">
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/22f2742d-71d0-4f52-b985-7f6ed59ffb00"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b047b34c-82ac-4fed-accc-ea6e16883de9"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C925DFA3-2ECB-4178-A803-DA206DECA0F1">
    <pav:lineageUri>urn:domeoserver:annotation:D1B47B41-FBC6-4FFD-A0A4-639256DE3B40</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F03C1F3D-D405-431F-AC1A-11BF805DF0F8"/>
    <pav:createdOn>2015-11-05 10:36:34 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c1483618-10e4-4e5c-86ba-c162c53a6216">
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/327478b0-d1e3-4a28-a87a-88fa1bf94c2c"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/28a4164c-b385-4cd9-9579-52dee3a3d025"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bab9e4de-d268-4b5c-ac3c-0d3793cdbcbd">
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N2d8b50094ec5480fb2d64c57aa621c52"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1676db5e-dbc8-473c-86bd-33b5d2304126</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:a514c52c-b64b-497a-98b5-59a862279980"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a88ad973-8e54-4b60-85f9-76b2db05031e">
    <pav:lineageUri>urn:domeoserver:annotation:c80e6eb5-4677-4797-b488-b393499f07a7</pav:lineageUri>
    <pav:lastSavedOn>2015-11-02 14:22:34 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nc367044a1f834099918d4c5d538adfbf"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C65039E6-D84A-4870-BEBB-54C2253633F2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:31A9C144-668C-4A87-B041-12809B461F68</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e7f11df6-195a-4f69-bacc-e8c628e30b37">
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/25bf3cc7-0ff9-4b84-a304-11e4073282af"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6fc2f815-7682-44a9-9533-c870a7e5b473"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:391cd575-ca0b-41da-bcc0-612d6ee43ef3">
    <ao:context rdf:resource="urn:domeoclient:uuid:13bf58c4-7b8e-4e9c-8871-e3697e55b743"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Nda7196d78a9c4bc2ab5e3d5e9e26dbfb"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:5dbfb0a9-257c-4072-94d1-111f9b905d5f</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:15bffb41-cd0a-4e36-bcad-4d7eb157bb44</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e7c24ad0-71da-4c08-b2ef-47880fc82e31">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ac8c65cd-9c15-4cbd-be9a-73f607fba988"/>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/386f7fe2-8ce0-49a8-afa5-1f7963f60eb6"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:712D9618-25B7-4CF7-8F1F-7A34EB1CBA5C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-09-14 11:00:37 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:51345ed7-4a77-421a-9c54-6238824e84d7"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f8c37ca6-8862-43d0-812a-66e06bf7def2</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:3815a2c6-4f72-4aa5-8ced-8201f3638733</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Nd66a67d010494112a88c429fdbecf20a"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-10-28 15:23:30 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N91d85a4cab8e4d10981e3c26ce7f243d">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:439F9211-D925-4ADE-A1F3-FB3A3B2E6737">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:794AF275-38FD-4082-BA1D-CB9029261F0A"/>
    <dikbD2R:comment>Combined lopinavir/ritonavir dose</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:237cf9f5-88ab-44e9-9e36-97a9da921b21">
    <pav:createdOn>2015-08-20 13:53:28 -0400</pav:createdOn>
    <domeo:uuid>b5b04e33-e27d-4816-81b5-9d0f204ec9de</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>ions (5.1)] .   Ketoconazole   </ao:prefix>
    <ao:exact>The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole. Patients who use GILENYA and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is greater.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F49B6361-85D7-450D-93B6-D2F097E0450A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F49B6361-85D7-450D-93B6-D2F097E0450A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Conversely, decreases in plas</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-29 11:27:52 -0400</pav:createdOn>
    <ao:exact>Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressants.</ao:exact>
    <domeo:uuid>F49B6361-85D7-450D-93B6-D2F097E0450A</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A25E90E4-454D-4DE4-8C12-C5CADCA63BA6">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d84db147-31a5-4a31-a6a2-7e80181e39dc">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ffabb2e0-e86b-4909-b1d2-fade666dccb7"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6c0850fa-9f5d-4f6a-90ef-af201fd49bc7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>ketoconazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E3E1944-C5DE-44AE-9FFA-57DF08EEBE0C">
    <ao:prefix>ients receiving maprotiline .  </ao:prefix>
    <ao:exact>Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.</ao:exact>
    <domeo:uuid>4E3E1944-C5DE-44AE-9FFA-57DF08EEBE0C</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
    <pav:createdOn>2015-10-29 10:28:18 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4E3E1944-C5DE-44AE-9FFA-57DF08EEBE0C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9eff6fbe-acef-473f-9896-39aa444ea6d5">
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/94c636d5-3d66-4b0b-8405-3698ff617604"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/24f844a1-6502-4f0e-b6bb-ad80c37fa5f5"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2ca7c011-6a97-4750-b293-78aad27f16ad">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:e7c24ad0-71da-4c08-b2ef-47880fc82e31"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6CFE257C-BF0A-4225-A0D7-D25F385C84A9">
    <pav:lastSavedOn>2015-11-05 15:24:24 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:a80a885a-21a8-41f6-8e6f-1f2c43009aaa</pav:previousVersion>
    <ao:body rdf:nodeID="Nc770c55746a04776bcc04c6a07b0a53b"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-05 15:21:43 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:0A9199C8-46E1-451B-83D3-AB7B680E9EE7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6B667D8-A53B-44E0-8BF0-8C06B726C03B">
    <pav:lineageUri>urn:domeoserver:annotation:A665CC85-78C0-4AE3-84A8-239535541433</pav:lineageUri>
    <pav:createdOn>2015-11-05 10:39:16 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:9148B206-ADF6-449D-A6FE-0AD4574D1D7B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N28ac32d758674f14ae081f1d4dcb4f31"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:282E16BF-4C3D-4E52-A13D-9EF41DD22824">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:44E0EBB0-041E-4CF4-9A06-CA1AF1A850DE"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D3BA8D3-08EF-4C52-A9EB-CEE8B14CDE1A">
    <domeo:uuid>9D3BA8D3-08EF-4C52-A9EB-CEE8B14CDE1A</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9D3BA8D3-08EF-4C52-A9EB-CEE8B14CDE1A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg), a potent CYP3A4 inhibitor, decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram. </ao:exact>
    <pav:createdOn>2015-11-02 14:33:29 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>   7.16 Ketoconazole   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8218580d-6c0f-41bc-90e6-99362ced4763">
    <domeo:belongsToSet>urn:domeoserver:annotationset:905B8E6E-449C-4743-9902-9E6497B1AC90</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 10:38:52 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:9C911B37-5E38-4828-811C-A0F97D404207"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:4403f91d-5c20-4b55-a967-6acec9fbd3cb</pav:lineageUri>
    <ao:body rdf:nodeID="N2f875a63ce1d4414bd66fd8ab9cedb38"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:9BBF4668-61FA-4B8A-BFCE-BE4D3CEF4613">
    <pav:previousVersion>urn:domeoclient:uuid:0c0ab69d-6687-430e-a892-5b5533243c9e</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1adcb574-a332-4eb1-a8a8-46c14ccd2101"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:4127f651-7064-4971-80c2-81de9e406a8e</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N00e7ae5447ba4bdf9e6f997073226ef2"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-10-29 09:10:04 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na276de35f00f48a08a8a71d15781feb1">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E42F6B1-6D16-46D4-9D9C-6C8C2FA0E227">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-04 14:18:35 -0500</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>1E42F6B1-6D16-46D4-9D9C-6C8C2FA0E227</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1E42F6B1-6D16-46D4-9D9C-6C8C2FA0E227"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:dbf859d2-8eca-48e6-96b9-c612be78bc1f">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:4AAB3974-2AF1-45E9-87F2-267A096DEF6E"/>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:10387F9A-9BD6-4D83-8F90-B7496B827EB5</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-27 14:17:34 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N33f1314a9de04936bca82e746d0d7ce0"/>
    <pav:lineageUri>urn:domeoserver:annotation:7703c8fb-8587-4cd9-9665-54f5cf4e1854</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3133921C-C62F-4811-8C24-1E467A827DF7">
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>6</dikbD2R:auc>
    <dikbD2R:preciptDuration>16</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1E25CA12-3785-4031-BDF4-E5E083AE41F3"/>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BE33CA4E-F2EB-4423-815D-F0BFA085F26A"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>3</dikbD2R:t12>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>40</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:03EC91C6-1133-4B13-B357-1B3DFE07AA22">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:386E944F-CC01-43EF-BFA6-0D177461C68B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5a64af67-499c-4ea4-b8e6-e3b9795c8882">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/98352f88-b57b-4f76-bc43-bf79e8c42266"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4060fdfc-8296-44b2-a184-74f2bef4521f"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A5B8DE27-AF12-4FB0-BD8C-166677E24BD3">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:58F74976-17DE-433F-9D02-2ED2792B9860"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A641BC7D-7B49-47F4-9F72-4B9DE3EE1D3A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7EFCDCD6-1E71-41B8-85CD-86C3D1269979"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>32</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B0DA0F5D-0193-4AA8-8232-5282B80AD7FE"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34AB8C7C-97CA-4843-8197-FB8C3C55216B">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>In a second healthy volunteer study,</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-05 16:02:38 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a healthy volunteer study, ritonavir 100 mg twice daily reduced the AUC and Cmax of bupropion by 22% and 21%, respectively. The exposure of the hydroxybupropion metabolite was decreased by 23%, the threohydrobupropion decreased by 38%, and the erythrohydrobupropion decreased by 48%. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:34AB8C7C-97CA-4843-8197-FB8C3C55216B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/cfca7b9f-402c-4a09-b5cb-c46981030fc7">
    <rdfs:label>maprotiline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F150CE21-F727-434D-B914-C86D3F1D1E74">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/12DF7F9B-CCC5-4505-A6CD-A659B835AB25"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>8</dikbD2R:auc>
    <dikbD2R:cmax>5</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>13</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5C5E3A41-DAB3-4C35-B5B7-D1B8C1045D40"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:78f83393-81d3-405f-b0bd-18db51919a98">
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a29bae01-5bfd-47e1-901e-b472ca98b3a8"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6ddb70de-9c3b-4e1f-acb4-ec99050dcba9"/>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6424BAC9-05E2-4B40-B6AE-6E98318239CE">
    <pav:createdOn>2015-11-05 16:10:22 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">25</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:6A2852CE-D29C-4BED-A012-2BB24F2DA21C</pav:previousVersion>
    <pav:lastSavedOn>2015-11-05 16:13:14 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:626DE9C1-C3EA-4E68-BCC0-7B4A2A5D68B3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Na046a76f2d69456cb35910d64c408488"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/33676272-5498-4e42-8a6e-20718439e0cb">
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:37716415-8AAE-4DA8-9481-DE174028FF2E">
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0171A817-E74F-4DD2-B75B-7C19CD268758"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>Percent</dikbD2R:t12Type>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/72E4E4CD-4A4B-44F2-B078-7853EAB06E27"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12>26</dikbD2R:t12>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmax>24</dikbD2R:cmax>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptDuration>8</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7487DC0A-C307-4A1A-9564-8601F8F17047">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ritonavir</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>600</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:05C027E2-9A30-4E70-8CDD-88ECC6A6C81E">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9E219433-888B-4994-B02B-CB82E67AFBE2"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6cc36614-48a6-4812-aafd-b8c8614d2de1">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B6309ABA-529A-4772-A3B0-8E92BB7534A0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A10613F7-0C13-4C8C-A483-28F020B077A6</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:9137ace8-0fcb-4284-bf74-7d88658cee2c</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:4ee03487-3bdc-4688-b337-d4e854cced27</pav:previousVersion>
    <pav:lastSavedOn>2015-10-27 13:28:11 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N883b2a40423f4808b42e1b5546499bb9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-03 15:45:10 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A13F1E79-D47B-4217-BA0E-25F026EA4893">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ADE8693E-7159-4148-A5FD-417A5FBD6EBB"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B26CD913-F144-4BFF-8967-7F740FF37133">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:97020E1A-6E28-45D5-A4DA-64A1B59C3BF9"/>
    <pav:createdOn>2014-02-19 12:35:40 -0500</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:8803D2BD-5758-4131-9F54-9AEAC91645F8</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:357321A7-5793-4DE5-BB38-BF5FA7A5D72C</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
    <pav:lastSavedOn>2014-02-19 12:35:49 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F6ABA109-B5CD-4E2A-80C2-512984D54F24">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B4E138B0-A024-44D6-B3F5-73FBF5C26DBD"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7A057117-3806-4DCE-B7FD-9B1DE8C1142A"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9dd2b6c5-5e73-498d-9406-49873126f649">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3c23d7ed-6140-4fb3-acff-8a11a697f354"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BE55D4AB-BD78-4529-B3A7-9CDF6C1CEAF0">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:02F2AA6F-085A-41CB-AC05-CD30658DB927"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f11f91ea-d728-420a-b7db-a1b3dd281805">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:241974ac-88f0-4dca-b2bb-7e0e518218f8"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2d5efba58f994e678fc80ae16fb2f55c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18ce2f6c-8703-4d6f-90ec-c9ccea256cee">
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:54621CFD-3C2E-437C-80B7-494435CD8704</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:1B8E9826-13E0-4F96-A86D-E14F8925F303"/>
    <ao:body rdf:nodeID="N9400e7898aed4d4696c7818178ee6094"/>
    <pav:lineageUri>urn:domeoserver:annotation:67f91240-e409-46e2-9170-747d802aa0e9</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-02 13:32:33 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:232c5b44-11b6-4304-adbc-3a228f5b5f20">
    <ao:context rdf:resource="urn:domeoclient:uuid:74CD3DB9-B8D5-4D61-BBF2-D28C2855F030"/>
    <pav:lastSavedOn>2015-10-27 14:13:01 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nb7679cb9f78241d7beb383a52e6f459b"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:5f277f64-7569-4100-9f86-bc53bb98d643</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:51FD3734-7223-4B4E-9A91-A00D5B0D8C2A</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9583203D-84EB-44CA-9251-012BD2D73A0A">
    <pav:lineageUri>urn:domeoserver:annotation:D04CA3A4-3F54-4555-9A93-CF7D01D68AD4</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-05 10:40:11 -0500</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:451EBDF2-14C7-4CD2-B0CC-20BB805FBEE6"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N10b40185cd3b4f6eafe63af454ec98fd"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E9CA7EB-4A14-4686-9DDE-CF7FEFC189A7">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdOn>2015-10-27 15:34:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N94936af8f91d4c64980c8835f1033ea1"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:A73F818A-C7D7-47B7-B083-A8AE6A8BD318"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:71bde1dc-fd0c-4414-b350-a39b7b67bf03">
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/fdc9e04c-c726-4f2f-85dc-f38f71d99d45"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/562927a6-69ef-4d07-954f-e413400d6887"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B17E7FC2-C6B2-4477-B4CA-E40382D95E21">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FCCFFD5C-4699-4E0F-B0E2-2310CBBF05CE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8AAAA596-1E1F-4FC7-80DB-2818693CDEBD">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1695E16A-CCD8-4D1F-86A4-AF7C1BAC36A8"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9AC2E427-C645-477F-A4A1-AF548A1D6900">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">18</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 15:54:43 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:875151A5-D31E-45AB-AD04-978CDF27BB67"/>
    <pav:createdOn>2015-11-05 15:54:37 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:AAD16B3A-194E-4163-9E3C-32C4FE81FD7E</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a33ef419-38d1-4867-880f-27271a423023">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:09776643-eea6-4a3b-a146-a688d5091f35"/>
    <domeo:uuid>0892d270-5860-48c7-9872-2fa13546bda0</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5119753d-26cc-46f0-a0c1-89d46ee0cf2c">
    <domeo:uuid>b30650c0-297d-40fb-890b-dcd0cfdf12ba</domeo:uuid>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>atment switch is recommended.  </ao:prefix>
    <ao:exact>Digoxin-There was no pharmacokinetic interaction between Savella (200 mg/day) and digoxin    (0.2 mg/day Lanoxicaps) following multiple-dose administration to healthy subjects. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/09845d67-2ea8-4aa7-a31e-47ff718f5480">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8643186B-738E-462F-8AB6-4B58B2F3D1F9">
    <ao:context rdf:resource="urn:domeoclient:uuid:5100C690-A6A2-49E5-B9BC-41945BD4D929"/>
    <pav:lastSavedOn>2015-11-05 15:54:43 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-05 15:54:25 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">18</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:AAD16B3A-194E-4163-9E3C-32C4FE81FD7E</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc0146dab964e43ada023a9f504b115b9">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/11B7452B-BF3D-4E5D-A899-E463C7BEE0E7">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>warfarin</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E32B74F4-F5CA-48D4-9535-D85976BA6860">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>carbamazepine</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3eeeade3-9d53-41a6-9564-ec2890062106">
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e407e5fe-f991-46a9-ad05-2eb50a027535"/>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/994c7ebb-ea8a-4193-9bda-f30d04539351"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C1BB8811-15F0-4F9B-8B92-3EE3BA1894C0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:210AF33D-6FDB-4675-8B59-F063C650552F"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C385EDE-D4A8-44AB-871F-1BBC7AE0E1A5">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>, respectively. The exposures of hydroxybupropion were decreased.   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Prasugrel: In healthy subjects, prasugrel increased bupropion Cmax and AUC values by 14% and 18%, respectively, and decreased Cmax and AUC values of hydroxybupropion by 32% and 24%, respectively.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-05 15:48:20 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4C385EDE-D4A8-44AB-871F-1BBC7AE0E1A5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8786378c-76d7-4d42-a7d7-59e8fd6feccf">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluoxetine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1A20B0E-483B-4C59-822A-659EF53FC366">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A1A20B0E-483B-4C59-822A-659EF53FC366"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A1A20B0E-483B-4C59-822A-659EF53FC366</domeo:uuid>
    <ao:exact>Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.</ao:exact>
    <ao:prefix>ients receiving maprotiline .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-29 10:28:36 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E937EBEE-A3C6-4315-A23C-12E016A41454">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7B346538-1943-424A-ABEB-F1C41597978D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/79E464C6-8708-4D47-86F0-50DB8659ABE6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b7d7360a-1a66-49af-a5df-33f47e310a27">
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/30e54c9a-cfcb-4dc4-b99e-fa8bdf9eefa9"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6b057895-f904-42e6-9ec6-100238727c74"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:auc></dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d27b10c6-3380-4518-912f-c75959c28fe9">
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1c47a772-7c00-4982-af21-81c5f276b8dd"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ce594858-8377-4d84-833d-9b20f2580ee1"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b1c556b0-8b87-45c2-a4b4-11d4b45a9ac9">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8786378c-76d7-4d42-a7d7-59e8fd6feccf"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4272c177-e7d8-4e23-a00a-3eb3d46cf1f8"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6a5e0107-c341-47e5-841f-a53765e2cb50">
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:t12></dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4ee6e782-fb9c-45e2-8a34-9c13d9e13a78"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b4602b56-8569-43f5-b67f-fb207fe8a237"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AB65EA97-12D8-4EF8-A68A-4F068036583F">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/915AD176-7ABD-453D-BB2E-AEA085BA5BCB"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/29C767B7-F372-43D6-AD91-4CE8CD8620CC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:31f38884-9b43-493c-ba81-506aae56911f">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8931c33c-a420-4d7f-a22f-2770f90e76b4"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6b99aee1-fb46-4e24-a561-308271db46f6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:auc></dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N41571b1377ee41cd8e1be805bd530456">
    <domeo:sets rdf:resource="urn:pddi:uuid:99A3A07C-B4AF-4EFD-A0C2-C9581ABBDA64"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08FD5455-C61E-46AA-BB91-9EE24D2C0BF5">
    <pav:lastSavedOn>2015-11-05 15:28:35 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:C5FDBA0F-92FB-46C2-AC52-A6E0F2C4DDF4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-05 15:28:22 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:830D5D6B-C940-441B-A31A-9B0C4421863B</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:56038CF2-04AD-4B10-9023-EBFF4B28EF2C">
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6D53F261-3F66-4C72-BA5C-B46B0C62C597"/>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmax>2.5</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/22F80333-CE08-409B-AF77-5A58F78778DA"/>
    <dikbD2R:numOfParticipants>14</dikbD2R:numOfParticipants>
    <dikbD2R:t12>3</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:auc>6</dikbD2R:auc>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE74DB2C-6DCB-41AC-AC68-5F4BAED43826">
    <ao:exact>Warfarin – There were no effects on the prothrombin or bleeding times or upon the pharmacokinetics of R-warfarin when nefazodone (200 mg BID) was administered for 1 week to subjects who had been pretreated for 2 weeks with warfarin. Although the coadministration of nefazodone did decrease the subjects’ exposure to S-warfarin by 12%, the lack of effects on the prothrombin and bleeding times indicates this modest change is not clinically significant. Although these results suggest no adjustments in warfarin dosage are required when nefazodone is administered to patients stabilized on warfarin, such patients should be monitored as required by standard medical practices.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FE74DB2C-6DCB-41AC-AC68-5F4BAED43826"/>
    <domeo:uuid>FE74DB2C-6DCB-41AC-AC68-5F4BAED43826</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-06 15:46:55 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>nefazodone by other highly bound drugs.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E5E34683-BEF6-4995-AC59-BA347353C443">
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-27 15:39:59 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:8872a306-d2fa-4e76-a9b6-982b676faa59</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:df313953-f237-4ac9-8f20-53c8c165a57e"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Ndedb8254d77e4045b1aa4e12adaebd16"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:b7d5809f-30ea-4475-ad8d-9905ef2e6a0d</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:cf091acb-c26b-4d0e-a3ca-64d4b84ff90e">
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b2af2c64-7c65-43bb-9a52-dfb408553e6e"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/af911d25-506a-4b2a-a019-fe8ead522f55"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4d29080d-bf65-45e7-b83b-fe5d4baac8e9">
    <domeo:uuid>45248661-ac1e-4b95-b96e-8d9292e9fc8b</domeo:uuid>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <ao:prefix> B3 (OATP1B1/1B3) substrates   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f08e08b7-bb87-4c4e-9d76-1cb3aa1c8bc3">
    <domeo:uuid>ae4216b1-ba42-4299-aab5-c6b439b17ec6</domeo:uuid>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:71D1EC37-66B8-49BF-BF79-6790566492CB">
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B2BD95D8-562F-432F-BD0C-4326B9681AF8"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cl>3</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clType>Fold</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FFC2367B-524B-480F-9458-7FEA9F81A91E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A0EAFDD-7491-496C-8A86-3F06B03B3223">
    <pav:createdOn>2015-10-29 11:30:11 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A0EAFDD-7491-496C-8A86-3F06B03B3223"/>
    <domeo:uuid>5A0EAFDD-7491-496C-8A86-3F06B03B3223</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:cdab081c-2536-49df-9581-5f0639e22882">
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/27b88280-47af-4189-bfa5-9f61854e17d7"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/357d6bbd-856d-4908-b650-b2c9cbe4e7c8"/>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5F961701-0A70-4FD1-81A8-BAFD68443F85">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1C103A43-6AF3-4BA0-A6B0-7253FA2AF508"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C662E8BA-BC9C-41AE-8CD8-635008F6D89B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8EBC3A86-CAF7-4AEB-8718-D2C34C496981">
    <rdfs:label>Required</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <dct:description>A required test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DB66086F-61A5-452A-B4E7-D5EEE6B47C49">
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/59DBF457-C7E9-4796-9895-F64A1966B640"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/513F1AB9-086D-43FD-B12C-26069E1BAF6B"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d46a91e3-87fb-4c9c-8c07-6fa432c03d1c">
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/47a1d48e-41f9-4b40-b368-ae2b45087063"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9ab59316-cef3-48fe-a64b-3868aca9e0d3"/>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:3F2DF541-1212-4311-B37E-AED945D5660D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:BCAA9FCA-F171-4F2D-A3B2-B2797B7B79FE</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-11-03 12:56:19 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:12c57b9d-6b16-4b8e-93eb-603837baf625"/>
    <permissions:permissions rdf:nodeID="N64b093b0706a4e4c91b0b2f24eec6868"/>
    <pav:lineageUri>urn:domeoserver:annotationset:99a4256f-7476-494c-a0cd-35cd054f096d</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:052A6B6C-2961-4268-B3BF-A668E7BF8EC4">
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F4E55738-F67C-4DCC-862A-8DC8424BF6D1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <pav:createdOn>2015-10-27 15:28:27 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1B50D262-6912-4222-AC3F-A2A941FC809F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A733790D-7AAE-49D8-A00D-C3957D0255E2"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:0053D67A-D687-48A1-912E-91C90EC641E8">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8a327e78-0d2a-4141-a1f8-3257d5c43500"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:4c836e45-8764-4f21-b54f-c89329c490a3</pav:previousVersion>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:80a8fd08-be35-46de-b50b-468cd931e908</pav:lineageUri>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N43513c56ab764b6f82a902e8b062c5c8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DEDDC9C8-BA5C-4C38-AA1F-BDB5B34BD866">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-06 15:37:50 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:EE4C5063-81A4-4E66-9371-A540CFDB01E5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:27387736-AEB3-4AB1-866E-8ED6BF3888BC</pav:previousVersion>
    <pav:createdOn>2015-11-06 15:37:01 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B3C6C155-684C-4977-BE60-F523ABFD676C">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:15105987-F027-446B-B840-CD318A805D66"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96FF54D7-9899-4A14-98A3-7880D30E249D">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>    Clozapine   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-27 15:22:17 -0400</pav:createdOn>
    <domeo:uuid>96FF54D7-9899-4A14-98A3-7880D30E249D</domeo:uuid>
    <ao:exact>Elevated serum levels of clozapine have been reported in patients taking fluvoxamine maleate and clozapine. Since clozapine-related seizures and orthostatic hypotension appear to be dose related, the risk of these adverse events may be higher when fluvoxamine and clozapine are coadministered. Patients should be closely monitored when fluvoxamine maleate and clozapine are used concurrently. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:96FF54D7-9899-4A14-98A3-7880D30E249D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6b99aee1-fb46-4e24-a561-308271db46f6">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38a3b6dd-64ac-4dac-90ea-bed79bfa3acd">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:807f6ff4-536e-45d9-86d4-35ec83ea818e"/>
    <domeo:uuid>733214de-cec3-4313-80ae-d98383b9dd7f</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2154c63b-aab0-48d5-bea5-4896efcce630">
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ae3967d9-09f3-4506-b221-07b3c6cbd273"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/487b81df-8dd5-4717-a6a1-92bb8fdf5393"/>
    <dikbD2R:clType></dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ed9ceac0-aa4f-468a-bb91-dc1bf56eafaf">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:75274403-bcf5-426a-98c4-65397e525efc"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:159e7cad-c066-4904-86ee-9c259903fd45">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8580b7ce-0328-4ccd-96f0-8f3bc369cb39"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ae24c19c-6c32-43f9-978a-278a3537f64d">
    <pav:lineageUri>urn:domeoserver:annotation:94766b2d-6120-41cd-8faa-030c7827c9e5</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:d159fc10-9d1a-4f5b-9fcb-e81b8b5d6cb9"/>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:cf6ec675-c122-4820-8849-28b2358fb154</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N83b01053b2be4c13bb3b67da95edfae5"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:187bf2ac-a432-4ddc-bad5-dd4ed31ce96d">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8ef16f1f-0062-41d4-8d01-c8335d75382b"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7fb442a2-92dd-40e8-ba35-e7a41884e52e">
    <domeo:uuid>e3ac938a-60ed-448c-8de5-94732f4db4b7</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:18649ed6-6a3e-4372-a03d-3ba4eb4315ab"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:840B8551-B4AC-4F9E-AF1A-915F3B409E35">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0C7DB4B9-AD07-4B4F-953D-2C0E504EDF05"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:80d5c67c-d0a5-418b-968a-68bb762a3e24">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:df1ba755-a0c8-4541-83e9-13625b8ed9ce"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2ccc5293-4aca-452e-a2ed-4e25b5863670">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-10-14 12:07:40 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:4eac74ba-8461-4e6d-add2-0f0adc26db73</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:45e00331-2a3c-48a9-9082-4986d7b1fefe</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:9670ef97-8523-4cb4-a89c-e8909be1961e"/>
    <ao:body rdf:nodeID="N2170fd16ca0d44d0892b503cb031238d"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2F9EC50F-66B4-42B9-8595-2B6CE61728AA">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>500</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>desipramine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/98297606-edf5-497c-8fd5-ba703a504344">
    <pav:lineageUri>urn:domeoserver:annotationset:22b5e32e-88fd-4373-b907-ecdc92777b13</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-26 15:38:23 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:ff67d80e-3362-4c69-9c87-73a5ee07b454"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:3F6B2FC2-1C80-43F1-B7F0-CE2C820D8184</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-26 15:38:23 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5bad3adf-9caf-4d6d-abf2-c12d985c08d0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:821ec7e5-77bc-403c-87fa-4ba541f49d97"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>a51c0ce9-7618-4356-b73c-85d901c6c447</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:721720fc-488e-447c-8386-18bedc7b3d20">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <ao:prefix>tantly administered rifampin.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>b8f558ee-e966-4743-be94-a03babd05cb3</domeo:uuid>
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C16B858F-2ED4-4D72-9186-5824945540E9">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>30</dikbD2R:dose>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BD7FC77-ACA5-4CE9-8093-25EC1F3869AC">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <pav:createdOn>2015-10-27 14:27:01 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:nodeID="N66d7f359c57d4895866c8464dcd00ccc"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4FD5C8B8-AC43-454D-B3B9-2736A012C8D5"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B19016AA-1639-420A-B594-59F3CC8DF372">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:524333E3-2C0F-4990-8C6D-188FEFF01D59</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:C23749C8-CD2A-4D5D-84FC-3B79948EA8AE"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/959fb86a-4a1a-4fad-af3b-1c178b42ffdd"/>
    <permissions:permissions rdf:nodeID="Nd2cff9feb50c4a34b90f0b826c7f3bea"/>
    <pav:lineageUri>urn:domeoserver:annotationset:8ef31bd1-f7e0-4603-8d36-48793058314d</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:F3E8A080-87D0-4805-9E6E-BF93250883A3"/>
    <pav:lastSavedOn>2015-10-28 16:37:51 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-26 15:40:28 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A60BEA15-85D6-4BBA-AB8A-467A09C58262"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0E56A3E4-1743-4CBC-8C27-9ACD1EB0C4C9"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46f84712-993b-4f4a-8501-fe9df5e71602">
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8AB883F9-D79C-4C6B-88B5-EAB2092BAA10</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:6C5BBADF-C72E-400B-97F6-E2A1265E6622"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:22e8a812-8a7b-4fd4-aad3-32b8d514f92f</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N553ca15df269459b859e5e06166994f3"/>
    <pav:lastSavedOn>2015-11-02 14:27:26 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/71E9CA78-9533-4E9F-93BE-2452A2885E03">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>warfarin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>2 to 9</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:98D71E7C-4C30-47DE-980C-D4814F49B1D5">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:097D2FF0-FD02-48D2-8AB4-9712B29351C2"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A937F4C-96F9-4410-B00E-BA0518627421">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-11-05 15:25:53 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-05 15:25:55 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C47181F5-512B-4E03-8661-1C2A3061E8BE"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1EE88710-0B98-407A-B6EB-CAF24A7B0439</pav:previousVersion>
    <ao:body rdf:nodeID="N0d0c739a82eb48eeab17a651b9aa17f8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a8df9a1a-f528-49dc-bc66-dc68eef7a342">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>AUBAGIO</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C2888FCB-E2CE-4E40-BE43-5F7DD49A64D5">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D1A7C886-B340-4346-AEDD-B454190DF225"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C9A3AEFF-8159-43C8-A24E-FB92FAA8C5EE">
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B5AA4C70-0C5C-422C-9191-BB1B1825A2E0">
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/19ACFFF3-C240-4043-AE61-A114C98B77D7"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>22</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:cl>16</dikbD2R:cl>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F1EB0B76-6419-4157-A380-D87C51B587EF"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectFormulation>IV</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F210FD11-A089-4263-89B1-25BD3EF2F28F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-29 11:26:06 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-29 11:18:38 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:D0B78559-71D5-4CC5-BCD3-BB3727DA702E</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:83D76B22-B626-4E0A-89D6-BE781064F3DC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:71D708AF-2B60-4651-BEEB-A2591DBE78DC"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5B0C656D-DC3B-453A-9B1B-3048733D55CD">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdfs:label>citalopram</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66713D6C-E17E-4C19-B978-B9FEB0BA8D62">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:nodeID="Ndaac2dbfac5b4042b99a14d86c6bf6b3"/>
    <pav:previousVersion>urn:domeoclient:uuid:a80a885a-21a8-41f6-8e6f-1f2c43009aaa</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D8232B27-703A-40E2-AFD3-B8CC8B7E3550"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-05 15:24:23 -0500</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 15:24:24 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/cda6160b-7a52-417f-a8a9-78de32ccfce8">
    <rdfs:label>TCA</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3194CA5-6966-495E-9CAA-166C6BB03F0E">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:B3836FD1-A210-46BC-8C0B-0E4D2C327AF7</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A6C3FEE-6019-4C03-B728-54EE5F290879"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N7d507c9054494213b18d11100832820f"/>
    <pav:createdOn>2015-11-05 10:38:06 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b07ac358-5acd-49fa-84f7-095d1f9cc764">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:42cd868a-38b4-4aab-bfe3-4ba60bb8258f</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8b2e6641-8e64-44cd-a239-fd56f6fd3d07"/>
    <permissions:permissions rdf:nodeID="N844dc44bc19744d1bd753493981386a9"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12c57b9d-6b16-4b8e-93eb-603837baf625">
    <pav:lineageUri>urn:domeoserver:annotation:110c4eb3-a9fb-4649-a65b-c4533f48675f</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:3F2DF541-1212-4311-B37E-AED945D5660D</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:611992D3-F33A-4D6C-92B3-C91319D52515"/>
    <ao:body rdf:nodeID="Nbd998ae207d247e6b2a1bd4a269b942c"/>
    <pav:lastSavedOn>2015-11-03 12:56:19 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5349d9ba-9d80-4373-8982-8084819456b2">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>clomipramine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2597</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E4141EC9-A9BB-4586-B9EF-279C37D2B90A">
    <permissions:permissions rdf:nodeID="Nf669069d945b4f2595f0c3b70ce4a304"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/60b62933-8e3f-4d68-8d24-1dc04f6b4172"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:bfd60df6-eac7-452f-9587-7ea52bff27d5</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2015-10-26 15:38:46 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:DD53A511-02D7-409B-8D0D-29C5AE07CDD5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:74371F34-96E0-4051-AD9C-184AB3A81161"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 11:47:00 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>urn:domeoclient:uuid:55e79272-ad51-470b-abed-f028edef9bb6</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D9726408-750C-41C4-AC6B-F7731E1DC95D">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>desipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:461871F3-C034-438D-A1BA-A546B48AA584">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:33f9df31-7218-4c3c-8711-813a68183b81"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:c6ec0dae-6f57-4eec-bec4-58844840cfcd</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:69cc2866-42d6-4124-88f2-7b061014783d</pav:previousVersion>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N6e87ee95bf324a4da3f3836edc66eb79"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-10-28 15:25:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B0A650FC-AF06-473C-9DD1-FFCC354C3CC1">
    <rdfs:label>mirtazapine</rdfs:label>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6fbd3aba-d6a0-45be-90c5-3206e713537a">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:cd913437-356d-4afe-9005-3c6c52f906b1"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6EB924A-2DC4-4E8A-BB66-643B19E876E7">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-05 10:39:35 -0500</pav:createdOn>
    <ao:body rdf:nodeID="N6eff8448f0bc4137a460339ba7c15655"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:C6DDCF14-6C45-49AA-BF55-5135BFFC5772"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:5346C482-C0C7-45AE-BD40-6BE13726E994</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:093D2DE2-86EA-450F-96BE-9485ABE5FAF8">
    <permissions:permissions rdf:nodeID="Nc29d9de5df504121bd6644dd2dfbba87"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8f1afa0a-47c7-437b-ac8a-45893f03d9cc"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:11de250c-1ff7-4923-93e5-fa2747408796</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c01171dd-7cf7-4c4f-8d93-3ec296d66dc2</pav:lineageUri>
    <pav:lastSavedOn>2015-10-27 15:39:35 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5b8129e3-a17c-4abc-a794-306ee68e4882">
    <ao:body rdf:nodeID="N71e3a3107337424194c092e740b3d754"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-02 14:48:13 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:3b4942d9-7add-41d9-98be-706632f23085</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B6192156-5215-4F6E-B3C6-3F293A9625D1</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:C014BD05-31D8-4D00-8179-925A94CB7D12"/>
    <pav:previousVersion>urn:domeoclient:uuid:10aaf547-e689-40fc-9cbf-fb5155933eed</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8A7FAE58-902A-4619-B67B-0F275C7DC452">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>mirtazapine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ab910aa-966d-465b-93ca-21f97867a457">
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:96E0C7A5-10FA-4F95-BF86-28FB3B2D7161</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A0C1CE5C-2016-48AE-BD2E-067126FD0D04"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:66398baa-a401-4867-bef4-ce2d5aba8376</pav:lineageUri>
    <pav:lastSavedOn>2015-10-29 11:36:33 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N6644edfc716444cf92b0f44be5efbbde"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB452058-2FA0-4AAE-9550-A00439838E36">
    <pav:lastSavedOn>2015-11-05 15:25:55 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5883A0CA-5EA6-47DE-9205-DCB0043E716B"/>
    <pav:createdOn>2015-11-05 15:25:40 -0500</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:1EE88710-0B98-407A-B6EB-CAF24A7B0439</pav:previousVersion>
    <ao:body rdf:nodeID="N3e48d1eff88344c2b210a040dfba5cbd"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:eb6b38cf-162f-43b7-b2b3-4c2a03c09a53">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:c8c0e695-8785-401d-a4ae-3d0e9976e859</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:09a39c26-b9ce-4012-837b-8b5454eae147</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:637de586-25bd-46a8-99e3-e8da3bcdaa68"/>
    <ao:body rdf:nodeID="N9103a227e921444280343fbe369ac52c"/>
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D99F7F7-99EA-4BA1-96D2-CFA9D45AB9DD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D99F7F7-99EA-4BA1-96D2-CFA9D45AB9DD"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>1D99F7F7-99EA-4BA1-96D2-CFA9D45AB9DD</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <pav:createdOn>2015-10-27 14:15:20 -0400</pav:createdOn>
    <ao:exact>Phenylpropanolamine (PPA)    In subjects who had received EMSAM 6 mg per 24 hours for 9 days, co-administration with PPA (25 mg every 4 hours for 24 hours) did not affect the pharmacokinetics of PPA. There was a higher incidence of significant blood pressure elevations with the co-administration of EMSAM and PPA than with PPA alone, suggesting a possible pharmacodynamic interaction [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e4f9f0d0-7a90-4afc-b517-74177eb9303d">
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8527abfc-5cfc-4ef2-8147-f3c0d0dd95e7"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/cfee08e1-a248-4a1a-a35d-4b4983bff720"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/230847e3-82f2-4b70-9e2a-afd2e32de96c">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:e1e5165e-f44f-4e43-9e41-f927267f0df9"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-26 15:41:28 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:lastSavedOn>2015-10-26 15:41:28 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0d6da63c-aeab-4ebe-9ba4-586d7a2a4d73">
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:384615ea-3ce8-4c13-b021-eef1ee96ebe7"/>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:d301db3a-48e7-4930-8f1f-6a59d63f2bfa</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:207c976d-94ea-413e-bdd5-6c80a013f944</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nf45dd07ebec24812a55b1be35cb23ac5"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C1DE089-B819-4FC3-837E-4B16B46DBCB4">
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D998AA0-150F-4852-94C7-A9E11062E28B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B91F60BA-5777-46EB-933C-BE75733F18BA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-29 10:28:55 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-29 10:29:25 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:F9C18440-3A29-43A7-B6DE-BABF9ABC37E5</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8dd21478-ec17-413a-bc58-6af4f4a34181">
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/225534b4-2d8a-4fd5-bb3b-52767000ee5c"/>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7a4ba008-53e4-4516-9789-7312965c8216"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucType></dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62C562F0-3A35-43B3-BE41-518CE3B75265">
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:45E4A44F-A62A-47C4-9AD9-D85506F62B90"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-27 14:25:23 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9F45CE3E-A65D-4B36-9F63-9F9A3E36B917">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:87222EFA-DA81-466F-8C47-B1457FFA361C"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:89BE092C-DE4D-49F8-AF8A-D1981A3F35B0">
    <pav:createdOn>2015-09-14 10:25:07 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:657debd3-6f4f-40df-a01b-424880a094bd</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:2a697652-e70a-44fe-be1e-bc4dab4feb4e"/>
    <pav:lastSavedOn>2015-10-28 14:38:28 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:previousVersion>urn:domeoclient:uuid:21f84011-6ff0-4d3b-8c78-40e8f283524a</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N4ea6e6d50cb144dba474681e9d3fb235"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:C0B2C907-F897-4896-BA9E-FB49739DCA69">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9efe1893-a4f0-420f-91b2-f43de3da156a</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:2CE2028F-70BE-4DF1-95FB-CEE788682B8B</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N5ea53f80024d418cb48242ce304ce9d7"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:99a98311-d32a-4914-a5f4-1b171e4865d0"/>
    <pav:lastSavedOn>2015-10-28 15:25:57 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5e976eb2-821a-4a78-8653-8f02df9b0b09">
    <ao:item rdf:resource="urn:domeoclient:uuid:ceea744a-d74a-402f-b378-c0dfa14aa993"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N9924c77ee9664159b8781b006c01182e"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:54d36343-48ce-4c93-babc-a3d2b85350c6</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a65b1502-21c8-4ccd-8b9b-c5752da1719a">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/22dc9bcd-7862-4140-8f62-a97b19a8426e"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e30d50fe-3a8e-4680-8792-285b32ee4d37"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DCBCDCD2-4E14-409B-9930-D21CDD9FBAC0">
    <pav:createdOn>2015-10-29 09:42:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Dose adjustment is recommended when FETZIMA is co-administered with strong inhibitors of CYP3A4 (e.g. ketoconazole) [see Dosage and Administration (2.7)]. An in vivo study showed a clinically meaningful increase in levomilnacipran exposure when FETZIMA was co-administered with the CYP3A4 inhibitor ketoconazole (see Figure 1). </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>ther Drugs to Affect FETZIMA   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:hasSource>
    <domeo:uuid>DCBCDCD2-4E14-409B-9930-D21CDD9FBAC0</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DCBCDCD2-4E14-409B-9930-D21CDD9FBAC0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F86C9668-0BB6-411C-BB37-CD5E367DCC1F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">25</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-05 16:13:14 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N80ab9894dc4d4e92863aa8f043e38092"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:6A2852CE-D29C-4BED-A012-2BB24F2DA21C</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:644CD15A-06D4-4908-ADFA-44DF683E12D4"/>
    <pav:createdOn>2015-11-05 16:12:15 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95483E66-DFBA-4453-B46D-99FC7A13E3E2">
    <ao:prefix> of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:suffix>metabolite were decreased by 50% and 31%, respectively.</ao:suffix>
    <pav:createdOn>2015-11-05 16:09:07 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>hydroxybupropion </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:95483E66-DFBA-4453-B46D-99FC7A13E3E2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N124da2e9727c4a589fad9b14a9b1343a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:95963186-0DDA-48F8-8FD1-8ABA4A5D57D6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CF4BEBD5-99E4-4580-8D38-FD1D1F3F393E"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f1da7b7f-cc82-46fb-9101-21f535f956ae">
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5605df64-91b6-4fba-a401-9504d56416b3"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/307aa3d0-77d0-4742-84ec-5772971a190f"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:28EC3532-6E1F-441B-AE6C-CD2F7D4E0471">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/70FF2AD2-9FC6-4F73-835A-B1779EC24733"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CF7C69D5-7BB8-4CA8-9AD3-117FF9A65B78"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectDuration>28</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/253d3c1b-4782-422d-b9d2-7801f58cf378">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>milnacipran</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>25</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:26C29A29-9D4D-4124-AA05-3F6A63894B34">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>urn:domeoclient:uuid:b1489dd3-693b-4c2a-9bf6-8ae3481db4b4</pav:previousVersion>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N3ec2f1bd2e05407692526475195d506e"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-02 13:56:21 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:153ccfdf-ce35-4523-8fb7-bbc722ddff5c</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:f28e573c-90af-4ebc-af95-0c43caf57cb2"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:536E063F-3624-4028-BFA1-9B22A6301E65">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1E23824B-FE7C-4F5C-BDD5-C84FD1DA458C"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:140cbe36-7b8c-4643-b19c-da2af444b8bc">
    <ao:item rdf:resource="urn:domeoclient:uuid:e7c7efb4-58dc-4c70-af88-ed9b6fed53eb"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Na7b90ea8d0bc4eefab0b14e3da9fccb3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:9573e023-6d9b-46bd-8bff-3df2c1bea8cd</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9bd0adf7-75fb-43ff-bf27-96664e917c39">
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:b5080d6c-be5c-4b45-a381-b07af5e82796</pav:lineageUri>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N7ad4a0301b5e4953acb1891e457c433a"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:09b4e6fc-fe59-4ba5-b13f-ad2f5f2a2270"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:d3da1baf-f36a-4b7d-9ac3-e54b6856f9a0</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e1e5165e-f44f-4e43-9e41-f927267f0df9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>creatinine</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> clearances ranging from 7 to 60 mL</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-10-26 15:41:28 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:e1e5165e-f44f-4e43-9e41-f927267f0df9"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/16CF7826-AE57-48CD-9FEF-B8CE28A70990">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ketoconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3390169D-640C-48A1-9899-D6D25BEFEC61">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E4ED55C9-05EB-4679-B370-734DA86F904E">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Bupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:261604a0-8631-4ff3-bdf8-99f2460cb1cf">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3b9404e4-3469-4937-b51d-af9c266cc36e</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4D70620-2D9B-432D-8F66-97CC591BA87F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:19FF64F2-B860-468D-8B6A-0EE44BE103B9</pav:previousVersion>
    <pav:lastSavedOn>2015-11-05 15:43:18 -0500</pav:lastSavedOn>
    <ao:body rdf:nodeID="N1c4067178e724962873c481987e2a743"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-05 15:43:16 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:59E4B724-3D9F-402B-8205-20A8DFEE0982"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5ece42ba-08c3-4709-bffc-ddcb28edbbb9">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:dd573506-ff39-49d9-81d5-4ae81d197777</domeo:belongsToSet>
    <ao:body rdf:nodeID="N41f49a0423514086b6ec1686a4ffe976"/>
    <pav:lineageUri>urn:domeoserver:annotation:19056f20-ef3a-4ebd-bbb7-99ed5e1013b0</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:bc4e52bb-2b48-4bdd-9e3d-7e06e9a634ff"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e8f7e10a-ad20-45b5-923d-6887371781f2">
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-10-13 11:13:09 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:annotatesResource>
    <pav:createdOn>2015-10-13 11:13:09 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:372f193d-4c8a-4edb-a4cf-d158cfb34fad"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N607db3eb2c7b4aec98f9e95c0aed9e11"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:e94e1958-f12f-4d7d-b40d-14318f4f7705</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5B76E840-6485-4782-97F3-6000B8A733CD">
    <dikbD2R:dose>15</dikbD2R:dose>
    <rdfs:label>alprazolam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3C10322A-6A5C-4CCE-BBF6-10B87F365EF7">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>30 mmol</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>lithium</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:75F3454A-EF58-42D9-9140-ACBCFB3011D1">
    <dikbD2R:auc>43</dikbD2R:auc>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>8</dikbD2R:preciptDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmax>39</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5E9577B7-6EFE-4F3E-A59B-4C2F73688DEB"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/863AB85D-F6D6-4E4F-BF38-63680C8A32B8"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectDuration>21</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ba48ba0c-7ffe-484b-a8a9-fc87211f7494">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-24 15:38:09 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:25A24A17-01FE-454C-9CC1-52EAA235C475"/>
    <pav:lineageUri>urn:domeoserver:annotation:e49d203f-1494-44ca-95d4-fa34d844d6ee</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:86DCADF4-8760-4542-8980-77F72E0F44F6</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-28 17:22:13 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N99408f56f3a14cfcbce2740d2e9f7843"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f2609359-5f09-46a1-b4e3-ec8fb37a350f">
    <pav:lineageUri>urn:domeoserver:annotation:ff2651a9-67af-4168-bf57-337104688ee2</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N4554ea5292c84d9d94fb03a965c7d8be"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:83dbff64-fb18-442c-a03a-29d9b0589e57"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:0f5b0fd1-f6b8-4aab-bf1e-88ee1dee66d5</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/2bb96f9b-fe8f-4c41-89df-f7d5718c57da"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DDA7D5C1-9A98-484F-8F24-BD3007D41FC7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DA8DE504-0594-418F-BA0B-514BC5A86474"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BFB4AA35-8B98-43A6-A4FD-742049F43D8A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2DF58087-03A0-4939-A295-087AD40A9235"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:169DFBED-1B89-4F0E-9529-5CA65AB67C10"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E3194CA5-6966-495E-9CAA-166C6BB03F0E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CC0259EC-8534-42C5-8146-84BF35F35FD5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9583203D-84EB-44CA-9251-012BD2D73A0A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E6EB924A-2DC4-4E8A-BB66-643B19E876E7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:64E2AA7B-C817-4DC3-8DA4-D5650B00F250"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:7F9BAD25-0C3E-4967-AA22-C45C8C4D7029"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8FB4BA8F-105F-4335-9FB6-A81ADF6721FE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:14369192-A740-4716-8724-40A8F3471FFC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DDDDBB73-607B-46A9-9E52-5E90A4B66B54"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E13ABBED-1734-49DA-A187-5ECE091CB52A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:36E380A4-D4FC-4A19-8633-71825303E8D2"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:07F9557F-DC24-4B48-82CC-0C579C302470"/>
    <pav:lineageUri>urn:domeoserver:annotationset:994b3987-a688-488a-83ec-76243da34598</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:E6B667D8-A53B-44E0-8BF0-8C06B726C03B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA7D4A21-4CAC-4E78-9AD8-CA536C05579C"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:a52f81db-9b58-4e87-9a26-2b50f0c8c159</pav:previousVersion>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B5F8C78F-FA93-4A00-A84A-0380C0A6B829"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B60854C8-28EA-4DAC-BD4E-48AE162C75D2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E3C12AAD-425A-4D90-A370-476976CF22EE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E66D0601-C54A-4DC8-95C6-5BFCF14C7FAA"/>
    <pav:createdOn>2015-10-26 15:36:05 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N502abc081bb0440b894c09a6330e5485"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:781B41C0-34DA-4E67-B058-A775757C09BC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:21A96475-2B40-4C80-BEEA-E9DCA5D231CE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6BD0404B-10CF-47F1-ADB4-AD9F5C146D6D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6BB02FE4-0F09-4B90-B15B-B4F23A4243A1"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:C925DFA3-2ECB-4178-A803-DA206DECA0F1"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:09FE9163-3F21-491C-94F0-EBB12BEF6F16">
    <pav:previousVersion>urn:domeoclient:uuid:95099ffa-9c8f-46e8-a43f-b25ca52fe375</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:e60beacd-9b86-4ae4-bc85-8a57d7a54644</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:C56659D4-8298-4468-B969-47772B8B51D1"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:8ED5E692-F32D-42E9-A802-F0941D286A1A"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:F58B04C5-3A70-4F3E-98E8-D59B7266A4A3"/>
    <permissions:permissions rdf:nodeID="Nc0146dab964e43ada023a9f504b115b9"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/8353cf71-b835-4d4f-a37c-0fe8b9bcc2db"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A1CA0131-423F-4A28-ABBB-BAAFAD2DFA81"/>
    <pav:createdOn>2015-10-26 15:36:49 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3cf2c7fd-04e6-44b1-a8b5-c05ab452168d">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C52059B-6935-480B-BBC7-0C6D4BB1DDB1</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-26 15:41:32 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5c6bba8f-dc3b-4ef3-8c9c-70e35edc08ff</pav:lineageUri>
    <pav:lastSavedOn>2015-10-26 15:41:32 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:db655804-81bd-4296-82cc-09a2dc1a5d15"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A08A7985-6DF1-4E33-9678-662D96CD2447">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>EMSAM</rdfs:label>
    <dikbD2R:dose>6</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40ECC315-F67E-4FAB-862E-13DA8D9AD510">
    <domeo:uuid>40ECC315-F67E-4FAB-862E-13DA8D9AD510</domeo:uuid>
    <pav:createdOn>2015-10-27 15:39:58 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean 5-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>olol and Other Beta-Blockers   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:40ECC315-F67E-4FAB-862E-13DA8D9AD510"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N38f69ae12cd043478bbd6bed41183526">
    <domeo:sets rdf:resource="urn:pddi:uuid:E6B1B8BB-AB17-40FA-A625-3EC27B1E5790"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1DE77620-FB49-4DB3-A986-1EA84CC2745F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1DE77620-FB49-4DB3-A986-1EA84CC2745F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1DE77620-FB49-4DB3-A986-1EA84CC2745F</domeo:uuid>
    <ao:suffix> may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (</ao:suffix>
    <pav:createdOn>2015-10-29 11:35:35 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:exact>TCA</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:351413C6-5C39-455E-AE02-4CDA416BEEBE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:351413C6-5C39-455E-AE02-4CDA416BEEBE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>cimetidine </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:prefix>There is evidence that </ao:prefix>
    <pav:createdOn>2015-11-05 10:29:48 -0500</pav:createdOn>
    <domeo:uuid>351413C6-5C39-455E-AE02-4CDA416BEEBE</domeo:uuid>
    <ao:suffix>inhibits the elimination of tricyclic antidepressants. Downward adjustment of SURMONTIL dosage may be required if cimetidine therapy is initiated; upward adjustment if cimetidine therapy is discontinued.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2ebf8e0974af4f6193c47394b48f86e1">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d6580d23-d1e1-41f2-8040-dceafab0d6bb">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/49370236-3c85-474d-b7ef-f1933d68e299"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/33676272-5498-4e42-8a6e-20718439e0cb"/>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a09bfbfc-510b-4f2d-b0c6-b92ff887bd41">
    <permissions:permissions rdf:nodeID="N8537060f09cf4958a04efef64306c751"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:a466d3c3-01c1-441c-920a-ffda63f61a38"/>
    <pav:lineageUri>urn:domeoserver:annotationset:919480af-51c8-4183-93c0-edd8e506fdff</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2e03c0b1-1136-448e-b2ea-8d1e2cdddd2f">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cbc149c6-cfb6-4199-ab22-607776fc0e60">
    <pav:lineageUri>urn:domeoserver:annotation:e285c14d-c27c-4f33-b8ee-859073ea329d</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:fcb60ea5-63e9-48a4-8ec6-cc9a813c9807</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N990f453309c74be099053ed4e735d0db"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:08048a70-583b-484e-81be-249f0d6501ea"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b71ce947-8d34-4274-9b24-88b6beeb1087">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>d.  Fosamprenavir / Ritonavir  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>885eaef6-bb0f-4b42-aee8-8015f5a199ae</domeo:uuid>
    <pav:createdOn>2015-09-14 11:32:07 -0400</pav:createdOn>
    <ao:exact>Coadministration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cadc682d-418b-4599-ad49-0e8f12a268bb">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:25b89398-e646-4b42-ac27-65f478e5db6d</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:97ab5251-cf4f-4925-985e-05e51157ab94"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N711ade3cbd7f49d5ab19b1a1b12982e9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:d198994a-b5c0-4024-9b94-ee1ee033062e</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cdc98dd2-ca40-4fb9-a0b0-a8ef9a0e25cb">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N9b729b4f243649aa814cfd0950e842a8"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:26f7b6a5-51a4-4283-914d-e7de76ce1077"/>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:5414acb8-0a3f-47fc-a40d-81530abdcfdf</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72BA2EF1-7A2F-47C8-9C8A-ED18DD950825">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:EE61C169-4A88-409A-9F23-4C9FC658D2A3"/>
    <pav:lineageUri>urn:domeoserver:annotation:FFEFA09E-2E07-42B0-8FEE-DCE14E780222</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0D56CBB6-C44E-44FD-8A32-E7EFF20B9DA9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-28 14:37:55 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-28 14:38:28 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na6e2bed70daa4443b0726af78fda19d6">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bde5726b-50db-4178-a39e-3a1bf15f78ff">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="Na58376e7a6654b98a3a298c6e60599a3"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:2cdcb5ef-cde9-448a-bba2-52caa1006d71"/>
    <pav:lineageUri>urn:domeoserver:annotationset:c50aa06b-8603-4009-aa44-7ddf8edcf1d7</pav:lineageUri>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/bc469497-bb98-4903-b396-5b71f858c141">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>abiraterone acetate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04A94528-5E42-4250-A1B6-C2E5309A5ED7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>(50 mg b.i.d. for 7 days) on the single dose pharmacokinetics of </ao:prefix>
    <pav:createdOn>2015-10-27 15:25:17 -0400</pav:createdOn>
    <ao:suffix>(200 mg) was evaluated in six healthy Japanese males. The clearance of mexiletine was reduced by 38% following coadministration with fluvoxamine compared to mexiletine alone. If fluvoxamine and mexiletine are coadministered, serum mexiletine levels shoul</ao:suffix>
    <domeo:uuid>04A94528-5E42-4250-A1B6-C2E5309A5ED7</domeo:uuid>
    <ao:exact>mexiletine </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:04A94528-5E42-4250-A1B6-C2E5309A5ED7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:165d91e3-8a76-4562-b2f9-b66d53316f3e">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:74B6C9D1-3EE0-4CD7-A3D7-D4CA1732386F</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4BE1ACE-0602-403B-964A-242B96EBDDAF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:df7a9b48-fdd5-4847-9891-8473529a7246</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nc848a868a6e24f5992599cc4c07fd577"/>
    <pav:lastSavedOn>2015-10-27 14:13:55 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5AC9E0CB-B444-46F1-BB07-1B6DCE1BCC09">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32968</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6E21DC0E-AC80-4F91-86C1-7010708BCB85">
    <pav:lineageUri>urn:domeoserver:annotationset:41f65b0b-df0c-41c9-817b-6fd48b092f3f</pav:lineageUri>
    <permissions:permissions rdf:nodeID="Nd695f83a1dac40ebb759b308dcb60bce"/>
    <pav:previousVersion>urn:domeoclient:uuid:6024d546-fc17-4aa2-b447-8e4f83d8f6fd</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:bb9d26df-1b99-43d1-994d-661989c91a36"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e83ecad5-d5f9-4a5a-93f3-6bbbb851caee">
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2d81b5aa-330a-4a9d-aee9-349c8b7a4fdb"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7970dd9d-4bde-4615-b09c-4adad86ec0a3"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:150AD41F-E365-4996-9439-3F57B9816BB9">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2DB92658-4E0F-4CD4-A84B-74BC5EA15F3A"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75121eba-b283-4645-b5df-f8224e169a5a">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:E2195887-8E08-4064-90FC-A46A2FC7F612"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-29 11:26:06 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:133AAB4C-75DA-45B9-B12F-E9695F11D97B</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:1a785153-388c-4fac-b0e9-e59b0a87d308</pav:lineageUri>
    <ao:body rdf:nodeID="N6131c5bb76d74a858199c240f9088f00"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B9492B68-46B5-4579-BA43-39D076003F44">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BDD9D242-5568-499D-8537-9CD798606D52"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E9BE0FC-751E-42FB-ABD3-98B7407DE970">
    <domeo:uuid>8E9BE0FC-751E-42FB-ABD3-98B7407DE970</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-02 14:01:26 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <ao:exact>Imipramine and Other Tricyclic Antidepressants (TCAs) - In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown. Nevertheless, caution is indicated in the coadministration of TCAs with Celexa.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8E9BE0FC-751E-42FB-ABD3-98B7407DE970"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF0DB672-0993-4DF9-BB33-C00CC5BBA8AC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Co-administration of</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-10-29 11:19:05 -0400</pav:createdOn>
    <ao:exact>Co-administration of haloperidol with CMI increases plasma concentrations of CMI. </ao:exact>
    <domeo:uuid>FF0DB672-0993-4DF9-BB33-C00CC5BBA8AC</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FF0DB672-0993-4DF9-BB33-C00CC5BBA8AC"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/471e0f08-fbfd-48d9-af67-203a40eba34e">
    <rdfs:label>Teriflunomide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C1B78A95-0376-43E1-B24E-91F166401E47">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax>1.7</dikbD2R:cmax>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FE5A0A95-450F-4EAC-99DA-FFD5F239C263"/>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>4</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>4</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BC5FC967-FC0D-4BE3-8C26-2A355CEDD0CC"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CB6E5200-8E6D-41C4-8721-F3D75AA71617">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>6</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D39EA529-6402-4592-B7F5-E2D177559AAE">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>bupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5D7D1AA-39CA-4E48-A91F-50B42EFA386D">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>bolizing enzymes.  Cimetidine  </ao:prefix>
    <ao:exact>Cimetidine inhibits many cytochrome P450 (oxidative) enzymes. In a study where paroxetine (30 mg once daily) was dosed orally for 4 weeks, steady-state plasma concentrations of paroxetine were increased by approximately 50% during coadministration with oral cimetidine (300 mg three times daily) for the final week. Therefore, when these drugs are administered concurrently, dosage adjustment of paroxetine after the 20 mg starting dose should be guided by clinical effect. The effect of paroxetine on cimetidine’s pharmacokinetics was not studied.</ao:exact>
    <domeo:uuid>A5D7D1AA-39CA-4E48-A91F-50B42EFA386D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <pav:createdOn>2015-10-28 15:09:16 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A5D7D1AA-39CA-4E48-A91F-50B42EFA386D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EF2BF2FC-EEB2-4F1C-8761-504B6E9F5297">
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E7BAB156-6867-4E8C-B5AF-62D13EC083E0"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/091539D9-C38B-4CF5-8573-15E765E5707B"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C911B37-5E38-4828-811C-A0F97D404207">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:prefix>  Ketoconazole  </ao:prefix>
    <domeo:uuid>9C911B37-5E38-4828-811C-A0F97D404207</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-29 10:38:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In healthy, male, Caucasian patients (n=24), coadministration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30-mg dose of mirtazapine by approximately 40% and 50%, respectively.    Caution should be exercised when coadministering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, or nefazodone.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C911B37-5E38-4828-811C-A0F97D404207"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e974deef-90c6-4c49-8711-f7b9700e01c9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:dd3ef7b5-9277-4837-a554-d25fd47bc5aa</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:b2d493e4-2cbc-42b6-97ad-aca9c5fa01ff"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N7050802cd08c4553ad0d9c05e47d31b5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2195887-8E08-4064-90FC-A46A2FC7F612">
    <pav:createdOn>2015-10-29 11:19:14 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2195887-8E08-4064-90FC-A46A2FC7F612"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Co-administration of CMI with phenobarbital increases plasma concentrations of phenobarbital </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E2195887-8E08-4064-90FC-A46A2FC7F612</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:prefix>plasma concentrations of CMI . </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1422CE8D-F3C4-40DD-B50E-E19B70A9C645">
    <pav:lineageUri>urn:domeoserver:annotation:66961AFA-D1AF-41FD-9A7F-03BC042E7470</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:839BD25C-87F1-4F53-AF2C-A0B04774BD45"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N06fe751661bf49efa2162830f171dea4"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-04 14:21:12 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:createdOn>2015-11-04 14:20:31 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bf38e6cc-243c-48b3-ad3e-84cc000009e3">
    <ao:context rdf:resource="urn:domeoclient:uuid:52B8805E-E8A5-4D42-BF78-0CA1C48B2D65"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:6a740ab4-f4c1-45b1-9221-e8243cced6c4</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N47ced6b5e25349afb2b1d70716e9cd94"/>
    <pav:lastSavedOn>2015-10-28 15:26:32 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D5DD1E34-940F-4606-8DA9-E72F658D29B9</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7d3e84bf-f1ce-4f0b-931e-ab3de78ae1be">
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>55</dikbD2R:auc>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/46640f06-2b04-4191-b718-e068e787b04b"/>
    <dikbD2R:cmax>18</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/d69859f9-626d-47d5-ba31-79485787ce72"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B605897-8200-4C13-953F-30416867B42C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdOn>2015-10-27 15:35:39 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nd053ae72bee446859ae9cb34c8d4abdf"/>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:B3947C31-90AC-4508-8E6C-6D07E0336232"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ned3f3247bc9746e091f59c468228e33c">
    <domeo:sets rdf:resource="urn:pddi:uuid:F701B842-A4F1-4C5F-8F25-42E4128F2430"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:175fa498-acab-4321-a79e-31230d5099db">
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/354ff13b-577b-4c1d-a7ad-cf974ce2deae"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f550648b-e8af-403e-856c-3458a485920e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6721659c-7f63-40e3-98f7-50f68a2a546e">
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <ao:exact>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).</ao:exact>
    <domeo:uuid>5ae7e47f-17a5-422d-9d29-22ce8d2a5539</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>see Drug Interactions (7) ] .  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:422f4355-d1e5-49d8-adda-ad6765323210">
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>8ea9d9d2-5b43-4781-a92c-909aeb297600</domeo:uuid>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e24c66c8-9b47-432c-8d4d-9be48ed0cef0">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="Nf0f1ddfac063471a8bfc63c8c4f9d0ec"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-08-20 10:29:59 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 10:29:59 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:a8f308d3-462d-45a8-91ba-a9aa8e19528c"/>
    <pav:lineageUri>urn:domeoserver:annotationset:2daff827-dd7c-4488-9fac-70e8e332adfe</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA71FD8A-2323-4BBA-88FC-F3B78D523339">
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:790BEF03-2A89-4985-B285-9874C6F4B552"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-27 15:22:01 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F90F8933-4877-40C7-8C71-7D0A2F9B0844">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2839D80C-9236-49D3-8772-834EB4B8350A"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/923B8529-23BF-486C-9C88-EEE2B8DC98BF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/33D2A299-F8AB-46A5-8682-93552F77DB96">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2d0f38d4-3457-41ff-b228-5424937bfb9b">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:416b8957-0336-4c4d-9e50-6fe428ba6d44">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-02 14:32:33 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:309BB39A-A8A0-43A0-BA83-BF57F0F7F1C4</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3D8B2F0C-030E-4085-8F18-3A0B5871468B"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nbf448d0146ff46549db367d600b30304"/>
    <pav:lineageUri>urn:domeoserver:annotation:e4240c27-f9f5-47b9-98f5-7636456eb013</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5851e8cc-c009-438c-af1c-210fdac08992">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7477443b-a5f7-4bcb-bd49-c15ee62f98e6"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7f8bde98-7275-4a2c-a670-e67c1ac1b0d8">
    <rdfs:label>Teriflunomide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:28F8675C-8B03-469A-87DA-5FEB46415C85">
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:3bdb135b-1a99-4220-8502-6bc716bdee25"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <permissions:permissions rdf:nodeID="Nadfe592a10eb4730be3dcd98db06a0a3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>urn:domeoclient:uuid:d71c347d-bbff-4ead-8b44-c3824dab4443</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:79b5cc5a-7a64-4dc1-b3bb-02fcd11bc91a</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-09 13:32:08 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/06d54b86-deff-4e00-939c-a079d6651171">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>4-8</dikbD2R:dose>
    <rdfs:label>risperidone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:660ec989-e444-444a-ad55-0e1c1a28b457">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:803c8d9a-fe0f-4e3e-bce4-ef9f5afb1093"/>
    <domeo:uuid>453257e1-6e2d-4e54-aa95-6f5f4aa4d35f</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:07fe037a-5ccc-45ad-816d-326b3d71658b">
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/aa3585f6-5f57-4267-82b8-db4b44e634d2"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6366bda1-2531-49ca-bd6b-cf3a11bb7ece"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12></dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:3F6B2FC2-1C80-43F1-B7F0-CE2C820D8184">
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/98297606-edf5-497c-8fd5-ba703a504344"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-10-26 15:38:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:22b5e32e-88fd-4373-b907-ecdc92777b13</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:9be82b85-d835-4e59-a19b-5c21b9779c77</pav:previousVersion>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <rdfs:label>NER Sets</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N6e3cde8217464e93a18e25a6acaf1dce"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:F4018177-4FBF-4667-B388-68BB93CC7009"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fb2c96c4-3b7d-4e4d-b07f-2f4beb9c8a09">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:90B3FE17-FB25-427B-A839-756EDF659FD5</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:7B2871CE-EA24-4E2D-9DE3-C431DE27226C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:ef45d280-74a7-47e1-8f60-45ac71502e95</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N16705a4ebca346e4ab031974d9dd65ec"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-27 14:17:34 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N58c1ef5a3636478baa23edc13e501a9e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:1DC876DC-F1E0-423B-A480-AC459B0CBE9C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-10-28 17:17:45 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:4b197a19-b08a-442b-85ab-3e3a37d2dc89</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Ned36b9a31ca544ee90a823c9b29dd077"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2015-09-24 15:28:55 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:aa9bb773-bea1-4778-a885-6d558f96f33e"/>
    <pav:previousVersion>urn:domeoclient:uuid:26488489-2c70-4685-8abc-9c37e00660bd</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:9C89AEDE-63FE-44CA-B4FD-1EEBC1D58CEA">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:ccc3c25e-b506-4cf5-8271-9cd06b4a7a3d"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:cd45ff6e-2ffc-4734-a93e-2e682236ce20</pav:lineageUri>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:51a0fe0d-5c3c-4720-aef0-c401894b6abd</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N40c21c2d44c6404fb52b4879c762558b"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/540d7c37-535c-48c7-abe2-536178c2ef68">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:15105987-F027-446B-B840-CD318A805D66">
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/395FD156-CC71-45E6-BCD7-936600D613B7"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/60935797-6186-4AB7-BF0F-B5D9587454FC"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b7e13ad9-ec1b-4a83-b9b6-a8e18b4d34f7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>phenothiazines</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1bfff068-5ff1-499a-a76e-cae4a4b56e20">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:638d38cc-b86c-4caa-82c9-cd55abbb2d1d"/>
    <pav:lastSavedOn>2015-09-14 11:32:07 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-14 11:32:07 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:a9019a1d-0815-475d-ac16-171e0aa2ea1f</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N43c61bd3af744ce4a6226d460a82b390"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4AB8E31A-E3B7-49D1-90B4-B9CCCBBEC165">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4AB8E31A-E3B7-49D1-90B4-B9CCCBBEC165</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-11-02 16:13:02 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Olanzapine — Fluoxetine (60 mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance. The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4AB8E31A-E3B7-49D1-90B4-B9CCCBBEC165"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0D3E37EB-5715-4D3B-8839-B544C0318C25">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>1</dikbD2R:dose>
    <rdfs:label>digoxin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ee53199a-d11b-460b-b8ca-50d1a8859253">
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8646ee8a-5b9d-46d6-8503-2889c39df890"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/009ab856-779e-4231-acb1-917c2c971099"/>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC7C2526-0D4B-414C-8239-694E9DC0B6CF">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC7C2526-0D4B-414C-8239-694E9DC0B6CF"/>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 15:32:01 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:baab44e2-0ef4-4d03-bc67-918924327145">
    <domeo:belongsToSet>urn:domeoclient:uuid:635a7090-85cd-4916-a005-f60c3e248012</domeo:belongsToSet>
    <ao:body rdf:nodeID="N0dc62955792d4ac6b4ec09c6f2fee4b3"/>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:4d1e4291-4c0d-46b1-bba9-0c4354c47950"/>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:a478fd10-506b-4c3f-a95f-5f0004f1c65c</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8a5e148e-6a79-43f7-91e9-6e46fb821965">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <dikbD2R:dose>30</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:19387379-0a79-4f78-8165-a98ef7778341">
    <permissions:permissions rdf:nodeID="Nbaf2af59fa1d456da0cab9e86413c6fd"/>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:d0cde747-7c7c-45ac-9d99-539d5039039e</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:21907306-57e2-4165-a1ab-eecc64773dd9"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B789842D-BC1D-4B52-A16C-141712ADA773">
    <pav:lastSavedOn>2015-10-27 13:28:11 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:adbc9ca6-1576-4717-841a-358fd51065b5</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:14b4a40e-d096-4336-a0a3-23179a2d3e92</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-10-02 15:20:43 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:62d64070-365c-422b-9094-ae3c64eca5b0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Ncca73be11260466fb373adb9c812ee1d"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9c3d2737-3c09-457b-adc3-440d0f15756b">
    <domeo:belongsToSet>urn:domeoclient:uuid:87fd42e6-eb0d-4fb5-8e50-b2a870164ded</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:6eecc334-a12a-41f4-ade2-5af5410704b7</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1b39f385-be6d-4f62-8713-188111981a62"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N6c3a79d9e4ac431c8d983183689297eb"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1001bb38-6afa-46eb-bae2-483e0d464fbd">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:a0fd9bad-bf27-4df6-a482-d22a7a260fa9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>be5916e6-8de6-4d7a-ac46-39de0103ad2c</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1EE0A47-3168-4941-BF7F-9CEC065537A9">
    <ao:prefix>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>F1EE0A47-3168-4941-BF7F-9CEC065537A9</domeo:uuid>
    <pav:createdOn>2015-11-04 14:19:32 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F1EE0A47-3168-4941-BF7F-9CEC065537A9"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DADEE818-5ED6-4AD0-93F8-799155FC800F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:29F65489-914C-4712-947C-75C96191EC88"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e79980d7-47b5-47f8-8c29-bff1264cd1c9">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <rdfs:label>Rifampin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/111ef8fc-dcaf-4c4e-bc60-3bbde2767bef">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:97F5F689-104B-4B44-A5E9-F94FC313FA04">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CC2580C2-D65B-4693-BAD0-A138C53EE2FC"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F1D1F48A-5A61-447F-9979-13D0F5998480"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2284FFD0-2303-4B1F-B336-F65C434CE709">
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:467836C7-9ADC-490F-9404-77ED77633412</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-06 15:36:55 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:42AE6905-DD7E-4CC8-BA39-6D18E8C510FC"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-06 15:35:55 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FDA9A854-8492-46B4-84A6-0940A4CE35FF">
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:172B4563-4648-4E3C-9ADA-0C2A2E655F90">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <pav:createdOn>2015-10-28 17:21:25 -0400</pav:createdOn>
    <ao:exact>In vitro studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the Cmax and AUC of desipramine increased approximately 25% and 17%, respectively. When 400 mg (8 times the recommended 50 mg dose) was administered, the Cmax and AUC of desipramine increased approximately 50% and 90%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug [see Drug Interactions (7.5)].</ao:exact>
    <domeo:uuid>172B4563-4648-4E3C-9ADA-0C2A2E655F90</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:172B4563-4648-4E3C-9ADA-0C2A2E655F90"/>
    <ao:prefix>, metoprolol , atomoxetine )   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:90de22fd-85e7-42c4-bc65-3433113412e3">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4732e899-4ed8-4d7e-b5ed-26d55bf192f6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B7870964-BBFE-49F2-8ACB-3B25C3AB2673">
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:9fd09b54-4746-4331-82fb-3bde60c2663c</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:95c57983-3208-462e-9a1c-8f0709a8567e"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:5a2615c7-b04d-4b25-8b47-057e371472ff</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N355bd01d424d40eab8a9ef75ce496514"/>
    <pav:lastSavedOn>2015-10-29 10:33:12 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:C397F3D7-D462-4F97-8A7F-D50A88A55469">
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/8a3f45f0-1ede-4c37-b66f-94011a58f5b5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0BED03F0-8E0E-4F53-9AE5-0B6D055B59E4"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0ad2caca-4550-424f-aad2-6b75d62a2214</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:annotatesResource>
    <pav:createdOn>2015-10-26 15:37:31 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N77a0d4f2834244d9b704c0c30fd9ced1"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:62b1d62c-e1cd-45e9-8b38-4ab9723b863b</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 09:45:11 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:78663589-F9AD-496D-907B-E70693832F7B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B9D6BA71-DB5A-40DF-853A-CD33D3656182">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>30 mmol</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>lithium</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F8CE630-F8EF-47C8-87C1-EBE912609938">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F8CE630-F8EF-47C8-87C1-EBE912609938"/>
    <pav:createdOn>2015-11-04 14:20:49 -0500</pav:createdOn>
    <ao:prefix>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>8F8CE630-F8EF-47C8-87C1-EBE912609938</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:971C7820-2663-40F7-8019-F3EBC13A6575">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2858A178-24D9-472B-BE99-812F1B1CFD50"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/803C4BF5-3D5F-4649-8090-A66824A336D8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ac37d682-4ea3-4be6-a17a-a9d2b1c04b7b">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:fc97c714-0a10-42d7-aa73-ece5d87c4723"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/696ce589-98e2-474e-b1d5-491be0403d14">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>pioglitazone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8440DE83-5B2F-48CB-B6D9-4B886805595B">
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EE9A35EC-F5C9-4CE3-892C-2B674061FDAE"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A083FA00-4955-4A90-AFD3-B4B898A19F55"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cab1a445-82e4-4e30-9239-eaf37a1c3672">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nea9edafc67fd4bd487238248108af8f3"/>
    <pav:lineageUri>urn:domeoserver:annotation:369d5389-1e54-4c84-b2de-2c27962d0645</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A03DDA98-3E63-412B-93BF-F7759CCD2CB7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BC917887-241A-47D1-8DF1-BDCF66117D70</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c690f73e-2339-439f-b5f2-ce813d107388">
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:499d4d64-b3e9-43f8-8074-d0363ea7b606</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N60f9d19799304492adce3a102f9e7b73"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:c863d380-029c-47e4-9738-fbd233c9d66b"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A733790D-7AAE-49D8-A00D-C3957D0255E2">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2D761C04-2758-42B7-B1E1-7D47C91191D3"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C4B0ADA6-0BAA-438C-AFC9-2DE7FD63F829"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:797348f1-fe91-4734-a141-f27afd4297cc">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:a6d02742-82bd-4497-be46-4e50e03ea8ab"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AFEA092F-A14C-4CD1-BB29-86D0231890B9">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/95c78963-6986-4f03-82be-bf5bbcc9a3ae">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D78EC978-BF12-42E0-A78C-FDE24FFFEF71">
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:auc>66</dikbD2R:auc>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4881C787-F8E3-4414-81AC-DD07E3240F6B"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>62</dikbD2R:cmax>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/22142CA4-11B9-4B93-B63A-656632F2886F"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:CC25777F-B8E5-46FF-A194-D243F2B44210">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:db0e1f27-51bf-4c3a-81fa-a570c5d8a9d0"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5E3DB743-5935-485F-A2DD-9ECD1392D3B0</pav:previousVersion>
    <pav:lastSavedOn>2015-11-03 12:56:19 -0500</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N69e0cef487574bc7897e7fb6f6f71b11"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:664f0498-595a-4527-a861-133124c16c6b</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A032EDE-54D3-4848-B61A-7717F80F3883">
    <pav:createdOn>2015-10-27 14:26:03 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Ne0ec3d5ba1a34221b8b9c4439849ceaf"/>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F4234895-42FC-4CE0-8A08-8B1BF4544420"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:35291613-E433-4969-A249-28F19B95C3BC">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:56038CF2-04AD-4B10-9023-EBFF4B28EF2C"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E6B1B8BB-AB17-40FA-A625-3EC27B1E5790">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D74DF87F-814B-4FC3-8E69-DC64814EF8AB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4cbc767f-9c50-4043-b361-69cc86d1da58">
    <ao:context rdf:resource="urn:domeoclient:uuid:4BF6E489-3D75-4997-BF08-6C6C2C5B6A6C"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:cd4b1fdb-c7de-461f-87d9-d0e844e9fdbb</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoclient:uuid:0638f142-df0b-4ec0-a150-c4fcb1f2631d</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:9B2A10FB-A843-483F-ADE7-0BBF5CE7A00A</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 10:48:13 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N5e47d1ff7a1349599cb92dc6cca55b3f"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3d1161bc-7cd5-4906-9b4b-56609c467a54">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6d0c3c0d-1047-400d-b58c-8c85e3dd95d9"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a9dc0aab-95ee-4311-8b21-3ad65f71d7f6"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7970dd9d-4bde-4615-b09c-4adad86ec0a3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N83ac88a9f6514cd8a793f5aae6787457">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15A1BBA7-0D5C-4282-A64C-EF20766FA9F6">
    <ao:exact>No relevant clinical effects or significant changes in pharmacokinetics have been observed in healthy male subjects on concurrent treatment with subtherapeutic levels of lithium (600 mg/day for 10 days) at steady state and a single 30-mg dose of mirtazapine. The effects of higher doses of lithium on the pharmacokinetics of mirtazapine are unknown.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>  Lithium  </ao:prefix>
    <pav:createdOn>2015-10-29 10:48:13 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>15A1BBA7-0D5C-4282-A64C-EF20766FA9F6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15A1BBA7-0D5C-4282-A64C-EF20766FA9F6"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2c1fb7bf-9548-42d9-af4f-4646a00f3732">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-26 15:41:08 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c4a875d9-0edd-42b9-a1d2-af1fdfc9491f</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6480ba45-6243-41eb-a0f8-d38b95d3fd58"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D21F7444-0694-40EE-BEBB-19138C9D3A3F</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-26 15:41:08 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:28B8819C-FACB-470B-B82D-9B499A63B4B6">
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DBEE5221-D401-40BE-B949-C3C7B4828E78"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmax>50</dikbD2R:cmax>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/72EAB02E-B97A-43B0-AC73-B67740393484"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D9B002C4-004B-4DA1-9EC8-B7DF51D8A4F6">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8FD2711D-5BD2-4CFC-9202-578B267F6B47">
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/37D583E5-5B1B-4D2E-9AFC-DDF1D21D8512"/>
    <dikbD2R:cmax>50</dikbD2R:cmax>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ADE1F100-FF93-4C96-A376-BB17E2036EA9"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:16020a08-b9b2-4a03-9f15-eb3f2a733e4f">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d5fd3385-f0fd-415a-ae53-0baf111ab79a"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C312DCF4-7BE7-409F-ACFA-A1E3C8AB0CAB">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N5104392e30cc462b83fd06fa635716af"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-05 15:29:38 -0500</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B7BE1296-FCF1-443C-B8E8-FA07AD2AC3D4</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8723B5A2-1463-4E00-8C97-849A6B27BA04"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:lastSavedOn>2015-11-05 15:30:13 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6FD15A0C-0770-4A9E-AB6F-F3ACF5A86142">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9FAE172C-E425-4669-80BF-3225135F5006"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2a697652-e70a-44fe-be1e-bc4dab4feb4e">
    <pav:lastSavedOn>2015-10-28 14:38:28 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N96819434f1ca4819821f03b42a8f24b6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:EC1B08AA-FBBA-4D9C-9A6C-CC98ACEE2568"/>
    <pav:createdOn>2015-09-14 10:25:07 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:2d1c56f3-6bb2-4730-b1b6-f0d0826efef4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89BE092C-DE4D-49F8-AF8A-D1981A3F35B0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2953d13d-bf11-4341-8850-095dac3e8c22">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8dd21478-ec17-413a-bc58-6af4f4a34181"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1fae078f-c814-43fe-875f-47db931332b6">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:d8a2ebeb-cad5-4571-977d-fd6d54219bd4"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Nfcc43477cf314d8ca9486d9cec52b02d"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:358114c5-6285-49f7-bff7-15e5fbe2fe10</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/233E1779-D913-4A5A-81E0-F1F4A26F36A4">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4053</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>erythromycin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B01014F1-2BD5-41DC-9CD5-46941B420262">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9BE7208A-31F6-4889-80F7-5437B259089F"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:312E826B-20AF-4BDE-A339-26DEE6333413">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N2564a8d460f54abe902448bda64f82de"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5B16E11D-4A0B-4982-BD7B-1C6FB3DFDFD4</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <pav:lastSavedOn>2015-11-05 15:48:28 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-05 15:48:20 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:4C385EDE-D4A8-44AB-871F-1BBC7AE0E1A5"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BEEA7C5B-9654-4244-9C6C-8D96EEC7842C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N71f8c542a4f0492db5acd17228235a68"/>
    <pav:createdOn>2015-11-05 15:42:41 -0500</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 15:42:42 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:81946427-E8CC-4FDB-8FD1-22A0D561298D</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A8AD40CF-1945-442D-A3B4-373AC8E7B15A"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:61bbf6cb-ae90-4232-85aa-9ebf7600cabd">
    <ao:body rdf:nodeID="N0ad8d340a467402eaed9bb9ded6ee41b"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2F3CB7C2-BE04-48F6-A831-60BE526797C1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-27 15:38:36 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:dbd2caa0-998f-48a2-b6d7-d669664e8baa</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E571972A-4EC7-4480-8000-4A9FEDF958A7</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ddffd58b-f05b-48c5-9676-1772bfd65429">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/56946</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paclitaxel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2870A02C-6ED1-45AE-802C-243EA5D102DB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42330</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>terfenadine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0f606eec-3dba-4075-ba1a-5253cbbb7764">
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0db0d5c8-15ea-44cd-8f0e-3894f007c5ea"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b1df51f6-8759-4adb-a58a-8c5fb5ee4cd0"/>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8e06dac1-d04b-4e9d-bbb9-949405dcbf2f">
    <ao:item rdf:resource="urn:domeoclient:uuid:10cfcb0e-8c2b-41a8-b34a-9ff579c20c02"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="Nc1e6806b2db043d0a5cd57cd23f1c0df"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-09 13:39:25 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:6af70527-7490-41ae-ba8a-88bcc8456840</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-09 13:39:25 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BE7DDE94-24BC-4324-9856-F896DC577B26">
    <rdfs:label>mirtazapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>30</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0841C075-602C-4F86-9DF0-FE17FC65705F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>800</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>ibuprofen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0c426a6d-5c38-4c4d-967c-4072b6e22f88">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:d615093b-2fa6-4225-867f-f5f3f18c6ddc"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
    <domeo:uuid>a2e426f9-cfcb-4631-848c-6d43cfc9126f</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71785B52-CF7E-41E2-9AD6-03F6ECE94463">
    <ao:prefix>s of CYP3A4 ( ketoconazole )   </ao:prefix>
    <pav:createdOn>2015-10-28 17:20:07 -0400</pav:createdOn>
    <ao:exact>CYP3A4 is a minor pathway for the metabolism of desvenlafaxine. In a clinical study, ketoconazole (200 mg BID) increased the area under the concentration vs. time curve (AUC) of desvenlafaxine (400 mg single dose) by about 43% and Cmax by about 8%. Concomitant use of desvenlafaxine with potent inhibitors of CYP3A4 may result in higher concentrations of desvenlafaxine. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:71785B52-CF7E-41E2-9AD6-03F6ECE94463"/>
    <domeo:uuid>71785B52-CF7E-41E2-9AD6-03F6ECE94463</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29103046-22d2-4540-95bf-f19eb037108d">
    <pav:lineageUri>urn:domeoserver:annotation:cd128c22-eb65-400b-bc3e-5f73388b02b0</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:7140387d-2bdb-48f9-b9cd-02b8b11523ca</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:2ac723cc-6808-4d41-b5f9-cc3cc46518eb"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N74c622ac32b34e14b27c46b9a5210b2a"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9cf9b37e-236e-4191-83db-2d6e99958800">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7036F77F-8326-4700-8587-001839F15EA1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:74B5DF46-170D-48DA-9F73-90F0895A77D9"/>
    <dikbD2R:comment>3-fold concentration increase</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:87222EFA-DA81-466F-8C47-B1457FFA361C">
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>21</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FDEEC25B-F6DF-4F00-BA9C-F735D2E7E7DD"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0F1A2F27-E719-4C32-85E7-CCC9B7175CA3"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BED03F0-8E0E-4F53-9AE5-0B6D055B59E4">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C397F3D7-D462-4F97-8A7F-D50A88A55469</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-29 09:44:38 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F4F2C662-49AB-4D03-93C5-B21F2E01D42C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N092c9442dc8d40a681c66e34c6850423"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-29 09:45:11 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:8C6D4795-B7B5-45FF-BD20-2D8A9335E886</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f94b7dd8-9be2-477d-8eab-4df82b537c45">
    <pav:createdOn>2015-09-10 14:41:16 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:4AB8E31A-E3B7-49D1-90B4-B9CCCBBEC165"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2719D41D-BE05-4B53-9F79-2EC3AB1C97A2</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:2bca436e-c2dd-4e07-98b9-256058736fa9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nc105c42c3c6e41e08e006d8c06660616"/>
    <pav:lastSavedOn>2015-11-02 16:13:06 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cb595e91-e1ba-4a6d-83a9-d86fa5159961">
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:prefix>er tricyclic antidepressants.  </ao:prefix>
    <domeo:uuid>e5421ac8-8e62-4846-a906-2d685145ebb1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:17E19BC9-3C76-4B2F-AC75-FA619D4CB9D2">
    <pav:lastSavedOn>2015-11-02 14:30:38 -0500</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="Nc57568bb7fc048b3ad7aa879075d9b77"/>
    <pav:previousVersion>urn:domeoclient:uuid:9f764c11-7f9f-4856-86ed-984f118eb2a3</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:1ef2e6a4-7677-4319-8d61-712cb7954c83"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:d37a3a39-acab-456d-8ee4-2e510644ed4a</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CF763442-9F98-46B3-9D4A-7928FCF835AD">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1BF1A01B-3BA6-41AE-8051-F265CDDADEA7"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b45d9269-19ba-4d37-bcf9-77eb27dcd79f">
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/62be5ad6-591d-4bfb-9e45-8333befbaddf"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e923d82d-a8bb-47a8-b245-3b89ca5b4582"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:40C952BF-5CC9-4F9E-9A1C-E9430E07F888">
    <dikbD2R:comment>Combined moieties of threohydrobupropion and erythrohydrobupropion</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BCBCAF85-FFE0-4818-B942-0489DD3E75F3"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/279684fe-a069-453b-8d14-23eb35d9a2cc">
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A7AE82BF-B99F-4549-AF3C-3506B47DB5BA">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42330</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>terfenadine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:eaf2fd7e-9ac7-472f-9d79-08541fb6f666">
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3e46d2c8-5b14-4301-a0d9-8fedeedd9593"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/035f8aaf-3a12-423a-b5ef-a9de8521e8fc"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54AB6A26-6737-414A-832E-83E0F0B18EAD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>54AB6A26-6737-414A-832E-83E0F0B18EAD</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <ao:exact>lithium </ao:exact>
    <ao:suffix>(30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:54AB6A26-6737-414A-832E-83E0F0B18EAD"/>
    <ao:prefix> (40 mg/day for 10 days) and </ao:prefix>
    <pav:createdOn>2015-11-02 14:26:35 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F1A3DB4F-0849-40F6-B489-795A6F0C6AA6">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/80BFBF5F-5D12-4245-A436-F08EE6F5850A"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3101FF80-E3B3-4B2B-B800-B478744873D4"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bca5edf3-fdea-462c-ab45-93d161f014ae">
    <domeo:belongsToSet>urn:domeoclient:uuid:5f4e182e-5b18-43ca-89a0-e58769bb7987</domeo:belongsToSet>
    <ao:body rdf:nodeID="Nd284c39ece6e449994a2dbe39e3a5820"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:af40e5fe-8c70-43a0-9cc3-f5ce1e1674d5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:e2c7ec63-3a0d-4a44-a69f-f59faf5c6434</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3AC99F8D-E316-4138-856D-AF3DD84F5D89">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:9154CCD4-1194-4206-AB0D-3451A8874499</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:54AB6A26-6737-414A-832E-83E0F0B18EAD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D21F7444-0694-40EE-BEBB-19138C9D3A3F</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-02 14:27:27 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-02 14:26:35 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B56751B4-AF9C-4DBF-A5E2-C85185834522">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75b873eb-3b7d-4683-b123-18c27d67a5c7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:caa0c76f-96ca-4959-b0e7-f4267d3ba603</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N53cc8e39f84a4d6b8e05d650cdffe1be"/>
    <pav:lineageUri>urn:domeoserver:annotation:8f468815-5a1d-4661-8e0b-8d3e3a224cd5</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:001cfa14-7746-4bf4-a4df-51a6bcf45623"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d3da1baf-f36a-4b7d-9ac3-e54b6856f9a0">
    <permissions:permissions rdf:nodeID="N1679a3905f5542eb9916468bd9383ce5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9bd0adf7-75fb-43ff-bf27-96664e917c39"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:60dec65e-c82b-4dfe-b7e0-d16675c1c8ea</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99107690-14ae-48c9-b6a3-8b74a0fb6004">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:9a2525c3-0bae-4abb-84bc-9b9f02dd5282</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:c3d55034-f27a-4d8e-bc99-f4aa1c00f3fc"/>
    <ao:body rdf:nodeID="Na0c65db134684ec883fa2c998d5b495c"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:5af06d30-0e48-4634-bcac-3f2f53d15576</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4934ef62-8db5-4ef4-8abd-1690c71c5814">
    <ao:body rdf:nodeID="Nc3098b71bea64e4ea047948892850079"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-10 14:41:16 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:546ccce8-ddc6-48b5-83f3-94101284a5b8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B975DC3F-9F3B-40A0-AAAF-AD9E9DEAD722</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-02 16:12:40 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2D7C8F33-3F77-4103-A6A8-BC8795CCBCD3"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:35ac8c94-8788-4a60-b0fa-06c5366818b9">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/c200a0ab-e8ec-4ad5-90e8-fe467fab6f75"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b7c9990f-962e-40bb-9654-4b5c06c3298d"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:aaeeb785-a4ea-42a3-b83f-33ba137ff1c2">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:b557e3b2-7f5f-41f4-b619-89a7660fc3c3"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:2ecef709-37db-4e40-9658-34000ff7c38e</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N08cec0140ff84942a0c1acf8613dcd07"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:2312a14b-9113-428c-98ca-6a84fe3ef43b</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:216744d1-4f9b-41a9-aeac-ff03ccaee95c">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N7f6231e6eede42978cb7a8a82844ef87"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:3ae3b9b0-a127-4669-95c5-8271246642a9</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:87dd2aa7-737b-4670-acac-935fb7d7547c"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4131B4A8-D97D-4570-9B36-BC1D177DE005">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2B3C3834-BFFF-4D50-BEAC-DB1B916682B9"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/854d7ea8-6d10-46cb-bd32-c757a1f4d867">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>olanzapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6BD0404B-10CF-47F1-ADB4-AD9F5C146D6D">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:F840A893-B78E-4E40-BD7C-B8D2E57A15F2</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:71B5DDC3-C204-4EE1-B675-C0039CFBD9A6"/>
    <pav:createdOn>2015-11-05 10:36:35 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9041d0b2-fde1-4222-a6b2-ba1b41613c4c">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nf09e9e18d3d244ad9e7055402bbc0b42"/>
    <pav:lineageUri>urn:domeoserver:annotation:d032fbca-a642-49b2-9d8f-5ebaa7ebfe38</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C6F4FDC1-8820-48F1-AC68-629C968A965D</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-27 14:17:34 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:249C5208-00A9-4C04-A032-E7CFBDFA5552"/>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f588d43c-35d3-402b-b240-10b7d6e3b1ac">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6083b192-cbb6-4db3-b058-99b4a5d36f52"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/d81705c8-02a7-4db3-a04d-950b70aa13a7"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7014615f-a989-431a-bafe-bda154de4fb1">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-28 16:46:43 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1D62F0FD-B317-469D-8729-9DB0ADF6D587</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:06c80a14-b87d-4730-8f7a-f4af8f126f31</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:47EAD704-8F7F-4017-B0ED-49D8D6DC6D6B"/>
    <ao:body rdf:nodeID="N7f970c479402456d9f79e6cae8db7067"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-10-09 13:32:08 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F35B5C59-2605-4012-90C0-CB0C838A711F">
    <pav:previousVersion>urn:domeoserver:annotationset:751FBB26-E5EB-4878-A2EA-2B9845EC5906</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-05 16:07:34 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-05 16:06:44 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">23</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:EE04A105-63F1-49FD-825D-5DE83F516579"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/34BD3DB9-5249-442C-8A9A-E3E536702D1B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>mirtazapine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>30</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:183e162d-172e-4e51-89e9-be54836b04e2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:30b508d8-c205-4f8b-ac86-0550292837bc</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:3d5bf9ae-1c0e-43e6-890b-585e9b48a857"/>
    <permissions:permissions rdf:nodeID="N28622fc77bef4155b53d740d82e4bb3b"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6A66CE40-FD62-418A-8033-06BAC3DD9E03">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D74D48F-FE26-442A-9CD1-BE6D3AAB0CD0">
    <ao:prefix>    Theophylline   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7D74D48F-FE26-442A-9CD1-BE6D3AAB0CD0</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 15:31:15 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>The effect of steady-state fluvoxamine (50 mg bid) on the pharmacokinetics of a single dose of theophylline (375 mg as 442 mg aminophylline) was evaluated in 12 healthy non-smoking, male volunteers. The clearance of theophylline was decreased approximately 3-fold. Therefore, if theophylline is coadministered with fluvoxamine maleate, its dose should be reduced to one-third of the usual daily maintenance dose and plasma concentrations of theophylline should be monitored. No dosage adjustment is required for fluvoxamine maleate tablets.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7D74D48F-FE26-442A-9CD1-BE6D3AAB0CD0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf712b56bdaa24a56884c8c2854d247f8">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33f9df31-7218-4c3c-8711-813a68183b81">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:461871F3-C034-438D-A1BA-A546B48AA584</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-28 15:25:57 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2F90AB56-153C-470E-BDB9-94F2B9204172"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nc7fcd7031cd44801b722667f446cefe2"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:2a1263e5-7af6-4db6-acb0-784f64bb6979</pav:lineageUri>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:43c9947e-0432-494c-9dbd-82554c92fd50">
    <ao:item rdf:resource="urn:domeoclient:uuid:0e603e8e-68be-471b-b161-99ec92d48d47"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N7cad7ec25a2b4ecdb3bc2e032aac47e8"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:8da6a86a-9179-4ef2-8065-428351d25bc1</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7bdad30e-d65f-4e9b-b295-a929e28682ef">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:98b0e936-9255-4595-b05d-b2719efa3385</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:E51BF9BD-A111-4938-9E6A-2702C8889B87"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-11-02 14:00:45 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nc9db14ed4d454aa2b1cb2279d5caa798"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D4144D4B-58CC-487F-A4EB-E611D622A2C5</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a8f308d3-462d-45a8-91ba-a9aa8e19528c">
    <pav:createdOn>2015-08-20 10:29:59 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:e24c66c8-9b47-432c-8d4d-9be48ed0cef0</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:978cf9c8-5d70-4aaf-a45b-0a0dc99400c3"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-08-20 10:29:59 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N435d48c6e13c441e9876c089a472251d"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:789a9b01-2d83-41ee-a80c-9f7656b54181</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/60935797-6186-4AB7-BF0F-B5D9587454FC">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e945bdf6-5b3d-45d7-9264-a708c2349f5d">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:41744ACC-292A-4E40-BD26-311E80CF8160</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-29 10:33:12 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:12db3a9d-e637-4a74-89cb-85f09e1cc1b7</pav:lineageUri>
    <ao:body rdf:nodeID="N732212ce980b485989c0ef46ac57f199"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:7FCFFF78-4590-4380-A581-6EF965495DEA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:27BB3D6B-C148-4A9F-B65D-EFEC7336F040">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6ED2BF46-8719-4A4A-917F-A5A9B854A088"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:608AC101-BC3B-4B0F-97DD-A1EE6CA20CB3">
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-05 15:32:16 -0500</pav:createdOn>
    <ao:body rdf:nodeID="N65b7f2dffe4e45b996f70bb47f103a6d"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:B0C387A6-CEA4-4C12-8E2E-28EB2A0E1A89"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a4b4b310-c7aa-4dd8-8981-be90134b4ecb">
    <dikbD2R:dose>60</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/28fd3e88-85ff-452c-9d78-fdf289fd103a">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>propafenone</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d5fd3385-f0fd-415a-ae53-0baf111ab79a">
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1953ca2e-773e-4b33-afd4-ed3e79e2cfa4"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:t12></dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/45e53bba-b48f-44f8-b954-fc34181bc8a8"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5c50debd-1884-4895-8e46-93cc834ab3fe">
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8f7b32bd-de00-4a01-bb60-c178df00fcb9"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/feeaf27b-e993-4b63-8fa0-1bc1a2f74dff"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:142D170C-7C70-46F7-91E6-F859F3C5486F">
    <ao:exact>Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism. Nonetheless, at this time, it is recommended that plasma phenytoin concentrations be monitored following initiation of sertraline therapy with appropriate adjustments to the phenytoin dose, particularly in patients with multiple underlying medical conditions and/or those receiving multiple concomitant medications.</ao:exact>
    <ao:prefix>should be contraindicated (see CONTRAINDICATIONS ).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:142D170C-7C70-46F7-91E6-F859F3C5486F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <domeo:uuid>142D170C-7C70-46F7-91E6-F859F3C5486F</domeo:uuid>
    <pav:createdOn>2015-10-28 16:31:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9687cd1a-e6ed-4c90-b235-6224ce97a607">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <rdfs:label>Rifampin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8E0C017F-2FCA-47CB-B0AA-BF96985476E5">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/db0c596c-d59f-4bfb-9d87-a0017bb988f1">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>GILENYA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N56a8a8c2473f4ff9839e9570aac0ead1">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:984127CA-0CB4-4B98-A0D7-CAE7C8419D3B">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:71DC25B5-D060-436F-8B88-8BE8EB8117FE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06debe12-5d72-48aa-8e49-5375b6342ed9">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N162be5447a5748efa9a9550973596581"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0556E268-C456-4FB3-85D0-93EE6D99C185"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:334c95cd-0e24-48ec-9380-92dc8b5e1b16</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:640C8BB6-6FA8-45D2-8960-97F7036356BE</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1D7DF3BF-E708-4923-9D2B-C1A353FF8E82">
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2BC37D91-8AC1-4381-BDC9-FA7F8FB7C731"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A550C9E3-FC7B-4A62-8D2D-87F0720034C6"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/915AD176-7ABD-453D-BB2E-AEA085BA5BCB">
    <rdfs:label>sertraline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:735951cc-134f-4d32-b09e-9c50fa3c961f">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:d123a3ef-b6ae-459f-959c-96bcf6287519"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:ec8ef2a6-836c-47bc-a029-dc1416e17095</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="Ne4f245178cc04a5ba1ab5672510aa12d"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ad19eba9-2e55-467d-b3e7-60ebe47297e0">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, levomethadyl acetate, methadone, halofantrine, mefloquine,</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>pentamidine</ao:exact>
    <ao:prefix>e.g., </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
    <pav:createdOn>2015-10-26 15:38:58 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ad19eba9-2e55-467d-b3e7-60ebe47297e0"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CE6CE54F-7070-4B0E-B47B-D7598A860A30">
    <rdfs:label>citalopram</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3EEC50B0-D1AA-4EF5-90C3-8F4C7664A640">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F11B639F-D14D-41E0-B966-EFF0F5152A8C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CF726AFD-136E-411F-AC25-A57B7FB07BB9"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/46747E2F-0D7F-4D6E-8DC2-D949CDDE63A3">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>lithium</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6A63B9B0-5F83-49BB-BC48-999F9B98B3FD">
    <pav:previousVersion>urn:domeoclient:uuid:1eb316f8-1c9f-4776-a243-3a9b90d3a6c5</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N80da1c0b15b042aba065289d4ffaa822"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0489ad88-e17f-430d-b65d-c185b4085dc8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-29 10:48:13 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:ba38d8d5-2d85-40b5-9ada-edaf24933a71"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b5a0fa47-e550-4e64-9983-f20df680f54f">
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/248a6a6c-a6ae-4204-b274-ac68a6ca28e6"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/540d7c37-535c-48c7-abe2-536178c2ef68"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a364b50f-902d-4788-9844-0856fb48fe2b">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:36bb758d-7962-4b22-bdf6-57aaebf94890"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:69bf4570-7cc3-496a-acec-ebe817b4cd44</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N02ee295b3e70431393fa828add0a6774"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d68a7e83-2db1-4b52-8d0c-f508bedf2ea4">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-14 11:31:14 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:0a34b577-3435-415e-a078-740ca0ebb0fc"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:0d361f35-852e-4183-badb-7e87ce40912e</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Nb91d05c08fee4b28bb91c7e6046504f4"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-09-14 11:31:14 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9db617cc-4cc4-4a22-8fd3-f94334b441f7">
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/111ef8fc-dcaf-4c4e-bc60-3bbde2767bef"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/00ae1745-7b73-4cfc-9265-63d2b07e6526"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B53C4692-910D-4231-950C-E7D8337BCE85">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>triazolam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:fb2e4917-a598-4982-b4b1-8c8ee1aaefed">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7dd43fa1-64fa-4f2f-94dd-fe3e42b7a100"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>0</dikbD2R:auc>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2adcf075-88d1-4e1e-be30-692e51ca7594"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21907306-57e2-4165-a1ab-eecc64773dd9">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N7a07f8a9e11941b289c5ed77b05c5d51"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:265b7456-47bb-4f0d-913f-88d64a1e8dac"/>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:19387379-0a79-4f78-8165-a98ef7778341</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:b96cf70a-a239-4f6c-9f11-b70ead452dcf</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5AB58091-AC2C-401B-85A0-EA5266CABF70">
    <ao:context rdf:resource="urn:domeoclient:uuid:2428DC59-E25A-435C-B9A2-4C12DD4BFD05"/>
    <pav:createdOn>2015-11-04 14:11:15 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:03B6ABBE-79C8-4C4D-9731-0C193AFA08C0</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CCEC1329-CCE3-423A-BBB5-249641FC0A19">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/57258</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>tizanidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66FF0DF3-C777-4A3D-971F-8E83B304FDCC">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:33F29679-E217-4D93-9174-2D69A0E1B032"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C0D4F41F-0FCC-446B-A746-DAED97C65270"/>
    <pav:createdOn>2014-02-19 12:27:56 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:357321A7-5793-4DE5-BB38-BF5FA7A5D72C</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2014-02-19 12:28:11 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E62C93E3-E9D2-4338-BF38-206615042C69"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c36900f8-721a-4107-91c6-10956a4ed789">
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e923d82d-a8bb-47a8-b245-3b89ca5b4582">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC0259EC-8534-42C5-8146-84BF35F35FD5">
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:A8F9F367-C451-4DEA-A2A9-F34B4F47E713</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-05 10:36:45 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:94616415-2204-41A8-80A9-821B98B9F14A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:207c976d-94ea-413e-bdd5-6c80a013f944">
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:b315b880-7985-4033-b487-70b1bd5efdcf</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N510960d1003a4032afee1471e786d41d"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:0d6da63c-aeab-4ebe-9ba4-586d7a2a4d73"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3860D410-0829-4E39-A0C2-B42464272E52">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-11-05 15:30:48 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nc64f0f75670e4bd9b852430e56cb47ef"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F79554C-ED5D-4852-9EDC-6A7D47F2827E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6252181e-2778-4810-b740-fe9ddbcd08f0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>-type compounds it does not act primarily by stimulation of </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-10-26 15:36:05 -0400</pav:createdOn>
    <ao:exact>amphetamine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:prefix> the central nervous system is not known.  However, unlike </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6252181e-2778-4810-b740-fe9ddbcd08f0"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BBB4B1F4-1427-48DF-A2FE-D44826CBFE99">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoconazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N165d6bfbb6c54f3f84aab23d055327db">
    <domeo:sets rdf:resource="urn:pddi:uuid:6A4322F0-9674-49E3-8475-647A19CCF969"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B97125FC-7478-43ED-A9DB-23F5DD137E27">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-27 14:25:24 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:635588D6-9C7D-4195-8C4E-ABA04FEA0EFD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e5e3aefd-43e8-4404-a1a0-b4782eac7c74">
    <ao:item rdf:resource="urn:domeoclient:uuid:e75aab40-f419-4d24-8e66-c728da39c5af"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-29 11:41:50 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:725dbf2b-04be-49e6-abee-331b5e625ab4</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 11:41:50 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="Nd0bf591ee26f47f0bade9a2a7ba13c7f"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F9EF5409-587E-4F77-B13D-B8BFCDED8352">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E26A02DE-1B00-4788-832C-E19DF32B50B9"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:auc>60</dikbD2R:auc>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>40</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3435CD43-B04F-4198-B706-A5183DEEF024"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:464A1097-F8F0-463F-A3BC-A99C3ABC4E8B">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9C12C9D9-C60E-4ABD-866D-8EC85AC83651"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31F23EAA-072E-43E6-BFB7-012238CA5CCF">
    <pav:createdOn>2015-10-29 11:11:37 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C52059B-6935-480B-BBC7-0C6D4BB1DDB1</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-29 11:11:52 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3C670D2A-ED8B-4504-8A4E-4F270B3AA666"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:32B6DFC4-1905-42C2-A5AA-BE88CBAE76E9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E47DA08F-E823-42A4-91F6-0B5368E43338">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A25E90E4-454D-4DE4-8C12-C5CADCA63BA6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/00656A3D-14AB-4F23-9ECA-68D3CA9130EC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D97FB6D6-3D79-48FB-99F4-A0276B7CF996">
    <ao:exact>Drugs Metabolized by P450 3A4–In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D97FB6D6-3D79-48FB-99F4-A0276B7CF996"/>
    <pav:createdOn>2015-10-28 16:36:03 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>D97FB6D6-3D79-48FB-99F4-A0276B7CF996</domeo:uuid>
    <ao:prefix>dDOSAGE AND ADMINISTRATION .   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f58da160-c057-42d3-958d-f7689c8c755c">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N6432344cf657415ea59789495607291d"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:f86a8ce6-a378-47ec-a59e-cba8b7579ccc</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:cd7ad75a-1cac-41f5-9d00-56dd125f2dcf</domeo:belongsToSet>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:48d40742-a353-4391-a81a-01147c5662aa"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57E7EF26-0D09-449D-A1A1-51B1F5AE50F8">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <domeo:uuid>57E7EF26-0D09-449D-A1A1-51B1F5AE50F8</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole). </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-27 15:34:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:57E7EF26-0D09-449D-A1A1-51B1F5AE50F8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8b06d4be-e63b-4424-b936-e65052e0dc2a">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:efd7dd82-0616-4897-8ac1-a059755e579b</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:4983c1ec-51f7-4614-a562-994eaa0d251d"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nf89410b6c01d4a06ac1ae3dd698ab92d"/>
    <pav:lineageUri>urn:domeoserver:annotation:08064c0c-1f4b-4d95-b0df-39bbf246bb0f</pav:lineageUri>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2EA86E9B-E227-4168-8AE9-224AADE1B6C3">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4BB8DE85-E964-4619-83A9-C03ED9DE4AEC"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/85F7F538-5161-4833-A8AB-394995538904"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:899b275f-5883-41cf-baa1-0a8638dce6a3">
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/cf4bbf3a-0a9f-4b66-a996-83a70cd33e4e"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6c0850fa-9f5d-4f6a-90ef-af201fd49bc7"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6D8BDD50-6E8C-4A56-B754-6CECD65536FE">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42330</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>terfenadine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:807f586b-cd12-4e18-88eb-4eb88ecc7adb">
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1d62a35b-f11d-4fce-bdab-bb10ce5195ee"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/923542f0-f3df-414d-bcb0-f0f8f6032e63"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8C5843FC-C2EC-4D50-8F5B-6C27A25DAAA9">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BC2738C7-8F6D-4200-8FFC-621B7782D593"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:004DE312-2A25-4A78-B4DD-7A99086DA390">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/20EE8D38-341E-43E5-9A87-6621C3C3B922"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EF1AAC1F-B881-4B69-B143-00BDB343D713"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:BC917887-241A-47D1-8DF1-BDCF66117D70">
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Nce7f903107334208b117a2a964353b69"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:340ff08e-3964-4f34-8a6c-2a120cc3c45b</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>urn:domeoclient:uuid:a2db8ac2-cdf4-4a5a-85ea-bee381f6815f</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:cab1a445-82e4-4e30-9239-eaf37a1c3672"/>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/230076de-72d8-432f-8536-e54d0dce4d1c">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>warfarin</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D12502C-B52C-45BC-8BF1-52230341DDE1">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N211f91c0f7a2477fb57263d58239f2c1"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:4B860F2C-ED8D-4736-BCCA-32256E8414F3</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C8EFABA7-9AE3-4C90-BFF9-A7FEAE02F64F"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-06 15:55:21 -0500</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-11-06 15:56:02 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A083FA00-4955-4A90-AFD3-B4B898A19F55">
    <dikbD2R:dose>15</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>mirtazapine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5910395-E670-41B4-A50F-A4A5034D7CF6">
    <pav:createdOn>2015-10-29 10:40:17 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:e5208d0d-d470-424b-a0e0-4a4b5da16c0e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E536FE66-FAD0-488D-B7C0-39E59CBD9678</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:9540ed61-ff6a-4399-86bc-04d7b87b26df</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N9f4f251bf0e34e1d9f77d07d6b78ea35"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C161A942-F681-4204-AD79-5AB4563FDE16"/>
    <pav:lastSavedOn>2015-10-29 10:41:13 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5518CE4F-CD8F-4138-B3F4-FDC829B95F8C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6813</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>methadone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/77AA7F22-4E42-453E-9D65-5AD6AE9AD2E6">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c57e4dd6-5f22-4ef7-8169-8bfb0987ac74">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:d523bed0-a3e8-49f6-8c56-9cfe2c143cd9"/>
    <domeo:uuid>02d0715a-ee9e-40f0-b296-029983c96a45</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D946C533-B69B-42B6-B679-B6ADF9769A1A">
    <ao:exact>Triazolam - Combined administration of Celexa (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.</ao:exact>
    <domeo:uuid>D946C533-B69B-42B6-B679-B6ADF9769A1A</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D946C533-B69B-42B6-B679-B6ADF9769A1A"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <pav:createdOn>2015-11-02 13:48:00 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/bcc449a8-9db9-43c8-b120-eff11a90b8c2">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>Teriflunomide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:205CB033-E181-459F-82FC-82AA818285EE">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N103e5ec7fc6242018baa179a507cdd2d"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:add6212d-ed1c-4726-a4ad-dd613e1a240e</pav:lineageUri>
    <pav:lastSavedOn>2015-10-27 13:28:11 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:94c5d273-2ea0-4353-b339-5b3fec267fbb"/>
    <pav:previousVersion>urn:domeoclient:uuid:c43d3628-3977-41f4-b162-6395a8dbb683</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:createdOn>2015-10-02 15:20:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5ec3436a-d8aa-49ac-b5f7-477074f2646c">
    <pav:lastSavedOn>2015-10-29 09:24:53 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:nodeID="N739d9d380ccc4cb881dec78e728212b6"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D0D7121F-E97F-4C54-9440-3CC2792F8168</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:3ead1254-1003-47ca-8ced-1f7baba210aa</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:E7654C85-E13E-46DC-A164-A5AA3EC6E90B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f34391a1-8aac-46a6-bceb-c36f3b39e0d4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ea0e1478-fdd1-42a1-bc55-89e9d51c34ef">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8CBFBAB4-EBD4-4864-8822-7D4ADCEC9EDA">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:43606530-1B05-47AD-8316-BEA446BB0050"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:066340e2-1581-4fa3-af9e-052965e1836c">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6e1476fa-63e9-4e7d-afb3-608a3b41d288"/>
    <domeo:uuid>c088173c-55fd-4e81-8a58-2dfe59d79929</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:92BDEDE7-5D85-4A72-91FD-957960200EA5">
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B430E0ED-0582-4122-8303-437847C4BF99"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ECA41CEF-2740-41E8-A5C3-8C972888A3B4"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56A8B7BB-1B12-493F-9559-F29C8E5BFDAF">
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:56A8B7BB-1B12-493F-9559-F29C8E5BFDAF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 15:33:32 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FC1EF1C1-AEC1-422A-AFBD-214CAA420520">
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8F379DE4-8C59-44B8-A5CA-3361856585EF"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12>2</dikbD2R:t12>
    <dikbD2R:auc>5</dikbD2R:auc>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>2</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>15</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/328C64E1-C04C-4719-B59C-C9E2B3FAC510"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E60CD6BC-68A2-4AB0-B95D-7DE55D4670C0">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-05 15:30:31 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0EFDED3C-25C8-41BC-90FC-4AE2531D7CFA"/>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <ao:body rdf:nodeID="N04bad6258b294b56ad02ebb8f4c396db"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ED469DA0-660F-4DA0-B689-AF741C45CF8F">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/67DE52A1-C60E-4EF9-B19C-4518533701BC"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E247FAFC-EF4F-4E91-BB88-AF779BFCD2C0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7e1c91a7-c9ee-4912-b31c-95e75309c666">
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9665947d-c923-4619-87be-8767b99ede67"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/04bc1ee4-92ee-4d7f-b74e-7a3807fca2f5"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1853035A-F02E-4842-88EF-299E4A98D1BB">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F8B5E454-D91B-45E2-B1ED-59C037AA2F0E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3BA8F70-5D65-457D-999E-A4E6CB5137FD">
    <ao:body rdf:nodeID="N81bafe2755a4405e9d7a442b15c56f8e"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-29 11:11:52 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:168F2DF5-17B3-472A-B69B-45BD4A9B2076"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C52059B-6935-480B-BBC7-0C6D4BB1DDB1</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:565524FE-B190-4A40-A9BC-462453A4A64B</pav:lineageUri>
    <pav:createdOn>2015-10-29 11:11:53 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/be3efcff-28cd-424c-90b3-8c16e3e0ab2c">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>atorvastatin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83367</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:843A06CF-D7EB-4F0F-ABF8-FFCC240EEE88">
    <dikbD2R:auc>57</dikbD2R:auc>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmax>57</dikbD2R:cmax>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/54FE29F8-67DF-442E-97E5-D70CAB0E1869"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B9F4A374-3EC8-4754-858A-30543762004D"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a0a19fb2-ef3c-410e-874f-6ae9cba1afd3">
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:23f79bb6-4566-41bc-96f7-28a967dbee3d</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N6d6fd3cc64574887b4ba408640de452c"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:e9c46bd3-f480-4fdd-9568-ce7329da7d48"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5485E5A6-69C2-4AEA-910B-C538C897751B">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/54FB9D2C-7E25-49A3-BE0D-67EA37E3C777"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4E15909C-3068-4431-9179-892A475F46E8"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>12</dikbD2R:auc>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8424E02E-7F1A-4993-B07A-EDF16EF62F50">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-29 09:04:44 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:840818b1-bbde-4d26-86bb-bb6ecf118ce7"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>urn:domeoclient:uuid:6e342e32-25df-456d-aaf4-6e6186bc151b</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:cc884a2c-b023-4599-aa91-b81cb5b9b1dc</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N735de150f65745b79883e46a8094a03e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:22FF7872-7D7B-4663-A4F9-F5180305E827">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-28 15:24:09 -0400</pav:createdOn>
    <domeo:uuid>22FF7872-7D7B-4663-A4F9-F5180305E827</domeo:uuid>
    <ao:prefix>y clinical effect.  Phenytoin  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>When a single oral 30 mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone. In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS: Postmarketing Reports).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:22FF7872-7D7B-4663-A4F9-F5180305E827"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9c3f0177-4817-4c5f-a17a-8c007986e088">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:a3af321c-f0eb-42d7-ad44-d271b7e73879"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F1EB0B76-6419-4157-A380-D87C51B587EF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <rdfs:label>tolbutamide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10635</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d217f685-3bcb-413f-98bb-e6b9bb2c7dd9">
    <domeo:belongsToSet>urn:domeoserver:annotationset:2B05CAB9-B97B-452D-A22E-D8E84D97D603</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:855DC2B6-14E7-43CD-8309-D6BF558D411D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:8b016760-dff5-48c5-9f62-f59b985fe646</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N2e93559a911e4112a8bb491c26aa072a"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-11-02 14:35:22 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f71bb8a5-f38a-4ee1-9eea-46d7f7755ac8">
    <ao:context rdf:resource="urn:domeoclient:uuid:16AB8E7B-C09D-4172-AB6A-89210F0EE316"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:35D69913-BB90-494A-B3C2-EA35074CA04C</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N60cd1f09ba48407bb5869ead5452ebee"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-11-02 13:32:33 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:c7569c33-9618-490f-8052-a4bc9751152b</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76f7167b-97bd-44f2-8786-cf8b650ae385">
    <domeo:uuid>624588f8-395c-47bd-8a65-8afcb2869a98</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8716c71f-dbf4-4991-b9d1-e3905d4507ea"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/d59310da-5ec4-4374-a5fb-046373afd83b">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:905DAE6E-BEF6-4FFC-9532-867CF5C95BA3">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FE2CA90D-2D47-48DF-8FF1-2F1435B3694C"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>5</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>IV</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AFA19CB7-C8EB-4BC5-8F6E-0859BA58CE1A"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e740dc3d-d8a9-4d2c-9e90-1bc396adb9ed">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>levothyroxine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F52D3B9B-07D9-4910-A342-FF48AFE49DE8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <ao:prefix> of these changes is unknown.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium.</ao:exact>
    <pav:createdOn>2015-10-28 16:29:00 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>F52D3B9B-07D9-4910-A342-FF48AFE49DE8</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F52D3B9B-07D9-4910-A342-FF48AFE49DE8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9a2837f6-f015-40d1-8cc9-6620a60e04f3">
    <pav:lineageUri>urn:domeoserver:annotation:8f429031-5575-4a2a-b8cc-16d4ee9aa864</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N75e2e0afc0a34dd9b557fdc99ccce6ac"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:3d69bd6c-f6f9-4ce6-9c5e-e5812f3b2678</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:38a3b6dd-64ac-4dac-90ea-bed79bfa3acd"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9CFA0214-E245-462A-B431-39BDC3A7B02A">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-04 14:17:33 -0500</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:64C30A90-955E-4373-A58D-AB831766717A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4f6bb99c-9324-494f-8b73-04d939bb21d5">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/bc469497-bb98-4903-b396-5b71f858c141"/>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/696ce589-98e2-474e-b1d5-491be0403d14"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>46</dikbD2R:auc>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N49623bff5e7344f9bb708a06c5c8ff79">
    <domeo:sets rdf:resource="urn:pddi:uuid:047fd431-9efb-4389-81e7-c44d49f139bf"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8ef16f1f-0062-41d4-8d01-c8335d75382b">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/903be69e-6e8d-49cc-a08f-38f140cb00b5"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9b84351d-2776-4ff6-856b-c28dc3fa301e"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:75274403-bcf5-426a-98c4-65397e525efc">
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/46b6988c-2244-4153-9138-a0c413c98871"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/08251c19-284c-411f-a606-95b56c9f31ce"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0480ffda-e35d-478f-a6ea-7cbd43129679">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:64dc6d1c-a2b5-4024-807e-2e4ac2c0cfc4</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N9bdceadc95f644dbb1422ca5011a1fdc"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:44646423-61e2-40e5-90cd-8bd6645b0311"/>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8CA43AFB-D0E3-48EC-9DF0-B60E29D7E322">
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A517C6F7-066B-4288-8145-3964B97E34AF"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:auc>3</dikbD2R:auc>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/992373E2-28CA-480C-9749-ECA29D628CFA"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C791A172-C783-423B-990F-54562331192F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-05 16:11:19 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In another healthy volunteer study, lopinavir 400 mg/ritonavir 100 mg twice daily decreased bupropion AUC and Cmax by 57%. The AUC and Cmax of hydroxybupropion metabolite were decreased by 50% and 31%, respectively.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C791A172-C783-423B-990F-54562331192F"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:prefix>erythrohydrobupropion decreased by 68%.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N02ee295b3e70431393fa828add0a6774">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93F2B1F8-F0ED-44F2-B364-46676A4A53D7">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>93F2B1F8-F0ED-44F2-B364-46676A4A53D7</domeo:uuid>
    <ao:exact>Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold [see WARNINGS AND PRECAUTIONS (5.12)]. </ao:exact>
    <pav:createdOn>2015-10-29 09:10:03 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:93F2B1F8-F0ED-44F2-B364-46676A4A53D7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bc675420-00c7-416c-9423-ebf1dc8b1adb">
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N094d84f3b1ac407ea2563f6c64326fb9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:7f78ade1-c833-4649-805d-4d70b06050a3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:887f44c3-7665-4f8c-8535-b5433c5b1998</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/cd9b1e69-4b71-4c36-8dcd-ec19bc75537f">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AFA19CB7-C8EB-4BC5-8F6E-0859BA58CE1A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/22dc9bcd-7862-4140-8f62-a97b19a8426e">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/358262</dailymed:activeMoietyRxCUI>
    <rdfs:label>fosamprenavir</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/02231e50-040c-4090-838e-b3cd2fb0f912">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>150</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>pregabalin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ae5c73ec-238a-4645-8580-1e46655de61e">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N7c8d474ac6354527b1d2c3cf27a584c6"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:475f7cd2-1791-4ee5-9e34-844ff53d14d8</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:7e0dcbfa-20e5-40fa-9c8d-dc8473f2694e</pav:lineageUri>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:f3a170cc-69ca-442a-b54c-5a268bf2b574"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97020E1A-6E28-45D5-A4DA-64A1B59C3BF9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. (</ao:suffix>
    <pav:createdOn>2014-02-19 12:35:40 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:97020E1A-6E28-45D5-A4DA-64A1B59C3BF9"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Poor metabolizers treated with Plavix at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function</ao:exact>
    <domeo:uuid>97020E1A-6E28-45D5-A4DA-64A1B59C3BF9</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E926BAC0-480E-42D1-A370-D339FE2F94F1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2015-10-27 14:25:30 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:4D94EEB9-E9E7-4B86-BEEE-A6909BB8AEF9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e7c7efb4-58dc-4c70-af88-ed9b6fed53eb">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:140cbe36-7b8c-4643-b19c-da2af444b8bc</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:a15e0c30-7c54-425c-a1de-0543b6124667</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nc19ddecb4cf64c5783f38c64d8d793da"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:ec2635a4-1e64-45d1-b406-84dfe0dfec8b"/>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N70b62e3ca72e46e3b7b835812120fc5f">
    <domeo:sets rdf:resource="urn:pddi:uuid:13751F53-3574-46E2-8D10-63F08B2414B1"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/225534b4-2d8a-4fd5-bb3b-52767000ee5c">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7F018DBA-2072-429C-A9BD-C57D4A12ECE9">
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>Q12</dikbD2R:objectRegimens>
    <dikbD2R:cmax>3-4</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:auc>6-8</dikbD2R:auc>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C688CC46-3AB0-4F9A-96D8-A90D1E25BB08"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C6C9D870-611B-465B-A010-E1CBCF0BFE97"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6B12D9AC-F09A-4157-8E26-ACDF40ECBB03">
    <pav:lastSavedOn>2014-02-09 21:22:48 -0500</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="Nccd95ae68d884af88a5aa853a686566a"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:2DDE57E8-8DE6-4ED1-ADB7-2F109930DB5D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:97462094-EB47-4D8E-A3F1-3B41A3ABEFF5</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2014-02-09 21:22:24 -0500</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:473D0896-0D53-4D70-8D36-6C39BAEF5E24">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BF06E08E-6D7B-4118-AA3F-FDCB992EE01F"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-05 15:32:36 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <ao:body rdf:nodeID="N684fc78be4224f6aa9517e494d3a44c2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ac8c5505-0c3a-42c0-9143-5dcc800968fa">
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluoxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b2af2c64-7c65-43bb-9a52-dfb408553e6e">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluoxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:973c8611-d87e-45a0-81d8-6bad40d6c692">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:55C73C1E-BA2B-4FA2-BFD5-0DBCF10B57D5"/>
    <ao:body rdf:nodeID="Nc38d3fbae3884d9d9d80f34f876ec9e5"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:698DFEB4-F93A-4958-B754-EC50EA7D3AFC</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:7d074b77-0f76-4f75-b9e2-2cb18fc0ceb4</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-11-02 14:30:38 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:475f7cd2-1791-4ee5-9e34-844ff53d14d8">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3f1159ae-24d3-472a-a756-86a1880edd71</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Nf0707eb79db94d738db324cf42e48aee"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:ae5c73ec-238a-4645-8580-1e46655de61e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bb8d6d07-ae0c-42ae-a1d2-bbd3cc12e908">
    <ao:prefix>AUBAGIO on CYP1A2 substrates   </ao:prefix>
    <ao:exact>Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>277c10de-8a61-4e0d-a7bc-08f152fd969b</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C4ED5DD-C4A4-4733-A69E-E8EC8227439E">
    <ao:prefix>  Ketoconazole  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>9C4ED5DD-C4A4-4733-A69E-E8EC8227439E</domeo:uuid>
    <pav:createdOn>2015-10-29 10:40:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C4ED5DD-C4A4-4733-A69E-E8EC8227439E"/>
    <ao:exact>In healthy, male, Caucasian patients (n=24), coadministration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30-mg dose of mirtazapine by approximately 40% and 50%, respectively.    Caution should be exercised when coadministering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, or nefazodone.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0c44bb3d-5748-4cf9-9c0d-d698b13a2bc0">
    <domeo:belongsToSet>urn:domeoclient:uuid:2909e420-c871-4705-9d8c-2b965a568479</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:b3bda8a6-be81-4645-a38f-f75d110d8fcf"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:a048c3f5-0d29-44e1-bed7-ee490078f62e</pav:lineageUri>
    <ao:body rdf:nodeID="N5590a9f49c6e4c15a993fd0d72dc4087"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4060fdfc-8296-44b2-a184-74f2bef4521f">
    <rdfs:label>terfenadine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42330</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:cbe46642-5c5a-492c-9dbe-04cfe9648a19">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8c1c4b74-8e11-46a3-8532-8d5c8e308fb2"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1EA29F2B-1B4D-4AF1-9ABC-4E5B5DA1949D">
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:auc>2</dikbD2R:auc>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:cl>50</dikbD2R:cl>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12>2</dikbD2R:t12>
    <dikbD2R:cmax>2</dikbD2R:cmax>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>QID</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/75EFC158-7E06-4BEF-8283-13603C930042"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9ED830EC-AFE5-4D97-B032-EBCE0F379077"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5045dc47e7d84fd9bc6659d8010bd2ae">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:73BDD15E-B6A8-472C-BEED-B2C113AC3572">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:6A2852CE-D29C-4BED-A012-2BB24F2DA21C</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:95483E66-DFBA-4453-B46D-99FC7A13E3E2"/>
    <pav:createdOn>2015-11-05 16:09:07 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-05 16:13:14 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">25</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6AC8B57B-13CB-4E98-BB4D-38F52490E171">
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/425AE49E-984D-4EBD-BF94-B2FC79BBE063"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/009705CC-583F-4B1C-826D-C8689C3BF49F"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E7BAB156-6867-4E8C-B5AF-62D13EC083E0">
    <rdfs:label>nefazodone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9478da06eb134f7a8f7d785eb7cd2957">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e09e1802-efc5-4ef0-8448-022b2420c4e9">
    <domeo:belongsToSet>urn:domeoserver:annotationset:265E6570-98CA-4921-B843-277E2B90BED4</domeo:belongsToSet>
    <ao:body rdf:nodeID="Na008356b57e649c4b479410c55ab25c1"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-29 10:48:13 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:4629676b-3b1c-42bf-a8d5-05cf19549e52</pav:lineageUri>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A6FB01B-C51E-43F8-A416-4DDDB8E0FC00"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2d1d7af3-09a9-46a5-8e5b-f89fd0ae6c87">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:32c9b6d3-a4e0-4166-a508-0020d26efcda"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7ae9c448-e28d-4732-9bf7-269cf9b7c206">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:e83ecad5-d5f9-4a5a-93f3-6bbbb851caee"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87ef6c97-0630-429e-99e5-b7b9f2a0ecf8">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:94e8c5a0-9195-4d72-9070-d643e9674c76</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:9D3BA8D3-08EF-4C52-A9EB-CEE8B14CDE1A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4995AB8A-EB6D-4671-9103-EA13C6AABF91</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-02 14:33:30 -0500</pav:lastSavedOn>
    <ao:body rdf:nodeID="N048484f8d3554b18a64da0816e43c3dd"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE72B2A4-A8DB-4125-A4EC-54C56B37DD3A">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-05 16:02:39 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:9C59DBBA-611F-45DF-97D3-AB2284DD8838</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">20</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-05 16:02:38 -0500</pav:createdOn>
    <ao:body rdf:nodeID="Nfc83956052504df19823accd944f0627"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:34AB8C7C-97CA-4843-8197-FB8C3C55216B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c2369e13-18a4-42a5-b62d-75933efc26fb">
    <pav:lineageUri>urn:domeoserver:annotationset:99eb2225-4f33-425a-b3e0-d4470e4c820a</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:cfcf7fbc-051d-4a78-ba49-05b6dcfc9296"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="Ne338e2974e774d5db10d74a917b6a0c9"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E873080E-D1C0-4492-8281-8417A78248C7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:5584447B-F4AB-448A-B04E-247C32F49738"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-29 10:56:03 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C52059B-6935-480B-BBC7-0C6D4BB1DDB1</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-29 11:09:04 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:A8BC3402-B8A0-43A1-85DB-A9CE535DBEF7</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b3bda8a6-be81-4645-a38f-f75d110d8fcf">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0c7cae18-72dd-417d-9008-94c4b213fceb"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>10e6bd36-5fdb-48be-8bf0-73558158a2f5</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08adbe42-977a-4605-9ae0-b047bf6bc267">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6f8a521f-d07f-4d6a-9332-cc6ba6ebbc4d"/>
    <domeo:uuid>a14a0c55-8458-40b6-8e2f-1a3bb07b34e6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/994c7ebb-ea8a-4193-9bda-f30d04539351">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
    <rdfs:label>omeprazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0e603e8e-68be-471b-b161-99ec92d48d47">
    <pav:lineageUri>urn:domeoserver:annotation:48251316-e5a9-4b9b-ad52-85d73770c489</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:43c9947e-0432-494c-9dbd-82554c92fd50</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:b9d005cb-08d4-43ed-9c9e-eb3394df8945"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Ncc3d13e426b14ca3b120d684c9a72b71"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a9ffeca3-5648-4d0d-a46e-c21fb3d4b20b">
    <domeo:belongsToSet>urn:domeoclient:uuid:f4b904b3-c7a5-4a2c-af73-4f075cb45f8e</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 13:53:28 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:921a39a2-e272-4660-b6df-5918a6c6640f"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:01226464-7176-483b-872f-a957d11f1aca</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 13:53:28 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N6eab6e0e4224460da1873f137792a695"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:fdede33f-2fbd-4cef-8401-76f422425bf7">
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ff960fd6-5402-4161-9d61-a498d7eb8919"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9199938c-5f01-4d56-9ddb-8e2514b7d30f"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B2259126-699E-4A07-921F-D2897A84F270">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>10</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DEE9B652-27F3-44FB-97C1-DEC62C8A7E6D"/>
    <dikbD2R:cmax>12</dikbD2R:cmax>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12>3</dikbD2R:t12>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>4</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:auc>33</dikbD2R:auc>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D6D9F7D0-4995-49CC-8743-DCF82A8841AD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A37D2FCE-2C99-4C71-8140-AD7527A114F8">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C18603DF-B344-4BF7-B514-7A84CCD042C5"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/031D367A-CA33-47A6-90B4-7052206A3E15"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48c08855-f398-4789-b347-ba8e3a1a26fd">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:0470240f-1235-4dd2-acd5-3fcbc9b8bbb0</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N57393de735c94d778cf95a3ce8f6c54b"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-10-13 11:13:09 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-13 11:13:09 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:749ea430-dcaa-4333-a269-df1b9dfa1b8a"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:21d19ade-9b9f-46d2-9a73-44434e68c293">
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/dda29cc3-e63c-4755-9a39-b5d7d2ffc4ed"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0219573b-2527-4ff9-919a-b584b661e03d"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F88F061B-60F1-4A91-9CDB-C267823AE600">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:234DC7BA-C3E1-4BB2-B8A8-FB356E25ACD0"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1B06494-F145-4A3F-AAF8-FD4F85BD23BE">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>max were reduced by about 35%).   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <pav:createdOn>2015-10-28 16:37:38 -0400</pav:createdOn>
    <domeo:uuid>D1B06494-F145-4A3F-AAF8-FD4F85BD23BE</domeo:uuid>
    <ao:exact>Drugs Metabolized by P450 2D6–Many drugs effective in the treatment of major depressive disorder, e.g., the SSRIs, including sertraline, and most tricyclic antidepressant drugs effective in the treatment of major depressive disorder inhibit the biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase), and, thus, may increase the plasma concentrations of co-administered drugs that are metabolized by P450 2D6. The drugs for which this potential interaction is of greatest concern are those metabolized primarily by 2D6 and which have a narrow therapeutic index, e.g., the tricyclic antidepressant drugs effective in the treatment of major depressive disorder and the Type 1C antiarrhythmics propafenone and flecainide. The extent to which this interaction is an important clinical problem depends on the extent of the inhibition of P450 2D6 by the antidepressant and the therapeutic index of the co-administered drug. There is variability among the drugs effective in the treatment of major depressive disorder in the extent of clinically important 2D6 inhibition, and in fact sertraline at lower doses has a less prominent inhibitory effect on 2D6 than some others in the class. Nevertheless, even sertraline has the potential for clinically important 2D6 inhibition. Consequently, concomitant use of a drug metabolized by P450 2D6 with sertraline may require lower doses than usually prescribed for the other drug. Furthermore, whenever sertraline is withdrawn from co-therapy, an increased dose of the co-administered drug may be required (see Tricyclic Antidepressant Drugs Effective in the Treatment of Major Depressive Disorder under PRECAUTIONS).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D1B06494-F145-4A3F-AAF8-FD4F85BD23BE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b47cf10f-281d-4906-8e21-d6b9ff088b42">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <ao:prefix>beta blockers or diltiazem )   </ao:prefix>
    <ao:exact>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)]</ao:exact>
    <domeo:uuid>d6eb3781-dc99-4457-b2c9-2cfcf044d8b0</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0f6c8311-ba0b-4155-9f60-64db0e0a09d0">
    <ao:exact>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].</ao:exact>
    <domeo:uuid>815303c5-a38b-4a45-bdee-3aeb52766228</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>beta blockers or diltiazem )   </ao:prefix>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fc5a065e-7b25-467c-9cf2-7d5a795904a7">
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:b0084614-128f-471f-8d8b-856f969575f6"/>
    <pav:lineageUri>urn:domeoserver:annotationset:b10d0b09-faea-46a0-b670-dfb3aeba5e25</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N04e6f6860cbb427584f04c6aa2730037"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2839D80C-9236-49D3-8772-834EB4B8350A">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>lorazepam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>2</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B205AFBC-01E7-4529-9251-D3C6872BF14A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>30</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>mirtazapine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfb6644c453f740c7b9ad62ce7b0507e2">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na7b90ea8d0bc4eefab0b14e3da9fccb3">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f5e58104-0fbb-4c7f-87c3-2ab7e40cde4d">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:23aa1121-b186-44e7-80e1-6373944e680a"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/fccfea76-d76a-4b5e-8be5-8dfe33b43d99">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>teriflunomide</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DD213A82-BA39-45B5-8675-A7E880E75033">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>95</dikbD2R:auc>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E32B74F4-F5CA-48D4-9535-D85976BA6860"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7F4B0D91-4E20-44CE-9F64-3C791CF6D663"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33f6bae8-4158-4aee-af6b-8b3264843545">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:2dca5fc9-4b04-42ce-a86a-088d9a681b0e</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:6d0e1cb7-0734-4510-9b43-030f6511d239"/>
    <ao:body rdf:nodeID="Na4798ee51f714a71a97f4f031040495f"/>
    <pav:lineageUri>urn:domeoserver:annotation:7fe72daf-8f41-4d66-8a06-e368d4f4eec0</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53E91269-BCB0-42E8-96A8-679520D8F273">
    <ao:prefix>apy is initiated or stopped.   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Cimetidine–In a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), Cmax (24%) and half-life (26%) compared to the placebo group. The clinical significance of these changes is unknown.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:53E91269-BCB0-42E8-96A8-679520D8F273"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <domeo:uuid>53E91269-BCB0-42E8-96A8-679520D8F273</domeo:uuid>
    <pav:createdOn>2015-10-28 16:27:22 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b4602b56-8569-43f5-b67f-fb207fe8a237">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluoxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E3A13CB0-7535-44B0-8414-4FAB8BBFD4F0">
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ef1ac1e2-2eed-44f0-9309-d28da1e19fe7"/>
    <permissions:permissions rdf:nodeID="N7498068c73ca4d2db16cd003bea68ad5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:c31ad5c9-7e3f-427c-8ee4-3d0318e69c77</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-11-02 14:22:34 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:e172c7ee-6127-4955-98df-83c2a0102d84</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E058E15-D991-43C4-A820-5D7E54C9A9E7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:AE71BD64-5FBE-481F-B031-067BC86895E2"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:8EE4F288-19C8-4519-85CB-791C9E9709D8</pav:previousVersion>
    <ao:body rdf:nodeID="N1b190130bf9e455eb7c2fb9b4568d754"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-06 15:43:14 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdOn>2015-11-06 15:43:12 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nef96cf07755c488cb3acc28c9cfa7592">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ade66370-85a2-4983-9d3a-605d8b7dc6fd">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nc1fdae06612249ca90e3e976b9a85e33"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:08C173DD-1EED-44CC-9644-9AF4722B27BF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:010a8007-3f4c-486b-8cfe-f156282de76a</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-02 14:00:45 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC5BFC2D-2FB5-406E-8932-5DD171C1137D"/>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d9251d83-cbcb-45b5-abe5-4b415b738b14">
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/09845d67-2ea8-4aa7-a31e-47ff718f5480"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/233c7124-34ea-4661-a1e3-06e7364169a7"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9DB621FD-6FEE-49B3-B2B3-C459589B1F5C">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N259d27a173d948a8a43191a58c308880"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-04 14:11:48 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:80695332-F519-4703-9434-46AA4D4746EF"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:032863E1-F6A1-4625-8A55-5372BD729E43</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6564db00-5c1f-4d7e-8f0e-a81e09babc75">
    <ao:prefix> with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <pav:createdOn>2015-10-26 15:40:15 -0400</pav:createdOn>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>clomipramine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6564db00-5c1f-4d7e-8f0e-a81e09babc75"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:53A87639-B19F-4E3A-B778-816F8DA56B00">
    <dikbD2R:auc>2</dikbD2R:auc>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CD6A0ECF-BD80-499C-AE72-8CB5A55A2F46"/>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:cmax>2</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FB3DDA45-C3F3-40A1-B07A-02752BB251EE"/>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12>Unk</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5429897E-9915-4055-9D6A-4061572DCCD0">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <dikbD2R:dose>6</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C59480D-EBE0-40CC-9354-66AD95191331">
    <ao:context rdf:resource="urn:domeoclient:uuid:A83DB83E-0DCF-4DAB-AAFD-EDE49043EB21"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N376b1e8dea664cb8b4ef59f76f668520"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:8F1FF68B-3156-455C-A618-19E380955F6C</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 16:17:38 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">27</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-05 16:17:37 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52efb2e9-9018-4de5-9351-4a3a5c1f523e">
    <pav:lineageUri>urn:domeoserver:annotation:b1ec8417-8fd7-4cb5-8f37-310f5b2944d2</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0FC91DA4-6ED1-411B-9877-77E98B69CB2E</domeo:belongsToSet>
    <ao:body rdf:nodeID="N5afbfb2a31074fd78067f743f2709abc"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:88E17D98-1D5F-4663-8D26-E5B000A79DF2"/>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ae2beb82-4001-40e8-9533-481b87824b77">
    <domeo:uuid>ec1ecd18-f091-4172-a849-f8674c7537e2</domeo:uuid>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:17EBA8A8-8840-4D08-9FC0-185819CC6057">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A38D3124-29F8-48FA-BFD9-AA8A380A6166"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FBDA916D-82F6-4FE0-ADF7-A37807AE87E6">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:D272258B-AF8E-464E-B6FD-60953E36BB61"/>
    <pav:createdOn>2015-10-27 14:22:20 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:6426edbd-e01c-45ce-9151-eac311cb230b</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 14:23:19 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/72a170c9-6650-4ab4-ae52-45d2267bf88b">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Rifampin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95c57983-3208-462e-9a1c-8f0709a8567e">
    <pav:lastSavedOn>2015-10-29 10:33:12 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:87315DAB-63F9-4523-8CF6-405F0735F8BA"/>
    <ao:body rdf:nodeID="N9238a5e772344fe5b1f763f2fe993981"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B7870964-BBFE-49F2-8ACB-3B25C3AB2673</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:1e8ea9c6-6004-43c1-9b17-a29e6eebbd70</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2169AC62-7C62-46B8-BB47-83542CBEC579">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> (50 mg t.i.d.) was administered concomitantly with </ao:prefix>
    <ao:exact>warfarin </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2169AC62-7C62-46B8-BB47-83542CBEC579"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>for 2 weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged. Thus patients receiving oral anticoagulants and fluvoxamine maleate tablets should have their prothrombin time monitored and their anticoagulant dose adjus</ao:suffix>
    <pav:createdOn>2015-10-27 15:31:42 -0400</pav:createdOn>
    <domeo:uuid>2169AC62-7C62-46B8-BB47-83542CBEC579</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fde07283-7a9d-49a5-8f05-d8a70a8da941">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>c8b406e3-abef-4576-966b-9dcb9024622e</domeo:uuid>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:10F1508B-6C37-4762-AFD2-E4F3D7F43D56">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D9726408-750C-41C4-AC6B-F7731E1DC95D"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5C26D993-EE7D-4353-9443-03E2CFBEA779"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56CE6883-91AB-4795-B3FF-4FEF027B21CA">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-04 14:17:30 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2E74FDBE-8981-4DF5-8EB6-F7752BC50EDE"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8f1afa0a-47c7-437b-ac8a-45893f03d9cc">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:16780937-5082-40CF-B19B-D85C88E98145"/>
    <pav:lineageUri>urn:domeoserver:annotation:e4625e15-a4f5-486d-9d7e-768387c508ae</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:093D2DE2-86EA-450F-96BE-9485ABE5FAF8</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-27 15:39:35 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N4dcaa86a6aed468aaeb652ffd5b5636b"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b14675f5-2771-42d7-b808-9022d4452bf5">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e8e75e5b-2d64-462a-a176-67dfa9d7d8a0"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/28b59ec8-d75c-4f7a-9c65-38016280f7c7"/>
    <dikbD2R:auc>46</dikbD2R:auc>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:32c9b6d3-a4e0-4166-a508-0020d26efcda">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0f83c33c-64c8-4562-9bd6-6ccca58a5082"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f7ff637e-2116-4e28-92fc-d850037f65c3"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3c663223-5aec-4927-a514-57918306b6c7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:d9ad2e5a-6eb0-48a8-b9b2-4caaf6488bee"/>
    <domeo:uuid>0c4b8ecf-e840-43f5-b357-5d9ed1346912</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DA7151E2-BBE8-4FB9-96BD-3BEDC60F5BEF">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2F738B51-79E5-47C8-9C15-F27C6851322D"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clDirection>Increase</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clType>Fold</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>24</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/49990E5C-42C2-49B7-A0AA-02166D9C3650"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cl>2</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:833DCF24-F810-43B1-B057-C08C0098CA91">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:1eed1ec1-cfca-4cae-972d-ee609b7db453</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:0205E257-606B-450C-A489-34DEA2A198E9</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:6e856a41-108d-4b59-b7ae-482e1fb6381a"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N8ea672f10585420bb8031bfc76d8a132"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-27 14:13:01 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:187BB272-AB9E-4D45-899D-5CB7C8321076">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:bc24890a-8fb3-4404-ba59-6868f5573431"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2015-10-29 10:29:25 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-30 12:41:52 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:0d74d40c-87d7-4cb4-abfd-2f4e296a7bfa</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>urn:domeoclient:uuid:fee1cb2c-7dd7-4dfe-8065-8975173a1a9d</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N9faef2f374654ac094cc89031662c7ba"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7E8A3C38-11C3-4C68-A0D0-D2809FA4BAA3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CC8A7FAC-D75B-444A-A803-250802A81237"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/12D3F5DD-1059-4CB2-A92B-8A6CF14BF81E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8B0C913D-6ACC-4291-BDFE-62A5987AC530">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EF13BCCC-8CEF-4F34-9747-DA64D027808D"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:da68f7ea-ebbe-4bb3-b465-829acc2b9c48">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:b14675f5-2771-42d7-b808-9022d4452bf5"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b1929c2e-85cd-480f-b52b-7ae54d9b3a8b">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>verapamil</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11170</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:059162CA-8607-488B-90F3-72A2EAFA63DD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>059162CA-8607-488B-90F3-72A2EAFA63DD</domeo:uuid>
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:059162CA-8607-488B-90F3-72A2EAFA63DD"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 15:36:09 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B6F85A79-E96B-4EB0-9429-1D4BECC50EA9">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D1DBB8AE-2CA0-4A49-8028-ADE998079C2F"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b74e2f88-22ff-45d5-adf8-2e2603816c18">
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N4804f050699e4211a44c5f6f5cc0a900"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:7f0b5c67-bd0c-46a0-9b6e-ad316b8e92d1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:07a675d5-5c2d-499e-bc3f-8ef5e743a8e3</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:58f2cf5b-b440-4e8a-a9aa-fa02509423ed</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65D77875-0AD8-4CB8-AC80-444C4034FF6F">
    <ao:suffix>The clearance of benzodiazepines metabolized by glucuronidation (e.g.,</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:65D77875-0AD8-4CB8-AC80-444C4034FF6F"/>
    <pav:createdOn>2015-10-27 14:25:49 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BBD3B06-87A7-4FDC-9628-A01095DBD083">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-27 14:26:32 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N97a8c69c32584e31aeeb343586388356"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:61462986-1B77-4139-B35F-47373B511D58"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8810ef8a-64af-49db-8af2-9dc06839752c">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:dac5033d-3754-4a53-8194-fdfe97c9db21</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:03d58462-8c6f-41de-b8f7-2a9f48627bea</pav:lineageUri>
    <ao:body rdf:nodeID="Ne8f085d1e0d64a26bea046e8f473063e"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:90637796-9d7a-4623-8db6-54132982b6de"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9199938c-5f01-4d56-9ddb-8e2514b7d30f">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>Teriflunomide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8527abfc-5cfc-4ef2-8147-f3c0d0dd95e7">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>teriflunomide</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndaac2dbfac5b4042b99a14d86c6bf6b3">
    <domeo:sets rdf:resource="urn:pddi:uuid:6B105B20-534F-413B-9D33-B98D4C36A8DB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:502CE403-A542-476C-BCE7-4BAED669CD7D">
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N9d1f5af31f794d9ea79d1e856dde222a"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:a8e424a6-047d-44ee-b5e3-1fdd13a79a22"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-11-02 14:35:22 -0500</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1283a74d-2ac8-4ea9-8867-bbe6a5b5b3e2</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:68677d0b-f6a1-410a-89ed-5e3fd29f0e89</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/70FF2AD2-9FC6-4F73-835A-B1779EC24733">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>0.25</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
    <rdfs:label>triazolam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C2725CEB-AF84-4C34-9F9B-2055DB44786A">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7F018DBA-2072-429C-A9BD-C57D4A12ECE9"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/22532B6F-28E6-4A9D-B21B-848E8CE21C87">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdfs:label>desvenlafaxine succinate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:367C2452-773F-4F99-BD33-55370E01A2AD">
    <pav:lastSavedOn>2015-10-27 15:40:46 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:9e5c0d1c-d7e7-4dc7-baa9-ca866612bbeb"/>
    <permissions:permissions rdf:nodeID="Nf0bd6919095d4b309044b3c122b27f96"/>
    <pav:lineageUri>urn:domeoserver:annotationset:bd5fd105-4b60-4372-8aac-13153db61b69</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <pav:previousVersion>urn:domeoclient:uuid:8218b469-193c-415f-b9ad-eb2e56a28625</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5599e5f2-ed60-4a78-b519-93cb46687ee2">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:07fe037a-5ccc-45ad-816d-326b3d71658b"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ceec9eb4-2ea5-4a45-853a-38ea62a3f3df">
    <ao:prefix>AUBAGIO on CYP2C8 substrates   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <domeo:uuid>47001bb0-23e7-498c-9e4e-d07737d97705</domeo:uuid>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:07EAA892-C452-4033-BE15-372E276275C6">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B2259126-699E-4A07-921F-D2897A84F270"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d10d8722-e0ad-4a5c-ae3a-9941092a678b">
    <ao:body rdf:nodeID="N6e6c89c8637346bd95e9759e6e779be8"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:5c0fc8a7-2cb7-452c-92fb-aa77c509bfc1</pav:lineageUri>
    <pav:lastSavedOn>2015-11-02 14:27:26 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:1314381E-8245-407A-838C-B141F1235DA5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CBA0B0B2-92E5-4B9D-AB23-DB1E1723AB92</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9c3938ba-6227-49fb-bf02-154979bf8945">
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:CF4DF8E2-D7F0-4E58-9F4C-0769AAF4E08B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N73c4850a50e840a8b0efea697b817036"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:291FC4FD-BDE1-418B-A2E7-0D40C3C80056</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-27 14:13:55 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:cb847d22-d80e-427c-8baa-2d9485367b34</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4a10aca5-c484-4b4f-b9f2-14bcad1e3637">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>18</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b3340703-4ecd-4c48-bcb4-9a4b2ae1239e"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/777ac785-883e-4c0d-950a-69fdb40168bd"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F8B5E454-D91B-45E2-B1ED-59C037AA2F0E">
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D50CA07E-2A4C-4CBE-9AF9-1D3DF56F53E3"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>18</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>IV</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>8</dikbD2R:numOfParticipants>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AEAC5D5C-451D-4122-9A81-DBCA3EB5ACDF"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f94a35b5-9c13-4d5e-a1bc-12a69d918843">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:e4f9f0d0-7a90-4afc-b517-74177eb9303d"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EDDB83B7-891D-461D-BCF9-7BE2DEB58676">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D139F954-3B90-473D-9259-314026D432A8"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7ffbe5ff-11ef-43ef-b6f4-7e8d2ceacb86">
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F2E65CE7-05BB-403D-A7F8-3A0DAE0412F9</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-02 14:01:03 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:6bc815bf-51d5-4407-8566-267baf6b212a</pav:lineageUri>
    <ao:body rdf:nodeID="N4f21088443174fff88f666e348341931"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:307644AD-79DD-4FDE-9562-DB8727B7C5FE"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:611992D3-F33A-4D6C-92B3-C91319D52515">
    <ao:exact>Tricyclic Antidepressants (TCAs) — In 2 studies, previously stable plasma levels of imipramine and desipramine have increased greater than 2- to 10-fold when fluoxetine has been administered in combination. This influence may persist for 3 weeks or longer after fluoxetine is discontinued. Thus, the dose of TCAs may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:611992D3-F33A-4D6C-92B3-C91319D52515"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>611992D3-F33A-4D6C-92B3-C91319D52515</domeo:uuid>
    <pav:createdOn>2015-11-03 12:47:20 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2F738B51-79E5-47C8-9C15-F27C6851322D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>carbamazepine</rdfs:label>
    <dikbD2R:dose>400</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f44309b2-d2dc-4ffd-9434-d864a7571f6a">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC">
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:BF1F538A-51D9-4436-A77C-3621A118D58E"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F1B6D8B9-A626-4E5E-8B19-B18F63A39DCF"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:DFAD8994-E06A-4F7A-9CFD-949D21545A7E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:85EDE652-8757-4D48-8635-E319D43D6A22"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:74E53D1E-D490-4F1E-8104-B98B4132ADE4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2CC0744-CB78-4E44-9966-146A058F3C6D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8D12502C-B52C-45BC-8BF1-52230341DDE1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EC521944-0E2A-42D6-A4CB-E1F7ED604ECD"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:206DFE39-A44A-4DF7-9A51-FBBDB96F310D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED61FA0A-E015-48D6-A36F-19CAB973FE61"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6F98C475-6082-48DC-B766-01BDE834C6EA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:D0CFF406-ADD4-461B-81E4-F1B12B96F33E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AE8D545B-72D2-4DC5-8C2D-A8AD8C752A9B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BDEA25A2-2D72-4934-9CBA-250D3A617606"/>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:3AF5E73C-F233-44CE-AF2A-12F1216B6C6E</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:736074F8-3E40-40F4-88AA-63DA5A9AA92B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C04DBAA5-1224-4CED-8F23-14AEABEEB3F6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4E058E15-D991-43C4-A820-5D7E54C9A9E7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F33ADB58-54AD-43F0-BC2D-C7FC9333C76C"/>
    <permissions:permissions rdf:nodeID="Nc8440fe5041e47489d7fa695ae38215b"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/230847e3-82f2-4b70-9e2a-afd2e32de96c"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5EB72BDF-FA05-4439-8879-E53DAC77CBB3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:39578E9D-75DB-42E8-A1AC-9A5CD3ACB98B"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:2284FFD0-2303-4B1F-B336-F65C434CE709"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1427FFBF-A266-48CB-B923-7B75219567FB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DEDDC9C8-BA5C-4C38-AA1F-BDB5B34BD866"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:50926471-B635-40E9-A16A-8CBFABB1F4A2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E0EEC2F-7A54-49A0-8FF7-24FB307CFFA0"/>
    <pav:lastSavedOn>2015-11-06 15:56:01 -0500</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:838CD12F-6A70-434F-9AEE-A80528922A70"/>
    <pav:createdOn>2015-10-26 15:41:28 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8bfdbccb-d6db-42a5-9770-a1cd549e20d0">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f2f08985-d9b9-40fe-934d-75814128946d">
    <pav:createdOn>2015-10-09 13:18:59 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F782750E-AA75-484A-B1C7-696C3491621D</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:61D6F2D0-6072-4DC4-9717-C16FC18FFD23"/>
    <pav:lineageUri>urn:domeoserver:annotation:c435cd45-2501-441a-8051-c01fe39f57f0</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-28 15:23:31 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nb58a4ef3f104429da40183d56a09069d"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4900c17a-8ae0-4b71-bcb7-900980790ea5">
    <ao:exact>Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>6b99a516-34cc-4449-bf55-e56a3a4a52ee</domeo:uuid>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <ao:prefix> Immune-Modulating Therapies   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:afd33c7c-ba18-4e5d-a3a5-8872770ee82d">
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0f24a2a6-d6b9-4748-8808-84e3965ec948"/>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:cmax></dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3dc022f7-5f06-4604-aa57-5eb5a99b5e37"/>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4AA96B24-F8CB-42AE-A0AB-D97EE065E920">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:049B2C1B-AF1C-4519-9B51-0B4A1ADC87B6"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d91e327f-f192-4b77-8e02-8a70e7308c3e">
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N14ddc9801dd34a5499741668ccb907c5"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:9976536a-6ffd-4987-8d64-1df49c54074e</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:c7d8a670-40bf-4405-91ee-5a394a544f3e"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ae6e66ad-60ca-4338-8e8b-926d5115e5f0">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17eebe77-54f2-4dea-af9d-e421f5f711fe">
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
    <domeo:uuid>76fbc5a7-16a1-40a1-bb85-7b30dcf295d9</domeo:uuid>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16780937-5082-40CF-B19B-D85C88E98145">
    <domeo:uuid>16780937-5082-40CF-B19B-D85C88E98145</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16780937-5082-40CF-B19B-D85C88E98145"/>
    <ao:prefix>    Digoxin   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-27 15:39:34 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:af01d144-ceed-4a53-b608-938a370a0cfe">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9008893e-5e9d-469c-b6fb-8900023b8b76"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/02231e50-040c-4090-838e-b3cd2fb0f912"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7fb68157-a120-4859-a683-a89ed535b8c2">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:807f586b-cd12-4e18-88eb-4eb88ecc7adb"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CA514CC0-BCF8-4CAE-BE3F-314D067D5647">
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <rdfs:label>ritonavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8c7a1af1-dccb-4e18-864b-965ca7b89979">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1e74bd05-d6de-45fd-b824-d7d6a330ce14"/>
    <domeo:uuid>2777c354-1eed-42fd-b9d0-c53fd533b0bb</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CBC29AFD-3ED4-44B2-99EB-037E39A9E78B">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2B143EB5-75A9-4041-90D5-2EE86C9B8A80"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>Exposure decreased 50%</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ff67d80e-3362-4c69-9c87-73a5ee07b454">
    <pav:createdOn>2015-10-26 15:38:23 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>mipramine or citalopram. However, the concentration of the </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <ao:suffix> metabolite desipramine was increased by approximately 50%. </ao:suffix>
    <ao:exact>imipramine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ff67d80e-3362-4c69-9c87-73a5ee07b454"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9D5B64D-ACC6-48E2-97F3-1BFCF4042ABF">
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:74B8AAE7-18A1-48A4-88E9-42CE88A3179F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:F153E240-4C66-49D3-A4FA-323A752AB001</pav:previousVersion>
    <pav:createdOn>2015-11-05 15:51:27 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-05 15:52:07 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nc1b9957a777b4c068c3dcc99dcca4815"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:190B9053-9CAA-4E89-B172-4472749A4E04">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2C670E10-FD19-4267-9C5F-C4D31BC43253"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e9259a46-2244-4ccf-9964-aefe6b085941">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:80bac15d-f570-49ef-9a5e-0447e8ae785b">
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:e717cb02-32b3-419f-b9c7-4ef13bb08058</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-29 09:00:42 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N82aaca76a6e848449b90615b04a41a34"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F041F7E4-4BE7-4AC0-9B66-3A40FEC0D2EE"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4F262876-1771-4451-92A1-EB80E6047D3B</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4df043fb-de9f-437e-aacd-d6b5befcfff3">
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:c619bd1d-ed1b-41ef-9d5f-78ababccbe72"/>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:81ae0f5b-ea83-49d4-b8ac-4fcf521b67e3</domeo:belongsToSet>
    <ao:body rdf:nodeID="Nd84f92e0fb03498db904060d91c827e9"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:97e4fc71-5e21-4cad-a3f4-5d52d1ddfe77</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2cdcb5ef-cde9-448a-bba2-52caa1006d71">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:bde5726b-50db-4178-a39e-3a1bf15f78ff</domeo:belongsToSet>
    <ao:body rdf:nodeID="N5f1da3757e60452394d4aed310f55df8"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:bb49a44b-b0e8-4683-9d94-3ed4c859ece6</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:cb1adde1-409e-4ee3-a827-a190a40a773b"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AD294F6C-4519-4132-BA69-F5BF75EC53EF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>20</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0a254d4b-887d-466e-9a2b-34c6e79f7af6">
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N773b7816ea46417cb47340cf6c5abfc6"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9d1fa203-c6c6-4960-8762-fff326136ef5"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5a6c9cb0-d8b8-4212-876c-8c7d9b9ca6c2</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/74E4C44B-34CE-4ACC-9C76-B6514EAEE220">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdfs:label>Celexa</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:215c0e14-24da-483c-9ae1-c636dc538cf3">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:38749D70-4E6C-499F-A879-5A4F9E9F6532</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N29ac1be0cfad4229b60b52c6a886e2a5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:b9bd4547-fbc6-4295-934f-1b8f534fb9de</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:22792633-0A0D-4820-9A3E-4433C813EC8A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-29 10:35:24 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7F4B0D91-4E20-44CE-9F64-3C791CF6D663">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>hydroxynefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC31EB53-9A4E-43B6-9687-DDD11F8CA71B">
    <pav:lastSavedOn>2015-11-05 15:30:13 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BAED069D-E790-4AB0-BE49-21F957A37D6D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-05 15:28:39 -0500</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B7BE1296-FCF1-443C-B8E8-FA07AD2AC3D4</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:713A7036-1151-42F3-8EE8-D11C70C93142">
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:da0c7a93-613a-4556-bd80-3b194f80a990</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:7b24799c-fb25-4d67-833b-94c2e27abd39</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-10-27 14:13:55 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N564385dc1d3844d58d10cb1d9b756de6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:cb01932a-d4e7-4984-b15f-5dbf16204256"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c7d8a670-40bf-4405-91ee-5a394a544f3e">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:d91e327f-f192-4b77-8e02-8a70e7308c3e</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5899831c-1027-42fe-9f30-02e63dcfc747"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N49c693d2402e422cbc6e68d4a81c50c7"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:2ef6f388-9059-4c16-a476-e58541d11a96</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9107CAA2-30C3-4F85-8981-6406C7D8CCA8">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/11B7452B-BF3D-4E5D-A899-E463C7BEE0E7"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/74E4C44B-34CE-4ACC-9C76-B6514EAEE220"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7ad0eef3-2cf2-4a42-9157-08d5191bc419">
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f15f7eb2-c5dd-4641-8cfb-999f5699fc76"/>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a45668a1-b6c5-473d-a009-224f231f296a"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cl></dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e1430434f70e501434f711b6e0000">
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:lastname>Boyce</foafx:lastname>
    <foafx:email>rdb20@pitt.edu</foafx:email>
    <foafx:firstname>Richard</foafx:firstname>
    <foafx:middlename></foafx:middlename>
    <foafx:title></foafx:title>
    <rdfs:label>boycer</rdfs:label>
    <foafx:name>boycer</foafx:name>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:homepage></foafx:homepage>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cfcf7fbc-051d-4a78-ba49-05b6dcfc9296">
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3fd02430-193e-44b6-ad6c-14d05b6d2cd9"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:a40ae9a8-c50d-4068-a4af-5470ef8d6c88</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:c2369e13-18a4-42a5-b62d-75933efc26fb</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nbc1c5a18197b474897dc0ab7b04834bb"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:28796307-0af1-4642-b0ca-d729392a1eae">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:08b11b32-6119-4306-a70c-a1b1a7e5a570"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D54B9F3-0F7E-4060-A5C8-530585B6D27F">
    <ao:suffix>, azole antifungals, </ao:suffix>
    <ao:prefix> with potent CYP3A4 inhibitors, </ao:prefix>
    <ao:exact>HIV protease inhibitors</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5D54B9F3-0F7E-4060-A5C8-530585B6D27F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>5D54B9F3-0F7E-4060-A5C8-530585B6D27F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <pav:createdOn>2015-10-29 10:39:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b3338899-2df5-494c-b67c-e12f818c96b8">
    <domeo:belongsToSet>urn:domeoclient:uuid:51624579-d062-408c-ac03-82f5474706e2</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:07272d8f-097c-449a-8aa6-c2c1208f5e55</pav:lineageUri>
    <ao:body rdf:nodeID="N27edb478881d4f199ee3d297daf9dc75"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:ecd7e563-4625-4f47-b3a0-1d5e00d06b9f"/>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:61462986-1B77-4139-B35F-47373B511D58">
    <ao:prefix>, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:61462986-1B77-4139-B35F-47373B511D58"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 14:26:32 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EEBAA25-941A-423B-93DA-83D71C8877F7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine. </ao:exact>
    <pav:createdOn>2015-10-27 15:38:02 -0400</pav:createdOn>
    <ao:prefix>    Carbamazepine   </ao:prefix>
    <domeo:uuid>7EEBAA25-941A-423B-93DA-83D71C8877F7</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7EEBAA25-941A-423B-93DA-83D71C8877F7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:45E4A44F-A62A-47C4-9AD9-D85506F62B90">
    <ao:suffix>, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, </ao:prefix>
    <ao:exact>midazolam</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:45E4A44F-A62A-47C4-9AD9-D85506F62B90"/>
    <pav:createdOn>2015-10-27 14:25:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4746783-A12C-4F89-850F-A34B481E1D2D">
    <pav:createdOn>2015-10-29 11:35:35 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:2CADD409-2D7E-4124-8839-E2F12408D066</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1DE77620-FB49-4DB3-A986-1EA84CC2745F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4594917B-2AC9-4FBB-B89D-E2B111AC53CD</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-29 11:36:34 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f4674124-4b2c-4d50-8c79-307504164f59">
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>02523a5c-5e2e-46b4-ac11-2bf792f09f58</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5bd286db-c0c9-4866-bcd2-5abf3ec1750d">
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ae65b9ee-4172-4a6d-a0ea-8c7430e4d4a6"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4f7e2dd9-fa3c-40d4-8c5d-2d766fec732c"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucType></dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:105f8e95-d0b1-4570-b393-12f2520801d6">
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N5cba98aa240e4f5cbb4e5bbeda67232f"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:db768188-26c4-480e-9f9c-fcfb21a4260c</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:fd1a5196-6e1a-4c60-8763-ab278a13fa59"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2A343CF1-A846-4357-B79C-593494E7045A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>HIV protease inhibitors</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5622b045-28f2-4a28-985b-a734a92e22e2">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:4bcaa1c3-4507-49c6-8b20-ba63d5b64fff</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:d376e0d3-8a90-420d-8296-eedc79f28fdb</pav:lineageUri>
    <ao:body rdf:nodeID="N91b49433a4914179bc6063f353e4dae9"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:d06cf6eb-e181-4199-815b-eb7cfce8097b"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d7cbbea4-45cc-44c0-abb4-789ed2fa0d94">
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a3c29e6c-e18e-4564-ab8b-cf321b71fc0f"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f6c7872b-d9c6-4e9a-a8e5-9f973e7ab81b"/>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4eb771ff-d3bf-4334-8132-17b73ef866f5">
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1835049a-eb90-431e-ac38-197f12190eb1"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9e2218dc-96d7-4ace-82cd-84e4ae0ddb84"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A83DB83E-0DCF-4DAB-AAFD-EDE49043EB21">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In vitro, bupropion and hydroxybupropion are CYP2D6 inhibitors. In a clinical study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of CYP2D6, bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and T1/2 of desipramine by an average of approximately 2-, 5-, and 2-fold, respectively. The effect was present for at least 7 days after the last dose of bupropion. Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>Drugs Metabolized by CYP2D6    </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A83DB83E-0DCF-4DAB-AAFD-EDE49043EB21"/>
    <pav:createdOn>2015-11-05 16:17:37 -0500</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94232E79-3674-4468-B130-EB1D12A847A9">
    <ao:suffix>) is unlikely to be affected by fluvoxamine. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:94232E79-3674-4468-B130-EB1D12A847A9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact>temazepam</ao:exact>
    <pav:createdOn>2015-10-27 14:25:31 -0400</pav:createdOn>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2629B00B-C687-48AE-A969-B1BF9A47FD12">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C7068E65-FA22-40F8-8485-2D37123C380F"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-27 15:35:07 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <ao:body rdf:nodeID="N84bd46df63054c3890384269efcb9322"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9a2525c3-0bae-4abb-84bc-9b9f02dd5282">
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:530bdc7a-970c-44f4-a990-37fb7492ce19</pav:lineageUri>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nc581ed10bbf2423f9537f4ff1c5020c2"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:99107690-14ae-48c9-b6a3-8b74a0fb6004"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:abc6c0dd-579a-4b9c-820b-b49d2df1dd39">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nbd35b563c3e64bdf85d981d9b744c255"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7d96b14f-4dad-4bd6-9236-5339a945e2f3"/>
    <pav:lineageUri>urn:domeoserver:annotationset:75cab04f-43ac-4c50-a921-06d524d820e4</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6E587473-562E-4E27-AB4C-D4C88FF17827">
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1994900A-B5A8-43AE-AC05-26F7BCC635D2"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CD794FFD-8A46-4805-B4A4-159A2320FAFD"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25A24A17-01FE-454C-9CC1-52EAA235C475">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25A24A17-01FE-454C-9CC1-52EAA235C475"/>
    <pav:createdOn>2015-10-28 17:21:52 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:exact>In vitro, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme. In a clinical study, desvenlafaxine 400 mg daily (8 times the recommended 50 mg dose) was co-administered with a single 4 mg dose of midazolam (a CYP3A4 substrate). The AUC and Cmax of midazolam decreased by approximately 31% and 16%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP3A4 can result in lower exposures to that drug. </ao:exact>
    <domeo:uuid>25A24A17-01FE-454C-9CC1-52EAA235C475</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ized by CYP3A4 ( midazolam )   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5f732e09-f9d1-4528-950b-3d4d02f8216f">
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7e1d4e98-8085-47b7-b41f-ab21f11344c8"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f44309b2-d2dc-4ffd-9434-d864a7571f6a"/>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/45a4a811-6e08-428a-bd54-9e7606aced4c">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>GILENYA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cd922454-de0b-462e-be38-732259bf5a0e">
    <domeo:uuid>b709268b-6066-4aee-a940-94608b9c9d8f</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1509a88d-c2ae-4e99-8741-6ab8612c477b">
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N8d5b4556961a4ef2b90e562b800150b5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6bb03847-d695-4d5a-bc1d-18e714ff4e78"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:d134e8f6-94df-448e-9a0a-652a1f99ffcd</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e86fd690-50e1-4859-81af-821f8aa5c225">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/07123443-a81b-413e-b452-e7ba1f23118b"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/bbc428e2-932d-423f-b16e-c8950035cc35"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ae3967d9-09f3-4506-b221-07b3c6cbd273">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>saquinavir</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5abf81fd-83be-47fa-92c9-ccd0235af27b">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d6580d23-d1e1-41f2-8040-dceafab0d6bb"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76b35fbc-c6f9-4f03-b385-d6a42f7c9eab">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:1b82084e-9346-4112-8d17-aa85763cad38"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:ff709317-51f2-4ffc-9390-501949bcfa31</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nb798a79d4c0748cf8faa8ba9f36f0b32"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46A3F825-D3C6-437F-9311-635F5C1E0D6F">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>46A3F825-D3C6-437F-9311-635F5C1E0D6F</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-11-04 14:11:21 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46A3F825-D3C6-437F-9311-635F5C1E0D6F"/>
    <ao:prefix>(TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/435bb8ee-22ab-4b1c-8151-d2798b4b94d4">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D1806BB-FE81-49F6-AB8F-3E00071D634F">
    <ao:prefix>     </ao:prefix>
    <pav:createdOn>2015-11-04 14:10:24 -0500</pav:createdOn>
    <domeo:uuid>3D1806BB-FE81-49F6-AB8F-3E00071D634F</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3D1806BB-FE81-49F6-AB8F-3E00071D634F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:exact>Drugs Metabolized by P450 2D6 – The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:720B0D00-827A-4552-8794-0F2E895C4F63">
    <pav:createdOn>2015-11-05 15:52:06 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:720B0D00-827A-4552-8794-0F2E895C4F63"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>and AUC values of hydroxybupropion by 32% and 24%, respectively.   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Cimetidine: Following oral administration of bupropion 300 mg with and without cimetidine 800 mg in 24 healthy young male volunteers, the pharmacokinetics of bupropion and hydroxybupropion were unaffected. However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7DB449CA-E59D-4070-9C87-2409B06D1CD0">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6E587473-562E-4E27-AB4C-D4C88FF17827"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:comment>Exposure decreased by 78%</dikbD2R:comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9d1fa203-c6c6-4960-8762-fff326136ef5">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N2be91561ea6240cfbd0bb24919bc60bd"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:0a254d4b-887d-466e-9a2b-34c6e79f7af6</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:42ad04ec-e994-46f0-a41b-9abc650418a7"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:8a7ccd39-1eb4-46fc-b69e-345d7aca3e14</pav:lineageUri>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4983c1ec-51f7-4614-a562-994eaa0d251d">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6ce2837e-c8bf-4a62-9e5a-e911a80b4441"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2f19d53b-d6ee-40e7-92fc-a35577b9b6cd</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DBEE5221-D401-40BE-B949-C3C7B4828E78">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>hydroxybupropion</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1B6D8B9-A626-4E5E-8B19-B18F63A39DCF">
    <pav:previousVersion>urn:domeoserver:annotationset:8EE4F288-19C8-4519-85CB-791C9E9709D8</pav:previousVersion>
    <pav:createdOn>2015-11-06 15:41:58 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-06 15:43:14 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:082B38D4-2CA9-411C-BCCF-F10786673E1A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1ef2e6a4-7677-4319-8d61-712cb7954c83">
    <domeo:belongsToSet>urn:domeoserver:annotationset:17E19BC9-3C76-4B2F-AC75-FA619D4CB9D2</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:415df5ed-3e43-4362-b014-6f78923c75d9</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-02 14:30:38 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:09FD78A7-2A8B-43EE-968F-DED2D5A36394"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Neb348141470d41239d24a734202d46aa"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1AF94052-E330-4051-8005-E54DB2E43846">
    <pav:lineageUri>urn:domeoserver:annotation:FF6F423E-23D4-4FCA-925C-050E57F1D8F7</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N27919b5304b14e3086ffcf5621948b35"/>
    <pav:createdOn>2015-10-27 15:38:02 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-27 15:38:04 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7EEBAA25-941A-423B-93DA-83D71C8877F7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f69dabe4-861f-4ad9-b832-4dede4370688">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>bc3f3506-588f-4a61-9a95-0951018c863b</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D372C1A1-12B4-4D25-87A5-3DF2636CBC88">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:97F5F689-104B-4B44-A5E9-F94FC313FA04"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08448F7B-D11F-45B3-8826-2026F21BF1EE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>08448F7B-D11F-45B3-8826-2026F21BF1EE</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:08448F7B-D11F-45B3-8826-2026F21BF1EE"/>
    <ao:exact>Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
    <pav:createdOn>2015-10-29 10:27:55 -0400</pav:createdOn>
    <ao:prefix>ients receiving maprotiline .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:407B4C8A-51DA-4B66-AA21-EBB6D96A9B5F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:407B4C8A-51DA-4B66-AA21-EBB6D96A9B5F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>407B4C8A-51DA-4B66-AA21-EBB6D96A9B5F</domeo:uuid>
    <pav:createdOn>2015-10-29 11:35:44 -0400</pav:createdOn>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:aad1fe6f-573a-4a4a-8da9-8f0c2d0a7380">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:f9c0e6af-57b4-4146-afb1-eff062bb0174"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:aadfc38e-82f0-4372-a2d9-d4bed2f786eb">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0bb5da0d-5259-48a9-8ebf-c79c4d5f0792"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:auc></dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/107d6308-5a3e-40ae-8437-f7d748d8038f"/>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clType></dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7964d204-a56a-424b-9b6e-b9adf06526e4">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fingolimod</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6516e0d7-fb6d-499c-8189-ccb5c18969d6">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:fb2e4917-a598-4982-b4b1-8c8ee1aaefed"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7d3b3fc4-7754-47da-9c4f-64e4fa9b0c27">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2090329D-C51C-42D6-AC2E-7DA928206F38"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-27 14:15:20 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D55E50B1-2373-4502-8F9B-738483B8825E</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:0eb9ae6e-afa7-4280-a8ef-47be791e360a</pav:lineageUri>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nb31ba692fdaf494bae633bbf31eb3945"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B6341142-1234-43C3-8A6C-9AE3BD1057CF">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/03894FA9-51A8-4A4D-AB56-1BCB8D65334C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B03726DF-56F0-4ABD-B1DA-C6D74529E8B8"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0C5F551E-0DEA-471F-965C-06AF59B7D04F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c89589bf-e6be-462d-b9ae-58141206b775">
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:68333eaa-f034-4ac3-882a-4db1945896cc"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:78a72542-3bd2-4c71-9411-acd39ada15f6</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N76a95b25df3649d8ad3bd4f93c2996e4"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9035692c-e9a7-4faa-b26d-7c52cdfdf0ea">
    <ao:prefix>BAGIO on oral contraceptives   </ao:prefix>
    <domeo:uuid>6bcc5f85-6fb2-444d-bb23-8f907d7a64f2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. Consideration should be given to the type or dose of contraceptives used in combination with AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e64b8c1d-4d57-4486-bd02-58ea8058d1a9">
    <ao:body rdf:nodeID="N37a20fc99ac94f479e0c5fd8d5291550"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:c8400279-aa48-4d41-ad9d-f8b015557c4a"/>
    <pav:lineageUri>urn:domeoserver:annotation:b778d0b4-6a42-4a9e-a87d-1898cfd12f0b</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:d7e30ee7-64cc-4b9b-b0df-35977d585583</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:08C173DD-1EED-44CC-9644-9AF4722B27BF">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:a4937c02-deec-4a94-9c57-9d7bee5596e4</pav:previousVersion>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-11-02 14:00:45 -0500</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:22bcc862-4125-4827-bc03-ff7dcc9988f1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Nb5c5f2c092e94ca196c899a0b201964e"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ade66370-85a2-4983-9d3a-605d8b7dc6fd"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:781B41C0-34DA-4E67-B058-A775757C09BC">
    <ao:context rdf:resource="urn:domeoclient:uuid:B1F4C464-1EA2-4A8C-B7AB-47AE10A9D744"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:3754DAFD-6247-4856-9467-76C95F66AF90</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-05 10:29:52 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5b2aba61-2387-41ee-a3a7-59c848406762">
    <ao:exact>FETZIMA</ao:exact>
    <pav:createdOn>2015-10-26 15:37:31 -0400</pav:createdOn>
    <ao:suffix> 120 mg, the mean Cmax value is 341 ng</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>lnacipran is approximately 12 hours. After daily dosing of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5b2aba61-2387-41ee-a3a7-59c848406762"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:79b346b0-7da6-452f-b827-e74b7d6a3f34">
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b1f191c3-68fb-4e42-9802-eb1b5c437a45"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/32205567-16ef-490f-a7c6-488711e8a36a"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8EA14293-DB7D-400C-B242-F9B5D6F323E4">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3403606C-F1C1-4B87-884A-43995B6BEE31"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ccc3c25e-b506-4cf5-8271-9cd06b4a7a3d">
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F49B6361-85D7-450D-93B6-D2F097E0450A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N260470b89225488b839d8b67886c6117"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:9C89AEDE-63FE-44CA-B4FD-1EEBC1D58CEA</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:99b5e951-bb92-4bc0-a6ce-49e23835b79d</pav:lineageUri>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2a98b4c8-9de6-4010-b40e-519dd43052de">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ff79c20d-04b6-474d-8577-351ec0b53c17"/>
    <domeo:uuid>ab61afbd-ca39-4a96-ba4f-b9e7540599c1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D1A7C886-B340-4346-AEDD-B454190DF225">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9E300BB6-7811-40E7-B37E-EBB3AD9F1199"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>2 to 10</dikbD2R:cmax>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/670556ED-C98D-4F3D-913F-976D299D8558"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a451459c-3a3b-42a1-a95b-8a99bb4e9421">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:af01d144-ceed-4a53-b608-938a370a0cfe"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B91BF932-E2E5-49B5-A795-184F1C14AEA9">
    <rdfs:label>maprotiline</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd1a8233e234f41148e935e750ace8c1b">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/584ef18c-fd09-4d5c-88c6-1291d37ffd50">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>ketoconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:EF211B54-A145-4798-B735-2EB39AEE1268">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:f7a2e8d5-215b-4da8-8f2a-a85dd3993744"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-10-09 13:32:08 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nce597b5be967400bba26d8f3ea71353b"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:a0b6c37c-c4c6-4508-a626-c4a996a2ce6c</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:297a16cc-68c9-479a-b15c-24d511542f92</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-28 16:46:43 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AEAC5D5C-451D-4122-9A81-DBCA3EB5ACDF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83258F28-2323-4A34-8E0C-B5B3A85840AE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>83258F28-2323-4A34-8E0C-B5B3A85840AE</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <pav:createdOn>2015-10-27 15:33:40 -0400</pav:createdOn>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole). </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83258F28-2323-4A34-8E0C-B5B3A85840AE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b9906588-d389-4c18-9332-839631e7d449">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:c8335217-2032-427a-87b4-a2215a7a10d1"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:FFE6496B-5EFD-4728-A5B5-AB339211F0D6">
    <permissions:permissions rdf:nodeID="N98f2e24024524a2bbbe338fa486547b9"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:274d0466-ce79-4b75-902c-a1c97fdf50d7</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f69322b8-8d73-4d15-bd35-ef90e8a4d434</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:5d6fdcc9-7144-47e6-90a9-acd95a63513a"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-11-02 14:30:38 -0500</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4F520324-073F-4FDD-8659-E3CC0835058B">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D4C34A53-7C73-478B-8A7B-A735627D0323"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DF63DB85-7352-4779-9D43-53BACB271EC3"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2B143EB5-75A9-4041-90D5-2EE86C9B8A80">
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/067048C1-38D6-496D-AA4F-0F426A977ED3"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DD4EDCB1-63BE-4122-8A26-56BA7F9E402D"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a927782c-fe41-485d-a97d-093df13c9902">
    <rdfs:label>lithium carbonate</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42351</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c859c12d-8c32-4a7d-8a9d-3949b5970949">
    <ao:context rdf:resource="urn:domeoclient:uuid:fbe89beb-ce5f-4e31-848b-bb12fbf9b8e3"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:f4d5b966-3835-45a4-bf04-cdea69aa3d12</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:cd7bbb8e-cac0-4fe8-b9a9-7a838f8044ad</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N47db844d1ae44ed9933dddf0fb754b35"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:830171A4-E5A4-4A32-A8DA-2660C029C413">
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>15</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C2A8D258-09E4-4DE6-8757-F02BCC742629"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/71E9CA78-9533-4E9F-93BE-2452A2885E03"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12>Unk</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B4A82391-AD32-4AD9-B2CA-B344D91CB1E6">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>warfarin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B975DC3F-9F3B-40A0-AAAF-AD9E9DEAD722">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:4934ef62-8db5-4ef4-8abd-1690c71c5814"/>
    <pav:lastSavedOn>2015-11-02 16:12:40 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-09-10 14:41:16 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:4ebbdb4c-80c0-4e9d-919e-cf783901ae93</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Na69a0d0df565446d8ad96ad29d317530"/>
    <pav:lineageUri>urn:domeoserver:annotationset:7c795615-fb9a-464a-b7ce-f615293bb91e</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1f567f03-c77f-43bb-bf1d-5353f675580a">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>tricyclic antidepressant</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N37a20fc99ac94f479e0c5fd8d5291550">
    <domeo:sets rdf:resource="urn:pddi:uuid:47664063-536b-44c1-a588-b7113b976411"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6e1476fa-63e9-4e7d-afb3-608a3b41d288">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> The effect of</ao:suffix>
    <ao:exact>Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.</ao:exact>
    <domeo:uuid>c8ccfa38-4897-4f4e-b6f4-4a80a28ddc8b</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9f8b1153-a08e-47ae-9593-8ca4369d626c">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>beta blockers</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:856b917c-b61f-4832-a35d-f0c0d6d8ef6f">
    <ao:prefix> B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]</ao:exact>
    <domeo:uuid>c3ac4773-0a3c-4a2f-a294-9a7cab1d611a</domeo:uuid>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74B8AAE7-18A1-48A4-88E9-42CE88A3179F">
    <ao:exact>Cimetidine: Following oral administration of bupropion 300 mg with and without cimetidine 800 mg in 24 healthy young male volunteers, the pharmacokinetics of bupropion and hydroxybupropion were unaffected. However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-05 15:51:27 -0500</pav:createdOn>
    <ao:prefix>and AUC values of hydroxybupropion by 32% and 24%, respectively.   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:74B8AAE7-18A1-48A4-88E9-42CE88A3179F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B1AB0DC5-E229-46CB-99CD-8964B49E8210">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Nfad263c21d084bb99f411d036cd22c13"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-24 15:47:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:481ed158-67ee-4520-bc34-22387963ccbe</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-10-29 08:58:27 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:064328db-121f-417d-80f1-6d9749db3eb9"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:e26122fe-2b88-4483-a9d2-e9be2d392d55</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0db0d5c8-15ea-44cd-8f0e-3894f007c5ea">
    <rdfs:label>phenothiazines</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FCEA670-FDB7-45A7-A6D2-1117F83CD763">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:B6EE59E2-ADA6-4DBA-BA3B-6D60FA250AFE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:lastSavedOn>2015-10-27 15:20:54 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Ne6c377bc0f00405eaa1ca35f4ad9d58d"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1BA882E4-1468-4E4C-809D-8627B0CCA3B2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-10-27 15:19:40 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:cd913437-356d-4afe-9005-3c6c52f906b1">
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/279684fe-a069-453b-8d14-23eb35d9a2cc"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3c9ed332-013c-432a-93ca-0efdd57f3e67"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:274ccfe9-9f11-4035-90d9-c01c57d880d1">
    <pav:lineageUri>urn:domeoserver:annotationset:9daab2b5-156e-4e75-9fcf-f2e0f358e6a4</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-08-20 10:29:59 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-08-20 10:29:59 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:d7a5e294-fd88-45d7-964f-33655ebad849"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Nd2fd913ad08844deae0ba8d8acde146c"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4aaf6f09-9eb1-4dbc-9de0-0304c7682f2d">
    <ao:body rdf:nodeID="N8b53de79fd3f4d82b1b1ad53c8ae61a0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:820bf18d-5974-4514-9e4f-0e52c18f3847</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:a103a56b-2deb-47b8-be39-69caecd31508</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:b5508530-ec46-46ae-9ae2-d542a75e8533"/>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3bdb135b-1a99-4220-8502-6bc716bdee25">
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-09 13:32:08 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:510bd380-0e08-4718-a3f6-03b36f1fdfb3</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2280FAFA-BEA2-4B8E-B7F1-2DBC7D343EA0"/>
    <ao:body rdf:nodeID="N6692032c607b431b86249597aeabf517"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:28F8675C-8B03-469A-87DA-5FEB46415C85</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7B346538-1943-424A-ABEB-F1C41597978D">
    <rdfs:label>hydroxybupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0DDC0503-0E10-47CD-9C67-774F67A74350">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>1</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7E43A3E2-7BAE-4042-B9EA-CF146721DE2F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6ED9986C-92AE-4FCF-B344-7A60A67656F4"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8a327e78-0d2a-4141-a1f8-3257d5c43500">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:c59a1bec-45d8-465d-8bac-8365bf8ecd71</pav:lineageUri>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0053D67A-D687-48A1-912E-91C90EC641E8</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nb7b0ca2535d9462dbb7d30d7e611c157"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:90DAE13F-76B8-49C3-B450-15539C7AFCF6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6889d9dc-e32a-492e-8f48-4b26ab621711">
    <pav:lineageUri>urn:domeoserver:annotation:a4774fb2-16aa-4d9f-8234-6e0c057a26f7</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1F409B11-21D7-490C-B8BA-422F298573A3"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-10-09 13:32:08 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N0882d3e076614d74945709238285c66a"/>
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F56270D9-805E-4042-AECF-43B8EF01F8B5</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N80da1c0b15b042aba065289d4ffaa822">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:466c6db3-9987-4157-be09-3dd5435a6e7d">
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N4eec5d5b0e634f08a21ac400e27fbd52"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:c57e4dd6-5f22-4ef7-8169-8bfb0987ac74"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:c4d4452f-6c26-4922-98e6-3e34f0134e50</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:a60a106d-cfc1-4084-9936-7ac21f48d468</pav:lineageUri>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1ffbb219-39f6-4c21-a69c-5b7968802a7f">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:495218a3-bff6-4895-b9ba-e63ce67758c6"/>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="Nd6b3f7b118e3437fb557cb0c31d3c4ad"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:c0ce7dfa-831c-48af-9383-46d8b65ce3f9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17f0f778-b71b-4e30-9421-99cc71fcc7b4">
    <domeo:uuid>0c6d85bd-1210-4799-9ee0-8bafbcceec77</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:da032a0b-8fbb-4be0-879a-38b2186c3c8e"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B904ADD5-BC92-492F-8D2B-B5D8F9C19A80">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>levomilnacipran</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5e54e261-20ac-4fa7-8926-1eeb48584f52">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f9c0e6af-57b4-4146-afb1-eff062bb0174">
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/974740ee-9cdf-4293-a438-37a7805de5ff"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/046215fc-e890-4356-8c88-64a9aa3a491b"/>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9b729b4f243649aa814cfd0950e842a8">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ab7382b2-626b-490f-b623-b496facb30d8">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N7c55cc039afb4221af0e616cc0eb782e"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:f270d6de-b017-4ad1-8409-b6edabd305c2</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:42eb3278-983d-4168-b408-4bb96850ce93"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:35efd329-5b77-46df-80da-c02c94be7c0a</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/bfbdd8a4-ebef-47f2-8f51-7c8914730eca">
    <dikbD2R:dose>0.25</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A54C1212-DD2C-4552-9AB2-B56185D59A18">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N8df554ddbae24f9182f84b3b678542f9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:65D77875-0AD8-4CB8-AC80-444C4034FF6F"/>
    <pav:createdOn>2015-10-27 14:25:49 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5590a9f49c6e4c15a993fd0d72dc4087">
    <domeo:sets rdf:resource="urn:pddi:uuid:159e7cad-c066-4904-86ee-9c259903fd45"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5100C690-A6A2-49E5-B9BC-41945BD4D929">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Citalopram</ao:exact>
    <pav:createdOn>2015-11-05 15:54:25 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>threohydrobupropion and erythrohydrobupropion .   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5100C690-A6A2-49E5-B9BC-41945BD4D929"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47BB2BB9-37E2-47ED-8A73-EAA48EE1CA15">
    <pav:lineageUri>urn:domeoserver:annotationset:21ab3694-0521-45a0-aac4-063bbf59cd54</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:10C3949B-A0F5-4885-AE5C-0AE517D0212D"/>
    <pav:createdOn>2015-11-04 14:05:43 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:9f66b4af-6083-4081-b81c-bd2656e0280a</pav:previousVersion>
    <pav:lastSavedOn>2015-11-04 14:10:24 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd2cff9feb50c4a34b90f0b826c7f3bea">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E66D0601-C54A-4DC8-95C6-5BFCF14C7FAA">
    <pav:createdOn>2015-11-05 10:36:47 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:216CC4DF-64B4-46E1-BA25-4B3A06C88678</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:D1327C66-60BD-40DF-AE92-5B380A6861C1"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1C9ECA4A-5865-4525-A32B-153BFD579AB4">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F90F8933-4877-40C7-8C71-7D0A2F9B0844"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A72D1BE3-A365-4956-8523-775DBA27592A">
    <ao:prefix>, and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A72D1BE3-A365-4956-8523-775DBA27592A</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A72D1BE3-A365-4956-8523-775DBA27592A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>paroxetine</ao:exact>
    <ao:suffix>, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated </ao:suffix>
    <pav:createdOn>2015-11-04 14:17:35 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/504D359A-444C-4512-883B-5A7C1F5F88C5">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>ketoconazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c2ceb124-463e-421b-9f39-42bdf43e6228">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>AUBAGIO on CYP2C8 substrates   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <domeo:uuid>7e534aa3-9328-4586-8789-714c0549204e</domeo:uuid>
    <ao:exact>Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1BF1A01B-3BA6-41AE-8051-F265CDDADEA7">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9851A37E-AB7D-40AC-B56A-06ED0895502D"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>10</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/36C38F40-B5EA-41E1-B8D8-1870E816C4D3"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:749ea430-dcaa-4333-a269-df1b9dfa1b8a">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:48c08855-f398-4789-b347-ba8e3a1a26fd</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:ccfe8550-fbd6-4148-8cf8-37d0a31b0898</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N07f53e1e8fd54f11945d936066ed8989"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-13 11:13:09 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:a4de8a69-aeba-4cb8-a243-cdf491e30382"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-13 11:13:09 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:384615ea-3ce8-4c13-b021-eef1ee96ebe7">
    <domeo:uuid>edb35981-6966-453c-ab36-6ec9d71c8a0b</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ae2beb82-4001-40e8-9533-481b87824b77"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/770B80CE-44DA-41AF-BBC5-DDADCA818751">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:552C48E1-1973-4FAB-A8BE-44B465F504FC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>552C48E1-1973-4FAB-A8BE-44B465F504FC</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <pav:createdOn>2015-10-29 09:08:32 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> Drugs Metabolized by CYP1A2   </ao:prefix>
    <ao:exact>In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity. Therefore, an increase in the metabolism of CYP1A2 substrates (e.g., theophylline, caffeine) resulting from induction is not anticipated, although clinical studies of induction have not been performed. Duloxetine is an inhibitor of the CYP1A2 isoform in in vitro studies, and in two clinical studies the average (90% confidence interval) increase in theophylline AUC was 7% (1% to 15%) and 20% (13% to 27%) when co-administered with duloxetine (60 mg twice daily). </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:552C48E1-1973-4FAB-A8BE-44B465F504FC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfcc43477cf314d8ca9486d9cec52b02d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB8BF502-2AC4-4D04-8534-8608A60BBE94">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>FB8BF502-2AC4-4D04-8534-8608A60BBE94</domeo:uuid>
    <ao:prefix> fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam. In these subjects (N = 8), the clearance of diazepam was reduced by 65% and that of </ao:prefix>
    <pav:createdOn>2015-10-27 15:19:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>N-desmethyldiazepam</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FB8BF502-2AC4-4D04-8534-8608A60BBE94"/>
    <ao:suffix> to a level that was too low to measure over the course of the 2 week long study. </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBE2B329-4E6C-4915-91A7-775A43D4D87E">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#absorption-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Absorption Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a increase in absorption of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fac26abe-0029-4ecd-abae-47e8b7985bb8">
    <permissions:permissions rdf:nodeID="Nffa912ecf92047bcb20df52d81331d2b"/>
    <pav:lineageUri>urn:domeoserver:annotationset:c2eab210-d9d5-41f8-9d0c-ddb7f4823631</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:f69dfc19-f679-4e1d-b25c-44c4a39c447e"/>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20235a92-f1dc-4046-afe8-0e1aa9ddeed3">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
    <ao:prefix>tantly administered rifampin.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <domeo:uuid>e59b27fd-593f-4180-a809-94645fee0fd6</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E13ABBED-1734-49DA-A187-5ECE091CB52A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:createdOn>2015-11-05 10:36:36 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9FEFD790-8DD0-423C-96A3-E861C6A7B48A"/>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:7F728795-B34E-4558-A14A-95A7174324E1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/30e54c9a-cfcb-4dc4-b99e-fa8bdf9eefa9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D0BBF476-9BAB-4930-A220-A2AC9EFDF1E6">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E937EBEE-A3C6-4315-A23C-12E016A41454"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FF02DC40-646C-414D-B6EE-15EF6035504B">
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/55F00EF8-6945-46D3-B00C-CE311FDCD781"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>70</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>3</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>190</dikbD2R:auc>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1A6DC028-1017-415F-82CA-F8BDF155D596"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:237701de-1eb8-4cdf-a541-3968522ba3e6">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3ab4b215-505b-4566-a09a-d2294acb91aa"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:55a7bd33-18e0-406a-8d34-05a92cc29744</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N2ddaf4e87814430ab90c90e10788b93d"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A47E09CA-DF5F-42DE-9045-56346A45E20C">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3F5FD123-51D0-4172-BE56-5A4E04C2DDAF"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ec2635a4-1e64-45d1-b406-84dfe0dfec8b">
    <domeo:uuid>4198edce-38b3-4069-861e-ee682ad99ef1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9d4c4b6a-4133-4533-b329-e69b9d02603f"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10C3949B-A0F5-4885-AE5C-0AE517D0212D">
    <pav:createdOn>2015-11-04 14:05:43 -0500</pav:createdOn>
    <ao:prefix> and</ao:prefix>
    <domeo:uuid>10C3949B-A0F5-4885-AE5C-0AE517D0212D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> tricyclic antidepressants </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressant. The patient should be informed that the response to alcohol may be exaggerated.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:10C3949B-A0F5-4885-AE5C-0AE517D0212D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7050802cd08c4553ad0d9c05e47d31b5">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:36523EF1-0D46-4E70-8BF4-8B58C93C8B18">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BE1877D5-CE87-456D-B0B0-383C3AD7A47F"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectDuration>28</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CE687A17-81FB-420A-8A08-AFC4D6A37E72"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B60854C8-28EA-4DAC-BD4E-48AE162C75D2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-05 10:39:02 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:25C5CED5-01BD-4BD0-8D05-0425CBE752FB</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N568cc74a3f0e4be089d888d6b9de6cf3"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:235AACC2-387B-43B3-94E9-EB936C13A3E3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:78094332-6CB9-4DDD-A3C8-591D25626204">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E632AC59-3CE0-42D4-A9E1-0F00D27DD792"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74371F34-96E0-4051-AD9C-184AB3A81161">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E4141EC9-A9BB-4586-B9EF-279C37D2B90A</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N79297ff56fc34443ba6f9cb79c248dc5"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-27 11:46:58 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:2ADDD967-D945-449A-889D-4306F8B4F77D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:29F4CEA2-667F-4AFC-86C5-D1C19703B418"/>
    <pav:lastSavedOn>2015-10-27 11:47:01 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6e64e70e-dc75-4f4c-af7d-7b0dc90c98ec">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b7e13ad9-ec1b-4a83-b9b6-a8e18b4d34f7"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/beb23711-0027-42ab-beea-44811b1ad281"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c437dc4d-4845-4a58-9f04-5b30d085134e">
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <ao:exact>Lorazepam-There was no pharmacokinetic interaction between a single dose of Savella (50 mg) and lorazepam (1.5 mg). </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>pharmacokinetics of lithium .  </ao:prefix>
    <domeo:uuid>129cdca6-e123-4208-8372-03c16c53c0cb</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94b8748c-175b-4f25-b1b7-704cf6034cd6">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:af263b14-7152-4bcd-96e8-815d2b4a62be</pav:lineageUri>
    <ao:body rdf:nodeID="Ned3f3247bc9746e091f59c468228e33c"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E9E451EA-02CF-4420-A4AF-BB99CBB6232B"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:31F0D165-0794-445D-8066-39BDFE176116</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B74DA635-F4B4-4057-A933-F66626887174">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64E2AA7B-C817-4DC3-8DA4-D5650B00F250">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nb7e2e14a14dc42c29dfc9154d3698337"/>
    <pav:createdOn>2015-11-05 10:39:51 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:50D1EF4E-FFB2-4E3B-AF9C-FAD38063C452"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:319079DE-8AB2-44CD-AC32-BB834B963A9D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N568cc74a3f0e4be089d888d6b9de6cf3">
    <domeo:sets rdf:resource="urn:pddi:uuid:166FE726-B175-4B66-AD2E-94D1BC32272A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/023177C2-5341-48E6-A56B-0137577E12E8">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdfs:label>sertraline</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d2dd2caf-dddd-4283-92e2-3579f1efe1d1">
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ae6e66ad-60ca-4338-8e8b-926d5115e5f0"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/60b39a58-c1f7-46e0-9ba5-f8541ad22bda"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:472b0b18-0442-4b58-8284-d2fe8c21894e">
    <ao:suffix>, fluoxetine</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-26 15:42:48 -0400</pav:createdOn>
    <ao:exact>cimetidine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:472b0b18-0442-4b58-8284-d2fe8c21894e"/>
    <ao:prefix>e.g., </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9a43c052-fe65-4bd1-8e7d-07255c1f8c63">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:53F066AE-D01F-4402-8BBD-1137AFB1C7AA</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A1A20B0E-483B-4C59-822A-659EF53FC366"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N4450083cf6d249c2b85fbeb1d526bbf1"/>
    <pav:lastSavedOn>2015-10-29 10:29:25 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-30 12:41:52 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:1d048adf-6242-41e4-b11d-57bfb2d27dc0</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FFC2367B-524B-480F-9458-7FEA9F81A91E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>50</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D139F954-3B90-473D-9259-314026D432A8">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/38D9ACB3-AC18-42A2-A53A-645AB9778C39"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/30514888-2B3A-4703-A890-1191D9210E04"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e4694bad-2a2b-4bb6-b3d9-04859ea4e632">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:175fa498-acab-4321-a79e-31230d5099db"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:648B1DA0-FE0E-441B-95B7-CAD3D7CDDE5A">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>Potential for Other Drugs to Affect WELLBUTRIN XL    </ao:prefix>
    <pav:createdOn>2015-11-05 15:40:31 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:648B1DA0-FE0E-441B-95B7-CAD3D7CDDE5A"/>
    <ao:exact>In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by CYP2B6. Therefore, the potential exists for drug interactions between WELLBUTRIN XL and drugs that are inhibitors or inducers of CYP2B6. In addition, in vitro studies suggest that paroxetine, sertraline, norfluoxetine, fluvoxamine, and nelfinavir, inhibit the hydroxylation of bupropion.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0469DA73-556A-46EF-84C8-BD8CAFE4D9CC">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N9a9783a59800459295ded1abd456b2f3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E40278BE-0FB1-4BD1-9F5B-FE798B960907"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-27 15:35:58 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N515c6d7e39ce44f5a1b40dd3ff682d84">
    <domeo:sets rdf:resource="urn:pddi:uuid:55C14E19-1575-4410-B332-ABF42F357A04"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:35033243-7C72-414E-8B8D-BEBBAA2FD1E9">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E8D47830-2805-4776-8255-1907F39942D2"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:88eb3458-0723-4637-b5e1-d12f4d2c4c7d">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>yclic Antidepressants (TCAs)   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>27649175-a585-498b-b33b-95881f2af878</domeo:uuid>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <ao:exact>Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7FE72EF-2550-431C-95D0-360F034A90C4">
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole). </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B7FE72EF-2550-431C-95D0-360F034A90C4"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>B7FE72EF-2550-431C-95D0-360F034A90C4</domeo:uuid>
    <pav:createdOn>2015-10-27 15:33:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4EBCE9E9-6545-42B5-ADFF-1BAC26A2BD9E">
    <rdfs:label>Bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:dcec4046-c7c7-411e-8b2b-5285dc38ed9a">
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7fedd340-f32a-4e77-b24e-fbfde5eca329"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a25b4eb6-103d-4b50-b894-da0fa309d678"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N390fd89b0e4d497697528ce223b2bbc9">
    <domeo:sets rdf:resource="urn:pddi:uuid:04C26A1A-97DB-4615-B900-85384281BA4D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BCBCAF85-FFE0-4818-B942-0489DD3E75F3">
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F1F1EC19-4132-407B-8CA6-DFA79CCD1FCB"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:auc>16</dikbD2R:auc>
    <dikbD2R:cmax>32</dikbD2R:cmax>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>24</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4D49EE33-3482-4217-94C9-665266824616"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:dca61e64-9b44-46ec-b825-5e636e827350">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:7968921e-a689-4fdb-af03-1aba9fdce59a</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:ebbaa0d8-4935-4b82-bf5b-954be3808c28"/>
    <permissions:permissions rdf:nodeID="Nabbe1c3cb7544a49b30fb475f2a73d81"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:de69f687-e05b-451f-a50a-e9f36fceef06">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:c4c4054a-68df-4add-abe5-86cdc8389c92</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:df7e4439-518d-43af-852a-7553ef341d34</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:efc0f3b5-e6f0-4596-a8a4-38d04126ed99"/>
    <ao:body rdf:nodeID="N648d96e531404f97ac17c1cb47a60924"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:159C40A3-2CEB-484F-9396-A5DFFE3954D0">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:552DC9F9-BC80-42C4-A20E-76CD50328768"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0768CA5A-42B5-4AEE-898D-336AADC10B13">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Comment>what an awesome annotation!</poc:Comment>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9670ef97-8523-4cb4-a89c-e8909be1961e">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>b68d5f42-fe87-4d9f-bd6e-1f8d7b0c18f2</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:389e266c-5db2-4337-b08d-1274ce71f17b"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50CA3CE3-F0B0-45F0-8EE0-A8F0487940D2">
    <pav:createdOn>2015-10-27 15:36:24 -0400</pav:createdOn>
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <domeo:uuid>50CA3CE3-F0B0-45F0-8EE0-A8F0487940D2</domeo:uuid>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:50CA3CE3-F0B0-45F0-8EE0-A8F0487940D2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0fc38d3caf4547efa6f0afde5b7b2c5a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5428bd64-9644-4759-9880-6ba3111a77f6">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:bb03298a-1efc-4e4d-aa18-d3bf593fe9b7"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:029c7551-dbe1-41f9-bde3-08d5a961d4a5">
    <permissions:permissions rdf:nodeID="N6adab0a1e66b489fa05b199b51a9dd08"/>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:89e3d375-1b0a-4b50-9afa-2e3c5c9f4fd5</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:1f373ec0-8432-462e-aa2d-1f1dfb1bc80c"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:55C14E19-1575-4410-B332-ABF42F357A04">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:51D2FCCF-39C7-41CB-B64F-17E20095455E"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:84C097A0-6245-4286-9C98-7ED4A6354A47">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/57727E7C-91AD-44ED-9312-A65638E9FAE1"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12>3</dikbD2R:t12>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:auc>5</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax>2</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AD294F6C-4519-4132-BA69-F5BF75EC53EF"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6686CF4E-F395-4A00-9B7C-24E29A14028A">
    <ao:body rdf:nodeID="N912271702f784c7d816ae4927609f3ba"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-04 14:21:12 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:48C99CDE-5A1B-4CB3-A4C6-E5090C37919D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:2E9FFB95-8DEB-4A5A-B905-8113CD1F121A</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-11-04 14:21:12 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F3EB56B6-EC97-4D62-AC33-69410D3C3670">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CA8D80D7-3C6A-4DE3-94ED-ABD92FF21AF6"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0D903A8D-295D-4CCE-BDD1-4D10A6D4A031">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C2897B28-AA34-4A23-AD93-B7F4B782030D"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B4A82391-AD32-4AD9-B2CA-B344D91CB1E6"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>14</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/698b78c6-8b4d-472e-8f96-7ac7e237981e">
    <rdfs:label>simvastatin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36567</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/cd23061b-83ce-4129-83e5-bc28e53b6ede">
    <pav:lastSavedOn>2015-10-26 15:38:26 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:createdOn>2015-10-26 15:38:26 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:4c4a1401-3e77-43fc-96fd-5b86bac0418b"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DA68951-B82C-4701-A781-ACEC78A94503">
    <pav:createdOn>2015-11-06 15:37:02 -0500</pav:createdOn>
    <ao:exact>nefazodone </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0DA68951-B82C-4701-A781-ACEC78A94503"/>
    <ao:suffix>(200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <domeo:uuid>0DA68951-B82C-4701-A781-ACEC78A94503</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>(1 mg BID) and </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C32CC6A-5196-4913-84F7-7FAC36BD2F6A">
    <ao:body rdf:nodeID="N769a2170f4394352bdb5ec2e95e1e95b"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-04 14:13:23 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E17EBCC5-B429-4DC3-8E8B-5F0484FB99D1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:E25073D4-E9C3-4CA8-969F-6B4A37E533A8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00d4430e-1921-41fd-896e-64b1938df939">
    <ao:body rdf:nodeID="N0eb973480fb445aba9f858d7752941da"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BC7D481F-E414-4C89-916F-D487364E34BF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-02 14:33:30 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:79651312-0a33-4f0c-af66-5179941a938f</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:CCD4DAAC-62F2-4EE7-B3A1-D12C7696FAAD"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8eaacc16-bab5-4b46-912f-8889c54b0adc">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:3b8e147d-7ebc-4333-90ad-97a058d86669</pav:lineageUri>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:36F6DE1B-9AA6-494D-8935-7F4B68EC3061</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N8cad520aa4bd49f4b3ea1e90be5e8082"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A0EAFDD-7491-496C-8A86-3F06B03B3223"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fe245ea9-9fce-46aa-a1ba-bb27340570a4">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N9d22559f9af24123b36581f86468ac35"/>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:c58067aa-8508-4fa5-b9b7-058157b2ded6</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:9f95ee54-bf68-4c66-b3ee-82152df8b026"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74CD3DB9-B8D5-4D61-BBF2-D28C2855F030">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <pav:createdOn>2015-10-27 14:12:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>74CD3DB9-B8D5-4D61-BBF2-D28C2855F030</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Ibuprofen    In subjects who had received EMSAM 6 mg per 24 hours for 11 days, combined administration with the CYP2C9 substrate ibuprofen (800 mg single dose) did not affect the pharmacokinetics of either selegiline or ibuprofen [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:74CD3DB9-B8D5-4D61-BBF2-D28C2855F030"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:99fbde00-3ec5-48cf-be05-1de86fb463e1">
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/638739ed-3dc6-485a-ba80-1ecd9f5bfa9f"/>
    <dikbD2R:auc></dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2e03c0b1-1136-448e-b2ea-8d1e2cdddd2f"/>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clType></dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1470d07c-375e-4080-bb71-2a0c3804de10">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3E27FAE9-EDF7-4B3B-B054-36E694B88D89"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:f87754d5-16c7-41cb-a276-907433864e1a</pav:lineageUri>
    <ao:body rdf:nodeID="N712566e019d844629181eefa9fc69d30"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-11-02 14:48:13 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5CDA3E2-B50C-46D0-B521-358756C618CB</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d7a5e294-fd88-45d7-964f-33655ebad849">
    <domeo:belongsToSet>urn:domeoclient:uuid:274ccfe9-9f11-4035-90d9-c01c57d880d1</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-08-20 10:29:59 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 10:29:59 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:f00053f9-1bff-4b11-be13-aa274e542e8d"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N8798fd5a3c174f6896993790e49c87c6"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:4df1d96b-1b32-4531-b737-78940c06d693</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A2BABFE-1C7D-4040-8DC8-35A60F10ACF9">
    <pav:createdOn>2015-11-05 16:04:01 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:63E48FD2-977C-48E2-B8C1-F43C053E708E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-05 16:04:06 -0500</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N3111281aff4d4962aee8b893d5d911ad"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6D859AE4-5765-4675-8A3E-853BBC2E5D12</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">21</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:802c72ff-26a5-4169-a681-8cbc0bc8f37c">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <domeo:uuid>63e82e6a-62f8-422f-8af2-046663d90769</domeo:uuid>
    <ao:prefix>nsporter 3 (OAT3) substrates   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F665787C-AC4C-42B7-94BC-8B640D83014D">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EDEBAB6D-55DE-4EB4-A24B-71D5DB3D3DAA"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N254c928d07784c9cb95f381822912b3b">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:041436E4-A70B-4508-835A-927ABD07F4D9">
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>35</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/339296C3-38F9-4412-9136-6EF2C9CA89FA"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/88550DBE-60A6-49BE-91B8-1FF71D043E81"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AB1ABFC1-12C1-4177-97E8-4BA1A3FD076C">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>22</dikbD2R:auc>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CBC872BA-50CA-4B6D-9878-1CDF1C0592B6"/>
    <dikbD2R:cmax>21</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BD3CD8BD-E739-4903-8967-FC84481AA89E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8FB4BA8F-105F-4335-9FB6-A81ADF6721FE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:15AF2DCA-9508-47D5-AC5B-BDADC21B1888</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-05 10:36:40 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BE77B80A-38B1-4669-A7B0-6BEE7481BD08"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5F235CB3-EA79-4FFB-849C-9E8629488B0D">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E2FE1AD0-52DF-4C90-97B6-0832E82C64B3"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/143887BF-B919-4260-9BC5-5766DCA4B2DF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:873022ae-d4ad-4825-9f08-218cc38fa61c">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6a46d0c8-51ed-48cf-b190-92fdc97fefe7"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:3f6427c9-1e24-4fd0-b7c3-6e71a0dbcf90</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:7c019fcf-77eb-47af-b80f-32a0c9417666</pav:lineageUri>
    <ao:body rdf:nodeID="Na26cf9e758fb493ead2bb28578a1251c"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48174C77-8AA2-4177-A9C8-F0F6197B6446">
    <domeo:uuid>48174C77-8AA2-4177-A9C8-F0F6197B6446</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:48174C77-8AA2-4177-A9C8-F0F6197B6446"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>T</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <ao:suffix>. (</ao:suffix>
    <pav:createdOn>2014-02-19 12:37:38 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>ests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D92B9C92-3F95-4EEA-88C5-CF605AC5F11A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>4</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>lorazepam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d08bc5a8-e096-4eeb-b90c-32944522639c">
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e357203d-3fc0-4906-b802-a57fd1dc3382"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>2.8</dikbD2R:cmax>
    <dikbD2R:auc>2.9</dikbD2R:auc>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0f0c781d-5610-4ce2-a2b9-6b1a7ce08d06"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cd7ad75a-1cac-41f5-9d00-56dd125f2dcf">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:30a67455-0657-40b3-845d-50c7c2f8627b</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:f58da160-c057-42d3-958d-f7689c8c755c"/>
    <permissions:permissions rdf:nodeID="Nfbc6643b0fb243808488b38fff64bb55"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F654BDDB-235C-4284-9515-25EC3E182501">
    <pav:lastSavedOn>2015-11-04 14:10:24 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-04 14:07:01 -0500</pav:createdOn>
    <ao:body rdf:nodeID="N4a050cdc035f48159d7798e69ca52f08"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:434EB3AD-3AE0-494E-8B5A-AEFE7AF594A2"/>
    <dikbD2R:evidenceType>evidence-challenges</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoclient:uuid:9f66b4af-6083-4081-b81c-bd2656e0280a</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:21ab3694-0521-45a0-aac4-063bbf59cd54</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03390AC1-85E8-4A41-94DA-5A6229862117">
    <domeo:uuid>03390AC1-85E8-4A41-94DA-5A6229862117</domeo:uuid>
    <ao:exact>lithium </ao:exact>
    <ao:prefix> did not significantly alter steady-state </ao:prefix>
    <pav:createdOn>2015-10-28 16:28:35 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>levels or the renal clearance of lithium.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:03390AC1-85E8-4A41-94DA-5A6229862117"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57229497-C009-4B65-A612-416CA524262D">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-05 15:33:32 -0500</pav:createdOn>
    <ao:body rdf:nodeID="N49851ce4f8d04ae29c8acb56d17edd8a"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:56A8B7BB-1B12-493F-9559-F29C8E5BFDAF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D1DBB8AE-2CA0-4A49-8028-ADE998079C2F">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/88F8ED64-25D2-457F-BBF7-01D5B02DFF94"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1BE6118C-5E0D-4FBC-83BC-FEC7CAE56539"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B35DC339-2222-424E-8E87-E72C2F20FDA2">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:auc>2</dikbD2R:auc>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/23249E24-5BDD-4F47-BCFF-05AF42843756"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ABCB6AE4-8133-4635-BEFC-C8F8BE4822A1"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4924e38b-ac50-4c76-8a78-436fca290d9f">
    <rdfs:label>alprazolam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7DA7E943-210C-4B40-84F2-06D579481838">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A52BC1D5-997F-4D60-B609-A3E04C5A6B86"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:62c026ba-9838-4fe3-abe0-183c15d23a76">
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/d97aa291-5e7a-40c0-aad3-dc1b9ea32c0b"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/c36900f8-721a-4107-91c6-10956a4ed789"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:71DC25B5-D060-436F-8B88-8BE8EB8117FE">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9EEAE3AF-D1B3-4E8F-BDCB-AE767BA3CB03"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B205AFBC-01E7-4529-9251-D3C6872BF14A"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/336aacdf-befb-4ff3-9f0c-1ff1431bcd09">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>SSRIs</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:317781a1-88d6-4ab8-92cd-198c609b2cb9">
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/336aacdf-befb-4ff3-9f0c-1ff1431bcd09"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7decdeed-d302-4e69-880a-ebca9d71f756"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA57C8DA-4E2A-4BD7-836A-F0FCB2F8397A">
    <pav:lineageUri>urn:domeoserver:annotation:4886B20B-9A2B-49A6-9CB4-CD9FC6A543AA</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:34FA67E7-DE23-4297-A120-0786C4BE3820"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-29 11:35:54 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4594917B-2AC9-4FBB-B89D-E2B111AC53CD</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-29 11:36:34 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:C75AAB7A-111D-4CB2-BDB0-9064DB312EB9">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:6d2c79a9-1a1e-4221-a39d-76297267660b</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:6da6026f-7fd2-4460-a15b-4b34c029ef93</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N2cbfc80a679a42dfb70ce00cebccb3c2"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-11-02 14:48:13 -0500</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:6f76e69a-693f-4c42-9e3a-7a94704139f6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N06de8e2615a34442ad6339613a3261bb">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2E83C99F-3813-4426-ABB6-89402A8B36F5">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>oxazepam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:697b2fbd-3d5c-48c8-bdbd-a8c57f885c65">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7d3e84bf-f1ce-4f0b-931e-ab3de78ae1be"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16FDB844-0908-4D9D-9647-601A4C547C45">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9f968a74-720d-4f92-9b86-47fb9104fb5f">
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nc45fc4722cf348009bbe7acc18e9c79d"/>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:b89afd5c-2c3f-44ad-946d-12bba6f73186</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:9a170ac2-b839-4e2e-a6c8-672908900fd1"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:41744ACC-292A-4E40-BD26-311E80CF8160">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:e945bdf6-5b3d-45d7-9264-a708c2349f5d"/>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 10:33:12 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:be3433a0-1562-47d7-a19d-611fdba523a8</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N0f35765c3609440bbeed9444d1790941"/>
    <pav:previousVersion>urn:domeoclient:uuid:549dfab4-7c92-4d9d-8e62-c2133cc44a6a</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:02F2AA6F-085A-41CB-AC05-CD30658DB927">
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6D8BDD50-6E8C-4A56-B754-6CECD65536FE"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/77AA7F22-4E42-453E-9D65-5AD6AE9AD2E6"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:939C6A70-88A3-41E0-B347-184B5F87D9ED">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>IV</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/85BD4D34-4389-4062-A70F-24FE4188F731"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectDuration>5</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3C10322A-6A5C-4CCE-BBF6-10B87F365EF7"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ebbaa0d8-4935-4b82-bf5b-954be3808c28">
    <pav:lineageUri>urn:domeoserver:annotation:65873741-cc8b-4699-a9a1-c272fed1cbd4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:b3763b4e-692f-4661-8b44-13804cdd9df2"/>
    <ao:body rdf:nodeID="N0cb05d5bd57f4ffdb302955e8d5c90d6"/>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:dca61e64-9b44-46ec-b825-5e636e827350</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DEE9B652-27F3-44FB-97C1-DEC62C8A7E6D">
    <dikbD2R:dose>4</dikbD2R:dose>
    <rdfs:label>tizanidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/57258</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f550648b-e8af-403e-856c-3458a485920e">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ba38d8d5-2d85-40b5-9ada-edaf24933a71">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:15A1BBA7-0D5C-4282-A64C-EF20766FA9F6"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:54c326b5-588a-4f60-ba15-55a0a2bc103c</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-29 10:48:13 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Ncfd3ce4810714b3ca900ef31c1be90ec"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6A63B9B0-5F83-49BB-BC48-999F9B98B3FD</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N99b159222610472ab8d253906b608c15">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c0111372-d777-4e40-9d81-e87db6b4ec3d">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:544e9b08-6a79-4d3f-adaf-808db77cb9cf"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5945AB2-CACD-4305-9C95-807C77BA5143">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E5945AB2-CACD-4305-9C95-807C77BA5143"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <pav:createdOn>2015-11-05 15:34:06 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f7c4993f-1635-4d38-bad5-1cdeaa4ea413">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:e729dc1c-fcd6-4ae9-8c00-c222e953becc"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:8da725d2-10ca-4098-a390-68bf5b85f8e6</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:029f67a4-d157-4e99-9f15-b3dbaa8d9a4b</pav:lineageUri>
    <ao:body rdf:nodeID="N9ec66023b679461ab4ac8196dd759b7d"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C8BF38F4-DA71-40A4-9F8E-E11F55E98978">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4659CE78-DDBE-48FE-950E-F73A5DB20BCA"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48C99CDE-5A1B-4CB3-A4C6-E5090C37919D">
    <domeo:uuid>48C99CDE-5A1B-4CB3-A4C6-E5090C37919D</domeo:uuid>
    <ao:prefix>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-04 14:21:12 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:48C99CDE-5A1B-4CB3-A4C6-E5090C37919D"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:736074F8-3E40-40F4-88AA-63DA5A9AA92B">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-06 15:41:55 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:0E29F518-DDFA-432D-8F0B-9022216435EE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:lastSavedOn>2015-11-06 15:43:14 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:8EE4F288-19C8-4519-85CB-791C9E9709D8</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4a8b3cb8-00c4-4cdd-8e1e-3294a0331814">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB826BB0-B6E3-45B5-8FC7-9FA296421D13"/>
    <ao:body rdf:nodeID="N91e0634072e84764a9df45db4b9a83fa"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:69BF3208-059A-4333-9CD2-3927C5799F14</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:0eb4a0f6-8131-45b6-9afc-29820e990542</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-02 14:00:44 -0500</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:770fcf28-72b6-473c-82a2-503dc5995759">
    <ao:body rdf:nodeID="N7f35b55ddccb4840b04422e418e4d1fe"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:f3c72c10-fc44-41e5-9545-4696a4a2bf62</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-30 12:41:52 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:e98caffa-df76-47f7-8c21-6c211095ea60</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:0f42742b-759d-4f13-b367-2b11a712d59e"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-30 12:41:52 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4D6B7A01-8D07-42D8-9C76-0B9CBDE938CE">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>antidepressants</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/610F9D4F-70F5-410C-BEDC-ED9D38092078">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ketoconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB90BDF7-4F93-4A3F-BED4-D370D59F9F20">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:226C71F4-D8C2-40B2-AF4A-E7B81A5A59BF</pav:lineageUri>
    <ao:body rdf:nodeID="Nd054dcedf07d4266b57530aecfc3cbe7"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-04 14:12:27 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:043D28A5-9185-45C3-866E-6DD43963C8B3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1327C66-60BD-40DF-AE92-5B380A6861C1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-05 10:36:47 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D1327C66-60BD-40DF-AE92-5B380A6861C1"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <domeo:uuid>D1327C66-60BD-40DF-AE92-5B380A6861C1</domeo:uuid>
    <ao:exact>TCA </ao:exact>
    <ao:suffix>interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class </ao:suffix>
    <ao:prefix>SSRI </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3313aa37-ebb5-4291-9897-937890e2dd3b">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-26 15:40:40 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E536FE66-FAD0-488D-B7C0-39E59CBD9678</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:e5208d0d-d470-424b-a0e0-4a4b5da16c0e</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-26 15:40:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:89e4d45a-8a7b-43e6-b823-9bbfcfb1f959"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0a6231f4-0ef4-4180-994c-66d631a75d4c">
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:C48A3121-DCB7-428F-A13C-57A0AC0F0020">
    <pav:createdOn>2015-09-16 15:31:12 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-28 16:36:26 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:2ee85825-3738-4153-86cc-0b983813fc85"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:2cb623d1-e8af-4acc-a379-6db21e21dd52</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N68921c562e9d4a5bb1852f3489a0ccd4"/>
    <pav:lineageUri>urn:domeoserver:annotationset:545ac9da-d55c-4480-96df-dd7e8ac394b6</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/55F00EF8-6945-46D3-B00C-CE311FDCD781">
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>100</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37DDEDB4-2423-46DF-880E-A2D411563078">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A26A390E-AB65-462C-81C3-438BDBA41B70"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C3D5761B-F1E9-43C2-9D22-5854F1ED38ED"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:1ED20ED1-FB0C-422E-8105-1ED7D0D52049"/>
    <pav:createdOn>2014-02-19 12:41:17 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2014-02-19 12:41:40 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:0B909215-7514-42AE-8D33-022CB8C17D3A</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1232A1FB-E79C-4412-9A8E-E1A5CA0D8714">
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:D078977F-2B32-4064-B6AA-1846767F4D30"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:createdOn>2015-11-04 14:17:23 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3e46d2c8-5b14-4301-a0d9-8fedeedd9593">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>0.2</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>digoxin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6a9da872-1768-4766-9c43-3f133009420d">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N2fb8f3a80a5b4f318b3150049ba2f11b"/>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:d4ec1f34-70d3-48cb-946d-a09f7ba95450</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:3de6cb16-92ce-49e2-b57e-474c82c00b31"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2173078f-59fb-4128-be3f-a0f12936d751">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/dddf31f3-d927-412a-901c-9d91efdfde5e"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>29</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0678ad5e-1656-4aa0-9512-36bb82a1426b"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>19</dikbD2R:auc>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5eac8ca0-0caa-4082-b77c-2f13c8df1e24">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>2a6bd4b8-7947-4a9b-b087-eff39e004840</domeo:uuid>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CAEE6D50-1C2A-4DFB-A77B-6C6CB973DC61">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/046215fc-e890-4356-8c88-64a9aa3a491b">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ibuprofen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:043D28A5-9185-45C3-866E-6DD43963C8B3">
    <ao:prefix>(TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <pav:createdOn>2015-11-04 14:12:27 -0500</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>043D28A5-9185-45C3-866E-6DD43963C8B3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:043D28A5-9185-45C3-866E-6DD43963C8B3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bfeabd35-0da4-48a7-b1d8-e665e60406dc">
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:b1e5ed99-ed40-4d0e-a2da-83ae06b74c71</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:f85ffba1-be30-44ed-902c-2421acea262f"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nf077f99f85a84e1786444e91063fd43f"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:406cae68-246b-4c4c-9b8c-387b4ceb1436">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>tantly administered rifampin.  </ao:prefix>
    <domeo:uuid>9477cd32-e6ff-41e3-9f0d-8bd5b369eb96</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0d2fa762-e7af-4551-b164-fe636f989d7a">
    <ao:prefix> be an inhibitor of P450 2D6.  </ao:prefix>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>b81c25b3-c4c1-429a-80e5-b6f3d9f56fb2</domeo:uuid>
    <ao:exact>The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8f0d64d7-f8d4-402e-91e2-68bd69f25bfc">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <domeo:uuid>458393c7-d274-47c3-9002-d3264a2e8340</domeo:uuid>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9b84cfa0-f89e-4785-a173-ed743e90dc75">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:df8d82f7-d09e-4227-a792-ba593d70e7e5</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:d05ebd6d-12ee-4e85-9c2f-86f4e04be04b"/>
    <ao:body rdf:nodeID="N90685b11e1264d969c4d9a9f5406703e"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:68bad76b-46b3-4d1a-826c-ef50165fe8e5</pav:lineageUri>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7C08565B-2B8F-4541-8F6E-10D96EDD148A">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, respectively, of the combined moieties of </ao:prefix>
    <pav:createdOn>2015-11-05 15:52:28 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>threohydrobupropion and erythrohydrobupropion</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7C08565B-2B8F-4541-8F6E-10D96EDD148A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D718D234-A320-4634-947A-3554098B1E9D">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FFB8E54C-978E-4FA9-906C-3E4F31503BFE"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B53C4692-910D-4231-950C-E7D8337BCE85"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:90D400C1-885B-49C4-B0C7-DA180752721F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7F1DA58E-69CE-4710-A6C1-E59509102F40"/>
    <dikbD2R:comment>Exposure decreased 48%</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b3a4c86b-d78f-4233-a22c-737cd8954570">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:525baee6-0e6f-45ce-a15b-84dc5b76febb"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E0EEC2F-7A54-49A0-8FF7-24FB307CFFA0">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:E786F7DC-C42E-4265-8923-103099474CC7</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:828A2903-CDBE-465E-9978-00472C6256D7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-06 15:45:24 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-06 15:45:23 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Ncc44e6d26557410184a0f9b0217b4d80"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3403606C-F1C1-4B87-884A-43995B6BEE31">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/948DB70B-5DD5-4BDC-A6D6-EBF466F9704B"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/42095240-C276-4989-B7B1-45C3FE90A30F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9148B206-ADF6-449D-A6FE-0AD4574D1D7B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).    In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).    Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <domeo:uuid>9148B206-ADF6-449D-A6FE-0AD4574D1D7B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 10:39:16 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:prefix>Drugs Metabolized by P450 2D6   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9148B206-ADF6-449D-A6FE-0AD4574D1D7B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:23D80B4C-79B5-4BC8-8A7D-ECA168B4CA80">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:843A06CF-D7EB-4F0F-ABF8-FFCC240EEE88"/>
    <dikbD2R:comment>Combined lopinavir/ritonavir dose</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a6f1e57a-796d-4d50-846e-2c28539f7b8b">
    <domeo:uuid>9e499c4b-f0ce-47ad-b5d0-8ed050024aef</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:17eebe77-54f2-4dea-af9d-e421f5f711fe"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:870efd42-c0e4-4bbb-901d-46ad988e85a8">
    <pav:lineageUri>urn:domeoserver:annotationset:8f2b26f0-1fa7-47b1-8c84-a784af9d30ac</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nc44c2901b08b4b879e45befe84c38b94"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:0ab047d4-d254-4885-91ec-df0fcc1a22f3"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/579AA6FC-D39C-4B2B-BC89-F0CDAA231330">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>efavirenz</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>600</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/195085</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BDD9D242-5568-499D-8537-9CD798606D52">
    <dikbD2R:objectDuration>10</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B468326A-7B19-40E3-950B-9E8E4A36D3E5"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B9D6BA71-DB5A-40DF-853A-CD33D3656182"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>IV</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>5</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb31ba692fdaf494bae633bbf31eb3945">
    <domeo:sets rdf:resource="urn:pddi:uuid:48C9E6D2-977A-4F6F-B79C-462474032E43"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B72C1409-C979-4256-ABD4-645391F04597">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:exact>In a healthy volunteer study, ritonavir 100 mg twice daily reduced the AUC and Cmax of bupropion by 22% and 21%, respectively. The exposure of the hydroxybupropion metabolite was decreased by 23%, the threohydrobupropion decreased by 38%, and the erythrohydrobupropion decreased by 48%. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 16:05:44 -0500</pav:createdOn>
    <ao:prefix>Inducers of CYP2B6    Ritonavir and Lopinavir :  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B72C1409-C979-4256-ABD4-645391F04597"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:398AC8BF-6D92-412D-BFEC-D9E429D5E116">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-24 15:28:24 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:5b236434-2100-49ff-9a14-d6b309892e6c</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>urn:domeoclient:uuid:cdbe8414-eda8-495c-bffe-c3d56af4a93d</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N41ae9824e70b4339aa392e823f4d908f"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:b01eba92-f6ad-43cd-b6bd-375123fa4bd4"/>
    <pav:lastSavedOn>2015-10-28 17:17:45 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N25d6b3635bc845568e1c4e9197326721">
    <domeo:sets rdf:resource="urn:pddi:uuid:d46b9abd-1a47-4753-906f-fdd94a0df121"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2dc10cbd-66d6-4a50-8baf-b73787b0e7f1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:425e8eae-b2a6-4a63-a0b5-918fff34c122"/>
    <domeo:uuid>2f5531d9-0dfb-40d8-bc1f-437a705063c0</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:23aa1121-b186-44e7-80e1-6373944e680a">
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8501d432-8163-451f-b0b2-86f04a812b3b"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/cd9b1e69-4b71-4c36-8dcd-ec19bc75537f"/>
    <dikbD2R:cmax>37</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:auc>35</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07F9557F-DC24-4B48-82CC-0C579C302470">
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N0b6dd150eaa44bbc85e7753adb31a1cb"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8534BA4A-5106-4EE1-9F28-6F3F08B390E8"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:createdOn>2015-11-05 10:38:27 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:78AF55B4-E4C6-44D0-A4C1-E4E233648D4F</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFAD8994-E06A-4F7A-9CFD-949D21545A7E">
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-06 15:42:30 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-06 15:43:14 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N5368d0c0e3c94533aa7c10e5f80a886b"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:8EE4F288-19C8-4519-85CB-791C9E9709D8</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:26A0C09C-9C40-44F2-A448-CE418BB6CF1E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B2016776-7095-486F-AA64-F403CF517D84">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>TID</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/44FB8388-EB10-45BA-B444-97ADD318152E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6793DF1B-7B9E-4C39-8C7D-28B794DEC68F"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectDuration>14</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34FA67E7-DE23-4297-A120-0786C4BE3820">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:34FA67E7-DE23-4297-A120-0786C4BE3820"/>
    <ao:prefix>). While all the selective serotonin reuptake inhibitors (</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <pav:createdOn>2015-10-29 11:35:54 -0400</pav:createdOn>
    <domeo:uuid>34FA67E7-DE23-4297-A120-0786C4BE3820</domeo:uuid>
    <ao:exact>SSRIs</ao:exact>
    <ao:suffix>), e.g., </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B580C2A-B83B-4D67-B56C-5325FB709ED1">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:suffix>TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one cl</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7B580C2A-B83B-4D67-B56C-5325FB709ED1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-05 10:36:46 -0500</pav:createdOn>
    <ao:prefix>, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which </ao:prefix>
    <domeo:uuid>7B580C2A-B83B-4D67-B56C-5325FB709ED1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>SSRI </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/009705CC-583F-4B1C-826D-C8689C3BF49F">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6CB45E95-B7F8-40BE-B740-194013F50E39">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Nd638f95ca8e04df2b2efb209dc1afac1"/>
    <pav:createdOn>2015-10-29 10:29:26 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-29 10:29:25 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:607B6291-E2F8-4375-A455-21A80DBCA522</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:DAF5C424-DCFA-4489-9AB7-9D4CE00AE1AC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D998AA0-150F-4852-94C7-A9E11062E28B</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:57F2D7E5-0713-4D70-8981-11D8D44961B2">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6DC35B05-59EC-4B27-BBE0-FB631517D8CA"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C65039E6-D84A-4870-BEBB-54C2253633F2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>   7.7 Cimetidine   </ao:prefix>
    <ao:exact>In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg twice a day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively. The clinical significance of these findings is unknown. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C65039E6-D84A-4870-BEBB-54C2253633F2"/>
    <domeo:uuid>C65039E6-D84A-4870-BEBB-54C2253633F2</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <pav:createdOn>2015-11-02 14:22:01 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1314381E-8245-407A-838C-B141F1235DA5">
    <domeo:uuid>1314381E-8245-407A-838C-B141F1235DA5</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1314381E-8245-407A-838C-B141F1235DA5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when Lexapro and lithium are coadministered</ao:exact>
    <pav:createdOn>2015-11-02 14:26:56 -0500</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7f35b55ddccb4840b04422e418e4d1fe">
    <domeo:sets rdf:resource="urn:pddi:uuid:e8f938be-61c2-452b-8405-7db4a3ff1682"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DF041D0D-4D3D-40C7-9D72-DB37F5BC9AFF">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:7A63508D-B4E4-4703-A023-9A42679FA3A3</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N73be3df2f166417c8b2dd90099903e19"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F7484837-005F-42CC-BF22-27A2954637E0"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdOn>2015-11-05 15:46:50 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 15:46:57 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b01eba92-f6ad-43cd-b6bd-375123fa4bd4">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:398AC8BF-6D92-412D-BFEC-D9E429D5E116</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:A02C3322-A287-432C-9065-C5ED1C54E42E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N098d8f0bf1e5423f9689daf467e1d721"/>
    <pav:createdOn>2015-09-24 15:28:24 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-28 17:17:45 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:c00a1b06-507f-417a-ae5f-860a5b91dbe0</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fbe89beb-ce5f-4e31-848b-bb12fbf9b8e3">
    <domeo:uuid>7cc590e8-4634-4455-a7a6-d08f64cab962</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:c3f26c56-481d-4e68-b8da-4816ba998c27"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e843d464-cb31-491e-93d1-b8b51097c0c2">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:ee11f2ad-1ff5-43b1-89ef-ed99b269bc63</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N17b45a351fd34209a47da4a678d139a7"/>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:f898a49c-9757-462a-af1d-1a9bf8c394d3</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:07c6d849-4abe-410e-8e1a-4d88a324fbbc"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7eb8e24a-2225-4612-bb67-34f87c72b573">
    <domeo:uuid>498d5e3d-a8a2-4576-aa54-8060fc381356</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:eb979a0a-3185-44fc-9881-c6050b92e754"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB826BB0-B6E3-45B5-8FC7-9FA296421D13">
    <ao:exact>Ketoconazole - Combined administration of Celexa (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.</ao:exact>
    <pav:createdOn>2015-11-02 13:57:11 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>AB826BB0-B6E3-45B5-8FC7-9FA296421D13</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB826BB0-B6E3-45B5-8FC7-9FA296421D13"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96003E4F-1304-4028-BF04-20D3BFE7C71F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N43332f5f50e44c81afd886ca675ff4f5"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-11-04 14:12:05 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:8A6A3702-DA02-43AD-8F58-DAA1D68C4EBE</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:191BFE99-76A2-4D56-B743-6FEBFB6AA693"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f3fe5dd4-fe2e-471b-b27d-e87ff59a9e5e">
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5e54e261-20ac-4fa7-8926-1eeb48584f52"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/eed7fd9b-8f52-4171-8326-589bdab03aea"/>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:840818b1-bbde-4d26-86bb-bb6ecf118ce7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:fb36a118-4a30-4a31-b4f3-002773c4e6f0</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:B6C3AFC8-BDC5-4A6B-BF9B-D19944767C04"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8424E02E-7F1A-4993-B07A-EDF16EF62F50</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-29 09:04:44 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N34046dd519564dc5ae29cfe4e05b3583"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:4F262876-1771-4451-92A1-EB80E6047D3B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9b84b5a6-43a8-428b-be92-0612d2f346dc</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:535c4a56-71d4-4954-bebc-2929b5f8ff0d</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:80bac15d-f570-49ef-9a5e-0447e8ae785b"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-10-29 09:00:42 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N232ec7a994ee46d1be985b0a0d4d532d"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:951D4AB3-DD90-4F43-94EC-A4100FC1584E">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DA7151E2-BBE8-4FB9-96BD-3BEDC60F5BEF"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3B8FE6DF-6883-402F-B55B-4D779076DE3D">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A12CD05F-1116-4578-99EA-928B54401550"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3CDF481D-46BC-406C-BF9F-8FC8510E2FCF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D732851A-BBC6-44BD-9210-4AEF3BF9CEB9">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D732851A-BBC6-44BD-9210-4AEF3BF9CEB9"/>
    <ao:exact>Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs. Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine. Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side-effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen. Discontinuation of cimetidine in well-controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.</ao:exact>
    <ao:prefix>Hyperpyrexia has been reported when tricyclic antidepressants are administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.  </ao:prefix>
    <pav:createdOn>2015-11-04 14:17:00 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>D732851A-BBC6-44BD-9210-4AEF3BF9CEB9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/98352f88-b57b-4f76-bc43-bf79e8c42266">
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7f78ade1-c833-4649-805d-4d70b06050a3">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:aa9d60da-ac4e-493f-ad7b-402fbfc4db5d</pav:lineageUri>
    <ao:body rdf:nodeID="N481ad5ca933548198483f448e080abda"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:bc675420-00c7-416c-9423-ebf1dc8b1adb</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:b681de8c-2326-48f7-a7f1-f8824130ddf2"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:A9CBFEBF-E565-4053-92BF-51C2BF6E1469">
    <pav:lineageUri>urn:domeoserver:annotationset:92670d33-50df-4612-a5a9-95dc3ee1d4a2</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="Ne84536653a08459fbee36cf0ceb62f4c"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:dbb41089-668c-4ada-938a-6f27644f029c</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5895490c-1e8a-45f6-bcc4-f54fc19ebd16"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52B8805E-E8A5-4D42-BF78-0CA1C48B2D65">
    <domeo:uuid>52B8805E-E8A5-4D42-BF78-0CA1C48B2D65</domeo:uuid>
    <ao:exact>The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when it is given with paroxetine.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:52B8805E-E8A5-4D42-BF78-0CA1C48B2D65"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-28 15:26:27 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1eb5b851-8707-42c5-b6c3-ed440120f6a7">
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/72a170c9-6650-4ab4-ae52-45d2267bf88b"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/09ebd28b-89b4-4dee-a2b2-a9d5bcedd275"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:DC14BEEA-BCA1-4540-93E6-982BB400369B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:452197d9-9703-4fc1-9b34-49bf39291fa7"/>
    <permissions:permissions rdf:nodeID="N38ffcfb0f97e4d2383c8c71c6cbf688e"/>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:a7a02aba-6639-4479-b240-9d0f2a288d48</pav:lineageUri>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <pav:previousVersion>urn:domeoclient:uuid:f102cd9c-6872-4c29-93bb-85217613903e</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3BE0DCC1-E8B5-45EF-8297-AD853259980E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>60</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:30AE0552-A927-4E46-90ED-CD6BC60720E5">
    <pav:previousVersion>urn:domeoclient:uuid:de57a763-ed89-46ba-bf72-44bc452ed934</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:c1a5c0c7-8f32-417f-8808-dd231063c3bf</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:aa53822d-06cf-4afb-a959-c5eadfccb77a"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-10-29 10:35:24 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N28e9951569e14893abbcb5feb0b08fc3"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:265E6570-98CA-4921-B843-277E2B90BED4">
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:e58beb35-6591-417f-b368-979b1d71bf7b</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:e09e1802-efc5-4ef0-8448-022b2420c4e9"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N56a8a8c2473f4ff9839e9570aac0ead1"/>
    <pav:previousVersion>urn:domeoclient:uuid:e64aa032-5d02-4921-81a9-eaa1f1794f90</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 10:48:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1f70402a-1465-4802-8e95-a52d65cd5ae8">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0f44bd4a-14d8-45e4-ac34-44d5a42d1800"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:ede8dc7f-80f5-4473-a706-8604a69cc63b</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Na6e2bed70daa4443b0726af78fda19d6"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/46640f06-2b04-4191-b718-e068e787b04b">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>teriflunomide</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:811234aa-4310-481f-a814-75ce1e5eb949">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:525194d7-24d7-48ed-b4f8-10ba39a6a4e3"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EF842FDA-C3C3-42A3-81E1-52FB58664270">
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CF9F4140-CD46-4309-BA07-1C6997E1970C"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2E25F195-3CEF-4BCA-983A-991D62B647DC"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:449BD368-F1C8-43E4-B3CF-A186BC3B8E98">
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8B5439C9-8621-4444-952C-A806A7DD7A2B"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CE6CE54F-7070-4B0E-B47B-D7598A860A30"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B430E0ED-0582-4122-8303-437847C4BF99">
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Mirtazapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:89C12BE2-A24C-40DF-9F8E-F7129BE66428">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D3D9CE0D-95AB-422E-B21C-7B575372FD42"/>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/31A98F03-9D36-40F9-8A57-D891C17D251B"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectDuration>35</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:32BB57ED-1D90-4578-B51B-073DDD619008">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CDCFFC8E-450A-4665-8A7A-D08E684BA3DF"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>62</dikbD2R:cmax>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3BE0DCC1-E8B5-45EF-8297-AD853259980E"/>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:auc>151</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12>Unk</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C161A942-F681-4204-AD79-5AB4563FDE16">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C161A942-F681-4204-AD79-5AB4563FDE16"/>
    <pav:createdOn>2015-10-29 10:40:17 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:exact>In healthy, male, Caucasian patients (n=24), coadministration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30-mg dose of mirtazapine by approximately 40% and 50%, respectively.    Caution should be exercised when coadministering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, or nefazodone.</ao:exact>
    <domeo:uuid>C161A942-F681-4204-AD79-5AB4563FDE16</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>  Ketoconazole  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EEFEB881-A5E0-4B31-B687-86A0B7E22F71">
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7074413E-49C3-4358-83D4-10D958ACE242"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmax>5</dikbD2R:cmax>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0C34953F-CA44-4A9D-9EEB-DCBF7B47451B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8170DAE8-A314-4B9D-9021-E3ABC0799879">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8170DAE8-A314-4B9D-9021-E3ABC0799879"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 10:36:32 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:prefix>may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (</ao:prefix>
    <ao:exact>quinidine</ao:exact>
    <ao:suffix>; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline,</ao:suffix>
    <domeo:uuid>8170DAE8-A314-4B9D-9021-E3ABC0799879</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FB3DDA45-C3F3-40A1-B07A-02752BB251EE">
    <dikbD2R:dose>400</dikbD2R:dose>
    <rdfs:label>carbamazepine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8de60281-2d8d-4315-9b12-12934ab0ea5e">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-02 14:22:34 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D273B59C-5C0B-4FEA-B4FF-102CD0105837"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D8D3B5BD-7C2F-40CC-9A9F-FBDC207AB43D</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N1aba95f6dae842328c05f223dc80380a"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:9bda4c76-65c1-4d8f-88db-5fc686ecf2f4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E247FAFC-EF4F-4E91-BB88-AF779BFCD2C0">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3AD8E5FE-F810-4C4E-AAB5-055AD2FBB60D">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-29 11:36:01 -0400</pav:createdOn>
    <domeo:uuid>3AD8E5FE-F810-4C4E-AAB5-055AD2FBB60D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3AD8E5FE-F810-4C4E-AAB5-055AD2FBB60D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.0alpha-040">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:homepage></foafx:homepage>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:build>040</foafx:build>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <foafx:version>2.0alpha</foafx:version>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2f02e557b83d4de295ac617f530477c2">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:da032526-108e-48be-8a0a-c878f4ae79b8">
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:8953d9ca-b2cc-4c8b-a8e9-6be0ffb07e2d"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:668dee0e-0ab8-4a79-8c2a-06749351688c</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:3d6eb7ef-7356-46f4-8d66-d4a1c97f22ec</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N499b601a38504e1e862628e97a756457"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8754B695-04B4-4CA2-B837-CB0BA450A23B">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:comment>Exposure decreased by 38%</dikbD2R:comment>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DB66086F-61A5-452A-B4E7-D5EEE6B47C49"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:592DFA35-F147-4508-9404-B15EDE7C828B">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:87E15AB9-9BF9-42E9-BC2E-C43EEFA88474"/>
    <ao:body rdf:nodeID="Ne962070e479c447788fb99ff2e13f9cc"/>
    <pav:createdOn>2015-10-27 15:33:53 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:2719D41D-BE05-4B53-9F79-2EC3AB1C97A2">
    <permissions:permissions rdf:nodeID="N254c928d07784c9cb95f381822912b3b"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2015-11-02 16:13:06 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:45db4233-3ea7-43d2-8359-0b1d8b87f4c0</pav:lineageUri>
    <pav:createdOn>2015-09-10 14:41:16 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:c8a0c138-86f3-4952-a80c-c20d6b882c38</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:f94b7dd8-9be2-477d-8eab-4df82b537c45"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5883A0CA-5EA6-47DE-9205-DCB0043E716B">
    <ao:exact>Ritonavir, Lopinavir, and Efavirenz: Concomitant treatment with these drugs can decrease bupropion and hydroxybupropion exposure. Dosage increase of WELLBUTRIN XL may be necessary when coadministered with ritonavir, lopinavir, or efavirenz but should not exceed the maximum recommended dose [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5883A0CA-5EA6-47DE-9205-DCB0043E716B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 15:25:40 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>Clinical Pharmacology (12.3) ].   Inducers of CYP2B6    </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6710B061-622E-41EB-9C33-F4B1DA18CBC4">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmax>8</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D9655317-3D95-4886-B8D8-B513DA376EEB"/>
    <dikbD2R:auc>43</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/504D359A-444C-4512-883B-5A7C1F5F88C5"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd6b3f7b118e3437fb557cb0c31d3c4ad">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd838fbfff0e64ba1b655eb164b95ba73">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/906696AC-E2A8-48F5-B0AE-EC2C502258AA">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>2</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <rdfs:label>lorazepam</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c863d380-029c-47e4-9738-fbd233c9d66b">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N0eff91c4870647f99f1ec09c8f427fc0"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:c690f73e-2339-439f-b5f2-ce813d107388</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:96fddaed-47e8-4075-bfaa-a31655a9851e"/>
    <pav:lineageUri>urn:domeoserver:annotation:42bf206d-4cab-4f03-8048-bc12aa23dd30</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08150f78-ae3a-4d4b-9577-61432401e9a7">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:263840C3-C8D5-40AC-A465-5111FD082080"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:7bcda204-d9b4-4618-8f76-ba3730a29f5a</pav:lineageUri>
    <pav:lastSavedOn>2015-11-02 14:32:17 -0500</pav:lastSavedOn>
    <ao:body rdf:nodeID="N7ad0d27b43eb447f8b3675a08c1a332b"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2F072DDC-B8A8-4A79-BB67-C247D90426BC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F24BDC3F-D5C8-4EE9-93FA-AE4585AE6612">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0D903A8D-295D-4CCE-BDD1-4D10A6D4A031"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:comment>12% exposure decrease</dikbD2R:comment>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:352e062f-96fc-43f6-99b6-9e46f0aaec7e">
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/253d3c1b-4782-422d-b9d2-7801f58cf378"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/230076de-72d8-432f-8536-e54d0dce4d1c"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B03E580F-9D80-4F4F-8A09-8D85B5B8A723">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:004DE312-2A25-4A78-B4DD-7A99086DA390"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/54B987B8-831B-4EEC-AA4D-9A1D6801708F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2ee85825-3738-4153-86cc-0b983813fc85">
    <ao:body rdf:nodeID="Nfd7da4378d1140f4967518fe4332c92a"/>
    <pav:createdOn>2015-09-16 15:31:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C48A3121-DCB7-428F-A13C-57A0AC0F0020</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-28 16:36:26 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:3B127109-4D2B-419E-8484-52ECF937B916"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:e5ea2cc1-a05b-4254-ad11-52c7c46b78a6</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CCD4DAAC-62F2-4EE7-B3A1-D12C7696FAAD">
    <ao:exact>Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>CCD4DAAC-62F2-4EE7-B3A1-D12C7696FAAD</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CCD4DAAC-62F2-4EE7-B3A1-D12C7696FAAD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>   7.15 Triazolam   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <pav:createdOn>2015-11-02 14:32:48 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:40B0D50E-C95A-45AE-BAE6-48AD5B4FD227">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ED1ECE0A-8DC6-4002-A8CF-9A4FF9FCE144"/>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:auc>40</dikbD2R:auc>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>40</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8BD8B58E-6562-4BAB-AFC5-34464692A07A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06622E87-E360-445F-B0CB-BE8262FABD89">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-29 10:39:52 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E536FE66-FAD0-488D-B7C0-39E59CBD9678</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A16731CD-1F0D-4780-A60C-33F06C7E13C3"/>
    <pav:lastSavedOn>2015-10-29 10:41:13 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:e5208d0d-d470-424b-a0e0-4a4b5da16c0e</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:9540ed61-ff6a-4399-86bc-04d7b87b26df</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8C69CF3-92B5-4335-8221-AA495100DE39">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-27 14:26:18 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C8C69CF3-92B5-4335-8221-AA495100DE39"/>
    <ao:exact>Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. </ao:exact>
    <ao:prefix>    Benzodiazepines   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f69dfc19-f679-4e1d-b25c-44c4a39c447e">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N1858e331cb8a42fc9ef3e20e73d5adeb"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:fac26abe-0029-4ecd-abae-47e8b7985bb8</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:6f504ad2-183f-4cd0-a772-8a6059408837</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:3e4a0fce-9301-4363-be03-79cdbd954122"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75d49ddd-c175-4cf2-932f-2c765ccfff9e">
    <domeo:belongsToSet>urn:domeoclient:uuid:08f31c18-2c15-470f-b269-6611615a6c44</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N5cd8a62e55bb46fdbc589a8eb2e7dd3c"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:79e5eb7f-05b7-4f5f-840f-a8a9e4ddbd87</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:64a06fa0-df56-4ad7-a768-2fc0fca45597"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F4C8A3AB-9878-4F37-8D42-B4B41C35CB65">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/30AA535D-762C-41C0-9286-71AC521F88F7"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BBB4B1F4-1427-48DF-A2FE-D44826CBFE99"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:47664063-536b-44c1-a588-b7113b976411">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:23b7ef5e-6ef2-4b6d-a10b-72d563a454db"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:905B8E6E-449C-4743-9902-9E6497B1AC90">
    <pav:lineageUri>urn:domeoserver:annotationset:16268a32-5f01-495b-b9c2-ba819389dd62</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 10:38:52 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:fcb5b1da-f6ec-4189-b84d-6c104a4f13f3</pav:previousVersion>
    <permissions:permissions rdf:nodeID="Nf9693bda79b048e2bf67e4089a6b0981"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:8218580d-6c0f-41bc-90e6-99362ced4763"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b5f796ab-32e9-4857-9fa4-189817ebace8">
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:c590b8d4-fa58-496d-a28e-0846a38099a7</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:a5719c4c-ef59-4c50-9564-50196d850cc0</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nadffd4f1ad6f40dc97b1205783a82746"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:cd52caae-4616-4a13-b493-619eb9b2ae66"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:40F0C806-D446-4EBB-89B8-392167F4F83E">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:75F3454A-EF58-42D9-9140-ACBCFB3011D1"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3bece2ee-1606-4773-ab43-be186f7c6af8">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:67930fe5-f499-4fda-bf4e-cac5f748bad3"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0f42742b-759d-4f13-b367-2b11a712d59e">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>899c0ca7-a449-4b8b-aed7-4f62acc0da94</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0ec2a8ca-649c-4eda-8e2a-b1de19c5a717"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fabe5174-86b7-4704-9e14-07ad36972d87">
    <domeo:uuid>03ae0bc1-2b97-4820-b992-7c6f7077fa4d</domeo:uuid>
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b248efa4-0504-4615-a4f8-7697c49568f1">
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9687cd1a-e6ed-4c90-b235-6224ce97a607"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/fccfea76-d76a-4b5e-8be5-8dfe33b43d99"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1A65E25D-9757-47F6-9655-59083C9A3124">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>EMSAM</rdfs:label>
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:24e1d63c-13c6-45d9-b697-1ef3bc06574f">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-13 11:13:09 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:d6918065-e978-4070-be41-461b3c003eaf</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:32ebec4b-81c7-40a7-afa5-259a3e1741bf</domeo:belongsToSet>
    <ao:body rdf:nodeID="N606ecaabbe884fda97924a2caf4b5e5e"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-13 11:13:09 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:b5a9cd2d-64ea-4446-94a0-dc9fe47cbf29"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d96e0074-fa19-4c26-a4c6-1364dc9cb7db">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3eeeade3-9d53-41a6-9564-ec2890062106"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D6D9F7D0-4995-49CC-8743-DCF82A8841AD">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdfs:label>Fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f8d54d99-de19-49e9-9115-0d8648dc3711">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>51215a75-77a4-4125-a5db-fdc4c9683edf</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6a46d0c8-51ed-48cf-b190-92fdc97fefe7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:664566f7-09c3-422c-b83d-9e2301b8a342"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid>314f6b30-9fa4-4d74-a561-d8f861e10553</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F5D8EC3B-5C90-4232-8825-4103A22D50E8">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FE9F12A1-D547-405E-BA48-ABEF1169B998"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D5B65DFE-1729-47A3-A03F-AFEB2F4332A0"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9FAE172C-E425-4669-80BF-3225135F5006">
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5B76E840-6485-4782-97F3-6000B8A733CD"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5429897E-9915-4055-9D6A-4061572DCCD0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9b95720d-0d36-4464-a020-7cfbcd2d64ca">
    <ao:context rdf:resource="urn:domeoclient:uuid:9310403c-d8e8-46a3-a5c6-db9f29cf8560"/>
    <pav:createdOn>2015-10-14 12:10:56 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:68ab60dc-4a3d-4902-a852-e861f212a928</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N1e6cdf182b4e4e4586115fd1433e01dc"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:e809e800-8516-4eb6-9400-fba86f4040d6</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F9BAD25-0C3E-4967-AA22-C45C8C4D7029">
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:20E16FD0-A19C-4727-A2F8-66476D5D36AE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-05 10:29:55 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:6B6F2C09-88ED-4069-B1C3-372A20E4741B</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:47B79AF8-3797-4198-BD35-A3EF9EE9BE7A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8654184E-59C6-4F65-8B6B-B0DBFB83032A"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/34F02C7F-C76F-4224-AEB1-088F33A9F97C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d8a2ebeb-cad5-4571-977d-fd6d54219bd4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:1fae078f-c814-43fe-875f-47db931332b6</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:36ac94c6-b016-4e1f-8c72-eb9150096a6d"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:b0c6dc29-8b7f-4792-a74b-3409b1599147</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N5eaf6cf6fa5840379477ce2c3a2d350b"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:86F3052D-4E9B-4131-ABE3-6D49778F2626">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8EE66C33-C850-4A44-B471-B426996500DD"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e8e75e5b-2d64-462a-a176-67dfa9d7d8a0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>pioglitazone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>1000</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7b5176af-defd-4d7e-af90-32b9fdf0c797">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FA6E3D16-2F6D-4EFC-B607-E400E4D673DB</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:ad19eba9-2e55-467d-b3e7-60ebe47297e0"/>
    <pav:lastSavedOn>2015-10-26 15:38:58 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:50710251-c1a7-4ab0-9343-d3c82dd20bfa</pav:lineageUri>
    <pav:createdOn>2015-10-26 15:38:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32ebec4b-81c7-40a7-afa5-259a3e1741bf">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:24e1d63c-13c6-45d9-b697-1ef3bc06574f"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:d66e062a-6aa2-4735-9b11-d7dafc326694</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-13 11:13:09 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-13 11:13:09 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N6e50da75ebc3496a885439fc61506464"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:451EBDF2-14C7-4CD2-B0CC-20BB805FBEE6">
    <domeo:uuid>451EBDF2-14C7-4CD2-B0CC-20BB805FBEE6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).    In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).    Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <ao:prefix>Drugs Metabolized by P450 2D6   </ao:prefix>
    <pav:createdOn>2015-11-05 10:40:11 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:451EBDF2-14C7-4CD2-B0CC-20BB805FBEE6"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/04bc1ee4-92ee-4d7f-b74e-7a3807fca2f5">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/49FAE029-FF46-450D-9D53-75B50F07AF26">
    <rdfs:label>lorazepam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4595d2b7-e304-48dd-823e-5733f189ccc1">
    <ao:body rdf:nodeID="Ne89336980d134b67b7c18dd6d00282ab"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 11:41:50 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:7cb30f71-c3f0-4d0b-8fd5-796312d9cae4</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:5831e197-040a-4893-a0d8-bd9de0e57ed8</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 11:41:50 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:34e16d6a-3fe5-4e7f-abce-5cd5f8301eb8"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:121CEF2D-2F3C-4D73-B93C-6FD4D2B21CF7">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:21ab3694-0521-45a0-aac4-063bbf59cd54</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6C470D42-9671-409B-9407-76C19FDF8DF1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:9f66b4af-6083-4081-b81c-bd2656e0280a</pav:previousVersion>
    <pav:createdOn>2015-11-04 14:10:02 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-04 14:10:24 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C0D4F41F-0FCC-446B-A746-DAED97C65270">
    <rdfs:label>Not Important</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:129CAA08-A94A-4346-8B38-F5FAFFC7D138">
    <ao:prefix>When a single oral 0.25 mg dose of </ao:prefix>
    <domeo:uuid>129CAA08-A94A-4346-8B38-F5FAFFC7D138</domeo:uuid>
    <pav:createdOn>2015-11-06 15:35:54 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>triazolam </ao:exact>
    <ao:suffix>was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. Nefazodone plasma concentrations were unaffected by triazolam. </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:129CAA08-A94A-4346-8B38-F5FAFFC7D138"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:428EF2EE-2046-4420-B6C8-770A69774BCC">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6AC8B57B-13CB-4E98-BB4D-38F52490E171"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58d6ff98-f8a2-4505-aae1-242ad9510758">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:3f1aab4d-ead2-4209-a405-91cbafaddd08</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:0bca722f-9d20-4a4d-b3a4-259b2262dfe2</pav:lineageUri>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nc8f1fa1b73484169ab5fe8e11306e1f5"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:17f0f778-b71b-4e30-9421-99cc71fcc7b4"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N595885f17f124697bff6d4bd2cf47e60">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:087e6b89-9919-4ce0-87d8-70b7a86407a5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:a5437e98-6ada-4edd-816e-cd8eaf2a7922"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:978cf9c8-5d70-4aaf-a45b-0a0dc99400c3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7c00adad-393e-4420-b386-35d417facccd"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:hasSource>
    <domeo:uuid>6b18a919-be45-48d6-a487-a15a97411f85</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6114e32e-4e4e-4219-a9ae-b01a415f2f58">
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Nb5e7360cd9dc4633aeda64cc59dd6440"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:8b3b9485-a214-4c0f-a3af-6b8bdaed79f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:6972cc89-f11a-48bb-91a9-39e306f11e37"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4c4a1401-3e77-43fc-96fd-5b86bac0418b">
    <ao:prefix>in some studies to have a more rapid onset of  action than </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4c4a1401-3e77-43fc-96fd-5b86bac0418b"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-26 15:38:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>imipramine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <ao:suffix> or amitriptyline. The initial clinical effect may occur  wi</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a55fcc9d-1eae-4cd6-88dc-8afa3291dd01">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>olanzapine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:07ECF42F-1960-4FB1-911D-E81375702C9E">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0296FD38-BFFA-4717-A31D-39B58851381F"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C7CF1BBC-BD5B-4AC2-BDB8-8C59B49BE9ED"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:698DFEB4-F93A-4958-B754-EC50EA7D3AFC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N91414caf80e6434d8b21de5d984621eb"/>
    <pav:lineageUri>urn:domeoserver:annotationset:189c6dc8-45d5-475f-94c6-5f8ce96ae44c</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-02 14:30:38 -0500</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>urn:domeoclient:uuid:f570ec0e-57d8-40fd-bf1d-d08700c0fb27</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:973c8611-d87e-45a0-81d8-6bad40d6c692"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f4e3133d-2e0c-43e0-921e-b567dbe8b7bf">
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/18be67bf-2a60-46b3-9e77-5475c8b93a2a"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8bfdbccb-d6db-42a5-9770-a1cd549e20d0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66C06BB6-10D8-4C4F-93A1-352AF9CB1F95">
    <pav:createdOn>2015-11-05 15:41:13 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nfd43138db7bc40e488cab205433253a2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:B00589C1-4255-4B08-93BD-3C7909C8804D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:74BAF9C2-86FD-4C09-9153-BEDF3C491F61</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-05 15:42:05 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/57E199AA-DB18-433A-9F82-D0D050EE4DB8">
    <rdfs:label>Celexa</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E17EBCC5-B429-4DC3-8E8B-5F0484FB99D1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>(TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E17EBCC5-B429-4DC3-8E8B-5F0484FB99D1"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>E17EBCC5-B429-4DC3-8E8B-5F0484FB99D1</domeo:uuid>
    <pav:createdOn>2015-11-04 14:13:23 -0500</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:875a9659-1e7c-441d-8aa9-333100c8c1a0">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:eaf2fd7e-9ac7-472f-9d79-08541fb6f666"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CEF16EAB-5AA2-4FE4-B67F-3F67CCC15F78">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A5684B54-632D-4E00-AF80-C1D2B64C4C20"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4ECA2368-8A7D-49AD-9B9D-4045D186F3D6">
    <rdfs:label>triazolam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>0.25</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E993C666-D1C6-4612-817D-D7C87B1560EB">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:92BB0852-289C-4A2F-8E7A-1C494C5C15B8"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8E66559D-1344-4165-875A-990BD8968C67">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4ECA2368-8A7D-49AD-9B9D-4045D186F3D6"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EEBFFB57-7439-4454-AD3D-F8C277BEFF7C"/>
    <dikbD2R:preciptDuration>28</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5C26D993-EE7D-4353-9443-03E2CFBEA779">
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2f27b443-4240-40d2-aebc-5eb8b4b77e59">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2c82c4b8-1419-474f-93f7-d90bc18455a7"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE04A105-63F1-49FD-825D-5DE83F516579">
    <ao:prefix>metabolite was decreased by 78%, the </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-05 16:06:44 -0500</pav:createdOn>
    <ao:suffix>decreased by 50%, and the erythrohydrobupropion decreased by 68%. </ao:suffix>
    <ao:exact>threohydrobupropion </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EE04A105-63F1-49FD-825D-5DE83F516579"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2090329D-C51C-42D6-AC2E-7DA928206F38">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2090329D-C51C-42D6-AC2E-7DA928206F38"/>
    <ao:exact>Olanzapine    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with olanzapine, a substrate for CYP1A2, CYP2D6, and possibly CYP2A6, did not affect the pharmacokinetics of selegiline or olanzapine [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-27 14:14:17 -0400</pav:createdOn>
    <domeo:uuid>2090329D-C51C-42D6-AC2E-7DA928206F38</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE61C169-4A88-409A-9F23-4C9FC658D2A3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <pav:createdOn>2015-10-28 14:37:55 -0400</pav:createdOn>
    <ao:suffix>, will elevate plasma levels of thioridazine. Therefore, it is recommended that paroxetine not be used in combination with thioridazine (see </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EE61C169-4A88-409A-9F23-4C9FC658D2A3"/>
    <domeo:uuid>EE61C169-4A88-409A-9F23-4C9FC658D2A3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>paroxetine</ao:exact>
    <ao:prefix> study suggests that drugs which inhibit CYP2D6, such as </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c8335217-2032-427a-87b4-a2215a7a10d1">
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/c0930835-5fea-44a9-8d3e-9381f972d0a7"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a628c369-090c-427f-8a8d-d4058d533087"/>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8E53BBF2-1D26-44A9-B935-8B5C46B4AB0C">
    <rdfs:label>Mirtazapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:efd7dd82-0616-4897-8ac1-a059755e579b">
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:8b06d4be-e63b-4424-b936-e65052e0dc2a"/>
    <permissions:permissions rdf:nodeID="N7385ac056fa1453499bce3836549824d"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:78d9f7a6-cda0-41f5-a1ee-f27b55032e02</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:114B037B-6768-48E2-8348-EE4531EF05AD">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1C038C2F-D2F9-435C-8E25-30CEAD2FEE27"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F90FBF7A-F587-4502-AB78-95004CF55511"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9715997F-2002-4E04-A15D-A06859A12C8B">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-04 14:20:14 -0500</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:F9BEF68C-7CBB-43A3-9F62-2DDE8E095EA9</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:C97D3CCC-8D48-4625-816A-4AF220ABDAEF"/>
    <ao:body rdf:nodeID="Nadeb5e09f18f4c009b0b6f80269a5a1e"/>
    <pav:lastSavedOn>2015-11-04 14:21:12 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8A8BE3CD-5251-4D57-87B3-850568CCDA99">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F91D9438-255F-460A-87D2-6B3F5573A0D4"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F068D28E-EC58-493C-B53C-9C6F1C17BCAC">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>TID</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectDuration>28</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9665FA07-3B81-4DC9-BAE7-C0FE23938531"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/54951BA2-4D81-4CF4-A27E-83C6E2C639D8"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/328C64E1-C04C-4719-B59C-C9E2B3FAC510">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>150</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:dc408320-dd05-4501-9d92-32c242528116">
    <domeo:uuid>5cfbe1cf-3390-4cb6-ae8f-001a2904f193</domeo:uuid>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84735175-44EB-4BFE-B714-0C099CA2BB4B">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N7831d7737f4f4c5992ef0fdd666ec28b"/>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-27 15:36:36 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0B9DC291-E2C1-4052-B7F0-494CB17BB73D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09FD78A7-2A8B-43EE-968F-DED2D5A36394">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-02 14:30:37 -0500</pav:createdOn>
    <ao:exact>Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>   7.13 Warfarin   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:09FD78A7-2A8B-43EE-968F-DED2D5A36394"/>
    <domeo:uuid>09FD78A7-2A8B-43EE-968F-DED2D5A36394</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78C8A78D-BC0B-41EC-B63D-B9866D87DF36">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:3732314F-1EE7-47E6-93E3-7C8DD7D8614C</pav:lineageUri>
    <pav:createdOn>2015-11-04 14:19:32 -0500</pav:createdOn>
    <ao:body rdf:nodeID="N0dfbf7824c204dd3a6d6624133f8b3a2"/>
    <pav:lastSavedOn>2015-11-04 14:21:12 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F1EE0A47-3168-4941-BF7F-9CEC065537A9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81ae0f5b-ea83-49d4-b8ac-4fcf521b67e3">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:4df043fb-de9f-437e-aacd-d6b5befcfff3"/>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:13047708-1756-4e4f-aa14-5401e10de859</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N08db3056a03b431ba8ba8743f472af51"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a8e424a6-047d-44ee-b5e3-1fdd13a79a22">
    <domeo:belongsToSet>urn:domeoserver:annotationset:502CE403-A542-476C-BCE7-4BAED669CD7D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:BDEB9DCE-CD37-4008-8991-D51F895D9B5E"/>
    <pav:lastSavedOn>2015-11-02 14:35:22 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nafc204628c94429ea67b897e60270bc9"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:21d8c791-aabd-4ff8-bf9f-df5bac0118b0</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d25356a0-51b6-4ec9-a0ed-a8b9b8d3b9c8">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/584ef18c-fd09-4d5c-88c6-1291d37ffd50"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7964d204-a56a-424b-9b6e-b9adf06526e4"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:auc>1.7</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/36C38F40-B5EA-41E1-B8D8-1870E816C4D3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d254abbb-5939-4f17-8250-44e68d2804e9">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:f37fcdeb-37b6-46b1-80bf-7bacdf0fc1b2</pav:lineageUri>
    <ao:body rdf:nodeID="Nea8341b2258f402b8f5f441962be03c8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2884C04C-5C92-40CB-AD40-01680FAB45E5"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5B2950F2-8CF2-41F1-8F38-65247766F227</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-02 13:32:33 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4E15909C-3068-4431-9179-892A475F46E8">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f1ccb4b5-da09-41a1-b1a3-e901e649db75">
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8065299d-136d-428b-bb7b-b274b88a87f5"/>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/286e3056-d44a-4d61-8531-78bc83f29d2f"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44ee5508-4bd5-46f1-b6ff-0c0dd8e9779b">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-02 13:56:21 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3D00524-B281-4890-8D47-6B4E74176962</domeo:belongsToSet>
    <ao:body rdf:nodeID="N1337e4198cfc49ed8c2e1ba3c8321f29"/>
    <pav:lineageUri>urn:domeoserver:annotation:9b248fbe-6504-4239-a2db-4a000c8c353b</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9126986A-EA0F-40F2-8C3C-C3EBCC310D69"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3435CD43-B04F-4198-B706-A5183DEEF024">
    <dikbD2R:dose>75</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>clopidogrel</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32968</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:302160fe-60a8-40d8-81e9-65140cc1f7e0">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:e86fd690-50e1-4859-81af-821f8aa5c225"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6CD0807-1447-4428-BB54-6463F5867D5C">
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 15:31:43 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B6CD0807-1447-4428-BB54-6463F5867D5C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:86E395CA-D3A4-45D4-94DE-A2157366C7CF">
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>11</dikbD2R:objectDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6FB6F12D-2ACC-415F-B387-F2925BF1A33B"/>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EC9D8D54-AB19-4B5C-86B4-19D8632C801D"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1128a740-23e9-4a84-8d26-e73c85015028">
    <pav:lineageUri>urn:domeoserver:annotation:97c5c8af-bfee-415f-a2b2-d99bc867e7ac</pav:lineageUri>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:b4e8d318-358e-46d5-9d70-2cd68f48bf69</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N6a7d459043564cc9922117645e455d64"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3f1f6312-8692-47a4-aee1-359a69c1f32e"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/777ac785-883e-4c0d-950a-69fdb40168bd">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>30</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BB7996C9-5E4F-4CC3-9F7D-4EEE93E3254F">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:84C097A0-6245-4286-9C98-7ED4A6354A47"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N55ebe16fe9d94b628a935393e33baf19">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9F6C40C3-8C70-4AEC-A98F-0456CFB6A3CC">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:69A93264-C7D7-4FDD-BFC4-BA90453394F7"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E496388F-0968-4AAC-AE44-0C0382150E50">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9CC336FC-B343-4718-A7DA-E000ADCBE2BA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>(25 mg b.i.d. for one week) on </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>thioridazine </ao:exact>
    <pav:createdOn>2015-10-27 14:21:07 -0400</pav:createdOn>
    <ao:suffix>steady-state concentrations was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9CC336FC-B343-4718-A7DA-E000ADCBE2BA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a466d3c3-01c1-441c-920a-ffda63f61a38">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:01d65773-28ea-4f89-9a3e-e0853b017729</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N8658005e63674a24bc5a9d33aff996ff"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:a09bfbfc-510b-4f2d-b0c6-b92ff887bd41</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0ff23933-6dda-496e-bb0f-9ebbd6c66e5b"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A6C3FEE-6019-4C03-B728-54EE5F290879">
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).    In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).    Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Drugs Metabolized by P450 2D6   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <pav:createdOn>2015-11-05 10:38:06 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>6A6C3FEE-6019-4C03-B728-54EE5F290879</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A6C3FEE-6019-4C03-B728-54EE5F290879"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:80b840e9-3207-4d00-8d91-9d9d2ab0ad63">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>57b9a0f0-607a-44af-a65b-275e889106f5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2555F0D-F6FF-4961-8CEB-7B8E9BD7A280">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>is a potent inhibitor of CYP1A2 and </ao:prefix>
    <ao:exact>tizanidine </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F2555F0D-F6FF-4961-8CEB-7B8E9BD7A280"/>
    <pav:createdOn>2015-10-27 14:22:21 -0400</pav:createdOn>
    <ao:suffix>is a CYP1A2 substrate. The effect of fluvoxamine (100 mg daily for 4 days) on the pharmacokinetics and pharmacodynamics of a single 4 mg dose of tizanidine has been studied in ten healthy male subjects. Tizanidine C</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne7a458a80a9d47d08ecbc0367344698c">
    <domeo:sets rdf:resource="urn:pddi:uuid:35291613-E433-4969-A249-28F19B95C3BC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f67daa8c-0d5f-4361-8dfc-29a0544ddddc">
    <ao:prefix>BAGIO on oral contraceptives   </ao:prefix>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. Consideration should be given to the type or dose of contraceptives used in combination with AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>213caccc-654d-4279-8819-8d10ac904157</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9B0CFAFA-5356-49EC-AEF1-384F091799E2">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:43A5EEF2-A478-45AB-8F51-693594396CBD"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e1a7276e-b078-4625-9913-4c49fa21673b">
    <domeo:uuid>97563ff9-1d6d-49de-ba73-d1a43f311be7</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0c3204cb-32f8-4d58-b002-cb9807343236"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:834560AA-1E49-41EA-BE70-AB001B40F97E">
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0EDDA661-7FEA-49EA-85DB-C28A8536B926"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DB5BC21E-57CF-45BA-AB45-CC3AF11A6885"/>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9665FA07-3B81-4DC9-BAE7-C0FE23938531">
    <dikbD2R:dose>300</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0afd341f-828b-4020-8886-b1d5dbba6ae3">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>rifampin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b28b1184-72a9-40bc-811d-7ba9a8a245e1">
    <ao:prefix>beta blockers or diltiazem )   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>68f830dd-320a-4e62-91da-21402aca3379</domeo:uuid>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <ao:exact>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)]</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bb9d26df-1b99-43d1-994d-661989c91a36">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6E21DC0E-AC80-4F91-86C1-7010708BCB85</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N41571b1377ee41cd8e1be805bd530456"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:f7a2ce04-1909-4c84-93e5-35134ce9bde4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:DA2B6BDC-1B0C-4529-8D5C-79342F46D71C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0C7DB4B9-AD07-4B4F-953D-2C0E504EDF05">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EAEEFAFA-7809-45A8-8FB9-7D1359CBA2C7"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E496388F-0968-4AAC-AE44-0C0382150E50"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:372f193d-4c8a-4edb-a4cf-d158cfb34fad">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:e8f7e10a-ad20-45b5-923d-6887371781f2</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:b8cd2ed9-1344-4df7-81da-48d71df442fd"/>
    <pav:lastSavedOn>2015-10-13 11:13:09 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N95998ed8dc9b4daaa85e1d6464d1b9d8"/>
    <pav:createdOn>2015-10-13 11:13:09 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:3e418be1-b336-4998-86c1-8ebb23a8a0b5</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:307644AD-79DD-4FDE-9562-DB8727B7C5FE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:307644AD-79DD-4FDE-9562-DB8727B7C5FE"/>
    <domeo:uuid>307644AD-79DD-4FDE-9562-DB8727B7C5FE</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-11-02 14:01:01 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Imipramine and Other Tricyclic Antidepressants (TCAs) - In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6. Coadministration of Celexa (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram. However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%. The clinical significance of the desipramine change is unknown. Nevertheless, caution is indicated in the coadministration of TCAs with Celexa.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:67a1b4a2-850c-48c9-b301-13bb1f8f3cf6">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:fbcdaf7e-0a2f-45aa-84dc-53cae1496929</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:3e9bcb64-6f70-4084-85f7-17e9f3b83e87"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N4ca8a22295b14d4c9b8919891aee2518"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:0D338E16-D8C4-4103-A46D-BB3BC01B3103">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:d176658e-3cf3-490e-90ce-c9849d7e04d1</pav:previousVersion>
    <pav:lastSavedOn>2015-11-02 14:00:44 -0500</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Nacd4779056744f0eba8ef94cfdd867e7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0467888a-ea7d-4332-a828-51a4b9b4de4a"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:b8360910-53fb-499b-9c5a-bdc9b955455c</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:de90e5e5-b639-4449-9445-b6421797ae4a">
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nad593040d09b42ce8085b6a9753aa566"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:e0bc3e28-6ef0-4203-8648-af6ad5039f91</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:3d5a6168-cfbf-470b-b697-653a5815557f"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:192955d8-e1b3-42cd-9d44-e646e6b05f59</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:87887A6A-E522-4787-AC33-7850E826DFBB">
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:auc>100</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>40</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0B5625A0-AC19-4325-BB37-765EA2A0C1BB"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/16C86CC7-33B4-4757-9EF1-C2F6D936A131"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf2d9c8d28f8f489196c05cd536d7e563">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FB1C7216-BF30-464C-9ECA-23C0318EE134">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e8bd9676-79e1-4501-93a4-a577d2ac3359">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:99fbde00-3ec5-48cf-be05-1de86fb463e1"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B958EDE-4B07-480E-8919-8195B58C0EB6">
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:2298ABEA-9371-4D03-B904-936D3631AD23"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-27 15:22:29 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:13A964AC-D51C-49B5-AE90-6BCCB6688028">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E3443685-CB43-45B7-BC03-1430D374FD0A"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/79146705-5D0B-479E-8BA1-07F598CB2A91"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9641a202-c202-455c-9f26-944c65e753ae">
    <ao:body rdf:nodeID="N2e3ebddbfd534877ba63f079cda6007a"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:06946905-2a65-4535-917b-f46411dbdef6</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:fb01480f-ff31-447a-9b7c-82db5281a48a</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:da979eef-1133-47dc-bcb6-5fcaf76f224d"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6d346686-fe95-4079-83a5-0be13cbd2e22">
    <domeo:uuid>dd760735-5e65-40a2-8e39-52ab4a45cfbb</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Potent CYP and transporter inducers: Rifampin did not affect the pharmacokinetics of teriflunomide.</ao:exact>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <ao:prefix>ct of Other Drugs on AUBAGIO   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/12c3b949-bda1-44a0-85b5-77bd382363a3">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>duloxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:602767b5-bfe6-477d-90da-f76a4c6a200d">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:ed2ef392-bf85-4f78-9940-ade4c66914d9"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N40c2c64effae44ce8059e13942a4a102"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:dec39c75-53c7-4e31-a8d9-f8a296e29193</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0016e129-8dc1-40dc-a6a6-4bc18374bf8d">
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0a6231f4-0ef4-4180-994c-66d631a75d4c"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/be3efcff-28cd-424c-90b3-8c16e3e0ab2c"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3637aedf-f9b9-4efa-aab9-beb485d37117">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>selective serotonin reuptake inhibitors</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0132436C-62D7-49DE-8254-2FDA7121BE0C">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].</ao:exact>
    <pav:createdOn>2015-10-27 14:12:59 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>0132436C-62D7-49DE-8254-2FDA7121BE0C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0132436C-62D7-49DE-8254-2FDA7121BE0C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c7f6f5a3-1f32-47e0-b430-e082af5e579e">
    <ao:exact>There was an increase in mean ethinylestradiol Cmax and AUC0–24 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC0–24 (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide [see Drug Interactions (7)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>(7) ] .   Oral Contraceptives  </ao:prefix>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <domeo:uuid>b658e38b-2b08-4921-9352-c68ed6be203b</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50D27F86-B485-4FD3-9B02-6D20C66C1B7C">
    <ao:prefix>(plasma level:dose) ratios have been reported when </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:50D27F86-B485-4FD3-9B02-6D20C66C1B7C"/>
    <ao:exact>fluvoxamine maleate</ao:exact>
    <domeo:uuid>50D27F86-B485-4FD3-9B02-6D20C66C1B7C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-27 15:22:32 -0400</pav:createdOn>
    <ao:suffix> was administered to patients receiving maintenance </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D0E1A3C-C4B4-4B7A-AA4D-F4AF2FB07A20">
    <pav:createdOn>2015-10-27 15:21:55 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7EEBD589-980F-4087-9AA6-844C0AE51C83"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56F908E4-D00F-4A85-8963-635BA1958420">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:CE9F7FEC-FBC8-4345-9E83-FD4D7E357C8D"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdOn>2015-10-27 15:26:01 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N0fb51740f5ea48838bd95447490a7e12"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5921a5f4-69f2-48c3-8cb8-f6039eb31ee2">
    <domeo:uuid>8b89b035-58d7-452e-9012-7f1fea651e7e</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0e7ddb57-871e-4883-8c62-615b2016c175"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D8D3B5BD-7C2F-40CC-9A9F-FBDC207AB43D">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-11-02 14:22:34 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:4b58c181-7391-4841-b8f8-e1426a015a09</pav:lineageUri>
    <permissions:permissions rdf:nodeID="Nbdfd5f3eec1f408fbc8cf39153139ec5"/>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>urn:domeoclient:uuid:181f09b7-3bf0-4332-bb43-d888ad36a05d</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:8de60281-2d8d-4315-9b12-12934ab0ea5e"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:169609b8-695c-43f5-a9f9-9cb29455ee0d">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <domeo:uuid>96a1472d-577e-4955-be63-1f00b6c51f9a</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0f6c8311-ba0b-4155-9f60-64db0e0a09d0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:72286BB9-C578-41EC-9E0D-082D5E24ABF7">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FFECE2BC-7148-4883-98B1-12280CA4C520"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54D11215-2768-43FE-A9F4-08A4D14AD931">
    <pav:createdOn>2015-11-05 10:37:15 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>54D11215-2768-43FE-A9F4-08A4D14AD931</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).    In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).    Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Drugs Metabolized by P450 2D6   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:54D11215-2768-43FE-A9F4-08A4D14AD931"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3947C31-90AC-4508-8E6C-6D07E0336232">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B3947C31-90AC-4508-8E6C-6D07E0336232"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <domeo:uuid>B3947C31-90AC-4508-8E6C-6D07E0336232</domeo:uuid>
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <pav:createdOn>2015-10-27 15:35:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2124DCFE-AF88-4C06-8031-3A323FD122BB">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>azole antifungals</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CF8E8B63-CBC6-4D5F-A9D3-C3F1488586F8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluoxetine</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/57F6F661-08CF-42DB-979F-C1A7EEA14A88">
    <dikbD2R:dose>50</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7D3E5D57-6320-472F-84BB-62CEE19998B8">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C5716382-9548-43C7-AF5F-2BFE4C11A6DF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fd1a5196-6e1a-4c60-8763-ab278a13fa59">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:105f8e95-d0b1-4570-b393-12f2520801d6</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:3c663223-5aec-4927-a514-57918306b6c7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nc0c59d7c06c94ee18543c176b6240200"/>
    <pav:lineageUri>urn:domeoserver:annotation:e8f63cc8-6006-4b21-96ba-b2a6d69875ea</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/20EE8D38-341E-43E5-9A87-6621C3C3B922">
    <rdfs:label>warfarin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N580ae195a7924f2c82e287c9d9188d04">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5A698259-814F-45CB-89DA-7D2481C5ED38">
    <dikbD2R:objectDuration>10</dikbD2R:objectDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0888ADEE-2436-4845-B2A0-F912324F129A"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/788801A3-E126-4A13-A5A7-1F1BF89D0918"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptDuration>5</dikbD2R:preciptDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>IV</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94cf3e93-a84e-4d64-859f-7561a870477f">
    <ao:prefix>as well.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 11:41:50 -0400</pav:createdOn>
    <domeo:uuid>81b91b05-5a3f-405d-a398-8ac4d07b03b7</domeo:uuid>
    <ao:exact> Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18c86de9-724e-42b8-991e-f98dcff255ac">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:237d2d40-40a7-4c9e-9c3d-e28fe1555f43"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="Nd1d3a27ede4f45e5b8133e546363f522"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:7b7ac35c-dc57-46a5-aa71-7fe7ecd504c0</pav:lineageUri>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:841571D1-493E-42B0-8350-051059BDE2B4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:841571D1-493E-42B0-8350-051059BDE2B4"/>
    <pav:createdOn>2015-10-27 15:25:16 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluvoxamine </ao:exact>
    <domeo:uuid>841571D1-493E-42B0-8350-051059BDE2B4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>(50 mg b.i.d. for 7 days) on the single dose pharmacokinetics of mexiletine (200 mg) was evaluated in six healthy Japanese males. The clearance of mexiletine was reduced by 38% following coadministration with fluvoxamine compared to mexiletine alone. If </ao:suffix>
    <ao:prefix>The effect of steady-state </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4cd111f1-6079-4f96-a2cf-2b60c8bdc6e9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nbe55ae8ce7394498a2a26c48e468aa15"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F5A7EEBC-EA09-40A9-A95D-1901093AC47E</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-27 14:15:20 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D99F7F7-99EA-4BA1-96D2-CFA9D45AB9DD"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:ae10e898-00d8-41ea-886f-00ec34fed89b</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44DCEE28-2526-4FEB-9778-BE97FA2BDF6D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:44DCEE28-2526-4FEB-9778-BE97FA2BDF6D"/>
    <pav:createdOn>2015-11-02 14:29:45 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>   7.10 Pimozide and Celexa   </ao:prefix>
    <domeo:uuid>44DCEE28-2526-4FEB-9778-BE97FA2BDF6D</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DB0A3F5-19B3-45AE-90C7-C90BB235CB05">
    <ao:exact>Ibuprofen    In subjects who had received EMSAM 6 mg per 24 hours for 11 days, combined administration with the CYP2C9 substrate ibuprofen (800 mg single dose) did not affect the pharmacokinetics of either selegiline or ibuprofen [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <pav:createdOn>2015-10-27 13:28:10 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0DB0A3F5-19B3-45AE-90C7-C90BB235CB05"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid>0DB0A3F5-19B3-45AE-90C7-C90BB235CB05</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:807f6ff4-536e-45d9-86d4-35ec83ea818e">
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <ao:prefix>macokinetics of milnacipran .  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Lithium-Multiple doses of Savella (100 mg/day) did not affect the pharmacokinetics of lithium. </ao:exact>
    <domeo:uuid>f7712ea9-94a7-47f9-9644-1e7c157ac5fd</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:176beeec-5737-4b5e-9b2f-5ca875056688">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:fff5a1b9-593a-4aa9-a540-cf2643d99482</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:63856aff-1f69-4ce6-9fcb-228b033dfea1"/>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N4ccb86d940b14246a8f62fa2acbf34ff"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B6F9EA1C-95FB-4271-A406-8EA7240E37A3">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1E77B9E3-6E52-4607-BF12-DA003CF3F36B"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:117EBBD8-31C6-42CF-9294-03F319F4CED9">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C2AF4E52-5DD3-43B9-99FC-1A52E6335565"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:723DE511-9EDA-4737-8867-821FAC432FB5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:723DE511-9EDA-4737-8867-821FAC432FB5"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>   7.5 Lorazepam   </ao:prefix>
    <domeo:uuid>723DE511-9EDA-4737-8867-821FAC432FB5</domeo:uuid>
    <ao:exact>Under steady-state conditions for duloxetine (60 mg Q 12 hours) and lorazepam (2 mg Q 12 hours), the pharmacokinetics of duloxetine were not affected by co-administration. </ao:exact>
    <pav:createdOn>2015-10-29 09:04:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16DB41D8-05F0-4046-8F36-8AA2C8492805">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16DB41D8-05F0-4046-8F36-8AA2C8492805"/>
    <ao:prefix>XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:exact>Drugs that require metabolic activation by CYP2D6 to be effective (e.g., tamoxifen), theoretically could have reduced efficacy when administered concomitantly with inhibitors of CYP2D6 such as bupropion. Patients treated concomitantly with WELLBUTRIN XL and such drugs may require increased doses of the drug [see Clinical Pharmacology (12.3)].</ao:exact>
    <pav:createdOn>2015-11-05 15:36:15 -0500</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8ce97d0f-5bd3-44a7-90ce-4b4f419692dc">
    <ao:prefix>e Drug Interactions (7.1) ] .  </ao:prefix>
    <ao:exact>In a separate clinical pharmacokinetic interaction study of healthy subjects, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see Drug Interactions (7.1)].</ao:exact>
    <pav:createdOn>2015-08-20 11:32:27 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>a8b4702f-49cf-4432-97e6-46a274cfdbba</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:88b3ad51-3f1a-4fc4-8966-47a8afcbdbac">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>982a2097-6a8d-4c24-8b3f-2fc8816a34f3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>stration to healthy subjects.  </ao:prefix>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <ao:exact>Fluoxetine-Switching from fluoxetine (20 mg once a day), a strong inhibitor of CYP2D6 and a moderate inhibitor of CYP2C19, to milnacipran (100 mg/day) without a washout period did not affect the pharmacokinetics of milnacipran. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8580b7ce-0328-4ccd-96f0-8f3bc369cb39">
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4924e38b-ac50-4c76-8a78-436fca290d9f"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12></dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ff27b70a-5240-4bf2-95c6-e10fda72db8b"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4d4899d6-1f9c-4a9c-a070-6045bcf38fe1">
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/12c3b949-bda1-44a0-85b5-77bd382363a3"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/bcc449a8-9db9-43c8-b120-eff11a90b8c2"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DD84EF36-17DE-4FCB-B447-52BDFC787EE3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1C87BCC9-B913-4BF8-BD1C-EC5D2F19F6FF"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0A6547D9-5F06-4BAD-9EDA-EBF2B9541E67"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BC09D4F-295B-4383-8C8C-E97550202974">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9BC09D4F-295B-4383-8C8C-E97550202974"/>
    <ao:exact>Ritonavir, Lopinavir, and Efavirenz: Concomitant treatment with these drugs can decrease bupropion and hydroxybupropion exposure. Dosage increase of WELLBUTRIN XL may be necessary when coadministered with ritonavir, lopinavir, or efavirenz but should not exceed the maximum recommended dose [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>Clinical Pharmacology (12.3) ].   Inducers of CYP2B6    </ao:prefix>
    <pav:createdOn>2015-11-05 15:27:05 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:875151A5-D31E-45AB-AD04-978CDF27BB67">
    <ao:prefix> </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 15:54:37 -0500</pav:createdOn>
    <ao:exact>Citalopram </ao:exact>
    <ao:suffix>did not affect the pharmacokinetics of</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:875151A5-D31E-45AB-AD04-978CDF27BB67"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:48CDFD2C-A735-46A1-A0B1-5C700E15C5EA">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F43AEE97-B207-40B4-9395-136255B6DFD3"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5059B838-6797-461A-A9C9-602802BF8629">
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <ao:body rdf:nodeID="Nc7e793445516405ca947508fadbdb637"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-05 15:31:04 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B04C100-ABBF-4527-8D7F-3771D405F33B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a5719c4c-ef59-4c50-9564-50196d850cc0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nd9ece3cc235a43249e1207bfefc8f700"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:b5f796ab-32e9-4857-9fa4-189817ebace8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:7619ba42-b6d6-4762-81e2-3e9aeaf1934a</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:db5daa5a-e41f-44bd-861c-2f2a7851eb50">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/eb0c49c8-4ad7-455f-9764-f52761776bb5"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6434f339-6956-4d1f-aaf5-2143cfbbb87a"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:auc></dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66e7b711-1593-49da-a95d-dec53305b39c">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.</ao:exact>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>4f344b15-f444-456e-9376-f00484614b91</domeo:uuid>
    <ao:prefix> be an inhibitor of P450 2D6.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4C006546-0F74-4740-BB15-DF940CA3989E">
    <rdfs:label>methamphetamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0CFF406-ADD4-461B-81E4-F1B12B96F33E">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:E2875D36-6D74-49ED-B548-9CC86771941E</pav:lineageUri>
    <pav:createdOn>2015-11-06 15:55:50 -0500</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2B94823-7C38-4D49-90BA-8E9BC977DBC9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-06 15:56:02 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N31b2f671ec42420ebea9a1d6c7f7a414"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1d272e64-b3a1-471e-8bec-4a398c3393e6">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:E8C1FCFF-D626-4F30-AADF-9546F374EB44"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N63247e6551894d41a605c6987e373128"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-28 15:25:57 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D8056D38-6718-4AED-87A8-4EB5DC6338EF</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:708515fd-f0de-4705-913a-ebfb93aad0dd</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/88422EA6-528C-4AA3-8C30-D74168B078D9">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>mirtazapine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D084F98D-37B8-45EF-B029-E0E5DC9B5022">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D084F98D-37B8-45EF-B029-E0E5DC9B5022"/>
    <ao:prefix>) and many that are substrates for P450 2D6 (many other </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, phenothiazines, and the Type 1C antiarrhythmics </ao:suffix>
    <ao:exact>antidepressants</ao:exact>
    <domeo:uuid>D084F98D-37B8-45EF-B029-E0E5DC9B5022</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-04 14:10:53 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/38F6CD96-96ED-4020-BF5B-E5FD8C084CD9">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>lamotrigine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AD060308-4E45-46B1-A88B-6DDBCE57C454">
    <rdfs:label>phenothiazines</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BDEA25A2-2D72-4934-9CBA-250D3A617606">
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdOn>2015-11-06 15:44:45 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <ao:body rdf:nodeID="Neba3c12d8d0344d588f3a198cd0ea22c"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-06 15:45:24 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:E786F7DC-C42E-4265-8923-103099474CC7</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:09438C0B-85B9-412C-AD28-3D09EF0E7ACA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/19ACFFF3-C240-4043-AE61-A114C98B77D7">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>sertraline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4BB8DE85-E964-4619-83A9-C03ED9DE4AEC">
    <rdfs:label>escitalopram</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2858A178-24D9-472B-BE99-812F1B1CFD50">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A6030E3C-BE47-4A0C-89CC-A97207BA08E5">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F4C8A3AB-9878-4F37-8D42-B4B41C35CB65"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F33ADB58-54AD-43F0-BC2D-C7FC9333C76C">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-06 15:37:49 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:27387736-AEB3-4AB1-866E-8ED6BF3888BC</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nbb1bcc5eca0647509648dc49152dcf3f"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:3014BE9D-A10F-40CF-A616-5246B39213D2"/>
    <pav:lastSavedOn>2015-11-06 15:37:50 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e9bbeafc-92a4-4d19-ad0f-419bdb6f419a">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>quinidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fb6217ae-8618-4cfa-8c2f-7283a841d73c">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:f242f443-e177-4608-ae22-6653160b6732"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <domeo:uuid>62a57684-d8bb-48eb-8b14-4bb94afa80ea</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0a35250c-054c-41aa-9b98-1d944dcd7347">
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N4b9e677a3eff4fd782a658dd6e29eea6"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:5d0a7dc5-0566-4a70-b476-56562d8e7b96</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:b6790782-15b7-4bb1-8880-581c3153d020"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6ca015e765e84d8da58b0658b0fcf278">
    <domeo:sets rdf:resource="urn:pddi:uuid:BF624178-2F3A-41B3-9042-EC5765ED6BD5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8723B5A2-1463-4E00-8C97-849A6B27BA04">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-05 15:29:38 -0500</pav:createdOn>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8723B5A2-1463-4E00-8C97-849A6B27BA04"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8A0FFA5E-4E5A-4CCE-A649-3D8521FFC2EF">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:89C12BE2-A24C-40DF-9F8E-F7129BE66428"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69216ede-c72b-44f5-ae01-5186a6039d38">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>451655e4-5cab-4a6d-8c40-4cd2e040025a</domeo:uuid>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <ao:prefix>e in plasma AUC of the TCA ).  </ao:prefix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FDAC04F6-41E7-4D95-B822-8D86185C2EEB">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:971C7820-2663-40F7-8019-F3EBC13A6575"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf45dd07ebec24812a55b1be35cb23ac5">
    <domeo:sets rdf:resource="urn:pddi:uuid:f10c2968-f89e-4cf0-b5ef-ba63f654f36c"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5B0937DA-4024-4DD7-850B-53C052CED981">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>flecainide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:768AA5C0-0BAE-4E02-BB05-5AD320E6CE2E">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6DA2E84E-AB19-4725-8587-594694E37E5B"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:082B38D4-2CA9-411C-BCCF-F10786673E1A">
    <ao:prefix>not be used in combination with either terfenadine , </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-06 15:41:58 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:082B38D4-2CA9-411C-BCCF-F10786673E1A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>082B38D4-2CA9-411C-BCCF-F10786673E1A</domeo:uuid>
    <ao:suffix>, cisapride, or pimozide </ao:suffix>
    <ao:exact>astemizole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26f7b6a5-51a4-4283-914d-e7de76ce1077">
    <ao:body rdf:nodeID="Ne20323474df847bb897a0a57c9259d43"/>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:7a732bf1-9a34-43c0-8a62-aff60e4b943e"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:cdc98dd2-ca40-4fb9-a0b0-a8ef9a0e25cb</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:6e282b61-495a-4382-971b-505e62cb8f28</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE71BD64-5FBE-481F-B031-067BC86895E2">
    <pav:createdOn>2015-11-06 15:43:12 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Potential Terfenadine, Astemizole, Cisapride, and Pimozide Interactions   </ao:prefix>
    <domeo:uuid>AE71BD64-5FBE-481F-B031-067BC86895E2</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AE71BD64-5FBE-481F-B031-067BC86895E2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Terfenadine, astemizole, cisapride, and pimozide are all metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has been demonstrated that ketoconazole, erythromycin, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine, astemizole, cisapride, and pimozide are associated with QT prolongation and with rare cases of serious cardiovascular adverse events, including death, due principally to ventricular tachycardia of the torsade de pointes type. Nefazodone has been shown in vitro to be an inhibitor of CYP3A4. Consequently, it is recommended that nefazodone not be used in combination with either terfenadine, astemizole, cisapride, or pimozide (see CONTRAINDICATIONS and PRECAUTIONS).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8646ee8a-5b9d-46d6-8503-2889c39df890">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EC91E328-6717-4DC4-A626-501948A85F29">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/61B4EC1F-599A-46BB-8998-D5818426F08A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/579AA6FC-D39C-4B2B-BC89-F0CDAA231330"/>
    <dikbD2R:auc>55</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>34</dikbD2R:cmax>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:EBC5B786-4892-4544-85FB-2E855ECB0199">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:91a91a01-1cae-4fc7-9d0f-7e094d676a47</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:4a1817ee-bda7-4fcc-99cb-182c37d7469c</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:d35c2fa6-90ad-4c9d-90c2-83e00233d7aa"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="Nb554125ec7194ecc96a4fb8c061ec515"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-09-16 15:31:12 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/22f2742d-71d0-4f52-b985-7f6ed59ffb00">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7ab7c91f61c942239258e902e4291820">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b246dc4b-35d2-4a89-91ce-971ef1006b97">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>bc278c15-f406-4516-b74a-4ccedc412cce</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>pran and 150 mg pregabalin .  </ao:prefix>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <ao:exact>Warfarin-Steady-state milnacipran (200 mg/day) did not affect the pharmacokinetics of R-warfarin and S-warfarin or the pharmacodynamics (as assessed by measurement of prothrombin INR) of a single dose of 25 mg warfarin. The pharmacokinetics of Savella were not altered by warfarin. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0EFA116F-E61E-4263-87B6-51161516E5C8">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:suffix>metabolite was decreased by 78%, the threohydrobupropion decreased by 50%, and the erythrohydrobupropion decreased by 68%. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 16:06:43 -0500</pav:createdOn>
    <ao:exact>hydroxybupropion </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> by 66% and 62% respectively. The exposure of the </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0EFA116F-E61E-4263-87B6-51161516E5C8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA8DE504-0594-418F-BA0B-514BC5A86474">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:7D6021A9-5FFF-44DF-9814-D78A2D9D210F</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <ao:body rdf:nodeID="N00340cfc6deb4fa787ba7ec5d53e7493"/>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:94B2550C-10F2-44E2-B860-6F6B9674F815"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-11-05 10:38:45 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6DC35B05-59EC-4B27-BBE0-FB631517D8CA">
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>21</dikbD2R:auc>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/79A65627-1326-4D52-B5FE-EA6544D88DEF"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/694D237B-14CB-44CD-8AB5-C81A74249FF6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax>10</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3f1f6312-8692-47a4-aee1-359a69c1f32e">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6e1bf271-6425-4eda-b438-479632c1dc01"/>
    <domeo:uuid>81bb7268-c3b3-48b8-a706-50b9393618b0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2DF58087-03A0-4939-A295-087AD40A9235">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:772764DF-E9BB-474D-9A07-9892A4D865E2</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-11-05 10:37:15 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:54D11215-2768-43FE-A9F4-08A4D14AD931"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N7d7e6154c2e846278398cdf4a62edd12"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9a170ac2-b839-4e2e-a6c8-672908900fd1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:9f968a74-720d-4f92-9b86-47fb9104fb5f</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:d45b7f21-02b3-4a6c-afb0-0f708a83ef13</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N25d6b3635bc845568e1c4e9197326721"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:8c2d59d2-f2d1-41ce-9284-e794b2f79fde"/>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:62CF0CF6-3022-4EDC-BB58-8706F755E604">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5B46C7ED-6836-406F-A6D9-751B1978C0FD"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne5572a5ab0914fa6a594410e6cce8cfa">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A48ED874-922D-46FD-9450-226F361E4A85">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D78EC978-BF12-42E0-A78C-FDE24FFFEF71"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:955e8807-d714-4998-807e-78bfe31e1606">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:cd220c6f-e103-41fd-8493-15146fa4c308"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:9726cd10-4858-4848-b747-96f5f0600a56</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N8815e943db8b4d798393436e3cfb2d7c"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:32be9a83-c8ea-49b6-98c5-c487eb12a8c2</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0AE73FC2-FF83-4292-9B7A-2D52AFF5DAF8">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>hydroxybupropion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:90B3FE17-FB25-427B-A839-756EDF659FD5">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nf34fe22c02f542d0a8882d92ed0222c7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-27 14:17:34 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:2349fd75-98b7-4b9e-93af-bf96d9ffc62a</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:fb2c96c4-3b7d-4e4d-b07f-2f4beb9c8a09"/>
    <pav:lineageUri>urn:domeoserver:annotationset:47413547-1cd0-44ca-b0f8-bd96cfe85572</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4659CE78-DDBE-48FE-950E-F73A5DB20BCA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/708D45F7-889E-4E0D-95AD-A1FF84F406AF"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/83B55ADC-0E96-4293-ABFD-179ACB5D2077"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CDB48ED9-BBB4-4DA1-8A9B-0417F097EA9A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>digoxin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2e637f03-2b09-4edd-a5e7-8ec326626e6d">
    <ao:prefix>0</ao:prefix>
    <domeo:uuid>92958af5-028b-4095-aae9-4143cf6f21a6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <ao:exact>Other substances, particularly barbiturates and alcohol, induce liver enzyme activity and thereby reduce tricyclic antidepressant plasma levels. Similar effects have been reported with tobacco smoke.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:860D5D85-357C-4060-AC23-A6F12DB1068A">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6B9D53EA-3274-474C-BEE7-316C4C087C1F"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c200a0ab-e8ec-4ad5-90e8-fe467fab6f75">
    <dikbD2R:dose>50</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>lorazepam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A904ED53-6540-41CF-A820-BE05493B3448">
    <pav:createdOn>2015-10-28 15:10:50 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A904ED53-6540-41CF-A820-BE05493B3448"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Phenobarbital induces many cytochrome P450 (oxidative) enzymes. When a single oral 30 mg dose of paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of paroxetine on phenobarbital pharmacokinetics was not studied. Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment of paroxetine is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect.</ao:exact>
    <ao:prefix>s not studied.  Phenobarbital  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A904ED53-6540-41CF-A820-BE05493B3448</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/84ad187e-7fdd-42bb-8964-df89e8465523">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>dextrorphan</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F98C475-6082-48DC-B766-01BDE834C6EA">
    <pav:previousVersion>urn:domeoserver:annotationset:8EE4F288-19C8-4519-85CB-791C9E9709D8</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-11-06 15:42:56 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-06 15:43:14 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F74460A3-FA3F-40CC-A25A-C8BD22BCEB29"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N97e1080567e54433b59b4c9d50443165"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EA058153-469B-4EE9-94C8-2F99B709453F">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/023177C2-5341-48E6-A56B-0137577E12E8"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CDB48ED9-BBB4-4DA1-8A9B-0417F097EA9A"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>17</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>10</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7484837-005F-42CC-BF22-27A2954637E0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Ticlopidine, Clopidogrel: In a study in healthy male volunteers, clopidogrel 75 mg once daily or ticlopidine 250 mg twice daily increased exposures (Cmax and AUC) of bupropion by 40% and 60% for clopidogrel, by 38% and 85% for ticlopidine, respectively. The exposures of hydroxybupropion were decreased. </ao:exact>
    <ao:prefix>    Inhibitors of CYP2B6    </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 15:46:50 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F7484837-005F-42CC-BF22-27A2954637E0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BEDF189-9480-4DEE-89E2-EED5CA5E3A45">
    <domeo:uuid>9BEDF189-9480-4DEE-89E2-EED5CA5E3A45</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9BEDF189-9480-4DEE-89E2-EED5CA5E3A45"/>
    <ao:exact>ketoconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, or strong CYP3A4 inhibitors (e.g., </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <pav:createdOn>2015-10-27 11:46:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>) is necessary when these drugs are used in combination with </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3B605ED7-ED2C-42CA-A09F-72F733E903FB">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FDE74EB4-3679-48DA-8C40-5A05900D845B"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a96702ae-a3f2-494b-bd27-5146edf90452">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:fb350350-0137-457b-ae9c-c95d3ce0ed46"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N5045dc47e7d84fd9bc6659d8010bd2ae"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:2b595f7b-a8ae-4825-80c6-5e80322b6572</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f4b904b3-c7a5-4a2c-af73-4f075cb45f8e">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:a9ffeca3-5648-4d0d-a46e-c21fb3d4b20b"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N8258063cb08444a1a48f8960de18ab57"/>
    <pav:lineageUri>urn:domeoserver:annotationset:237f35f2-2672-482a-a150-6d184df2a25b</pav:lineageUri>
    <pav:createdOn>2015-08-20 13:53:28 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-08-20 13:53:28 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A6FB01B-C51E-43F8-A416-4DDDB8E0FC00">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>5A6FB01B-C51E-43F8-A416-4DDDB8E0FC00</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>  Amitriptyline  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In healthy, CYP2D6 extensive metabolizer patients (n=32), amitriptyline (75 mg daily), at steady state, did not cause relevant changes in the pharmacokinetics of steady state mirtazapine (30 mg daily); mirtazapine also did not cause relevant changes to the pharmacokinetics of amitriptyline.</ao:exact>
    <pav:createdOn>2015-10-29 10:46:55 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A6FB01B-C51E-43F8-A416-4DDDB8E0FC00"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:69BF3208-059A-4333-9CD2-3927C5799F14">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-11-02 14:00:44 -0500</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:4a8b3cb8-00c4-4cdd-8e1e-3294a0331814"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:d292ddba-b387-49b5-ae4b-f1e60a9f41d7</pav:previousVersion>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="Ne1b53a7aaa7d4185b8cd53723ed77519"/>
    <pav:lineageUri>urn:domeoserver:annotationset:dceb9476-ba26-4dec-9061-aa3a2fc1f532</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:efc0f3b5-e6f0-4596-a8a4-38d04126ed99">
    <domeo:uuid>bb1567e3-c25a-4490-99e2-84ca313d1819</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2fc1a4a0-3b89-41c7-aa77-fc1e37454e20"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:169DFBED-1B89-4F0E-9529-5CA65AB67C10">
    <pav:lineageUri>urn:domeoserver:annotation:20CA9709-5FC5-42E7-8D76-598723FB5ED6</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:7B580C2A-B83B-4D67-B56C-5325FB709ED1"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-05 10:36:46 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0EFDED3C-25C8-41BC-90FC-4AE2531D7CFA">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <pav:createdOn>2015-11-05 15:30:31 -0500</pav:createdOn>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0EFDED3C-25C8-41BC-90FC-4AE2531D7CFA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6B9D53EA-3274-474C-BEE7-316C4C087C1F">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4D6B7A01-8D07-42D8-9C76-0B9CBDE938CE"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/67FEB7DB-D850-4529-9945-70CC52DB7464"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DF63DB85-7352-4779-9D43-53BACB271EC3">
    <rdfs:label>ketoconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:041c7855-95f8-4ddc-8053-533a5e692709">
    <pav:createdOn>2015-09-03 15:43:15 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-09-03 15:43:15 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:98cb7a35-5365-43f1-b65a-ce324def7981</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="Ndecacff3fb3d42209b0dcffabdd05a63"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:e3093c1b-7b23-4281-8b8e-e79247762353"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ba3eefb6-8292-477d-b48a-7641c8415019">
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e16777bc-550b-41fc-9feb-032edee4e05f"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/bef9cd4f-d0e6-444f-8300-8ffa4d4528e0"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:auc></dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:886f785e-465a-4038-96d5-14ca200025bb">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8369340f-e14c-45c6-a021-5db740fab9d1"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7d75d730-59d6-4220-a92f-21d1c77f2cc4"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57F17CF9-9308-4760-851C-F357958B8144">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:57F17CF9-9308-4760-851C-F357958B8144"/>
    <ao:exact>    Citalopram: Citalopram did not affect the pharmacokinetics of bupropion and its three metabolites.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>.</ao:prefix>
    <pav:createdOn>2015-11-05 15:55:34 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nba10e3acf6ae421f87848a9aa8f79cd9">
    <domeo:sets rdf:resource="urn:pddi:uuid:187bf2ac-a432-4ddc-bad5-dd4ed31ce96d"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ed76938e-7f79-4891-b429-f6cb6235a1f9">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5f732e09-f9d1-4528-950b-3d4d02f8216f"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635">
    <pav:previousVersion>urn:domeoserver:annotationset:47A2106C-5354-420D-9E05-D9E4F945B6D0</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B9CE845-DC5C-4C1A-B610-A49E5EABC515"/>
    <permissions:permissions rdf:nodeID="Na2914eb339314231b1a120eae924c2f4"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2014-02-19 12:41:40 -0500</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:37DDEDB4-2423-46DF-880E-A2D411563078"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:66FF0DF3-C777-4A3D-971F-8E83B304FDCC"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:B26CD913-F144-4BFF-8967-7F740FF37133"/>
    <pav:createdOn>2014-02-19 12:23:10 -0500</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:18CB9938-6266-493E-A282-DB819CD3E51A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:633CA52C-A1B8-4DA1-936D-70D2F0106564"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:357321A7-5793-4DE5-BB38-BF5FA7A5D72C</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52D6E96B-7A61-42FB-B7F6-3AE957575C36">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 15:33:50 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:52D6E96B-7A61-42FB-B7F6-3AE957575C36"/>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1389b841-3efe-48fd-9664-ed76f8a7548b">
    <permissions:permissions rdf:nodeID="Naaa049861b0d426cbe187bf4d464ddf9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:c6442882-4154-46da-bc11-5b7fb15ea176</pav:lineageUri>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:6fb13d58-36d3-4b9e-868b-9fd33563bc16"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8c5e5f91-8437-459f-ba31-752d55d5f577">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <domeo:uuid>0298a4a7-3580-41ae-892a-edb94a6b4e63</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C35FE4A2-AFA9-4715-B647-8ABA65C1FF95">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>CMI</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7D2F705-12C8-4309-89D6-397AB84891A5">
    <pav:createdOn>2015-11-04 14:14:31 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CD9E7CE1-2EDB-4CF5-8C39-1341B3BDE9B4"/>
    <ao:body rdf:nodeID="N7724fb55daef408f8c53feb527d32fd1"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:B56227FB-55C5-4B55-A34F-A7C173FE2786</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B60FC03C-7E2F-46CB-9EBC-6C04FC16FD54">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>antidepressants</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2E0884CB-3CDE-4AAD-A1DC-DD69B6BC8291">
    <rdfs:label>ritonavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3087234F-2B79-4EA5-B4A1-77DDE8D85249">
    <pav:lastSavedOn>2015-11-05 15:40:32 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C814894A-0420-415A-9A41-21CEAB6AAD3E</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-05 15:40:31 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:648B1DA0-FE0E-441B-95B7-CAD3D7CDDE5A"/>
    <ao:body rdf:nodeID="N1876eab6e1ec44dd9eabf475a447a016"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D51BFAD4-356D-482E-9711-4B9CBE65B766">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>phenytoin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c4a79c3e-0a1d-4117-bb96-dc2fad389e12">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:b7d7360a-1a66-49af-a5df-33f47e310a27"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/25bf3cc7-0ff9-4b84-a304-11e4073282af">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>CMI</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:393cd8d5-05de-46c5-a0a6-d2939ab21d75">
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ca26dec2-c067-4624-bcc9-07586715137b"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6216f237-06f1-4b23-af95-64e791b0ce90"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2E7E6846-B3ED-4D77-8AFD-9CBF1690E31F">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3CE2B674-435E-4B88-9486-BFEF711F58FB"/>
    <dikbD2R:cl>38</dikbD2R:cl>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>6</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B5C200B1-5014-4B11-8CC6-306B17072D8F"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12>Unk</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6BB02FE4-0F09-4B90-B15B-B4F23A4243A1">
    <pav:createdOn>2015-11-05 10:30:13 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1750C7E8-CF9F-4608-8DFD-584C1F264EDE"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:7B3CB0E6-DDA5-4370-8C9B-E0E837145467</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N997c28abeb03449a91fb69ae9bfef287"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/694D237B-14CB-44CD-8AB5-C81A74249FF6">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ketoconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2AEF6EFE-861B-4DE5-A749-12E2401F48B8">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-29 10:48:14 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-29 10:47:32 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:172CFC40-7634-4251-BF29-E17A2F299A2B</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E536FE66-FAD0-488D-B7C0-39E59CBD9678</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:1E4C23D6-E976-4A8B-8E85-4FD7B240DEA9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N04e6f6860cbb427584f04c6aa2730037">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2738FA0-0D70-4DE6-9274-DA0C53EA1827">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F2738FA0-0D70-4DE6-9274-DA0C53EA1827"/>
    <pav:createdOn>2015-11-05 16:04:11 -0500</pav:createdOn>
    <ao:suffix>metabolite was decreased by 23%, the </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:prefix> by 22% and 21%, respectively. The exposure of the </ao:prefix>
    <ao:exact>hydroxybupropion </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nae628e59d64b4cdfa9e1723b4221d663">
    <domeo:sets rdf:resource="urn:pddi:uuid:4C511CB4-33BA-4123-AA4B-CF65005565E9"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7a4ba008-53e4-4516-9789-7312965c8216">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>repaglinide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/73044</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB9B67A7-9AA1-4C75-AF75-9F525F42A852">
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdOn>2015-11-05 16:04:11 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-05 16:05:45 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F2738FA0-0D70-4DE6-9274-DA0C53EA1827"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">22</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:4F598533-EB1E-421C-AADA-97962DA8B220</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3c23d7ed-6140-4fb3-acff-8a11a697f354">
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/48a619e4-1899-4755-a515-4b0f19998818"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/943902d4-b563-436d-a69a-27c508b36baa"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5BFFF98F-C336-4970-8D87-CB9011228EC5">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8C8F7427-CD63-4D51-88F8-29B985E8FCAE"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/11b52f45-96ef-49d4-8eb3-36d05bc11bdb">
    <rdfs:label>GILENYA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5AE0D453-B766-4124-B840-2034C7C7B5EC">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>triazolam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>0.25</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8862F260-44F9-4907-B1EB-6D3E0EBF6698">
    <ao:prefix> fluvoxamine maleate tablets.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8862F260-44F9-4907-B1EB-6D3E0EBF6698</domeo:uuid>
    <ao:exact>Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol. Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8862F260-44F9-4907-B1EB-6D3E0EBF6698"/>
    <pav:createdOn>2015-10-27 15:40:26 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne4ffb4b383c84f4d87cfaa8b9ae2b968">
    <domeo:sets rdf:resource="urn:pddi:uuid:B01014F1-2BD5-41DC-9CD5-46941B420262"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:9471B72F-5B68-49FC-A139-7D70D90BA0D1">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:01abc207-86df-4cfc-9c65-e56ca9ee51f4"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:c32dd49e-44c2-4993-b819-de0a0b863fc2</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-29 10:48:14 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Nb33797ff17e8407b9ef6e41261bf3ea9"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:ea0fd004-e0b7-4043-881a-678f38a0dcfa</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:bc0856f5-f706-477c-a23e-d68c067485e5">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:39e90d3a-f87a-42f0-813b-e20db40826ed"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:390020D0-6B01-4EAF-8412-B59F7E16B5BF">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FB4F777E-6B0A-4E09-B405-345E42287E2A"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/62B00FDA-4413-4298-AFE6-150AFE81F8D8">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/679314</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>9-hydroxyrisperidone</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e3e211db-5da1-49c4-ba80-dfeefb6afeec">
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a927782c-fe41-485d-a97d-093df13c9902"/>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/bc946f26-731c-4ae0-b55d-3f67c7e646f6"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9D7E039B-4D66-4366-B79F-EEEDC4561511">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BCEC0F0-D6D7-43AB-962C-DBB87E4B09FA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>Inducers of CYP2B6    Ritonavir and Lopinavir :  </ao:prefix>
    <ao:exact>In a healthy volunteer study, ritonavir 100 mg twice daily reduced the AUC and Cmax of bupropion by 22% and 21%, respectively. The exposure of the hydroxybupropion metabolite was decreased by 23%, the threohydrobupropion decreased by 38%, and the erythrohydrobupropion decreased by 48%. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0BCEC0F0-D6D7-43AB-962C-DBB87E4B09FA"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 16:05:05 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:032ea422-f1c6-4ed5-8aab-abf65c9b167a">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ca47e3d9-ce64-48b1-8c0a-c45bde949d0b"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/d59310da-5ec4-4374-a5fb-046373afd83b"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fc8d2d6a-5089-472c-9680-14b0687c4ab6">
    <domeo:belongsToSet>urn:domeoserver:annotationset:D2C0DCED-F203-4E56-8095-93413ED156CD</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-29 11:09:04 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nb6317273cddb4abc9e04e6daa2da1be3"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:A7BE0D18-597F-464A-9C37-83E9C5C42AB8"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:a36b3cfe-8403-4945-9653-2428bed36636</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/926C0CA5-E021-4A57-A07C-0A8797724BEA">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68333eaa-f034-4ac3-882a-4db1945896cc">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N27b7fd6b2f5c4ef28fe12f18a984d3cb"/>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:49582ed1-a55c-4ea3-8786-f47a45f74bb9"/>
    <pav:lineageUri>urn:domeoserver:annotation:0c81f3ba-d65b-4641-adcc-04bb18bee4ef</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:c89589bf-e6be-462d-b9ae-58141206b775</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EDEBAB6D-55DE-4EB4-A24B-71D5DB3D3DAA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7408B8E7-E0D8-4C25-91DA-8918CC13EE6B"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/612702FD-A9D4-4852-AE07-4D0351FEB979"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ae139417-fe54-4592-b426-fdba76d48487">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nbdaf6ed677334707a0bc314d690648f7"/>
    <pav:lastSavedOn>2015-11-02 14:33:30 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:005A2D87-B281-4CCE-96A2-54758E78669A</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:E3597903-8A20-4F68-80F9-5BE6716C1172"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:b0cea16b-4007-42fb-8f1b-c9f97e57d1fc</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/562927a6-69ef-4d07-954f-e413400d6887">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD53A511-02D7-409B-8D0D-29C5AE07CDD5">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-27 11:46:38 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9BEDF189-9480-4DEE-89E2-EED5CA5E3A45"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:792D614E-D400-4F3F-8A56-9575B592B1DA</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-27 11:47:01 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E4141EC9-A9BB-4586-B9EF-279C37D2B90A</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7aed815d-0d6b-47ac-903a-06cca05649de">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:e3e211db-5da1-49c4-ba80-dfeefb6afeec"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0826dacf-9806-4cdf-85b1-e61256b81be8">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 11:32:27 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:5fe21ecc-56d5-4754-a5cd-7fad59e956c5</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:e0817f91-3013-4727-b7d2-aef97bab71e9</pav:lineageUri>
    <ao:body rdf:nodeID="N32a0b7e59b9e4151bd38210f47a12936"/>
    <pav:lastSavedOn>2015-08-20 11:32:27 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:31b265c2-9183-41fb-9ed6-5c8ea005caeb"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CD794FFD-8A46-4805-B4A4-159A2320FAFD">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>ritonavir</rdfs:label>
    <dikbD2R:dose>600</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:77C4CB18-7DEC-4BC6-A16A-D59CC3A7F458">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:31B00EED-C22A-4452-944D-38253763AE3A"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:53BB4D87-460B-4C1F-92F7-10CBBADBB5D4">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B476F7CB-5A5D-4D10-9EE4-AB261781CD6F"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C47181F5-512B-4E03-8661-1C2A3061E8BE">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Ritonavir, Lopinavir, and Efavirenz: Concomitant treatment with these drugs can decrease bupropion and hydroxybupropion exposure. Dosage increase of WELLBUTRIN XL may be necessary when coadministered with ritonavir, lopinavir, or efavirenz but should not exceed the maximum recommended dose [see Clinical Pharmacology (12.3)].</ao:exact>
    <pav:createdOn>2015-11-05 15:25:53 -0500</pav:createdOn>
    <ao:prefix>Clinical Pharmacology (12.3) ].   Inducers of CYP2B6    </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C47181F5-512B-4E03-8661-1C2A3061E8BE"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D89E6669-526A-41B2-AD15-B08DC587227F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>3</dikbD2R:dose>
    <rdfs:label>risperidone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1834472A-B62A-42F1-8C3E-B730C4DBD100">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7375ED7A-FC8E-42E3-9F7A-F2828540223E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8781AE6D-3AE0-47D5-A7F9-A1788E689198"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d46b9abd-1a47-4753-906f-fdd94a0df121">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4a4e316b-04d9-4897-b407-b1d6a4aa4bf2"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66a6209e-7f39-4b94-b85b-6f3182974c8e">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:aa05604c-eb94-49a3-b5d7-2b25f10b3682</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:2ce1112f-d494-4516-82ae-d60b877bf3ca</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N9ef7cffb10cb4a17b53cf13dbda0ccd4"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:3df619dd-bac9-405c-a617-5223cc7bb51a"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63cd69eb-9f18-4dc8-a80f-2fc6ed845170">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In a clinical study to determine the effects of abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily) on a single 100 mg dose of the CYP1A2 substrate theophylline, no increase in systemic exposure of theophylline was observed.</ao:exact>
    <domeo:uuid>b748f7e8-d5c9-492c-95d6-c16609ab4bf4</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 11:30:25 -0400</pav:createdOn>
    <ao:prefix>e Drug Interactions (7.2) ] .  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c19ee125-1ed0-4374-bf98-5794460d7a19">
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/698b78c6-8b4d-472e-8f96-7ac7e237981e"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/eff49ccd-d55b-4392-af98-78ffbe4c4dfd"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2753BAA-6626-4C65-9789-F05F3DDDFE82">
    <pav:createdOn>2015-11-05 16:08:15 -0500</pav:createdOn>
    <ao:body rdf:nodeID="N1051dcc76a1c484fa87d375e42461ead"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:D3E0B9A2-A8CA-469F-99FD-FCF42D346320</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:28DA8AB6-0277-4537-909A-F41B5BE2910E"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-05 16:08:54 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37d9e027-4c23-4da6-ae4c-e4e87d74455a">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:12eba460-c01b-4f47-9e2d-37aef0f50474"/>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:2a8e6bff-64f1-479e-87f9-4cecb23d9f1d</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nd08416142d254613ac92271d309fde8c"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EA8B9D02-6FF6-41F1-B57E-13B9A76BA42B">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5EA3A394-5ED5-4519-99C7-0D36E400AD3A"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2BC37D91-8AC1-4381-BDC9-FA7F8FB7C731">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>3000</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>theophylline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76b11940-70b9-4605-b45f-b88a94709215">
    <domeo:uuid>845e73d1-0fd1-4b34-830f-4301e1c6b9df</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2326c666-5bf7-4e4f-aaac-b7e00816423e"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ECEB36F8-4F28-49AD-81C8-67E8B7F65193">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>5</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>haloperidol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:443bb69e-a4f9-40b2-964d-0cac7fb8e46d">
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ba9a793a-8751-4a7e-b37e-c92df7aabc6d"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/cf0e80ac-c635-4e33-b351-c50b0fbfe8a3"/>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/803C4BF5-3D5F-4649-8090-A66824A336D8">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>quinidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EF1AAC1F-B881-4B69-B143-00BDB343D713">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdfs:label>citalopram</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a29bae01-5bfd-47e1-901e-b472ca98b3a8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>methotrexate</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6851</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93E8EC02-1118-4CEE-B069-37762643AE77">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <ao:exact>propafenone </ao:exact>
    <domeo:uuid>93E8EC02-1118-4CEE-B069-37762643AE77</domeo:uuid>
    <pav:createdOn>2015-11-04 14:17:29 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:93E8EC02-1118-4CEE-B069-37762643AE77"/>
    <ao:suffix>and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problem</ao:suffix>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDF014D5-9BA2-41F3-B475-04BE0F75E220">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> tricyclic antidepressants</ao:exact>
    <ao:prefix>is reported to reduce hepatic metabolism of certain</ao:prefix>
    <pav:createdOn>2015-11-04 14:16:43 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CDF014D5-9BA2-41F3-B475-04BE0F75E220"/>
    <ao:suffix>, thereby delaying elimination and increasing steady-state concentrations of these drugs. Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine. Increases in plasma levels of tricycli</ao:suffix>
    <domeo:uuid>CDF014D5-9BA2-41F3-B475-04BE0F75E220</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6F9A8E2-D161-434A-A757-17E6930A3624">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C6F9A8E2-D161-434A-A757-17E6930A3624"/>
    <pav:createdOn>2015-11-04 14:13:56 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C6F9A8E2-D161-434A-A757-17E6930A3624</domeo:uuid>
    <ao:prefix>(TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D04845BF-A522-4128-ADFE-03C7500CDDBA">
    <pav:createdOn>2015-10-27 15:31:40 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:51946AF2-3A64-4436-A921-46849FF1FA53</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C58821FE-777A-4A0B-85F8-35EEB478ECFF"/>
    <pav:lastSavedOn>2015-10-27 15:32:38 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/42095240-C276-4989-B7B1-45C3FE90A30F">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
    <rdfs:label>flecainide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2406bca5-3882-400d-8ee4-1cc95b55d4f1">
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:prefix>er tricyclic antidepressants.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>46ce5b50-8933-47a2-adc2-ba9a905daef7</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48718b8f-1251-4d8f-8529-887877b19deb">
    <domeo:uuid>364445a5-c7df-42dc-bc79-cbe30581e87c</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9035692c-e9a7-4faa-b26d-7c52cdfdf0ea"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:99001f4e-5658-4154-80c1-eb368f40e204">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0016e129-8dc1-40dc-a6a6-4bc18374bf8d"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5b942e9f-0e12-4630-8a73-79090a6c9a76">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>rosuvastatin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8572A816-EAC0-4E94-8660-CE9845A27143">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>thioridazine</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10502</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:151B5405-B27C-48A0-BC2A-C8AF24078CCC">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E47DA08F-E823-42A4-91F6-0B5368E43338"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N63d377f3035a4874acd1f60c043e5fa5">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF06E08E-6D7B-4118-AA3F-FDCB992EE01F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-05 15:32:36 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BF06E08E-6D7B-4118-AA3F-FDCB992EE01F"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:77bdfe3f-1db9-4d6c-938f-66f80a6ad533">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:b4c1b7c7-ce79-41dd-84a5-33883b2edf98"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2517CCDB-7361-427B-A1E1-E06897A6750A">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B14001E8-4F68-4FC8-AC34-6F1A8A1AE85C"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5f4e182e-5b18-43ca-89a0-e58769bb7987">
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N9281d5f6882949c68e5e4d5fc6e96fa1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:bca5edf3-fdea-462c-ab45-93d161f014ae"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:3dfd529d-fed5-4fb0-a666-bdd21ed50ca9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2069810b-be47-406f-8cf3-127927cb2e27">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>Teriflunomide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N963d857fbdc245f2ac8934992feeadb3">
    <domeo:sets rdf:resource="urn:pddi:uuid:151B5405-B27C-48A0-BC2A-C8AF24078CCC"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6A7AAB68-7C3F-49E6-965D-661F2C8FA5D9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>bupropion</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ab3bc48d-0889-4faf-bd1d-5dcd0d61fb73">
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ddffd58b-f05b-48c5-9676-1772bfd65429"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/df78b232-98c6-476a-be03-35522815c3ee"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12></dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc105c42c3c6e41e08e006d8c06660616">
    <domeo:sets rdf:resource="urn:pddi:uuid:35033243-7C72-414E-8B8D-BEBBAA2FD1E9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:fbd5b18d-d3bb-47a6-9be8-e2b6dc7b9fdb">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:032ea422-f1c6-4ed5-8aab-abf65c9b167a"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:31F7988B-A343-4386-A6B3-301A3B602FDD">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:74785AAE-1127-425F-A8ED-83190C7E022C"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E5102D91-A2DF-46A9-B69F-2D0EB2D43E4C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F9EF5409-587E-4F77-B13D-B8BFCDED8352"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0bc47882-a472-4219-9929-d13a5bc2e2e3">
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5fa4ec36-ea6c-4a67-be20-3c89dd3664ab"/>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/265ed95a-fc92-45cf-9756-6238fc5d0179"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B069E0D9-6E39-4993-8F5C-A90012A6CAF6">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0A3ADF2B-84D6-4FA3-9139-5B6F044C5491"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1a58d1a8-7450-4fe3-8fee-36865e64b6f9">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:703f6d49-f622-4114-b7ae-3038d70cc2f4"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5d6fdcc9-7144-47e6-90a9-acd95a63513a">
    <pav:lineageUri>urn:domeoserver:annotation:69e2d236-aba7-43e0-8f71-2008d576e268</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-11-02 14:30:38 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FFE6496B-5EFD-4728-A5B5-AB339211F0D6</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Nc67639aaf20142e1bef801038ed4f534"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:44DCEE28-2526-4FEB-9778-BE97FA2BDF6D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d7e30ee7-64cc-4b9b-b0df-35977d585583">
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:aeabef64-10aa-4cff-bfd1-57947c52fc78</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:e64b8c1d-4d57-4486-bd02-58ea8058d1a9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N6adec9118a3c4045898fe95f68cd78f2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51624579-d062-408c-ac03-82f5474706e2">
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N17469ec254584c12aafd9c264b733c90"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:2a37e03a-6007-4e42-a601-d3fbe8fdfbcb</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:b3338899-2df5-494c-b67c-e12f818c96b8"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:7CA24CE0-A689-41AC-9467-CE01C89837EE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:866ea3c1-fb9d-49fe-a09a-6cb40aa85284"/>
    <pav:createdOn>2015-09-03 15:51:47 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-27 14:13:01 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:1e3ed9f9-c926-4fe1-a085-165a31f480ba</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:C9052A3F-13B2-4F81-98B0-25A3EDAFC34D</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Nd21f8eefbb664b4498f17a57565d6b79"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/212ff18e-8660-4823-b55e-414f6a337d58">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7831d7737f4f4c5992ef0fdd666ec28b">
    <domeo:sets rdf:resource="urn:pddi:uuid:972A90A0-83CC-45FE-A3C9-1EAC24C5ED7F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ba159dc1-909c-4c0f-958b-c943b18244e6">
    <pav:lastSavedOn>2015-08-20 12:53:42 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-08-20 12:53:42 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:b2279feb-58eb-4e23-888e-d82bd5091366"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0d2ed214-64bc-4a5f-9a98-f6020cf8a4c4</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N7aaeaa532d214ec9be038ec2fef6b056"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/19da5b87-4a74-48de-bd68-ab77513ec9cd">
    <dikbD2R:dose>1.5</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>Savella</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:51FD3734-7223-4B4E-9A91-A00D5B0D8C2A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:232c5b44-11b6-4304-adbc-3a228f5b5f20"/>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N4cd158f1c92a45b497cf2d20ccd9d84d"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:2b019d5a-da56-4736-b9be-ee1f71bbb805</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>urn:domeoserver:annotationset:11B130C5-41EE-4EF1-9836-F7B34513440D</pav:previousVersion>
    <pav:lastSavedOn>2015-10-27 14:13:01 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12fbf759-09a9-4021-be31-50135eb8e847">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>d3fe7599-0178-4050-984a-8ca39430925f</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <ao:exact>Antipsychotics — Some clinical data suggests a possible pharmacodynamic and/or pharmacokinetic interaction between SSRIs and antipsychotics. Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant fluoxetine. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:555B1075-C935-454E-9F61-0D1D762CE9F7">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-16 15:31:12 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:9fef9a75-6463-4465-a536-26bc7f9c1e96</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N124da2e9727c4a589fad9b14a9b1343a"/>
    <pav:lineageUri>urn:domeoserver:annotationset:d4a9d5bd-89f8-4b38-8d3b-dd36ff53a4ca</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-28 16:36:26 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:bd882a7c-3cdf-4966-bac9-f2170eb6535f"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F84CF2A5-400B-49CC-8DE4-63DCB5246C8C">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:93E8EC02-1118-4CEE-B069-37762643AE77"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-11-04 14:17:29 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e77fa0f8-efde-475f-8cb1-5c7a486b502d">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8134</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>phenobarbital</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/063B1786-DA9A-4C73-A2E8-C02A93F0993C">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>triazolam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d3e49d27-223f-43bd-b7ce-0ebdfda869a3">
    <domeo:uuid>ce0c4c0f-5083-4dd2-824c-c4e3d51c6fff</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs. </ao:exact>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:972A90A0-83CC-45FE-A3C9-1EAC24C5ED7F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:78823B07-A365-4BD6-B202-E748D9BAE895"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/cae3fc36-8a22-412e-a360-864098cf8258">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/73044</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>repaglinide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:2F072DDC-B8A8-4A79-BB67-C247D90426BC">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:08150f78-ae3a-4d4b-9577-61432401e9a7"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoclient:uuid:f56f7e89-e14c-4b5d-82ba-655c28d36c86</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:5939636c-ad89-4ef6-9b3f-fd77bc99863a</pav:lineageUri>
    <pav:lastSavedOn>2015-11-02 14:32:17 -0500</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N19c20ee5784d451d89c8326b7f00abba"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/df78b232-98c6-476a-be03-35522815c3ee">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>Teriflunomide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/107d6308-5a3e-40ae-8437-f7d748d8038f">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
    <rdfs:label>flecainide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E9A62C43-6B82-4022-941D-B3F31E2037BC">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7f1eb49a-1695-453c-93d9-6f76e2c5476c">
    <ao:prefix>nsporter 3 (OAT3) substrates   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <domeo:uuid>ef744892-5e1b-4d18-83e0-cae57865a8b9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4afa184f0b994f64a3c26449f2699822">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B31243FB-9E7F-4F0A-A2E9-77182523168C">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:1C52059B-6935-480B-BBC7-0C6D4BB1DDB1">
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/3cf2c7fd-04e6-44b1-a8b5-c05ab452168d"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E873080E-D1C0-4492-8281-8417A78248C7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5c6bba8f-dc3b-4ef3-8c9c-70e35edc08ff</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:31F23EAA-072E-43E6-BFB7-012238CA5CCF"/>
    <pav:lastSavedOn>2015-10-29 11:11:52 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
    <pav:previousVersion>urn:domeoserver:annotationset:2FFAB85A-7765-44A0-A9D5-6C954B21AF9F</pav:previousVersion>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:createdOn>2015-10-26 15:41:32 -0400</pav:createdOn>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:B3BA8F70-5D65-457D-999E-A4E6CB5137FD"/>
    <permissions:permissions rdf:nodeID="N952c12fe9c6d47eb95f8a19bfc9f5be9"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8AB883F9-D79C-4C6B-88B5-EAB2092BAA10">
    <ao:item rdf:resource="urn:domeoclient:uuid:46f84712-993b-4f4a-8501-fe9df5e71602"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:42d5421b-8262-4b8d-b5a8-f78b2d7cc977</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N8250874737564521bba77ac68f09102f"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-11-02 14:27:26 -0500</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>urn:domeoclient:uuid:7b4e530c-01c1-473a-be72-8a1bbad20aa2</pav:previousVersion>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/d97aa291-5e7a-40c0-aad3-dc1b9ea32c0b">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>barbiturates</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:47CCA907-5E9C-4A08-BE7A-219B08F913A5">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CA514CC0-BCF8-4CAE-BE3F-314D067D5647"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B94199DB-287D-46E0-B629-9A861CE8EC38"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ae5ebd88-e5d8-4712-9e87-93de42d0fed4">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>quinidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ef1ac1e2-2eed-44f0-9309-d28da1e19fe7">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:51b5671f-d8ab-4e44-8c5e-db15b210ae8c</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:68EDB648-003F-448B-A9EF-8C7FC80FF1E9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-02 14:22:34 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Ne53b2f6ceaf84b638976dff49490419f"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E3A13CB0-7535-44B0-8414-4FAB8BBFD4F0</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:71d159cd-b93e-406a-a11e-3b921f522c38">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0bc47882-a472-4219-9929-d13a5bc2e2e3"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F9C5A907-6A52-42A9-AA16-553C4FABE5CA">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>N-desmethyldiazepam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09a39c26-b9ce-4012-837b-8b5454eae147">
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Ndf0a3d147ca94378bbdf3756b786ed77"/>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:eb6b38cf-162f-43b7-b2b3-4c2a03c09a53"/>
    <pav:lineageUri>urn:domeoserver:annotationset:b39e476c-f988-4acb-9840-96306e16484c</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15a0b0bd-fd3a-4ca5-b348-79c5ced27e55">
    <ao:prefix>nsporter 3 (OAT3) substrates   </ao:prefix>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <domeo:uuid>d675be84-3fe5-4d83-8cec-1847b523f551</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:271e06e6-c2a5-4f25-bbde-106cd9b11328">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:fa3818b7-af78-488e-94cb-62f1c88d7f96</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:723DE511-9EDA-4737-8867-821FAC432FB5"/>
    <pav:lastSavedOn>2015-10-29 09:04:02 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6382E5B8-141E-425E-B811-E264B7FDC891</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Na55e078f39394ec8983ea14eb026437e"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:802E8BCE-9C50-4403-B034-CA9D0463799E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A641BC7D-7B49-47F4-9F72-4B9DE3EE1D3A"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87d3a626-d9cb-4012-aca2-d11f64351fb4">
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>f9326076-8aaa-4fc1-a837-95831feaa702</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C97D3CCC-8D48-4625-816A-4AF220ABDAEF">
    <pav:createdOn>2015-11-04 14:20:14 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>C97D3CCC-8D48-4625-816A-4AF220ABDAEF</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C97D3CCC-8D48-4625-816A-4AF220ABDAEF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1CBC52AB-2630-4311-A3B2-FF9304FA9A5A">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:createdOn>2015-11-04 14:13:38 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N0e786c44136e48b0847a2dda851d5104"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:F223AAD7-61B3-4FDE-A312-D56D24FD2C57</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:AC007E85-5B0A-4100-A5C4-5502104C8066"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e8c95c09-f673-4c0d-a38f-5c1c9d179877">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3443</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>diltiazem</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FEFD790-8DD0-423C-96A3-E861C6A7B48A">
    <domeo:uuid>9FEFD790-8DD0-423C-96A3-E861C6A7B48A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9FEFD790-8DD0-423C-96A3-E861C6A7B48A"/>
    <ao:suffix>, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which S</ao:suffix>
    <ao:exact>phenothiazines</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <pav:createdOn>2015-11-05 10:36:36 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7AB8AE53-31E4-42BD-BDB1-B0F1162CA000">
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:db1c2961-ffcd-4d04-9652-aa5d00dd98fb">
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:9b3b333f-6948-4090-9996-5ddb144fdd06</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nc75d721ea2114ee19f593491b85308c1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:10ffc8d3-87b6-4271-a772-4c1fdd0a0d19"/>
    <pav:lineageUri>urn:domeoserver:annotation:52c669dd-a0ed-42d2-adf5-8c28e6145121</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a4f5eb61-abfd-40ed-bb0c-6f30d6a9b611">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <domeo:uuid>82ce2a97-00f6-4734-b0cb-f597a7bd8316</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:e42724ce-4281-4724-b99c-179e97146f35"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2b6799fe-0cf2-4f62-a5f5-6c8cb9a6063f">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-28 17:20:12 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:5282e848-46e0-492a-8d23-cba9c05696db</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:71785B52-CF7E-41E2-9AD6-03F6ECE94463"/>
    <ao:body rdf:nodeID="N12887919935c483eae639dc18b72cd27"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:46EF9377-2982-450F-9837-22275F6A0C45</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-24 15:38:09 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B5AB9A73-5222-4C33-9092-E09514AD7770">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>2</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <rdfs:label>pimozide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A79EDC8-2A07-4FC3-9988-642EA225CB1D">
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-05 15:28:30 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7D04949A-A207-4CA1-B998-93CDE7625313"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:830D5D6B-C940-441B-A31A-9B0C4421863B</pav:previousVersion>
    <pav:lastSavedOn>2015-11-05 15:28:35 -0500</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3262D20A-7712-45B8-B166-CD95455FCFCF">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8E3EA5A4-6470-4DF2-BF35-A040F9630D32"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CC0E5AE8-5540-446A-A5AD-05FDE3F4CD03">
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8572A816-EAC0-4E94-8660-CE9845A27143"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6610A0B6-E6CC-4C1F-B588-4DDDF4CFDEF8"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/12DF7F9B-CCC5-4505-A6CD-A659B835AB25">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10318</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>tacrine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:914834f9-7b6b-493a-b5c0-3172b1a4b0f2">
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9cf9b37e-236e-4191-83db-2d6e99958800"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/d2c6aa03-a7e7-469a-8d09-323566d6c23c"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94B2550C-10F2-44E2-B860-6F6B9674F815">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).    In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).    Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <pav:createdOn>2015-11-05 10:38:45 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:94B2550C-10F2-44E2-B860-6F6B9674F815"/>
    <ao:prefix>Drugs Metabolized by P450 2D6   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>94B2550C-10F2-44E2-B860-6F6B9674F815</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3659834C-2F17-4669-BB95-9C4C8E5456D0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>24</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1CE1A55B-B661-46D7-9CE1-7148E5B176CA"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7039FFB8-1DA1-4ED1-9955-F08DBF8AE21F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7a732bf1-9a34-43c0-8a62-aff60e4b943e">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:86e9a542-be4f-48a2-bd2a-040b33f0be44"/>
    <domeo:uuid>70e6cf6f-32c9-4c59-ab57-b5d62403e88c</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8B5439C9-8621-4444-952C-A806A7DD7A2B">
    <rdfs:label>imipramine</rdfs:label>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BA7C9D31-CBDC-48B2-A42B-0A592E676B26">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8134</dailymed:activeMoietyRxCUI>
    <rdfs:label>phenobarbital</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A1272DD0-7D73-4991-A96B-45AF5CA58117">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A80025D9-244D-47CF-A16A-810A6FA92A8D">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-05 16:08:53 -0500</pav:createdOn>
    <ao:body rdf:nodeID="N929ca454053145b5b9d8482cab88c540"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">24</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:4E285678-094D-4539-9200-4A5C0E18223A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D3E0B9A2-A8CA-469F-99FD-FCF42D346320</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 16:08:54 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D09BD622-2E80-4419-9A99-34C81624511C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B80235F-B5BC-4011-9742-F1F77077BB69">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0B80235F-B5BC-4011-9742-F1F77077BB69"/>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <pav:createdOn>2015-11-05 15:33:12 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:df313953-f237-4ac9-8f20-53c8c165a57e">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5E34683-BEF6-4995-AC59-BA347353C443</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:40ECC315-F67E-4FAB-862E-13DA8D9AD510"/>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N05118991901b491f835d02ca4a7d7d30"/>
    <pav:lastSavedOn>2015-10-27 15:39:59 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:c6e0920d-f711-4f93-aa5c-b9e135f2508e</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BBE22183-ABEB-49DD-B386-838584CB7566">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc314a25863af42e78fb5c1964934cb7b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:02d78a6f-2c4b-446b-acef-dc3312221f4f">
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/95f14f59-8a3f-4761-9fa2-9d08e3b72ac6"/>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/56eb2747-593f-4cfb-990a-0a6bd4a08663"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmax></dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8e57484f664747cb96bc9cb0acbb9354">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F47B4D44-9141-45AA-BA2D-69BE6D04B04E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-27 09:16:42 -0400</pav:createdOn>
    <ao:exact>PROZAC</ao:exact>
    <domeo:uuid>F47B4D44-9141-45AA-BA2D-69BE6D04B04E</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F47B4D44-9141-45AA-BA2D-69BE6D04B04E"/>
    <ao:prefix>When using </ao:prefix>
    <ao:suffix> and olanzapine in combination, also refer to the Use in Specific Populations section of the package insert for Symbyax.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b2d493e4-2cbc-42b6-97ad-aca9c5fa01ff">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nad89d75f2f1645dab8c73a09ad8fab41"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:d69638a8-bef1-40fa-9e3e-eb912a161768"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:8df72857-4adf-4980-80a6-fd7d959412f2</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:e974deef-90c6-4c49-8711-f7b9700e01c9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/54951BA2-4D81-4CF4-A27E-83C6E2C639D8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N69e0cef487574bc7897e7fb6f6f71b11">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AE60F2E4-4C0D-47F1-AB91-BF564DE9343C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A0C16A5E-F5CE-4CE5-AC78-BE8D72CD75EF"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N71863d7eadb746dc90392781a6be377d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6c86458a-def9-4c7d-8118-996ee2bbbd0e">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:10375a83-5d58-478d-8b53-d21699603367"/>
    <domeo:uuid>4a0300e0-708e-4153-b438-b7eb1234f0f8</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C9510408-CB6F-4DF4-8397-9CC1702F1F95">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3659834C-2F17-4669-BB95-9C4C8E5456D0"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c809d21f-3eea-4d1f-9a00-c946168f1bb9">
    <ao:context rdf:resource="urn:domeoclient:uuid:134682C9-0DBD-4749-9801-00B84C5475FE"/>
    <ao:body rdf:nodeID="N1ebfa00d6cad464584a25cb191632d5a"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:43D68940-BA31-4A9C-9ADD-320B16D178CB</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:3ac00f3c-96e2-4e9a-9251-0b2c10356b9d</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-11-02 13:32:33 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N486bfc90d0464f0c8a011eef882f38f1">
    <domeo:sets rdf:resource="urn:pddi:uuid:7574aa93-c0db-4400-a114-79a677666162"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ad2e2f34-5481-4a9a-89a0-bf56f1a4f3fd">
    <pav:createdOn>2015-09-14 11:03:10 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nb3e73c51516c4ccfa8e01d05cc9268b4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:7ef6d86d-8e4f-4200-bdaf-9f612108f830"/>
    <pav:lineageUri>urn:domeoserver:annotationset:e4529f2d-7925-45a1-9c0e-67fbd3468c1b</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-09-14 11:03:10 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5E48D73C-7A2F-416F-B21A-E5DD5408A5CD">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>theophylline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N28e9951569e14893abbcb5feb0b08fc3">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F409B11-21D7-490C-B8BA-422F298573A3">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <domeo:uuid>1F409B11-21D7-490C-B8BA-422F298573A3</domeo:uuid>
    <ao:exact>Drugs Metabolized by P450 3A4–In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).</ao:exact>
    <ao:prefix>dDOSAGE AND ADMINISTRATION .   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-28 16:35:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1F409B11-21D7-490C-B8BA-422F298573A3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:46EF9377-2982-450F-9837-22275F6A0C45">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoclient:uuid:0689ed70-8dcf-45fa-93a0-1d9e2b8197a9</pav:previousVersion>
    <pav:lastSavedOn>2015-10-28 17:20:12 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c9ae1886-8dea-45bf-8ae7-6c3410c03988</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-24 15:38:09 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:2b6799fe-0cf2-4f62-a5f5-6c8cb9a6063f"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N2ebf8e0974af4f6193c47394b48f86e1"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3EE42BF-EB88-4CA4-8F5D-EA836AFCAEA1">
    <domeo:uuid>B3EE42BF-EB88-4CA4-8F5D-EA836AFCAEA1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B3EE42BF-EB88-4CA4-8F5D-EA836AFCAEA1"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>is not an inhibitor of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, P-gp, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2. </ao:prefix>
    <ao:exact>Concomitant use of FETZIMA with alprazolam or carbamazepine, substrates of CYP3A4, had no significant effect on alprazolam or carbamazepine plasma concentrations </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-29 09:44:52 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b3340703-4ecd-4c48-bcb4-9a4b2ae1239e">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>80</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>propranolol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:189EF30F-86D5-4DBC-BBBB-57E7B9584324">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N34c23da5575b4d659356a7c16d88dd6c"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-29 10:48:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:b094b71e-0898-4dee-83d2-e07642db1ae9</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:0d62acf7-6f15-4585-b6b3-8bf0427d94cb"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:b69d8a28-f237-441a-90ab-9b8c99f4b939</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:00D5E0CF-2682-4CBD-9DED-38CA8C1BA3B6">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:13A964AC-D51C-49B5-AE90-6BCCB6688028"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0072395E-ECD2-44E5-BF74-6A08E239FD85">
    <rdfs:label>Ticlopidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2E25F195-3CEF-4BCA-983A-991D62B647DC">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdfs:label>citalopram</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N88c1b52b5ca5496d9c25101144216c20">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na43fc9b358b24bd3a8c6da9a11e70c54">
    <domeo:sets rdf:resource="urn:pddi:uuid:2e5f4573-a267-46db-86da-7769df974504"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92FA08EC-8F77-4381-A0D0-783B6EFFC898">
    <ao:context rdf:resource="urn:domeoclient:uuid:5D54B9F3-0F7E-4060-A5C8-530585B6D27F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:9540ed61-ff6a-4399-86bc-04d7b87b26df</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-29 10:39:43 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E536FE66-FAD0-488D-B7C0-39E59CBD9678</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:e5208d0d-d470-424b-a0e0-4a4b5da16c0e</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-10-29 10:41:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b1137d71-70f4-4a68-af08-55209a1dfb87">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:3901971F-C222-471B-A82C-004E188A07CA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:E42BA8F8-37D0-44F0-A473-B7C3920CEC7F"/>
    <ao:body rdf:nodeID="Nee98f17fd56a4b8da03521d0c633896e"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-29 09:30:25 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-24 15:47:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:d940b726-8e1b-4715-ad08-6f619aced9de</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89e4d45a-8a7b-43e6-b823-9bbfcfb1f959">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:89e4d45a-8a7b-43e6-b823-9bbfcfb1f959"/>
    <ao:exact>REMERON</ao:exact>
    <ao:prefix>the individual investigators. Patients receiving continued </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> treatment experienced significantly lower relapse rates ove</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <pav:createdOn>2015-10-26 15:40:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C58821FE-777A-4A0B-85F8-35EEB478ECFF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>When </ao:prefix>
    <ao:suffix> (50 mg t.i.d.) was administered concomitantly with warfarin for 2 weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged. Thus patients receiving oral anticoagulants and fluvoxamine maleate tablets should have their </ao:suffix>
    <pav:createdOn>2015-10-27 15:31:40 -0400</pav:createdOn>
    <ao:exact>fluvoxamine maleate</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C58821FE-777A-4A0B-85F8-35EEB478ECFF"/>
    <domeo:uuid>C58821FE-777A-4A0B-85F8-35EEB478ECFF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9008893e-5e9d-469c-b6fb-8900023b8b76">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>50</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>milnacipran</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E40278BE-0FB1-4BD1-9F5B-FE798B960907">
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E40278BE-0FB1-4BD1-9F5B-FE798B960907"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-27 15:35:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E40278BE-0FB1-4BD1-9F5B-FE798B960907</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9FCDCE17-D5EF-491F-AD49-6CD4BC4B8359">
    <rdfs:label>nortriptyline</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7531</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2615D048-46FA-4557-B691-24297A4787D9">
    <poc:MedicalCondition>tmc</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8308F0B0-CAB5-4632-971F-2B697F113C03">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>metoprolol</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6918</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E5C2F9ED-2BA2-4EA0-875C-8A421F00DBA8">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6A66CE40-FD62-418A-8033-06BAC3DD9E03"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/76C7D088-D503-4353-BB0C-3EE5F74F920F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:99285CF8-1BA4-4B96-9DD0-3BF3B88D7585">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CB51C0E9-51E7-4453-A999-418ECC4D4271"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a0d575c2-9934-435a-880f-dae07fa4a961">
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>64c3b51b-cb8d-4f64-9ecf-ebb723443e74</domeo:uuid>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b2e96e76-d0ed-49f6-abc6-bd3f41f28444">
    <domeo:uuid>dc6b639f-f15c-4c7c-9cf1-0bf21a0cd1ae</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:bb8d6d07-ae0c-42ae-a1d2-bbd3cc12e908"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2be91561ea6240cfbd0bb24919bc60bd">
    <domeo:sets rdf:resource="urn:pddi:uuid:dd6c9163-7c76-4f6d-95bf-01ec0ab95a98"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C81AD14-8F85-443B-8E85-57A5D1A07D70">
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:04A94528-5E42-4250-A1B6-C2E5309A5ED7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-27 15:25:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e16777bc-550b-41fc-9feb-032edee4e05f">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E285678-094D-4539-9200-4A5C0E18223A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>erythrohydrobupropion decreased by 48%. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 16:08:53 -0500</pav:createdOn>
    <ao:exact>In a second healthy volunteer study, ritonavir 600 mg twice daily decreased the AUC and Cmax of bupropion by 66% and 62% respectively. The exposure of the hydroxybupropion metabolite was decreased by 78%, the threohydrobupropion decreased by 50%, and the erythrohydrobupropion decreased by 68%. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4E285678-094D-4539-9200-4A5C0E18223A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:349c3be4-5feb-4ecc-8740-53ae1a7badbd">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:ea9f1b28-8113-45c8-8df1-3eafe598674d</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N49623bff5e7344f9bb708a06c5c8ff79"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:6652583d-8abd-4b79-8d53-9342b9af5c0b</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:af9e06ef-d5ac-4d26-bc27-a356259891a1"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E320F65-4CEC-42FF-AD4B-2FD2CA437883">
    <pav:createdOn>2015-10-29 10:40:38 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1E320F65-4CEC-42FF-AD4B-2FD2CA437883"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>  Ketoconazole  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>1E320F65-4CEC-42FF-AD4B-2FD2CA437883</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:exact>In healthy, male, Caucasian patients (n=24), coadministration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30-mg dose of mirtazapine by approximately 40% and 50%, respectively.    Caution should be exercised when coadministering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, or nefazodone.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA56DDC9-04A4-4F52-8E2A-FC8244334FD7">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:prefix>(TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>CA56DDC9-04A4-4F52-8E2A-FC8244334FD7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CA56DDC9-04A4-4F52-8E2A-FC8244334FD7"/>
    <pav:createdOn>2015-11-04 14:14:49 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14a183fe-fa54-4111-94d2-92007999254c">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:7a05e3ad-a367-4086-8846-6403343f29f2"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N3d9078c856da4971a457279e8bb10bdd"/>
    <pav:lastSavedOn>2015-09-29 11:41:50 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:2586d780-f0bc-49fe-bf1a-9edb11cbf072</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:d7f6f33e-808d-4e62-a88c-2fd79dbed552</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-29 11:41:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A8AD40CF-1945-442D-A3B4-373AC8E7B15A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A8AD40CF-1945-442D-A3B4-373AC8E7B15A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by CYP2B6. Therefore, the potential exists for drug interactions between WELLBUTRIN XL and drugs that are inhibitors or inducers of CYP2B6. In addition, in vitro studies suggest that paroxetine, sertraline, norfluoxetine, fluvoxamine, and nelfinavir, inhibit the hydroxylation of bupropion.</ao:exact>
    <pav:createdOn>2015-11-05 15:42:41 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Potential for Other Drugs to Affect WELLBUTRIN XL    </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA7D4A21-4CAC-4E78-9AD8-CA536C05579C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-11-05 10:29:48 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:36030F86-5D53-4309-A621-31A9BDD46219</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:351413C6-5C39-455E-AE02-4CDA416BEEBE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C7804B5F-7695-4935-B702-077D589B2F8B">
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">26</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:4CEE8D0E-B023-48E0-A038-A0024F43A84E</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:24F2C0F8-FD20-4342-ABBE-3799C1E2D587"/>
    <pav:createdOn>2015-11-05 16:13:25 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-11-05 16:15:31 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7f8b6f90-796b-42c9-bf4c-3fd14f71173d">
    <rdfs:label>GILENYA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9126986A-EA0F-40F2-8C3C-C3EBCC310D69">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Triazolam - Combined administration of Celexa (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.</ao:exact>
    <pav:createdOn>2015-11-02 13:47:37 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <domeo:uuid>9126986A-EA0F-40F2-8C3C-C3EBCC310D69</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9126986A-EA0F-40F2-8C3C-C3EBCC310D69"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4FF1CE8-CD65-4C89-A734-19251BD03557">
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-27 15:22:25 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:EF728104-9086-45A4-8249-7CA437C8FDD7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:634DB228-84C4-453E-B4AD-9A29DAB711AB">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6351F1D0-8091-47FF-9C3E-F0AD612A8179"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:495218a3-bff6-4895-b9ba-e63ce67758c6">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N102c8fd8233a40c4a2332586df560953"/>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:104925a5-f4f4-4e22-847b-46dc8b76ed96</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:caf1bad2-4ee7-4e5e-9d63-bfec180cb1ad"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:1ffbb219-39f6-4c21-a69c-5b7968802a7f</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48E7CC6E-29ED-4979-A040-C521F1CBBAFA">
    <ao:body rdf:nodeID="N24fdaf4d08574618bcfa99bb9044106d"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D205CAB4-5679-4CCF-B936-6403E5A4E3C6"/>
    <pav:createdOn>2015-11-04 14:14:19 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:DD89BABF-778B-4DAA-A32C-E240FE63B94A</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9A9EB19-D8D7-495B-B220-E480F358A6B4">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N88ebd42f3b4b4719a75f10c80909ed03"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F361E9BF-3C74-4E3F-8B50-485E7C009AE8"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-04 14:21:12 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-04 14:19:55 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:5BA53462-495D-4BB1-8674-10326634A9D1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:668dee0e-0ab8-4a79-8c2a-06749351688c">
    <permissions:permissions rdf:nodeID="Nff9472b2ead046e6a2f8743d3671be1d"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0cbbb50-7468-4584-886f-07dd536cf0ad</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:da032526-108e-48be-8a0a-c878f4ae79b8"/>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4a820e80-98f5-47e8-805a-05a2d56144eb">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ff49bf15-7f16-4836-838d-b8e6694ae732"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N739d9d380ccc4cb881dec78e728212b6">
    <domeo:sets rdf:resource="urn:pddi:uuid:5B3BA270-4E36-4CF8-B0E3-525F6AB4EC49"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1F66C45B-3D3D-4E17-817A-7F28547138D9">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/770FD37D-7B87-4FAE-8BB4-C357DCF90F3D"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>21</dikbD2R:objectDuration>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AF8B21B0-31C4-487F-B745-EF0BA3079B91"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CE687A17-81FB-420A-8A08-AFC4D6A37E72">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Celexa</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E198D86C-C690-4917-8A99-E227F400F74B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>prasugrel</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60aa1780-e126-4f63-84f8-37baa7ad7c05">
    <pav:lineageUri>urn:domeoserver:annotation:41a3e60f-52d6-4d3b-89d5-26fe2f6377cd</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:b60b8ebc-a9af-4ecb-b424-9987e1ce03ae</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:20976f02-5b6f-495e-bd1a-f679f827df40"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nc648fc5e78104a38827ab22a69404cf2"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:344BDBE4-D00E-4219-8F90-A1550269DB93">
    <ao:body rdf:nodeID="N2aece38644434b4bb38c2f4d58fcc10e"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lastSavedOn>2015-11-05 15:25:55 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:1EE88710-0B98-407A-B6EB-CAF24A7B0439</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E06FED75-7AA4-41F0-8342-8033A6EE4E2C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-05 15:25:08 -0500</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C470D42-9671-409B-9407-76C19FDF8DF1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>ucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of </ao:prefix>
    <ao:exact>tricyclic antidepressants</ao:exact>
    <ao:suffix> (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6C470D42-9671-409B-9407-76C19FDF8DF1"/>
    <pav:createdOn>2015-11-04 14:10:02 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>6C470D42-9671-409B-9407-76C19FDF8DF1</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:640C8BB6-6FA8-45D2-8960-97F7036356BE">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:8fbd22cc-66f3-4d29-bcf4-c442ccba846f</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:06debe12-5d72-48aa-8e49-5375b6342ed9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:921c5886-2078-4408-99e4-4c96d3848187</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nde63d9274eac4065ae23fae6c5e2c113"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na6c21559b8cc4d2985710a421e8f5dd7">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f5c41af5-a1da-4df3-9244-8c8e8faed15d">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nbc4cccc1f9ba491fbb3e4c156ade38aa"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:4782c563-4803-4885-a377-61bb9d1255b6</pav:lineageUri>
    <pav:createdOn>2015-09-16 15:31:12 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F52D3B9B-07D9-4910-A342-FF48AFE49DE8"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:89D701E6-757D-40AC-8868-90907A1298F9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2ede8d10-1816-43aa-a80d-2ba06c4492b4">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e356a273-ecfe-4063-8cd7-a1bf84eba699"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>2.9</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b64a0753-272c-4b43-ad9e-0c670a4de269"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmax>2.8</dikbD2R:cmax>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:efea82a6-b569-4370-ba71-b2c719f663fd">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>11</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f731032c-28e7-43c2-b0d4-2b859056d571"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/d4947c01-e7b1-412b-9ae0-5bd7059769f6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:bb124b9c-6376-4801-8be2-8f60efd73cad">
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/374a8725-725f-4371-b1a2-a1ba08c8ff2a"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/565a7640-175f-44c9-a8a1-cd0648ec76e7"/>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N02e3495cf15e43f681f03e521e919e6c">
    <domeo:sets rdf:resource="urn:pddi:uuid:4AA96B24-F8CB-42AE-A0AB-D97EE065E920"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/60b39a58-c1f7-46e0-9ba5-f8541ad22bda">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>theophylline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd1d3a27ede4f45e5b8133e546363f522">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1750C7E8-CF9F-4608-8DFD-584C1F264EDE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1750C7E8-CF9F-4608-8DFD-584C1F264EDE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Drug Interactions   Cimetidine   </ao:prefix>
    <ao:exact>There is evidence that cimetidine inhibits the elimination of tricyclic antidepressants. Downward adjustment of SURMONTIL dosage may be required if cimetidine therapy is initiated; upward adjustment if cimetidine therapy is discontinued.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <pav:createdOn>2015-11-05 10:30:13 -0500</pav:createdOn>
    <domeo:uuid>1750C7E8-CF9F-4608-8DFD-584C1F264EDE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3014BE9D-A10F-40CF-A616-5246B39213D2">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>    Alprazolam   </ao:prefix>
    <ao:exact>When alprazolam (1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coadministered with nefazodone, a 50% reduction in the initial alprazolam dosage is recommended. No dosage adjustment is required for nefazodone.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3014BE9D-A10F-40CF-A616-5246B39213D2</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3014BE9D-A10F-40CF-A616-5246B39213D2"/>
    <pav:createdOn>2015-11-06 15:37:49 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:772af0f4-6c30-4526-baf5-40a181be8d52">
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/c151acc8-599f-413d-b947-9a09a3c64280"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/262948f5-2072-447f-9004-c290946d3008"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/aa3585f6-5f57-4267-82b8-db4b44e634d2">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4dd351b2-54ea-4452-a1d0-9b022b88631a">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:b5a0fa47-e550-4e64-9983-f20df680f54f"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0a38cb0a-85d5-452c-8382-bc4a1ced5ade">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/48a619e4-1899-4755-a515-4b0f19998818">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f016cacc-2e36-42f3-8131-8f6ffc5ab26d">
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6ed80242-eb61-4dfa-aa6e-fc185ad808cc"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0e0f8333-4cec-403e-a5f7-80057758dd08"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2aaaf00e-8c02-4a33-a692-b2be9f942d88">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/92ff139f-ebf2-41c8-a3b8-60ce94ee3d43"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/19da5b87-4a74-48de-bd68-ab77513ec9cd"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0B4038B5-E006-4313-91F5-7CCCE46EA9AA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:601BFD5F-013B-47DA-8D37-376A25A6B3E6"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:comment>Increased plasma levels</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:82E3243F-7C87-4AD8-827F-7C4BE42771A9">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C986B85B-8F13-44FB-98D9-DF52F50FF1E6"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96E6C0DA-FDEE-4329-BA81-BE3E851AF0CB">
    <ao:exact>The coadministration of triazolam and nefazodone causes a significant increase in the plasma level of triazolam (see WARNINGS and PRECAUTIONS), and a 75% reduction in the initial triazolam dosage is recommended if the two drugs are to be given together. Because not all commercially available dosage forms of triazolam permit a sufficient dosage reduction, the coadministration of triazolam and nefazodone should be avoided for most patients, including the elderly.</ao:exact>
    <domeo:uuid>96E6C0DA-FDEE-4329-BA81-BE3E851AF0CB</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:96E6C0DA-FDEE-4329-BA81-BE3E851AF0CB"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-06 15:34:43 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>). Nefazodone hydrochloride tablets are also contraindicated in patients who have demonstrated hypersensitivity to nefazodone hydrochloride, its inactive ingredients, or other phenylpiperazine antidepressants.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c893fcc9-7b8e-4bb5-8e92-7b3efda86157">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>pregabalin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>50</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N44d00d4b81fa425da02189e0560f162f">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b9a2ae4e-e8b4-4aec-93f5-ca7f854b3244">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6a5e0107-c341-47e5-841f-a53765e2cb50"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e9a81ed8-0f9f-4549-bdb8-c35a76903a2d">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:80125efd-1e23-4aef-828e-721779e1e531</pav:lineageUri>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:93F2B1F8-F0ED-44F2-B364-46676A4A53D7"/>
    <pav:lastSavedOn>2015-10-29 09:10:04 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:41625D29-6F4B-4A7E-99A2-D244302C1BF8</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nb18536bda7044bfba216522ae2e30903"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:225c4d97-3709-4e62-9f8f-997db4488e12">
    <ao:body rdf:nodeID="N486bfc90d0464f0c8a011eef882f38f1"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5bc91b6c-1baa-4fe4-a629-cbb682593e72"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:f863f8c8-60b9-43c6-80f1-68b06586edc4</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:211cfe0b-c5b9-4b9d-ac40-bcae5c56aa99</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6d4555b2-cc68-423d-9485-1744eaf1c0ec">
    <pav:lastSavedOn>2015-08-20 11:17:13 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1a493233-368d-4d94-bb15-e36c7da09715</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 11:17:13 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:f988e802-61db-47f9-b5e3-f3afd5989f1e"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N791d8de2d3684c13aaa7e19217aadef0"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E29F518-DDFA-432D-8F0B-9022216435EE">
    <domeo:uuid>0E29F518-DDFA-432D-8F0B-9022216435EE</domeo:uuid>
    <ao:exact>nefazodone </ao:exact>
    <ao:suffix>not be used in combination with either terfenadine, astemizole, cisapride, or pimozide </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-06 15:41:55 -0500</pav:createdOn>
    <ao:prefix> to be an inhibitor of CYP3A4. Consequently, it is recommended that </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0E29F518-DDFA-432D-8F0B-9022216435EE"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C6A170C2-A5E2-4F44-A36D-4894970C211E">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N791d8de2d3684c13aaa7e19217aadef0">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9c1cb9cd-a248-40dd-888f-248b5558bec0">
    <ao:body rdf:nodeID="Nbb30bd37f2cb4c2dbe6e6e4087a1f102"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3ac7b267-4605-4ab0-9276-dce68f099dfb"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:c7b79d1d-fdcc-43c9-892c-ab4fc3156ffa</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:1bc41f21-b747-4089-b098-0b9708482aa0</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/78232219-A6A8-4D5E-A3CF-2D6771803AEB">
    <rdfs:label>ritonavir</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e5212226-b28b-4e3a-9d68-92b82fca3556">
    <domeo:belongsToSet>urn:domeoclient:uuid:3c3c8de2-3ec5-4c1e-b0ce-4d1102b85c1c</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:2b89682c-b231-4eef-9c76-bb463efa109a</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Nb58ac260616d4aaba5d090aa46fc5a6d"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:08adbe42-977a-4605-9ae0-b047bf6bc267"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EAB4D6B0-7033-47D1-984F-A7B24C4733ED">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4ACFC3E8-6973-4B6D-9ECF-AFEAC0DFFDD7"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6e7e82fa-aca0-417d-9717-a0e52fd9a692">
    <ao:prefix>e in plasma AUC of the TCA ).  </ao:prefix>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <domeo:uuid>13a98905-4131-4f4b-b2fb-483a3a5371db</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e559ac7f-bdc3-4ab1-be29-737343adf1d8">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:9fa11d20-7a47-4503-a4e5-0dccb1d780de</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-03 15:43:15 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:f48bf7c1-bfef-4c17-99cb-9dba33f9d7dc</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:84c31609-09b3-420d-af86-5786bd5b7545"/>
    <ao:body rdf:nodeID="N09408f4c10fd4bf6ab9f054bf2a670eb"/>
    <pav:createdOn>2015-09-03 15:43:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N91b49433a4914179bc6063f353e4dae9">
    <domeo:sets rdf:resource="urn:pddi:uuid:584c1bb8-4995-4d6b-aecc-acde9a1825d3"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/498c06fd-f756-4339-8883-6d8792b31ccc">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>teriflunomide</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:AFA8CC09-93EE-45C1-97FF-36A9DE513EBA">
    <ao:item rdf:resource="urn:domeoclient:uuid:6991e6a3-29d3-448e-95dd-682bf9fbdc3c"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-25 10:05:58 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-10-29 09:45:10 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:7689a7c1-2b6a-4876-8267-ccc9b7e0e6c2</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N6aef5e0edb2049008b0e4dc29e51fddf"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:7f8345d6-8c84-4382-88f7-64e6ed4c715d</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58F74976-17DE-433F-9D02-2ED2792B9860">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/906696AC-E2A8-48F5-B0AE-EC2C502258AA"/>
    <dikbD2R:preciptRegimens>Q12</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0823FCC2-AF2E-41AC-BCE4-4D74E1DF3E0F"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>Q12</dikbD2R:objectRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d256acd9-f09d-4421-b2ec-09fe46d412e6">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:2dc10cbd-66d6-4a50-8baf-b73787b0e7f1"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:8172188e-20d2-488a-9448-55d8b5327838</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nb4801bf589f44e59a46f796d6ddfa199"/>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:9bb8e9f2-452f-4f30-acc5-8fd4e343c78d</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/035f8aaf-3a12-423a-b5ef-a9de8521e8fc">
    <rdfs:label>Savella</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1F4C464-1EA2-4A8C-B7AB-47AE10A9D744">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>tricyclic antidepressants</ao:exact>
    <ao:prefix>inhibits the elimination of </ao:prefix>
    <ao:suffix>. Downward adjustment of SURMONTIL dosage may be required if cimetidine therapy is initiated; upward adjustment if cimetidine therapy is discontinued.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B1F4C464-1EA2-4A8C-B7AB-47AE10A9D744"/>
    <pav:createdOn>2015-11-05 10:29:52 -0500</pav:createdOn>
    <domeo:uuid>B1F4C464-1EA2-4A8C-B7AB-47AE10A9D744</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6ABC1A3F-1658-49EB-A538-AD58A2E168E1">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>escitalopram</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1b39f385-be6d-4f62-8713-188111981a62">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ca921531-4a26-4523-85a8-20ed1b4402c3"/>
    <domeo:uuid>3ec9b5f2-24e2-470b-a639-53c69ff92b2e</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:80695332-F519-4703-9434-46AA4D4746EF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>80695332-F519-4703-9434-46AA4D4746EF</domeo:uuid>
    <ao:prefix>(TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:80695332-F519-4703-9434-46AA4D4746EF"/>
    <pav:createdOn>2015-11-04 14:11:48 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99680311-2397-4C17-998B-D0286325C338">
    <pav:createdOn>2015-11-05 15:28:21 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:prefix> XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>venlafaxine</ao:exact>
    <ao:suffix>, </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:99680311-2397-4C17-998B-D0286325C338"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:820bf18d-5974-4514-9e4f-0e52c18f3847">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:4aaf6f09-9eb1-4dbc-9de0-0304c7682f2d"/>
    <permissions:permissions rdf:nodeID="Nbc2b17111c804e83a0e229d51dca1b12"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:7494a900-8f7e-42ae-99ea-887f03c506db</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:dd573506-ff39-49d9-81d5-4ae81d197777">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:b18792c1-08fc-4eac-bb98-ca8e64f57fba</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:5ece42ba-08c3-4709-bffc-ddcb28edbbb9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Na742c44b67b348e49fd0516501f0df87"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9DD1108C-1D41-47CE-B0A4-275E98FF1684">
    <ao:exact>Theophylline - Combined administration of Celexa (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <domeo:uuid>9DD1108C-1D41-47CE-B0A4-275E98FF1684</domeo:uuid>
    <pav:createdOn>2015-11-02 13:38:11 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9DD1108C-1D41-47CE-B0A4-275E98FF1684"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f29879d0-467a-4432-a31a-b37fb7c7d9df">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0f98c87e-21d5-4437-95c7-76c253ceec78">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0b09d906-f72f-4a52-8fab-c217ced719f9</domeo:uuid>
    <ao:prefix>e in plasma AUC of the TCA ).  </ao:prefix>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70621f87-7ebc-4737-b4eb-a89561877d92">
    <domeo:uuid>f4ede7c7-ba1b-4cc9-ae3e-577c0ab003b5</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <ao:exact>Anticonvulsants — Patients on stable doses of phenytoin and carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation of concomitant fluoxetine treatment.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/25102e78-a221-448f-b13f-2f0987d20e6b">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/57258</dailymed:activeMoietyRxCUI>
    <rdfs:label>tizanidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4ce6c94d-b81e-4b93-9601-87445b6b8889">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>bicalutamide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:24e474b9-768b-4b59-99f3-88d632e635df">
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucType></dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/26702a42-d4bf-41e8-8cf5-6d0f018c4c42"/>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/58b71b7f-cc36-4516-bae2-367144fbc149"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e1673257-113b-49c5-9174-5f33e5432297">
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/c31f853f-d27a-4947-8b9f-10e6ee093c4f"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f59ff367-3f3c-437a-a985-00d6a771509a"/>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Type></dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:68dded0b-c29e-4829-9269-00cd645485d8">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d2dd2caf-dddd-4283-92e2-3579f1efe1d1"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7A057117-3806-4DCE-B7FD-9B1DE8C1142A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdfs:label>carbamazepine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6ce2837e-c8bf-4a62-9e5a-e911a80b4441">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <domeo:uuid>129cafcf-26cd-4e2e-91cf-90cfee7465f2</domeo:uuid>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2CB047FB-3614-4E9C-B521-6D1717B92E98">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2CB047FB-3614-4E9C-B521-6D1717B92E98"/>
    <domeo:uuid>2CB047FB-3614-4E9C-B521-6D1717B92E98</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:exact>In healthy, CYP2D6 extensive metabolizer patients (n=32), amitriptyline (75 mg daily), at steady state, did not cause relevant changes in the pharmacokinetics of steady state mirtazapine (30 mg daily); mirtazapine also did not cause relevant changes to the pharmacokinetics of amitriptyline.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>  Amitriptyline  </ao:prefix>
    <pav:createdOn>2015-10-29 10:46:30 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/dda29cc3-e63c-4755-9a39-b5d7d2ffc4ed">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>rosuvastatin</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C662E8BA-BC9C-41AE-8CD8-635008F6D89B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>40</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b4f4bbfb-2aaa-44d6-b977-9b0848d10492">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4181D6E9-2718-4EF8-B37F-C48D360D03B3</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:8E9BE0FC-751E-42FB-ABD3-98B7407DE970"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-02 14:01:28 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:7681b39f-6cf8-4b42-b3ca-e93692a5239a</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N7ae517bf44cd44afa071a91c36b1b99c"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:01ED7DD5-1FD9-4832-8008-51570F2C9D7C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FBB2D93A-4125-4710-9BB8-1E2593082591"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7FCFFF78-4590-4380-A581-6EF965495DEA">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7FCFFF78-4590-4380-A581-6EF965495DEA"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>  Phenytoin  </ao:prefix>
    <pav:createdOn>2015-10-29 10:33:12 -0400</pav:createdOn>
    <ao:exact>In healthy male patients (n=18), phenytoin (200 mg daily) increased mirtazapine (30 mg daily) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 45%. Mirtazapine did not significantly affect the pharmacokinetics of phenytoin.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>7FCFFF78-4590-4380-A581-6EF965495DEA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6CE00BC9-DCCA-412D-B793-3D9050678C0D">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdOn>2015-10-27 15:33:07 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:DB3EBE32-164E-43F1-87D1-5952E684C01A"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:da979eef-1133-47dc-bcb6-5fcaf76f224d">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8b5bf592-b230-4039-adaa-52304059cbe6</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3921f40b-2287-4697-b3ec-e0d89f2616b1"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/313A783C-3A1D-4BAD-A738-5ADCDB130B4C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Bupropion</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/708D45F7-889E-4E0D-95AD-A1FF84F406AF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>4</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>lorazepam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N43513c56ab764b6f82a902e8b062c5c8">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3c3c8de2-3ec5-4c1e-b0ce-4d1102b85c1c">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:e5212226-b28b-4e3a-9d68-92b82fca3556"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="Nb6a664f9fc9f42f6bf182ef2ee639cc0"/>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f17eb737-1e0b-4568-bd91-ebc816dacef9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e2c0acef-a7a2-4e2e-80a2-ef32efa7d2b5">
    <rdfs:label>saquinavir</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B127109-4D2B-419E-8484-52ECF937B916">
    <domeo:uuid>3B127109-4D2B-419E-8484-52ECF937B916</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p &lt; 0.03). There was a 23% increase in Tmax for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p &lt; 0.03). The clinical significance of these changes is unknown.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-28 16:27:44 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <ao:prefix>unknown.   CNS Active Drugs– </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3B127109-4D2B-419E-8484-52ECF937B916"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:288bdb34-640b-456e-b17e-198a25764e08">
    <domeo:uuid>fa87ecf5-1282-4bec-a1da-a60cbfa4f335</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6721659c-7f63-40e3-98f7-50f68a2a546e"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CAD54B20-B5E9-4402-8688-6843EC93EBFE">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/321A08AC-867C-414E-8B5B-A4AEF4B9107E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/34C2F861-CC2C-4D71-A3F3-E6FD02713F1C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:41D198C5-5028-4861-8DE3-B20B90E78A54">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D0C90DB4-6D99-4A07-8AC9-B902E0CF1037"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8D998AA0-150F-4852-94C7-A9E11062E28B">
    <ao:item rdf:resource="urn:domeoclient:uuid:6CB45E95-B7F8-40BE-B740-194013F50E39"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:4C1DE089-B819-4FC3-837E-4B16B46DBCB4"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/354502f2-0986-4732-9122-b462908d3476"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1aa03ef4-019f-43b6-9086-df6c24d9606a</pav:lineageUri>
    <pav:createdOn>2015-10-26 15:42:48 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N8acc5a83eb90474ab2884bca10d3cdfb"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:c56eebd5-adce-48a2-9610-7be6aeec6bae</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 10:29:25 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e9c46bd3-f480-4fdd-9568-ce7329da7d48">
    <ao:context rdf:resource="urn:domeoclient:uuid:50f78647-e11a-4479-9ac1-303a4b2087a1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:a0a19fb2-ef3c-410e-874f-6ae9cba1afd3</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:5d0e7e1e-fc68-48ac-ad87-a2cf5014fd1f</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N9aa02a624f8442f8ba6c7f724d3cd3d0"/>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3f6427c9-1e24-4fd0-b7c3-6e71a0dbcf90">
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N814872f8739846c99fc9aea6db6ff249"/>
    <pav:lineageUri>urn:domeoserver:annotationset:d8099a55-9227-404e-8867-9b5bba64686d</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:873022ae-d4ad-4825-9f08-218cc38fa61c"/>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3BB75DE6-A3F1-45E5-BF5F-F8D5BC8D56C9">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>sertraline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e8870973-cbc8-43be-813b-62f2cb600399">
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-27 13:28:11 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AF5E7138-652C-43B1-B901-2485B3ED9DD7</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:09a5a219-530e-4190-845f-87030e6bc3af</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0DB0A3F5-19B3-45AE-90C7-C90BB235CB05"/>
    <ao:body rdf:nodeID="N390fd89b0e4d497697528ce223b2bbc9"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2e5f4573-a267-46db-86da-7769df974504">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:fb7020ff-8ea2-487c-83d4-2ae5e67eabf8"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f7a2e8d5-215b-4da8-8f2a-a85dd3993744">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:3AB8F0AF-32C4-4E3B-AF3A-120B8D84DE16"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:fb3a8018-3f07-4f0f-82ae-48ff736ae286</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EF211B54-A145-4798-B735-2EB39AEE1268</domeo:belongsToSet>
    <ao:body rdf:nodeID="N5af4fb65145b4557b099a88b89ac208e"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-09 13:32:08 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-28 16:46:43 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6d0c3c0d-1047-400d-b58c-8c85e3dd95d9">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>milnacipran</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:CE30BA3A-EC97-4FF5-AD74-D796A845417B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-28 15:23:30 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:previousVersion>urn:domeoclient:uuid:11cff2f2-0dbd-49a2-998c-d7a0114b5cf0</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:5c962074-6934-4690-8232-84ea412d2b25"/>
    <pav:createdOn>2015-09-14 11:03:10 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:a60723b5-0b06-4e5f-bfb4-aada9e78632b</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N33b1d7d23a614ca7a5c213c8506c7a6b"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N64b093b0706a4e4c91b0b2f24eec6868">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D869AC5-11A1-47C6-B72D-5D0285ABE2A1">
    <ao:body rdf:resource="urn:linkedspls:uuid:BFDA94B6-C3E3-4254-B29F-1D8EE09A501D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CAB63AF9-D23A-4109-A615-275C9421E6CB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:94611C47-47D7-4D38-8EEF-17379EF5BB78"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBE2B329-4E6C-4915-91A7-775A43D4D87E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2615D048-46FA-4557-B691-24297A4787D9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F46AEEA-D7F6-4F1F-A426-9F20EDEB76A3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA18BF65-3F61-4179-8A1D-B73034A9E587"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8AD21D6C-B585-4986-9335-FAD5A45407B9</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:0768CA5A-42B5-4AEE-898D-336AADC10B13"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:82327B05-8BB1-401E-ACB4-42C3E0930D57"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:56EA7F48-3179-452B-BB6A-F74C96533A0D"/>
    <pav:createdBy>urn:person:uuid:080e1430434f70e501434f711b6e0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:8EBC3A86-CAF7-4AEB-8718-D2C34C496981"/>
    <pav:lineageUri>urn:domeoserver:annotation:E07CBE6D-93C5-4C75-8C1F-2BADEA50F654</pav:lineageUri>
    <pav:createdOn>2014-02-20 13:49:37 -0500</pav:createdOn>
    <pav:lastSavedOn>2014-02-20 13:49:40 -0500</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:16FDB844-0908-4D9D-9647-601A4C547C45"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF13ABBA-974C-4D13-B3D9-09EF5A6BB2FA"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:23530D0B-F4A5-407A-AED0-EE99C0B30E6D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D046132-84C4-4ABF-8B1C-EC07A0D07CA1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B808F3F-443A-4D13-B5FF-6F8FDF5C5836">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 15:28:35 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-05 15:28:21 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:99680311-2397-4C17-998B-D0286325C338"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:830D5D6B-C940-441B-A31A-9B0C4421863B</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:504f7070-f4c7-4176-96a0-e36b648c3981">
    <domeo:belongsToSet>urn:domeoclient:uuid:417391c2-68ce-4f5d-be06-c844ffdc41f4</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nfaa7bdf488994ca491ebffdcbf4e08aa"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:29052478-1e9e-4a2c-a69a-ebe021bd96dc"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:d2bf1ce8-9190-4a7a-8802-676a4baa52ee</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/40BC6619-23DD-4A7D-B03F-A2D37167EA14">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdfs:label>Fluoxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>60</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e9001232-e48e-444f-b992-dc8d94aec5cf">
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:8408c072-a469-4d33-8e50-b8fe8c3f4591</pav:lineageUri>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N6f94e2d651f444d1b160be5ffd8bc2e6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:dcfd172a-fe2d-447e-a47e-8ade5dcb207b</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:0cffe297-6116-434a-8f1f-e0879a939d90"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BFB4AA35-8B98-43A6-A4FD-742049F43D8A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:50BB2F3F-C1B8-4824-A657-9522F53AEFC6</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E6CE3958-8C23-4ECB-A13F-77A495409A43"/>
    <pav:createdOn>2015-11-05 10:29:53 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:073116c5-e0cd-4e86-82cd-3161bcc4155a">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/11cb1950-035b-40f1-9ce3-bb971fce9ba2"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmax>2.65</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:auc>2.51</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5b942e9f-0e12-4630-8a73-79090a6c9a76"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DDA7D5C1-9A98-484F-8F24-BD3007D41FC7">
    <pav:lineageUri>urn:domeoserver:annotation:B76B5A6C-5361-4F7E-B756-B35DEB2774F3</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:CF7BAACF-0678-428B-A323-3FE4F669E0ED"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-05 10:36:38 -0500</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c0930835-5fea-44a9-8d3e-9381f972d0a7">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>darunavir</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:097D2FF0-FD02-48D2-8AB4-9712B29351C2">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F7857B32-EB3B-4BA5-9840-6F500F78A32D"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/427365A9-65B7-4540-83C0-DAE0C3F1632E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E3D00524-B281-4890-8D47-6B4E74176962">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>urn:domeoclient:uuid:b5f62eca-b94f-46b7-8bcc-c6b1a54c58a7</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N6d6fc27c58064afe8df17f3f8d6d5a24"/>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-11-02 13:56:21 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:a5e660f7-3328-418f-bb97-29113aa0e57c</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:44ee5508-4bd5-46f1-b6ff-0c0dd8e9779b"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/12D3F5DD-1059-4CB2-A92B-8A6CF14BF81E">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Efavirenz</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/195085</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nde63d9274eac4065ae23fae6c5e2c113">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A1CA4C2-69FD-4899-A78A-8E053D6C80C5">
    <ao:exact>erythrohydrobupropion </ao:exact>
    <pav:createdOn>2015-11-05 16:06:46 -0500</pav:createdOn>
    <ao:suffix>decreased by 68%. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2A1CA4C2-69FD-4899-A78A-8E053D6C80C5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>decreased by 50%, and the </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:431ae753-de82-42f1-badc-c0309ae483c9">
    <ao:item rdf:resource="urn:domeoclient:uuid:cab6fc43-8f84-4fc3-ae14-cd200b712360"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1bd47c83-a318-4320-91a6-a771a22e3e06</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N192c31aef6eb4b6fbed0886e476d94e6"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:761ecfdd-7324-4cd5-9264-84e8aa6a202c">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N2c367049ccbb40bb8d37a686abace94b"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F4B3D0A-42A3-449C-861D-6C9096AD9208"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:cf658799-5946-432e-b767-abb982bd2e83</pav:lineageUri>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-29 10:35:24 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:596D4AD3-9632-4711-A25E-B9C0DF875BA5</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:CECA99DA-8FA8-4891-A150-E815F325EA3A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9e738bbc-6091-42f5-8ac2-68c5c3c4aaaa"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:27789bed-772a-43d5-8d3d-e3d4a6c6b79f</pav:previousVersion>
    <permissions:permissions rdf:nodeID="Nf2d9c8d28f8f489196c05cd536d7e563"/>
    <pav:lineageUri>urn:domeoserver:annotationset:01c55705-de9c-4138-b994-ac6bf65a7606</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7BC7FEE1-876D-498D-A265-01FBD45C0B8E">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/67A5A73F-7A0C-40F7-876E-83C519E10C0C"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/62B00FDA-4413-4298-AFE6-150AFE81F8D8"/>
    <dikbD2R:auc>10</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9460D459-A760-43CA-BB5A-B07A013A73C4">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2a5b4993-5500-4f5c-8418-f7f46b85bcfb">
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate. Therefore, patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with ZYTIGA [see Clinical Pharmacology (12.3)].</ao:exact>
    <domeo:uuid>40e9f147-3e41-4b6a-a2e5-d39f1f3860ef</domeo:uuid>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:596D4AD3-9632-4711-A25E-B9C0DF875BA5">
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:dfafa58e-04ad-40ff-b2bd-357423c239db</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N88ccdee004184896b21c709848f0334e"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>urn:domeoclient:uuid:04d992ac-0153-4ffc-8c05-56dfa723b34c</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 10:35:24 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:761ecfdd-7324-4cd5-9264-84e8aa6a202c"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/dddf31f3-d927-412a-901c-9d91efdfde5e">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ketoconazole</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B87CCB4D-9591-41EB-9B0E-35AFB8C2A6C6">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E90246C3-EDEE-42EC-B9A5-274C8F5E4151">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ECA0147D-A883-4690-B967-2814E7616BE9"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:024e6ecb-1872-4b1a-9dc8-448b89601c59">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-25 10:05:58 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:21369E3B-C781-4B22-950D-D2734AC81CFF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:c9456eb8-bc04-4996-b0ae-6c8b77417508</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:33F84CD2-4F0A-443A-81FB-57FAE9C3F91E"/>
    <ao:body rdf:nodeID="N8c94553666654017bff49f7c06c8ba4a"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-29 09:45:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5487AE94-E404-4EC8-BDB1-2C08F2FE239E">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:830171A4-E5A4-4A32-A8DA-2660C029C413"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8534BA4A-5106-4EE1-9F28-6F3F08B390E8">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8534BA4A-5106-4EE1-9F28-6F3F08B390E8</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).    In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).    Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <ao:prefix>Drugs Metabolized by P450 2D6   </ao:prefix>
    <pav:createdOn>2015-11-05 10:38:27 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8534BA4A-5106-4EE1-9F28-6F3F08B390E8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90DAE13F-76B8-49C3-B450-15539C7AFCF6">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>90DAE13F-76B8-49C3-B450-15539C7AFCF6</domeo:uuid>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-10-29 11:30:20 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:90DAE13F-76B8-49C3-B450-15539C7AFCF6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1474ebf5-3841-40da-bd10-9e11dfa540fe">
    <domeo:uuid>4f31c01a-efd5-4170-8bbe-7be964242ae5</domeo:uuid>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <ao:exact>Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>AUBAGIO on CYP1A2 substrates   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:916371f8-5c7b-497f-8a95-b09a7c5fa9f8">
    <domeo:uuid>f38bd1cb-d86f-49e8-9b60-00d64a5e5bf3</domeo:uuid>
    <ao:prefix> B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]</ao:exact>
    <pav:createdOn>2015-08-20 12:53:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2de13a78-5394-4708-b9d9-330402d73860">
    <rdfs:label>SSRIs</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA174FDA-075C-4A3F-BE05-648A1F4A71B3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-04 14:14:49 -0500</pav:createdOn>
    <ao:body rdf:nodeID="N59c3e13c781244ea8d55dc9d837dbe4f"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:CA56DDC9-04A4-4F52-8E2A-FC8244334FD7"/>
    <pav:lineageUri>urn:domeoserver:annotation:0428203F-B4FA-43DE-824C-277B49A37422</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A517C6F7-066B-4288-8145-3964B97E34AF">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>50</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>desipramine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1EF44FB4-771B-416F-AD61-759B3603A20B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>15</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>alprazolam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:95465721-1A44-48F9-A3B5-1FF636EEF31F">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9FE150AB-472E-44AB-8D85-9F3FC3DE99F9"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/950753BD-72DB-431D-87E3-2963005AD9AD"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ECA41CEF-2740-41E8-A5C3-8C972888A3B4">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>800</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:61a5a0bf-4aa0-4913-a64c-dc6595e1afa8">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ad13a882-c1d3-44b4-8e1d-50f85ad3be9f"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na4798ee51f714a71a97f4f031040495f">
    <domeo:sets rdf:resource="urn:pddi:uuid:fbd5b18d-d3bb-47a6-9be8-e2b6dc7b9fdb"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N34c23da5575b4d659356a7c16d88dd6c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ac8c65cd-9c15-4cbd-be9a-73f607fba988">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>phenytoin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CB6AF163-EF2A-4EC0-B5B9-335196D42F58">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7768BEC5-5B7A-4927-8C1C-16251C4EFD86"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c7b79d1d-fdcc-43c9-892c-ab4fc3156ffa">
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N9dd33e09295b4fc0833e075472f29486"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:8fcc44b0-fd50-44a3-ba5e-c3fb4b465254</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:9c1cb9cd-a248-40dd-888f-248b5558bec0"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/545887A4-8F7B-46C3-ACFB-ABDD4706EA9F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>hydroxybupropion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EF87ADCC-927E-4772-8DCF-81F31A76091E">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:37B9F7C1-46B7-42EE-95A6-8964904C256B"/>
    <pav:lastSavedOn>2015-10-27 14:25:13 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:140D5529-FD9F-4AF8-BA0C-9429231AADBA</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-27 14:25:12 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N7c478461982f4cbf86aa76ff67d0e709"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6652583d-8abd-4b79-8d53-9342b9af5c0b">
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:03a3fcce-4ee6-4c95-89c6-db61339de9e3</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:349c3be4-5feb-4ecc-8740-53ae1a7badbd"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nab98954bd2d44ab585a8e9d389a2087c"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8d236f6a-fbce-4a95-b88f-afc26278b1c3">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:562e2eca-b0be-4303-80b2-42ca27877d9c</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:ea3cd1ee-e4c2-4bf2-bdb0-9ce6b030153c</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N23e650b5ae154cf489c95df5a1a1a4c5"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8c7a1af1-dccb-4e18-864b-965ca7b89979"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1FC07F5-B5DE-48B7-AC58-B75B34DDC12B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-27 14:22:13 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:exact>The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentrations was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.    Thioridazine administration produces a dose-related prolongation of the QTc interval, which is associated with serious ventricular arrhythmias, such as torsades de pointes-type arrhythmias, and sudden death. It is likely that this experience underestimates the degree of risk that might occur with higher doses of thioridazine. Moreover, the effect of fluvoxamine may be even more pronounced when it is administered at higher doses.    Therefore, fluvoxamine and thioridazine should not be coadministered [see Contraindications (4.1)]. </ao:exact>
    <ao:prefix>5.4 Potential Thioridazine Interaction  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D1FC07F5-B5DE-48B7-AC58-B75B34DDC12B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/537355bf-9900-4d44-a6c3-7197ef87fff1">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:53F066AE-D01F-4402-8BBD-1137AFB1C7AA">
    <ao:item rdf:resource="urn:domeoclient:uuid:9a43c052-fe65-4bd1-8e7d-07255c1f8c63"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2015-10-29 10:29:25 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>urn:domeoclient:uuid:49d7e549-69dd-40fe-bb27-c1aa510cfb32</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N0ede17d6670a400dbe2d10f45befafe5"/>
    <pav:createdOn>2015-09-30 12:41:52 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:a6a797da-08f5-4f03-ad2e-57f66e0a5e38</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0823FCC2-AF2E-41AC-BCE4-4D74E1DF3E0F">
    <dikbD2R:dose>60</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>duloxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:790BEF03-2A89-4985-B285-9874C6F4B552">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix> and </ao:prefix>
    <pav:createdOn>2015-10-27 15:22:01 -0400</pav:createdOn>
    <ao:exact>clozapine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:790BEF03-2A89-4985-B285-9874C6F4B552"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>790BEF03-2A89-4985-B285-9874C6F4B552</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. Since clozapine-related seizures and orthostatic hypotension appear to be dose related, the risk of these adverse events may be higher when fluvoxamine and clozapine are coadministered. Patients should be closely monitored when fluvoxamine maleate and </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1562cd54-c734-4ae1-a717-729f3459f2a7">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:2c5ab9c5-f643-4bb2-822b-ee0683e63d06</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:e4ea7d35-7698-42d5-bc4e-86f28ea6f5d6</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N64fe80eb524342d18491e601ba189e58"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:76b11940-70b9-4605-b45f-b88a94709215"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A73F818A-C7D7-47B7-B083-A8AE6A8BD318">
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole). </ao:exact>
    <domeo:uuid>A73F818A-C7D7-47B7-B083-A8AE6A8BD318</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-27 15:34:24 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A73F818A-C7D7-47B7-B083-A8AE6A8BD318"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8716c71f-dbf4-4991-b9d1-e3905d4507ea">
    <domeo:uuid>ce85fde5-68fa-4684-9832-d2f6af43833b</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:17:13 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In an in vivo drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily). The AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3 fold [see Drug Interactions (7.2)].</ao:exact>
    <ao:prefix>CYP2C9, CYP2C19 and CYP3A4/5.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:dbec2d04-51f8-49c5-b6fa-f3f46d5f03bd">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f7b56718-5eca-446e-8c59-636a9f41e7f7</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:fbee9c4c-db96-4914-a26b-600107849626"/>
    <permissions:permissions rdf:nodeID="Ne203e8b62f4d49f185c806c0ab0758e3"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25b22107-de56-44d9-918f-d3bfe032a8bd">
    <domeo:uuid>166e6a23-021c-4060-a791-82c6d55e3d97</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5d774104-7234-43e1-be2e-688c16f781b1">
    <ao:body rdf:nodeID="N4a1078876bdd44078a6fc1b7b8aeba3c"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:e464d403-e203-4b9e-b65b-a6a5e65364ed</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:1f419043-027c-4031-ade6-d281dcfb136a</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:bf235d27-c44a-40e5-b868-37ec9e774183"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/28b59ec8-d75c-4f7a-9c65-38016280f7c7">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>abiraterone acetate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0c7cae18-72dd-417d-9008-94c4b213fceb">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Benzodiazepines — The half-life of concurrently administered diazepam may be prolonged in some patients [see Clinical Pharmacology (12.3)]. Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam plasma concentrations and in further psychomotor performance decrement due to increased alprazolam levels. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>4c8ef2e9-ae1a-4c18-be0e-a764f8ecaf8e</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4d211731-d3b4-42d4-a6f5-b8318076b467">
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-14 11:31:14 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:createdOn>2015-09-14 11:31:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0a7a48ba-53f3-40a2-bfda-649908762b21</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:ce406fc0-e044-43be-ac4a-24f5f011c5aa"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N756c729866874920bc1a5c6038972a63"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34124877-4109-47d4-9d31-a58d41dcf845">
    <domeo:uuid>5ab4258e-403d-4f2d-8d47-a586af303ea8</domeo:uuid>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2d81b5aa-330a-4a9d-aee9-349c8b7a4fdb">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>mitoxantrone</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BA9EAA95-B02B-4F34-9A83-2D790B8EE4D2">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/73315268-ECC5-4B73-A441-DD362873D3DC">
    <rdfs:label>TCA</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a1464bec-aab0-4c9f-8c58-f15050cbb11a">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:509fcd46-377b-45e6-af8a-410391a2dd48">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:71bde1dc-fd0c-4414-b350-a39b7b67bf03"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3E170858-1634-4C3C-BC77-FEB770B02B60">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D97811C-104D-424F-B7B5-69C0B3D4AB93">
    <pav:createdOn>2015-11-05 16:07:33 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">23</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nbe9751c80c3848c7b02777cbebea42d1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:471EE520-5AA1-40C5-B51E-59BEE36B2B4A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:751FBB26-E5EB-4878-A2EA-2B9845EC5906</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-05 16:07:34 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8fbf2351-d973-4d57-bade-cf029a716559">
    <rdfs:label>cefaclor</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A60BEA15-85D6-4BBA-AB8A-467A09C58262">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B19016AA-1639-420A-B594-59F3CC8DF372</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-28 16:37:51 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:DAC89F06-D854-4441-A6EE-D3851DDFD2F4</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D1B06494-F145-4A3F-AAF8-FD4F85BD23BE"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-28 16:37:38 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Na96cc1e6339d4d82a972839a2df78b3b"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A03DDA98-3E63-412B-93BF-F7759CCD2CB7">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-02 13:34:54 -0500</pav:createdOn>
    <domeo:uuid>A03DDA98-3E63-412B-93BF-F7759CCD2CB7</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Pimozide - In a controlled study, a single dose of pimozide 2 mg co-administered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A03DDA98-3E63-412B-93BF-F7759CCD2CB7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EE6EBD70-2EC7-44FD-8C18-7C0A9FF26D11">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>2</dikbD2R:auc>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2BF414AA-94F7-4EBB-B325-1ABB968AA088"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4C006546-0F74-4740-BB15-DF940CA3989E"/>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F90AB56-153C-470E-BDB9-94F2B9204172">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-28 15:25:58 -0400</pav:createdOn>
    <domeo:uuid>2F90AB56-153C-470E-BDB9-94F2B9204172</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> The effect of</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2F90AB56-153C-470E-BDB9-94F2B9204172"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9803516-9F11-42EF-BAFB-32FB6A010A78">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdOn>2015-11-05 15:32:57 -0500</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <ao:body rdf:nodeID="N54e9a37030b8408fa79e0b8f48494699"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:CE257385-3E77-46DF-BCC6-0EDDE829CEDB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d198994a-b5c0-4024-9b94-ee1ee033062e">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:208fa6b8-4564-4fa7-8139-a6f26ee1079e</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N55ebe16fe9d94b628a935393e33baf19"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:cadc682d-418b-4599-ad49-0e8f12a268bb"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E62C93E3-E9D2-4338-BF38-206615042C69">
    <ao:suffix>. (</ao:suffix>
    <domeo:uuid>E62C93E3-E9D2-4338-BF38-206615042C69</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-02-19 12:27:56 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E62C93E3-E9D2-4338-BF38-206615042C69"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <ao:exact>Effectiveness of Plavix depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5895490c-1e8a-45f6-bcc4-f54fc19ebd16">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:9305bc2c-eaa4-4706-86e4-623929db71f4</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A9CBFEBF-E565-4053-92BF-51C2BF6E1469</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N80a29a24576147f084ec24ef542622a1"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D390F44B-CB2A-4326-BAD4-B2F2C7D03E30"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3b0a6976f10c4d30bb1ee14a5049ae7d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/d69859f9-626d-47d5-ba31-79485787ce72">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>caffeine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/1886</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9b84351d-2776-4ff6-856b-c28dc3fa301e">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:af40e5fe-8c70-43a0-9cc3-f5ce1e1674d5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:f35af00d-cafb-44b9-8572-21c6050caebb"/>
    <domeo:uuid>d006f1f4-0b03-4946-8afe-ae960e4e44d5</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:417391c2-68ce-4f5d-be06-c844ffdc41f4">
    <permissions:permissions rdf:nodeID="Nc9dbf9d4227d4cf88efb17fda1763f39"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:504f7070-f4c7-4176-96a0-e36b648c3981"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:27e3bfc0-3708-4b04-806c-d40ef4cac9e8</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne58317e9b7414b5a9637a30a586b124c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:927acb84-d563-41db-8572-347a400d1729">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0cbbbe09-8c1d-41c8-a6f0-3154f52c6fd3"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1cf675c1-6cf0-44b6-9b1e-585afdd4bc5b">
    <pav:lineageUri>urn:domeoserver:annotation:f8cf7c62-79c2-493e-9834-ba69fb65ee02</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 11:32:27 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 11:32:27 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Na86c0403cad84b2a93a15a864fe62711"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:5e23a293-9958-4e8c-b04e-87ee5b2a6faa</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:800e6a6a-d187-4ee7-a71b-6f5db1fd97c8"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2437C682-01DF-4B57-BF3E-A737C6426FA2">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CC0E5AE8-5540-446A-A5AD-05FDE3F4CD03"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7748cb6a-f169-47fd-828b-3d35b03c40f1">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:d98b9db8-bb1d-42e2-aaec-a43209aa0ca3"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:e2564167-db18-4264-b2cd-5c3ae96583ac</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N6d263f2fe90a4e4ebce0488cf92732eb"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 11:30:25 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 11:30:25 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0605D3E8-5910-432E-ABFA-3ADA636D3736">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>6</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC5BFC2D-2FB5-406E-8932-5DD171C1137D">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>DC5BFC2D-2FB5-406E-8932-5DD171C1137D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <ao:exact>Ketoconazole - Combined administration of Celexa (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.</ao:exact>
    <pav:createdOn>2015-11-02 13:56:51 -0500</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC5BFC2D-2FB5-406E-8932-5DD171C1137D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3e4a0fce-9301-4363-be03-79cdbd954122">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3ccafb05-ca33-4e37-bf94-8e543fdc5d1e"/>
    <domeo:uuid>986dce30-f49e-4d1a-9859-a99f903129e2</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20976f02-5b6f-495e-bd1a-f679f827df40">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8caecff2-b5d2-4433-8a37-6b9ac027b535"/>
    <domeo:uuid>9e1d1c07-65d2-4bb2-b373-e80c3c05a435</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:25DFFE33-F9B6-472C-B49A-54BF1DF841D3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FA98AECF-689C-4236-84C7-63A0618F25E9"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/48063866-91BE-4B69-A667-97112E8AEC80"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/233c7124-34ea-4661-a1e3-06e7364169a7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>risperidone</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C56659D4-8298-4468-B969-47772B8B51D1">
    <domeo:belongsToSet>urn:domeoserver:annotationset:09FE9163-3F21-491C-94F0-EBB12BEF6F16</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-29 11:27:43 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:57BC23B8-F940-45E8-A3F2-85C83919E167</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:08D39A39-3238-4337-B638-3FC9B51B7CC8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ceea744a-d74a-402f-b378-c0dfa14aa993">
    <pav:lineageUri>urn:domeoserver:annotation:3cf407f9-7b42-48a1-9e54-8bf3229c2f65</pav:lineageUri>
    <ao:body rdf:nodeID="N48438963fcd5483482caf474466b0a33"/>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:5e976eb2-821a-4a78-8653-8f02df9b0b09</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:288bdb34-640b-456e-b17e-198a25764e08"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63E48FD2-977C-48E2-B8C1-F43C053E708E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63E48FD2-977C-48E2-B8C1-F43C053E708E"/>
    <ao:prefix>I</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-05 16:04:01 -0500</pav:createdOn>
    <ao:exact>n a healthy volunteer study, ritonavir 100 mg twice daily reduced the AUC and Cmax of bupropion by 22% and 21%, respectively. The exposure of the hydroxybupropion metabolite was decreased by 23%, the threohydrobupropion decreased by 38%, and the erythrohydrobupropion decreased by 48%. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/89FE148C-2544-4A1A-902C-C8BFB3B83E7B">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>nefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3d5a6168-cfbf-470b-b697-653a5815557f">
    <domeo:uuid>243f9bd0-19a7-421c-8a25-cd57d77edacb</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0f98c87e-21d5-4437-95c7-76c253ceec78"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56BC2FA2-8F69-4C15-8175-D383A04D506E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>hydroxybupropion </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 15:24:32 -0500</pav:createdOn>
    <ao:prefix> and </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>exposure. Dosage increase of </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:56BC2FA2-8F69-4C15-8175-D383A04D506E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B468326A-7B19-40E3-950B-9E8E4A36D3E5">
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F167758F-1F4C-4606-8117-3BA4B92CA356">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-28 14:37:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, will elevate plasma levels of </ao:prefix>
    <domeo:uuid>F167758F-1F4C-4606-8117-3BA4B92CA356</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <ao:suffix>. Therefore, it is recommended that paroxetine not be used in combination with thioridazine (see </ao:suffix>
    <ao:exact>thioridazine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F167758F-1F4C-4606-8117-3BA4B92CA356"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8EFABA7-9AE3-4C90-BFF9-A7FEAE02F64F">
    <domeo:uuid>C8EFABA7-9AE3-4C90-BFF9-A7FEAE02F64F</domeo:uuid>
    <pav:createdOn>2015-11-06 15:55:21 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C8EFABA7-9AE3-4C90-BFF9-A7FEAE02F64F"/>
    <ao:exact>Lorazepam – When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>may be necessary when coadministered with nefazodone .  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:96a65f33-6bcb-4e10-a0a7-d090ced2d265">
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6072d0cc-f6c5-48c2-be4c-4eb2895fd57e"/>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/77443745-9e96-4d51-99bd-4aa1d4debee0"/>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cl></dikbD2R:cl>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2ecef709-37db-4e40-9658-34000ff7c38e">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:4488631a-618b-479b-826c-e5538a927682</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:aaeeb785-a4ea-42a3-b83f-33ba137ff1c2"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N580ae195a7924f2c82e287c9d9188d04"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/d258ea10-1fe6-4f77-9636-4201f8a108d9">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>midazolam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38abbb1a-c4b2-4eb8-9f53-87decd84c7f7">
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:059a4fbc-9181-4707-9b38-5065abe99bca</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:0d6d48d4-a545-47f1-b1c4-4405e51bd4ae</domeo:belongsToSet>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N9ce2d1cdfa7849c3adc58b2e1dd02bdd"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:d5fd249b-ef43-4f0e-8f2d-e61b2c58b96b"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/406476A8-071B-4A70-A095-F35D3C11B4CC">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6f283a64a7604eb98788ab2619b08065">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/18887DA6-4A05-4BB8-8864-CB0B883338B6">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dikbD2R:dose>25</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D79272CF-C733-4559-A232-9D174813C454">
    <pav:lastSavedOn>2015-11-05 16:05:45 -0500</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:4F598533-EB1E-421C-AADA-97962DA8B220</pav:previousVersion>
    <pav:createdOn>2015-11-05 16:04:08 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:69B39E48-972C-4A96-8AC2-3AD1A0B01071"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">22</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/71673b97-4f3c-424a-bebf-db379bf0ae96">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>sertraline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/009ab856-779e-4231-acb1-917c2c971099">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2F83D44-363B-4535-BB38-C3AB8DB27127">
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:841571D1-493E-42B0-8350-051059BDE2B4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-27 15:25:16 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0109A8C-5671-4C34-941A-B796C0001165">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-27 15:21:59 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A0109A8C-5671-4C34-941A-B796C0001165"/>
    <ao:exact>fluvoxamine maleate</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and clozapine. Since clozapine-related seizures and orthostatic hypotension appear to be dose related, the risk of these adverse events may be higher when fluvoxamine and clozapine are coadministered. Patients should be closely monitored when fluvoxamin</ao:suffix>
    <domeo:uuid>A0109A8C-5671-4C34-941A-B796C0001165</domeo:uuid>
    <ao:prefix>have been reported in patients taking </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bb06e020-af04-4864-a0cc-539dfae8effd">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6d64278b-00ce-4b9a-b318-3b31b2d476f7"/>
    <domeo:uuid>5316900a-5d94-4928-8f02-45046d49cee9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0cbbbe09-8c1d-41c8-a6f0-3154f52c6fd3">
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmax>1.5</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:auc>1.9</dikbD2R:auc>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/02d44ac8-6cc1-42d8-8401-ff1d58eafdf6"/>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1a92d9cc-891e-4a52-9c7e-6768abb24ebe"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cb1adde1-409e-4ee3-a827-a190a40a773b">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0d2fa762-e7af-4551-b164-fe636f989d7a"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <domeo:uuid>7a115a5d-ee82-40b8-b69e-f5978db19ad6</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1f373ec0-8432-462e-aa2d-1f1dfb1bc80c">
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:029c7551-dbe1-41f9-bde3-08d5a961d4a5</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:8e2c716f-5103-481a-a8d4-c978bc988ae6</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N00b3fc899f8246eeb5083f16edfc9b14"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:b0b7eddf-93e6-42fc-8d39-826a621810ef"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:BC7D481F-E414-4C89-916F-D487364E34BF">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:00d4430e-1921-41fd-896e-64b1938df939"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:400a1e4b-d877-483f-a041-ca48ea3d42eb</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="Nfb6644c453f740c7b9ad62ce7b0507e2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2015-11-02 14:33:30 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:9ed0577b-25b2-4225-be82-0513c16efed6</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d46cfe4f-4f8c-48a2-867e-67fdbaf68b82">
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:56a82b44-33ef-4713-97b3-59e38cdcf971</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:51b1bf0c-1856-45fe-b29e-182dc5b62081"/>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="Nf6d2b06db14344e5b51f3ef4b6fc402e"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:48C9E6D2-977A-4F6F-B79C-462474032E43">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0D0B84AF-AB09-428C-8667-3A081C2450D1"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b5508530-ec46-46ae-9ae2-d542a75e8533">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7491d451-dddc-47ef-ba1c-7124681a15b0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <domeo:uuid>24e06975-90b4-45d5-ad81-7543ea58ccfa</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0dd49bfbfc7b4e5d86363aeeaf847d6e">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:043496E3-8479-4B04-A488-DED34CB30620">
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0841C075-602C-4F86-9DF0-FE17FC65705F"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>11</dikbD2R:preciptDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ACB6BEB4-A8F3-4393-A584-EDEDCD6BE388"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4ca8a22295b14d4c9b8919891aee2518">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9F75EAB-A75D-4664-A915-3EC4552F4132">
    <ao:suffix>. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:suffix>
    <pav:createdOn>2015-10-27 14:25:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B9F75EAB-A75D-4664-A915-3EC4552F4132"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by </ao:prefix>
    <ao:exact>fluvoxamine</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A05FDCF1-828D-4AF0-893D-FC0387C6E176">
    <ao:prefix>The coadministration of </ao:prefix>
    <ao:exact>carbamazepine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A05FDCF1-828D-4AF0-893D-FC0387C6E176</domeo:uuid>
    <pav:createdOn>2015-11-06 15:44:01 -0500</pav:createdOn>
    <ao:suffix>200 mg BID with nefazodone 200 mg BID, at steady state for both drugs, resulted in almost 95% reductions in AUCs for nefazodone and hydroxynefazodone, likely resulting in insufficient plasma nefazodone and hydroxynefazodone concentrations for achieving a</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A05FDCF1-828D-4AF0-893D-FC0387C6E176"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2298ABEA-9371-4D03-B904-936D3631AD23">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-27 15:22:29 -0400</pav:createdOn>
    <ao:exact>methadone </ao:exact>
    <domeo:uuid>2298ABEA-9371-4D03-B904-936D3631AD23</domeo:uuid>
    <ao:prefix>(plasma level:dose) ratios have been reported when fluvoxamine maleate was administered to patients receiving maintenance </ao:prefix>
    <ao:suffix>treatment, with symptoms of opioid intoxication in one patient. Opioid withdrawal symptoms were reported following fluvoxamine maleate discontinuation in another patient. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2298ABEA-9371-4D03-B904-936D3631AD23"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/45e53bba-b48f-44f8-b954-fc34181bc8a8">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluoxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93528B14-0ADC-4837-8A60-81F9A3A181E2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:93528B14-0ADC-4837-8A60-81F9A3A181E2"/>
    <pav:createdOn>2015-10-27 14:23:29 -0400</pav:createdOn>
    <ao:suffix>is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. An increased plasma concent</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Pimozide </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9E300BB6-7811-40E7-B37E-EBB3AD9F1199">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
    <rdfs:label>imipramine</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5fb48171-efb1-4e97-ba07-85bfe1da93c0">
    <ao:exact>lamotrigine</ao:exact>
    <pav:createdOn>2015-10-26 15:39:34 -0400</pav:createdOn>
    <ao:prefix>significant effects on the single-dose pharmacokinetics of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5fb48171-efb1-4e97-ba07-85bfe1da93c0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> in 12 healthy volunteers.                                  </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/75EFC158-7E06-4BEF-8283-13603C930042">
    <dikbD2R:dose>1</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37b83851-9377-4599-833c-c782bead232c">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-25 10:05:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:85edf440-b690-42d5-b4a7-6439ea8bf96a</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D285DCED-B51D-474F-B761-69F917B7B95F</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-29 09:45:11 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N99b84241624148fd96f016f912ece3bc"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:DCBCDCD2-4E14-409B-9930-D21CDD9FBAC0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81A9031B-88B8-436E-B2E2-9A08647FAD62">
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-04 14:16:40 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0393E4D6-5304-41D2-A25C-DACC2797FAF1"/>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/af6c0260-816e-4466-b557-69cfc9858e27">
    <rdfs:label>CMI</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BF624178-2F3A-41B3-9042-EC5765ED6BD5">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0A695369-965B-4E1E-A972-1BA89AF625BC"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:DC53FFB5-89EF-4111-932E-48418846D393">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-27 14:16:45 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:8acae0e9-b5ad-489d-9dd3-108a76cb1410"/>
    <permissions:permissions rdf:nodeID="Nef96cf07755c488cb3acc28c9cfa7592"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:d2486d48-233a-42f2-98b2-5ed16dca5a7a</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:136fc87a-dce6-42bc-8f7b-1df58efcd677</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0f44bd4a-14d8-45e4-ac34-44d5a42d1800">
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N19e0e561c1ec4bd08f66431936a74b76"/>
    <pav:lineageUri>urn:domeoserver:annotation:88964190-da43-4015-9bee-4f2e2d6fe6e4</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:1f70402a-1465-4802-8e95-a52d65cd5ae8</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:5921a5f4-69f2-48c3-8cb8-f6039eb31ee2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:08DF11B7-705A-4815-A4C2-3C505089182F">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2896B582-2953-4429-A299-8BAA4A648ED0"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9BD348AD-A5D1-4CB3-93A7-0E179B85C86B">
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EF5F176B-3941-4908-B23A-FE35ACA096F6"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E59CB2D6-D1A1-4771-AE33-9048BE8E4CEC"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB9A9AB4-74BB-432B-A0B6-0F19BB47AB23">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 15:27:18 -0500</pav:createdOn>
    <ao:exact>Ritonavir, Lopinavir, and Efavirenz: Concomitant treatment with these drugs can decrease bupropion and hydroxybupropion exposure. Dosage increase of WELLBUTRIN XL may be necessary when coadministered with ritonavir, lopinavir, or efavirenz but should not exceed the maximum recommended dose [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EB9A9AB4-74BB-432B-A0B6-0F19BB47AB23"/>
    <ao:prefix>Clinical Pharmacology (12.3) ].   Inducers of CYP2B6    </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e0bc3e28-6ef0-4203-8648-af6ad5039f91">
    <pav:lineageUri>urn:domeoserver:annotationset:78160bcf-6385-4b00-b73e-b0dbc2203b96</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:de90e5e5-b639-4449-9445-b6421797ae4a"/>
    <permissions:permissions rdf:nodeID="N7ab7c91f61c942239258e902e4291820"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c7c868da-0b38-4ae1-81eb-93ac849f6d5d">
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>cc873006-5d0d-4e2f-828e-7bf4b20ebc00</domeo:uuid>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB88A8EB-F03C-4ED6-8C15-27BB85F94920">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-05 15:33:12 -0500</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <ao:body rdf:nodeID="N00c7548e4f6044149c37a7084d45e3d5"/>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0B80235F-B5BC-4011-9742-F1F77077BB69"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7717c842092e40bda884fff9a456423f">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D4C34A53-7C73-478B-8A7B-A735627D0323">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>citalopram</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:41A0910A-A1F3-4EA5-A7BF-473F44830232">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9376491D-F635-4C58-B7FF-95BCFDC8486C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B7D1C3D8-AB88-4BC7-A8BE-FD40E4E047F2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:843e8424-4ead-45cf-b6cf-3f515630a33e">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/471e0f08-fbfd-48d9-af67-203a40eba34e"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/25102e78-a221-448f-b13f-2f0987d20e6b"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:248e2ba9-769e-4666-9a23-d81979bde681">
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>c90a6c89-dae2-47bb-b168-0142f672da83</domeo:uuid>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97671749-5d9a-4b07-827e-ae2b78a53a9e">
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N59085b1a5069480e9850350d58a2c5c3"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:7119f066-0a03-40ab-bb6b-017cf28601e3"/>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1d320480-2269-4dd0-9759-88f520e9bf6c</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbdfd5f3eec1f408fbc8cf39153139ec5">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0888ADEE-2436-4845-B2A0-F912324F129A">
    <rdfs:label>lithium</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>30 mmol</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b047b34c-82ac-4fed-accc-ea6e16883de9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11413</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>zidovudine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BE215695-7291-4E57-896E-FDE3FF2AD96E">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/08A99BE8-FF56-415F-B722-976BC9616313"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1B8C178E-7D58-4C51-BDA2-E50BCEEEC9C6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:F2E65CE7-05BB-403D-A7F8-3A0DAE0412F9">
    <pav:previousVersion>urn:domeoclient:uuid:7c58f7f8-c060-4a1a-84e8-6993094c054c</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-11-02 14:01:03 -0500</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:624dff0d-d484-4c18-8d11-e7e314b85fa3</pav:lineageUri>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Ne5572a5ab0914fa6a594410e6cce8cfa"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7ffbe5ff-11ef-43ef-b6f4-7e8d2ceacb86"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/921f6520-0468-403a-8b48-e8c0f66ecd1a">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>alprazolam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na87a054904d74db5828a0bc76d108bda">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5FDBA0F-92FB-46C2-AC52-A6E0F2C4DDF4">
    <pav:createdOn>2015-11-05 15:28:22 -0500</pav:createdOn>
    <ao:suffix>(e.g. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C5FDBA0F-92FB-46C2-AC52-A6E0F2C4DDF4"/>
    <ao:prefix>paroxetine , fluoxetine , and sertraline ), </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>antipsychotics </ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25AE618C-1355-4395-B7C5-0C02149C971A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25AE618C-1355-4395-B7C5-0C02149C971A"/>
    <pav:createdOn>2015-11-05 16:15:30 -0500</pav:createdOn>
    <ao:prefix>metabolite were decreased by 50% and 31%, respectively.   </ao:prefix>
    <ao:exact>Efavirenz: In a study of healthy volunteers, efavirenz 600 mg once daily for 2 weeks reduced the AUC and Cmax of bupropion by approximately 55% and 34%, respectively. The AUC of hydroxybupropion was unchanged, whereas Cmax of hydroxybupropion was increased by 50%.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83dbff64-fb18-442c-a03a-29d9b0589e57">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:721720fc-488e-447c-8386-18bedc7b3d20"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>525b85f2-64d3-429d-9265-7cd97b0bff12</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AF8B21B0-31C4-487F-B745-EF0BA3079B91">
    <dikbD2R:dose>1</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>digoxin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nccd95ae68d884af88a5aa853a686566a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3c9ed332-013c-432a-93ca-0efdd57f3e67">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D243C195-F972-4153-AC7A-2289874C2675">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D243C195-F972-4153-AC7A-2289874C2675"/>
    <pav:createdOn>2015-11-04 14:19:06 -0500</pav:createdOn>
    <domeo:uuid>D243C195-F972-4153-AC7A-2289874C2675</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:16B26536-147A-4AEA-A64B-EEDD24D7DAEF">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E331D723-CDCC-4E26-AE0E-04D3957918B0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:11D4B1CD-61DD-4CA4-9DCF-F0548507CA91">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-05 16:06:31 -0500</pav:createdOn>
    <ao:prefix>erythrohydrobupropion decreased by 48%. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a second healthy volunteer study, ritonavir 600 mg twice daily decreased the AUC and Cmax of bupropion by 66% and 62% respectively. The exposure of the hydroxybupropion metabolite was decreased by 78%, the threohydrobupropion decreased by 50%, and the erythrohydrobupropion decreased by 68%. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:11D4B1CD-61DD-4CA4-9DCF-F0548507CA91"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59E4B724-3D9F-402B-8205-20A8DFEE0982">
    <pav:createdOn>2015-11-05 15:43:16 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:exact>In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by CYP2B6. Therefore, the potential exists for drug interactions between WELLBUTRIN XL and drugs that are inhibitors or inducers of CYP2B6. In addition, in vitro studies suggest that paroxetine, sertraline, norfluoxetine, fluvoxamine, and nelfinavir, inhibit the hydroxylation of bupropion.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Potential for Other Drugs to Affect WELLBUTRIN XL    </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:59E4B724-3D9F-402B-8205-20A8DFEE0982"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fbee9c4c-db96-4914-a26b-600107849626">
    <pav:lineageUri>urn:domeoserver:annotation:77f12884-c860-4c7b-a6be-3f6be0a8f0f6</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:dbec2d04-51f8-49c5-b6fa-f3f46d5f03bd</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nb75ab700bfa24b3e86da150af687d61d"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:72d91b2a-0741-48ab-81fb-2ef0147b9860"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1f419043-027c-4031-ade6-d281dcfb136a">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N0189c77cec4840eb91a85c6989fe64d5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5d774104-7234-43e1-be2e-688c16f781b1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:d99b442f-886b-4c17-bc4d-3247bd21ecd5</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F79554C-ED5D-4852-9EDC-6A7D47F2827E">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-05 15:30:48 -0500</pav:createdOn>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F79554C-ED5D-4852-9EDC-6A7D47F2827E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ddda2fb6-4187-452b-86d5-3ab68f55667f">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>26fd7365-3c3a-47e2-b5d1-2509bb7082e7</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>e in plasma AUC of the TCA ).  </ao:prefix>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F03C1F3D-D405-431F-AC1A-11BF805DF0F8">
    <ao:prefix>; </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>cimetidine</ao:exact>
    <pav:createdOn>2015-11-05 10:36:34 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:suffix>) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxet</ao:suffix>
    <domeo:uuid>F03C1F3D-D405-431F-AC1A-11BF805DF0F8</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F03C1F3D-D405-431F-AC1A-11BF805DF0F8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9F88591-2F38-463B-9F26-D5DD24E843E7">
    <pav:previousVersion>urn:domeoserver:annotationset:B170CAAA-860E-44B8-A1BD-171CE3E86595</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lastSavedOn>2015-11-05 15:27:20 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N0946f1a86af44ab6be52ef56bffd13cd"/>
    <pav:createdOn>2015-11-05 15:27:18 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:EB9A9AB4-74BB-432B-A0B6-0F19BB47AB23"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87E15AB9-9BF9-42E9-BC2E-C43EEFA88474">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87E15AB9-9BF9-42E9-BC2E-C43EEFA88474"/>
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <pav:createdOn>2015-10-27 15:33:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole). </ao:exact>
    <domeo:uuid>87E15AB9-9BF9-42E9-BC2E-C43EEFA88474</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18649ed6-6a3e-4372-a03d-3ba4eb4315ab">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-14 11:31:14 -0400</pav:createdOn>
    <ao:exact>Under steady-state conditions, diazepam does not appear to affect paroxetine kinetics. The effects of paroxetine on diazepam were not evaluated.</ao:exact>
    <ao:prefix>taken with caution.  Diazepam  </ao:prefix>
    <domeo:uuid>38c28b17-34bc-4300-8c42-fc9f18d504e2</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncca73be11260466fb373adb9c812ee1d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4f7e2dd9-fa3c-40d4-8c5d-2d766fec732c">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>saquinavir</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:13767b15-9122-4414-b1f2-91d3521d6fdf">
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:auc></dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/ffe19e59-bd70-4f30-b434-1715f94d924d"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5adb13de-b0ce-446f-ad49-16fe6b902e5c"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F91D9438-255F-460A-87D2-6B3F5573A0D4">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/38F6CD96-96ED-4020-BF5B-E5FD8C084CD9"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/22A7FE72-50A8-4FAD-A352-899C105ECDA0"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/22002285-26DF-429B-BC8F-153FC65EA94E">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>antidepressants</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E6A0643D-8116-46A0-A691-7F806105339B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>400</dikbD2R:dose>
    <rdfs:label>desipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5E9577B7-6EFE-4F3E-A59B-4C2F73688DEB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/94EBF2EB-203F-4B2F-A505-0DADC1E2ABD5">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8a42c678-10fe-4aef-a024-493695f78fe4">
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:48718b8f-1251-4d8f-8529-887877b19deb"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:ea4b560d-023a-46df-b6dd-b753b7fd8472</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N64a7641b57744023802b9c690965c836"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:b191020a-fd09-45cd-a698-c126461230a3</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/31833f6b-cfc9-43e2-8378-748266586508">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ethinylestradiol</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfd00bfcb24b34f92973257d2d02a0351">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N38ffcfb0f97e4d2383c8c71c6cbf688e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76c0b930-4be9-47a4-9ef4-70565212485c">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>e in plasma AUC of the TCA ).  </ao:prefix>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>6817deba-55a9-4c32-91c5-eb3437e6314f</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8DDBD5CA-FB6B-4D4D-BDBD-F19852E3D3E6">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-04 14:17:28 -0500</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E027C279-6420-4887-8E6C-5FD005D4E850"/>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1b5fc232-c084-4970-833a-b171cd706975">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:80b840e9-3207-4d00-8d91-9d9d2ab0ad63"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <domeo:uuid>fa92af4b-9630-4cae-8d0b-245fea990ada</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B7150E40-97A7-4D99-BCB4-48BCF3DB490E">
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4ABA366-BA67-49A1-9D81-9D308B4F74A3">
    <pav:createdOn>2015-11-05 15:53:52 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>and AUC values of hydroxybupropion by 32% and 24%, respectively.   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4ABA366-BA67-49A1-9D81-9D308B4F74A3"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Cimetidine: Following oral administration of bupropion 300 mg with and without cimetidine 800 mg in 24 healthy young male volunteers, the pharmacokinetics of bupropion and hydroxybupropion were unaffected. However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/72E4E4CD-4A4B-44F2-B078-7853EAB06E27">
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:005A2D87-B281-4CCE-96A2-54758E78669A">
    <pav:lineageUri>urn:domeoserver:annotationset:af0a40c4-25dd-4e9e-a1ba-739ae654ede2</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="Nfa3ddbe8e1524b2499fd1267cb4187ef"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-11-02 14:33:30 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoclient:uuid:756e7237-f996-4725-b6eb-d2814a9d37b7</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:ae139417-fe54-4592-b426-fdba76d48487"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0571470B-C5A2-477D-92DA-95B207F58399">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>mirtazapine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4D49EE33-3482-4217-94C9-665266824616">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>800</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:091fe1c3-1830-41c0-b780-280c48d3ea86">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:8c8f891d-2930-4614-a195-91c3504d01a5</pav:lineageUri>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:5231a6d3-811d-4a55-929b-ded0cbd2374e"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N06de8e2615a34442ad6339613a3261bb"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21067eaa-6f1d-4e66-9ca6-03d6085baecc">
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N4963ba5a934641438ebb93aa08d57d35"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:64574bb1-d248-4de3-b50d-3ba279a5ae8c"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:71874bf7-ed90-4385-b2c3-3dd94cf4b0cc</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:439ad6ea-b22f-45f3-8293-cb0cf2b6382a</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED61FA0A-E015-48D6-A36F-19CAB973FE61">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <ao:body rdf:nodeID="Nbf1366c42b8e4e738f43f4817d45b678"/>
    <pav:createdOn>2015-11-06 15:38:24 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B38F81C8-AC6B-461C-878E-E8523FC3F803"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:8EE4F288-19C8-4519-85CB-791C9E9709D8</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-06 15:43:14 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8551B156-C941-41DD-B228-B433B74B1B86">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:a80a885a-21a8-41f6-8e6f-1f2c43009aaa</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:54D43BBC-050B-4C4F-ACA9-520DA64D0F05"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdOn>2015-11-05 15:24:04 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-05 15:24:24 -0500</pav:lastSavedOn>
    <ao:body rdf:nodeID="N5529e71f12a24a468633c2432d69cb4a"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97ab5251-cf4f-4925-985e-05e51157ab94">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid>05595c3b-a772-4e86-9e5f-15016524b284</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1474ebf5-3841-40da-bd10-9e11dfa540fe"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D3401B5F-E88C-4B9B-90A2-F592987F2301">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1EA29F2B-1B4D-4AF1-9ABC-4E5B5DA1949D"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B4E138B0-A024-44D6-B3F5-73FBF5C26DBD">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>levomilnacipran</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E7C844E5-2FA8-4494-A242-004123173C26">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D09BD622-2E80-4419-9A99-34C81624511C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/953D7047-4DE9-452C-A4E6-93FAD792F9A1"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:dd3eb8b9-c22b-4046-8bfa-fb1c0ffa5cd7">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:ab64d65c-8507-438c-ae82-623ccf7ebb1e</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:f3d6c982-d2e2-41e0-8efa-6e06a5f29283</domeo:belongsToSet>
    <ao:body rdf:nodeID="N77f87248cbeb4a52914c5b215e1ddd84"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:fb6217ae-8618-4cfa-8c2f-7283a841d73c"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7C7E2EDF-EDFF-4F80-B69F-B185AC137C8C">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1846d100-f88c-48f4-b448-53ac47422ed5">
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:00570013-f7b3-487f-b97b-0bd00a3173cf</pav:lineageUri>
    <ao:body rdf:nodeID="N767bf3fb2982494f90d866f39e2589e1"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoclient:uuid:b4bcb545-b9aa-412b-b772-55699651ec75</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:560e4e4b-12c9-44d5-81e0-5a5673afd438"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb91d05c08fee4b28bb91c7e6046504f4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1BA882E4-1468-4E4C-809D-8627B0CCA3B2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1BA882E4-1468-4E4C-809D-8627B0CCA3B2"/>
    <domeo:uuid>1BA882E4-1468-4E4C-809D-8627B0CCA3B2</domeo:uuid>
    <pav:createdOn>2015-10-27 15:19:40 -0400</pav:createdOn>
    <ao:prefix>   Diazepam  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>The coadministration of fluvoxamine maleate tablets and diazepam is generally not advisable. Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic coadministration.    Evidence supporting the conclusion that it is inadvisable to coadminister fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam. In these subjects (N = 8), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study.    It is likely that this experience significantly underestimates the degree of accumulation that might occur with repeated diazepam administration. Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.    Accordingly, diazepam and fluvoxamine should not ordinarily be coadministered. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A38D3124-29F8-48FA-BFD9-AA8A380A6166">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/99C4590F-7BBC-4D32-98D8-B70D269C5412"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E4ED55C9-05EB-4679-B370-734DA86F904E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6434f339-6956-4d1f-aaf5-2143cfbbb87a">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CC8A7FAC-D75B-444A-A803-250802A81237">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>hydroxybupropion</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C37B601D-FBF3-4C23-996D-9381844D7222">
    <pav:createdOn>2015-10-27 15:22:48 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C37B601D-FBF3-4C23-996D-9381844D7222"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>C37B601D-FBF3-4C23-996D-9381844D7222</domeo:uuid>
    <ao:prefix>    Methadone   </ao:prefix>
    <ao:exact>Significantly increased methadone (plasma level:dose) ratios have been reported when fluvoxamine maleate was administered to patients receiving maintenance methadone treatment, with symptoms of opioid intoxication in one patient. Opioid withdrawal symptoms were reported following fluvoxamine maleate discontinuation in another patient. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:85EDE652-8757-4D48-8635-E319D43D6A22">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-06 15:41:56 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-06 15:43:14 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:8EE4F288-19C8-4519-85CB-791C9E9709D8</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:96CA1954-A3A8-4274-AA81-5B7785E08750"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:25356FFB-DB38-4B3F-B9E2-3E7EE298211D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B35DC339-2222-424E-8E87-E72C2F20FDA2"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FE5A0A95-450F-4EAC-99DA-FFD5F239C263">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>triazolam</rdfs:label>
    <dikbD2R:dose>0.25</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2AD242D5-C64B-4051-8107-A3C1B72B9E54">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:6426edbd-e01c-45ce-9151-eac311cb230b</pav:previousVersion>
    <pav:createdOn>2015-10-27 14:23:17 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-27 14:23:19 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D40A25C4-DB51-4114-91EA-4CE3D6380167"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N1bd7a0f03a7847b18975ab6a9a66f6f9"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E3443685-CB43-45B7-BC03-1430D374FD0A">
    <dikbD2R:dose>800</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N17bfa2b91e0d4bfeb4780b9c9bd9d0a8">
    <domeo:sets rdf:resource="urn:pddi:uuid:55D26C94-3AA9-49F6-B004-E7B31D5AC85C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N83e6a36d201b42f39a29fbd5984f44c3">
    <domeo:sets rdf:resource="urn:pddi:uuid:600DC4DF-8428-4EC0-B9DA-53C93F607E9D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:61D6F2D0-6072-4DC4-9717-C16FC18FFD23">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-28 15:05:40 -0400</pav:createdOn>
    <ao:exact>In a controlled study of healthy volunteers, after paroxetine was titrated to 60 mg daily, coadministration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone. The increase in pimozide AUC and Cmax is due to the CYP2D6 inhibitory properties of paroxetine. Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and paroxetine is contraindicated (see CONTRAINDICATIONS).</ao:exact>
    <ao:prefix>IONS and WARNINGS .  Pimozide  </ao:prefix>
    <domeo:uuid>61D6F2D0-6072-4DC4-9717-C16FC18FFD23</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:61D6F2D0-6072-4DC4-9717-C16FC18FFD23"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0E61F9F6-7606-43B0-9CF5-1CA0AEF0F5BC">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7451FAEA-5C6E-4DE8-A40B-193CAF5462F9"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N00b3fc899f8246eeb5083f16edfc9b14">
    <domeo:sets rdf:resource="urn:pddi:uuid:1a58d1a8-7450-4fe3-8fee-36865e64b6f9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2578664-1D75-48A3-AFA7-3836F25D953C">
    <ao:exact>Clinical studies have shown that desvenlafaxine (100 mg daily) does not have a clinically relevant effect on tamoxifen and aripiprazole, compounds that are metabolized by a combination of both CYP2D6 and CYP3A4 enzymes (Figure 2).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-28 17:17:31 -0400</pav:createdOn>
    <ao:prefix>CYP3A4 substrates (Figure 2).  </ao:prefix>
    <domeo:uuid>E2578664-1D75-48A3-AFA7-3836F25D953C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2578664-1D75-48A3-AFA7-3836F25D953C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BB9CEDCE-13CB-47BA-837F-0FC94375C49E">
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2A080FCF-3F46-416D-AF77-BAEC6DF7AB70">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35255</dailymed:activeMoietyRxCUI>
    <rdfs:label>cisapride</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0d6d48d4-a545-47f1-b1c4-4405e51bd4ae">
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1ce0c8f9-72fe-43db-a646-268235235cd1</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:38abbb1a-c4b2-4eb8-9f53-87decd84c7f7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N81a96b69a18d4b4fbec69f1cdf9dd1c3"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4622e5eb-5521-4783-b58f-ff8e603f7006">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:68B82816-11A0-4F71-A29C-EB26E27431E6</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:06563ad7-25c5-411b-9d27-c90724e02752</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:9DD1108C-1D41-47CE-B0A4-275E98FF1684"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N165d6bfbb6c54f3f84aab23d055327db"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A39EFA50-ADE0-4CD9-889C-A3899ED085D1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-27 15:28:29 -0400</pav:createdOn>
    <ao:suffix>16 mg and fluvoxamine, the AUC for ramelteon increased approximately 190-fold and the C</ao:suffix>
    <ao:prefix>100 mg twice daily was administered for 3 days prior to single-dose coadministration of </ao:prefix>
    <ao:exact>ramelteon </ao:exact>
    <domeo:uuid>A39EFA50-ADE0-4CD9-889C-A3899ED085D1</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A39EFA50-ADE0-4CD9-889C-A3899ED085D1"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E74FDD61-47B2-40D7-AD4B-8E13506411BF">
    <rdfs:label>theophylline</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>300</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8630f58c-3fde-4f74-97f6-50cb1e06c70b">
    <domeo:uuid>c8963229-9497-432d-b4f7-e589310ace56</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:113ac7bf-323b-4193-a763-42ddad46df84"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:644CD15A-06D4-4908-ADFA-44DF683E12D4">
    <ao:exact>In another healthy volunteer study, lopinavir 400 mg/ritonavir 100 mg twice daily decreased bupropion AUC and Cmax by 57%. The AUC and Cmax of hydroxybupropion metabolite were decreased by 50% and 31%, respectively.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>erythrohydrobupropion decreased by 68%.  </ao:prefix>
    <pav:createdOn>2015-11-05 16:12:15 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:644CD15A-06D4-4908-ADFA-44DF683E12D4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BF8B7F3-A1F8-46D4-B993-E10F99513C98">
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-11-05 16:05:45 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-05 16:05:05 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">22</pav:versionNumber>
    <ao:body rdf:nodeID="Ne8bd1d6a3d9f488dbd760fd7a691cf09"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0BCEC0F0-D6D7-43AB-962C-DBB87E4B09FA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:4F598533-EB1E-421C-AADA-97962DA8B220</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E4F614F-4DD5-49CF-BECA-68ED4E06683D">
    <ao:exact>cisapride</ao:exact>
    <pav:createdOn>2015-11-06 15:42:00 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E4F614F-4DD5-49CF-BECA-68ED4E06683D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, or pimozide </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>not be used in combination with either terfenadine , astemizole , </ao:prefix>
    <domeo:uuid>3E4F614F-4DD5-49CF-BECA-68ED4E06683D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0e91e84c-9589-4471-843d-8e4b18171f9a">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:aadfc38e-82f0-4372-a2d9-d4bed2f786eb"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7626439D-6862-44C2-A493-3F7DC61F0170">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>4</dikbD2R:dose>
    <rdfs:label>midazolam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6bb03847-d695-4d5a-bc1d-18e714ff4e78">
    <domeo:belongsToSet>urn:domeoclient:uuid:1509a88d-c2ae-4e99-8741-6ab8612c477b</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:bb06e020-af04-4864-a0cc-539dfae8effd"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:afd96ded-7e7a-429a-adc2-f50bb387ebea</pav:lineageUri>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N21742f2f6280449f9152e40d3a77aa40"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/35E6057B-F407-4AA7-B7F6-D2B170F1CC2F">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>warfarin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DB7993C6-2489-40B0-93AB-B366A0720C09">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E41CCAB4-350E-4E95-83AF-8EAA72D51C91">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:A6316862-48B0-4147-AE57-9BD42BB9E6A8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-04 14:10:54 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:58976270-842E-4ABE-BB88-F7EAD951195F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6CE3958-8C23-4ECB-A13F-77A495409A43">
    <domeo:uuid>E6CE3958-8C23-4ECB-A13F-77A495409A43</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E6CE3958-8C23-4ECB-A13F-77A495409A43"/>
    <pav:createdOn>2015-11-05 10:29:53 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:suffix>dosage may be required if cimetidine therapy is initiated; upward adjustment if cimetidine therapy is discontinued.</ao:suffix>
    <ao:exact>SURMONTIL </ao:exact>
    <ao:prefix>. Downward adjustment of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B2BD95D8-562F-432F-BD0C-4326B9681AF8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdfs:label>theophylline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>375</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:309BB39A-A8A0-43A0-BA83-BF57F0F7F1C4">
    <pav:lastSavedOn>2015-11-02 14:32:33 -0500</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N61fddc590311414cbbf8efadc03557af"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:416b8957-0336-4c4d-9e50-6fe428ba6d44"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>urn:domeoclient:uuid:7f8b99eb-fe9f-4d67-b1dc-291ac7331c31</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:78c63ac8-627e-43a2-a83c-70c9f8889a6c</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N04bad6258b294b56ad02ebb8f4c396db">
    <domeo:sets rdf:resource="urn:pddi:uuid:08DF11B7-705A-4815-A4C2-3C505089182F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C185DF17-F70F-4F25-9D71-BA6FA47AA185">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/64825377-af06-4be7-9331-ba4ae3bb707d">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7c445ffb-25a1-4be4-b2c0-95880b280a5d">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:e7f11df6-195a-4f69-bacc-e8c628e30b37"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:10872bb7-50d4-4505-a1d4-bf5448624d4b">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1ee70a95-6198-4073-aee1-4656159da355"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:745fecc5-f8ed-475e-9368-9b1f012ee3cf">
    <ao:body rdf:nodeID="Nc685c90adb30460cb964a2dce5ce83e6"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:831BDB6A-28AF-4C5B-9157-A7E24E24DC11</domeo:belongsToSet>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:407B4C8A-51DA-4B66-AA21-EBB6D96A9B5F"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:eb2963c1-e6dc-4a02-90e9-69404fb6fe07</pav:lineageUri>
    <pav:lastSavedOn>2015-10-29 11:36:34 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DAF5C424-DCFA-4489-9AB7-9D4CE00AE1AC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DAF5C424-DCFA-4489-9AB7-9D4CE00AE1AC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.</ao:exact>
    <pav:createdOn>2015-10-29 10:29:26 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>DAF5C424-DCFA-4489-9AB7-9D4CE00AE1AC</domeo:uuid>
    <ao:prefix>is rapidly tapered in patients receiving maprotiline .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/30A71B53-B7D2-4E83-BB90-088FFD084549">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Efavirenz</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/195085</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B9CE845-DC5C-4C1A-B610-A49E5EABC515">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:05D1E91D-8E58-4E8E-995F-9FE6DBC6A3C3</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-02-19 12:41:40 -0500</pav:lastSavedOn>
    <pav:createdOn>2014-02-19 12:41:37 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5DDF6D10-A992-43D4-B1C2-B010E34F248F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4EB72DFA-1DF0-4016-9AF8-9E9AB9216686">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>phenothiazines</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7F1DA58E-69CE-4710-A6C1-E59509102F40">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D4DA3A63-3518-4147-B784-30125038917D"/>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2E0884CB-3CDE-4AAD-A1DC-DD69B6BC8291"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f28e573c-90af-4ebc-af95-0c43caf57cb2">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:532214D4-C47B-49C2-BAC5-486E86F1651E"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:56fdef2b-ed92-4c4c-8405-116b955c7550</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-02 13:56:21 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N652baea59cb2445e991212ba1c92900a"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:26C29A29-9D4D-4124-AA05-3F6A63894B34</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7140387d-2bdb-48f9-b9cd-02b8b11523ca">
    <ao:item rdf:resource="urn:domeoclient:uuid:29103046-22d2-4540-95bf-f19eb037108d"/>
    <permissions:permissions rdf:nodeID="Neb43b50944034fc2ba8896b26f2dab15"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f4216cf4-c508-45f0-b103-65507f929871</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1DE9C4E8-3313-4FC0-9DF5-926E9681AED0">
    <pav:createdOn>2015-11-04 14:17:25 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>) and many that are substrates for P450 2D6 (many other </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1DE9C4E8-3313-4FC0-9DF5-926E9681AED0"/>
    <ao:suffix>, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The </ao:suffix>
    <domeo:uuid>1DE9C4E8-3313-4FC0-9DF5-926E9681AED0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>antidepressants</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D997FE27-329C-4C1F-B4CF-2120417C0D14">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>90</dikbD2R:auc>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E6A0643D-8116-46A0-A691-7F806105339B"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A741B98B-3DF8-42FD-92C7-FB7461C30168"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmax>50</dikbD2R:cmax>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6eff8448f0bc4137a460339ba7c15655">
    <domeo:sets rdf:resource="urn:pddi:uuid:5D913B04-728A-4AD5-9E06-2F8E75D1E7BC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E632AC59-3CE0-42D4-A9E1-0F00D27DD792">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BBE22183-ABEB-49DD-B386-838584CB7566"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0561674C-7B8E-40DD-8D7C-BC3D00096736"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5FF6B35-2CDF-4450-831C-126721FE893B">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N1112f010208e4a8d828718ea4ebf11e6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E5945AB2-CACD-4305-9C95-807C77BA5143"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-05 15:34:06 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7F6E8B26-0798-4591-A35A-FD286D21BC5B">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>olanzapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64C30A90-955E-4373-A58D-AB831766717A">
    <ao:exact>fluoxetine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:64C30A90-955E-4373-A58D-AB831766717A"/>
    <ao:suffix>, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Neverth</ao:suffix>
    <domeo:uuid>64C30A90-955E-4373-A58D-AB831766717A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>), e.g., </ao:prefix>
    <pav:createdOn>2015-11-04 14:17:33 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cb01932a-d4e7-4984-b15f-5dbf16204256">
    <ao:context rdf:resource="urn:domeoclient:uuid:BCF33046-8773-4ECC-895C-44912210DB0F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:3720804a-7a30-4588-8a8d-720a82c18819</pav:lineageUri>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:713A7036-1151-42F3-8EE8-D11C70C93142</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N0e04d177b84f4173996dc8fe67ac3ea1"/>
    <pav:lastSavedOn>2015-10-27 14:13:55 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fb01480f-ff31-447a-9b7c-82db5281a48a">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:08461c3e-646a-4ed5-877a-a6cbe17623b3</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N9b09aac5ddfa45f6a46864d6a9dbac63"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:9641a202-c202-455c-9f26-944c65e753ae"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1b719f83-4360-4200-829e-80ab0390c854">
    <rdfs:label>propafenone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9BE7208A-31F6-4889-80F7-5437B259089F">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A358A616-8D27-4087-8D65-3EC986D52557"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6FB42CCC-65BB-44A9-ADD2-47ECB7F8D769"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/188631C7-0624-4A6C-8C2B-DFA879C2D35C">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0467888a-ea7d-4332-a828-51a4b9b4de4a">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N9ccd143939eb4b389f7350a804a22c16"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:6644b1e4-2609-4ffa-a3b2-fdb36c1fb275</pav:lineageUri>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0D338E16-D8C4-4103-A46D-BB3BC01B3103</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:06936DEA-D87D-409F-ACD6-3B46B0F7F61C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-02 14:00:44 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79144D90-8F25-410E-B7D9-583DD5E71DA9">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-04 14:17:32 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:F5E4E281-FACE-4D4E-8F8C-EEC853591305"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/11cb1950-035b-40f1-9ce3-bb971fce9ba2">
    <rdfs:label>teriflunomide</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09b4e6fc-fe59-4ba5-b13f-ad2f5f2a2270">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:f08e08b7-bb87-4c4e-9d76-1cb3aa1c8bc3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <domeo:uuid>c64fff80-fb3a-49b7-bce4-e14935482c95</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC521944-0E2A-42D6-A4CB-E1F7ED604ECD">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-06 15:36:55 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:467836C7-9ADC-490F-9404-77ED77633412</pav:previousVersion>
    <ao:body rdf:nodeID="Ncf4211df3d0c4fe18f607bba0dbae8a7"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:createdOn>2015-11-06 15:36:51 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:28242286-83F1-4123-BB80-CC63FAB8B940"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/42332AFF-D0BD-48D0-8A45-35ED498726A3">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N990f453309c74be099053ed4e735d0db">
    <domeo:sets rdf:resource="urn:pddi:uuid:a3cc324f-608a-4e17-8ae6-a425cdf3d8bf"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/42D5DED1-4A50-4235-9C3D-D2123B489DFF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>olanzapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B838713-7978-47A4-8388-9F4804CACE74">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-10-27 14:25:31 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4B838713-7978-47A4-8388-9F4804CACE74"/>
    <ao:exact>oxazepam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, temazepam) is unlikely to be affected by fluvoxamine. </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a4a42b82-ca0e-49d8-989d-d0b3b52e65ee">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d7cbbea4-45cc-44c0-abb4-789ed2fa0d94"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5FE87938-BCF2-40FD-AE17-AE7CFD0B5D7B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/943902d4-b563-436d-a69a-27c508b36baa">
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8bdb2436-184c-4935-bfc6-57703c59a2c5">
    <dikbD2R:auc></dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/aed2b5df-2414-466d-94a0-4da5af2174d3"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:cmax></dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6112bc5f-c5e0-47fd-9b02-41199319554a"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:t12></dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1195957e-f0f2-4846-80d1-242eb40790fa">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4a10aca5-c484-4b4f-b9f2-14bcad1e3637"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCBBFA9D-EEC8-42EE-B456-ADAEDC906CF0">
    <ao:prefix>decreased by 38%, and the </ao:prefix>
    <ao:suffix>decreased by 48%. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BCBBFA9D-EEC8-42EE-B456-ADAEDC906CF0"/>
    <ao:exact>erythrohydrobupropion </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 16:04:09 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16F7BA6E-9FF1-43FF-97A9-6747DDFB1A97">
    <ao:suffix>, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, cauti</ao:suffix>
    <ao:exact>sertraline</ao:exact>
    <pav:createdOn>2015-11-05 10:36:44 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16F7BA6E-9FF1-43FF-97A9-6747DDFB1A97"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>16F7BA6E-9FF1-43FF-97A9-6747DDFB1A97</domeo:uuid>
    <ao:prefix>, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:4FFBE488-8351-432D-91F9-4EE04E021A00">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:335741b4-9923-4512-a978-28f61e1b1328</pav:lineageUri>
    <pav:createdOn>2015-09-14 10:25:07 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:16f5fb29-d8d8-4054-96c8-c4527553339c</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N856c23b574aa4b308fa88a383b5449f6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:f50a8cfd-0afa-4395-8a23-47a8d03b3380"/>
    <pav:lastSavedOn>2015-10-28 14:38:28 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/248a6a6c-a6ae-4204-b274-ac68a6ca28e6">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>imipramine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/13b46c48-1551-4f30-aca0-e4a6a0606766">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>abiraterone acetate</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D0D7121F-E97F-4C54-9440-3CC2792F8168">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-10-29 09:24:53 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f34391a1-8aac-46a6-bceb-c36f3b39e0d4</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="Nad84ba9123f744db87a90f554e1b1f4c"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:5ec3436a-d8aa-49ac-b5f7-477074f2646c"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:C6F2D52D-9C73-4785-8CE1-1CBBE887667F</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7574aa93-c0db-4400-a114-79a677666162">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:02d78a6f-2c4b-446b-acef-dc3312221f4f"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N99408f56f3a14cfcbce2740d2e9f7843">
    <domeo:sets rdf:resource="urn:pddi:uuid:E90246C3-EDEE-42EC-B9A5-274C8F5E4151"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1a05a0ef24b245fd8396e9cf91ab54d3">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N14229f1dad194606aa660d024d576973">
    <domeo:sets rdf:resource="urn:pddi:uuid:410B00B3-F187-4C15-BFA1-53F39ACE92BF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E81248B-916B-451B-8F04-F260EE885023">
    <ao:exact>fluvoxamine </ao:exact>
    <pav:createdOn>2015-10-27 14:21:07 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>The effect of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>(25 mg b.i.d. for one week) on thioridazine steady-state concentrations was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coa</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5E81248B-916B-451B-8F04-F260EE885023"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d2824b60-f9ad-4ea3-b32d-f90f13a9bc13">
    <domeo:uuid>65e2d00d-b4cb-4989-b327-42e799c937ca</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <ao:prefix> B3 (OATP1B1/1B3) substrates   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:076e6fd5-188f-4c45-b6d4-0f39332b1319">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b26adfab-53c2-486b-9aa1-cc47d8d031e9"/>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e755d1eb-b9de-4ff8-8e97-4b0d182f6939"/>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71874bf7-ed90-4385-b2c3-3dd94cf4b0cc">
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:21067eaa-6f1d-4e66-9ca6-03d6085baecc"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N5b9b9f88b560459498f63183d9a45573"/>
    <pav:lineageUri>urn:domeoserver:annotationset:245f269a-ae29-4f01-99db-e938fc47b80a</pav:lineageUri>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2f219c1775194c5e961979f2621e856a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/d5a63b73-f6d0-47ab-9fbe-4e1c02650364">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>rosiglitazone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/84108</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E346B72E-0E66-4ACD-AFED-496CBF112A91">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/75D74469-9E15-4676-B9BB-CA83DF9A0963"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/86F02DA6-3F02-4FF8-BE36-0CA30945EA58"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:807c45de-562d-4e92-bd47-46d9e737e4e1">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:a4ef75e1-9591-4dcc-9846-8f184b9abb46"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd638f95ca8e04df2b2efb209dc1afac1">
    <domeo:sets rdf:resource="urn:pddi:uuid:41D198C5-5028-4861-8DE3-B20B90E78A54"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9A47646E-95B6-4AB3-90C4-78D4DE382EDD">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:36523EF1-0D46-4E70-8BF4-8B58C93C8B18"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FCCFFD5C-4699-4E0F-B0E2-2310CBBF05CE">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CCEC1329-CCE3-423A-BBB5-249641FC0A19"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/28A70C92-10BC-4703-B5EE-7C79DF903895"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1586ABF-DA16-476C-A029-6D283F1EB7DB">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C37B601D-FBF3-4C23-996D-9381844D7222"/>
    <ao:body rdf:nodeID="N219d717eeb4f46dab959bc7f88611d8f"/>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-27 15:22:48 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/513F1AB9-086D-43FD-B12C-26069E1BAF6B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>threohydrobupropion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:4181D6E9-2718-4EF8-B37F-C48D360D03B3">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-11-02 14:01:28 -0500</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="Ndd9c58f2a7114f5c96303bb2247b2d4a"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:aa164d8c-791f-4793-a2e0-ffd27a43832b</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:b4f4bbfb-2aaa-44d6-b977-9b0848d10492"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>urn:domeoclient:uuid:9067fd6e-f1ce-4f38-9f28-bf4d8964247b</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/427365A9-65B7-4540-83C0-DAE0C3F1632E">
    <rdfs:label>thioridazine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10502</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69c867c9-8334-477c-95e1-e3781f19677f">
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:3306a838-b03f-4f08-9913-05726ed8928f</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N1566b5576f684efb891a34613a13820b"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:bdd48305-369a-47eb-920b-a6b84a884738"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c35dbfb9-2e51-4dfa-9f42-c5c2217782b5">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6f262eb6-0bd7-4228-a2c6-8a63166bf314">
    <ao:context rdf:resource="urn:domeoclient:uuid:a75fb5df-7daf-4e6a-8c19-db4c78233b23"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:21ab3694-0521-45a0-aac4-063bbf59cd54</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-26 15:38:33 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-26 15:38:33 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8BD8B58E-6562-4BAB-AFC5-34464692A07A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>2</dikbD2R:dose>
    <rdfs:label>pimozide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/80BFBF5F-5D12-4245-A436-F08EE6F5850A">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>nelfinavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/134527</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na96cc1e6339d4d82a972839a2df78b3b">
    <domeo:sets rdf:resource="urn:pddi:uuid:8EA14293-DB7D-400C-B242-F9B5D6F323E4"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E4B9534E-CFF7-46D9-9DC7-64B103E1F707">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>omeprazole</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3ab4b215-505b-4566-a09a-d2294acb91aa">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:237701de-1eb8-4cdf-a541-3968522ba3e6</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:07a838d4-446c-4350-8d71-1980da3de1bc"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:87d003c0-cd8e-412c-9a37-34c2e8be30de</pav:lineageUri>
    <ao:body rdf:nodeID="N4aa157f7bea34e66b44e890263f90e5c"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8353cf71-b835-4d4f-a37c-0fe8b9bcc2db">
    <pav:createdOn>2015-10-26 15:36:49 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3f0d7588-8529-4b52-95e7-6212f57c6d4c"/>
    <pav:lineageUri>urn:domeoserver:annotationset:e60beacd-9b86-4ae4-bc85-8a57d7a54644</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:09FE9163-3F21-491C-94F0-EBB12BEF6F16</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2015-10-26 15:36:49 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/31a4f903-1c4a-4173-a4ca-fb1b4eb1e07b">
    <dikbD2R:dose>600</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>abiraterone acetate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7543B431-8ECB-455C-A470-42B5D47CA644">
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2264F182-4C37-40CE-9E84-3AC83C4F4642"/>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-04 14:17:20 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:dac5033d-3754-4a53-8194-fdfe97c9db21">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N22f0ccda4ac14e59970d565e517963c0"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:31160aa5-27c3-4384-8293-b3baa1a66322</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:8810ef8a-64af-49db-8af2-9dc06839752c"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A79D07F1-6CB3-49A7-BEAE-EB64560B7489">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Bupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:403160db-5fdd-461a-aa3c-d1bd250633b8">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:78f83393-81d3-405f-b0bd-18db51919a98"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F2565CCD-6E2D-44B7-95D7-8949B1CDF1B9">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:449BD368-F1C8-43E4-B3CF-A186BC3B8E98"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/aed2b5df-2414-466d-94a0-4da5af2174d3">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>flecainide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F43AEE97-B207-40B4-9395-136255B6DFD3">
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F62F5A44-B30F-48B0-8DD0-93AC24C56FDF"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3895638D-8C67-4383-BD42-532F5768CC2B"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ed2ef392-bf85-4f78-9940-ade4c66914d9">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:0c426a6d-5c38-4c4d-967c-4072b6e22f88"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:ba97ebb0-52fe-4b20-9476-62b08f41a3d9</pav:lineageUri>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:602767b5-bfe6-477d-90da-f76a4c6a200d</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N65d7cb095fc046f494a72475fa22ec35"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb5c5f2c092e94ca196c899a0b201964e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1D8BEC41-1043-4854-AF95-649EE120B891">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:32BB57ED-1D90-4578-B51B-073DDD619008"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF7BAACF-0678-428B-A323-3FE4F669E0ED">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>and </ao:prefix>
    <pav:createdOn>2015-11-05 10:36:38 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF7BAACF-0678-428B-A323-3FE4F669E0ED"/>
    <domeo:uuid>CF7BAACF-0678-428B-A323-3FE4F669E0ED</domeo:uuid>
    <ao:suffix>). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend </ao:suffix>
    <ao:exact>flecainide</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0d2c99f4-473f-4dd4-a770-e8ca2b77a858">
    <rdfs:label>clomipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2597</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0ba100b5-1173-4507-9d41-d393cfd913e5">
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/a1464bec-aab0-4c9f-8c58-f15050cbb11a"/>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:clType></dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/e9bbeafc-92a4-4d19-ad0f-419bdb6f419a"/>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:auc></dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81ad4b82-319a-485b-b356-fa43c79d4508">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:5ded21bc-9e1c-4d40-920d-e787a1e874c4"/>
    <permissions:permissions rdf:nodeID="N596ca3d30dda4797a56a38185c808664"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:971ba4fc-f79e-4d10-a5b1-b5f544744a2f</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-29 09:27:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b2279feb-58eb-4e23-888e-d82bd5091366">
    <domeo:belongsToSet>urn:domeoclient:uuid:ba159dc1-909c-4c0f-958b-c943b18244e6</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N6583b28fa16f4aa697c16fcb7a79100a"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 12:53:42 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 12:53:42 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3751e6da-8fc1-4575-aa29-8958c804f78b"/>
    <pav:lineageUri>urn:domeoserver:annotation:c8a36840-e1a8-42c4-a180-56a4661e7a9e</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15205c46-00e6-4b20-91e1-7b604903fdf2">
    <pav:lineageUri>urn:domeoserver:annotation:f0edadaf-e9fa-42ec-9dbc-10577138aa44</pav:lineageUri>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:4e7f3830-c3b2-43fb-87a4-c71659910983</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Na56f676294154c66804f40ef1a7eca4f"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:169609b8-695c-43f5-a9f9-9cb29455ee0d"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86e9a542-be4f-48a2-bd2a-040b33f0be44">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <ao:exact>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).</ao:exact>
    <domeo:uuid>e89f987b-7e07-4c3f-80af-30b8c494b74c</domeo:uuid>
    <ao:prefix>see Drug Interactions (7) ] .  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7c3e5a3e-aeca-4a8e-9d68-ff7647dc16a7">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:e67c3eb4-b749-419f-89c2-a22b408af8ec"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4d2ea06c-67b8-4760-bafd-0acdb80434e2">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>25</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>Savella</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6e856a41-108d-4b59-b7ae-482e1fb6381a">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:fe79631e-a647-4ec7-b008-c689126c8f97</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:833DCF24-F810-43B1-B057-C08C0098CA91</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:9005E612-DEFD-4B7F-8FA7-F593C5D62654"/>
    <ao:body rdf:nodeID="N285b7b2a03c84e059069cf819cd696b0"/>
    <pav:lastSavedOn>2015-10-27 14:13:01 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4ee6e782-fb9c-45e2-8a34-9c13d9e13a78">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C121A421-8DBC-41A4-9B5B-4F136D2305C9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>amitriptyline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/704</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>75</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/959fb86a-4a1a-4fad-af3b-1c178b42ffdd">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8d47bd04-786b-4588-a67a-384db4149542"/>
    <pav:lineageUri>urn:domeoserver:annotationset:8ef31bd1-f7e0-4603-8d36-48793058314d</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2015-10-26 15:40:28 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B19016AA-1639-420A-B594-59F3CC8DF372</domeo:belongsToSet>
    <pav:createdOn>2015-10-26 15:40:28 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:85744EE4-C6E3-43CF-9D87-A3EA114378E5">
    <ao:exact>Efavirenz: In a study of healthy volunteers, efavirenz 600 mg once daily for 2 weeks reduced the AUC and Cmax of bupropion by approximately 55% and 34%, respectively. The AUC of hydroxybupropion was unchanged, whereas Cmax of hydroxybupropion was increased by 50%.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 16:14:19 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:85744EE4-C6E3-43CF-9D87-A3EA114378E5"/>
    <ao:prefix>metabolite were decreased by 50% and 31%, respectively.   </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/591e49d1-3e58-43fd-895b-0462e962e599">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>barbiturates</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1a92d9cc-891e-4a52-9c7e-6768abb24ebe">
    <rdfs:label>bicalutamide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/add85373-a8a0-4fc1-a2e0-1f672655a4f4">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:2E89F899-B5BE-4081-A778-6C6EF96E93B4">
    <pav:createdOn>2015-09-24 15:38:09 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Na87a054904d74db5828a0bc76d108bda"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:cdedaa7f-d2bd-4668-a964-637ee626cdec"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:92c4068c-6bde-4bdc-a673-a364d5607067</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:22047a98-ec2b-4035-868e-37b5873b5bd2</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-10-28 17:22:11 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9B7003CB-BB99-4A92-A8D6-7E0E9FF488E7">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/31144B92-3B12-45BF-9218-D0C18CE802AE"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C35FE4A2-AFA9-4715-B647-8ABA65C1FF95"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6aef5e0edb2049008b0e4dc29e51fddf">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0556E268-C456-4FB3-85D0-93EE6D99C185">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0556E268-C456-4FB3-85D0-93EE6D99C185"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-27 15:37:14 -0400</pav:createdOn>
    <ao:exact>A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone. </ao:exact>
    <ao:prefix>   Lorazepam  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0556E268-C456-4FB3-85D0-93EE6D99C185</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96CA1954-A3A8-4274-AA81-5B7785E08750">
    <domeo:uuid>96CA1954-A3A8-4274-AA81-5B7785E08750</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>not be used in combination with either </ao:prefix>
    <ao:exact>terfenadine</ao:exact>
    <pav:createdOn>2015-11-06 15:41:56 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, astemizole, cisapride, or pimozide </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:96CA1954-A3A8-4274-AA81-5B7785E08750"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6fc2f815-7682-44a9-9533-c870a7e5b473">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C42FCFD8-0A10-4301-B999-03B395377674">
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <ao:body rdf:nodeID="N7a7862df0f294b7e8a391156c45d40ac"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-05 15:40:32 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:16DB41D8-05F0-4046-8F36-8AA2C8492805"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C814894A-0420-415A-9A41-21CEAB6AAD3E</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-05 15:36:15 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9F47AC04-1EB8-4851-A741-3F51527D4017">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>bupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0495ca1b-45f6-4e70-ab90-fd00898ae72d">
    <ao:exact>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).</ao:exact>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <domeo:uuid>1f2687ff-b752-4387-89a0-ee16c3743521</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>see Drug Interactions (7) ] .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:191BFE99-76A2-4D56-B743-6FEBFB6AA693">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:191BFE99-76A2-4D56-B743-6FEBFB6AA693"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>191BFE99-76A2-4D56-B743-6FEBFB6AA693</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>(TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <pav:createdOn>2015-11-04 14:12:05 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/638739ed-3dc6-485a-ba80-1ecd9f5bfa9f">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>phenytoin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9beb7beb-84b0-4bc5-9afb-b4d3cb3855a8">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>d2d35941-3e26-4407-9940-131037c10dd1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N14ddc9801dd34a5499741668ccb907c5">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb798a79d4c0748cf8faa8ba9f36f0b32">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A39DFE91-A153-456A-B7C1-626760ECE97C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C2A8D258-09E4-4DE6-8757-F02BCC742629">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>duloxetine</rdfs:label>
    <dikbD2R:dose>60  or 120</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2fc1a4a0-3b89-41c7-aa77-fc1e37454e20">
    <domeo:uuid>7af2c0ce-15df-4e12-a1b7-ec5c68e30665</domeo:uuid>
    <ao:prefix>nsporter 3 (OAT3) substrates   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EC9EAD2C-5617-4FEC-8FF8-F60E4DBD2413">
    <rdfs:label>citalopram</rdfs:label>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10cfcb0e-8c2b-41a8-b34a-9ff579c20c02">
    <pav:lastSavedOn>2015-10-09 13:39:25 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:6bdf5a6c-2688-4bf1-a9bc-66dcfde8e0c1"/>
    <pav:createdOn>2015-10-09 13:39:25 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:8e06dac1-d04b-4e9d-bbb9-949405dcbf2f</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:a35a3a75-93b3-4272-a1bc-970f69d366fd</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N838d15129ab54769a8940322198fe6b4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e30d50fe-3a8e-4680-8792-285b32ee4d37">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e87fbc93-34a6-486d-a58e-dbdc45992016">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>Percent</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12>35</dikbD2R:t12>
    <dikbD2R:t12Direction>Decrease</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/997d38ea-15c1-4649-ac1a-860bf32c64b5"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8a5e148e-6a79-43f7-91e9-6e46fb821965"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87315DAB-63F9-4523-8CF6-405F0735F8BA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>87315DAB-63F9-4523-8CF6-405F0735F8BA</domeo:uuid>
    <ao:prefix>  Phenytoin  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-29 10:32:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:exact>In healthy male patients (n=18), phenytoin (200 mg daily) increased mirtazapine (30 mg daily) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 45%. Mirtazapine did not significantly affect the pharmacokinetics of phenytoin.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87315DAB-63F9-4523-8CF6-405F0735F8BA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFC9B2CF-3F31-4A14-94C9-37420FD3E25F">
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:3FBEBFA6-F058-479F-8819-D42F2A400E48"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-04 14:17:24 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6B7529D-3CA2-42D4-8C8B-E0D23C3DD1D9">
    <pav:lineageUri>urn:domeoserver:annotation:29D7FE3D-0C9E-4E3E-8EE2-131D10111D28</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-04 14:21:12 -0500</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N2938a4d28b8442f2b32f2c0c4d9b6005"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F8CE630-F8EF-47C8-87C1-EBE912609938"/>
    <pav:createdOn>2015-11-04 14:20:49 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1BE6118C-5E0D-4FBC-83BC-FEC7CAE56539">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e143043ef9cf90143f8ea240c0005">
    <foafx:email></foafx:email>
    <foafx:name>Katrina</foafx:name>
    <foafx:email>kak59@pitt.edu</foafx:email>
    <foafx:lastname>Romagnoli</foafx:lastname>
    <foafx:name>katrina</foafx:name>
    <foafx:picture></foafx:picture>
    <foafx:firstname>Katrina</foafx:firstname>
    <foafx:middlename></foafx:middlename>
    <foafx:homepage></foafx:homepage>
    <foafx:title></foafx:title>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:lastname></foafx:lastname>
    <rdfs:label>katrina</rdfs:label>
    <rdfs:label>Katrina</rdfs:label>
    <foafx:firstname></foafx:firstname>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BD1C4FF-5749-4CB8-9588-7BE67B1E525D">
    <ao:context rdf:resource="urn:domeoclient:uuid:7F49C4F1-8C35-4B06-967C-710EA6BE82E9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E536FE66-FAD0-488D-B7C0-39E59CBD9678</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:e5208d0d-d470-424b-a0e0-4a4b5da16c0e</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:9540ed61-ff6a-4399-86bc-04d7b87b26df</pav:previousVersion>
    <pav:createdOn>2015-10-29 10:39:47 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-29 10:41:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB3EBE32-164E-43F1-87D1-5952E684C01A">
    <ao:prefix>), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-27 15:33:07 -0400</pav:createdOn>
    <ao:exact>alprazolam</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DB3EBE32-164E-43F1-87D1-5952E684C01A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>), and CYP2C19 (e.g., </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>DB3EBE32-164E-43F1-87D1-5952E684C01A</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82f90ada-99b2-4d0b-ba9b-7bf6d0decc19">
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:a33ef419-38d1-4867-880f-27271a423023"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:4f851737-ac84-430b-bed7-95616cbc3228</domeo:belongsToSet>
    <pav:createdOn>2015-09-10 15:01:13 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N370e93fbe3ec4f05ba82b078a427efcf"/>
    <pav:lineageUri>urn:domeoserver:annotation:a20c22e6-1d3a-451e-861f-2b3b1a52e464</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F7D20CD-DA6C-4E21-BE68-4843C96E2BFD">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0F7D20CD-DA6C-4E21-BE68-4843C96E2BFD"/>
    <domeo:uuid>0F7D20CD-DA6C-4E21-BE68-4843C96E2BFD</domeo:uuid>
    <ao:suffix>and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problem</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-05 10:36:37 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:prefix>, and the Type 1C antiarrhythmics </ao:prefix>
    <ao:exact>propafenone </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C5BBADF-C72E-400B-97F6-E2A1265E6622">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <ao:prefix>   7.9 Lithium  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Coadministration of racemic citalopram (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when Lexapro and lithium are coadministered. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6C5BBADF-C72E-400B-97F6-E2A1265E6622"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-02 14:27:25 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>6C5BBADF-C72E-400B-97F6-E2A1265E6622</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08D39A39-3238-4337-B638-3FC9B51B7CC8">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:08D39A39-3238-4337-B638-3FC9B51B7CC8"/>
    <ao:suffix> can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressants.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <domeo:uuid>08D39A39-3238-4337-B638-3FC9B51B7CC8</domeo:uuid>
    <pav:createdOn>2015-10-29 11:27:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and</ao:prefix>
    <ao:exact> tricyclic antidepressants</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8781AE6D-3AE0-47D5-A7F9-A1788E689198">
    <rdfs:label>psychostimulants</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9a43aa1d-af6d-4248-85bd-ab0c86136e4a">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:db5daa5a-e41f-44bd-861c-2f2a7851eb50"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2C087E38-767E-48CC-8619-6D6235E8E09B">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8440DE83-5B2F-48CB-B6D9-4B886805595B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62d64070-365c-422b-9094-ae3c64eca5b0">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 13:28:11 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B789842D-BC1D-4B52-A16C-141712ADA773</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:3DEE2CBA-9782-4CC4-82D4-7E310EDBE581"/>
    <pav:lineageUri>urn:domeoserver:annotation:8f4f0ae5-7f76-4a5c-8f2d-594c9062a1f4</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-02 15:20:43 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Ne9a42d3b71064889b5087517eb4fd0a7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:906F3FA6-8000-486A-B628-F0F7EEA2E6F5">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-11-04 14:17:25 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1DE9C4E8-3313-4FC0-9DF5-926E9681AED0"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f6db2bd1-0d97-4aff-a1d8-0cc44d9c8de9">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7e1c91a7-c9ee-4912-b31c-95e75309c666"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1adcb574-a332-4eb1-a8a8-46c14ccd2101">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:6e747112-1cb1-4314-a89c-7660df2b33b4</pav:lineageUri>
    <ao:body rdf:nodeID="N46739bce56124b9eac2e491c113a8e6a"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:9BBF4668-61FA-4B8A-BFCE-BE4D3CEF4613</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:552C48E1-1973-4FAB-A8BE-44B465F504FC"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-29 09:10:04 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:214a2140-7249-40a5-98b0-b986a77d9587">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <domeo:uuid>cc625cb8-d9d6-4281-b0f1-7cf354156746</domeo:uuid>
    <ao:prefix> B3 (OATP1B1/1B3) substrates   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7a84140d-0985-4ee7-a95a-bb06e3f813bc">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:62A5F1A2-FEBD-438B-9D5A-2E6D98358166</domeo:belongsToSet>
    <ao:body rdf:nodeID="N3ab8c197e78247ca807cfd7a0d1baa65"/>
    <pav:createdOn>2015-09-24 15:38:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:868c84f7-973d-4452-9ded-d7399350775a</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C94F9049-B6EE-4E48-9DC9-62F313EA8878"/>
    <pav:lastSavedOn>2015-10-28 17:20:54 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f75a0488-e9fe-423d-a368-62d4a09b99f5">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:443bb69e-a4f9-40b2-964d-0cac7fb8e46d"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:86fec734-86b8-41ea-9d50-3262c80bd6cc">
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b88a1901-1f1c-4c3d-bd85-6d464ec19318"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:t12></dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/b82eb72f-d58c-4ce2-b14b-73666ee99b7c"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94c5d273-2ea0-4353-b339-5b3fec267fbb">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:a18a2680-8d56-4323-9cbb-35fb0368aba4</pav:lineageUri>
    <pav:lastSavedOn>2015-10-27 13:28:11 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:C963BD83-FC2E-4C9F-BC3B-03ED3156CD41"/>
    <pav:createdOn>2015-10-02 15:20:43 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N9b5695d220e941f8ab15fd05c7b29f72"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:205CB033-E181-459F-82FC-82AA818285EE</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA2984D2-433D-4D1A-95B2-5BC3937E7381">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EA2984D2-433D-4D1A-95B2-5BC3937E7381"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-27 15:36:48 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>EA2984D2-433D-4D1A-95B2-5BC3937E7381</domeo:uuid>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12f63dd4-b6a8-45d0-93c0-abe9cd468593">
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-16 15:31:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:17E418A6-5BE7-4999-B747-3AD484A638B6</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N92cee00c9bc14e8c86a7160f407c3ca5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:147653d1-fdc6-4ee1-9cc5-439c9407a56c</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:53E91269-BCB0-42E8-96A8-679520D8F273"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:67930fe5-f499-4fda-bf4e-cac5f748bad3">
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/f650a6f3-f488-48a8-8926-b8daac5ca510"/>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/26b1e5d4-fa96-4647-8c3c-480b78b32977"/>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4DBA7B4-CD0B-4EEE-8B59-9B0428F2C0A1">
    <domeo:uuid>A4DBA7B4-CD0B-4EEE-8B59-9B0428F2C0A1</domeo:uuid>
    <pav:createdOn>2015-11-02 14:47:42 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>olized by Cytochrome P4502D6   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A4DBA7B4-CD0B-4EEE-8B59-9B0428F2C0A1"/>
    <ao:exact>In vitro studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/67DE52A1-C60E-4EF9-B19C-4518533701BC">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e4ea7d35-7698-42d5-bc4e-86f28ea6f5d6">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:bfdbfef3-39b1-4617-aa97-aae5a8079cd6</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N1978423c6dd744e5ad6c58db943fc84a"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:1562cd54-c734-4ae1-a717-729f3459f2a7"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6f76e69a-693f-4c42-9e3a-7a94704139f6">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:A4DBA7B4-CD0B-4EEE-8B59-9B0428F2C0A1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N29e7222a488e45df8c004b523fdff983"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C75AAB7A-111D-4CB2-BDB0-9064DB312EB9</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:70bae5b0-37ca-4f57-bf0e-a3a0dbcd1501</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-02 14:48:13 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7a05e3ad-a367-4086-8846-6403343f29f2">
    <domeo:uuid>dab65397-b552-4837-8864-11c4bae506d7</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3670085b-21f7-453b-bb89-4514b926986f"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne84536653a08459fbee36cf0ceb62f4c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13bf58c4-7b8e-4e9c-8871-e3697e55b743">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:b246dc4b-35d2-4a89-91ce-971ef1006b97"/>
    <domeo:uuid>d5eaf54f-0109-4870-8c19-f982e6f54bd7</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ff23933-6dda-496e-bb0f-9ebbd6c66e5b">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <domeo:uuid>f6e5ab01-5475-440a-af3a-ec54e76129ea</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:f69dabe4-861f-4ad9-b832-4dede4370688"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CEF2EC9E-DF93-4417-977C-5AA74AA3BB22">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2CBB9425-767E-4B80-A5A2-4AFFF6B51E32"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A1B28CD8-B293-407F-91D3-F8116978A071"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6a1d4126-6472-4af0-b5e0-8307e6d61666">
    <pav:lineageUri>urn:domeoserver:annotationset:47014ae6-1c46-48b4-a067-6ea5417a010c</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:a7552df6-4b8d-41c3-a267-281f2e4cf031"/>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="Nee474e7de0e74a5da3cd2a36a9dec7c8"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc9dbf9d4227d4cf88efb17fda1763f39">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCF33046-8773-4ECC-895C-44912210DB0F">
    <pav:createdOn>2015-10-27 14:13:54 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Olanzapine    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with olanzapine, a substrate for CYP1A2, CYP2D6, and possibly CYP2A6, did not affect the pharmacokinetics of selegiline or olanzapine [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>BCF33046-8773-4ECC-895C-44912210DB0F</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BCF33046-8773-4ECC-895C-44912210DB0F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4A38A493-8AFD-48AD-BF4B-BA10E3DB4A24">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>erythrohydrobupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/737FCF99-E840-4209-872F-039C6EF9C37D">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>antipsychotics</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ab4bebbb-9ce9-4ccd-8588-e00abe2bcb89">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <rdfs:label>pimozide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>2</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3d9078c856da4971a457279e8bb10bdd">
    <domeo:sets rdf:resource="urn:pddi:uuid:7c445ffb-25a1-4be4-b2c0-95880b280a5d"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BFD8459A-1C50-400C-97DB-A01261990570">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6F87DEF1-707A-4561-83D4-D9A596238A13"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6480ba45-6243-41eb-a0f8-d38b95d3fd58">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-10-26 15:41:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <ao:exact>desipramine</ao:exact>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> with the tricyclic antidepressant </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6480ba45-6243-41eb-a0f8-d38b95d3fd58"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B5FEDBD6-FDAF-4372-97D2-D0933C5B217A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:9716a47b-825b-4c6e-8ae2-271752fe0384</pav:previousVersion>
    <pav:lastSavedOn>2015-10-29 11:26:06 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:9d24ce03-afb4-49b2-ae6d-6f879313d81a</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N998c19f1757d41dabffa0cdc7472ca17"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:cd023039-00ce-400d-9146-f58ffd941877"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ca26dec2-c067-4624-bcc9-07586715137b">
    <rdfs:label>levonorgestrel</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6373</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:434EB3AD-3AE0-494E-8B5A-AEFE7AF594A2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>434EB3AD-3AE0-494E-8B5A-AEFE7AF594A2</domeo:uuid>
    <ao:suffix> The patient should be informed that the response to alcohol may be exaggerated</ao:suffix>
    <ao:exact>Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressant.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:434EB3AD-3AE0-494E-8B5A-AEFE7AF594A2"/>
    <pav:createdOn>2015-11-04 14:07:00 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C2897B28-AA34-4A23-AD93-B7F4B782030D">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5763E47C-017C-4E4B-BB24-79C697FE917E">
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6A7AAB68-7C3F-49E6-965D-661F2C8FA5D9"/>
    <dikbD2R:auc>18</dikbD2R:auc>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E198D86C-C690-4917-8A99-E227F400F74B"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:cmax>14</dikbD2R:cmax>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5eaf6cf6fa5840379477ce2c3a2d350b">
    <domeo:sets rdf:resource="urn:pddi:uuid:fcc85c0f-7eec-440d-8b74-3e83355fb2c8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c4d4452f-6c26-4922-98e6-3e34f0134e50">
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N0b365805418346b6874048389bb0fd9d"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:d6370890-c097-4d8d-8104-361a1886e60a</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:466c6db3-9987-4157-be09-3dd5435a6e7d"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4e0bfd21-7f14-4db6-9ede-b6805c1f975f">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:prefix>er tricyclic antidepressants.  </ao:prefix>
    <domeo:uuid>db21b56e-7580-4710-b1dd-0ed432cb4503</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9fb72584-f1bf-41b3-b487-67935b39aee4">
    <rdfs:label>ethinylestradiol</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:72366495-7b3f-4931-8e2a-104ec3899a46">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4eb771ff-d3bf-4334-8132-17b73ef866f5"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28242286-83F1-4123-BB80-CC63FAB8B940">
    <domeo:uuid>28242286-83F1-4123-BB80-CC63FAB8B940</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-06 15:36:51 -0500</pav:createdOn>
    <ao:prefix>    Triazolam   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>When a single oral 0.25 mg dose of triazolam was coadministered with nefazodone (200 mg BID) at steady state, triazolam half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. Nefazodone plasma concentrations were unaffected by triazolam. Coadministration of nefazodone potentiated the effects of triazolam on psychomotor performance tests. If triazolam is coadministered with nefazodone, a 75% reduction in the initial triazolam dosage is recommended. Because not all commercially available dosage forms of triazolam permit sufficient dosage reduction, coadministration of triazolam with nefazodone should be avoided for most patients, including the elderly. In the exceptional case where coadministration of triazolam with nefazodone may be considered appropriate, only the lowest possible dose of triazolam should be used (see CONTRAINDICATIONS and PRECAUTIONS).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28242286-83F1-4123-BB80-CC63FAB8B940"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na732a57e80384b158e4410f8f4b36459">
    <domeo:sets rdf:resource="urn:pddi:uuid:A47E09CA-DF5F-42DE-9045-56346A45E20C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/294ABC2F-243F-49ED-9DEC-165CBB938C4E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>150</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1ED20ED1-FB0C-422E-8105-1ED7D0D52049">
    <rdfs:label>None</rdfs:label>
    <dct:description>none</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N08db3056a03b431ba8ba8743f472af51">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB4012A4-8440-40AA-92FF-784FDC2F95DF">
    <ao:body rdf:nodeID="N7543e896860748cab66223683a284d78"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdOn>2015-11-05 15:31:43 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B6CD0807-1447-4428-BB54-6463F5867D5C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/29C767B7-F372-43D6-AD91-4CE8CD8620CC">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>phenytoin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f8e96222-c3b2-4044-a4ae-5d476ecb838e">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:c19ee125-1ed0-4374-bf98-5794460d7a19"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FDFBBDA1-FAD7-4F01-BE07-CB62D83D0B17">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D8232B27-703A-40E2-AFD3-B8CC8B7E3550">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Ticlopidine and Clopidogrel: Concomitant treatment with these drugs can increase bupropion exposures but decrease hydroxybupropion exposure. Based on clinical response, dosage adjustment of WELLBUTRIN XL may be necessary when coadministered with CYP2B6 inhibitors (e.g., ticlopidine or clopidogrel) [see Clinical Pharmacology (12.3)].</ao:exact>
    <pav:createdOn>2015-11-05 15:24:23 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D8232B27-703A-40E2-AFD3-B8CC8B7E3550"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:prefix>XL and drugs that are inhibitors or inducers of CYP2B6.   Inhibitors of CYP2B6    </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F966B506-6D61-49B3-9C94-8C8823E84A1A">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:09075926-828F-459F-8784-80EAE0C6630B"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:166FE726-B175-4B66-AD2E-94D1BC32272A">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:07ECF42F-1960-4FB1-911D-E81375702C9E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a8358570-c250-4b5f-8854-0a089e90f6ce">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>imipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:866ea3c1-fb9d-49fe-a09a-6cb40aa85284">
    <pav:lineageUri>urn:domeoserver:annotation:94301bc9-6288-4acd-a044-050748c19f48</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0132436C-62D7-49DE-8254-2FDA7121BE0C"/>
    <ao:body rdf:nodeID="N358a4da1ec5c477fa746ed54630db5bc"/>
    <pav:createdOn>2015-09-03 15:51:47 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7CA24CE0-A689-41AC-9467-CE01C89837EE</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-27 14:13:01 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC1B08AA-FBBA-4D9C-9A6C-CC98ACEE2568">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>EC1B08AA-FBBA-4D9C-9A6C-CC98ACEE2568</domeo:uuid>
    <pav:createdOn>2015-10-28 14:30:48 -0400</pav:createdOn>
    <ao:prefix>).  Drug-Drug Interactions    </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EC1B08AA-FBBA-4D9C-9A6C-CC98ACEE2568"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08f31c18-2c15-470f-b269-6611615a6c44">
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:75d49ddd-c175-4cf2-932f-2c765ccfff9e"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N27fb1386d4da41838733fc1dc8f90044"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:1f57f33a-8b31-49b5-8082-10d1be11a792</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:78EA69AA-9256-4778-8B5B-DF45F3C421C1">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3EEC50B0-D1AA-4EF5-90C3-8F4C7664A640"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nff9472b2ead046e6a2f8743d3671be1d">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f80789e5-efff-448b-842c-02a82bdb4423">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>selegiline</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:225847C4-68BD-4417-BE91-CE55BF7E78E7">
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:6426edbd-e01c-45ce-9151-eac311cb230b</pav:previousVersion>
    <pav:createdOn>2015-10-27 14:22:21 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-27 14:23:19 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F2555F0D-F6FF-4961-8CEB-7B8E9BD7A280"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/08da0031-c130-4fc8-8227-1794d460a312">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <rdfs:label>rifampin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:B6192156-5215-4F6E-B3C6-3F293A9625D1">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-09-09 14:15:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5F457462-1E65-414F-A6B8-152CEC48CC37</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3b4942d9-7add-41d9-98be-706632f23085</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:5b8129e3-a17c-4abc-a794-306ee68e4882"/>
    <permissions:permissions rdf:nodeID="N1639de93418b4bc9bbfdccdd54f774a7"/>
    <pav:lastSavedOn>2015-11-02 14:48:13 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:179e407b-085c-4f15-8752-fa7bf3392f0a">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2ede8d10-1816-43aa-a80d-2ba06c4492b4"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:43D68940-BA31-4A9C-9ADD-320B16D178CB">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:dad2d738-c63b-4090-bf0e-869ff0a788dc</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:7d071575-e58b-4d04-93a2-879f2fe78e74</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N2d5efba58f994e678fc80ae16fb2f55c"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-09 13:25:44 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:c809d21f-3eea-4d1f-9a00-c946168f1bb9"/>
    <pav:lastSavedOn>2015-11-02 13:32:33 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:974e5d39-48ec-49d5-b3de-0896e9e5ac9c">
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:3a5ca36f-9da1-4239-9224-65a22b6d9c4d"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="Nc314a25863af42e78fb5c1964934cb7b"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:9a7a5c41-083e-4a45-9190-0d010254fa63</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9d4c4b6a-4133-4533-b329-e69b9d02603f">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].</ao:exact>
    <domeo:uuid>8a9a2b15-14f4-4a86-84e8-9bb6905b63e5</domeo:uuid>
    <ao:prefix>beta blockers or diltiazem )   </ao:prefix>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABE46A55-6147-466A-8750-29C6C8A38D5A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>). Nefazodone hydrochloride tablets are also contraindicated in patients who have demonstrated hypersensitivity to nefazodone hydrochloride, its inactive ingredients, or other phenylpiperazine antidepressants.  The coadministration of </ao:prefix>
    <domeo:uuid>ABE46A55-6147-466A-8750-29C6C8A38D5A</domeo:uuid>
    <pav:createdOn>2015-11-06 15:33:49 -0500</pav:createdOn>
    <ao:suffix>and </ao:suffix>
    <ao:exact>triazolam </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ABE46A55-6147-466A-8750-29C6C8A38D5A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c24d8eb0-78d3-4fb2-b803-5c643e732524">
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>tantly administered rifampin.  </ao:prefix>
    <domeo:uuid>978b6dc9-bc1e-4d72-83fe-66b70231c9cc</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4AAB3974-2AF1-45E9-87F2-267A096DEF6E">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4AAB3974-2AF1-45E9-87F2-267A096DEF6E</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Warfarin    Warfarin is a substrate for CYP2C9 and CYP3A4 metabolism pathways. In healthy volunteers titrated with Coumadin®# (warfarin sodium) to clinical levels of anticoagulation (INR of 1.5 to 2), co-administration with EMSAM 6 mg per 24 hours for 7 days did not affect the pharmacokinetics of the individual warfarin enantiomers. EMSAM did not alter the clinical pharmacodynamic effects of warfarin as measured by INR, Factor VII or Factor X levels [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <pav:createdOn>2015-10-27 14:17:34 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4AAB3974-2AF1-45E9-87F2-267A096DEF6E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1e7aa226-e6d9-4cd1-9b3d-9f67f7f344fa">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:145d9362-1291-4f98-b695-f9adc4309857"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <domeo:uuid>796e6744-0a82-4f9c-b46c-ecba0967569c</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b60b8ebc-a9af-4ecb-b424-9987e1ce03ae">
    <permissions:permissions rdf:nodeID="N0a7d81149379460aa574ff69c1cab7cc"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:60aa1780-e126-4f63-84f8-37baa7ad7c05"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:9e8b43e8-9778-4aea-92f3-6718892fe576</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f46fba28-4e95-42e3-bb3e-e70de1cdc13d">
    <domeo:uuid>74eecae1-ae6a-49d9-981d-18322fe17909</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2e637f03-2b09-4edd-a5e7-8ec326626e6d"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C4B0ADA6-0BAA-438C-AFC9-2DE7FD63F829">
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>duloxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E9A62CA3-EFD9-4609-9A41-F7C56DD6730D">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:59594494-231D-4FFC-991C-6A3105D5F07A"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f59ff367-3f3c-437a-a985-00d6a771509a">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>GILENYA</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF1F538A-51D9-4436-A77C-3621A118D58E">
    <ao:context rdf:resource="urn:domeoclient:uuid:465B3927-F649-4C3A-8323-1683980B3815"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-06 15:42:01 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:8EE4F288-19C8-4519-85CB-791C9E9709D8</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-06 15:43:14 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC37D59A-A1D5-46A3-A339-64FD1259E0D0">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-11-05 15:42:05 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:42CDF3D8-206B-4339-A4F1-E3270243FB5B"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N515c6d7e39ce44f5a1b40dd3ff682d84"/>
    <pav:previousVersion>urn:domeoserver:annotationset:74BAF9C2-86FD-4C09-9153-BEDF3C491F61</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdOn>2015-11-05 15:42:03 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N259d27a173d948a8a43191a58c308880">
    <domeo:sets rdf:resource="urn:pddi:uuid:9E7D01D2-6379-4CCD-A5DF-4416922C8755"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/262948f5-2072-447f-9004-c290946d3008">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0C387A6-CEA4-4C12-8E2E-28EB2A0E1A89">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B0C387A6-CEA4-4C12-8E2E-28EB2A0E1A89"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <pav:createdOn>2015-11-05 15:32:16 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B5D43310-BC0F-457C-A969-72FBAF39F48D">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>hydroxybupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f9994c9a-4b18-4dc5-9126-0e31b5557f1c">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/08da0031-c130-4fc8-8227-1794d460a312"/>
    <dikbD2R:preciptDuration>6</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/31a4f903-1c4a-4173-a4ca-fb1b4eb1e07b"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>55</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N902c67cc5c5d4d24b9700d3cdb64411e">
    <domeo:sets rdf:resource="urn:pddi:uuid:78EA69AA-9256-4778-8B5B-DF45F3C421C1"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/950753BD-72DB-431D-87E3-2963005AD9AD">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdfs:label>sertraline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N60f9d19799304492adce3a102f9e7b73">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e755d1eb-b9de-4ff8-8e97-4b0d182f6939">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D046132-84C4-4ABF-8B1C-EC07A0D07CA1">
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <rdfs:label>Active ingredient</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:38749D70-4E6C-499F-A879-5A4F9E9F6532">
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:215c0e14-24da-483c-9ae1-c636dc538cf3"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="N028a2aef425945f39e1f15f16f2191bc"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-29 10:35:24 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:b05390f2-9cdc-4cb2-9db8-cdaa56c641bc</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>urn:domeoclient:uuid:ab8059c4-f0ab-40e6-a997-9ab1f143489f</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8caecff2-b5d2-4433-8a37-6b9ac027b535">
    <domeo:uuid>34a4a2a4-ba91-4440-a451-1eb72f0b7fd5</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>e in plasma AUC of the TCA ).  </ao:prefix>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DD4EDCB1-63BE-4122-8A26-56BA7F9E402D">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>ritonavir</rdfs:label>
    <dikbD2R:dose>600</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8c1c4b74-8e11-46a3-8532-8d5c8e308fb2">
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8edb70a4-6cf4-492c-a86e-29979a22dd2b"/>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmax></dikbD2R:cmax>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2069810b-be47-406f-8cf3-127927cb2e27"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5177fb23-de92-452e-95da-08c6ffba0ae1">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N7bc2d25aff7d43409bd91ecfa2a53daf"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9566CEDA-2AC4-49C3-9F21-103B158AFCAA"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:1b241af3-85ac-435e-8e84-5c38d0c46edd</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:376344B6-F6C8-49EF-A853-3DD9408625EF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-09-09 13:53:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1E77B9E3-6E52-4607-BF12-DA003CF3F36B">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0072395E-ECD2-44E5-BF74-6A08E239FD85"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8A9C13EC-3311-4E90-8FBE-527F5A5572C8"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/43b506b5-57fa-43c4-b591-838c17ba700c">
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA18BF65-3F61-4179-8A1D-B73034A9E587">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/788801A3-E126-4A13-A5A7-1F1BF89D0918">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2154613A-DE7F-4BFB-A173-C3CE6239EB7F">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdfs:label>selegiline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AEAFC682-DC51-4E8A-A59D-77FBCCE46E6F">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-05 15:30:12 -0500</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:18878E66-C4A2-4B51-A02C-B2004D0AFEFB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <ao:body rdf:nodeID="Nce2eeb4ca72e469182ecc9ad41b57d53"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-05 15:30:13 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B7BE1296-FCF1-443C-B8E8-FA07AD2AC3D4</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16AB8E7B-C09D-4172-AB6A-89210F0EE316">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-02 13:32:30 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Digoxin - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of Celexa and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.</ao:exact>
    <domeo:uuid>16AB8E7B-C09D-4172-AB6A-89210F0EE316</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16AB8E7B-C09D-4172-AB6A-89210F0EE316"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N40c2c64effae44ce8059e13942a4a102">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87fd42e6-eb0d-4fb5-8e50-b2a870164ded">
    <permissions:permissions rdf:nodeID="Naa76528543764fc290e2d3ecd2b1aac9"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:9c3d2737-3c09-457b-adc3-440d0f15756b"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:e4243f79-809d-475c-8a1e-798c693f3c06</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0d1ae9dd-71a4-4552-b5cd-6b97174f33a2">
    <domeo:uuid>ce8b0d64-05bd-4f84-b13c-8af395f425bd</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The metabolism of saquinavir is mediated primarily by CYP3A. Additionally, saquinavir is a substrate for P-glycoprotein (P-gp). Therefore, drugs that affect CYP3A and/or P-gp may modify the pharmacokinetics of saquinavir. Coadministration with drugs that are potent inducers of CYP3A (e.g., phenobarbital, phenytoin, carbamazepine) may result in decreased plasma concentrations of saquinavir and reduced therapeutic effect.</ao:exact>
    <ao:prefix>ther Drugs to Affect INVIRASE  </ao:prefix>
    <pav:createdOn>2015-10-13 11:13:09 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0A3ADF2B-84D6-4FA3-9139-5B6F044C5491">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CBD343E7-A986-4095-B804-7961ABDD4715"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0D5DD3EE-2CF2-40D9-8415-0FDF9D9550DD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5ea53f80024d418cb48242ce304ce9d7">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/74B3A68B-C237-4EAC-942B-630953D80997">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3F5FAB0-91AD-4BF9-AF2C-5FDF2A7F257E">
    <ao:body rdf:nodeID="Nba3373e49e6e49ebae5e7b984ccdbe84"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D1FC07F5-B5DE-48B7-AC58-B75B34DDC12B"/>
    <pav:previousVersion>urn:domeoclient:uuid:6426edbd-e01c-45ce-9151-eac311cb230b</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-27 14:23:19 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-27 14:22:13 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F11B639F-D14D-41E0-B966-EFF0F5152A8C">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluoxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N481ad5ca933548198483f448e080abda">
    <domeo:sets rdf:resource="urn:pddi:uuid:10872bb7-50d4-4505-a1d4-bf5448624d4b"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/00ae1745-7b73-4cfc-9265-63d2b07e6526">
    <rdfs:label>diazepam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a4025d67-fe81-400d-a9cb-1e16eae415f1">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:c4fcd40d-23e5-4b17-b235-288f3494df35"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:282D5FA7-46D5-4E29-B860-F26CDA0287B5">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:168E4F0F-8128-4D26-8885-5834F2569B36"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:244CD2F1-584D-4BEC-BDFF-77883BE78446">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nd456b061ca954643b9c7954d9e5afa4f"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:AAA7B13D-FEF6-43F4-B77A-DC20C46716E4"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdOn>2015-10-27 15:34:07 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N028a2aef425945f39e1f15f16f2191bc">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18CB9938-6266-493E-A282-DB819CD3E51A">
    <pav:createdOn>2014-02-19 12:38:23 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBC29E8F-3018-4FB3-9D06-66D1FC3641AB"/>
    <pav:lastSavedOn>2014-02-19 12:41:40 -0500</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E73D6B7D-A3A8-4817-A2C4-32DE510299C5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:80427841-8733-4D31-B75E-C7B5AC762B29"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:E28A51D7-37BE-4BCB-B3E3-5F03A528E03B</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d9e6c955-262b-4ee2-8ac1-62ecc538f260">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N83719a013d994065bcab5dfa588eee10"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f57a2830-e483-4dc2-a503-c2a99c37dabf</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:b2583a58-f0a5-4c95-b767-75cf4dfe819f"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na2914eb339314231b1a120eae924c2f4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4da3045b-781b-4b23-a68e-4439ffc837e2">
    <pav:lineageUri>urn:domeoserver:annotation:e52a7c31-67bd-4d2b-8748-0a4b8f1d1d10</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:24F19B15-541E-40A3-AA24-406A11F767AB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7D8503CE-4A92-4F09-89E3-8F59A55247BE</domeo:belongsToSet>
    <ao:body rdf:nodeID="N5b0507ee56c8413aaf328934ac19d39e"/>
    <pav:lastSavedOn>2015-10-29 10:49:25 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-25 10:47:09 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6f19e658-ea51-4218-867d-510be8488d55">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5dbe1418-f39e-4a38-947b-6280ea8e1fbd"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd84f92e0fb03498db904060d91c827e9">
    <domeo:sets rdf:resource="urn:pddi:uuid:e6528c34-6c53-42f9-ae1c-1f0c908efa02"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b82eb72f-d58c-4ce2-b14b-73666ee99b7c">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c3f26c56-481d-4e68-b8da-4816ba998c27">
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8717c581-c3b8-4bc3-8b34-20511cdadb31</domeo:uuid>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:dc4408b1-376a-4747-a000-ecf70973b669">
    <pav:createdOn>2015-09-03 15:43:15 -0400</pav:createdOn>
    <ao:prefix>ffect of Other Drugs on EMSAM  </ao:prefix>
    <domeo:uuid>cc9207c5-053f-4bda-b0e9-10e94aea2206</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Carbamazepine is contraindicated with MAOIs, including selegiline [see Contraindications (4), Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)]. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B0DA0F5D-0193-4AA8-8232-5282B80AD7FE">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>75</dikbD2R:dose>
    <rdfs:label>amitriptyline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/704</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EEBFFB57-7439-4454-AD3D-F8C277BEFF7C">
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2d8b50094ec5480fb2d64c57aa621c52">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6b057895-f904-42e6-9ec6-100238727c74">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0E8DB85B-FDB2-493D-9745-A34FD3DC99E3">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8a3f45f0-1ede-4c37-b66f-94011a58f5b5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:C397F3D7-D462-4F97-8A7F-D50A88A55469</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5b2aba61-2387-41ee-a3a7-59c848406762"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:0ad2caca-4550-424f-aad2-6b75d62a2214</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-26 15:37:31 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-26 15:37:31 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/99C4590F-7BBC-4D32-98D8-B70D269C5412">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>risperidone</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4EDABFCF-47CB-476B-AFB0-D4F7BB62475D">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/00B56D88-3179-4E80-8967-DEFC44C2ADD0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EA59DF72-5BE9-44BE-891D-BCC6F456FF67"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBDBDF71-0B3E-49B2-9397-6C608A61AFE2">
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5D74BC65-DCBB-4189-9CA6-19B1ED432ADD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-10-27 15:29:28 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N5c4cf92f962c457ca8b519957412ebb7"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8d3abe04-eda4-4bbe-846f-fece83622e9e">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:fd9b5244-196b-419d-8911-e84e3a482bbf"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b0084614-128f-471f-8d8b-856f969575f6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nc935d78043014c1a81aac8de279c5152"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:fc5a065e-7b25-467c-9cf2-7d5a795904a7</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:e5eb1fa6-bea7-4ce1-a774-7deb593eca44</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:7eb8e24a-2225-4612-bb67-34f87c72b573"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f242f443-e177-4608-ae22-6653160b6732">
    <ao:exact>Based on in vitro data, ZYTIGA is a substrate of CYP3A4.    In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during ZYTIGA treatment. If a strong CYP3A4 inducer must be co-administered, increase the ZYTIGA dosing frequency [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].</ao:exact>
    <domeo:uuid>22060c07-cfbb-45b8-9289-14495a8f08ff</domeo:uuid>
    <ao:prefix>ibit or Induce CYP3A4 Enzymes  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/54E57302-AD8E-4E3A-9D0B-891498EB3B0F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>flecainide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d5d4ff71-70d4-42b6-ab85-aaff3ab62743">
    <domeo:uuid>eb8e66d0-7ffa-4349-80a3-86fb04ca34c2</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <ao:prefix>tantly administered rifampin.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4FB730C3-5350-46D6-96A0-A2AE3788CCA4">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdfs:label>Celexa</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f85ffba1-be30-44ed-902c-2421acea262f">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N1c3333fc2ccf4579a7d7a232010a17c8"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:bfeabd35-0da4-48a7-b1d8-e665e60406dc</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:8630f58c-3fde-4f74-97f6-50cb1e06c70b"/>
    <pav:lineageUri>urn:domeoserver:annotation:b30a78c2-bab1-4d1b-8c05-189b1f098bdc</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C688CC46-3AB0-4F9A-96D8-A90D1E25BB08">
    <rdfs:label>atomoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/38400</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1C87BCC9-B913-4BF8-BD1C-EC5D2F19F6FF">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:629953da-8c05-4179-b781-acd0e222fffe">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:b45d9269-19ba-4d37-bcf9-77eb27dcd79f"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4018177-4FBF-4667-B388-68BB93CC7009">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:4AD1E89F-4FEA-4E60-8731-F4EE30EEFF59</pav:lineageUri>
    <pav:createdOn>2015-11-02 13:33:34 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:3F6B2FC2-1C80-43F1-B7F0-CE2C820D8184</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:07B0F158-E47A-4723-AF8C-D90125D46833"/>
    <pav:lastSavedOn>2015-11-02 13:38:35 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d5fd249b-ef43-4f0e-8f2d-e61b2c58b96b">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:fad6e7e0-c08e-477b-8e71-582238a31dd6"/>
    <domeo:uuid>6d7073fa-76a2-4ee1-8219-98a59d2e075a</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E4E84D77-E1E6-434B-9941-AD3E9116E80A">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>propafenone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f087b590-5887-4ea6-9aa1-e7abce96ea09">
    <pav:lastSavedOn>2015-10-27 14:13:01 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8C4C44EC-E1D3-445E-8E2C-44519FB2A340</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:F4090A61-420C-4451-8E06-1D335F7E7D76"/>
    <ao:body rdf:nodeID="N70b62e3ca72e46e3b7b835812120fc5f"/>
    <pav:lineageUri>urn:domeoserver:annotation:c33b0bdd-ca1a-4759-81a5-c2ddd4d78ff6</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CDCFFC8E-450A-4665-8A7A-D08E684BA3DF">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>pimozide</rdfs:label>
    <dikbD2R:dose>2</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6309ABA-529A-4772-A3B0-8E92BB7534A0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B6309ABA-529A-4772-A3B0-8E92BB7534A0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 13:23:48 -0400</pav:createdOn>
    <domeo:uuid>B6309ABA-529A-4772-A3B0-8E92BB7534A0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Alprazolam    In subjects who had received EMSAM 6 mg per 24 hours for 7 days, co-administration with alprazolam (15 mg per day), a CYP3A4 and CYP3A5 substrate, did not affect the pharmacokinetics of alprazolam or selegiline [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A757D9A2-ECC6-4E61-AA56-4604AF6960CD">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4EDABFCF-47CB-476B-AFB0-D4F7BB62475D"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26A0C09C-9C40-44F2-A448-CE418BB6CF1E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:26A0C09C-9C40-44F2-A448-CE418BB6CF1E"/>
    <ao:exact>Terfenadine, astemizole, cisapride, and pimozide are all metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has been demonstrated that ketoconazole, erythromycin, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine, astemizole, cisapride, and pimozide are associated with QT prolongation and with rare cases of serious cardiovascular adverse events, including death, due principally to ventricular tachycardia of the torsade de pointes type. Nefazodone has been shown in vitro to be an inhibitor of CYP3A4. Consequently, it is recommended that nefazodone not be used in combination with either terfenadine, astemizole, cisapride, or pimozide (see CONTRAINDICATIONS and PRECAUTIONS).</ao:exact>
    <domeo:uuid>26A0C09C-9C40-44F2-A448-CE418BB6CF1E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-06 15:42:30 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>Potential Terfenadine, Astemizole, Cisapride, and Pimozide Interactions   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/706149EF-D03D-46D8-B966-A48EC3A2C7B3">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48d40742-a353-4391-a81a-01147c5662aa">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <domeo:uuid>cd4de3b2-c9f7-4963-96e5-360e30839138</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1e0d2908-7cae-4a9d-8328-3906f818d0cf"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8E3EA5A4-6470-4DF2-BF35-A040F9630D32">
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/88422EA6-528C-4AA3-8C30-D74168B078D9"/>
    <dikbD2R:numOfParticipants>24</dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>6.5</dikbD2R:preciptDuration>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/16CF7826-AE57-48CD-9FEF-B8CE28A70990"/>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmax>40</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/79146705-5D0B-479E-8BA1-07F598CB2A91">
    <rdfs:label>mirtazapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>30</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:21369E3B-C781-4B22-950D-D2734AC81CFF">
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-25 10:05:58 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-10-29 09:45:10 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:c596cfe2-64b4-47bd-b06d-88279615cc07</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:ce64f071-8054-44eb-9aff-ca1691037f7c</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:024e6ecb-1872-4b1a-9dc8-448b89601c59"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Nc9e15362f0b944e3afed17f9b74b9297"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:45CBDB2E-596B-4BBB-B0EB-25B5A20577C9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-28 16:37:52 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <ao:prefix>max were reduced by about 35%).   </ao:prefix>
    <domeo:uuid>45CBDB2E-596B-4BBB-B0EB-25B5A20577C9</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Drugs Metabolized by P450 2D6–Many drugs effective in the treatment of major depressive disorder, e.g., the SSRIs, including sertraline, and most tricyclic antidepressant drugs effective in the treatment of major depressive disorder inhibit the biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase), and, thus, may increase the plasma concentrations of co-administered drugs that are metabolized by P450 2D6. The drugs for which this potential interaction is of greatest concern are those metabolized primarily by 2D6 and which have a narrow therapeutic index, e.g., the tricyclic antidepressant drugs effective in the treatment of major depressive disorder and the Type 1C antiarrhythmics propafenone and flecainide. The extent to which this interaction is an important clinical problem depends on the extent of the inhibition of P450 2D6 by the antidepressant and the therapeutic index of the co-administered drug. There is variability among the drugs effective in the treatment of major depressive disorder in the extent of clinically important 2D6 inhibition, and in fact sertraline at lower doses has a less prominent inhibitory effect on 2D6 than some others in the class. Nevertheless, even sertraline has the potential for clinically important 2D6 inhibition. Consequently, concomitant use of a drug metabolized by P450 2D6 with sertraline may require lower doses than usually prescribed for the other drug. Furthermore, whenever sertraline is withdrawn from co-therapy, an increased dose of the co-administered drug may be required (see Tricyclic Antidepressant Drugs Effective in the Treatment of Major Depressive Disorder under PRECAUTIONS).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:45CBDB2E-596B-4BBB-B0EB-25B5A20577C9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33c3871d-f58e-4717-bd54-9cc8db773681">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:c7f6f5a3-1f32-47e0-b430-e082af5e579e"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>bcc0fe4e-393e-45c0-8670-4e09b70e3781</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2DDE57E8-8DE6-4ED1-ADB7-2F109930DB5D">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:C50E7F1C-48E9-4F98-A9E5-68CC7E0BFB32</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0F0B55C-92C3-42AC-BA8B-D25B34B24813"/>
    <pav:lastSavedOn>2014-02-09 21:22:48 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:929BF940-1099-4796-BBA3-341FACCD0F42"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:6B12D9AC-F09A-4157-8E26-ACDF40ECBB03</domeo:belongsToSet>
    <pav:createdOn>2014-02-09 21:23:27 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/46b6988c-2244-4153-9138-a0c413c98871">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluoxetine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ff26853a-3323-4ddf-ba8c-4a442559419a">
    <domeo:uuid>d2a72e7b-7c02-4703-85af-1fddf0c89d85</domeo:uuid>
    <ao:exact>The metabolism of saquinavir is mediated primarily by CYP3A. Additionally, saquinavir is a substrate for P-glycoprotein (P-gp). Therefore, drugs that affect CYP3A and/or P-gp may modify the pharmacokinetics of saquinavir. Coadministration with drugs that are potent inducers of CYP3A (e.g., phenobarbital, phenytoin, carbamazepine) may result in decreased plasma concentrations of saquinavir and reduced therapeutic effect.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-13 11:13:09 -0400</pav:createdOn>
    <ao:prefix>ther Drugs to Affect INVIRASE  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4234895-42FC-4CE0-8A08-8B1BF4544420">
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-27 14:26:03 -0400</pav:createdOn>
    <ao:exact>Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F4234895-42FC-4CE0-8A08-8B1BF4544420"/>
    <ao:prefix>    Benzodiazepines   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D40A25C4-DB51-4114-91EA-4CE3D6380167">
    <pav:createdOn>2015-10-27 14:23:17 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Fluvoxamine is a potent inhibitor of CYP1A2 and tizanidine is a CYP1A2 substrate. The effect of fluvoxamine (100 mg daily for 4 days) on the pharmacokinetics and pharmacodynamics of a single 4 mg dose of tizanidine has been studied in ten healthy male subjects. Tizanidine Cmax was increased approximately 12-fold (range 5-fold to 32-fold), elimination half-life was increased by almost 3-fold, and AUC increased 33-fold (range 14-fold to 103-fold). The mean maximal effect on blood pressure was a 35 mm Hg decrease in systolic blood pressure, a 20 mm Hg decrease in diastolic blood pressure, and a 4 beat/min decrease in heart rate. Drowsiness was significantly increased and performance on the psychomotor task was significantly impaired. Fluvoxamine and tizanidine should not be used together [see Contraindications (4.1)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D40A25C4-DB51-4114-91EA-4CE3D6380167"/>
    <ao:prefix>5.5 Potential Tizanidine Interaction  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:003b5253-2e58-4f48-980e-c85b8280d99a">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:d1e543d3-8687-4d9b-ae1a-b599912967cf</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N104cefc2303c4ef8a8e6b4f3e1132707"/>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:cafa5971-bfe1-4d84-b5aa-61c0c37d4142"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:439d3a3b-8d9a-4445-a7a4-8694e6d0c126">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:7fb442a2-92dd-40e8-ba35-e7a41884e52e"/>
    <pav:createdOn>2015-09-14 11:31:14 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:6f48a986-5e92-4249-9079-0dd0db354c90</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:b0f01395-ff79-4dbc-892b-da3586b50d6b</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-14 11:31:14 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N6f8cb1b09354442aa5c3743e99c9d580"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AEE7C1E9-FD2A-420E-A7C5-AFFBE49B20E6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6710B061-622E-41EB-9C33-F4B1DA18CBC4"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F74460A3-FA3F-40CC-A25A-C8BD22BCEB29">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Terfenadine, astemizole, cisapride, and pimozide are all metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has been demonstrated that ketoconazole, erythromycin, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine, astemizole, cisapride, and pimozide are associated with QT prolongation and with rare cases of serious cardiovascular adverse events, including death, due principally to ventricular tachycardia of the torsade de pointes type. Nefazodone has been shown in vitro to be an inhibitor of CYP3A4. Consequently, it is recommended that nefazodone not be used in combination with either terfenadine, astemizole, cisapride, or pimozide (see CONTRAINDICATIONS and PRECAUTIONS).</ao:exact>
    <domeo:uuid>F74460A3-FA3F-40CC-A25A-C8BD22BCEB29</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F74460A3-FA3F-40CC-A25A-C8BD22BCEB29"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Potential Terfenadine, Astemizole, Cisapride, and Pimozide Interactions   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-06 15:42:56 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6bdf5a6c-2688-4bf1-a9bc-66dcfde8e0c1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:b9231951-c0a3-4c03-952c-18839e69ed9f"/>
    <domeo:uuid>5611d39e-a2ff-4a3e-b242-c2d5b3e2666b</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/00B56D88-3179-4E80-8967-DEFC44C2ADD0">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EF728104-9086-45A4-8249-7CA437C8FDD7">
    <pav:createdOn>2015-10-27 15:22:25 -0400</pav:createdOn>
    <ao:exact>methadone </ao:exact>
    <domeo:uuid>EF728104-9086-45A4-8249-7CA437C8FDD7</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EF728104-9086-45A4-8249-7CA437C8FDD7"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Significantly increased </ao:prefix>
    <ao:suffix>(plasma level:dose) ratios have been reported when fluvoxamine maleate was administered to patients receiving maintenance methadone treatment, with symptoms of opioid intoxication in one patient. Opioid withdrawal symptoms were reported following fluvoxa</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C0147E50-E5D6-437A-9857-82B800A74369">
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71074d11-634e-4492-89b1-1d67aaee781e">
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N9794be27a4704735ab428711dd534205"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:a477ec68-46c0-4fb0-9829-c3846234b5f0</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:f21cd01f-ca4e-4374-8e11-22b8d00050d9</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:d9f6258f-60b7-4c4a-a301-0f3522dc0682"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B5F8C78F-FA93-4A00-A84A-0380C0A6B829">
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-05 10:36:32 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:8170DAE8-A314-4B9D-9021-E3ABC0799879"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:9ED17A98-7D32-46EA-A9C3-CFC351131BD7</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A9199C8-46E1-451B-83D3-AB7B680E9EE7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 15:21:43 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>XL and drugs that are inhibitors or inducers of CYP2B6.   Inhibitors of CYP2B6    </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:exact>Ticlopidine and Clopidogrel: Concomitant treatment with these drugs can increase bupropion exposures but decrease hydroxybupropion exposure. Based on clinical response, dosage adjustment of WELLBUTRIN XL may be necessary when coadministered with CYP2B6 inhibitors (e.g., ticlopidine or clopidogrel) [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A9199C8-46E1-451B-83D3-AB7B680E9EE7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4bd89788-6e1c-4fb9-a21d-586338a8c2d9">
    <ao:context rdf:resource="urn:domeoclient:uuid:1e7aa226-e6d9-4cd1-9b3d-9f67f7f344fa"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:26bece23-8ce7-4b4a-85c6-73f927646de0</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:26c22ae9-8b56-47b1-9fe8-dad7802e72f7</domeo:belongsToSet>
    <pav:createdOn>2015-08-20 11:17:13 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N972b7329faf34e668fafcf7c06bbd90d"/>
    <pav:lastSavedOn>2015-08-20 11:17:13 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:828A2903-CDBE-465E-9978-00472C6256D7">
    <domeo:uuid>828A2903-CDBE-465E-9978-00472C6256D7</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:828A2903-CDBE-465E-9978-00472C6256D7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-06 15:45:23 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The coadministration of carbamazepine 200 mg BID with nefazodone 200 mg BID, at steady state for both drugs, resulted in almost 95% reductions in AUCs for nefazodone and hydroxynefazodone, likely resulting in insufficient plasma nefazodone and hydroxynefazodone concentrations for achieving an antidepressant effect for nefazodone. Consequently, it is recommended that nefazodone not be used in combination with carbamazepine (see CONTRAINDICATIONS and PRECAUTIONS).</ao:exact>
    <ao:prefix>Interaction With Carbamazepine  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfad263c21d084bb99f411d036cd22c13">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B9DC291-E2C1-4052-B7F0-494CB17BB73D">
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0B9DC291-E2C1-4052-B7F0-494CB17BB73D"/>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 15:36:36 -0400</pav:createdOn>
    <domeo:uuid>0B9DC291-E2C1-4052-B7F0-494CB17BB73D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a696e103-2472-4072-8685-acff9987544e">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:afd33c7c-ba18-4e5d-a3a5-8872770ee82d"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFB0E4E2-8161-4326-A245-D59ED64BB363">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N9c0951bd081141c4bb9391477e717093"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-05 15:27:05 -0500</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:9BC09D4F-295B-4383-8C8C-E97550202974"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-05 15:27:20 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:B170CAAA-860E-44B8-A1BD-171CE3E86595</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2dca5fc9-4b04-42ce-a86a-088d9a681b0e">
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9e0a564b-0d9b-48ef-9b4f-48f35f974fbe</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N71863d7eadb746dc90392781a6be377d"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:33f6bae8-4158-4aee-af6b-8b3264843545"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a1404cab-4738-4e83-83aa-2f57311b85e0">
    <domeo:belongsToSet>urn:domeoclient:uuid:e087f9bd-f775-47f9-8a1d-e2cf284a4791</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:4d92108d-ed45-4866-98d0-850ccfd51551</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:abd3bbd1-8a63-4690-8b5b-2c4418ff048b"/>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nd7f616a298254b27a752437b4f888daa"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AA000288-CF26-4159-BAE9-2A967335FA8C">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3AA83FB6-6FE2-45EE-8771-63A50012CFE6"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E9A03FE5-9A58-44B7-B531-2CC63FAF4421">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D5762D34-9FA1-4269-8584-61C7F53EAEFE"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F1B3F448-C50F-4E04-890E-4078D4872F66"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42314dc7-6074-42ae-b2f2-81cd65a08eb0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N4665c72c9c2a41d3b9eac9a151b6a31a"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:a57ec363-3a62-4f8e-a163-112d32ab3435</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:0d7c0e0f-9bb3-4e1a-9943-9ce8465ac9b2"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:d0c93e20-9847-4e41-831f-b19e8fb2fc4e</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D42F2A10-10AF-4C66-922F-4C18E7027E7C">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:12A7ED1B-846C-494F-B1CD-DA9984CFD9DA"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A4B14B16-BBE1-43DF-8844-DEDE2AB4BCE6">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:53A87639-B19F-4E3A-B778-816F8DA56B00"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2326c666-5bf7-4e4f-aaac-b7e00816423e">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7b9aea57-52c7-436c-9cd6-132419a11b76</domeo:uuid>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a477ec68-46c0-4fb0-9829-c3846234b5f0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:bafef40c-835e-4e70-8cb6-f98172e58fcc</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="N002da491a7344605b48ce8dfc624270b"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:71074d11-634e-4492-89b1-1d67aaee781e"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/262AA3E4-378D-462F-9325-EF6516AACE0A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:1AC8D52E-9BA7-49E7-8733-4B07EC5BBECB">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>urn:domeoserver:annotationset:CE828507-92C8-490E-81FF-5DEDE8F972B6</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-10-29 09:30:04 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:32e57220-a5aa-4afc-9fd1-fb0cfe8dd4a0"/>
    <pav:lineageUri>urn:domeoserver:annotationset:17a181ae-5851-4cd7-aca9-c2f59433f11b</pav:lineageUri>
    <permissions:permissions rdf:nodeID="Ncda760b816ab483b8c2a869a222a7f21"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1288E615-D85A-45AD-9A15-8E220A79FD43">
    <pav:previousVersion>urn:domeoserver:annotationset:90DC26CD-1DE4-4018-BB02-C4FA859EF6ED</pav:previousVersion>
    <pav:createdOn>2015-11-05 15:49:43 -0500</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Ndeefe76572cc4d98ae062c16a2f0a5fa"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2845582A-54E7-48D8-B314-7E1539F0CA1F"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-05 15:49:45 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e729dc1c-fcd6-4ae9-8c00-c222e953becc">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:b47cf10f-281d-4906-8e21-d6b9ff088b42"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <domeo:uuid>8c3162cb-120f-42cf-b980-9bf361c3dfdf</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6F4AA0E2-D571-430C-A8CE-BD0532E742B3">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB9584DB-2B31-43F8-948B-D1E99BE0ED29">
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-11-04 14:18:10 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2C915451-1E49-4771-9D34-C76B114586B9"/>
    <ao:body rdf:nodeID="N38f69ae12cd043478bbd6bed41183526"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36ac94c6-b016-4e1f-8c72-eb9150096a6d">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:489e313f-80bc-4a67-8034-1d4f1a64447f"/>
    <domeo:uuid>da31dd2a-d54e-4672-b4a2-55a338affdd4</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3ccafb05-ca33-4e37-bf94-8e543fdc5d1e">
    <domeo:uuid>d12fa484-6766-4c5c-afba-b1b7b778f33d</domeo:uuid>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <ao:prefix>er tricyclic antidepressants.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08ACD79A-E041-4B16-9881-E26AA7E701A1">
    <ao:suffix> has been shown to produce a “stimulating” effect in some depressed patients.</ao:suffix>
    <pav:createdOn>2015-11-04 14:05:20 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:prefix> during therapy with a </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>08ACD79A-E041-4B16-9881-E26AA7E701A1</domeo:uuid>
    <ao:exact>tricyclic antidepressant</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:08ACD79A-E041-4B16-9881-E26AA7E701A1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AA3FABD1-33E4-48E1-821E-67F1D830A725">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C32469C4-4BED-4E9D-9522-590569B31027"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C9A3AEFF-8159-43C8-A24E-FB92FAA8C5EE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a0fd9bad-bf27-4df6-a482-d22a7a260fa9">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <domeo:uuid>e17df6c1-4241-4a12-a061-9997ccc6d5cd</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ed207b06-cfd8-4ee5-8e75-33e82defe23f">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>levothyroxine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N08717813da984e3c99144b2016814a54">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:47AF6767-AA39-43B3-BD4C-B03E8D8316DB">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1F66C45B-3D3D-4E17-817A-7F28547138D9"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D50CA07E-2A4C-4CBE-9AF9-1D3DF56F53E3">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>1.25</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>digoxin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D500054A-2575-4EC0-BFED-5509CE0C767C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D500054A-2575-4EC0-BFED-5509CE0C767C"/>
    <ao:suffix>(e.g. </ao:suffix>
    <ao:prefix>), beta-blockers (e.g., metoprolol), and Type 1C </ao:prefix>
    <pav:createdOn>2015-11-05 15:28:42 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>antiarrhythmics </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BAED069D-E790-4AB0-BE49-21F957A37D6D">
    <ao:prefix>), beta-blockers (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 15:28:39 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>metoprolol</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:suffix>), and Type 1C antiarrhythmics (e.g. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BAED069D-E790-4AB0-BE49-21F957A37D6D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:24F19B15-541E-40A3-AA24-406A11F767AB">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:24F19B15-541E-40A3-AA24-406A11F767AB"/>
    <ao:exact>Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON.</ao:exact>
    <pav:createdOn>2015-10-29 10:49:26 -0400</pav:createdOn>
    <domeo:uuid>24F19B15-541E-40A3-AA24-406A11F767AB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:prefix>  Diazepam  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:69A93264-C7D7-4FDD-BFC4-BA90453394F7">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C89BE45B-6DDD-40A2-962A-59CABF7AA9C7"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8ACA7EAD-7AB2-422D-9421-8E9FBCCD2DEC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B00589C1-4255-4B08-93BD-3C7909C8804D">
    <ao:prefix>Potential for Other Drugs to Affect WELLBUTRIN XL    </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-05 15:41:13 -0500</pav:createdOn>
    <ao:exact>In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by CYP2B6. Therefore, the potential exists for drug interactions between WELLBUTRIN XL and drugs that are inhibitors or inducers of CYP2B6. In addition, in vitro studies suggest that paroxetine, sertraline, norfluoxetine, fluvoxamine, and nelfinavir, inhibit the hydroxylation of bupropion.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B00589C1-4255-4B08-93BD-3C7909C8804D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N606ecaabbe884fda97924a2caf4b5e5e">
    <domeo:sets rdf:resource="urn:pddi:uuid:513edb52-bbb8-4100-bdea-08dff1288050"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D88F9D17-4565-49C7-8F5C-046CF2BCEFA6">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DE193BF-0F87-477B-B636-ABB34FBA2C89">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:720B0D00-827A-4552-8794-0F2E895C4F63"/>
    <ao:body rdf:nodeID="Naec944118ea849139012c807b28b680a"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-05 15:52:06 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-05 15:52:07 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:F153E240-4C66-49D3-A4FA-323A752AB001</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B314B36F-5452-4F63-BFCB-FA17BD1F66DB">
    <rdfs:label>risperidone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>2</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/374a8725-725f-4371-b1a2-a1ba08c8ff2a">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>hepatic enzyme inhibitors</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3a5ca36f-9da1-4239-9224-65a22b6d9c4d">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N5730b3de2de149dba8b3f4454efc18c9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:974e5d39-48ec-49d5-b3de-0896e9e5ac9c</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:ca33711e-6d1c-4aa5-a754-d773ab359904</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2a98b4c8-9de6-4010-b40e-519dd43052de"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4dfad2ba22804d9bb2ab91baf78449f1">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8AE83D3-0280-4B36-9E78-089494988065">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:16399B64-7253-44DD-9260-A8481C94767F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-04 14:17:34 -0500</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EA59DF72-5BE9-44BE-891D-BCC6F456FF67">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluoxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA2B6BDC-1B0C-4529-8D5C-79342F46D71C">
    <pav:createdOn>2015-10-29 11:29:06 -0400</pav:createdOn>
    <ao:suffix>Concurrent administration of</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <domeo:uuid>DA2B6BDC-1B0C-4529-8D5C-79342F46D71C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Certain drugs, particularly the psychostimulants and the phenothiazines, increase plasma levels of concomitantly administered tricyclic antidepressants through competition for the same metabolic enzyme systems. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DA2B6BDC-1B0C-4529-8D5C-79342F46D71C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8C4C44EC-E1D3-445E-8E2C-44519FB2A340">
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:f087b590-5887-4ea6-9aa1-e7abce96ea09"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:b1fe7441-8ba8-4213-ab78-8ee584d1df6c</pav:lineageUri>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N3371be5c1c154450b3a7746acf74c258"/>
    <pav:previousVersion>urn:domeoserver:annotationset:D5E30194-5A28-4ED3-9377-49C19FFF77AC</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-27 14:13:01 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1ee70a95-6198-4073-aee1-4656159da355">
    <dikbD2R:clDirection></dikbD2R:clDirection>
    <dikbD2R:aucDirection></dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/45a4a811-6e08-428a-bd54-9e7606aced4c"/>
    <dikbD2R:t12Type></dikbD2R:t12Type>
    <dikbD2R:auc></dikbD2R:auc>
    <dikbD2R:aucType></dikbD2R:aucType>
    <dikbD2R:cmaxType></dikbD2R:cmaxType>
    <dikbD2R:preciptDuration></dikbD2R:preciptDuration>
    <dikbD2R:objectDuration></dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0ddefc2b-4058-4728-a4ff-45fc9259cfd0"/>
    <dikbD2R:clType></dikbD2R:clType>
    <dikbD2R:objectFormulation></dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens></dikbD2R:objectRegimens>
    <dikbD2R:cl></dikbD2R:cl>
    <dikbD2R:t12></dikbD2R:t12>
    <dikbD2R:preciptRegimens></dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation></dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants></dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection></dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction></dikbD2R:t12Direction>
    <dikbD2R:cmax></dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:39724c07-2350-41a6-930a-b629d166d73d">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3c14989e-e92c-4b72-a598-0aee4ac2ee51"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3D5761B-F1E9-43C2-9D22-5854F1ED38ED">
    <domeo:uuid>C3D5761B-F1E9-43C2-9D22-5854F1ED38ED</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>. (</ao:suffix>
    <pav:createdOn>2014-02-19 12:41:17 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C3D5761B-F1E9-43C2-9D22-5854F1ED38ED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Reduced effectiveness in impaired CYP2C19 function: Avoid concomitant use with drugs that inhibit CYP2C19 (e.g., omeprazole)</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39578E9D-75DB-42E8-A1AC-9A5CD3ACB98B">
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N75768d155763448c8a20842f2414cf68"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:96E6C0DA-FDEE-4329-BA81-BE3E851AF0CB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-11-06 15:34:43 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-06 15:34:44 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:6472ac55-3b05-4f4f-ad50-9264fbcd6d9a</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D74BC65-DCBB-4189-9CA6-19B1ED432ADD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-27 15:29:28 -0400</pav:createdOn>
    <ao:exact>When fluvoxamine 100 mg twice daily was administered for 3 days prior to single-dose coadministration of ramelteon 16 mg and fluvoxamine, the AUC for ramelteon increased approximately 190-fold and the Cmax increased approximately 70-fold compared to ramelteon administered alone. Ramelteon should not be used in combination with fluvoxamine. </ao:exact>
    <domeo:uuid>5D74BC65-DCBB-4189-9CA6-19B1ED432ADD</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5D74BC65-DCBB-4189-9CA6-19B1ED432ADD"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>    Ramelteon   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:838CD12F-6A70-434F-9AEE-A80528922A70">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N516978d717d444368b8c4ffa2236331a"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-06 15:56:02 -0500</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-11-06 15:54:47 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9D146098-2EAF-4A7C-82ED-06C39413E92D"/>
    <pav:lineageUri>urn:domeoserver:annotation:976E5BDF-CD75-430B-9593-E8FDC8A69E74</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:425e8eae-b2a6-4a63-a0b5-918fff34c122">
    <domeo:uuid>77bf5c84-5265-4fc8-a4a2-9cad77e99f06</domeo:uuid>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <ao:prefix>nsporter 3 (OAT3) substrates   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/307aa3d0-77d0-4742-84ec-5772971a190f">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>haloperidol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2336E9E9-4E7E-406A-BCA9-6D8C7B525312">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>sertraline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/321A08AC-867C-414E-8B5B-A4AEF4B9107E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>phenothiazines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:033d1d47-608a-4d2a-8ad6-92bcf4e55f54">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:076e6fd5-188f-4c45-b6d4-0f39332b1319"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/923542f0-f3df-414d-bcb0-f0f8f6032e63">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/bc946f26-731c-4ae0-b55d-3f67c7e646f6">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5fa4ec36-ea6c-4a67-be20-3c89dd3664ab">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>goserelin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf077f99f85a84e1786444e91063fd43f">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F361E9BF-3C74-4E3F-8B50-485E7C009AE8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-04 14:19:55 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>F361E9BF-3C74-4E3F-8B50-485E7C009AE8</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F361E9BF-3C74-4E3F-8B50-485E7C009AE8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A5DE28E-2CA7-4820-AFB5-811A76EB966D">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:6426edbd-e01c-45ce-9151-eac311cb230b</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:createdOn>2015-10-27 14:21:07 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5E81248B-916B-451B-8F04-F260EE885023"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-27 14:23:19 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6083b192-cbb6-4db3-b058-99b4a5d36f52">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:41391B56-0A05-4D34-AA34-21D3B93A0F68">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:041436E4-A70B-4508-835A-927ABD07F4D9"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CD0227C5-C430-47AC-9EEA-A01EC48EDADE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CD0227C5-C430-47AC-9EEA-A01EC48EDADE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>CD0227C5-C430-47AC-9EEA-A01EC48EDADE</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone. </ao:exact>
    <ao:prefix>   Lorazepam  </ao:prefix>
    <pav:createdOn>2015-10-27 15:37:33 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3921f40b-2287-4697-b3ec-e0d89f2616b1">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <domeo:uuid>ae4c49c5-d410-43bb-8cd3-7b9ed6904464</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c7b621a5-213a-4e68-9690-c9886aeeae19">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-26 15:38:48 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:4594917B-2AC9-4FBB-B89D-E2B111AC53CD</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:e441a026-14f5-4290-9ab5-9e8573759848"/>
    <pav:lastSavedOn>2015-10-26 15:38:48 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:ff24524b-e247-49fc-bd0d-1312c5659cbc</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06936DEA-D87D-409F-ACD6-3B46B0F7F61C">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <ao:exact>Metoprolol - Administration of 40 mg/day Celexa for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol. Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of Celexa and metoprolol had no clinically significant effects on blood pressure or heart rate.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-02 13:57:43 -0500</pav:createdOn>
    <ao:prefix> AND CLINICAL PHARMACOLOGY ).  </ao:prefix>
    <domeo:uuid>06936DEA-D87D-409F-ACD6-3B46B0F7F61C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:06936DEA-D87D-409F-ACD6-3B46B0F7F61C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6FB42CCC-65BB-44A9-ADD2-47ECB7F8D769">
    <rdfs:label>aripiprazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/d81705c8-02a7-4db3-a04d-950b70aa13a7">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9566CEDA-2AC4-49C3-9F21-103B158AFCAA">
    <ao:exact>Warfarin - Administration of 40 mg/day Celexa for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9566CEDA-2AC4-49C3-9F21-103B158AFCAA"/>
    <domeo:uuid>9566CEDA-2AC4-49C3-9F21-103B158AFCAA</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-02 13:38:34 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/eb0c49c8-4ad7-455f-9764-f52761776bb5">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdfs:label>sertraline</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d06cf6eb-e181-4199-815b-eb7cfce8097b">
    <domeo:uuid>7b998a5a-659b-4155-abdd-cc995e384a7b</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2a5b4993-5500-4f5c-8418-f7f46b85bcfb"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N09408f4c10fd4bf6ab9f054bf2a670eb">
    <domeo:sets rdf:resource="urn:pddi:uuid:f6b2e8f3-019a-44eb-b633-c58b6915bf98"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3371be5c1c154450b3a7746acf74c258">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5B3BA270-4E36-4CF8-B0E3-525F6AB4EC49">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:51554DF2-DDF2-4251-8173-54A9DA6EB60F"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2cbfc80a679a42dfb70ce00cebccb3c2">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cab6fc43-8f84-4fc3-ae14-cd200b712360">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:1b519a54-7192-44c0-82bd-877e200235f5"/>
    <pav:lineageUri>urn:domeoserver:annotation:2e178165-eccd-4882-9c79-3ec35a4dc9bc</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:431ae753-de82-42f1-badc-c0309ae483c9</domeo:belongsToSet>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nbf1bd28f73d640d5a658b029ddb3d6a4"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a3b8a024-c1e4-466c-afe7-9e897f0235d9">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8bdb2436-184c-4935-bfc6-57703c59a2c5"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc44c2901b08b4b879e45befe84c38b94">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:643B49E0-891D-46F1-A2E6-25A43D608139">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the Cmax was increased about 2.5-fold, and duloxetine t1/2 was increased approximately 3-fold. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin [see WARNINGS AND PRECAUTIONS (5.12)]. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>643B49E0-891D-46F1-A2E6-25A43D608139</domeo:uuid>
    <ao:prefix>   7.1 Inhibitors of CYP1A2   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:643B49E0-891D-46F1-A2E6-25A43D608139"/>
    <pav:createdOn>2015-10-29 08:57:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42eb3278-983d-4168-b408-4bb96850ce93">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ddda2fb6-4187-452b-86d5-3ab68f55667f"/>
    <domeo:uuid>95bc230c-1666-4a9a-929a-3c71a9849736</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:A10613F7-0C13-4C8C-A483-28F020B077A6">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:9137ace8-0fcb-4284-bf74-7d88658cee2c</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N022c8c9a564f4028b1d7dc763e90ac78"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6cc36614-48a6-4812-aafd-b8c8614d2de1"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-03 15:45:10 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <pav:previousVersion>urn:domeoserver:annotationset:CB8C80A2-AEEF-4EC3-800E-C3BF3C12CC27</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 13:28:11 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E39F3498-8BD1-4604-BAF4-6E8AB33E1FD8">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Ne1fe254d6a2f4e0a8067a4ae31345128"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4ABA366-BA67-49A1-9D81-9D308B4F74A3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">17</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:650154DE-4762-4724-A410-9621094AE680</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 15:53:54 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-11-05 15:53:52 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CAB63AF9-D23A-4109-A615-275C9421E6CB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#increase-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Increase from baseline</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to increase the dose of the drug from the recommended baseline.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07c6d849-4abe-410e-8e1a-4d88a324fbbc">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:fde07283-7a9d-49a5-8f05-d8a70a8da941"/>
    <domeo:uuid>f4d82a80-6a41-4155-8441-274d60c52e21</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D273B59C-5C0B-4FEA-B4FF-102CD0105837">
    <ao:prefix>   7.8 Digoxin   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D273B59C-5C0B-4FEA-B4FF-102CD0105837</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <ao:exact>In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-02 14:22:18 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D273B59C-5C0B-4FEA-B4FF-102CD0105837"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E60D729F-84D5-4421-9FBE-ADF7CADD806E">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FB1C7216-BF30-464C-9ECA-23C0318EE134"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/67D0F870-A48B-4EDE-95AC-EA7ADBEA5274"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1135EFA3-67D9-4B8E-B010-CD51438236F7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacodynamicImpact>
    <rdfs:label>None</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>none.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nacd4779056744f0eba8ef94cfdd867e7">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3D26B95B-42F0-4F28-B170-105D26BAB680">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>propranolol</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:145d9362-1291-4f98-b695-f9adc4309857">
    <ao:exact>In an in vivo drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily). The AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3 fold [see Drug Interactions (7.2)].</ao:exact>
    <ao:prefix>CYP2C9, CYP2C19 and CYP3A4/5.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:17:13 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>3eafea29-f037-4ef4-954a-d93bf01f38db</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37B9F7C1-46B7-42EE-95A6-8964904C256B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:37B9F7C1-46B7-42EE-95A6-8964904C256B"/>
    <ao:prefix>5.7 Potential Alosetron Interaction  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Because alosetron is metabolized by a variety of hepatic CYP drug metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron. Fluvoxamine is a known potent inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9, and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg to 200 mg a day for 16 days, with coadministration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentration (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold [see Contraindications (4.1)] and Lotronex™† (alosetron) package insert. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 14:25:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FE2CA90D-2D47-48DF-8FF1-2F1435B3694C">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>lithium</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>30 mmol</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/02d44ac8-6cc1-42d8-8401-ff1d58eafdf6">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>midazolam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C7CF1BBC-BD5B-4AC2-BDB8-8C59B49BE9ED">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
    <rdfs:label>flecainide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63856aff-1f69-4ce6-9fcb-228b033dfea1">
    <domeo:belongsToSet>urn:domeoclient:uuid:176beeec-5737-4b5e-9b2f-5ca875056688</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:50f09c81-766b-4339-8507-adef4ae37dde"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N60a0e9ad40ec4e148d422f5849a84a80"/>
    <pav:lineageUri>urn:domeoserver:annotation:acdbf209-4a83-4b47-9ee9-632eb3a1cfa2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8f7b32bd-de00-4a01-bb60-c178df00fcb9">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>antiviral drugs</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F1F1EC19-4132-407B-8CA6-DFA79CCD1FCB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>threohydrobupropion and erythrohydrobupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E56A3E4-1743-4CBC-8C27-9ACD1EB0C4C9">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:6B78E6DF-3C83-497A-AB88-33FBA7989263</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-28 16:37:52 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:45CBDB2E-596B-4BBB-B0EB-25B5A20577C9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B19016AA-1639-420A-B594-59F3CC8DF372</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nd3da16208b9d405c978cfee8c3fff3e1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-28 16:37:51 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/95f14f59-8a3f-4761-9fa2-9d08e3b72ac6">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/95ea3119-40c1-413e-9f19-7296cb3daddc">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <rdfs:label>digoxin</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6DDCF14-6C45-49AA-BF55-5135BFFC5772">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-05 10:39:35 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C6DDCF14-6C45-49AA-BF55-5135BFFC5772</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).    In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).    Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <ao:prefix>Drugs Metabolized by P450 2D6   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C6DDCF14-6C45-49AA-BF55-5135BFFC5772"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3a68377c7d4c44d78eb67751bff42646">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6ED09715-10C4-44D3-90C4-3DF330DCCCD5">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B23E7E12-1788-466D-BC31-88B8498C9BAB"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/59144EDD-22D5-41E9-AE18-482F804EAF63">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>hydroxybupropion</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f00053f9-1bff-4b11-be13-aa274e542e8d">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:976cdd5d-18aa-4141-81b5-bf0992087b29"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>06afba38-83f8-48c0-b718-69d471202bdd</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0189c77cec4840eb91a85c6989fe64d5">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F716C59B-3BBD-45DF-A5A1-839E52FCF68E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N7c430fc2c3d546c3a7aeed6a1a1d8e18"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:B6EE59E2-ADA6-4DBA-BA3B-6D60FA250AFE</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:87BB16A8-BB38-4F6A-BD5E-FD2D22B216C7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-27 15:20:51 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-27 15:20:54 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd68ace3364c34b84b7d6716e81369961">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/54FB9D2C-7E25-49A3-BE0D-67EA37E3C777">
    <rdfs:label>phenytoin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>300</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:658759a9-ad95-4625-a301-32e6eff69f3e">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:f016cacc-2e36-42f3-8131-8f6ffc5ab26d"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/863AB85D-F6D6-4E4F-BF38-63680C8A32B8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>400</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:af9e06ef-d5ac-4d26-bc27-a356259891a1">
    <domeo:uuid>cfaa8e83-f29e-455c-b147-ae399a56f26e</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0495ca1b-45f6-4e70-ab90-fd00898ae72d"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1ffbf746-9181-41f4-83de-51f0afa8f3fd">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <rdfs:label>warfarin</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na58376e7a6654b98a3a298c6e60599a3">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5EA3A394-5ED5-4519-99C7-0D36E400AD3A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/79111EE0-D652-4955-97B5-F14164881B2E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/308EB9CE-FD35-4833-BFF0-1DB889EA32ED"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/34F02C7F-C76F-4224-AEB1-088F33A9F97C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:70C9AE3B-252E-4E47-B4C2-1F29B9140C15">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7489C129-C473-4D4B-AF73-E7D8D313FA14"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e80132f6-a8ce-4ae5-a1e2-3ef2b9908c21">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2173078f-59fb-4128-be3f-a0f12936d751"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4881C787-F8E3-4414-81AC-DD07E3240F6B">
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51b1bf0c-1856-45fe-b29e-182dc5b62081">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:d46cfe4f-4f8c-48a2-867e-67fdbaf68b82</domeo:belongsToSet>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nfe1b88e065914741914c75699d478ddc"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:1001bb38-6afa-46eb-bae2-483e0d464fbd"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:d573fb14-8788-4390-9b50-8bdae7d55913</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE4C5063-81A4-4E66-9371-A540CFDB01E5">
    <ao:suffix>(1 mg BID) and nefazodone (200 mg BID) were coadministered, steady-state peak concentrations, AUC and half-life values for alprazolam increased by approximately 2 fold. Nefazodone plasma concentrations were unaffected by alprazolam. If alprazolam is coad</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>When </ao:prefix>
    <pav:createdOn>2015-11-06 15:37:01 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EE4C5063-81A4-4E66-9371-A540CFDB01E5"/>
    <ao:exact>alprazolam </ao:exact>
    <domeo:uuid>EE4C5063-81A4-4E66-9371-A540CFDB01E5</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5584447B-F4AB-448A-B04E-247C32F49738">
    <ao:exact>TCA </ao:exact>
    <pav:createdOn>2015-10-29 10:56:03 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5584447B-F4AB-448A-B04E-247C32F49738"/>
    <ao:prefix>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9e0a51312049404e896eda603f8c39ac">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A78209D8-4446-4765-B592-02FA260569E4">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0852A8A4-FD74-4E88-BD1C-F6843FC6A4A2"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6D53F261-3F66-4C72-BA5C-B46B0C62C597">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6d263f2fe90a4e4ebce0488cf92732eb">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:50CEFDCD-023A-4A23-BCF6-9F6B8EECA572">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B7CF70E3-93F1-48B4-981E-C4F878BE2FC4"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:763F8A90-53E7-4FCC-8325-E9AACB11A872">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5763E47C-017C-4E4B-BB24-79C697FE917E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A734DFA3-4B42-40B6-A58F-00BD63342A8C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:52D6E96B-7A61-42FB-B7F6-3AE957575C36"/>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-11-05 15:33:50 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N09f1a73a19484844bf5da62d0fcc1b9c"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5A1B37FD-3B9D-444E-BDF9-388BAB48887F">
    <rdfs:label>desipramine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:591D3D6B-1CE7-4F46-B6F1-B58E2AD5A4A7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CAD54B20-B5E9-4402-8688-6843EC93EBFE"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6764f215529945b889db310b104a5e3d">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1953ca2e-773e-4b33-afd4-ed3e79e2cfa4">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1173d7c1-d785-4b40-be33-5461a8c83e88">
    <domeo:uuid>6d3c1d73-ea42-4236-b654-a25f13e1445e</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76c0b930-4be9-47a4-9ef4-70565212485c"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:878D979D-590C-494B-9A86-F9A71357DC10">
    <pav:createdOn>2015-11-04 14:16:43 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CDF014D5-9BA2-41F3-B475-04BE0F75E220"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf34fe22c02f542d0a8882d92ed0222c7">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b557e3b2-7f5f-41f4-b619-89a7660fc3c3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid>0517f2ea-6b44-4e23-92d5-157c11270c70</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4d29080d-bf65-45e7-b83b-fe5d4baac8e9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5a2df4fe-d938-4af8-8aba-24b38c6395c1">
    <ao:prefix>administration with Savella .  </ao:prefix>
    <domeo:uuid>d102a1f8-c4c0-48bb-ab07-afcb20594155</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <ao:exact>Clomipramine-Switching from clomipramine (75 mg once a day) to milnacipran (100 mg/day) without a washout period did not lead to clinically significant changes in the pharmacokinetics of milnacipran. Because an increase in adverse events (eg, euphoria and postural hypotension) was observed after switching from clomipramine to milnacipran, monitoring of patients during treatment switch is recommended. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/22A7FE72-50A8-4FAD-A352-899C105ECDA0">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N27919b5304b14e3086ffcf5621948b35">
    <domeo:sets rdf:resource="urn:pddi:uuid:840B8551-B4AC-4F9E-AF1A-915F3B409E35"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/27b88280-47af-4189-bfa5-9f61854e17d7">
    <rdfs:label>rifampin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:4594917B-2AC9-4FBB-B89D-E2B111AC53CD">
    <pav:lineageUri>urn:domeoserver:annotationset:ff24524b-e247-49fc-bd0d-1312c5659cbc</pav:lineageUri>
    <permissions:permissions rdf:nodeID="Necbd9553ad0b45fbb3feb8656ee09c7a"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <pav:createdOn>2015-10-26 15:38:48 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>NER Sets</rdfs:label>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-10-29 11:36:34 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:B4746783-A12C-4F89-850F-A34B481E1D2D"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="file:///home/yin2/domeo-tools/export-tool/c7b621a5-213a-4e68-9690-c9886aeeae19"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DA57C8DA-4E2A-4BD7-836A-F0FCB2F8397A"/>
    <pav:previousVersion>urn:domeoclient:uuid:901f6cbb-87e4-46ca-9933-cbd10db02b63</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/097D0A77-A3AF-4304-9FBE-A496FE588C10">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>150</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4F885F18-A22B-4E57-806B-38A9FE31D96F">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/233E1779-D913-4A5A-81E0-F1F4A26F36A4"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0571470B-C5A2-477D-92DA-95B207F58399"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/09ebd28b-89b4-4dee-a2b2-a9d5bcedd275">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/358262</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>fosamprenavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Neb43b50944034fc2ba8896b26f2dab15">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/23249E24-5BDD-4F47-BCFF-05AF42843756">
    <rdfs:label>carbamazepine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>6</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1d62a35b-f11d-4fce-bdab-bb10ce5195ee">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F05C56D7-4CD4-42F6-A8FE-779097F20087">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:6DA61A1D-9F9E-44EE-A452-145B92FA4439</pav:lineageUri>
    <pav:lastSavedOn>2015-10-27 09:16:54 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F47B4D44-9141-45AA-BA2D-69BE6D04B04E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FA6E3D16-2F6D-4EFC-B607-E400E4D673DB</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-27 09:16:42 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9f95ee54-bf68-4c66-b3ee-82152df8b026">
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:fe245ea9-9fce-46aa-a1ba-bb27340570a4</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:f3f7460c-63f9-4a62-a35a-b8ed7d871b3b</pav:lineageUri>
    <ao:body rdf:nodeID="N0d88c68dec3f46edb392932a125a20dd"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:7b44a281-73db-49d5-b28f-d11a5d7d6496"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f319c72f-30e8-4c28-a811-eb6b9e67c8ec">
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/eff49ccd-d55b-4392-af98-78ffbe4c4dfd">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B286D1A0-FEE2-400F-A626-9EB497D649EB">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:lastSavedOn>2015-10-27 15:32:38 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Na8e44bb815f3429a9c6d827187adc631"/>
    <pav:previousVersion>urn:domeoserver:annotationset:51946AF2-3A64-4436-A921-46849FF1FA53</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2015-10-27 15:32:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B2885CD9-49C8-485B-BD7B-B6D3831E3A09"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1d091652-cbab-466a-bfce-26f155cdfdb6">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>selective serotonin reuptake inhibitors</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5BCEC3DC-EEE2-4AC3-A0CB-EE547AB0ED79">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A68DAC74-FDF9-400A-8275-DC28BD698D4A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:95465721-1A44-48F9-A3B5-1FF636EEF31F"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8415ca50-1235-4a3a-bb99-df9c5d2e061f">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:899b275f-5883-41cf-baa1-0a8638dce6a3"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/56732509-4459-4720-B96F-F9295339AE68">
    <rdfs:label>astemizole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5a79a118-20f6-4089-ac50-03d388680c5b">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:21d19ade-9b9f-46d2-9a73-44434e68c293"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/357d6bbd-856d-4908-b650-b2c9cbe4e7c8">
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3895638D-8C67-4383-BD42-532F5768CC2B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/38400</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>atomoxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F73E5222-4E9B-466F-AE72-6BC5A904602E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ef0428b2-5a44-424f-a383-da4fdf81c546">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>75</dikbD2R:dose>
    <rdfs:label>milnacipran</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FBF37F2B-D151-45F2-AFF5-F9E594C9F260">
    <ao:exact>In another healthy volunteer study, lopinavir 400 mg/ritonavir 100 mg twice daily decreased bupropion AUC and Cmax by 57%. The AUC and Cmax of hydroxybupropion metabolite were decreased by 50% and 31%, respectively.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FBF37F2B-D151-45F2-AFF5-F9E594C9F260"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 16:13:12 -0500</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>erythrohydrobupropion decreased by 68%.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D927D87A-0730-4A0E-BA09-42987D40AF85">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A37D2FCE-2C99-4C71-8140-AD7527A114F8"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e17a13cb-7c59-490e-aa6b-f236f8b995a2">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>e31d5279-95a9-4ae6-abc2-4abbe2314820</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:prefix> B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/08A99BE8-FF56-415F-B722-976BC9616313">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9d1f5af31f794d9ea79d1e856dde222a">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N103e5ec7fc6242018baa179a507cdd2d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/fe7ef7e3-4a4f-4310-b009-6f845fbd94a7">
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-26 15:39:09 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-26 15:39:09 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:165908e2-6280-446d-ad91-9c8ffafdb9ef"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0c3204cb-32f8-4d58-b002-cb9807343236">
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>9af62a11-2572-45ce-9bac-eb27483b6ba8</domeo:uuid>
    <ao:exact>There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of organic anion transporter 3 (OAT3) in vivo [see Drug Interactions (7)].</ao:exact>
    <ao:prefix>2 in vivo .   OAT3 Substrates  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bdd48305-369a-47eb-920b-a6b84a884738">
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:c0cde7aa-afe2-4cc0-af07-6e36636bf5fe"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N78e55206cecb48b59c7116d0616a25b6"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoclient:uuid:69c867c9-8334-477c-95e1-e3781f19677f</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:e583ffb8-293b-4103-b00b-228eff79215d</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7BE0D18-597F-464A-9C37-83E9C5C42AB8">
    <ao:prefix>e in plasma AUC of the TCA ).  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <pav:createdOn>2015-10-29 10:56:48 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>A7BE0D18-597F-464A-9C37-83E9C5C42AB8</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A7BE0D18-597F-464A-9C37-83E9C5C42AB8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf0bd6919095d4b309044b3c122b27f96">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36bb758d-7962-4b22-bdf6-57aaebf94890">
    <ao:context rdf:resource="urn:domeoclient:uuid:ce760a96-2ae1-474a-af7a-18538dbe42ce"/>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:9dca8218-d0e4-403c-a119-6824d5034de8</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:a364b50f-902d-4788-9844-0856fb48fe2b</domeo:belongsToSet>
    <ao:body rdf:nodeID="Nba10e3acf6ae421f87848a9aa8f79cd9"/>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6ddb70de-9c3b-4e1f-acb4-ec99050dcba9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N43c61bd3af744ce4a6226d460a82b390">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d95d96b3-1b7f-4428-9629-6379f0038692">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4c9ac7e7-7a3e-45c8-a744-e0258055ab2e"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid>7e08eee9-5e89-48be-a889-41a1f9afb728</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B7D1C3D8-AB88-4BC7-A8BE-FD40E4E047F2">
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/22142CA4-11B9-4B93-B63A-656632F2886F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <rdfs:label>ritonavir</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>600</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8830e691-36fb-4c4d-8d27-b7482920ee0c">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>abiraterone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/30f38d08-0321-4172-ad4d-0959ae9c6813">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>barbiturates</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8d5b4556961a4ef2b90e562b800150b5">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/67E8E205-57E1-4722-87E0-B8338C9D2156">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5bde621e6eba4c2480d3a43e43847bb9">
    <domeo:sets rdf:resource="urn:pddi:uuid:9B4B8432-3C36-4730-8632-45BC14A5B023"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C04DBAA5-1224-4CED-8F23-14AEABEEB3F6">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:3E4F614F-4DD5-49CF-BECA-68ED4E06683D"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lastSavedOn>2015-11-06 15:43:14 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:8EE4F288-19C8-4519-85CB-791C9E9709D8</pav:previousVersion>
    <pav:createdOn>2015-11-06 15:42:00 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D7E7CC1D-6D84-46B4-A465-B9574B95CD4E">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C6A170C2-A5E2-4F44-A36D-4894970C211E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/721C2A2D-0C8A-41D0-BB1D-CA13EE7D9E2B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:235AACC2-387B-43B3-94E9-EB936C13A3E3">
    <ao:prefix>Drugs Metabolized by P450 2D6   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:235AACC2-387B-43B3-94E9-EB936C13A3E3"/>
    <pav:createdOn>2015-11-05 10:39:02 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).    In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).    Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <domeo:uuid>235AACC2-387B-43B3-94E9-EB936C13A3E3</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3DB242A5-6849-478B-B408-B08011C4DCCF">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/bbc428e2-932d-423f-b16e-c8950035cc35">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>mitoxantrone</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6127250-435C-4F5A-BEEE-41801DE0FC7B">
    <pav:createdOn>2015-10-27 15:22:32 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:50D27F86-B485-4FD3-9B02-6D20C66C1B7C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12eba460-c01b-4f47-9e2d-37aef0f50474">
    <ao:body rdf:nodeID="N534459e06bcf4c84b34ed095cd9de8d6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:aa021469-194c-42e1-8226-67fa40518664</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:37d9e027-4c23-4da6-ae4c-e4e87d74455a</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1b70b199-edfa-45fd-a312-3071337014ff"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F4F02943-8BF8-438F-A62E-89E7329BEA30">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:589E8E19-029C-4213-A0A9-D85714D83449"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:386E944F-CC01-43EF-BFA6-0D177461C68B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C185DF17-F70F-4F25-9D71-BA6FA47AA185"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/033AD75B-092D-4B04-805E-3AE11B85E4DF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32e57220-a5aa-4afc-9fd1-fb0cfe8dd4a0">
    <domeo:belongsToSet>urn:domeoserver:annotationset:1AC8D52E-9BA7-49E7-8733-4B07EC5BBECB</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:227eb54e-a397-400b-bf09-27b7de9b25be</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:498307F9-9F27-4AA4-A5F2-0CDEFE98C185"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N21ef4c95c94141c290a67e0c6a736a19"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-29 09:30:04 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:995e9560-a5e5-4dcd-a646-6c19f3f11f09">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <domeo:uuid>c311453d-3b36-417b-a663-c9cde2ac5c76</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07B0F158-E47A-4723-AF8C-D90125D46833">
    <pav:createdOn>2015-11-02 13:33:34 -0500</pav:createdOn>
    <domeo:uuid>07B0F158-E47A-4723-AF8C-D90125D46833</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>lithium </ao:exact>
    <ao:prefix> (40 mg/day for 10 days) and </ao:prefix>
    <ao:suffix>(30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:07B0F158-E47A-4723-AF8C-D90125D46833"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6014DB9D-8992-4573-BDCE-4A7D344B778D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6014DB9D-8992-4573-BDCE-4A7D344B778D"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Terfenadine, astemizole, cisapride, and pimozide are all metabolized by the cytochrome P450 3A4 (CYP3A4) isozyme, and it has been demonstrated that ketoconazole, erythromycin, and other inhibitors of CYP3A4 can block the metabolism of these drugs, which can result in increased plasma concentrations of parent drug. Increased plasma concentrations of terfenadine, astemizole, cisapride, and pimozide are associated with QT prolongation and with rare cases of serious cardiovascular adverse events, including death, due principally to ventricular tachycardia of the torsade de pointes type. Nefazodone has been shown in vitro to be an inhibitor of CYP3A4. Consequently, it is recommended that nefazodone not be used in combination with either terfenadine, astemizole, cisapride, or pimozide (see CONTRAINDICATIONS and PRECAUTIONS).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>Potential Terfenadine, Astemizole, Cisapride, and Pimozide Interactions   </ao:prefix>
    <domeo:uuid>6014DB9D-8992-4573-BDCE-4A7D344B778D</domeo:uuid>
    <pav:createdOn>2015-11-06 15:42:45 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9b5695d220e941f8ab15fd05c7b29f72">
    <domeo:sets rdf:resource="urn:pddi:uuid:25356FFB-DB38-4B3F-B9E2-3E7EE298211D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:56EA7F48-3179-452B-BB6A-F74C96533A0D">
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Required</rdfs:label>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:957ac464-8a4d-42bc-9005-db207d7ed25f">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:13767b15-9122-4414-b1f2-91d3521d6fdf"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C798082B-6017-4D26-9646-83FAA75450BB">
    <rdfs:label>EMSAM</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>6</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/93E316EB-615C-4FEE-B0CD-16B2E615FF3A">
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Lexapro</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:48fb298a-d361-44ad-b56d-1a80cc626456">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d25356a0-51b6-4ec9-a0ed-a8b9b8d3b9c8"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/49370236-3c85-474d-b7ef-f1933d68e299">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>amitriptyline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/704</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7408B8E7-E0D8-4C25-91DA-8918CC13EE6B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N607db3eb2c7b4aec98f9e95c0aed9e11">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28DA8AB6-0277-4537-909A-F41B5BE2910E">
    <pav:createdOn>2015-11-05 16:08:15 -0500</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:prefix>erythrohydrobupropion decreased by 48%. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28DA8AB6-0277-4537-909A-F41B5BE2910E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a second healthy volunteer study, ritonavir 600 mg twice daily decreased the AUC and Cmax of bupropion by 66% and 62% respectively. The exposure of the hydroxybupropion metabolite was decreased by 78%, the threohydrobupropion decreased by 50%, and the erythrohydrobupropion decreased by 68%. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:10D3B1F8-6CD8-41D2-A9A7-281515CC7DA4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EA058153-469B-4EE9-94C8-2F99B709453F"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:713DFBBE-3194-4016-A9E7-7147DF1DAFEC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:713DFBBE-3194-4016-A9E7-7147DF1DAFEC"/>
    <pav:createdOn>2015-10-28 14:38:28 -0400</pav:createdOn>
    <ao:prefix>Thioridazine administration alone produces prolongation of the QTc interval, which is associated with serious ventricular arrhythmias, such as torsade de pointes–type arrhythmias, and sudden death. This effect appears to be dose related.     </ao:prefix>
    <domeo:uuid>713DFBBE-3194-4016-A9E7-7147DF1DAFEC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>An in vivo study suggests that drugs which inhibit CYP2D6, such as paroxetine, will elevate plasma levels of thioridazine. Therefore, it is recommended that paroxetine not be used in combination with thioridazine (see CONTRAINDICATIONS and PRECAUTIONS). </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nadfe592a10eb4730be3dcd98db06a0a3">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7ab6aab85c3b4b398f84438a88823955">
    <domeo:sets rdf:resource="urn:pddi:uuid:C2888FCB-E2CE-4E40-BE43-5F7DD49A64D5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b779faef-df5f-48f7-a92d-85d1f7d1c229">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:393cd8d5-05de-46c5-a0a6-d2939ab21d75"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE77B80A-38B1-4669-A7B0-6BEE7481BD08">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BE77B80A-38B1-4669-A7B0-6BEE7481BD08"/>
    <pav:createdOn>2015-11-05 10:36:40 -0500</pav:createdOn>
    <ao:exact>SSRIs</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSR</ao:suffix>
    <domeo:uuid>BE77B80A-38B1-4669-A7B0-6BEE7481BD08</domeo:uuid>
    <ao:prefix>). While all the selective serotonin reuptake inhibitors (</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7decdeed-d302-4e69-880a-ebca9d71f756">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE8D545B-72D2-4DC5-8C2D-A8AD8C752A9B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <pav:lastSavedOn>2015-11-06 15:34:44 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:ABE46A55-6147-466A-8750-29C6C8A38D5A"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:6472ac55-3b05-4f4f-ad50-9264fbcd6d9a</pav:previousVersion>
    <pav:createdOn>2015-11-06 15:33:49 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:945A03C5-C85D-4B96-B6EB-1AE94912F4B3">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:46D6BD81-E1D0-4729-93AF-4980F3582826"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B91F60BA-5777-46EB-933C-BE75733F18BA">
    <ao:exact>barbiturates</ao:exact>
    <ao:prefix>) and decreased by concomitant administration with hepatic enzyme inducers (e.g., </ao:prefix>
    <domeo:uuid>B91F60BA-5777-46EB-933C-BE75733F18BA</domeo:uuid>
    <pav:createdOn>2015-10-29 10:28:55 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B91F60BA-5777-46EB-933C-BE75733F18BA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EE4EA623-BE83-41AA-B5B1-DA09807C8C8B">
    <rdfs:label>debrisoquin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:09fbe312-fe74-45ea-8d2d-7493b26da711">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5a64af67-499c-4ea4-b8e6-e3b9795c8882"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:10d9ef8d-2b05-4dec-a0fd-111fcd99e32e">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4d4899d6-1f9c-4a9c-a070-6045bcf38fe1"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N053c9d97e7b340939507e39fed098f00">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:09075926-828F-459F-8784-80EAE0C6630B">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5BCEC3DC-EEE2-4AC3-A0CB-EE547AB0ED79"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5E48D73C-7A2F-416F-B21A-E5DD5408A5CD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b6fed66e-512e-4a14-8479-1c6e65d88a54">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>milnacipran</rdfs:label>
    <dikbD2R:dose>150</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:85465149-3E94-4833-9DBB-5A7D3053F0D7">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CA8153B9-45AB-496F-B470-0563BE377921"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4A38A493-8AFD-48AD-BF4B-BA10E3DB4A24"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A1EFB38E-7A30-4B7B-A6A9-54D4E8A2043C">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:comment>Exposure decreased by 23%</dikbD2R:comment>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:47CCA907-5E9C-4A08-BE7A-219B08F913A5"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2428DC59-E25A-435C-B9A2-4C12DD4BFD05">
    <pav:createdOn>2015-11-04 14:11:15 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <domeo:uuid>2428DC59-E25A-435C-B9A2-4C12DD4BFD05</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of </ao:prefix>
    <ao:exact>TCA </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2428DC59-E25A-435C-B9A2-4C12DD4BFD05"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0039AF3F-3775-4EF2-8D79-0457D7A80013">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:229C4E87-7FFC-416F-AE55-F30D27EA1680"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9c3586d3-4294-41da-8aec-1ab9af86ff0b">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:d3e49d27-223f-43bd-b7ce-0ebdfda869a3"/>
    <domeo:uuid>a20d176d-6c53-44b8-8ab6-63ee40e491a2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A0EB2950-7505-4EC5-9796-6E82906B9CBD">
    <dikbD2R:dose>100</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c9e476b2-c06a-4e73-9591-c5f08ad5e899">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:17E418A6-5BE7-4999-B747-3AD484A638B6">
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:76a9e75a-2c3d-465a-a009-2748d034cdf9</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:12f63dd4-b6a8-45d0-93c0-abe9cd468593"/>
    <pav:lastSavedOn>2015-10-28 16:36:27 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-16 15:31:12 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:previousVersion>urn:domeoclient:uuid:e2b6bd44-51d2-4cdd-ae7a-57c5df33e50d</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N1f64a0fda11345bd93cbaa6bf9a4e535"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A9C994B2-F31B-45D3-B1DA-4DAACBB89426">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C0147E50-E5D6-437A-9857-82B800A74369"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/79C41A3F-350F-4B02-A294-D189CDE8A56A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ac809895-3ed6-4b43-ad44-65f777a8b6d5">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>milnacipran</rdfs:label>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23530D0B-F4A5-407A-AED0-EE99C0B30E6D">
    <ao:prefix>% and 7% for CYP2C9*2 and CYP2C9*3, respectively. Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9, and *11 alleles in Caucasians. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Warfarin-ab047628-67d0-4a64-8d77-36b054969b44.html </ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-02-20 13:49:37 -0500</pav:createdOn>
    <ao:exact>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle through inhibition of VKOR, a multiprotein enzyme complex. Certain single nucleotide polymorphisms in the VKORC1 gene (e.g., –1639G&gt;A) have been associated with variable warfarin dose requirements. VKORC1 and CYP2C9 gene variants generally explain the largest proportion of known variability in warfarin dose requirements.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:23530D0B-F4A5-407A-AED0-EE99C0B30E6D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>23530D0B-F4A5-407A-AED0-EE99C0B30E6D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ca47e3d9-ce64-48b1-8c0a-c45bde949d0b">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>warfarin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ff49bf15-7f16-4836-838d-b8e6694ae732">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4d2ea06c-67b8-4760-bafd-0acdb80434e2"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1ffbf746-9181-41f4-83de-51f0afa8f3fd"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A16731CD-1F0D-4780-A60C-33F06C7E13C3">
    <pav:createdOn>2015-10-29 10:39:52 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <domeo:uuid>A16731CD-1F0D-4780-A60C-33F06C7E13C3</domeo:uuid>
    <ao:prefix>  Ketoconazole  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A16731CD-1F0D-4780-A60C-33F06C7E13C3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In healthy, male, Caucasian patients (n=24), coadministration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30-mg dose of mirtazapine by approximately 40% and 50%, respectively.    Caution should be exercised when coadministering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, or nefazodone.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6F87DEF1-707A-4561-83D4-D9A596238A13">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8E53BBF2-1D26-44A9-B935-8B5C46B4AB0C"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/441B4064-F7BC-4292-B897-71AC507C5B45"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10ffc8d3-87b6-4271-a772-4c1fdd0a0d19">
    <domeo:uuid>04efa66c-83c6-412c-99fb-adb09a2b4133</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3feb7ea5-2747-4060-89de-c2c09f038bac"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9fa11d20-7a47-4503-a4e5-0dccb1d780de">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:3b939ada-2b63-40ed-920e-599cc4f6e4c0</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:e559ac7f-bdc3-4ab1-be29-737343adf1d8"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-09-03 15:43:15 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-03 15:43:15 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Ndc455bb8053041a19de67dadd5a81269"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6382E5B8-141E-425E-B811-E264B7FDC891">
    <pav:previousVersion>urn:domeoclient:uuid:f8b8de18-6038-4326-8c17-4d45c812eca4</pav:previousVersion>
    <pav:createdOn>2015-09-24 15:55:00 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:271e06e6-c2a5-4f25-bbde-106cd9b11328"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-29 09:04:02 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="Ncdfecff6cdce475dbc01de9e8f1e152a"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:de75f371-16ce-44e1-a709-f8134500da94</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16399B64-7253-44DD-9260-A8481C94767F">
    <ao:exact>sertraline</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-04 14:17:34 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16399B64-7253-44DD-9260-A8481C94767F"/>
    <domeo:uuid>16399B64-7253-44DD-9260-A8481C94767F</domeo:uuid>
    <ao:suffix>, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, cauti</ao:suffix>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:471EE520-5AA1-40C5-B51E-59BEE36B2B4A">
    <pav:createdOn>2015-11-05 16:07:33 -0500</pav:createdOn>
    <ao:exact>In a second healthy volunteer study, ritonavir 600 mg twice daily decreased the AUC and Cmax of bupropion by 66% and 62% respectively. The exposure of the hydroxybupropion metabolite was decreased by 78%, the threohydrobupropion decreased by 50%, and the erythrohydrobupropion decreased by 68%. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>decreased by 48%. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:471EE520-5AA1-40C5-B51E-59BEE36B2B4A"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8acae0e9-b5ad-489d-9dd3-108a76cb1410">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:0ac473bb-b9e4-40f4-87a5-0bdb0a87ad41</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N2fd4e260ea5846cbbeb496ad14292538"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:629AB3EE-7925-4673-A859-BE58ACD16E71"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DC53FFB5-89EF-4111-932E-48418846D393</domeo:belongsToSet>
    <pav:createdOn>2015-09-03 16:19:40 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-27 14:16:45 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9bc27358-9fa5-4e54-97df-bcf6fef24f1f">
    <ao:exact>Lithium — There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with fluoxetine. Cases of lithium toxicity and increased serotonergic effects have been reported. Lithium levels should be monitored when these drugs are administered concomitantly [see Warnings and Precautions (5.2)]. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>9aa9c94d-4815-488f-b589-750ffba98130</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e42724ce-4281-4724-b99c-179e97146f35">
    <ao:prefix>ed in healthy adult subjects.  </ao:prefix>
    <ao:exact>Carbamazepine-There were no clinically significant changes in the pharmacokinetics of milnacipran following co-administration of Savella (100 mg/day) and carbamazepine (200 mg twice a day). No changes were observed in the pharmacokinetics of carbamazepine or its epoxide metabolite due to co-administration with Savella. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>a0afcfdf-bc9e-4940-976f-b578aa8f0c83</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/992373E2-28CA-480C-9749-ECA29D628CFA">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>60</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>duloxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/85BD4D34-4389-4062-A70F-24FE4188F731">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FEB21963-21A2-42AB-8567-8ED1E3743C52">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>olanzapine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F62F5A44-B30F-48B0-8DD0-93AC24C56FDF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3B78AB4-5439-495D-9E60-E60DCBCBE345">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-27 15:36:48 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N468ea03a7e4246e7850ff0968450d81c"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:EA2984D2-433D-4D1A-95B2-5BC3937E7381"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F701B842-A4F1-4C5F-8F25-42E4128F2430">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D618F2B0-8C27-412E-9D8E-D1B4AFB367F8"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B5C200B1-5014-4B11-8CC6-306B17072D8F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6926</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>mexiletine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F4DBB50A-6647-4865-A95B-10B0A4931874">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:71D1EC37-66B8-49BF-BF79-6790566492CB"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ff79c20d-04b6-474d-8577-351ec0b53c17">
    <ao:exact>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).</ao:exact>
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>see Drug Interactions (7) ] .  </ao:prefix>
    <domeo:uuid>09481003-cf4c-4db3-97c8-52d601c4f3e9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:081F5CF2-9965-440E-8A1B-211D4F016DE5">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:25DFFE33-F9B6-472C-B49A-54BF1DF841D3"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0da9c05411544c54a1a1e6e8347952c6">
    <domeo:sets rdf:resource="urn:pddi:uuid:B6F9EA1C-95FB-4271-A406-8EA7240E37A3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7f970c479402456d9f79e6cae8db7067">
    <domeo:sets rdf:resource="urn:pddi:uuid:2269E5AC-C285-48E9-AE9C-C536F5421114"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FA98AECF-689C-4236-84C7-63A0618F25E9">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B2871CE-EA24-4E2D-9DE3-C431DE27226C">
    <pav:createdOn>2015-10-27 14:17:10 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7B2871CE-EA24-4E2D-9DE3-C431DE27226C"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid>7B2871CE-EA24-4E2D-9DE3-C431DE27226C</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Risperidone    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with risperidone (2 mg per day for 7 days), a substrate for CYP2D6, did not affect the pharmacokinetics of selegiline or risperidone [see Drug Interactions (7.4) and (7.5)].    Warfarin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94616415-2204-41A8-80A9-821B98B9F14A">
    <ao:prefix>, and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>94616415-2204-41A8-80A9-821B98B9F14A</domeo:uuid>
    <ao:exact>paroxetine</ao:exact>
    <ao:suffix>, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated </ao:suffix>
    <pav:createdOn>2015-11-05 10:36:45 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:94616415-2204-41A8-80A9-821B98B9F14A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a31e3265-4b55-4cce-87ad-ccdd04955d3e">
    <pav:createdOn>2015-10-26 15:40:15 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2015-10-26 15:40:15 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0D56CBB6-C44E-44FD-8A32-E7EFF20B9DA9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:4fdca1cc-8a4d-4451-b292-964852284e82</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6564db00-5c1f-4d7e-8f0e-a81e09babc75"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D11DF95F-4CCE-4E68-AF92-AE915C8DCDA2">
    <dikbD2R:cminType>UNK</dikbD2R:cminType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/57E199AA-DB18-433A-9F82-D0D050EE4DB8"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cminDirection>UNK</dikbD2R:cminDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmin>Unk</dikbD2R:cmin>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E74FDD61-47B2-40D7-AD4B-8E13506411BF"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:31B00EED-C22A-4452-944D-38253763AE3A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/78232219-A6A8-4D5E-A3CF-2D6771803AEB"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D39EA529-6402-4592-B7F5-E2D177559AAE"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1c47a772-7c00-4982-af21-81c5f276b8dd">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluoxetine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DD1291DC-6AD0-4D39-9AF7-255CA754E0AD">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>fluoxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:86891B77-F02A-44E8-BC1F-D624CD37D7EF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AA3FABD1-33E4-48E1-821E-67F1D830A725"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5e54d95b-9341-4626-b3f8-db9f5ae9c872">
    <ao:prefix>AUBAGIO on CYP1A2 substrates   </ao:prefix>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>9ebabcb9-75e5-4518-92b4-9158cad76074</domeo:uuid>
    <ao:exact>Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/04BD4A77-B4AF-417B-A1FA-ABD2B4CC7D44">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>cimetidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:598E6FC7-D724-435B-BBAA-BDDEDD2509F7">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A8181DB6-98C6-476E-BA4C-8D8832C5B16E"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ae65b9ee-4172-4a6d-a0ea-8c7430e4d4a6">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8134</dailymed:activeMoietyRxCUI>
    <rdfs:label>phenobarbital</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:21fdf362-b6d8-418c-be34-b3037d1e1a37">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:905c58e5-3722-40e4-b31a-b39167600429"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/54FE29F8-67DF-442E-97E5-D70CAB0E1869">
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <rdfs:label>ritonavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20E16FD0-A19C-4727-A2F8-66476D5D36AE">
    <pav:createdOn>2015-11-05 10:29:55 -0500</pav:createdOn>
    <ao:exact>cimetidine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>20E16FD0-A19C-4727-A2F8-66476D5D36AE</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:20E16FD0-A19C-4727-A2F8-66476D5D36AE"/>
    <ao:prefix>dosage may be required if </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>therapy is initiated; upward adjustment if cimetidine therapy is discontinued.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83262D58-1DEB-46D2-9ACE-E2E2411339F7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83262D58-1DEB-46D2-9ACE-E2E2411339F7"/>
    <pav:createdOn>2015-11-05 15:28:32 -0500</pav:createdOn>
    <ao:exact>metoprolol</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>), beta-blockers (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>), and Type 1C antiarrhythmics (e.g. </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c19b3f11-dfa6-4eed-a773-c0aaab12aca2">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>a275eed6-5ba0-4e84-90e3-6c5987ae1eb1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:dbcedb4c-0324-42ab-a274-08dcd74cd582"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26940A54-443A-4CC6-9627-1891284DBE46">
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">26</pav:versionNumber>
    <pav:createdOn>2015-11-05 16:13:27 -0500</pav:createdOn>
    <pav:lastSavedOn>2015-11-05 16:15:31 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:4CEE8D0E-B023-48E0-A038-A0024F43A84E</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:B52EBC06-DE23-4072-BFC9-3ECAD4C2889F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb19fc3419c99464cbbf9d7d0ffd5b222">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B5CAAAD5-F0F8-4495-93CA-75E4FA8279CC">
    <ao:context rdf:resource="urn:domeoclient:uuid:08ACD79A-E041-4B16-9881-E26AA7E701A1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-04 14:10:24 -0500</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-04 14:05:20 -0500</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:9f66b4af-6083-4081-b81c-bd2656e0280a</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:21ab3694-0521-45a0-aac4-063bbf59cd54</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d615093b-2fa6-4225-867f-f5f3f18c6ddc">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>4bd9675a-c0ce-425a-b32a-a7b0bf0b8991</domeo:uuid>
    <ao:exact>Antipsychotics — Some clinical data suggests a possible pharmacodynamic and/or pharmacokinetic interaction between SSRIs and antipsychotics. Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant fluoxetine. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/31144B92-3B12-45BF-9218-D0C18CE802AE">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>haloperidol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a9dc0aab-95ee-4311-8b21-3ad65f71d7f6">
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>carbamazepine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N104508a713364bfb8b3a73cbafb96556">
    <domeo:sets rdf:resource="urn:pddi:uuid:d71c4e94-ad3d-4a13-a0fd-02e2bafb1609"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ned36b9a31ca544ee90a823c9b29dd077">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1bd7a0f03a7847b18975ab6a9a66f6f9">
    <domeo:sets rdf:resource="urn:pddi:uuid:07EAA892-C452-4033-BE15-372E276275C6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:88E17D98-1D5F-4663-8D26-E5B000A79DF2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-02 13:34:35 -0500</pav:createdOn>
    <domeo:uuid>88E17D98-1D5F-4663-8D26-E5B000A79DF2</domeo:uuid>
    <ao:exact>Lithium - Coadministration of Celexa (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of citalopram, caution should be exercised when Celexa and lithium are coadministered.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:88E17D98-1D5F-4663-8D26-E5B000A79DF2"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b26adfab-53c2-486b-9aa1-cc47d8d031e9">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0f83c33c-64c8-4562-9bd6-6ccca58a5082">
    <rdfs:label>TCA</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BFDA94B6-C3E3-4254-B29F-1D8EE09A501D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://fakeuri.org/CYP2C9</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc68e6fa66f83446a98c46d6c3799db78">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cd220c6f-e103-41fd-8493-15146fa4c308">
    <domeo:uuid>cd8f7700-5258-4ee2-8036-077bf9ffd495</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5c7e8cea-a396-43f2-a53e-4c65fd358518"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2D19A517-9A79-4ADB-96C2-2274ACAD845F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>beta-blockers</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C32469C4-4BED-4E9D-9522-590569B31027">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>quinidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7768BEC5-5B7A-4927-8C1C-16251C4EFD86">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/097D0A77-A3AF-4304-9FBE-A496FE588C10"/>
    <dikbD2R:numOfParticipants>8</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cl>unmeasurable</dikbD2R:cl>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F9C5A907-6A52-42A9-AA16-553C4FABE5CA"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N094d84f3b1ac407ea2563f6c64326fb9">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D2C4E45D-CB3F-48CA-84DD-6EC6554304FA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D88F9D17-4565-49C7-8F5C-046CF2BCEFA6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5FCA8537-BF2B-433E-93B3-F44837036DA5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c6705b1c-536a-4b74-b0bc-baa51b656893">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:e1673257-113b-49c5-9174-5f33e5432297"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4D6EE8BE-79FA-42D9-93F1-2F1DA66E4A12">
    <ao:body rdf:nodeID="Nae628e59d64b4cdfa9e1723b4221d663"/>
    <pav:createdOn>2015-11-05 15:32:01 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC7C2526-0D4B-414C-8239-694E9DC0B6CF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:41838242-5198-43F6-88C6-ACBF480796BF</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-05 15:34:37 -0500</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/feeaf27b-e993-4b63-8fa0-1bc1a2f74dff">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <rdfs:label>Rifampin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:01235809-ce2a-4366-9e84-3061e834aa6c">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:bb124b9c-6376-4801-8be2-8f60efd73cad"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0ede17d6670a400dbe2d10f45befafe5">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6C308BCB-40C4-4A1C-9BF3-78ADB5D8984A">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluoxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4272c177-e7d8-4e23-a00a-3eb3d46cf1f8">
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/32eb83b6-00ce-4efe-a5d7-1f5654551e88">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>methotrexate</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6851</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/67A5A73F-7A0C-40F7-876E-83C519E10C0C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D390F44B-CB2A-4326-BAD4-B2F2C7D03E30">
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D390F44B-CB2A-4326-BAD4-B2F2C7D03E30</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D390F44B-CB2A-4326-BAD4-B2F2C7D03E30"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-29 11:30:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0cb87179-0e94-4ad5-b19b-b7e71ca538b4">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:f1ccb4b5-da09-41a1-b1a3-e901e649db75"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/770FD37D-7B87-4FAE-8BB4-C357DCF90F3D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d251fb19-577c-4ea2-aad9-6236765c7020">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9bc2d5ce-85ea-486d-82a2-e61a794fa2e3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid>55db1b17-0ecb-48bf-9c87-63379be5ac64</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7c430fc2c3d546c3a7aeed6a1a1d8e18">
    <domeo:sets rdf:resource="urn:pddi:uuid:CB6AF163-EF2A-4EC0-B5B9-335196D42F58"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B9B1E3FF-6F08-485E-AFC8-CC76921390F9">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>citalopram</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F7857B32-EB3B-4BA5-9840-6F500F78A32D">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Bupropion</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/91956349-ef7e-475f-8c61-72ed80aa4c9e">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>repaglinide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/73044</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:333fc3a3-3af7-4555-8434-5f05aecfbb3f">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:prefix> B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <domeo:uuid>e607bf3d-e529-4051-a294-32c3170c6791</domeo:uuid>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42ad04ec-e994-46f0-a41b-9abc650418a7">
    <domeo:uuid>e5771831-35ec-4f28-99de-fe42f1058db9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:c437dc4d-4845-4a58-9f04-5b30d085134e"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N98f2e24024524a2bbbe338fa486547b9">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9c25d43b-002a-4b60-8e1e-ff4017084189">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>tipranavir</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3BA8E33D-7D57-42BC-96F8-59347C7AE05B">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E9A03FE5-9A58-44B7-B531-2CC63FAF4421"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6EBF6209-A8F3-4532-8FE7-B5304E77BF97">
    <rdfs:label>thioridazine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10502</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6B691E86-E215-4DD2-AB5A-49A04ADABA9F">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-05 15:24:24 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-05 15:23:48 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:a80a885a-21a8-41f6-8e6f-1f2c43009aaa</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:CEE664C1-0267-4B81-ABD4-45D4BB28003A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7aaeaa532d214ec9be038ec2fef6b056">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0a34b577-3435-415e-a078-740ca0ebb0fc">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nbee8c88d146749e8aaf4292d62b4ff0d"/>
    <pav:lineageUri>urn:domeoserver:annotation:0b6d0e4a-5cd0-4feb-9b8a-aa336f3d628b</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-14 11:31:14 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-14 11:31:14 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:d68a7e83-2db1-4b52-8d0c-f508bedf2ea4</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:bcd813af-4851-4053-b6db-268acd42ed81"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9EEAE3AF-D1B3-4E8F-BDCB-AE767BA3CB03">
    <rdfs:label>lithium</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>600</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ab762727-95ba-4ba4-897e-84db4834082c">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ADE1F100-FF93-4C96-A376-BB17E2036EA9">
    <rdfs:label>desipramine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4eec5d5b0e634f08a21ac400e27fbd52">
    <domeo:sets rdf:resource="urn:pddi:uuid:c20c8019-d6f5-4d1b-9d08-696fc3405464"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/16C86CC7-33B4-4757-9EF1-C2F6D936A131">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>desipramine</rdfs:label>
    <dikbD2R:dose>50</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B9F4A374-3EC8-4754-858A-30543762004D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f7ff637e-2116-4e28-92fc-d850037f65c3">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>flecainide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0C138572-0533-4877-9861-BD4CE935C3FF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8E47204D-80A0-4FE9-84A1-16952758C48E">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>pimozide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d05ebd6d-12ee-4e85-9c2f-86f4e04be04b">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:c2ceb124-463e-421b-9f39-42bdf43e6228"/>
    <domeo:uuid>7b9ecca4-eb81-4941-9585-55e23106fff8</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e822f7c3-fcfb-488d-824c-f39145316a7e">
    <domeo:uuid>4258eaa3-cae2-491f-9b74-f4e818503caf</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4e377be1-c9a3-48e5-af46-b3a754558609"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9376491D-F635-4C58-B7FF-95BCFDC8486C">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:463d401f-8621-478e-a237-f23c815a9aef">
    <ao:item rdf:resource="urn:domeoclient:uuid:72f43f96-dbd5-4a3c-bf38-24784bbd01e8"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2015-08-20 11:30:25 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 11:30:25 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="Nb73bcb110d4b4d968a085c7d0a3abf92"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0b748c7c-a5c8-4851-80f7-54f58671df30</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90cc9434-2300-406e-8edc-348fcd0a1a59">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>0 mg) and lorazepam (1.5 mg).  </ao:prefix>
    <ao:exact>Pregabalin-There were no clinically significant changes in the steady-state pharmacokinetics of milnacipran or pregabalin following twice a day co-administration of 50 mg milnacipran and 150 mg pregabalin. </ao:exact>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <domeo:uuid>6c87c184-1bab-47fc-bd3e-50044fe69c14</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3bea9ccf64de41ea8d1e1b1180a87f36">
    <domeo:sets rdf:resource="urn:pddi:uuid:e9b628c8-4be0-44fd-b7fc-0837aa9533a6"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7fedd340-f32a-4e77-b24e-fbfde5eca329">
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/eeb4116d-9623-48ae-8564-a4da24422f50">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfe1b88e065914741914c75699d478ddc">
    <domeo:sets rdf:resource="urn:pddi:uuid:16fa9997-8c49-474a-8afe-f7b013fe4fc4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:465B3927-F649-4C3A-8323-1683980B3815">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>terfenadine , astemizole , cisapride , or </ao:prefix>
    <ao:suffix>(see</ao:suffix>
    <pav:createdOn>2015-11-06 15:42:01 -0500</pav:createdOn>
    <ao:exact>pimozide </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>465B3927-F649-4C3A-8323-1683980B3815</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:465B3927-F649-4C3A-8323-1683980B3815"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:81eb1baf-cd3f-4374-b6b0-8cfdd2b7507f">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:c985d708-0ea5-4fb0-8a90-b45076f46e88"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FFD9031A-454A-45E8-B895-04EA75ECEFC2">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a268bcae-58ad-4487-b259-0e421726bda2">
    <ao:body rdf:nodeID="N3c2d97916fba4970b8c9f52dbe2c7950"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3AD8E5FE-F810-4C4E-AAB5-055AD2FBB60D"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:38744850-3883-4689-9fdc-169b6e02671a</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:52C8BA72-3C4B-429D-92B1-89F1B16729B8</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-29 11:36:34 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4D74F517-FC1B-4651-9D7A-8655A123B08B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:body rdf:nodeID="N963d857fbdc245f2ac8934992feeadb3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-11-05 15:29:18 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:26AAAB91-C92A-4AC3-8593-70A1BA3D18AA"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-05 15:30:13 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B7BE1296-FCF1-443C-B8E8-FA07AD2AC3D4</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FFECE2BC-7148-4883-98B1-12280CA4C520">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/188631C7-0624-4A6C-8C2B-DFA879C2D35C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2E83C99F-3813-4426-ABB6-89402A8B36F5"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/bede2bda-c515-489b-858c-33a5616d2053">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>teriflunomide</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68EDB648-003F-448B-A9EF-8C7FC80FF1E9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <ao:prefix>   7.8 Digoxin   </ao:prefix>
    <domeo:uuid>68EDB648-003F-448B-A9EF-8C7FC80FF1E9</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-02 14:22:33 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:68EDB648-003F-448B-A9EF-8C7FC80FF1E9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of citalopram and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3f0d7588-8529-4b52-95e7-6212f57c6d4c">
    <pav:createdOn>2015-10-26 15:36:49 -0400</pav:createdOn>
    <ao:prefix>initiating TCA treatment in a patient being withdrawn from </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluoxetine</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, given the long half-life of the parent and active metaboli</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3f0d7588-8529-4b52-95e7-6212f57c6d4c"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf669069d945b4f2595f0c3b70ce4a304">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2c422209-2ed2-4014-86c7-8d636047e6cf">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ab3bc48d-0889-4faf-bd1d-5dcd0d61fb73"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D205CAB4-5679-4CCF-B936-6403E5A4E3C6">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D205CAB4-5679-4CCF-B936-6403E5A4E3C6"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:prefix>(TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>D205CAB4-5679-4CCF-B936-6403E5A4E3C6</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-04 14:14:19 -0500</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6D97B8BF-C394-487E-8DC7-22CE43D6D0A8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0946f1a86af44ab6be52ef56bffd13cd">
    <domeo:sets rdf:resource="urn:pddi:uuid:5BC5DBB8-30CE-4759-814A-5A9593029F3A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50926471-B635-40E9-A16A-8CBFABB1F4A2">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-11-06 15:35:54 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:467836C7-9ADC-490F-9404-77ED77633412</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:129CAA08-A94A-4346-8B38-F5FAFFC7D138"/>
    <pav:lastSavedOn>2015-11-06 15:36:55 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N022c8c9a564f4028b1d7dc763e90ac78">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/d2c6aa03-a7e7-469a-8d09-323566d6c23c">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>ciprofloxacin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N23e650b5ae154cf489c95df5a1a1a4c5">
    <domeo:sets rdf:resource="urn:pddi:uuid:1d85197e-7161-4cf1-9f7f-20276ed505d6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87BB16A8-BB38-4F6A-BD5E-FD2D22B216C7">
    <ao:prefix>   Diazepam  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87BB16A8-BB38-4F6A-BD5E-FD2D22B216C7"/>
    <domeo:uuid>87BB16A8-BB38-4F6A-BD5E-FD2D22B216C7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The coadministration of fluvoxamine maleate tablets and diazepam is generally not advisable. Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic coadministration.    Evidence supporting the conclusion that it is inadvisable to coadminister fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam. In these subjects (N = 8), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study.    It is likely that this experience significantly underestimates the degree of accumulation that might occur with repeated diazepam administration. Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.    Accordingly, diazepam and fluvoxamine should not ordinarily be coadministered. </ao:exact>
    <pav:createdOn>2015-10-27 15:20:51 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N75768d155763448c8a20842f2414cf68">
    <domeo:sets rdf:resource="urn:pddi:uuid:1D0FD825-E589-4C2A-99AD-282F3905D374"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c8dd2661-6d48-4de6-b9bd-1e5ff4843c5f">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4fe28337-f7e5-4585-bbf3-f32d24cd2a91"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DCC258F5-68A6-4A45-A982-EE377F530B7A">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:134C2AAB-D297-4C7E-AE41-B8A7974D416A"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:95b5bfdc-254f-4c68-b54e-154ba8381f72">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9eff6fbe-acef-473f-9896-39aa444ea6d5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64574bb1-d248-4de3-b50d-3ba279a5ae8c">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8f0d64d7-f8d4-402e-91e2-68bd69f25bfc"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <domeo:uuid>6e7b76f4-db5c-4593-b78a-8a6810a60a62</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1427FFBF-A266-48CB-B923-7B75219567FB">
    <pav:createdOn>2015-11-06 15:44:02 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5125476E-19BA-4871-895E-8F53E8BA5073"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-06 15:45:24 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:E786F7DC-C42E-4265-8923-103099474CC7</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53814A73-9DAC-4898-AE43-8E28A903859A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-27 14:27:00 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N78a2bc4c03074f65a7f52259ab6ab63e"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B8992F89-5466-4E93-B078-C7DF56E978EC</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-27 14:26:46 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D5D5AF78-FE2A-4685-AB34-3FE17035070F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ea3cd1ee-e4c2-4bf2-bdb0-9ce6b030153c">
    <permissions:permissions rdf:nodeID="N04fdc54bd4f64318a3ab773ce9c3f22a"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:8d236f6a-fbce-4a95-b88f-afc26278b1c3"/>
    <pav:lineageUri>urn:domeoserver:annotationset:7d2b4410-1ffa-4d2c-93a4-8032020dd2c9</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:839BD25C-87F1-4F53-AF2C-A0B04774BD45">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:839BD25C-87F1-4F53-AF2C-A0B04774BD45"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>839BD25C-87F1-4F53-AF2C-A0B04774BD45</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-04 14:20:31 -0500</pav:createdOn>
    <ao:prefix>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a514c52c-b64b-497a-98b5-59a862279980">
    <ao:context rdf:resource="urn:domeoclient:uuid:f46fba28-4e95-42e3-bb3e-e70de1cdc13d"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:bab9e4de-d268-4b5c-ac3c-0d3793cdbcbd</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N89610ded876149b596159c9fff286060"/>
    <pav:lineageUri>urn:domeoserver:annotation:1959f896-e697-4026-acc9-34e6a2fc8cea</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0f0c781d-5610-4ce2-a2b9-6b1a7ce08d06">
    <dikbD2R:dose>30</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>abiraterone acetate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8F379DE4-8C59-44B8-A5CA-3361856585EF">
    <rdfs:label>desipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>50</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7c55cc039afb4221af0e616cc0eb782e">
    <domeo:sets rdf:resource="urn:pddi:uuid:4dc6c242-e6bb-428d-9bfb-42a11322f817"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2981718a7b5143b09405f06337c06c06">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:46D6BD81-E1D0-4729-93AF-4980F3582826">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/74ED91C7-3D6C-4313-8869-417A69E0D201"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5AC9E0CB-B444-46F1-BB07-1B6DCE1BCC09"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33e06587-43de-473f-912b-ab91453c5405">
    <permissions:permissions rdf:nodeID="Nd103c9b98db24f17885a33d5cffa03cc"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:6a07c639-4fda-455c-b5ff-960c32b06834"/>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:bd974bab-cc4b-4539-8bea-a8118981e006</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6adec9118a3c4045898fe95f68cd78f2">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5aab3708-a0dd-40f2-b69b-8500e270918b">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:d5d4ff71-70d4-42b6-ab85-aaff3ab62743"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>fc9953e0-ed8f-4cca-b3d2-a2bb0d11b5a9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ce760a96-2ae1-474a-af7a-18538dbe42ce">
    <domeo:uuid>f3b04724-3083-4fd9-bd2b-9b42546b5fb7</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25b22107-de56-44d9-918f-d3bfe032a8bd"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2c646e75-e2b3-4ba5-8a3e-3df826f456f0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71D708AF-2B60-4651-BEEB-A2591DBE78DC">
    <ao:prefix> with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:71D708AF-2B60-4651-BEEB-A2591DBE78DC"/>
    <ao:exact>CMI </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>71D708AF-2B60-4651-BEEB-A2591DBE78DC</domeo:uuid>
    <pav:createdOn>2015-10-29 11:18:38 -0400</pav:createdOn>
    <ao:suffix>increases plasma concentrations of CMI. </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26AAAB91-C92A-4AC3-8593-70A1BA3D18AA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:26AAAB91-C92A-4AC3-8593-70A1BA3D18AA"/>
    <pav:createdOn>2015-11-05 15:29:18 -0500</pav:createdOn>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/41751547-2E36-4BD4-A020-F2EAFA8B071A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2170fd16ca0d44d0892b503cb031238d">
    <domeo:sets rdf:resource="urn:pddi:uuid:db610a3b-8c92-4dd6-9845-0adcd71a02bc"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09c3ee91-860e-4519-8b88-ae31fdc32411">
    <ao:prefix>e Drug Interactions (7.1) ] .  </ao:prefix>
    <pav:createdOn>2015-08-20 11:32:27 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate [see Drug Interactions (7.2)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>06f64769-f874-49d9-a7bc-3e898da85913</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2F0536B7-B5D5-4DB5-8CF0-744D6EA90763">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>mirtazapine</rdfs:label>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:04A4CB48-227D-4161-9C50-3D1693729A05">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7E21CA9A-17C6-434C-977F-C0BFE96BDCD5"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E027C279-6420-4887-8E6C-5FD005D4E850">
    <ao:suffix>, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose cl</ao:suffix>
    <ao:exact>antiarrhythmics</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E027C279-6420-4887-8E6C-5FD005D4E850</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E027C279-6420-4887-8E6C-5FD005D4E850"/>
    <ao:prefix>, and the Type 1C </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-04 14:17:28 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CA8153B9-45AB-496F-B470-0563BE377921">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>600</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <rdfs:label>ritonavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8bad76c4-78a1-441a-906c-55ce6233a34e">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e37d3588-5984-4728-91c8-76a02b31f6ad">
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <ao:prefix> B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <domeo:uuid>202c2c5f-1205-43bc-8744-fb2068177b70</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B8E9826-13E0-4F96-A86D-E14F8925F303">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1B8E9826-13E0-4F96-A86D-E14F8925F303"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-02 13:32:12 -0500</pav:createdOn>
    <ao:exact>Digoxin - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of Celexa and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>1B8E9826-13E0-4F96-A86D-E14F8925F303</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D04949A-A207-4CA1-B998-93CDE7625313">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>beta-blockers</ao:exact>
    <ao:prefix>), </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7D04949A-A207-4CA1-B998-93CDE7625313"/>
    <ao:suffix> (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. </ao:suffix>
    <pav:createdOn>2015-11-05 15:28:30 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EF5F176B-3941-4908-B23A-FE35ACA096F6">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>Citalopram</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34e16d6a-3fe5-4e7f-abce-5cd5f8301eb8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:c6e3e620-a290-4efe-94ff-6b924d37c8ae"/>
    <domeo:uuid>a3427efc-af21-4a5b-b97a-52db898da1aa</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3DD0FF69-5A98-4348-9A83-00D0D5486439">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8FD2711D-5BD2-4CFC-9202-578B267F6B47"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3504868-B1EB-4829-BD98-37C2A863F17F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-11-04 14:17:27 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:E30C17B7-EE7D-45ED-AAED-E3E3F90E1F55"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N232ec7a994ee46d1be985b0a0d4d532d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne7e6095a2d5c449092b53ea00366004d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/59DBF457-C7E9-4796-9895-F64A1966B640">
    <rdfs:label>ritonavir</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6b9fb4fe-f9e1-4129-a29c-18a2aaaf9eb6">
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>AUBAGIO on CYP2C8 substrates   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <domeo:uuid>212a4290-da09-4580-9cdf-e7c9d1860704</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbb30bd37f2cb4c2dbe6e6e4087a1f102">
    <domeo:sets rdf:resource="urn:pddi:uuid:81eb1baf-cd3f-4374-b6b0-8cfdd2b7507f"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9CF1B983-D0A7-4317-92B4-B5F3FEDE9853">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8134</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>phenobarbital</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7C99865D-4AE3-4DC8-843A-D4FD1AE6DC88">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D7E7CC1D-6D84-46B4-A465-B9574B95CD4E"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:410B00B3-F187-4C15-BFA1-53F39ACE92BF">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B6341142-1234-43C3-8A6C-9AE3BD1057CF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3AB8F0AF-32C4-4E3B-AF3A-120B8D84DE16">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3AB8F0AF-32C4-4E3B-AF3A-120B8D84DE16</domeo:uuid>
    <pav:createdOn>2015-10-28 16:40:20 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <ao:exact>Digoxin–In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ocking ability of atenolol .   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3AB8F0AF-32C4-4E3B-AF3A-120B8D84DE16"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D255F3E1-A02B-4C0D-AC18-4989C86416D2">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DF926A4B-CD53-4A10-A541-15C8C71AD1A1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1CA0131-423F-4A28-ABBB-BAAFAD2DFA81">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-29 11:28:49 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:4CB0127C-10C4-4937-A080-1AF7147575A5</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-29 11:30:54 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:09FE9163-3F21-491C-94F0-EBB12BEF6F16</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:EC4ABA66-5296-4ABB-A6D8-966B3652BA80"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50D1EF4E-FFB2-4E3B-AF9C-FAD38063C452">
    <pav:createdOn>2015-11-05 10:39:51 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).    In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).    Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <ao:prefix>Drugs Metabolized by P450 2D6   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>50D1EF4E-FFB2-4E3B-AF9C-FAD38063C452</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:50D1EF4E-FFB2-4E3B-AF9C-FAD38063C452"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4F2C662-49AB-4D03-93C5-B21F2E01D42C">
    <domeo:uuid>F4F2C662-49AB-4D03-93C5-B21F2E01D42C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Concomitant use of FETZIMA with alprazolam or carbamazepine, substrates of CYP3A4, had no significant effect on alprazolam or carbamazepine plasma concentrations </ao:exact>
    <ao:prefix> is not an inhibitor of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, P-gp, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2. </ao:prefix>
    <ao:suffix>(see</ao:suffix>
    <pav:createdOn>2015-10-29 09:44:38 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F4F2C662-49AB-4D03-93C5-B21F2E01D42C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D74855C2-3B82-49D1-B47B-24BD5B27B5AF">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bf235d27-c44a-40e5-b868-37ec9e774183">
    <domeo:uuid>66d99d3f-225b-41ba-a6b7-4566c93fb293</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:12fbf759-09a9-4021-be31-50135eb8e847"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0a7b8978-94ca-4057-807e-48d4646f1be1">
    <pav:lineageUri>urn:domeoserver:annotationset:096d956d-6c40-4fa4-b6ba-b25f42a50d5b</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-26 15:40:42 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-26 15:40:42 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8f0ea9cb-160e-4cce-9a62-fea291449a57"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:83D76B22-B626-4E0A-89D6-BE781064F3DC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb55e77b2a38742cd83c813be902be01d">
    <domeo:sets rdf:resource="urn:pddi:uuid:F966B506-6D61-49B3-9C94-8C8823E84A1A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/eed7fd9b-8f52-4171-8326-589bdab03aea">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1d85197e-7161-4cf1-9f7f-20276ed505d6">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:f1da7b7f-cc82-46fb-9101-21f535f956ae"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6972cc89-f11a-48bb-91a9-39e306f11e37">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:b874739e-4feb-4a59-8ea3-8b800269e267"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N4af3b4bc3ef04f56b309c1f0b1fb1429"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:a9a281c7-ab56-4425-a2c6-1bc9b694d65c</pav:lineageUri>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:6114e32e-4e4e-4219-a9ae-b01a415f2f58</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D6604E90-A752-455D-866E-C857E492EA2A">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6918</dailymed:activeMoietyRxCUI>
    <rdfs:label>metoprolol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>100</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4c9ac7e7-7a3e-45c8-a744-e0258055ab2e">
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
    <pav:createdOn>2015-09-03 15:42:22 -0400</pav:createdOn>
    <domeo:uuid>2a5ff295-6d56-46cf-a405-b7f61c8b2d74</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b7c9990f-962e-40bb-9654-4b5c06c3298d">
    <rdfs:label>Savella</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>1.5</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0a650de3-78ca-46b2-968d-35ee13d11aa6">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85248</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>alosetron</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E5D6005-CEEA-4512-93E7-6AD0AC87663C">
    <ao:prefix>), e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1E5D6005-CEEA-4512-93E7-6AD0AC87663C"/>
    <ao:exact>fluoxetine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <pav:createdOn>2015-11-05 10:36:41 -0500</pav:createdOn>
    <domeo:uuid>1E5D6005-CEEA-4512-93E7-6AD0AC87663C</domeo:uuid>
    <ao:suffix>, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Neverth</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1e0d2908-7cae-4a9d-8328-3906f818d0cf">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Lorazepam-There was no pharmacokinetic interaction between a single dose of Savella (50 mg) and lorazepam (1.5 mg). </ao:exact>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <ao:prefix>pharmacokinetics of lithium .  </ao:prefix>
    <domeo:uuid>a94b3761-e0e4-4c3c-86c2-d60ae6ea9b82</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/56eb2747-593f-4cfb-990a-0a6bd4a08663">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>methylphenidate</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3644D385-D4A0-41A1-AE04-CADF7E05C850">
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:lastSavedOn>2015-11-05 16:17:38 -0500</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">27</pav:versionNumber>
    <pav:createdOn>2015-11-05 16:16:21 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:A623F93F-F22D-478C-9983-65DDF008CDD2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8F1FF68B-3156-455C-A618-19E380955F6C</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93696DFA-114A-4C7F-9D8C-E2A9CE191ECB">
    <pav:createdOn>2015-11-02 13:34:23 -0500</pav:createdOn>
    <ao:exact>Lithium - Coadministration of Celexa (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of citalopram, caution should be exercised when Celexa and lithium are coadministered.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>93696DFA-114A-4C7F-9D8C-E2A9CE191ECB</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:93696DFA-114A-4C7F-9D8C-E2A9CE191ECB"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C1F11156-06DB-4E7D-8317-BCE6953056B5">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>theophylline</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb73bcb110d4b4d968a085c7d0a3abf92">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3da5a544-4864-4be0-a1cc-1e586c48e75a">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>levonorgestrel</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6373</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/948DB70B-5DD5-4BDC-A6D6-EBF466F9704B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdfs:label>sertraline</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0eff91c4870647f99f1ec09c8f427fc0">
    <domeo:sets rdf:resource="urn:pddi:uuid:f9219569-80bc-43de-aea9-6eeb95c5405d"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E26A02DE-1B00-4788-832C-E19DF32B50B9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b3763b4e-692f-4661-8b44-13804cdd9df2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:422f4355-d1e5-49d8-adda-ad6765323210"/>
    <domeo:uuid>23a1d1a3-931d-46dd-9c3a-63319082eea9</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N33f1314a9de04936bca82e746d0d7ce0">
    <domeo:sets rdf:resource="urn:pddi:uuid:8AAAA596-1E1F-4FC7-80DB-2818693CDEBD"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/60b62933-8e3f-4d68-8d24-1dc04f6b4172">
    <pav:createdOn>2015-10-26 15:38:46 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:b22b6f7d-505c-428b-acee-f7cff362cd66"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E4141EC9-A9BB-4586-B9EF-279C37D2B90A</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:bfd60df6-eac7-452f-9587-7ea52bff27d5</pav:lineageUri>
    <pav:lastSavedOn>2015-10-26 15:38:46 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6A56E714-739E-4262-8105-88C801F0B830">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E7E47972-9A4A-4957-85B5-77E51BA7242F"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f731032c-28e7-43c2-b0d4-2b859056d571">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N28622fc77bef4155b53d740d82e4bb3b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1978423c6dd744e5ad6c58db943fc84a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86de9401-7ab3-4acb-b90e-5d14dddfb9af">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:66e7b711-1593-49da-a95d-dec53305b39c"/>
    <domeo:uuid>cfc7d40b-7ebc-420d-a38b-cc18864df317</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F2ADB11E-7655-4106-841A-C0468A78118A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>norfluoxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a75fb5df-7daf-4e6a-8c19-db4c78233b23">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-26 15:38:33 -0400</pav:createdOn>
    <ao:exact>propafenone</ao:exact>
    <ao:suffix> and flecainide</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:prefix>pressants, phenothiazines, and the Type 1C antiarrhythmics </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:a75fb5df-7daf-4e6a-8c19-db4c78233b23"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AE2C2648-255D-4D0C-AFBE-6D9DA62FA280">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Bupropion</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb554125ec7194ecc96a4fb8c061ec515">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5FB81420-6ABA-4A37-BA68-CBB96D7C3C1C">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>sertraline</rdfs:label>
    <dikbD2R:dose>50-200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc1fdae06612249ca90e3e976b9a85e33">
    <domeo:sets rdf:resource="urn:pddi:uuid:AA000288-CF26-4159-BAE9-2A967335FA8C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3c2c8aad-c3a7-4446-af25-d5eac5bb0f0f">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:96a65f33-6bcb-4e10-a0a7-d090ced2d265"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:bda27dfc-23ab-4d3d-ac60-206a714a0f9e">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:fdede33f-2fbd-4cef-8401-76f422425bf7"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbc7173fcdb51450d8fdd4456ae6e072e">
    <domeo:sets rdf:resource="urn:pddi:uuid:403160db-5fdd-461a-aa3c-d1bd250633b8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na56f676294154c66804f40ef1a7eca4f">
    <domeo:sets rdf:resource="urn:pddi:uuid:b3a4c86b-d78f-4233-a22c-737cd8954570"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AD49C6CE-8DDE-49C2-ADB6-697FC39957A1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CEF2EC9E-DF93-4417-977C-5AA74AA3BB22"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N58d5be46f7564a1686e17afec56a592d">
    <domeo:sets rdf:resource="urn:pddi:uuid:a696e103-2472-4072-8685-acff9987544e"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Necbd9553ad0b45fbb3feb8656ee09c7a">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4D94EEB9-E9E7-4B86-BEEE-A6909BB8AEF9">
    <ao:prefix>. The clearance of benzodiazepines metabolized by glucuronidation (e.g., </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:suffix>
    <pav:createdOn>2015-10-27 14:25:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4D94EEB9-E9E7-4B86-BEEE-A6909BB8AEF9"/>
    <ao:exact>lorazepam</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b9d005cb-08d4-43ed-9c9e-eb3394df8945">
    <domeo:uuid>f2ebba2f-7ce0-41cf-ace8-69fbec8f7354</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:c7c868da-0b38-4ae1-81eb-93ac849f6d5d"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5923A030-CB73-463E-B299-4AB7FFAD4823">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2B2E7199-99B9-4D32-AB5D-82F58B49A785"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a24638b8-ca6f-40ca-8582-b90c172f43d4">
    <rdfs:label>hepatic enzyme inducers</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74A86F48-D8CB-4360-BDC7-210BFE619D2F">
    <ao:context rdf:resource="urn:domeoclient:uuid:F167758F-1F4C-4606-8117-3BA4B92CA356"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-28 14:37:56 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0D56CBB6-C44E-44FD-8A32-E7EFF20B9DA9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-28 14:38:28 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:BC3E864E-C46F-4999-9BF1-96E2FE58F7C3</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b6feb170-170a-46d6-91f0-773967276d84">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0ba100b5-1173-4507-9d41-d393cfd913e5"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1ebfa00d6cad464584a25cb191632d5a">
    <domeo:sets rdf:resource="urn:pddi:uuid:D6225BB5-4839-4138-A0EC-0B9D3FF414CA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CF463A6D-9DF0-4906-B521-A3A6566D4C37">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:88986DD6-354F-4EFF-8F9C-F86E4612349E"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7C5A73C6-C165-4198-B7D1-E977772C5F2A">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:41A0910A-A1F3-4EA5-A7BF-473F44830232"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A623F93F-F22D-478C-9983-65DDF008CDD2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A623F93F-F22D-478C-9983-65DDF008CDD2"/>
    <ao:exact>hydroxybupropion </ao:exact>
    <ao:prefix> and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>are CYP2D6 inhibitors. In a clinical study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of CYP2D6, </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-05 16:16:21 -0500</pav:createdOn>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:898787C7-20B1-406C-B9DB-39C1B6E3F391">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3B8FE6DF-6883-402F-B55B-4D779076DE3D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/478C9609-29BA-46CC-B2AA-BE6514A5F624">
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N27b7fd6b2f5c4ef28fe12f18a984d3cb">
    <domeo:sets rdf:resource="urn:pddi:uuid:9dd2b6c5-5e73-498d-9406-49873126f649"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6fb1386654bc4e2e89319ac1d55b1dd9">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5EA2D7C7-2D3D-4E59-8661-2333A395A5DF">
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C58292CD-9C7E-48D2-9400-4A40A04E2506"/>
    <ao:body rdf:nodeID="N8ee8f0757d334faf82fbd34d92b5fc36"/>
    <pav:createdOn>2015-10-27 14:28:55 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:6B9EFE1C-10E1-43D1-97B6-539175B9C711</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-27 14:28:56 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33F84CD2-4F0A-443A-81FB-57FAE9C3F91E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ketoconazole (see Figure 1 ).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:33F84CD2-4F0A-443A-81FB-57FAE9C3F91E"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>No dose adjustment of FETZIMA is needed when co-administered with a CYP3A4 inducer or substrate. In vivo studies showed no clinically meaningful change in levomilnacipran exposure when co-administered with the CYP3A4 inducer carbamazepine or the CYP3A4 substrate alprazolam (see Figure 1). </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>33F84CD2-4F0A-443A-81FB-57FAE9C3F91E</domeo:uuid>
    <pav:createdOn>2015-10-29 09:43:03 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7EFCDCD6-1E71-41B8-85CD-86C3D1269979">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>mirtazapine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7d96b14f-4dad-4bd6-9236-5339a945e2f3">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N629d07ad01bf4ebca1c9ada2187b4fc0"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:abc6c0dd-579a-4b9c-820b-b49d2df1dd39</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:138936ed-b01c-4cb8-bdea-9784c089196d"/>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:d5bbd650-7488-4b46-b5de-6ca5fc6b32b9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/75D74469-9E15-4676-B9BB-CA83DF9A0963">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56A74F63-26A2-4CC3-B26E-8C681A965BAE">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N60f9d6bff0404d66ac72d662f010ea3b"/>
    <pav:lineageUri>urn:domeoserver:annotation:DF598FA2-3BF7-442B-B08B-6E44791A421B</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:5EEB9DFF-5401-4185-A505-E183EF0C46F3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-11-05 16:18:31 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-05 16:18:29 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:821ec7e5-77bc-403c-87fa-4ba541f49d97">
    <ao:prefix>tantly administered rifampin.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>bb62745c-c99a-42a5-aaa6-032d54f0538a</domeo:uuid>
    <pav:createdOn>2015-10-14 11:57:06 -0400</pav:createdOn>
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6366bda1-2531-49ca-bd6b-cf3a11bb7ece">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>rosuvastatin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f4588c66-7648-42b1-a7ab-23e0ccf4f7e2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:f4674124-4b2c-4d50-8c79-307504164f59"/>
    <domeo:uuid>e6ef6954-6bc0-41dd-9e0f-232d0422403c</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84c31609-09b3-420d-af86-5786bd5b7545">
    <domeo:uuid>88bee878-387d-441d-9cc9-c74dc3eb3b63</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:dc4408b1-376a-4747-a000-ecf70973b669"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F15FCE0D-03BC-4C50-B4E9-0911A44190F5">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7BC7FEE1-876D-498D-A265-01FBD45C0B8E"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8d47bd04-786b-4588-a67a-384db4149542">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8d47bd04-786b-4588-a67a-384db4149542"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>leeding have also shown that concurrent use of an NSAID or </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-26 15:40:28 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <ao:suffix> may potentiate this risk of bleeding. Altered anticoagulant</ao:suffix>
    <ao:exact>aspirin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/105A0F92-D7CB-4505-8607-757457B6899B">
    <dikbD2R:dose>60</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>duloxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:c1640b22-8eec-4aea-9f0c-15a2a3c52c3e">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:a519a3a5-8070-47e8-bd49-9d06442cc06d"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D1F4782D-8D61-4989-8449-4BE95C800E70">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CE013527-AFE7-452A-BED1-B877E1B5BB53"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb7e2e14a14dc42c29dfc9154d3698337">
    <domeo:sets rdf:resource="urn:pddi:uuid:53BB4D87-460B-4C1F-92F7-10CBBADBB5D4"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf3eeec3dbe8c4ec8af091717398b422e">
    <domeo:sets rdf:resource="urn:pddi:uuid:A78209D8-4446-4765-B592-02FA260569E4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E30C17B7-EE7D-45ED-AAED-E3E3F90E1F55">
    <ao:suffix>, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which </ao:suffix>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid>E30C17B7-EE7D-45ED-AAED-E3E3F90E1F55</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E30C17B7-EE7D-45ED-AAED-E3E3F90E1F55"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-04 14:17:27 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>phenothiazines</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:803c8d9a-fe0f-4e3e-bce4-ef9f5afb1093">
    <pav:createdOn>2015-09-03 15:43:15 -0400</pav:createdOn>
    <domeo:uuid>d6e507d4-2c47-47af-b495-1a0d57c91122</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:prefix>nical Pharmacology (12.3) ] .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3feb7ea5-2747-4060-89de-c2c09f038bac">
    <domeo:uuid>2c0c7c74-3125-4db3-b78b-e3d826c53ce6</domeo:uuid>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58976270-842E-4ABE-BB88-F7EAD951195F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>58976270-842E-4ABE-BB88-F7EAD951195F</domeo:uuid>
    <ao:exact>phenothiazines</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:58976270-842E-4ABE-BB88-F7EAD951195F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, </ao:prefix>
    <ao:suffix>, and the Type 1C antiarrhythmics </ao:suffix>
    <pav:createdOn>2015-11-04 14:10:54 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4EFB0BB-D0A9-403F-9C34-A63EE321C695">
    <ao:context rdf:resource="urn:domeoclient:uuid:0EFA116F-E61E-4263-87B6-51161516E5C8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">23</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdOn>2015-11-05 16:06:43 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:751FBB26-E5EB-4878-A2EA-2B9845EC5906</pav:previousVersion>
    <pav:lastSavedOn>2015-11-05 16:07:34 -0500</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:65a7bd6b-f654-43f8-87a0-7c5a7cd295fd">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:073116c5-e0cd-4e86-82cd-3161bcc4155a"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:67BA4CDF-B8FE-44E4-9B6F-83873628181F">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:95706406-F367-4FD6-AF3A-C95786CB2CBB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D3B8F6A-12BF-425D-AD8E-9F3E90981312">
    <ao:exact>Ticlopidine, Clopidogrel: In a study in healthy male volunteers, clopidogrel 75 mg once daily or ticlopidine 250 mg twice daily increased exposures (Cmax and AUC) of bupropion by 40% and 60% for clopidogrel, by 38% and 85% for ticlopidine, respectively. The exposures of hydroxybupropion were decreased. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D3B8F6A-12BF-425D-AD8E-9F3E90981312"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:prefix>    Inhibitors of CYP2B6    </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 15:44:43 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FF41495F-3930-422C-BCE2-E56C300FCF0D">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ACDCE7CC-F73E-4E9A-9E3A-91B1277D97BA">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:B7BE1296-FCF1-443C-B8E8-FA07AD2AC3D4</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-05 15:29:56 -0500</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nf3eeec3dbe8c4ec8af091717398b422e"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:lastSavedOn>2015-11-05 15:30:13 -0500</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:37CF9F66-D61C-4B02-A765-691E21CBA197"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b5a9cd2d-64ea-4446-94a0-dc9fe47cbf29">
    <domeo:uuid>0277d67f-02d9-4e28-be05-f7b4127aa59f</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ff26853a-3323-4ddf-ba8c-4a442559419a"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/bef9cd4f-d0e6-444f-8300-8ffa4d4528e0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>ibuprofen</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e357203d-3fc0-4906-b802-a57fd1dc3382">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>dextromethorphan</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbd998ae207d247e6b2a1bd4a269b942c">
    <domeo:sets rdf:resource="urn:pddi:uuid:634DB228-84C4-453E-B4AD-9A29DAB711AB"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F1853878-BDBE-4B7D-8FDC-AF4735DFD6F7">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>propafenone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne203e8b62f4d49f185c806c0ab0758e3">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:249C5208-00A9-4C04-A032-E7CFBDFA5552">
    <pav:createdOn>2015-10-27 14:16:59 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Risperidone    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with risperidone (2 mg per day for 7 days), a substrate for CYP2D6, did not affect the pharmacokinetics of selegiline or risperidone [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:249C5208-00A9-4C04-A032-E7CFBDFA5552"/>
    <domeo:uuid>249C5208-00A9-4C04-A032-E7CFBDFA5552</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1EF7F49C-0E10-4BA2-B520-445A84319A11">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:6A2852CE-D29C-4BED-A012-2BB24F2DA21C</pav:previousVersion>
    <ao:body rdf:nodeID="Ndf6c89045cdb4580b7ce2493530001e9"/>
    <pav:createdOn>2015-11-05 16:13:12 -0500</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:FBF37F2B-D151-45F2-AFF5-F9E594C9F260"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">25</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-11-05 16:13:14 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:db18ff10-4429-47bf-ba51-83fe2ae8990c">
    <domeo:uuid>b5af86e7-7323-4713-afe3-f68fb0d90e89</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:214a2140-7249-40a5-98b0-b986a77d9587"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ce594858-8377-4d84-833d-9b20f2580ee1">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ec2a8ca-649c-4eda-8e2a-b1de19c5a717">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>ients receiving maprotiline .  </ao:prefix>
    <ao:exact>Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.</ao:exact>
    <domeo:uuid>404e1115-e7a2-43f0-ae52-2ec0bc053bc6</domeo:uuid>
    <pav:createdOn>2015-09-30 12:41:52 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7451FAEA-5C6E-4DE8-A40B-193CAF5462F9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9CF1B983-D0A7-4317-92B4-B5F3FEDE9853"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BBFC1C65-66D0-4A3B-9FCC-473D39C12D1B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4b9e677a3eff4fd782a658dd6e29eea6">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N17b45a351fd34209a47da4a678d139a7">
    <domeo:sets rdf:resource="urn:pddi:uuid:bc0856f5-f706-477c-a23e-d68c067485e5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f0781ca3-e1f1-425b-a7e3-bea6ccbda1f3">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:44751000-9e65-479d-a0c5-89686d5ab913</pav:lineageUri>
    <pav:createdOn>2015-09-14 11:32:07 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:5d7be9f1-8154-4b40-9c17-aa70bea06fca</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:e822f7c3-fcfb-488d-824c-f39145316a7e"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-14 11:32:07 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N3bea9ccf64de41ea8d1e1b1180a87f36"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E06FED75-7AA4-41F0-8342-8033A6EE4E2C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-05 15:25:08 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E06FED75-7AA4-41F0-8342-8033A6EE4E2C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:prefix>Clinical Pharmacology (12.3) ].   Inducers of CYP2B6    </ao:prefix>
    <ao:exact>Ritonavir, Lopinavir, and Efavirenz: Concomitant treatment with these drugs can decrease bupropion and hydroxybupropion exposure. Dosage increase of WELLBUTRIN XL may be necessary when coadministered with ritonavir, lopinavir, or efavirenz but should not exceed the maximum recommended dose [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/acfe51aa-53c0-4ba7-b40e-8e0805c0ff11">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>risperdione</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2a8a9f5b-de64-42b5-a7ee-030edf026906">
    <ao:prefix> Immune-Modulating Therapies   </ao:prefix>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>29a7ae06-6ffe-4ae6-b932-3314dbbb3f9b</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:26DFBA6E-8694-4CF0-830B-B2EB051A9838">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:28EC3532-6E1F-441B-AE6C-CD2F7D4E0471"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D8B2F0C-030E-4085-8F18-3A0B5871468B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>   7.15 Triazolam   </ao:prefix>
    <ao:exact>Combined administration of racemic citalopram (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <pav:createdOn>2015-11-02 14:32:32 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3D8B2F0C-030E-4085-8F18-3A0B5871468B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3D8B2F0C-030E-4085-8F18-3A0B5871468B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8a9402c368c84e92bfb898e579e4a163">
    <domeo:sets rdf:resource="urn:pddi:uuid:F24BDC3F-D5C8-4EE9-93FA-AE4585AE6612"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42AE6905-DD7E-4CC8-BA39-6D18E8C510FC">
    <ao:exact>nefazodone </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:42AE6905-DD7E-4CC8-BA39-6D18E8C510FC"/>
    <ao:suffix>(200 mg BID) at steady state, triazolam half-life and AUC increased 4 fold and peak concentrations increased 1.7 fold. Nefazodone plasma concentrations were unaffected by triazolam. </ao:suffix>
    <ao:prefix>was coadministered with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>42AE6905-DD7E-4CC8-BA39-6D18E8C510FC</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <pav:createdOn>2015-11-06 15:35:55 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:458B4870-C0B1-4D54-895C-15181F6B8B3E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F6ABA109-B5CD-4E2A-80C2-512984D54F24"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3597903-8A20-4F68-80F9-5BE6716C1172">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <pav:createdOn>2015-11-02 14:33:12 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E3597903-8A20-4F68-80F9-5BE6716C1172"/>
    <domeo:uuid>E3597903-8A20-4F68-80F9-5BE6716C1172</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg), a potent CYP3A4 inhibitor, decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram. </ao:exact>
    <ao:prefix>   7.16 Ketoconazole   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0fe3894aa6fb448e9f166b95d7e36e52">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF13ABBA-974C-4D13-B3D9-09EF5A6BB2FA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ns1:Alleles>ta</ns1:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/974740ee-9cdf-4293-a438-37a7805de5ff">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC4ABA66-5296-4ABB-A6D8-966B3652BA80">
    <ao:exact>phenothiazines</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:prefix>and the </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EC4ABA66-5296-4ABB-A6D8-966B3652BA80"/>
    <domeo:uuid>EC4ABA66-5296-4ABB-A6D8-966B3652BA80</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, increase plasma levels of concomitantly administered tricyclic antidepressants through competition for the same metabolic enzyme systems.</ao:suffix>
    <pav:createdOn>2015-10-29 11:28:49 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2f875a63ce1d4414bd66fd8ab9cedb38">
    <domeo:sets rdf:resource="urn:pddi:uuid:3262D20A-7712-45B8-B166-CD95455FCFCF"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3E74B343-A86E-4FEE-B9E7-2313AF593C2C">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdfs:label>theophylline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/997d38ea-15c1-4649-ac1a-860bf32c64b5">
    <rdfs:label>phenytoin</rdfs:label>
    <dikbD2R:dose>300</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B223767F-DB13-4A0A-9C2D-62B081E21D2B">
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:50CA3CE3-F0B0-45F0-8EE0-A8F0487940D2"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
    <ao:body rdf:nodeID="N30c960c734bf46c68ff7d713d2b2b339"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-27 15:36:24 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EAE3C703-C91D-4A1A-A489-73B4CB6B09D8">
    <domeo:uuid>EAE3C703-C91D-4A1A-A489-73B4CB6B09D8</domeo:uuid>
    <ao:prefix>  Risperidone  </ao:prefix>
    <ao:exact>In an in vivo, nonrandomized, interaction study, subjects (n=6) in need of treatment with an antipsychotic and antidepressant drug, showed that mirtazapine (30 mg daily) at steady state did not influence the pharmacokinetics of risperidone (up to 3 mg b.i.d.).</ao:exact>
    <pav:createdOn>2015-10-29 10:48:43 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EAE3C703-C91D-4A1A-A489-73B4CB6B09D8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55C73C1E-BA2B-4FA2-BFD5-0DBCF10B57D5">
    <domeo:uuid>55C73C1E-BA2B-4FA2-BFD5-0DBCF10B57D5</domeo:uuid>
    <pav:createdOn>2015-11-02 14:30:17 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55C73C1E-BA2B-4FA2-BFD5-0DBCF10B57D5"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>   7.12 Theophylline   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69B39E48-972C-4A96-8AC2-3AD1A0B01071">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:suffix>decreased by 38%, and the erythrohydrobupropion decreased by 48%. </ao:suffix>
    <ao:prefix> by 22% and 21%, respectively. The exposure of the hydroxybupropion metabolite was decreased by 23%, the </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69B39E48-972C-4A96-8AC2-3AD1A0B01071"/>
    <ao:exact>threohydrobupropion </ao:exact>
    <pav:createdOn>2015-11-05 16:04:08 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfa3ddbe8e1524b2499fd1267cb4187ef">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/265ed95a-fc92-45cf-9756-6238fc5d0179">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>bicalutamide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C6C9D870-611B-465B-A010-E1CBCF0BFE97">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>20</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a272c89c-4ae6-4871-bf19-a443042f6023">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>81b12532-29cd-4d6b-9390-9b2641bfe429</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:94cf3e93-a84e-4d64-859f-7561a870477f"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4336736A-0EF6-489B-A919-A212779276CC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:75FF611E-C9FB-47BB-ADE0-9F787F6E07BB"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/354502f2-0986-4732-9122-b462908d3476">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:472b0b18-0442-4b58-8284-d2fe8c21894e"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8D998AA0-150F-4852-94C7-A9E11062E28B</domeo:belongsToSet>
    <pav:createdOn>2015-10-26 15:42:48 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1aa03ef4-019f-43b6-9086-df6c24d9606a</pav:lineageUri>
    <pav:lastSavedOn>2015-10-26 15:42:48 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5231a6d3-811d-4a55-929b-ded0cbd2374e">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:091fe1c3-1830-41c0-b780-280c48d3ea86</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N5ec1457a1cd5438aa56c1d2a22370571"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:ca4b2eda-f1e8-40f8-b22f-c0a50308fa8a"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:996a0dfe-5d52-4063-ba45-d5e29de7b052</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2B94823-7C38-4D49-90BA-8E9BC977DBC9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Lorazepam – When lorazepam (2 mg BID) and nefazodone (200 mg BID) were coadministered to steady state, there was no change in any pharmacokinetic parameter for either drug compared to each drug administered alone. Therefore, dosage adjustment is not necessary for either drug when coadministered.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2B94823-7C38-4D49-90BA-8E9BC977DBC9"/>
    <pav:createdOn>2015-11-06 15:55:50 -0500</pav:createdOn>
    <domeo:uuid>D2B94823-7C38-4D49-90BA-8E9BC977DBC9</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <ao:prefix>may be necessary when coadministered with nefazodone .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/18be67bf-2a60-46b3-9e77-5475c8b93a2a">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42463</dailymed:activeMoietyRxCUI>
    <rdfs:label>pravastatin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc1e6806b2db043d0a5cd57cd23f1c0df">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:685E5052-2FEF-47F6-B369-47A92D19E730">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E346B72E-0E66-4ACD-AFED-496CBF112A91"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A52BC1D5-997F-4D60-B609-A3E04C5A6B86">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0E8DB85B-FDB2-493D-9745-A34FD3DC99E3"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BF7C2588-F959-4507-977C-39534E1C4B20"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/30AA535D-762C-41C0-9286-71AC521F88F7">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4AD05388-C1D0-472C-A129-60F73FF73E80">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>diazepam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1C103A43-6AF3-4BA0-A6B0-7253FA2AF508">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>ketoconazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D5762D34-9FA1-4269-8584-61C7F53EAEFE">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ad387288-5f50-4e3d-8c08-e4d020d78d83">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AF81C836-72F6-4534-AF05-F76926D461AB">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>bupropion</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A26A390E-AB65-462C-81C3-438BDBA41B70">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>None</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>none.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N499b601a38504e1e862628e97a756457">
    <domeo:sets rdf:resource="urn:pddi:uuid:ed76938e-7f79-4891-b429-f6cb6235a1f9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:211cfe0b-c5b9-4b9d-ac40-bcae5c56aa99">
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:8252e0fb-38a4-4632-b284-7dbe19c624f5</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:225c4d97-3709-4e62-9f8f-997db4488e12"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="Nc112c15489b846e68d11534136c55d64"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncda760b816ab483b8c2a869a222a7f21">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A741B98B-3DF8-42FD-92C7-FB7461C30168">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desvenlafaxine succinate</rdfs:label>
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:54BA2B86-CE76-4B15-9303-B5AFCC143189">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BE215695-7291-4E57-896E-FDE3FF2AD96E"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4e67b9e8e6b146b0a2c4a1b072cb0866">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d69638a8-bef1-40fa-9e3e-eb912a161768">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:51033c22-9337-4955-972c-89d8bf700bfb"/>
    <domeo:uuid>a383625c-a5a0-4a08-b415-74a3eb0a2a61</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8757D17B-8E07-4FB2-B697-37BBB1429A7F">
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:D732851A-BBC6-44BD-9210-4AEF3BF9CEB9"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-11-04 14:17:00 -0500</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <ao:body rdf:nodeID="Na1b4a163133d42d096c713623f300889"/>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBC29E8F-3018-4FB3-9D06-66D1FC3641AB">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>None</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>none.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18878E66-C4A2-4B51-A02C-B2004D0AFEFB">
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <pav:createdOn>2015-11-05 15:30:12 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:18878E66-C4A2-4B51-A02C-B2004D0AFEFB"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6a060f374dce4594bcd1d293840dcb1c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/395FD156-CC71-45E6-BCD7-936600D613B7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>duloxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb6e18290048b40f2b3cce19d391e00d3">
    <domeo:sets rdf:resource="urn:pddi:uuid:3A06C67A-6B19-4440-8A35-237A1AC869B9"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e407e5fe-f991-46a9-ad05-2eb50a027535">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8250874737564521bba77ac68f09102f">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0065C4F-ED7F-43E0-9AF5-6A0941357243">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E536FE66-FAD0-488D-B7C0-39E59CBD9678</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:9540ed61-ff6a-4399-86bc-04d7b87b26df</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N93e6b9fa12cd4ab48f198a14bea4770f"/>
    <pav:createdOn>2015-10-29 10:41:13 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-29 10:41:13 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:e5208d0d-d470-424b-a0e0-4a4b5da16c0e</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:EB616F1B-E294-49C1-902B-38E8CCE7CC39"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C0F2638-5394-46EA-BC83-C1799ADA2BEE">
    <ao:body rdf:nodeID="N43d4a438e4fb4798b6cd73b3b55158f5"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-28 14:38:28 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:713DFBBE-3194-4016-A9E7-7147DF1DAFEC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0D56CBB6-C44E-44FD-8A32-E7EFF20B9DA9</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-28 14:38:28 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:94CFFAD5-C6FB-4A24-867A-B18CD578838C</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8953d9ca-b2cc-4c8b-a8e9-6be0ffb07e2d">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <domeo:uuid>5fea35a6-203e-4fbd-9671-7aeb598137d4</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:cd922454-de0b-462e-be38-732259bf5a0e"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CF726AFD-136E-411F-AC25-A57B7FB07BB9">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>maprotiline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5cd8a62e55bb46fdbc589a8eb2e7dd3c">
    <domeo:sets rdf:resource="urn:pddi:uuid:96be1b54-d3b9-4140-a109-0046bad6ff14"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne1b53a7aaa7d4185b8cd53723ed77519">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e441a026-14f5-4290-9ab5-9e8573759848">
    <pav:createdOn>2015-10-26 15:38:48 -0400</pav:createdOn>
    <ao:prefix>                  Although doxepin HCl does have H1 and H2 </ao:prefix>
    <ao:suffix> receptor blocking actions, the exact mechanism by which dox</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:exact>histamine</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:e441a026-14f5-4290-9ab5-9e8573759848"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bc4e52bb-2b48-4bdd-9e3d-7e06e9a634ff">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:20235a92-f1dc-4046-afe8-0e1aa9ddeed3"/>
    <domeo:uuid>54686663-2fb1-40f8-a9e2-be6612b07bc5</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:abf3261a-125e-4d13-93d4-9c091bdf2559">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:b7a75c7a-0f92-407c-8af7-00ea1796b873"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>51dbfa2e-54d1-40dd-a1e6-a6f43f693641</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:138936ed-b01c-4cb8-bdea-9784c089196d">
    <domeo:uuid>0de5304c-8a1b-4998-9029-d315c7eb4884</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:261604a0-8631-4ff3-bdf8-99f2460cb1cf"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E2FE1AD0-52DF-4C90-97B6-0832E82C64B3">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>haloperidol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5899831c-1027-42fe-9f30-02e63dcfc747">
    <domeo:uuid>3f46490b-af4d-4465-8dbf-bcccba1c304f</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4e0bfd21-7f14-4db6-9ede-b6805c1f975f"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/339296C3-38F9-4412-9136-6EF2C9CA89FA">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>carbamazepine</rdfs:label>
    <dikbD2R:dose>400</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2d3e2d6829104446a01ac7e434e8d68d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/85F7F538-5161-4833-A8AB-394995538904">
    <rdfs:label>ritonavir</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>600</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2fb8f3a80a5b4f318b3150049ba2f11b">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b1f191c3-68fb-4e42-9802-eb1b5c437a45">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <rdfs:label>Rifampin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0561674C-7B8E-40DD-8D7C-BC3D00096736">
    <rdfs:label>desipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A8181DB6-98C6-476E-BA4C-8D8832C5B16E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0AE73FC2-FF83-4292-9B7A-2D52AFF5DAF8"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/31179A14-9FD9-41FA-BEDD-35E216221BF2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2885CD9-49C8-485B-BD7B-B6D3831E3A09">
    <ao:exact>When fluvoxamine maleate (50 mg t.i.d.) was administered concomitantly with warfarin for 2 weeks, warfarin plasma concentrations increased by 98% and prothrombin times were prolonged. Thus patients receiving oral anticoagulants and fluvoxamine maleate tablets should have their prothrombin time monitored and their anticoagulant dose adjusted accordingly. No dosage adjustment is required for fluvoxamine maleate tablets. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-27 15:32:37 -0400</pav:createdOn>
    <domeo:uuid>B2885CD9-49C8-485B-BD7B-B6D3831E3A09</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B2885CD9-49C8-485B-BD7B-B6D3831E3A09"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>   Warfarin  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N61fddc590311414cbbf8efadc03557af">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N63247e6551894d41a605c6987e373128">
    <domeo:sets rdf:resource="urn:pddi:uuid:BB7996C9-5E4F-4CC3-9F7D-4EEE93E3254F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/407BC1A2-C061-4B76-B5BE-4A63183A9483">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>phenytoin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4358ef34-271a-4444-925d-2be09ba568c2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:f67daa8c-0d5f-4361-8dfc-29a0544ddddc"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid>762a0cd2-c1a4-4add-a49a-bb2b208c08cb</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54D43BBC-050B-4C4F-ACA9-520DA64D0F05">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:prefix>XL and drugs that are inhibitors or inducers of CYP2B6.   Inhibitors of CYP2B6    </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Ticlopidine and Clopidogrel: Concomitant treatment with these drugs can increase bupropion exposures but decrease hydroxybupropion exposure. Based on clinical response, dosage adjustment of WELLBUTRIN XL may be necessary when coadministered with CYP2B6 inhibitors (e.g., ticlopidine or clopidogrel) [see Clinical Pharmacology (12.3)].</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-05 15:24:04 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:54D43BBC-050B-4C4F-ACA9-520DA64D0F05"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5CD80665-523A-46BE-9FBC-8D4B2192FA37">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-11-04 14:10:53 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D084F98D-37B8-45EF-B029-E0E5DC9B5022"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:C73F53C8-6D48-43AC-AE30-E7F541A71AC2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/86F02DA6-3F02-4FF8-BE36-0CA30945EA58">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>SSRIs</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0e0f8333-4cec-403e-a5f7-80057758dd08">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluoxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DB5BC21E-57CF-45BA-AB45-CC3AF11A6885">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>selegiline</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>6</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3FBEBFA6-F058-479F-8819-D42F2A400E48">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-04 14:17:24 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3FBEBFA6-F058-479F-8819-D42F2A400E48"/>
    <ao:exact>cimetidine</ao:exact>
    <ao:suffix>) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxe</ao:suffix>
    <domeo:uuid>3FBEBFA6-F058-479F-8819-D42F2A400E48</domeo:uuid>
    <ao:prefix>; </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9ab59316-cef3-48fe-a64b-3868aca9e0d3">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>furosemide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4603</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ABF0CC7E-AB36-42A4-8E12-6EB76AAEEF26">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>lopinavir</rdfs:label>
    <dikbD2R:dose>400</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/195088</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9F8726B0-BF39-463C-8B26-E35738412523">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc67639aaf20142e1bef801038ed4f534">
    <domeo:sets rdf:resource="urn:pddi:uuid:59095377-F278-432C-B985-6B6073682DF4"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N554abdc4cd5c4409977eeb962f133569">
    <domeo:sets rdf:resource="urn:pddi:uuid:cf129d37-0488-41b3-b230-8d0d985bca11"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9E451EA-02CF-4420-A4AF-BB99CBB6232B">
    <ao:prefix>renal elimination with aging.  </ao:prefix>
    <domeo:uuid>E9E451EA-02CF-4420-A4AF-BB99CBB6232B</domeo:uuid>
    <ao:exact>Certain drugs, particularly the psychostimulants and the phenothiazines, increase plasma levels of concomitantly administered tricyclic antidepressants through competition for the same metabolic enzyme systems.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E9E451EA-02CF-4420-A4AF-BB99CBB6232B"/>
    <pav:createdOn>2015-10-29 11:29:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ca921531-4a26-4523-85a8-20ed1b4402c3">
    <ao:prefix>atment switch is recommended.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Digoxin-There was no pharmacokinetic interaction between Savella (200 mg/day) and digoxin    (0.2 mg/day Lanoxicaps) following multiple-dose administration to healthy subjects. </ao:exact>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <domeo:uuid>53808f45-ffb9-4680-a410-7a788ee0d1c3</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7451b68b12764d5b800d2e4fcece29ea">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BC2738C7-8F6D-4200-8FFC-621B7782D593">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B74DA635-F4B4-4057-A933-F66626887174"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2870A02C-6ED1-45AE-802C-243EA5D102DB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F041F7E4-4BE7-4AC0-9B66-3A40FEC0D2EE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F041F7E4-4BE7-4AC0-9B66-3A40FEC0D2EE</domeo:uuid>
    <pav:createdOn>2015-10-29 09:00:40 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F041F7E4-4BE7-4AC0-9B66-3A40FEC0D2EE"/>
    <ao:prefix>ibition of CYP1A2 and CYP2D6   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and Cmax.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7dd43fa1-64fa-4f2f-94dd-fe3e42b7a100">
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>abiraterone acetate</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf9693bda79b048e2bf67e4089a6b0981">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DC2DECCB-4106-41B8-BC69-0B6293479A57">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:74A4C8E0-EDEE-4543-B553-61CA75394E32"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:064328db-121f-417d-80f1-6d9749db3eb9">
    <ao:body rdf:nodeID="Ne7a458a80a9d47d08ecbc0367344698c"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:643B49E0-891D-46F1-A2E6-25A43D608139"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-24 15:47:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-29 08:58:27 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1AB0DC5-E229-46CB-99CD-8964B49E8210</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:b99fbc51-cebf-4e69-ab8a-62a92403be5a</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:532214D4-C47B-49C2-BAC5-486E86F1651E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:532214D4-C47B-49C2-BAC5-486E86F1651E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>532214D4-C47B-49C2-BAC5-486E86F1651E</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-02 13:45:42 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Carbamazepine - Combined administration of Celexa (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of citalopram should be considered if the two drugs are coadministered.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4259d9b1-de34-43a4-85a8-41dd214e9177.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5fcb0c74-214f-4ba4-8e0f-a043347d4238">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:f1364b2c-1d29-4704-9ba5-a42fd1b39af7"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a3cc324f-608a-4e17-8ae6-a425cdf3d8bf">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:b1c556b0-8b87-45c2-a4b4-11d4b45a9ac9"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc685c90adb30460cb964a2dce5ce83e6">
    <domeo:sets rdf:resource="urn:pddi:uuid:3BA8E33D-7D57-42BC-96F8-59347C7AE05B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DDAB447B-7189-4753-8D16-337432150A41">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:92BDEDE7-5D85-4A72-91FD-957960200EA5"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:962C8851-3F0C-403D-81E3-DC5CB440336D">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:90E77CD4-EB99-4A2F-B1DD-B6F0F6456D4D"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N072b325bc1a940e0bf6f0bce5f38af26">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E1071A06-6C69-4001-A296-BB62A9135BEB">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>mirtazapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne823657d4b914ea7b067f31f6bcc3b44">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D7019389-A805-48BE-8F89-125FEF7C8631">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>omeprazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:911c8c76-df70-4633-9e30-54d1cb5fd738">
    <ao:exact>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].</ao:exact>
    <domeo:uuid>1811cc6c-0b55-442c-b786-e1c5ef716629</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 13:57:35 -0400</pav:createdOn>
    <ao:prefix>beta blockers or diltiazem )   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F24F8191-01EA-46A1-8C86-964ABEA6FD62">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>carbamazepine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D9DA556E-5460-451E-B020-4C08B903B03C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N77a0d4f2834244d9b704c0c30fd9ced1">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6CEF2950-8389-4385-89C4-7E31620BC4AC">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:87887A6A-E522-4787-AC33-7850E826DFBB"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:07A9F2C3-511F-469E-9269-D2FB39A88DA4">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8CA43AFB-D0E3-48EC-9DF0-B60E29D7E322"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc75d721ea2114ee19f593491b85308c1">
    <domeo:sets rdf:resource="urn:pddi:uuid:e4694bad-2a2b-4bb6-b3d9-04859ea4e632"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:fcc85c0f-7eec-440d-8b74-3e83355fb2c8">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:352e062f-96fc-43f6-99b6-9e46f0aaec7e"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6824DF76-BDE1-43ED-A937-21F6EF6C4AE6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:FA246F73-4ACE-44D8-9EAE-7DE41B03D2E3"/>
    <pav:createdOn>2015-11-05 15:28:24 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:830D5D6B-C940-441B-A31A-9B0C4421863B</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-05 15:28:35 -0500</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0C1CE5C-2016-48AE-BD2E-067126FD0D04">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A0C1CE5C-2016-48AE-BD2E-067126FD0D04</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <pav:createdOn>2015-10-29 11:36:07 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A0C1CE5C-2016-48AE-BD2E-067126FD0D04"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:416f025d-9bcc-453d-aea2-4686a93d5805">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:e87fbc93-34a6-486d-a58e-dbdc45992016"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9451b51c-2999-4a34-a5ef-c3209184b445">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:babe1c0f-27a4-4c12-9215-b76c75745278"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/465D2CB0-5AAF-45A4-8D77-670D95311862">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f270d6de-b017-4ad1-8409-b6edabd305c2">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0a4b9834-a0e9-4ce4-aff1-87611250f233</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:ab7382b2-626b-490f-b623-b496facb30d8"/>
    <permissions:permissions rdf:nodeID="N3cd947eef3d24b409520761f709667a4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CBD343E7-A986-4095-B804-7961ABDD4715">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5952BFEC-E144-479C-A264-FE43D8E0C3A5">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7C0AAC3F-C680-4881-8B38-8D6AD659D682"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:F5A7EEBC-EA09-40A9-A95D-1901093AC47E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2015-10-27 14:15:20 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:8bfbeebe-b90e-48cf-9faa-4562d4a6635b</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:7ce49671-db4e-4e04-abdd-5deaac61844b</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:4cd111f1-6079-4f96-a2cf-2b60c8bdc6e9"/>
    <permissions:permissions rdf:nodeID="N1afc9d8d36434d17a70d46a59b275e0d"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-02 15:28:05 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf4ca8328550142d2b1cac7dc2e8179f0">
    <domeo:sets rdf:resource="urn:pddi:uuid:EDF21874-3F1E-408A-82C8-E6F8EC1CD3DE"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8815e943db8b4d798393436e3cfb2d7c">
    <domeo:sets rdf:resource="urn:pddi:uuid:5abf81fd-83be-47fa-92c9-ccd0235af27b"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B60B1821-70C7-4161-8D8A-05E098C24A66">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9B94296E-EBC9-4F0F-ADCC-C38DBBC00081"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b62571cf-cc53-4b66-82ff-14271a96513a">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9d32ef53-af08-40cf-a035-176f8174db52"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>81a5daf4-db3b-42b3-9ded-6747b7fa7abd</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6C3AFC8-BDC5-4A6B-BF9B-D19944767C04">
    <domeo:uuid>B6C3AFC8-BDC5-4A6B-BF9B-D19944767C04</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B6C3AFC8-BDC5-4A6B-BF9B-D19944767C04"/>
    <ao:exact>Under steady-state conditions for duloxetine (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by co-administration. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-29 09:04:43 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <ao:prefix>   7.6 Temazepam   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A12CD05F-1116-4578-99EA-928B54401550">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>lorazepam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>2</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/49990E5C-42C2-49B7-A0AA-02166D9C3650">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>15</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>mirtazapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0b365805418346b6874048389bb0fd9d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72f43f96-dbd5-4a3c-bf38-24784bbd01e8">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:463d401f-8621-478e-a237-f23c815a9aef</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-08-20 11:30:25 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:3429de72-1fcf-47d3-85d8-7c2e7d087e58</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-08-20 11:30:25 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:1debaaaf-3d9c-476b-aa8e-fc61b9ea6232"/>
    <ao:body rdf:nodeID="Ne0e8ad4e24624572920410388ca26243"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C7313B66-D386-4849-9106-66CA54D79F51">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2EA86E9B-E227-4168-8AE9-224AADE1B6C3"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e8f938be-61c2-452b-8405-7db4a3ff1682">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:cdcb4550-818f-4e21-8b4a-99607c9fca93"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b9231951-c0a3-4c03-952c-18839e69ed9f">
    <domeo:uuid>5bba7984-c8de-4e5a-82e2-f33ac0f88649</domeo:uuid>
    <pav:createdOn>2015-10-09 13:39:25 -0400</pav:createdOn>
    <ao:prefix>uring treatment with ACIPHEX.  </ao:prefix>
    <ao:exact>Concomitant treatment with rabeprazole (20 mg daily) and ketoconazole in healthy subjects decreased the bioavailability of ketoconazole by 30% and increased the AUC and Cmax for digoxin by 19% and 29%, respectively. Therefore, patients may need to be monitored when such drugs are taken concomitantly with rabeprazole. Co-administration of rabeprazole and antacids produced no clinically relevant changes in plasma rabeprazole concentrations.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B52EBC06-DE23-4072-BFC9-3ECAD4C2889F">
    <ao:exact>hydroxybupropion </ao:exact>
    <ao:suffix>was increased by 50%.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B52EBC06-DE23-4072-BFC9-3ECAD4C2889F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-05 16:13:27 -0500</pav:createdOn>
    <ao:prefix>hydroxybupropion was unchanged, whereas C max  of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/03894FA9-51A8-4A4D-AB56-1BCB8D65334C">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:abd3bbd1-8a63-4690-8b5b-2c4418ff048b">
    <domeo:uuid>e4e802b9-fb7f-4596-ad9b-c6b3901cd59d</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69216ede-c72b-44f5-ae01-5186a6039d38"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2083b670-5f2b-4cc5-9371-baa94813b6ec">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:843e8424-4ead-45cf-b6cf-3f515630a33e"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F4DF85CF-6385-415D-BBC2-3A90824C5845">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>ticlopidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>250</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ABCB6AE4-8133-4635-BEFC-C8F8BE4822A1">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>L-amphetamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3A0C0832-3B1E-4FCC-AAD8-85FE87C1CE2A">
    <rdfs:label>sertraline</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AEE7AB83-6F25-49C3-9A31-96DC7750E478">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:996619A2-AFDD-4E31-9005-B6E80970C1FC"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0678ad5e-1656-4aa0-9512-36bb82a1426b">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdfs:label>rabeprazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82eabc7f-6719-4d94-a21e-0e66d6e821f6">
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <ao:exact>Anticonvulsants — Patients on stable doses of phenytoin and carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation of concomitant fluoxetine treatment. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>ba588f1f-6790-43a3-a51a-414996002b63</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5cba98aa240e4f5cbb4e5bbeda67232f">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49582ed1-a55c-4ea3-8786-f47a45f74bb9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9beb7beb-84b0-4bc5-9afb-b4d3cb3855a8"/>
    <domeo:uuid>b6f66614-4eed-4497-81b1-43b7934cebce</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8D1A77A1-50DE-4D2E-A95F-972818B92A1E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>urn:domeoclient:uuid:1ecc12f1-ebf9-43ea-8da8-ef25096a8672</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:6e79e785-0a04-4d19-b6f6-47e53976ec3b"/>
    <pav:lastSavedOn>2015-10-29 10:29:25 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdOn>2015-09-30 12:41:52 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:426b0869-603c-446d-a0c5-d64bb5fd20ea</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N7451b68b12764d5b800d2e4fcece29ea"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B7605E3C-245C-40B9-B3B9-DB42DDE0BACE">
    <dikbD2R:dose>25</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Phenylpropanolamine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/FDEEC25B-F6DF-4F00-BA9C-F735D2E7E7DD">
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AAA7B13D-FEF6-43F4-B77A-DC20C46716E4">
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole). </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-27 15:34:07 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AAA7B13D-FEF6-43F4-B77A-DC20C46716E4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>AAA7B13D-FEF6-43F4-B77A-DC20C46716E4</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:96be1b54-d3b9-4140-a109-0046bad6ff14">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:b248efa4-0504-4615-a4f8-7697c49568f1"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N05a000c1c57344fcbd7be0a0fc623905">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N83719a013d994065bcab5dfa588eee10">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/633D11ED-8993-4B40-A4F4-AE2C63D3FA61">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>benzodiazepines</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/d4947c01-e7b1-412b-9ae0-5bd7059769f6">
    <rdfs:label>pimozide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>2</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:878DA0F2-3B66-4D49-B6E7-4BEBE7484C72">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D97B2350-6EB5-4381-A83E-D3F14D907A7B"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A641BAC9-3C21-4625-B587-6449FBFD51D2">
    <rdfs:label>cimetidine</rdfs:label>
    <dikbD2R:dose>400</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/34C2F861-CC2C-4D71-A3F3-E6FD02713F1C">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8654184E-59C6-4F65-8B6B-B0DBFB83032A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
    <rdfs:label>flecainide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3751e6da-8fc1-4575-aa29-8958c804f78b">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:916371f8-5c7b-497f-8a95-b09a7c5fa9f8"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid>f2200cb9-f50f-4d19-aca9-ab41356fda6f</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:89A9AE52-D7AE-4834-B4BA-4A63F70DD4D2">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/67ABBE22-8F78-4D3D-86C0-BB7FD4ABB2FE"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B91BF932-E2E5-49B5-A795-184F1C14AEA9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:e6528c34-6c53-42f9-ae1c-1f0c908efa02">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:dcec4046-c7c7-411e-8b2b-5285dc38ed9a"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5C5E3A41-DAB3-4C35-B5B7-D1B8C1045D40">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D9655317-3D95-4886-B8D8-B513DA376EEB">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desvenlafaxine</rdfs:label>
    <dikbD2R:dose>400</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:37B8FC3F-3560-4A9B-914B-0E02E3AE2C6E">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FF02DC40-646C-414D-B6EE-15EF6035504B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b8cd2ed9-1344-4df7-81da-48d71df442fd">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0d1ae9dd-71a4-4552-b5cd-6b97174f33a2"/>
    <domeo:uuid>d9c36396-e79b-4006-95c5-fbb4ceb1fbf0</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a9735a74-fa87-4d86-8714-a17792524aa8">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6e64e70e-dc75-4f4c-af7d-7b0dc90c98ec"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9636E79E-1972-493F-94A2-66EF26CED855">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9107CAA2-30C3-4F85-8981-6406C7D8CCA8"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07a838d4-446c-4350-8d71-1980da3de1bc">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>dc22784a-3630-4c6d-9fcb-09746f16abc8</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8c5e5f91-8437-459f-ba31-752d55d5f577"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1679a3905f5542eb9916468bd9383ce5">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/79C41A3F-350F-4B02-A294-D189CDE8A56A">
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1E23824B-FE7C-4F5C-BDD5-C84FD1DA458C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C359C123-A452-4166-8E06-262C0897FBFC"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/063B1786-DA9A-4C73-A2E8-C02A93F0993C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0c247fed8eb04fcfabd9c65e3c0a095f">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c6e3e620-a290-4efe-94ff-6b924d37c8ae">
    <ao:prefix>er tricyclic antidepressants.  </ao:prefix>
    <pav:createdOn>2015-09-29 11:41:50 -0400</pav:createdOn>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>635d897f-477d-4757-879e-cc7aa97f4212</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9ED830EC-AFE5-4D97-B032-EBCE0F379077">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N91414caf80e6434d8b21de5d984621eb">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N04fdc54bd4f64318a3ab773ce9c3f22a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1f64a0fda11345bd93cbaa6bf9a4e535">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/224b124c-872b-4fe4-8a11-4ad818fe9dd7">
    <pav:createdOn>2015-10-26 15:39:34 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5fb48171-efb1-4e97-ba07-85bfe1da93c0"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-26 15:39:34 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A550C9E3-FC7B-4A62-8D2D-87F0720034C6">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdfs:label>citalopram</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:168E4F0F-8128-4D26-8885-5834F2569B36">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/36943F0B-A812-450B-A290-01BFDE8A84E1"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D9DA556E-5460-451E-B020-4C08B903B03C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:206DFE39-A44A-4DF7-9A51-FBBDB96F310D">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-06 15:44:01 -0500</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A05FDCF1-828D-4AF0-893D-FC0387C6E176"/>
    <pav:lastSavedOn>2015-11-06 15:45:24 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:42954409-bbf3-4a70-8ae4-d00b2fab3038</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:E786F7DC-C42E-4265-8923-103099474CC7</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB9490FA-5625-42F4-944E-81F22BF083EC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D078977F-2B32-4064-B6AA-1846767F4D30">
    <ao:prefix>may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (</ao:prefix>
    <ao:suffix>; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline</ao:suffix>
    <ao:exact>quinidine</ao:exact>
    <pav:createdOn>2015-11-04 14:17:23 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D078977F-2B32-4064-B6AA-1846767F4D30</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D078977F-2B32-4064-B6AA-1846767F4D30"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5FC7ACB8-10D2-488A-8882-3559BD635CE1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5FC7ACB8-10D2-488A-8882-3559BD635CE1"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>5FC7ACB8-10D2-488A-8882-3559BD635CE1</domeo:uuid>
    <pav:createdOn>2015-10-29 11:29:54 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:16fa9997-8c49-474a-8afe-f7b013fe4fc4">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:f3fe5dd4-fe2e-471b-b27d-e87ff59a9e5e"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9ec66023b679461ab4ac8196dd759b7d">
    <domeo:sets rdf:resource="urn:pddi:uuid:5fcb0c74-214f-4ba4-8e0f-a043347d4238"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f10c2968-f89e-4cf0-b5ef-ba63f654f36c">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0f606eec-3dba-4075-ba1a-5253cbbb7764"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1b519a54-7192-44c0-82bd-877e200235f5">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5119753d-26cc-46f0-a0c1-89d46ee0cf2c"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <domeo:uuid>90af3364-7d84-44fc-a565-499d5b769491</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9672191B-D72F-4881-9C96-E6E2BB06B380">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D997FE27-329C-4C1F-B4CF-2120417C0D14"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/033AD75B-092D-4B04-805E-3AE11B85E4DF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>SURMONTIL</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/565a7640-175f-44c9-a8a1-cd0648ec76e7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C94F9049-B6EE-4E48-9DC9-62F313EA8878">
    <ao:prefix>, metoprolol , atomoxetine )   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C94F9049-B6EE-4E48-9DC9-62F313EA8878"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:exact>In vitro studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the Cmax and AUC of desipramine increased approximately 25% and 17%, respectively. When 400 mg (8 times the recommended 50 mg dose) was administered, the Cmax and AUC of desipramine increased approximately 50% and 90%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug [see Drug Interactions (7.5)].</ao:exact>
    <pav:createdOn>2015-10-28 17:20:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>C94F9049-B6EE-4E48-9DC9-62F313EA8878</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/386f7fe2-8ce0-49a8-afa5-1f7963f60eb6">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
    <rdfs:label>imipramine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:de99662d-88b8-4cce-b7a2-8da3680c567e">
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:454a4298-5ee3-47bd-9bcf-01f8db203d24"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N6fb1386654bc4e2e89319ac1d55b1dd9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5820129c-9669-4b25-bf15-2afd30a111bb</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c6c1e53d-5fc7-4785-beee-f177867bf196">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:cab786e7-6ea7-4af3-ab1e-69f45d16aeda"/>
    <domeo:uuid>a2b890d8-5be7-4424-a819-1ba11dcc5a42</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D5BAA5DD-D9F8-47EC-BD0E-B87F48784868">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>Exposure decreased by 68%</dikbD2R:comment>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:85465149-3E94-4833-9DBB-5A7D3053F0D7"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3d69bd6c-f6f9-4ce6-9c5e-e5812f3b2678">
    <permissions:permissions rdf:nodeID="N63d377f3035a4874acd1f60c043e5fa5"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:9a2837f6-f015-40d1-8cc9-6620a60e04f3"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:e97a4868-43a0-4dd0-81b7-1044159f216b</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfbc6643b0fb243808488b38fff64bb55">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f6b2e8f3-019a-44eb-b633-c58b6915bf98">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:580bea3e-4ab8-48a5-8dbb-c3f8d4f85dbd"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2C3D8F7A-CA84-4F66-844F-EF59686D0871">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/48063866-91BE-4B69-A667-97112E8AEC80">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>propafenone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:393844CA-EF25-4606-A97E-C8748D50293C">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E7118659-6CDC-4724-AAB6-3F8DF448BD10"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc7e793445516405ca947508fadbdb637">
    <domeo:sets rdf:resource="urn:pddi:uuid:F88F061B-60F1-4A91-9CDB-C267823AE600"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/05280147-129C-45A4-AB2B-00780F7BB880">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:694B43E7-F271-407C-8B6C-F4CB0C8F5E94">
    <ao:context rdf:resource="urn:domeoclient:uuid:A0109A8C-5671-4C34-941A-B796C0001165"/>
    <pav:lastSavedOn>2015-10-27 15:29:30 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:4E8106AF-531B-4494-999F-E6F0EC060BCC</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-27 15:21:59 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C986B85B-8F13-44FB-98D9-DF52F50FF1E6">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9FCDCE17-D5EF-491F-AD49-6CD4BC4B8359"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E9A62C43-6B82-4022-941D-B3F31E2037BC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4e377be1-c9a3-48e5-af46-b3a754558609">
    <domeo:uuid>8d285b07-d3eb-46c5-9bcc-7be4db794f03</domeo:uuid>
    <pav:createdOn>2015-09-14 11:32:07 -0400</pav:createdOn>
    <ao:exact>Coadministration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>d.  Fosamprenavir / Ritonavir  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bbf41883-bfd8-4244-833c-3ec91a16e806">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <domeo:uuid>65402169-8d5c-4731-9fae-7b9283498c8c</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69387a10-ef1f-411f-bf00-a7b072488a85"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8369340f-e14c-45c6-a021-5db740fab9d1">
    <rdfs:label>Savella</rdfs:label>
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncdfecff6cdce475dbc01de9e8f1e152a">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4d1e4291-4c0d-46b1-bba9-0c4354c47950">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:c24d8eb0-78d3-4fb2-b803-5c643e732524"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>5f401330-19ac-49ce-935e-3ab71739e250</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:66392DB5-9BCB-40C6-9661-44C5D6504927">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:214A2D1B-F711-4199-97CC-E27AB8427FC8"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b1df51f6-8759-4adb-a58a-8c5fb5ee4cd0">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nce2eeb4ca72e469182ecc9ad41b57d53">
    <domeo:sets rdf:resource="urn:pddi:uuid:78094332-6CB9-4DDD-A3C8-591D25626204"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6432344cf657415ea59789495607291d">
    <domeo:sets rdf:resource="urn:pddi:uuid:8be1f147-d629-4c73-b9b2-45edf0c3b007"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/79111EE0-D652-4955-97B5-F14164881B2E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6e3cde8217464e93a18e25a6acaf1dce">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5d7be9f1-8154-4b40-9c17-aa70bea06fca">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:f0781ca3-e1f1-425b-a7e3-bea6ccbda1f3"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:273924a8-6ab1-4fd0-bf86-b27c472883cd</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <permissions:permissions rdf:nodeID="Nd838fbfff0e64ba1b655eb164b95ba73"/>
    <pav:createdOn>2015-09-14 11:32:07 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-14 11:32:07 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7c00adad-393e-4420-b386-35d417facccd">
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>5629fc05-bd1d-4a29-9588-f64972ef3bb8</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 10:29:59 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8658005e63674a24bc5a9d33aff996ff">
    <domeo:sets rdf:resource="urn:pddi:uuid:7fb68157-a120-4859-a683-a89ed535b8c2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/30A4DA43-F737-46B5-AC51-E4D39AEB3B72">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desvenlafaxine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>400</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6B105B20-534F-413B-9D33-B98D4C36A8DB">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:114B037B-6768-48E2-8348-EE4531EF05AD"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c0e57c53-a80b-457c-a6de-c560b185fda6">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>nsporter 3 (OAT3) substrates   </ao:prefix>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>bfba9bdd-af1b-42d2-a56f-1c70b0bea031</domeo:uuid>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne33766a25c5d43939ce229cfc8cd0228">
    <domeo:sets rdf:resource="urn:pddi:uuid:c1640b22-8eec-4aea-9f0c-15a2a3c52c3e"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C000DF83-03A0-43E4-A485-F936DE9054E4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8A9C13EC-3311-4E90-8FBE-527F5A5572C8">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>bupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N21742f2f6280449f9152e40d3a77aa40">
    <domeo:sets rdf:resource="urn:pddi:uuid:c4a79c3e-0a1d-4117-bb96-dc2fad389e12"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7E6F32C2-648E-4D4B-B976-F1C4D6BF68DE">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F1A3DB4F-0849-40F6-B489-795A6F0C6AA6"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9924c77ee9664159b8781b006c01182e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/beb23711-0027-42ab-beea-44811b1ad281">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9a9783a59800459295ded1abd456b2f3">
    <domeo:sets rdf:resource="urn:pddi:uuid:27BB3D6B-C148-4A9F-B65D-EFEC7336F040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2DCBAB84-202D-41C3-B8EB-9CD9D668C3DF">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>None</rdfs:label>
    <dct:description>none</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:55D26C94-3AA9-49F6-B004-E7B31D5AC85C">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:570DFBC9-829C-4A5E-90C6-00F9BA888882"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80427841-8733-4D31-B75E-C7B5AC762B29">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>None</rdfs:label>
    <dct:description>none</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/E4BB4DEF-0D75-4F18-A457-0725077929FD">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50f09c81-766b-4339-8507-adef4ae37dde">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:406cae68-246b-4c4c-9b8c-387b4ceb1436"/>
    <domeo:uuid>5ec5aa13-101d-4246-87aa-2cac613ce59b</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9d2530731bb5482c8be75450df59553f">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2A79B2EE-D427-4FDB-BB4B-1E0F7A6D3A34">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:comment>PPA given every 4 hours for 24 hours.</dikbD2R:comment>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:32E5C2F2-8FFF-4355-9A4A-D2791D308EF1"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A358A616-8D27-4087-8D65-3EC986D52557">
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>desvenlafaxine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:415CF7CD-2512-40CF-93F7-CE9B6EC6C933">
    <ao:context rdf:resource="urn:domeoclient:uuid:A34EFC22-6AFF-42BC-A78B-15EABBD46E2F"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-11-05 16:21:18 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdOn>2015-11-05 16:21:09 -0500</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N2876ccf7f34e490d9a4b055e78bd64a8"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:73C04C88-B9A3-40DD-BC34-FC5954D858A5</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/314968b4-f1e7-4367-bc08-aaeadfba1eed">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9E219433-888B-4994-B02B-CB82E67AFBE2">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/92BF7FDA-437A-4910-B4EC-198C6FA1B794"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AB40E85E-B52F-4918-9ECF-70320B13A3F9"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6e87ee95bf324a4da3f3836edc66eb79">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncc980231575c461d9c64498768000335">
    <domeo:sets rdf:resource="urn:pddi:uuid:807c45de-562d-4e92-bd47-46d9e737e4e1"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/79E464C6-8708-4D47-86F0-50DB8659ABE6">
    <rdfs:label>ritonavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na9e97fc893c940a58bcfc6834c5f61d7">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C7369983-9A06-4116-B9CF-E3E15963FAB2">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C58BC222-8C6F-41CD-BA41-244967C7201F">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:57E7EF26-0D09-449D-A1A1-51B1F5AE50F8"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-27 15:34:35 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:body rdf:nodeID="Ncaeceac612664fc49a65b7c2dd835d23"/>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5643869-6E9F-447C-AEE2-4328CCFF875D">
    <pav:createdOn>2015-11-05 15:44:43 -0500</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N9ebdc72b38c44757b01c59759eba906d"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D3B8F6A-12BF-425D-AD8E-9F3E90981312"/>
    <pav:lastSavedOn>2015-11-05 15:46:57 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:7A63508D-B4E4-4703-A023-9A42679FA3A3</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/26b1e5d4-fa96-4647-8c3c-480b78b32977">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluoxetine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8b53de79fd3f4d82b1b1ad53c8ae61a0">
    <domeo:sets rdf:resource="urn:pddi:uuid:b9a2ae4e-e8b4-4aec-93f5-ca7f854b3244"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:254ED692-020B-4F68-8746-725D20F675E2">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2AD2635B-9C45-4B85-AFEF-FAA086B0A351"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N998c19f1757d41dabffa0cdc7472ca17">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N39ca4e41fcb749dcac946a5bf5ec095a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BD3CD8BD-E739-4903-8967-FC84481AA89E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <rdfs:label>ritonavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5EAB7375-4962-4C30-9BE9-00753E5211EF">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DB75D1B8-BD87-485C-99C3-4AFE5D221AEA"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/354ff13b-577b-4c1d-a7ad-cf974ce2deae">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <rdfs:label>quinidine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:626DE9C1-C3EA-4E68-BCC0-7B4A2A5D68B3">
    <ao:prefix>erythrohydrobupropion decreased by 68%.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-11-05 16:10:22 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In another healthy volunteer study, lopinavir 400 mg/ritonavir 100 mg twice daily decreased bupropion AUC and Cmax by 57%. The AUC and Cmax of hydroxybupropion metabolite were decreased by 50% and 31%, respectively.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:626DE9C1-C3EA-4E68-BCC0-7B4A2A5D68B3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a628c369-090c-427f-8a8d-d4058d533087">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Rifampin</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9851A37E-AB7D-40AC-B56A-06ED0895502D">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
    <rdfs:label>Imipramine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne89336980d134b67b7c18dd6d00282ab">
    <domeo:sets rdf:resource="urn:pddi:uuid:e8bd9676-79e1-4501-93a4-a577d2ac3359"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:814acb66-664d-4c12-be2f-d59250861ed0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:f588d43c-35d3-402b-b240-10b7d6e3b1ac"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3df619dd-bac9-405c-a617-5223cc7bb51a">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:34124877-4109-47d4-9d31-a58d41dcf845"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>85bdc731-0785-47bb-b775-51632288a1ff</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N79297ff56fc34443ba6f9cb79c248dc5">
    <domeo:sets rdf:resource="urn:pddi:uuid:A6030E3C-BE47-4A0C-89CC-A97207BA08E5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9665947d-c923-4619-87be-8767b99ede67">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>propafenone</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:57ab35d3-2cbd-4003-9718-065ef53a744b">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:31f38884-9b43-493c-ba81-506aae56911f"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb1b3e580850741689e1922fa655cecdc">
    <domeo:sets rdf:resource="urn:pddi:uuid:6b64fa44-4b23-4f93-b0ac-70b02910bd4b"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:caf1bad2-4ee7-4e5e-9d63-bfec180cb1ad">
    <domeo:uuid>260fe0a8-9ad1-40dd-9fef-c73523b048b9</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15a0b0bd-fd3a-4ca5-b348-79c5ced27e55"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3DB7DDA8-408A-4B48-A14D-7853029A9B62">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>10</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9f8dd0ca-3146-4f14-ac93-c37a3ff9bedd">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ba3eefb6-8292-477d-b48a-7641c8415019"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbc1c5a18197b474897dc0ab7b04834bb">
    <domeo:sets rdf:resource="urn:pddi:uuid:f8e96222-c3b2-4044-a4ae-5d476ecb838e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF4DF8E2-D7F0-4E58-9F4C-0769AAF4E08B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 14:13:33 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF4DF8E2-D7F0-4E58-9F4C-0769AAF4E08B"/>
    <domeo:uuid>CF4DF8E2-D7F0-4E58-9F4C-0769AAF4E08B</domeo:uuid>
    <ao:exact>Levothyroxine    In healthy subjects who had received EMSAM 6 mg per 24 hours for 10 days, single dose administration with levothyroxine (150 mcg) did not alter the pharmacokinetics of either selegiline or levothyroxine [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbd35b563c3e64bdf85d981d9b744c255">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1c6e122b-aa6a-4657-be4c-815acb4666e2">
    <domeo:uuid>5a763e13-46f6-4b40-8fc9-3df4c2b19eb1</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7f1eb49a-1695-453c-93d9-6f76e2c5476c"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/923B8529-23BF-486C-9C88-EEE2B8DC98BF">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nefazodone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbc2b17111c804e83a0e229d51dca1b12">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4ccb86d940b14246a8f62fa2acbf34ff">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c31f853f-d27a-4947-8b9f-10e6ee093c4f">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>natalizumab</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B277CC13-768B-4004-BF78-723D147C8501">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7-10% of caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).    In addition, certain drugs inhibit the activity of the isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).    Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.</ao:exact>
    <ao:prefix>Drugs Metabolized by P450 2D6   </ao:prefix>
    <pav:createdOn>2015-11-05 10:37:42 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>B277CC13-768B-4004-BF78-723D147C8501</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B277CC13-768B-4004-BF78-723D147C8501"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3DEE2CBA-9782-4CC4-82D4-7E310EDBE581">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-10-27 13:24:46 -0400</pav:createdOn>
    <domeo:uuid>3DEE2CBA-9782-4CC4-82D4-7E310EDBE581</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3DEE2CBA-9782-4CC4-82D4-7E310EDBE581"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6c3a79d9e4ac431c8d983183689297eb">
    <domeo:sets rdf:resource="urn:pddi:uuid:4febf6d4-0759-40af-9534-f18a16c7eb8d"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf1d2053fc52c4e4d901ee21b1c2bd318">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1C038C2F-D2F9-435C-8E25-30CEAD2FEE27">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>hydroxybupropion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FEF277FE-2E3A-4A11-B3BD-D9B61B644DEE">
    <dikbD2R:comment>8 fold plasma concentration increase</dikbD2R:comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:40D083B5-563C-4F5E-AA62-01F4D689274C"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D97B2350-6EB5-4381-A83E-D3F14D907A7B">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B60FC03C-7E2F-46CB-9EBC-6C04FC16FD54"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/7C7E2EDF-EDFF-4F80-B69F-B185AC137C8C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N031fd98d293444e493a94b0f6d7631a1">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4cd158f1c92a45b497cf2d20ccd9d84d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F46AEEA-D7F6-4F1F-A426-9F20EDEB76A3">
    <dailymed:pharmgxDrug>http://fakeuri.org/Aripiprazole</dailymed:pharmgxDrug>
    <rdfs:label>Abacivir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BE1877D5-CE87-456D-B0B0-383C3AD7A47F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>triazolam</rdfs:label>
    <dikbD2R:dose>0.25</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b9e65f94-db35-4316-ac44-31abb9eb8e11">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:e37d3588-5984-4728-91c8-76a02b31f6ad"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid>613f76e9-74cf-49b6-ab08-f073a214e3dd</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C1040D1B-64AE-4624-AB46-B17C156B61A6">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0E69B322-8A4B-4DE9-B274-E5D5CEC877D7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2495865a-0dce-4d74-8a01-06206dd80418">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16bb992b-d01a-4812-a4ad-4fb7faa04c59"/>
    <domeo:uuid>8c8592c5-66a9-4b71-9eab-98e7ae32beb3</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4E55738-F67C-4DCC-862A-8DC8424BF6D1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F4E55738-F67C-4DCC-862A-8DC8424BF6D1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>When </ao:prefix>
    <pav:createdOn>2015-10-27 15:28:27 -0400</pav:createdOn>
    <ao:exact>fluvoxamine </ao:exact>
    <ao:suffix>100 mg twice daily was administered for 3 days prior to single-dose coadministration of ramelteon 16 mg and fluvoxamine, the AUC for ramelteon increased approximately 190-fold and the C</ao:suffix>
    <domeo:uuid>F4E55738-F67C-4DCC-862A-8DC8424BF6D1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f94f5167-d4a0-4e21-b820-4b68755fd8c3">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:cb3a2b17-fb65-4132-8dea-340415f0e7f8"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C781641D-BF17-4E60-B476-E59765D2E327">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>pseudoephedrine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>60</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE0339C1-03DF-4BA8-B0AF-BA7ED7EA24FC">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-11-04 14:13:56 -0500</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:22DED99F-2CB2-4799-912B-0C4BA96045CA</domeo:belongsToSet>
    <ao:body rdf:nodeID="N41b8846b49b2421aac42849d0a0b48ee"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C6F9A8E2-D161-434A-A757-17E6930A3624"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-11-04 14:14:49 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:9FDE15C3-7688-4A32-9015-8A7167292051</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DDF1BCA3-7919-4801-AE9B-F82800873321">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:258FF08E-C38A-4317-9E56-2529EAA66FAB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf0f1ddfac063471a8bfc63c8c4f9d0ec">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N856c23b574aa4b308fa88a383b5449f6">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1c4067178e724962873c481987e2a743">
    <domeo:sets rdf:resource="urn:pddi:uuid:7E6F32C2-648E-4D4B-B976-F1C4D6BF68DE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:855DC2B6-14E7-43CD-8309-D6BF558D411D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:855DC2B6-14E7-43CD-8309-D6BF558D411D"/>
    <domeo:uuid>855DC2B6-14E7-43CD-8309-D6BF558D411D</domeo:uuid>
    <pav:createdOn>2015-11-02 14:35:05 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>   7.17 Ritonavir   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A4480113-830E-4455-B404-39DEB9F559BD">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Lopinavir</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/195088</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1e74bd05-d6de-45fd-b824-d7d6a330ce14">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>15d6469e-7d28-4545-b4a3-8d10dcd19b41</domeo:uuid>
    <ao:prefix>er tricyclic antidepressants.  </ao:prefix>
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9C12C9D9-C60E-4ABD-866D-8EC85AC83651">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4A7D38C0-2D13-4324-BB04-53C94BF609CE"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A4480113-830E-4455-B404-39DEB9F559BD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:daeca897-be1b-494d-9695-334eb7006e10">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87d3a626-d9cb-4012-aca2-d11f64351fb4"/>
    <domeo:uuid>55e500db-f427-465b-9fe9-33c9e2d61789</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6072d0cc-f6c5-48c2-be4c-4eb2895fd57e">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N62403b66935244df81b02bb203ef513a">
    <domeo:sets rdf:resource="urn:pddi:uuid:6516e0d7-fb6d-499c-8189-ccb5c18969d6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5E4E281-FACE-4D4E-8F8C-EEC853591305">
    <domeo:uuid>F5E4E281-FACE-4D4E-8F8C-EEC853591305</domeo:uuid>
    <ao:exact>SSRIs</ao:exact>
    <ao:prefix>). While all the selective serotonin reuptake inhibitors (</ao:prefix>
    <ao:suffix>), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSR</ao:suffix>
    <pav:createdOn>2015-11-04 14:17:32 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F5E4E281-FACE-4D4E-8F8C-EEC853591305"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7e1d4e98-8085-47b7-b41f-ab21f11344c8">
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/47a1d48e-41f9-4b40-b368-ae2b45087063">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CA8D80D7-3C6A-4DE3-94ED-ABD92FF21AF6">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/04BD4A77-B4AF-417B-A1FA-ABD2B4CC7D44"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/78D16F31-5EE9-493C-8F78-68759658B14F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1b43bda6-818c-4649-b43d-a554b505b5b2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:856b917c-b61f-4832-a35d-f0c0d6d8ef6f"/>
    <domeo:uuid>db7f0e46-9970-4bbe-9809-aea94de7bd1e</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9EC5E026-38F9-4C27-A73A-EDABAF308CA2">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D243C195-F972-4153-AC7A-2289874C2675"/>
    <pav:lastSavedOn>2015-11-04 14:19:06 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:16203a91-80d6-42f9-9d7e-eb11acb0ff1b</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:FE820ED7-2881-456F-9B26-457D51658433</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-11-04 14:17:54 -0500</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:766b8667-fb4f-4e97-88b9-74ce5a967c7e</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nc2d05f60652a4a39a02b8378b952f6c6"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7039FFB8-1DA1-4ED1-9955-F08DBF8AE21F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>bupropion</rdfs:label>
    <dikbD2R:dose>300</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:049B2C1B-AF1C-4519-9B51-0B4A1ADC87B6">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/717DA49B-EA1A-466E-965A-EBDD2FC6CCBC"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2175D38D-CD24-4E11-B943-723D1E0F0CAD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5BC5DBB8-30CE-4759-814A-5A9593029F3A">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7E8A3C38-11C3-4C68-A0D0-D2809FA4BAA3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21A96475-2B40-4C80-BEEA-E9DCA5D231CE">
    <ao:context rdf:resource="urn:domeoclient:uuid:3482EC00-F34E-4A86-9427-08C44E43DAC4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-05 10:36:30 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:1C6F0D89-8E53-40DA-9802-BFC692CE58FB</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CD9E7CE1-2EDB-4CF5-8C39-1341B3BDE9B4">
    <domeo:uuid>CD9E7CE1-2EDB-4CF5-8C39-1341B3BDE9B4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-04 14:14:31 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CD9E7CE1-2EDB-4CF5-8C39-1341B3BDE9B4"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/e17dc299-f52d-414d-ab6e-e809bd6f8acb.html</ao:hasSource>
    <ao:prefix>(TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:633CA52C-A1B8-4DA1-936D-70D2F0106564">
    <ao:body rdf:resource="urn:linkedspls:uuid:1135EFA3-67D9-4B8E-B010-CD51438236F7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-02-19 12:41:40 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2DCBAB84-202D-41C3-B8EB-9CD9D668C3DF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:48174C77-8AA2-4177-A9C8-F0F6197B6446"/>
    <pav:createdOn>2014-02-19 12:37:38 -0500</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:8A890B84-DFB5-4F1E-AA94-2BFCA03E6EF0</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N78e55206cecb48b59c7116d0616a25b6">
    <domeo:sets rdf:resource="urn:pddi:uuid:10d9ef8d-2b05-4dec-a0fd-111fcd99e32e"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N483afa2556fe4024bbb937503a391f04">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b681de8c-2326-48f7-a7f1-f8824130ddf2">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:b28b1184-72a9-40bc-811d-7ba9a8a245e1"/>
    <domeo:uuid>6954d481-8544-4d7e-99d3-c00cc3ca48cb</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BD5CCED2-9DB5-43CB-91D2-70C1F14C2F94">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/770B80CE-44DA-41AF-BBC5-DDADCA818751"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/41751547-2E36-4BD4-A020-F2EAFA8B071A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C4D7B940-55CD-4FF2-9F07-2AC3E28AF9C5">
    <dikbD2R:dose>40</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>citalopram</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71B5DDC3-C204-4EE1-B675-C0039CFBD9A6">
    <pav:createdOn>2015-11-05 10:36:35 -0500</pav:createdOn>
    <ao:exact>antidepressants</ao:exact>
    <ao:prefix>) and many that are substrates for P450 2D6 (many other </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:71B5DDC3-C204-4EE1-B675-C0039CFBD9A6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/0177d783-773c-41bf-9db9-eb7e5c64474a.html</ao:hasSource>
    <domeo:uuid>71B5DDC3-C204-4EE1-B675-C0039CFBD9A6</domeo:uuid>
    <ao:suffix>, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The e</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EE9A35EC-F5C9-4CE3-892C-2B674061FDAE">
    <rdfs:label>diazepam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>15</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N43332f5f50e44c81afd886ca675ff4f5">
    <domeo:sets rdf:resource="urn:pddi:uuid:05C027E2-9A30-4E70-8CDD-88ECC6A6C81E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:a955d4a4-3dcd-47b0-9981-c38c581da707">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2154c63b-aab0-48d5-bea5-4896efcce630"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N732212ce980b485989c0ef46ac57f199">
    <domeo:sets rdf:resource="urn:pddi:uuid:190B9053-9CAA-4E89-B172-4472749A4E04"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4ea6e6d50cb144dba474681e9d3fb235">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37CF9F66-D61C-4B02-A765-691E21CBA197">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-11-05 15:29:56 -0500</pav:createdOn>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:37CF9F66-D61C-4B02-A765-691E21CBA197"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0D5DD3EE-2CF2-40D9-8415-0FDF9D9550DD">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nee474e7de0e74a5da3cd2a36a9dec7c8">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CBC872BA-50CA-4B6D-9878-1CDF1C0592B6">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndd9c58f2a7114f5c96303bb2247b2d4a">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:74A4C8E0-EDEE-4543-B553-61CA75394E32">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/22002285-26DF-429B-BC8F-153FC65EA94E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8E0C017F-2FCA-47CB-B0AA-BF96985476E5"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3f1aab4d-ead2-4209-a405-91cbafaddd08">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-09-29 11:28:40 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:11134c10-aed3-46bb-9408-214290fe4dc2</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:58d6ff98-f8a2-4505-aae1-242ad9510758"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N3b0a6976f10c4d30bb1ee14a5049ae7d"/>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbfe1a2f67bd4438b99850c906864f121">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7c478461982f4cbf86aa76ff67d0e709">
    <domeo:sets rdf:resource="urn:pddi:uuid:7013F43E-FBE3-4DA7-9E14-C5548930479A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N29d32061b29f45fa957cbf1918e0ee45">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:dd6c9163-7c76-4f6d-95bf-01ec0ab95a98">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:35ac8c94-8788-4a60-b0fa-06c5366818b9"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5A456C78-FA0B-4DCA-BDAF-38CC6D11563A">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5F961701-0A70-4FD1-81A8-BAFD68443F85"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/67ABBE22-8F78-4D3D-86C0-BB7FD4ABB2FE">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>maprotiline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0E2BE91C-77AC-4D82-BE84-077C18551974">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>0.15</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>levothyroxine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd456b061ca954643b9c7954d9e5afa4f">
    <domeo:sets rdf:resource="urn:pddi:uuid:B17E7FC2-C6B2-4477-B4CA-E40382D95E21"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C365B712-9191-4E7B-B556-6BAB89111E9E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A8A997D3-AD14-4712-A1D1-32036CC40162"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FF9FAB48-B7CC-4336-BC42-98DF58C7B9F4">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ED3048D5-BFFB-4654-BAD7-5C8E7260A311"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C7068E65-FA22-40F8-8485-2D37123C380F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C7068E65-FA22-40F8-8485-2D37123C380F"/>
    <domeo:uuid>C7068E65-FA22-40F8-8485-2D37123C380F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>is a relatively weak inhibitor of CYP2D6.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 15:35:07 -0400</pav:createdOn>
    <ao:exact>Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6. Such individuals have been referred to as “poor metabolizers” (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 “extensive metabolizers” (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6. Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine). </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7654C85-E13E-46DC-A164-A5AA3EC6E90B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>E7654C85-E13E-46DC-A164-A5AA3EC6E90B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Results of in vitro studies demonstrate that duloxetine does not inhibit activity. In a clinical study, the pharmacokinetics of S-warfarin, a CYP2C9 substrate, were not significantly affected by duloxetine [see DRUG INTERACTIONS (7.4)]. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <ao:prefix> Drugs Metabolized by CYP2C9   </ao:prefix>
    <pav:createdOn>2015-10-29 09:24:41 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E7654C85-E13E-46DC-A164-A5AA3EC6E90B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:800e6a6a-d187-4ee7-a71b-6f5db1fd97c8">
    <domeo:uuid>132f1b8b-792c-48f3-93a5-d3140d17e35a</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8ce97d0f-5bd3-44a7-90ce-4b4f419692dc"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE9F7FEC-FBC8-4345-9E83-FD4D7E357C8D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>    Mexiletine   </ao:prefix>
    <pav:createdOn>2015-10-27 15:26:01 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CE9F7FEC-FBC8-4345-9E83-FD4D7E357C8D"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The effect of steady-state fluvoxamine (50 mg b.i.d. for 7 days) on the single dose pharmacokinetics of mexiletine (200 mg) was evaluated in six healthy Japanese males. The clearance of mexiletine was reduced by 38% following coadministration with fluvoxamine compared to mexiletine alone. If fluvoxamine and mexiletine are coadministered, serum mexiletine levels should be monitored. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>CE9F7FEC-FBC8-4345-9E83-FD4D7E357C8D</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9b09aac5ddfa45f6a46864d6a9dbac63">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7013F43E-FBE3-4DA7-9E14-C5548930479A">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3133921C-C62F-4811-8C24-1E467A827DF7"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6ED2BF46-8719-4A4A-917F-A5A9B854A088">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D74855C2-3B82-49D1-B47B-24BD5B27B5AF"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/35E6057B-F407-4AA7-B7F6-D2B170F1CC2F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3CE2B674-435E-4B88-9486-BFEF711F58FB">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>50</dikbD2R:dose>
    <rdfs:label>fluvoxamine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1D0FD825-E589-4C2A-99AD-282F3905D374">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D718D234-A320-4634-947A-3554098B1E9D"/>
    <dikbD2R:comment>Increased plasma level</dikbD2R:comment>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/545D9FE6-7375-49C8-9F07-E725F85323D9">
    <rdfs:label>Bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N711ade3cbd7f49d5ab19b1a1b12982e9">
    <domeo:sets rdf:resource="urn:pddi:uuid:68dded0b-c29e-4829-9269-00cd645485d8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0cb05d5bd57f4ffdb302955e8d5c90d6">
    <domeo:sets rdf:resource="urn:pddi:uuid:c0111372-d777-4e40-9d81-e87db6b4ec3d"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f90149dc-c758-46f3-8700-d6c167270a16">
    <domeo:uuid>328068be-d544-4639-948a-b5d1a4d92956</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:e17a13cb-7c59-490e-aa6b-f236f8b995a2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B94199DB-287D-46E0-B629-9A861CE8EC38">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>hydroxybupropion</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4f21088443174fff88f666e348341931">
    <domeo:sets rdf:resource="urn:pddi:uuid:F2565CCD-6E2D-44B7-95D7-8949B1CDF1B9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5125476E-19BA-4871-895E-8F53E8BA5073">
    <pav:createdOn>2015-11-06 15:44:02 -0500</pav:createdOn>
    <domeo:uuid>5125476E-19BA-4871-895E-8F53E8BA5073</domeo:uuid>
    <ao:exact>nefazodone </ao:exact>
    <ao:suffix>200 mg BID, at steady state for both drugs, resulted in almost 95% reductions in AUCs for nefazodone and hydroxynefazodone, likely resulting in insufficient plasma nefazodone and hydroxynefazodone concentrations for achieving an antidepressant effect for</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/51ff7db5-aaf9-4c3c-86e6-958ebf16b60f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>200 mg BID with </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5125476E-19BA-4871-895E-8F53E8BA5073"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/00656A3D-14AB-4F23-9ECA-68D3CA9130EC">
    <rdfs:label>venlafaxine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/39786</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7CA3C576-3612-49BE-B189-E2A43C383F9E">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0A936C4A-B72B-43F1-875A-21ABBE83E9BE"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndfe9d6b1d2e84bf5a60dab6ce527b12c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N28ac32d758674f14ae081f1d4dcb4f31">
    <domeo:sets rdf:resource="urn:pddi:uuid:685E5052-2FEF-47F6-B369-47A92D19E730"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0956377d3c7249de988fb31e10fb6375">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7ad4a0301b5e4953acb1891e457c433a">
    <domeo:sets rdf:resource="urn:pddi:uuid:9a43aa1d-af6d-4248-85bd-ab0c86136e4a"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N64c8dc28b1a44ad6b77b922897dd51f3">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/48BBC616-F47F-476F-94DA-5FFDF84C3B40">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>warfarin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/88550DBE-60A6-49BE-91B8-1FF71D043E81">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdfs:label>citalopram</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>40</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5FCA8537-BF2B-433E-93B3-F44837036DA5">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc45fc4722cf348009bbe7acc18e9c79d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5e68407625854efea6e82dbffa00218f">
    <domeo:sets rdf:resource="urn:pddi:uuid:2659C5FA-AF80-461E-95E8-F25661252ADE"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7375ED7A-FC8E-42E3-9F7A-F2828540223E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D4579D5-300F-4A64-914F-5AB7F7055F84">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">22</pav:versionNumber>
    <pav:createdOn>2015-11-05 16:05:44 -0500</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N6c0ffd917c9843aab10317ec2a0eb48a"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B72C1409-C979-4256-ABD4-645391F04597"/>
    <pav:lastSavedOn>2015-11-05 16:05:45 -0500</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:4F598533-EB1E-421C-AADA-97962DA8B220</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2C9FD0B6-543A-4B22-9EA3-2C3006409323">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>nefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:59594494-231D-4FFC-991C-6A3105D5F07A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6C41E3DE-C97D-4A7B-90C7-3BB1F3BF3449"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CCB3039E-BFB1-4214-96F5-B83479DFB787"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:664566f7-09c3-422c-b83d-9e2301b8a342">
    <ao:prefix>AUBAGIO on CYP2C8 substrates   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 11:38:24 -0400</pav:createdOn>
    <domeo:uuid>56acddde-b6b3-4ec9-acd1-687df755e63e</domeo:uuid>
    <ao:exact>Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9281d5f6882949c68e5e4d5fc6e96fa1">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58f10bb8-e762-406a-b489-531c76a98251">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:10:08 -0400</pav:createdOn>
    <ao:prefix> on Drug Metabolizing Enzymes  </ao:prefix>
    <domeo:uuid>ac13ab39-77cb-4bd6-8910-d2c23217774a</domeo:uuid>
    <ao:exact>ZYTIGA is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. In a CYP2D6 drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily. Avoid co-administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index (e.g., thioridazine). If alternative treatments cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate drug [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C359C123-A452-4166-8E06-262C0897FBFC">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BAB2886E-1076-448F-AB1D-DF31180FC269">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>hydroxybupropion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:bf10491a-c682-4353-a2bb-8c06260e5070">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9a08aff7-01cd-462f-af7b-35c7f18dd810"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/903be69e-6e8d-49cc-a08f-38f140cb00b5">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58b84ef2-c9c5-4ba2-a78d-440a1cda1a48">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d27b10c6-3380-4518-912f-c75959c28fe9"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BDEB9DCE-CD37-4008-8991-D51F895D9B5E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <pav:createdOn>2015-11-02 14:35:21 -0500</pav:createdOn>
    <ao:prefix>   7.17 Ritonavir   </ao:prefix>
    <ao:exact>Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>BDEB9DCE-CD37-4008-8991-D51F895D9B5E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BDEB9DCE-CD37-4008-8991-D51F895D9B5E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:416FDEED-7EA5-46B2-AE41-AF6CF0A6CE88">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6FE56E27-2276-453D-BA7C-82F84AA55BF8"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BC5FC967-FC0D-4BE3-8C26-2A355CEDD0CC">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>nefazodone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/22F80333-CE08-409B-AF77-5A58F78778DA">
    <rdfs:label>duloxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>60</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3670085b-21f7-453b-bb89-4514b926986f">
    <ao:prefix>er tricyclic antidepressants.  </ao:prefix>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 11:41:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>51bf5d2d-e735-406b-9273-3a51c1919594</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6f94e2d651f444d1b160be5ffd8bc2e6">
    <domeo:sets rdf:resource="urn:pddi:uuid:ba54870f-5671-4871-9f7f-2d61f6428e95"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F449E4D0-4FF1-4773-831C-91720A096041">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:37716415-8AAE-4DA8-9481-DE174028FF2E"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/D5B65DFE-1729-47A3-A03F-AFEB2F4332A0">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>risperidone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>2</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nee98f17fd56a4b8da03521d0c633896e">
    <domeo:sets rdf:resource="urn:pddi:uuid:B3C6C155-684C-4977-BE60-F523ABFD676C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/31A98F03-9D36-40F9-8A57-D891C17D251B">
    <rdfs:label>carbamazepine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>400</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb4801bf589f44e59a46f796d6ddfa199">
    <domeo:sets rdf:resource="urn:pddi:uuid:033d1d47-608a-4d2a-8ad6-92bcf4e55f54"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:113ac7bf-323b-4193-a763-42ddad46df84">
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <domeo:uuid>400b2046-6d7a-4cb1-833e-b6314bbcd30e</domeo:uuid>
    <ao:exact>An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> In addition,</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Neecdc3cdde124f2ca04360e5b927044d">
    <domeo:sets rdf:resource="urn:pddi:uuid:DD34A168-80AF-45E5-9E93-ACB3257B5CB0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nad89d75f2f1645dab8c73a09ad8fab41">
    <domeo:sets rdf:resource="urn:pddi:uuid:65a7bd6b-f654-43f8-87a0-7c5a7cd295fd"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nba0f047c9b3c4688aa03568ded0093ce">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69387a10-ef1f-411f-bf00-a7b072488a85">
    <pav:createdOn>2015-09-29 09:58:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>er tricyclic antidepressants.  </ao:prefix>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <domeo:uuid>047cf846-8433-4803-a417-22280c262a42</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3A06C67A-6B19-4440-8A35-237A1AC869B9">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A1FCBE3B-2E25-4D35-B1D7-9811D3F113AF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2c367049ccbb40bb8d37a686abace94b">
    <domeo:sets rdf:resource="urn:pddi:uuid:DDAB447B-7189-4753-8D16-337432150A41"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9310403c-d8e8-46a3-a5c6-db9f29cf8560">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <domeo:uuid>d84606ec-1eca-47e4-bb74-aaac0359208c</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:d7d02ec3-9330-4842-8cc6-0d24fa8d94a4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F1C06564-7501-4B10-9C1C-0FBD52688BF0">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:89A9AE52-D7AE-4834-B4BA-4A63F70DD4D2"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51F8EEFA-A73A-460A-A289-86D68C779290">
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-27 15:19:54 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-27 15:20:54 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:B6EE59E2-ADA6-4DBA-BA3B-6D60FA250AFE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:FB8BF502-2AC4-4D04-8534-8608A60BBE94"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33F29679-E217-4D93-9174-2D69A0E1B032">
    <rdfs:label>None</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>none.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/24086ed6-fb76-40de-b816-eecb754fafe7">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>phenytoin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8be1f147-d629-4c73-b9b2-45edf0c3b007">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2aaaf00e-8c02-4a33-a692-b2be9f942d88"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:dbcedb4c-0324-42ab-a274-08dcd74cd582">
    <domeo:uuid>7c0e4c5c-2593-4a7a-8229-f407f7176063</domeo:uuid>
    <ao:prefix>ld be reduced.  Beta-Blockers  </ao:prefix>
    <ao:exact>In a study where propranolol (80 mg twice daily) was dosed orally for 18 days, the established steady-state plasma concentrations of propranolol were unaltered during coadministration with paroxetine (30 mg once daily) for the final 10 days. The effects of propranolol on paroxetine have not been evaluated (see ADVERSE REACTIONS: Postmarketing Reports).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-14 11:31:14 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N46ffe93af80c441fa5d9d2ae7e998c3b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N767bf3fb2982494f90d866f39e2589e1">
    <domeo:sets rdf:resource="urn:pddi:uuid:179e407b-085c-4f15-8752-fa7bf3392f0a"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8c2d59d2-f2d1-41ce-9284-e794b2f79fde">
    <domeo:uuid>2609e788-4d8f-4d95-8c56-97a86a7435e3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:fabe5174-86b7-4704-9e14-07ad36972d87"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8931c33c-a420-4d7f-a22f-2770f90e76b4">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0635e739-6428-4457-82be-4635179c1bd2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:f4e3133d-2e0c-43e0-921e-b567dbe8b7bf"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CCD34C2-F743-43D0-BD8C-7ECCCD371E17">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">17</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-05 15:52:28 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7C08565B-2B8F-4541-8F6E-10D96EDD148A"/>
    <pav:lastSavedOn>2015-11-05 15:53:54 -0500</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:650154DE-4762-4724-A410-9621094AE680</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2D010F3C-304F-490C-BEE3-BF7E867EC5EF">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>fluoxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:47f792a4-3574-47b3-87f0-3afce847ac85">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2c708c1e-cb8c-4d93-9c88-7959626ff352"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2909e420-c871-4705-9d8c-2b965a568479">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:77c80118-2045-4c45-bb35-3ddd5b79f69d</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N301c229120554ecfabb3ecd91ed973fd"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-09-10 14:36:47 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2015-09-10 14:36:47 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:0c44bb3d-5748-4cf9-9c0d-d698b13a2bc0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1566b5576f684efb891a34613a13820b">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N987b69631d3a46e4b95b56cd740335f3">
    <domeo:sets rdf:resource="urn:pddi:uuid:957ac464-8a4d-42bc-9005-db207d7ed25f"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncbe39700b731458c83dc97c852d267e4">
    <domeo:sets rdf:resource="urn:pddi:uuid:c536d7b6-4ffc-403f-ac8c-715de5c51808"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4ACFC3E8-6973-4B6D-9ECF-AFEAC0DFFDD7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4EB72DFA-1DF0-4016-9AF8-9E9AB9216686"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/CAEE6D50-1C2A-4DFB-A77B-6C6CB973DC61"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d905d7c3-b264-443c-8076-46f094aeb113">
    <domeo:uuid>9c94a13c-19eb-4a67-aaa0-52f03a361a3c</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:71762762-972b-4c03-91e4-59cd4ac1bda8"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F1B3F448-C50F-4E04-890E-4078D4872F66">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>propafenone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bcd813af-4851-4053-b6db-268acd42ed81">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid>e019fd0c-421f-4202-b3ae-386468308d87</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:a89b5f29-8f9b-459c-bdd3-bf954bedc2b7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:229C4E87-7FFC-416F-AE55-F30D27EA1680">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/33D2A299-F8AB-46A5-8682-93552F77DB96"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A1272DD0-7D73-4991-A96B-45AF5CA58117"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4138D86D-7673-4E65-BB61-B7556BAB77B2">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Nb55e77b2a38742cd83c813be902be01d"/>
    <pav:createdOn>2015-10-27 15:36:09 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:lastSavedOn>2015-10-27 15:37:39 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:059162CA-8607-488B-90F3-72A2EAFA63DD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6D7DA812-EF46-4E37-9A44-F9A93EE3C704</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C66A1029-7FFF-488D-821A-8DFADB963EC7">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:726D46E7-2558-47B2-A574-723C0898F849"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N77f87248cbeb4a52914c5b215e1ddd84">
    <domeo:sets rdf:resource="urn:pddi:uuid:61a5a0bf-4aa0-4913-a64c-dc6595e1afa8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:13751F53-3574-46E2-8D10-63F08B2414B1">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:834560AA-1E49-41EA-BE70-AB001B40F97E"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1337e4198cfc49ed8c2e1ba3c8321f29">
    <domeo:sets rdf:resource="urn:pddi:uuid:2517CCDB-7361-427B-A1E1-E06897A6750A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nde8d6393ac6b49dc91bb2abd773d77c6">
    <domeo:sets rdf:resource="urn:pddi:uuid:77bdfe3f-1db9-4d6c-938f-66f80a6ad533"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A34EFC22-6AFF-42BC-A78B-15EABBD46E2F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>    Lamotrigine: Multiple oral doses of bupropion had no statistically significant effects on the single-dose pharmacokinetics of lamotrigine in 12 healthy volunteers.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-11-05 16:21:09 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:prefix> by 30% and 40%, respectively. </ao:prefix>
    <domeo:uuid>A34EFC22-6AFF-42BC-A78B-15EABBD46E2F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A34EFC22-6AFF-42BC-A78B-15EABBD46E2F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C3239A6E-8969-4843-AED9-751A6C46A15C">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EF2BF2FC-EEB2-4F1C-8761-504B6E9F5297"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ffe19e59-bd70-4f30-b434-1715f94d924d">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Rifampin</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EDF21874-3F1E-408A-82C8-E6F8EC1CD3DE">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9BD348AD-A5D1-4CB3-93A7-0E179B85C86B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7C0AAC3F-C680-4881-8B38-8D6AD659D682">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5899D320-080D-4D20-BB6C-D1E916CFAED3"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/18E67656-6544-4DEC-9E54-19813E311731"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b0b7eddf-93e6-42fc-8d39-826a621810ef">
    <domeo:uuid>388998ac-4429-416b-9c59-2dd780997621</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:995e9560-a5e5-4dcd-a646-6c19f3f11f09"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd103c9b98db24f17885a33d5cffa03cc">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7a07f8a9e11941b289c5ed77b05c5d51">
    <domeo:sets rdf:resource="urn:pddi:uuid:f0482d26-50c2-4df9-ba8c-2e88b38f52ac"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ACB6BEB4-A8F3-4393-A584-EDEDCD6BE388">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>6</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d7d02ec3-9330-4842-8cc6-0d24fa8d94a4">
    <ao:exact>CYP 2D6 inhibitors: In healthy subjects, co-administration of pimozide 2 mg (single dose) and paroxetine 60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in pimozide Cmax compared to pimozide administered alone. The increase in pimozide AUC and Cmax is related to the CYP 2D6 inhibitory properties of paroxetine. Concomitant use of pimozide and paroxetine or other strong CYP 2D6 inhibitors are contraindicated (see CONTRAINDICATIONS).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-14 12:10:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7146920b-eb0a-48f2-b305-7ed6fa6de255</domeo:uuid>
    <ao:prefix>ed (See CONTRAINDICATIONS ).   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72d91b2a-0741-48ab-81fb-2ef0147b9860">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:248e2ba9-769e-4666-9a23-d81979bde681"/>
    <domeo:uuid>1fba8669-6222-4664-b292-0c5de9892bac</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/90C2CDCB-016A-4EFD-AE0C-2576563D80B4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B8E124E0-1E3B-468C-8846-C06CE7998697">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AB1ABFC1-12C1-4177-97E8-4BA1A3FD076C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2a97a09042c64e47bf3c89cb73d39b8b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:560e4e4b-12c9-44d5-81e0-5a5673afd438">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:58f10bb8-e762-406a-b489-531c76a98251"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>81761961-7aea-4e06-9251-7bf56b9d3ce6</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EC0D6D4-F4E1-47C8-9484-38C09E81707D">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-11-05 15:28:42 -0500</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-11-05 15:30:13 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f5f60ae8-616e-432f-a9cb-ef546aa9b0b4</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:B7BE1296-FCF1-443C-B8E8-FA07AD2AC3D4</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D500054A-2575-4EC0-BFED-5509CE0C767C"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:294573CE-B7FF-4A69-B96B-354737511FDF</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N59212061205e4e41ada9d453294a3f18">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/cfee08e1-a248-4a1a-a35d-4b4983bff720">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>GILENYA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8795ba1b-c5be-4b78-a2d9-e9e8575bf0a8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>leuprolide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9400e7898aed4d4696c7818178ee6094">
    <domeo:sets rdf:resource="urn:pddi:uuid:99285CF8-1BA4-4B96-9DD0-3BF3B88D7585"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1b600a5daf514abc83059c5921db1746">
    <domeo:sets rdf:resource="urn:pddi:uuid:087e6b89-9919-4ce0-87d8-70b7a86407a5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/76C7D088-D503-4353-BB0C-3EE5F74F920F">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:db655804-81bd-4296-82cc-09a2dc1a5d15">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <pav:createdOn>2015-10-26 15:41:32 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>or </ao:prefix>
    <ao:exact>serotonin</ao:exact>
    <ao:suffix> is believed by some to underlie the antidepressant activity</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:db655804-81bd-4296-82cc-09a2dc1a5d15"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0ddefc2b-4058-4728-a4ff-45fc9259cfd0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>calcium channel blockers</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ca4b2eda-f1e8-40f8-b22f-c0a50308fa8a">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9bc27358-9fa5-4e54-97df-bcf6fef24f1f"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
    <domeo:uuid>94ff7df0-7d9c-4d36-ba85-6f87ad06e166</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/37D583E5-5B1B-4D2E-9AFC-DDF1D21D8512">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>citalopram</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3CDF481D-46BC-406C-BF9F-8FC8510E2FCF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>nefazodone</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N93f362b5b9454f7d9d5b8b642b238b0d">
    <domeo:sets rdf:resource="urn:pddi:uuid:416f025d-9bcc-453d-aea2-4686a93d5805"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94611C47-47D7-4D38-8EEF-17379EF5BB78">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06827bcb-0a8b-4aa1-8786-80a95c843116">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:30:25 -0400</pav:createdOn>
    <domeo:uuid>755a7efb-97a7-40be-bf4e-171aa7b5b824</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>of theophylline was observed.  </ao:prefix>
    <ao:exact>Abiraterone is a substrate of CYP3A4, in vitro. In a clinical pharmacokinetic interaction study of healthy subjects pretreated with a strong CYP3A4 inducer (rifampin, 600 mg daily for 6 days) followed by a single dose of abiraterone acetate 1,000 mg, the mean plasma AUC∞ of abiraterone was decreased by 55% [see Drug Interactions (7.1)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6e7196470e744d19a13b718ebb396bfa">
    <domeo:sets rdf:resource="urn:pddi:uuid:0039AF3F-3775-4EF2-8D79-0457D7A80013"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C0520662-711F-4CC7-8F7E-AEA5F91D4129">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A0006AC5-A7C4-418C-928C-C41D90415342"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/af911d25-506a-4b2a-a019-fe8ead522f55">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>haloperidol</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/74ED91C7-3D6C-4313-8869-417A69E0D201">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:e88acfc7-2df9-4018-978d-3f37b180180b">
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N2ef971c80c3a47049062bef7a4db4e00"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-08-20 11:43:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:69c6c642-bd3a-4118-89b4-734f39df2215"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:f63b15b9-48f8-4414-a517-17004a2c7ee2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:cb9558d5-8801-4b03-b913-a3aa0a4d169a">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5c50debd-1884-4895-8e46-93cc834ab3fe"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6d6fc27c58064afe8df17f3f8d6d5a24">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/721C2A2D-0C8A-41D0-BB1D-CA13EE7D9E2B">
    <rdfs:label>Lopinavir</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/195088</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0bb5da0d-5259-48a9-8ebf-c79c4d5f0792">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8C0E2669-08A2-4B7B-A2AD-4C4E32D891A0">
    <rdfs:label>barbiturates</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b46e815a-d825-4f71-a66a-66bb80aebca7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Pregabalin-There were no clinically significant changes in the steady-state pharmacokinetics of milnacipran or pregabalin following twice a day co-administration of 50 mg milnacipran and 150 mg pregabalin. </ao:exact>
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <ao:prefix>0 mg) and lorazepam (1.5 mg).  </ao:prefix>
    <domeo:uuid>f457cdee-5237-4f07-b7da-697f11a0e27b</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:637de586-25bd-46a8-99e3-e8da3bcdaa68">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:88eb3458-0723-4637-b5e1-d12f4d2c4c7d"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>1b0d6dbf-e7b5-407e-a4b3-9082c6b09254</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e40df49a-0ec4-422e-8060-ca175ce73456">
    <rdfs:label>sertraline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6216f237-06f1-4b23-af95-64e791b0ce90">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>AUBAGIO</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c619bd1d-ed1b-41ef-9d5f-78ababccbe72">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:a0d575c2-9934-435a-880f-dae07fa4a961"/>
    <domeo:uuid>f999aa36-bf20-4d7f-bb1e-c08847fb795f</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5bef8cca-4e04-4588-849a-05c9ecfcd296">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:bf1d4d4d-7e1a-4484-8b53-5d78a39546c8"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0e7ddb57-871e-4883-8c62-615b2016c175">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>97df74c5-e974-44bf-ac84-973d823df5f3</domeo:uuid>
    <pav:createdOn>2015-08-20 12:50:04 -0400</pav:createdOn>
    <ao:prefix> B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:99A3A07C-B4AF-4EFD-A0C2-C9581ABBDA64">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1834472A-B62A-42F1-8C3E-B730C4DBD100"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f3a170cc-69ca-442a-b54c-5a268bf2b574">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <domeo:uuid>bfe5b37a-9e04-4c9f-9934-f284d42c9db1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:b46e815a-d825-4f71-a66a-66bb80aebca7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:55925b47-e19a-44c4-99f2-239e4ff2d350">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:c2554a22-a850-4127-a501-5c45c9e5faef"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ADE8693E-7159-4148-A5FD-417A5FBD6EBB">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BB9CEDCE-13CB-47BA-837F-0FC94375C49E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3DB242A5-6849-478B-B408-B08011C4DCCF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9FE150AB-472E-44AB-8D85-9F3FC3DE99F9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>carbamazepine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na008356b57e649c4b479410c55ab25c1">
    <domeo:sets rdf:resource="urn:pddi:uuid:802E8BCE-9C50-4403-B034-CA9D0463799E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9f4f251bf0e34e1d9f77d07d6b78ea35">
    <domeo:sets rdf:resource="urn:pddi:uuid:416FDEED-7EA5-46B2-AE41-AF6CF0A6CE88"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/18E67656-6544-4DEC-9E54-19813E311731">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na69a0d0df565446d8ad96ad29d317530">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c78ba8c8-6549-48b4-82c6-faf239bce66d">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nadeb5e09f18f4c009b0b6f80269a5a1e">
    <domeo:sets rdf:resource="urn:pddi:uuid:2F4217F4-3B1D-47C6-8A45-8A9552D57D65"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na86c0403cad84b2a93a15a864fe62711">
    <domeo:sets rdf:resource="urn:pddi:uuid:8415ca50-1235-4a3a-bb99-df9c5d2e061f"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58B59744-6B62-4952-879A-503E330A26BF">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5001F30A-C0CC-43F1-B7CB-4DB5573E6308"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A1B28CD8-B293-407F-91D3-F8116978A071">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>propafenone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90637796-9d7a-4623-8db6-54132982b6de">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:c0e57c53-a80b-457c-a6de-c560b185fda6"/>
    <domeo:uuid>65a182bb-6e82-4720-b80f-491f44ea9513</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EED083AC-6E5A-452D-AB8A-5EFF6F32E0C8">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5E869193-267D-447D-BA12-D914DE0E9BB7"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DDD031E5-D8DB-4237-8393-8751CD1E6E59">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:comment>Increased plasma concentration of warfarin</dikbD2R:comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B2016776-7095-486F-AA64-F403CF517D84"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N80ab9894dc4d4e92863aa8f043e38092">
    <domeo:sets rdf:resource="urn:pddi:uuid:6A56E714-739E-4262-8105-88C801F0B830"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f650a6f3-f488-48a8-8926-b8daac5ca510">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2626</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>clozapine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f43f5739-998d-4762-87ed-c34faedc1353">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N27fb1386d4da41838733fc1dc8f90044">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:22E3D5BF-8FEF-4BD9-BE43-5D35A4DE0120">
    <ao:prefix>XL and drugs that are inhibitors or inducers of CYP2B6.   Inhibitors of CYP2B6    </ao:prefix>
    <ao:exact>Ticlopidine and Clopidogrel: Concomitant treatment with these drugs can increase bupropion exposures but decrease hydroxybupropion exposure. Based on clinical response, dosage adjustment of WELLBUTRIN XL may be necessary when coadministered with CYP2B6 inhibitors (e.g., ticlopidine or clopidogrel) [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 15:21:27 -0500</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:22E3D5BF-8FEF-4BD9-BE43-5D35A4DE0120"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ff27b70a-5240-4bf2-95c6-e10fda72db8b">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N23da738550324245b419e15be2e5df4c">
    <domeo:sets rdf:resource="urn:pddi:uuid:C8BF38F4-DA71-40A4-9F8E-E11F55E98978"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N301c229120554ecfabb3ecd91ed973fd">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4A7D38C0-2D13-4324-BB04-53C94BF609CE">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <rdfs:label>hydroxybupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C014BD05-31D8-4D00-8179-925A94CB7D12">
    <domeo:uuid>C014BD05-31D8-4D00-8179-925A94CB7D12</domeo:uuid>
    <ao:prefix> CYP3A4 and -2C19 Inhibitors   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C014BD05-31D8-4D00-8179-925A94CB7D12"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/13bb8267-1cab-43e5-acae-55a4d957630a.html</ao:hasSource>
    <pav:createdOn>2015-11-02 14:47:11 -0500</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a25b4eb6-103d-4b50-b894-da0fa309d678">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluoxetine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nab98954bd2d44ab585a8e9d389a2087c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N735de150f65745b79883e46a8094a03e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0d7c0e0f-9bb3-4e1a-9943-9ce8465ac9b2">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid>0b28e212-ed53-4f38-94e6-9a1b8e088624</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:12353fec-0819-4a58-93e8-8c1f8ab850dd"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb486aa6de834440cb54a4b822aaed2bc">
    <domeo:sets rdf:resource="urn:pddi:uuid:5851e8cc-c009-438c-af1c-210fdac08992"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na742c44b67b348e49fd0516501f0df87">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/32205567-16ef-490f-a7c6-488711e8a36a">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>saquinavir</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9A27337F-880E-481E-B32C-A2FB50A08D90">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AB65EA97-12D8-4EF8-A68A-4F068036583F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C78A8ECB-1399-4158-99A5-5E93F9EB7017">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1D7DF3BF-E708-4923-9D2B-C1A353FF8E82"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0F1A2F27-E719-4C32-85E7-CCC9B7175CA3">
    <rdfs:label>digoxin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>1</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/cf4bbf3a-0a9f-4b66-a996-83a70cd33e4e">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>abiraterone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0c285221-c07a-42eb-851b-dc3ef1f9ea39">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:317781a1-88d6-4ab8-92cd-198c609b2cb9"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N96819434f1ca4819821f03b42a8f24b6">
    <domeo:sets rdf:resource="urn:pddi:uuid:D927D87A-0730-4A0E-BA09-42987D40AF85"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndf0a3d147ca94378bbdf3756b786ed77">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4C99E3F-34EF-4E44-90DF-C6552C4F6FD5">
    <ao:suffix>and the phenothiazines, increase plasma levels of concomitantly administered tricyclic antidepressants through competition for the same metabolic enzyme systems.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B4C99E3F-34EF-4E44-90DF-C6552C4F6FD5"/>
    <pav:createdOn>2015-10-29 11:28:47 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:prefix>Certain drugs, particularly the </ao:prefix>
    <domeo:uuid>B4C99E3F-34EF-4E44-90DF-C6552C4F6FD5</domeo:uuid>
    <ao:exact>psychostimulants </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C2AF4E52-5DD3-43B9-99FC-1A52E6335565">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/407BC1A2-C061-4B76-B5BE-4A63183A9483"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B2C50C89-17EA-4718-96C1-A1FF90A718BF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AB8EA8A8-CA09-44B8-9394-1378A877BD14">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/31565</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>nefazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7b44a281-73db-49d5-b28f-d11a5d7d6496">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>b0d6cc62-ab4b-4662-bbfb-5497b7925f31</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4900c17a-8ae0-4b71-bcb7-900980790ea5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/AB40E85E-B52F-4918-9ECF-70320B13A3F9">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>cimetidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5529e71f12a24a468633c2432d69cb4a">
    <domeo:sets rdf:resource="urn:pddi:uuid:598E6FC7-D724-435B-BBAA-BDDEDD2509F7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N88ccdee004184896b21c709848f0334e">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:92BB0852-289C-4A2F-8E7A-1C494C5C15B8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5B0937DA-4024-4DD7-850B-53C052CED981"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/BA9EAA95-B02B-4F34-9A83-2D790B8EE4D2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6793DF1B-7B9E-4C39-8C7D-28B794DEC68F">
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>50</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F4B3D0A-42A3-449C-861D-6C9096AD9208">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In healthy male patients (n=12), when cimetidine, a weak inhibitor of CYP1A2, CYP2D6, and CYP3A4, given at 800 mg b.i.d. at steady state was coadministered with mirtazapine (30 mg daily) at steady state, the Area Under the Curve (AUC) of mirtazapine increased more than 50%. Mirtazapine did not cause relevant changes in the pharmacokinetics of cimetidine. The mirtazapine dose may have to be decreased when concomitant treatment with cimetidine is started, or increased when cimetidine treatment is discontinued.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>7F4B3D0A-42A3-449C-861D-6C9096AD9208</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <pav:createdOn>2015-10-29 10:35:24 -0400</pav:createdOn>
    <ao:prefix>  Cimetidine  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F4B3D0A-42A3-449C-861D-6C9096AD9208"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N354826b58c2e4326877565f703e04570">
    <domeo:sets rdf:resource="urn:pddi:uuid:5a79a118-20f6-4089-ac50-03d388680c5b"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D618F2B0-8C27-412E-9D8E-D1B4AFB367F8">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/706149EF-D03D-46D8-B966-A48EC3A2C7B3"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AD060308-4E45-46B1-A88B-6DDBCE57C454"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5af4fb65145b4557b099a88b89ac208e">
    <domeo:sets rdf:resource="urn:pddi:uuid:10D3B1F8-6CD8-41D2-A9A7-281515CC7DA4"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb58a4ef3f104429da40183d56a09069d">
    <domeo:sets rdf:resource="urn:pddi:uuid:1D8BEC41-1043-4854-AF95-649EE120B891"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B04C100-ABBF-4527-8D7F-3771D405F33B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <pav:createdOn>2015-11-05 15:31:04 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B04C100-ABBF-4527-8D7F-3771D405F33B"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbee8c88d146749e8aaf4292d62b4ff0d">
    <domeo:sets rdf:resource="urn:pddi:uuid:f5e58104-0fbb-4c7f-87c3-2ab7e40cde4d"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ecd7e563-4625-4f47-b3a0-1d5e00d06b9f">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
    <domeo:uuid>5d496597-8531-4f0d-b64f-039d22b54976</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:70621f87-7ebc-4737-b4eb-a89561877d92"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14369192-A740-4716-8724-40A8F3471FFC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:16F7BA6E-9FF1-43FF-97A9-6747DDFB1A97"/>
    <pav:lineageUri>urn:domeoserver:annotation:260681A5-2B6B-40A1-A908-33DD64CC7566</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-05 10:36:44 -0500</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6735CAE6-4C40-44DB-97D7-B474AF131C11">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>tamoxifen</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EAEEFAFA-7809-45A8-8FB9-7D1359CBA2C7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>carbamazepine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/26702a42-d4bf-41e8-8cf5-6d0f018c4c42">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>imipramine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cf6ec675-c122-4820-8849-28b2358fb154">
    <pav:lineageUri>urn:domeoserver:annotationset:8c45b9c4-a981-497d-a85f-d03e2c5ef57f</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:ae24c19c-6c32-43f9-978a-278a3537f64d"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-01 10:31:02 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N056a30600a58470692566ede3b8a1347"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1CE1A55B-B661-46D7-9CE1-7148E5B176CA">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>800</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b874739e-4feb-4a59-8ea3-8b800269e267">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8b0687e8-b41f-4dd5-b451-4128c9d99e01"/>
    <domeo:uuid>de065c3d-39ee-4195-8591-c5932378335e</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/cf0e80ac-c635-4e33-b351-c50b0fbfe8a3">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>nateglinide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N60f9d6bff0404d66ac72d662f010ea3b">
    <domeo:sets rdf:resource="urn:pddi:uuid:7D3E5D57-6320-472F-84BB-62CEE19998B8"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/DE4FE060-7A3C-4588-89BB-26F6E263C48A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28929f5f-f73d-432a-861d-66ff4bf69938">
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:prefix>nsporter 3 (OAT3) substrates   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>8d2944d2-a6ad-400b-b113-1d11c950c38e</domeo:uuid>
    <pav:createdOn>2015-08-20 11:48:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:b22b6f7d-505c-428b-acee-f7cff362cd66">
    <ao:prefix>h alcohol, alprazolam, ibuprofen, olanzapine, risperidone, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:b22b6f7d-505c-428b-acee-f7cff362cd66"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:suffix>, and CYP3A4 inhibitors </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>levothyroxine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-26 15:38:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd9ece3cc235a43249e1207bfefc8f700">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N596ca3d30dda4797a56a38185c808664">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc38d3fbae3884d9d9d80f34f876ec9e5">
    <domeo:sets rdf:resource="urn:pddi:uuid:C78A8ECB-1399-4158-99A5-5E93F9EB7017"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/EC9D8D54-AB19-4B5C-86B4-19D8632C801D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ibuprofen</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>800</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N00c7548e4f6044149c37a7084d45e3d5">
    <domeo:sets rdf:resource="urn:pddi:uuid:DADEE818-5ED6-4AD0-93F8-799155FC800F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:db610a3b-8c92-4dd6-9845-0adcd71a02bc">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:efea82a6-b569-4370-ba71-b2c719f663fd"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1e6cdf182b4e4e4586115fd1433e01dc">
    <domeo:sets rdf:resource="urn:pddi:uuid:5bef8cca-4e04-4588-849a-05c9ecfcd296"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:134C2AAB-D297-4C7E-AE41-B8A7974D416A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9F8726B0-BF39-463C-8B26-E35738412523"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F666D039-B2BC-41A3-92C2-B30B9C539E10"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N81bafe2755a4405e9d7a442b15c56f8e">
    <domeo:sets rdf:resource="urn:pddi:uuid:B6F85A79-E96B-4EB0-9429-1D4BECC50EA9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1dab71a4847a48f8bc256022d441f1c5">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Naec944118ea849139012c807b28b680a">
    <domeo:sets rdf:resource="urn:pddi:uuid:E9CEF418-2F94-436C-B0D1-F12774A00594"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N814872f8739846c99fc9aea6db6ff249">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/9e2218dc-96d7-4ace-82cd-84e4ae0ddb84">
    <rdfs:label>carbamazepine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8df554ddbae24f9182f84b3b678542f9">
    <domeo:sets rdf:resource="urn:pddi:uuid:282D5FA7-46D5-4E29-B860-F26CDA0287B5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0219573b-2527-4ff9-919a-b584b661e03d">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CEE664C1-0267-4B81-ABD4-45D4BB28003A">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> exposures but decrease </ao:prefix>
    <ao:suffix>exposure. Based on clinical response, dosage adjustment of </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:exact>hydroxybupropion </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-05 15:23:48 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CEE664C1-0267-4B81-ABD4-45D4BB28003A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/308EB9CE-FD35-4833-BFF0-1DB889EA32ED">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>SSRIs</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a3c29e6c-e18e-4564-ab8b-cf321b71fc0f">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>GILENYA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ff960fd6-5402-4161-9d61-a498d7eb8919">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>penicillin G</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N468ea03a7e4246e7850ff0968450d81c">
    <domeo:sets rdf:resource="urn:pddi:uuid:117EBBD8-31C6-42CF-9294-03F319F4CED9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4a1078876bdd44078a6fc1b7b8aeba3c">
    <domeo:sets rdf:resource="urn:pddi:uuid:3bece2ee-1606-4773-ab43-be186f7c6af8"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0EDDA661-7FEA-49EA-85DB-C28A8536B926">
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4450083cf6d249c2b85fbeb1d526bbf1">
    <domeo:sets rdf:resource="urn:pddi:uuid:F1C06564-7501-4B10-9C1C-0FBD52688BF0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0B146568-3326-4771-B5D1-7F61850DF044">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:10F1508B-6C37-4762-AFD2-E4F3D7F43D56"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2E74FDBE-8981-4DF5-8EB6-F7752BC50EDE">
    <ao:prefix>and </ao:prefix>
    <ao:suffix>). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2E74FDBE-8981-4DF5-8EB6-F7752BC50EDE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>flecainide</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-11-04 14:17:30 -0500</pav:createdOn>
    <domeo:uuid>2E74FDBE-8981-4DF5-8EB6-F7752BC50EDE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1DB0610E-CF8B-4569-93EA-7477B040E50C">
    <rdfs:label>Bupropion</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/e356a273-ecfe-4063-8cd7-a1bf84eba699">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>abiraterone acetate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:489e313f-80bc-4a67-8034-1d4f1a64447f">
    <pav:createdOn>2015-09-30 10:48:18 -0400</pav:createdOn>
    <ao:exact>Warfarin-Steady-state milnacipran (200 mg/day) did not affect the pharmacokinetics of R-warfarin and S-warfarin or the pharmacodynamics (as assessed by measurement of prothrombin INR) of a single dose of 25 mg warfarin. The pharmacokinetics of Savella were not altered by warfarin. </ao:exact>
    <ao:prefix>pran and 150 mg pregabalin .  </ao:prefix>
    <domeo:uuid>1ac9d20c-87dd-44c9-bc89-4daaa0bf9d39</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/b88a1901-1f1c-4c3d-bd85-6d464ec19318">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>quinidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CF9F4140-CD46-4309-BA07-1C6997E1970C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>1</dikbD2R:dose>
    <rdfs:label>digoxin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4665c72c9c2a41d3b9eac9a151b6a31a">
    <domeo:sets rdf:resource="urn:pddi:uuid:797348f1-fe91-4734-a141-f27afd4297cc"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:568fb98f-defd-45b4-ba2c-28d6c684a89d">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:b71ce947-8d34-4274-9b24-88b6beeb1087"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid>4043d1fb-dfc4-402d-bd09-afb378031894</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/674458CE-98E3-4A90-BCE8-41C6A57D4D92">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A5684B54-632D-4E00-AF80-C1D2B64C4C20">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8E47204D-80A0-4FE9-84A1-16952758C48E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2C9FD0B6-543A-4B22-9EA3-2C3006409323"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:79A0AA33-EE91-47D1-96A1-777A4F572DEE">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5485E5A6-69C2-4AEA-910B-C538C897751B"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc8440fe5041e47489d7fa695ae38215b">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N71e3a3107337424194c092e740b3d754">
    <domeo:sets rdf:resource="urn:pddi:uuid:C7313B66-D386-4849-9106-66CA54D79F51"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4FD5C8B8-AC43-454D-B3B9-2736A012C8D5">
    <ao:exact>The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-27 14:27:01 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4FD5C8B8-AC43-454D-B3B9-2736A012C8D5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c975267b-9c1c-4559-b181-cffb551cb3ad">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N74c622ac32b34e14b27c46b9a5210b2a">
    <domeo:sets rdf:resource="urn:pddi:uuid:55925b47-e19a-44c4-99f2-239e4ff2d350"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2DC71D50-4C88-4128-9ECC-9BD222F6774F">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A5E72FC8-7711-4048-8268-94FBC922E11C"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A10CC62D-2800-4377-BA3D-DD2DB74860E6">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6B995E87-B595-4D63-864A-1C30ED34871F"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5B46C7ED-6836-406F-A6D9-751B1978C0FD">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A79D07F1-6CB3-49A7-BEAE-EB64560B7489"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A3B462E7-B917-45CC-B2EC-A1210E0157DF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N78a2bc4c03074f65a7f52259ab6ab63e">
    <domeo:sets rdf:resource="urn:pddi:uuid:72286BB9-C578-41EC-9E0D-082D5E24ABF7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9637eac75df5456080cd0cdc9c8807b4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc78546dc81de40b9923d2f73996718e6">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N19e0e561c1ec4bd08f66431936a74b76">
    <domeo:sets rdf:resource="urn:pddi:uuid:0635e739-6428-4457-82be-4635179c1bd2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/A30AC5C4-04EA-45C7-8434-43F16C34D5AE">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf7df831bd5d54f8cba8857953b70e0f3">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N03c9830a683040078f2c54fb507eca7f">
    <domeo:sets rdf:resource="urn:pddi:uuid:6f19e658-ea51-4218-867d-510be8488d55"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N285b7b2a03c84e059069cf819cd696b0">
    <domeo:sets rdf:resource="urn:pddi:uuid:FF9FAB48-B7CC-4336-BC42-98DF58C7B9F4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:59095377-F278-432C-B985-6B6073682DF4">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B35F575C-C858-4647-A75D-FFDF26747A6B"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8acc5a83eb90474ab2884bca10d3cdfb">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5ec1457a1cd5438aa56c1d2a22370571">
    <domeo:sets rdf:resource="urn:pddi:uuid:ed9ceac0-aa4f-468a-bb91-dc1bf56eafaf"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6051a8f6-3f18-4805-9613-42cf7bdd7281">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <ao:prefix>e in plasma AUC of the TCA ).  </ao:prefix>
    <domeo:uuid>363b6942-8ec9-485b-aa3b-afa26c5732b8</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf662a8d6686e44429496fa17c9bf9a3f">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/38D9ACB3-AC18-42A2-A53A-645AB9778C39">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>ketoconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:210AF33D-6FDB-4675-8B59-F063C650552F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F1853878-BDBE-4B7D-8FDC-AF4735DFD6F7"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B5AF7BA9-ED99-473A-A4A6-3C92A9FA2DCD"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B7AFB92A-6B48-45B0-BBFD-BC3E46B0F6B2">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/B03726DF-56F0-4ABD-B1DA-C6D74529E8B8">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2626</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>clozapine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:921a39a2-e272-4660-b6df-5918a6c6640f">
    <domeo:uuid>f99b3743-135b-4ff7-873f-7756eb1f1d19</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:237cf9f5-88ab-44e9-9e36-97a9da921b21"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Naaa049861b0d426cbe187bf4d464ddf9">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nafc204628c94429ea67b897e60270bc9">
    <domeo:sets rdf:resource="urn:pddi:uuid:DBCEDCD5-A254-43DE-8DC5-B44A167B0411"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/06C3D4BE-D638-4476-B823-ADD0020C5254">
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc1b9957a777b4c068c3dcc99dcca4815">
    <domeo:sets rdf:resource="urn:pddi:uuid:C9510408-CB6F-4DF4-8397-9CC1702F1F95"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cab786e7-6ea7-4af3-ab1e-69f45d16aeda">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <ao:prefix>stered with lithium.  Digoxin  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The steady-state pharmacokinetics of paroxetine was not altered when administered with digoxin at steady state. Mean digoxin AUC at steady state decreased by 15% in the presence of paroxetine. Since there is little clinical experience, the concurrent administration of paroxetine and digoxin should be undertaken with caution.</ao:exact>
    <domeo:uuid>8cff8471-2785-49b4-aa0d-a0fc9ac2022c</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44C6879D-DCFD-4556-AC6A-3D341BE774C2">
    <domeo:belongsToSet>urn:domeoserver:annotationset:B1566331-198A-449E-8B2B-48A4DBC53912</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:51946AF2-3A64-4436-A921-46849FF1FA53</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:c0077542-8664-4a3f-9384-f8ea320c3cd1</pav:lineageUri>
    <pav:lastSavedOn>2015-10-27 15:32:38 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2015-10-27 15:31:42 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2169AC62-7C62-46B8-BB47-83542CBEC579"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/13CF2FF2-163D-401F-824E-E1B3B4AF9DAB">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>propafenone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/72EAB02E-B97A-43B0-AC73-B67740393484">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>600</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/195085</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>efavirenz</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C105085-6A08-4692-BFB3-86F0EB8E5221">
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoclient:uuid:9540ed61-ff6a-4399-86bc-04d7b87b26df</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E536FE66-FAD0-488D-B7C0-39E59CBD9678</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:9C4ED5DD-C4A4-4733-A69E-E8EC8227439E"/>
    <pav:createdOn>2015-10-29 10:40:57 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N5bde621e6eba4c2480d3a43e43847bb9"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:e5208d0d-d470-424b-a0e0-4a4b5da16c0e</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-29 10:41:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/45737D8F-9B92-45BB-8734-810D48E4BF13">
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N65b7f2dffe4e45b996f70bb47f103a6d">
    <domeo:sets rdf:resource="urn:pddi:uuid:17EBA8A8-8840-4D08-9FC0-185819CC6057"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N22f0ccda4ac14e59970d565e517963c0">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncfd3ce4810714b3ca900ef31c1be90ec">
    <domeo:sets rdf:resource="urn:pddi:uuid:984127CA-0CB4-4B98-A0D7-CAE7C8419D3B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N89b4b8d5898146d1ab7cace2a8bb59e7">
    <domeo:sets rdf:resource="urn:pddi:uuid:B60B1821-70C7-4161-8D8A-05E098C24A66"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nad593040d09b42ce8085b6a9753aa566">
    <domeo:sets rdf:resource="urn:pddi:uuid:8d3abe04-eda4-4bbe-846f-fece83622e9e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31b265c2-9183-41fb-9ed6-5c8ea005caeb">
    <domeo:uuid>44398ec5-881d-47d1-b1ff-0f21f79d7be5</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:09c3ee91-860e-4519-8b88-ae31fdc32411"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60E6AF24-633B-4B2D-AB30-F8D39266FFF9">
    <ao:prefix>Clinical Pharmacology (12.3) ].   Inducers of CYP2B6    </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Ritonavir, Lopinavir, and Efavirenz: Concomitant treatment with these drugs can decrease bupropion and hydroxybupropion exposure. Dosage increase of WELLBUTRIN XL may be necessary when coadministered with ritonavir, lopinavir, or efavirenz but should not exceed the maximum recommended dose [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <pav:createdOn>2015-11-05 15:26:12 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60E6AF24-633B-4B2D-AB30-F8D39266FFF9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2e301c2554734f9bb9b295708e6868ac">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:635588D6-9C7D-4195-8C4E-ABA04FEA0EFD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-27 14:25:24 -0400</pav:createdOn>
    <ao:exact>triazolam</ao:exact>
    <ao:prefix>, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxam</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:635588D6-9C7D-4195-8C4E-ABA04FEA0EFD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29052478-1e9e-4a2c-a69a-ebe021bd96dc">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ceec9eb4-2ea5-4a45-853a-38ea62a3f3df"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid>a08f3350-2b06-4284-a1b7-c66693f9d921</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/24f844a1-6502-4f0e-b6bb-ad80c37fa5f5">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb6317273cddb4abc9e04e6daa2da1be3">
    <domeo:sets rdf:resource="urn:pddi:uuid:1CB379D5-79F4-4179-AA0D-1701504B2A62"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N469c940447af46fb9100cacd84a9a990">
    <domeo:sets rdf:resource="urn:pddi:uuid:B9492B68-46B5-4579-BA43-39D076003F44"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ba54870f-5671-4871-9f7f-2d61f6428e95">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:cdb6d72e-1c0e-4075-b2ab-3d94eb2671fe"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DDDDBB73-607B-46A9-9E52-5E90A4B66B54">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:AE0302EF-5DA6-47FB-A9B4-B477BC2576DF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-11-05 10:40:12 -0500</pav:lastSavedOn>
    <pav:createdOn>2015-11-05 10:36:37 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0F7D20CD-DA6C-4E21-BE68-4843C96E2BFD"/>
    <pav:lineageUri>urn:domeoserver:annotation:330E1C91-9AC3-4BCF-8C62-9137A2A9E162</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8537060f09cf4958a04efef64306c751">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EF175995-1661-48C6-9686-0AF7B66E0265">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5A698259-814F-45CB-89DA-7D2481C5ED38"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/67FEB7DB-D850-4529-9945-70CC52DB7464">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/327478b0-d1e3-4a28-a87a-88fa1bf94c2c">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7a7862df0f294b7e8a391156c45d40ac">
    <domeo:sets rdf:resource="urn:pddi:uuid:C0520662-711F-4CC7-8F7E-AEA5F91D4129"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/067048C1-38D6-496D-AA4F-0F426A977ED3">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>threohydrobupropion</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F666D039-B2BC-41A3-92C2-B30B9C539E10">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <rdfs:label>pimozide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2f231972897345ef96448bb49cd718f0">
    <domeo:sets rdf:resource="urn:pddi:uuid:f8b46576-0492-4941-ac45-c6e0967e9aab"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5899D320-080D-4D20-BB6C-D1E916CFAED3">
    <rdfs:label>temazepam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:234DC7BA-C3E1-4BB2-B8A8-FB356E25ACD0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DE4FE060-7A3C-4588-89BB-26F6E263C48A"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2336E9E9-4E7E-406A-BCA9-6D8C7B525312"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7074413E-49C3-4358-83D4-10D958ACE242">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>160</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <rdfs:label>propranolol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:265b7456-47bb-4f0d-913f-88d64a1e8dac">
    <domeo:uuid>b97f1d7a-5b64-40ab-985c-c41151b1ccb1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:911c8c76-df70-4633-9e30-54d1cb5fd738"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D9BAB021-461D-4B75-9894-5A04DF941246">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C7AD6DC1-3160-45B1-AB05-72F7BC8BE3AC"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1994900A-B5A8-43AE-AC05-26F7BCC635D2">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>hydroxybupropion</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6131c5bb76d74a858199c240f9088f00">
    <domeo:sets rdf:resource="urn:pddi:uuid:0E61F9F6-7606-43B0-9CF5-1CA0AEF0F5BC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5730b3de2de149dba8b3f4454efc18c9">
    <domeo:sets rdf:resource="urn:pddi:uuid:d96e0074-fa19-4c26-a4c6-1364dc9cb7db"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE257385-3E77-46DF-BCC6-0EDDE829CEDB">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CE257385-3E77-46DF-BCC6-0EDDE829CEDB"/>
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
    <pav:createdOn>2015-11-05 15:32:57 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/28A70C92-10BC-4703-B5EE-7C79DF903895">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2fd4e260ea5846cbbeb496ad14292538">
    <domeo:sets rdf:resource="urn:pddi:uuid:768AA5C0-0BAE-4E02-BB05-5AD320E6CE2E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne071d34994d04e8ca00bf0952ec4a111">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3ec2f1bd2e05407692526475195d506e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0A946F22-D8F8-493C-B29D-C4EFBADA668E">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/94EBF2EB-203F-4B2F-A505-0DADC1E2ABD5"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3D26B95B-42F0-4F28-B170-105D26BAB680"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2CBB9425-767E-4B80-A5A2-4AFFF6B51E32">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FB4F777E-6B0A-4E09-B405-345E42287E2A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EA885D76-4BD2-4B6C-BA56-3FD9FDF04AF0"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/42332AFF-D0BD-48D0-8A45-35ED498726A3"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1b70b199-edfa-45fd-a312-3071337014ff">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:f8d54d99-de19-49e9-9115-0d8648dc3711"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>83cae0c2-9128-4cb5-9d8b-51213252c0e1</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B23E7E12-1788-466D-BC31-88B8498C9BAB">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/49FAE029-FF46-450D-9D53-75B50F07AF26"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C7369983-9A06-4116-B9CF-E3E15963FAB2"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc703ddcf0a1d40e192a3051b80d68d69">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/a45668a1-b6c5-473d-a009-224f231f296a">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/8edb70a4-6cf4-492c-a86e-29979a22dd2b">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>cefaclor</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N002da491a7344605b48ce8dfc624270b">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:047fd431-9efb-4389-81e7-c44d49f139bf">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1a4308f1-a43c-4734-ad4f-8f9f8df487a7"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9B94296E-EBC9-4F0F-ADCC-C38DBBC00081">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/C1F11156-06DB-4E7D-8317-BCE6953056B5"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/16C1D983-B421-4EF7-B6E0-1EFABDE742FB"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C915451-1E49-4771-9D34-C76B114586B9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b8881a81-75d7-43e8-825f-37c352c146dc.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2C915451-1E49-4771-9D34-C76B114586B9"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics, propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquine hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called “poor metabolizers”); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <pav:createdOn>2015-11-04 14:18:50 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>2C915451-1E49-4771-9D34-C76B114586B9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N516978d717d444368b8c4ffa2236331a">
    <domeo:sets rdf:resource="urn:pddi:uuid:5EAB7375-4962-4C30-9BE9-00753E5211EF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d159fc10-9d1a-4f5b-9fcb-e81b8b5d6cb9">
    <domeo:uuid>ea6fb331-9f50-4941-8c45-b6da6e07c077</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5eac8ca0-0caa-4082-b77c-2f13c8df1e24"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50f78647-e11a-4479-9ac1-303a4b2087a1">
    <domeo:uuid>906118f2-d9cd-438c-8324-7bff275e28df</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6e7e82fa-aca0-417d-9717-a0e52fd9a692"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N58b9e38ba3cf425bb01f00407e658ac5">
    <domeo:sets rdf:resource="urn:pddi:uuid:47f792a4-3574-47b3-87f0-3afce847ac85"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbaf2af59fa1d456da0cab9e86413c6fd">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c8400279-aa48-4d41-ad9d-f8b015557c4a">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:802c72ff-26a5-4169-a681-8cbc0bc8f37c"/>
    <domeo:uuid>45e3f9f9-77a6-4578-baa4-16086ecb86f4</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/2adcf075-88d1-4e1e-be30-692e51ca7594">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>theophylline</rdfs:label>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:04C26A1A-97DB-4615-B900-85384281BA4D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:86E395CA-D3A4-45D4-94DE-A2157366C7CF"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndceb556106c64968866aefb393b66ab4">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndedb8254d77e4045b1aa4e12adaebd16">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6644edfc716444cf92b0f44be5efbbde">
    <domeo:sets rdf:resource="urn:pddi:uuid:A13F1E79-D47B-4217-BA0E-25F026EA4893"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N40c21c2d44c6404fb52b4879c762558b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N048484f8d3554b18a64da0816e43c3dd">
    <domeo:sets rdf:resource="urn:pddi:uuid:57F2D7E5-0713-4D70-8981-11D8D44961B2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6d0e1cb7-0734-4510-9b43-030f6511d239">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ace8823f-9600-451d-8810-5bc17e3898ff"/>
    <domeo:uuid>41227169-300a-446b-9c19-06242d0b472b</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:52163f37-15af-4a25-ad7f-6d0a6cea1dee">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:886f785e-465a-4038-96d5-14ca200025bb"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4BF6E489-3D75-4997-BF08-6C6C2C5B6A6C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4BF6E489-3D75-4997-BF08-6C6C2C5B6A6C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4BF6E489-3D75-4997-BF08-6C6C2C5B6A6C</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-29 10:45:56 -0400</pav:createdOn>
    <ao:exact>In an in vivo interaction study in healthy, CYP2D6 extensive metabolizer patients (n=24), mirtazapine (30 mg/day), at steady state, did not cause relevant changes in the pharmacokinetics of steady state paroxetine (40 mg/day), a CYP2D6 inhibitor.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:prefix>  Paroxetine  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N63b060470c5e4100b54b058df3f1c1fd">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N99f72856379f4e0393576aa01c0ccadf">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N056a30600a58470692566ede3b8a1347">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DBCEDCD5-A254-43DE-8DC5-B44A167B0411">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F9C6704F-2CAF-4609-9BDF-A4D3412C59C1"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:976cdd5d-18aa-4141-81b5-bf0992087b29">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 10:29:59 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>d07b8633-83eb-44a2-92d8-b8855bdc6f7d</domeo:uuid>
    <ao:exact>In vitro studies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Clinical studies have shown that with co-administration of bicalutamide, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5 fold (for Cmax) and 1.9 fold (for AUC). Hence, caution should be exercised when bicalutamide is co-administered with CYP 3A4 substrates.</ao:exact>
    <ao:prefix>de induces hepatic enzymes .   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N104cefc2303c4ef8a8e6b4f3e1132707">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N45074c9cb3404948a004a5bf5492fcc7">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0C34953F-CA44-4A9D-9EEB-DCBF7B47451B">
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1225b190-04ff-40da-83f8-bd8bdde53e80">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/143887BF-B919-4260-9BC5-5766DCA4B2DF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4dcaa86a6aed468aaeb652ffd5b5636b">
    <domeo:sets rdf:resource="urn:pddi:uuid:1853035A-F02E-4842-88EF-299E4A98D1BB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nda7196d78a9c4bc2ab5e3d5e9e26dbfb">
    <domeo:sets rdf:resource="urn:pddi:uuid:4a820e80-98f5-47e8-805a-05a2d56144eb"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/CEC5548E-5026-40AF-878A-42713C83EBE5">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>duloxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6731199D-9FB9-4198-84D9-5D38E5F07852">
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6918</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>metoprolol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cd52caae-4616-4a13-b493-619eb9b2ae66">
    <domeo:uuid>4aec78da-a077-44f3-8823-1d11cf820b98</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60df948a-7f0a-4da9-8a9c-06ebbdcdeef1"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B7CF70E3-93F1-48B4-981E-C4F878BE2FC4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/54E57302-AD8E-4E3A-9D0B-891498EB3B0F"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F73E5222-4E9B-466F-AE72-6BC5A904602E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0f24a2a6-d6b9-4748-8808-84e3965ec948">
    <rdfs:label>flecainide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/79A65627-1326-4D52-B5FE-EA6544D88DEF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>citalopram</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/164b68d7-1779-4c96-8064-368dc9c29860">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>Savella</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>0.2</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N564385dc1d3844d58d10cb1d9b756de6">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/4C80BE51-7CFC-43DC-B631-77858E0C5FD1">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>6</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N92cee00c9bc14e8c86a7160f407c3ca5">
    <domeo:sets rdf:resource="urn:pddi:uuid:F449E4D0-4FF1-4773-831C-91720A096041"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nad84ba9123f744db87a90f554e1b1f4c">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb18536bda7044bfba216522ae2e30903">
    <domeo:sets rdf:resource="urn:pddi:uuid:07A9F2C3-511F-469E-9269-D2FB39A88DA4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EF13BCCC-8CEF-4F34-9747-DA64D027808D">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/545D9FE6-7375-49C8-9F07-E725F85323D9"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2D19A517-9A79-4ADB-96C2-2274ACAD845F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/16C1D983-B421-4EF7-B6E0-1EFABDE742FB">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:f0482d26-50c2-4df9-ba8c-2e88b38f52ac">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2b9411d8-433e-45c5-aa92-d202b86010f5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0B5625A0-AC19-4325-BB37-765EA2A0C1BB">
    <dikbD2R:dose>20</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>escitalopram</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/953D7047-4DE9-452C-A4E6-93FAD792F9A1">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>quinidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/31179A14-9FD9-41FA-BEDD-35E216221BF2">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Ticlopidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/44FB8388-EB10-45BA-B444-97ADD318152E">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <rdfs:label>warfarin</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf89410b6c01d4a06ac1ae3dd698ab92d">
    <domeo:sets rdf:resource="urn:pddi:uuid:9f8dd0ca-3146-4f14-ac93-c37a3ff9bedd"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N510960d1003a4032afee1471e786d41d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8258063cb08444a1a48f8960de18ab57">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:29F65489-914C-4712-947C-75C96191EC88">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AE2C2648-255D-4D0C-AFBE-6D9DA62FA280"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6731199D-9FB9-4198-84D9-5D38E5F07852"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0eb6bf99df3744558965130dab64fead">
    <domeo:sets rdf:resource="urn:pddi:uuid:71d159cd-b93e-406a-a11e-3b921f522c38"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/36943F0B-A812-450B-A290-01BFDE8A84E1">
    <rdfs:label>alprazolam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a89b5f29-8f9b-459c-bdd3-bf954bedc2b7">
    <ao:prefix> not evaluated.  Procyclidine  </ao:prefix>
    <ao:exact>Daily oral dosing of paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.</ao:exact>
    <domeo:uuid>b91b99cf-592b-42d5-92eb-38579946d6d8</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-14 11:31:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0dc62955792d4ac6b4ec09c6f2fee4b3">
    <domeo:sets rdf:resource="urn:pddi:uuid:b9906588-d389-4c18-9332-839631e7d449"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CAB4D4AF-498C-485C-BD7F-C6380F109104">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BD5CCED2-9DB5-43CB-91D2-70C1F14C2F94"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/89DD806C-4753-49A5-9436-5CD201BABD13">
    <rdfs:label>pimozide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>2</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:d71c4e94-ad3d-4a13-a0fd-02e2bafb1609">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1070f69c-4312-43c3-976f-19b5273730fc"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:001cfa14-7746-4bf4-a4df-51a6bcf45623">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:82eabc7f-6719-4d94-a21e-0e66d6e821f6"/>
    <domeo:uuid>80b5ada7-21fe-4b35-a109-1119bf0457f8</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5f356c1b-96bd-4ef1-960c-91cf4905e6b1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EB346943-C7DC-4644-A6CF-19C93F13EB74">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:40B0D50E-C95A-45AE-BAE6-48AD5B4FD227"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nabbe1c3cb7544a49b30fb475f2a73d81">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N06fe751661bf49efa2162830f171dea4">
    <domeo:sets rdf:resource="urn:pddi:uuid:C66A1029-7FFF-488D-821A-8DFADB963EC7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9556fc22f69748538b85183633850df1">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0d88c68dec3f46edb392932a125a20dd">
    <domeo:sets rdf:resource="urn:pddi:uuid:c6705b1c-536a-4b74-b0bc-baa51b656893"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N978d28361c034d41b40fe3ca313ea5de">
    <domeo:sets rdf:resource="urn:pddi:uuid:DC2DECCB-4106-41B8-BC69-0B6293479A57"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B476F7CB-5A5D-4D10-9EE4-AB261781CD6F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3A0C0832-3B1E-4FCC-AAD8-85FE87C1CE2A"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A39DFE91-A153-456A-B7C1-626760ECE97C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5A96DB80-3720-434E-BB84-E5C1259F8E30">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/195088</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>400</dikbD2R:dose>
    <rdfs:label>lopinavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N48438963fcd5483482caf474466b0a33">
    <domeo:sets rdf:resource="urn:pddi:uuid:f25b8b83-c2e9-4559-b69b-835d8d0353ce"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f35af00d-cafb-44b9-8572-21c6050caebb">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>6b2c09e6-e88b-4f61-bd0c-804c415b0c80</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>e in plasma AUC of the TCA ).  </ao:prefix>
    <pav:createdOn>2015-09-29 09:04:36 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7f0b5c67-bd0c-46a0-9b6e-ad316b8e92d1">
    <domeo:uuid>b8a6760d-d83a-4821-bfbd-cbaba19e110a</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:88b3ad51-3f1a-4fc4-8966-47a8afcbdbac"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nffa912ecf92047bcb20df52d81331d2b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N53cc8e39f84a4d6b8e05d650cdffe1be">
    <domeo:sets rdf:resource="urn:pddi:uuid:658759a9-ad95-4625-a301-32e6eff69f3e"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1858e331cb8a42fc9ef3e20e73d5adeb">
    <domeo:sets rdf:resource="urn:pddi:uuid:9451b51c-2999-4a34-a5ef-c3209184b445"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/670556ED-C98D-4F3D-913F-976D299D8558">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluoxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82327B05-8BB1-401E-ACB4-42C3E0930D57">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/5EF69470-676F-49C0-B1D0-92CDB64557E1">
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>midazolam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1F973256-10FE-4D92-88DD-E736959600A8">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ketoconazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/61B4EC1F-599A-46BB-8998-D5818426F08A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2e93559a911e4112a8bb491c26aa072a">
    <domeo:sets rdf:resource="urn:pddi:uuid:86F3052D-4E9B-4131-ABE3-6D49778F2626"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc5c454eda46a490788066cf3a88eea6a">
    <domeo:sets rdf:resource="urn:pddi:uuid:f6db2bd1-0d97-4aff-a1d8-0cc44d9c8de9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N00340cfc6deb4fa787ba7ec5d53e7493">
    <domeo:sets rdf:resource="urn:pddi:uuid:081F5CF2-9965-440E-8A1B-211D4F016DE5"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N57326080ba534031ad912f6323ad9950">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2ac723cc-6808-4d41-b5f9-cc3cc46518eb">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:fb8b0b2b-98ef-4a08-b53a-06a872764fb2"/>
    <domeo:uuid>2dc1785a-5093-4806-90df-e0884a4ccf82</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N952c12fe9c6d47eb95f8a19bfc9f5be9">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N64a7641b57744023802b9c690965c836">
    <domeo:sets rdf:resource="urn:pddi:uuid:b779faef-df5f-48f7-a92d-85d1f7d1c229"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc112c15489b846e68d11534136c55d64">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:78823B07-A365-4BD6-B202-E748D9BAE895">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E4B9534E-CFF7-46D9-9DC7-64B103E1F707"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6D97B8BF-C394-487E-8DC7-22CE43D6D0A8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N83b01053b2be4c13bb3b67da95edfae5">
    <domeo:sets rdf:resource="urn:pddi:uuid:f94f5167-d4a0-4e21-b820-4b68755fd8c3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfaa7bdf488994ca491ebffdcbf4e08aa">
    <domeo:sets rdf:resource="urn:pddi:uuid:2c422209-2ed2-4014-86c7-8d636047e6cf"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd66a67d010494112a88c429fdbecf20a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne53b2f6ceaf84b638976dff49490419f">
    <domeo:sets rdf:resource="urn:pddi:uuid:D286A199-D548-4EA2-BDFD-6462391E4C3E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N84bd46df63054c3890384269efcb9322">
    <domeo:sets rdf:resource="urn:pddi:uuid:9F6C40C3-8C70-4AEC-A98F-0456CFB6A3CC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3F5FD123-51D0-4172-BE56-5A4E04C2DDAF">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F24F8191-01EA-46A1-8C86-964ABEA6FD62"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6F39CF04-EDDD-4BB3-AF7D-4206DCB8A57D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N57393de735c94d778cf95a3ce8f6c54b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5e6e3ad7d40d439e827fd855e6c4def4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0e04d177b84f4173996dc8fe67ac3ea1">
    <domeo:sets rdf:resource="urn:pddi:uuid:173F3E1B-30B8-4F52-ABA4-E3A7D2154165"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N358a4da1ec5c477fa746ed54630db5bc">
    <domeo:sets rdf:resource="urn:pddi:uuid:A4B14B16-BBE1-43DF-8844-DEDE2AB4BCE6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N355bd01d424d40eab8a9ef75ce496514">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2624a815236a4ce898ad3239fe41a528">
    <domeo:sets rdf:resource="urn:pddi:uuid:F4DBB50A-6647-4865-A95B-10B0A4931874"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0bda6c60c50f47329667a3cce1be1846">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf6d2b06db14344e5b51f3ef4b6fc402e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne4f245178cc04a5ba1ab5672510aa12d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F5DD2146-50E8-4086-AE46-22F41E301BA2">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35255</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cisapride</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c0cde7aa-afe2-4cc0-af07-6e36636bf5fe">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5e54d95b-9341-4626-b3f8-db9f5ae9c872"/>
    <domeo:uuid>c4dedde5-d1e0-4be3-abd5-2241a23dfa04</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D286A199-D548-4EA2-BDFD-6462391E4C3E">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EF842FDA-C3C3-42A3-81E1-52FB58664270"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1afc9d8d36434d17a70d46a59b275e0d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N49c693d2402e422cbc6e68d4a81c50c7">
    <domeo:sets rdf:resource="urn:pddi:uuid:43407a0b-4ca1-4a6d-b8eb-8a1c4c7063c7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08048a70-583b-484e-81be-249f0d6501ea">
    <domeo:uuid>35013a52-5407-4a73-966a-5eba4d86460c</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:cb595e91-e1ba-4a6d-83a9-d86fa5159961"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DDF6D10-A992-43D4-B1C2-B010E34F248F">
    <pav:createdOn>2014-02-19 12:41:37 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>5DDF6D10-A992-43D4-B1C2-B010E34F248F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>CYP2C19 inhibitors (e.g., omeprazole): Avoid concomitant use.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5DDF6D10-A992-43D4-B1C2-B010E34F248F"/>
    <ao:suffix> (</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd2fd913ad08844deae0ba8d8acde146c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne8f085d1e0d64a26bea046e8f473063e">
    <domeo:sets rdf:resource="urn:pddi:uuid:95b5bfdc-254f-4c68-b54e-154ba8381f72"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/706cbff6-f390-42f8-bced-260da4c97b0d">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9d22559f9af24123b36581f86468ac35">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndc455bb8053041a19de67dadd5a81269">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BF7C2588-F959-4507-977C-39534E1C4B20">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>FETZIMA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/ED1ECE0A-8DC6-4002-A8CF-9A4FF9FCE144">
    <rdfs:label>sertraline</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbc4cccc1f9ba491fbb3e4c156ade38aa">
    <domeo:sets rdf:resource="urn:pddi:uuid:3B605ED7-ED2C-42CA-A09F-72F733E903FB"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/07123443-a81b-413e-b452-e7ba1f23118b">
    <rdfs:label>GILENYA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N73c4850a50e840a8b0efea697b817036">
    <domeo:sets rdf:resource="urn:pddi:uuid:428EF2EE-2046-4420-B6C8-770A69774BCC"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0296FD38-BFFA-4717-A31D-39B58851381F">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6B995E87-B595-4D63-864A-1C30ED34871F">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/89FE148C-2544-4A1A-902C-C8BFB3B83E7B"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/56732509-4459-4720-B96F-F9295339AE68"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N88ebd42f3b4b4719a75f10c80909ed03">
    <domeo:sets rdf:resource="urn:pddi:uuid:C1BB8811-15F0-4F9B-8B92-3EE3BA1894C0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:76e3b1f9-718c-4c56-9e0d-a1eeb616ca47">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:f9994c9a-4b18-4dc5-9126-0e31b5557f1c"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9dd33e09295b4fc0833e075472f29486">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9238a5e772344fe5b1f763f2fe993981">
    <domeo:sets rdf:resource="urn:pddi:uuid:BFD8459A-1C50-400C-97DB-A01261990570"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fad6e7e0-c08e-477b-8e71-582238a31dd6">
    <ao:exact>A multiple-dose study has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate. However, due to the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with lithium.</ao:exact>
    <pav:createdOn>2015-09-14 11:21:10 -0400</pav:createdOn>
    <ao:prefix> taking paroxetine .  Lithium  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>3dbb5461-59a6-41e1-a936-32df31ac017a</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0eb973480fb445aba9f858d7752941da">
    <domeo:sets rdf:resource="urn:pddi:uuid:AC8BA089-5DA6-48A8-A88A-2C36A10CBF4E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne0e8ad4e24624572920410388ca26243">
    <domeo:sets rdf:resource="urn:pddi:uuid:76e3b1f9-718c-4c56-9e0d-a1eeb616ca47"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2b8ecde475d140179d86f9b6ffdc8d9a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5D913B04-728A-4AD5-9E06-2F8E75D1E7BC">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A9C994B2-F31B-45D3-B1DA-4DAACBB89426"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N82aaca76a6e848449b90615b04a41a34">
    <domeo:sets rdf:resource="urn:pddi:uuid:01ED7DD5-1FD9-4832-8008-51570F2C9D7C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:14B3F0E3-FD35-4859-BB56-B367505D9BBD">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FC1EF1C1-AEC1-422A-AFBD-214CAA420520"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2938a4d28b8442f2b32f2c0c4d9b6005">
    <domeo:sets rdf:resource="urn:pddi:uuid:390020D0-6B01-4EAF-8412-B59F7E16B5BF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd0bf591ee26f47f0bade9a2a7ba13c7f">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6eab6e0e4224460da1873f137792a695">
    <domeo:sets rdf:resource="urn:pddi:uuid:48fb298a-d361-44ad-b56d-1a80cc626456"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Naa76528543764fc290e2d3ecd2b1aac9">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6610A0B6-E6CC-4C1F-B588-4DDDF4CFDEF8">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4fdb0b8893a74b38874d96f70126457d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/1E25CA12-3785-4031-BDF4-E5E083AE41F3">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85248</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alosetron</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>1</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6f8a521f-d07f-4d6a-9332-cc6ba6ebbc4d">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.</ao:exact>
    <ao:prefix> be an inhibitor of P450 2D6.  </ao:prefix>
    <domeo:uuid>dccbe4e9-e44b-4257-8ae9-11f916ab66f6</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6112bc5f-c5e0-47fd-9b02-41199319554a">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6b64fa44-4b23-4f93-b0ac-70b02910bd4b">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:d810a411-8c08-4a20-9a9d-332a0dbcb250"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N95998ed8dc9b4daaa85e1d6464d1b9d8">
    <domeo:sets rdf:resource="urn:pddi:uuid:9c3f0177-4817-4c5f-a17a-8c007986e088"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N192c31aef6eb4b6fbed0886e476d94e6">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0a7d81149379460aa574ff69c1cab7cc">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/c151acc8-599f-413d-b947-9a09a3c64280">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7385ac056fa1453499bce3836549824d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c397f117-3ce0-422f-8772-b02afa3e8958">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid>7ebc55d4-7895-42e1-9589-58efc9c78af1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:333fc3a3-3af7-4555-8434-5f05aecfbb3f"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/C9784705-7323-40F4-A671-8C59F2C2E8B3">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>300</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0A6547D9-5F06-4BAD-9EDA-EBF2B9541E67">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E646185A-9C81-4B34-8A0A-B763F591CBD5">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/4EBCE9E9-6545-42B5-ADFF-1BAC26A2BD9E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DD1291DC-6AD0-4D39-9AF7-255CA754E0AD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/05DBE3E9-5885-4CAC-BA37-5F26DF4DA324">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>maprotiline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6C41E3DE-C97D-4A7B-90C7-3BB1F3BF3449">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Bupropion</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/58b71b7f-cc36-4516-bae2-367144fbc149">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N07f53e1e8fd54f11945d936066ed8989">
    <domeo:sets rdf:resource="urn:pddi:uuid:a955d4a4-3dcd-47b0-9981-c38c581da707"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1debaaaf-3d9c-476b-aa8e-fc61b9ea6232">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:06827bcb-0a8b-4aa1-8786-80a95c843116"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <domeo:uuid>fb643e9c-4400-4165-b9fe-a1ebffcb746b</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2896B582-2953-4429-A299-8BAA4A648ED0">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/313A783C-3A1D-4BAD-A738-5ADCDB130B4C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/67E8E205-57E1-4722-87E0-B8338C9D2156"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne2a7751ad83b41798f9ebd0abda6464f">
    <domeo:sets rdf:resource="urn:pddi:uuid:b0bb576e-4ad0-4c14-b9f0-39126483be09"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/410BBE7D-B70B-40BC-A97E-5AD7DECBF53B">
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>atenolol</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/1202</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3ac7b267-4605-4ab0-9276-dce68f099dfb">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5a2df4fe-d938-4af8-8aba-24b38c6395c1"/>
    <domeo:uuid>399a6a0f-ad11-42b2-b82b-df639188e773</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3cd947eef3d24b409520761f709667a4">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0f35765c3609440bbeed9444d1790941">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6d6fd3cc64574887b4ba408640de452c">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5c4cf92f962c457ca8b519957412ebb7">
    <domeo:sets rdf:resource="urn:pddi:uuid:37B8FC3F-3560-4A9B-914B-0E02E3AE2C6E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N94936af8f91d4c64980c8835f1033ea1">
    <domeo:sets rdf:resource="urn:pddi:uuid:CAB4D4AF-498C-485C-BD7F-C6380F109104"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4118820bb7ef43de82b1ff667b7367d2">
    <domeo:sets rdf:resource="urn:pddi:uuid:536E063F-3624-4028-BFA1-9B22A6301E65"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51033c22-9337-4955-972c-89d8bf700bfb">
    <pav:createdOn>2015-08-20 13:06:41 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>RP and OATP1B1/1B3 Substrates  </ao:prefix>
    <ao:exact>There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively), following repeated doses of teriflunomide , suggesting that teriflunomide is an inhibitor of BCRP transporter and organic anion transporting polypeptide 1B1 and 1B3 (OATP1B1/1B3) [see Drug Interactions (7)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>d5fa5a98-a077-45c9-94db-1559682c01f9</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbf448d0146ff46549db367d600b30304">
    <domeo:sets rdf:resource="urn:pddi:uuid:26DFBA6E-8694-4CF0-830B-B2EB051A9838"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:b0bb576e-4ad0-4c14-b9f0-39126483be09">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:eda2e093-7e07-41c3-a40b-6e0b8ca3dae6"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D74DF87F-814B-4FC3-8E69-DC64814EF8AB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/0C5F551E-0DEA-471F-965C-06AF59B7D04F"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/152FF263-6CA7-447E-AD60-F819C3B36F4E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4a96e95c39a9410f8dc1543dcef0d1ed">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3e48d1eff88344c2b210a040dfba5cbd">
    <domeo:sets rdf:resource="urn:pddi:uuid:7C99865D-4AE3-4DC8-843A-D4FD1AE6DC88"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7FDE70D7-14B5-4E50-B4AA-A68B51265ABA">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>prasugrel</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:cc3972a8-c732-4a33-90ae-0538507fc025">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:79b346b0-7da6-452f-b827-e74b7d6a3f34"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/7559f5e2-70fd-4459-a178-29bf077a7bcb">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc2d05f60652a4a39a02b8378b952f6c6">
    <domeo:sets rdf:resource="urn:pddi:uuid:FDAC04F6-41E7-4D95-B822-8D86185C2EEB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60df948a-7f0a-4da9-8a9c-06ebbdcdeef1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-01 10:49:57 -0400</pav:createdOn>
    <domeo:uuid>eb124a24-e8a8-49de-8033-dc7db2b83815</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>se in plasma AUC of the TCA).  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3308fcbfbbf942ebb3560c0b8337221a">
    <domeo:sets rdf:resource="urn:pddi:uuid:B15BA85B-19D4-42FD-A00B-A74D35AE722A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1c3333fc2ccf4579a7d7a232010a17c8">
    <domeo:sets rdf:resource="urn:pddi:uuid:09fbe312-fe74-45ea-8d2d-7493b26da711"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/3dc022f7-5f06-4604-aa57-5eb5a99b5e37">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb58ac260616d4aaba5d090aa46fc5a6d">
    <domeo:sets rdf:resource="urn:pddi:uuid:0cb87179-0e94-4ad5-b19b-b7e71ca538b4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d9f6258f-60b7-4c4a-a301-0f3522dc0682">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <domeo:uuid>b86dfedb-edf8-433f-af8d-2c37865d3738</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2a8a9f5b-de64-42b5-a7ee-030edf026906"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2e3ebddbfd534877ba63f079cda6007a">
    <domeo:sets rdf:resource="urn:pddi:uuid:ac37d682-4ea3-4be6-a17a-a9d2b1c04b7b"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N838d15129ab54769a8940322198fe6b4">
    <domeo:sets rdf:resource="urn:pddi:uuid:e80132f6-a8ce-4ae5-a1e2-3ef2b9908c21"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N73be3df2f166417c8b2dd90099903e19">
    <domeo:sets rdf:resource="urn:pddi:uuid:D255F3E1-A02B-4C0D-AC18-4989C86416D2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/fdc9e04c-c726-4f2f-85dc-f38f71d99d45">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>phenothiazines</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfc83956052504df19823accd944f0627">
    <domeo:sets rdf:resource="urn:pddi:uuid:B8E124E0-1E3B-468C-8846-C06CE7998697"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:389e266c-5db2-4337-b08d-1274ce71f17b">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Pimozide and Celexa: In a controlled study, a single dose of pimozide 2 mg coadministered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of Pimozide and Celexa or Lexapro is contraindicated (See CONTRAINDICATIONS).</ao:exact>
    <pav:createdOn>2015-10-14 12:07:40 -0400</pav:createdOn>
    <ao:prefix>ugs (see CONTRAINDICATIONS).   </ao:prefix>
    <domeo:uuid>662d6505-bc1d-416b-a7bd-b7b826c6cfae</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne6c377bc0f00405eaa1ca35f4ad9d58d">
    <domeo:sets rdf:resource="urn:pddi:uuid:67BA4CDF-B8FE-44E4-9B6F-83873628181F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N30493caa12e946f6961d9ede5f168c08">
    <domeo:sets rdf:resource="urn:pddi:uuid:01235809-ce2a-4366-9e84-3061e834aa6c"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/6F39CF04-EDDD-4BB3-AF7D-4206DCB8A57D">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>FETZIMA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79417F6C-DA72-4057-938A-8615D296B733">
    <ao:exact>Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors. Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6. Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g. propafenone, and flecainide). When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.</ao:exact>
    <pav:createdOn>2015-11-05 15:31:22 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a435da9d-f6e8-4ddc-897d-8cd2bf777b21.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:79417F6C-DA72-4057-938A-8615D296B733"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> Drugs Metabolized by CYP2D6   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0e7e60a1e3ae4ea282aeeec47cd16e29">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8CD1D4D6-CDC8-43F6-BC59-746BE9D0FD2B">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:67BD1A9B-50CB-4E32-B19C-6BDF2E55F585"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N60cd1f09ba48407bb5869ead5452ebee">
    <domeo:sets rdf:resource="urn:pddi:uuid:9F45CE3E-A65D-4B36-9F63-9F9A3E36B917"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N844dc44bc19744d1bd753493981386a9">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6FE56E27-2276-453D-BA7C-82F84AA55BF8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E1071A06-6C69-4001-A296-BB62A9135BEB"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2A343CF1-A846-4357-B79C-593494E7045A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7f6231e6eede42978cb7a8a82844ef87">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A0006AC5-A7C4-418C-928C-C41D90415342">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/05280147-129C-45A4-AB2B-00780F7BB880"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6735CAE6-4C40-44DB-97D7-B474AF131C11"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N773b7816ea46417cb47340cf6c5abfc6">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd053ae72bee446859ae9cb34c8d4abdf">
    <domeo:sets rdf:resource="urn:pddi:uuid:DCC258F5-68A6-4A45-A982-EE377F530B7A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:24A22D5F-649F-4B53-8523-F116DEF6E2E8">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E5C2F9ED-2BA2-4EA0-875C-8A421F00DBA8"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:513edb52-bbb8-4100-bdea-08dff1288050">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5bd286db-c0c9-4866-bcd2-5abf3ec1750d"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N27edb478881d4f199ee3d297daf9dc75">
    <domeo:sets rdf:resource="urn:pddi:uuid:72366495-7b3f-4931-8e2a-104ec3899a46"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N10b40185cd3b4f6eafe63af454ec98fd">
    <domeo:sets rdf:resource="urn:pddi:uuid:70C9AE3B-252E-4E47-B4C2-1F29B9140C15"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N376b1e8dea664cb8b4ef59f76f668520">
    <domeo:sets rdf:resource="urn:pddi:uuid:14B3F0E3-FD35-4859-BB56-B367505D9BBD"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7a441d78703848a1af141b0962fa87cb">
    <domeo:sets rdf:resource="urn:pddi:uuid:D42F2A10-10AF-4C66-922F-4C18E7027E7C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd054dcedf07d4266b57530aecfc3cbe7">
    <domeo:sets rdf:resource="urn:pddi:uuid:878DA0F2-3B66-4D49-B6E7-4BEBE7484C72"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3fd02430-193e-44b6-ad6c-14d05b6d2cd9">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:dc408320-dd05-4501-9d92-32c242528116"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>713802d9-ea3d-40a3-8aa0-6fd597d559bd</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9ec2790d7ac54db4b7448e0d8cb4b056">
    <domeo:sets rdf:resource="urn:pddi:uuid:9A47646E-95B6-4AB3-90C4-78D4DE382EDD"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc581ed10bbf2423f9537f4ff1c5020c2">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F90FBF7A-F587-4502-AB78-95004CF55511">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32968</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N435d48c6e13c441e9876c089a472251d">
    <domeo:sets rdf:resource="urn:pddi:uuid:bf10491a-c682-4353-a2bb-8c06260e5070"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N902a8c0aefab43cfb89add4ab5034760">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6e6c89c8637346bd95e9759e6e779be8">
    <domeo:sets rdf:resource="urn:pddi:uuid:EF175995-1661-48C6-9686-0AF7B66E0265"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0A936C4A-B72B-43F1-875A-21ABBE83E9BE">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/9460D459-A760-43CA-BB5A-B07A013A73C4"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D7019389-A805-48BE-8F89-125FEF7C8631"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9aa02a624f8442f8ba6c7f724d3cd3d0">
    <domeo:sets rdf:resource="urn:pddi:uuid:a4025d67-fe81-400d-a9cb-1e16eae415f1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:45c8ad2f-86fb-4273-b169-f567d8fa2d5f">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6b9fb4fe-f9e1-4129-a29c-18a2aaaf9eb6"/>
    <domeo:uuid>3bb6b9c3-df2b-45b1-9162-ff9070ad6595</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N25df53743540483493c94712d6445c37">
    <domeo:sets rdf:resource="urn:pddi:uuid:302160fe-60a8-40d8-81e9-65140cc1f7e0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6583b28fa16f4aa697c16fcb7a79100a">
    <domeo:sets rdf:resource="urn:pddi:uuid:5599e5f2-ed60-4a78-b519-93cb46687ee2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9bdceadc95f644dbb1422ca5011a1fdc">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1afaec78210944a595fa809bca04d417">
    <domeo:sets rdf:resource="urn:pddi:uuid:A10CC62D-2800-4377-BA3D-DD2DB74860E6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6e50da75ebc3496a885439fc61506464">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfe8c37df06134c0484daed6f1548ee51">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/44F4E8E4-CBB2-4020-865C-E8D64A64311A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E331D723-CDCC-4E26-AE0E-04D3957918B0">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/30A71B53-B7D2-4E83-BB90-088FFD084549"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8118454F-FECB-4563-AEFA-575878F61E80"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2876ccf7f34e490d9a4b055e78bd64a8">
    <domeo:sets rdf:resource="urn:pddi:uuid:8A8BE3CD-5251-4D57-87B3-850568CCDA99"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:165908e2-6280-446d-ad91-9c8ffafdb9ef">
    <ao:suffix> was reduced by about 50% and, therefore, fluvoxamine maleat</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:prefix>doses, respectively. In elderly patients, the clearance of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-10-26 15:39:09 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:165908e2-6280-446d-ad91-9c8ffafdb9ef"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5bc91b6c-1baa-4fe4-a629-cbb682593e72">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <domeo:uuid>47a3f6bd-345f-4935-b777-7fc30fd54e7f</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2406bca5-3882-400d-8ee4-1cc95b55d4f1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6064a994201b42f1ab972995283d6f01">
    <domeo:sets rdf:resource="urn:pddi:uuid:9A27337F-880E-481E-B32C-A2FB50A08D90"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D0C90DB4-6D99-4A07-8AC9-B902E0CF1037">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8C0E2669-08A2-4B7B-A2AD-4C4E32D891A0"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/05DBE3E9-5885-4CAC-BA37-5F26DF4DA324"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N60a0e9ad40ec4e148d422f5849a84a80">
    <domeo:sets rdf:resource="urn:pddi:uuid:cc3972a8-c732-4a33-90ae-0538507fc025"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbb8b3376cc4e4eb880a013c070f63aa6">
    <domeo:sets rdf:resource="urn:pddi:uuid:697b2fbd-3d5c-48c8-bdbd-a8c57f885c65"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb6a664f9fc9f42f6bf182ef2ee639cc0">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N76a95b25df3649d8ad3bd4f93c2996e4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd5a79912a47b4fb98c23c80c33d0d2b5">
    <domeo:sets rdf:resource="urn:pddi:uuid:BE55D4AB-BD78-4529-B3A7-9CDF6C1CEAF0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9cd8353b-ead7-4551-bd65-d6d2f7ce999c">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:255b8bae-4139-4afb-93e7-759c024d4dd3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>7c29f1f0-2e13-430d-b2ea-42a64307174e</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nba3373e49e6e49ebae5e7b984ccdbe84">
    <domeo:sets rdf:resource="urn:pddi:uuid:7036F77F-8326-4700-8587-001839F15EA1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3111281aff4d4962aee8b893d5d911ad">
    <domeo:sets rdf:resource="urn:pddi:uuid:A1EFB38E-7A30-4B7B-A6A9-54D4E8A2043C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0f1e581569ff42f4910a65669fb25c0b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndd2db3e276b8417496e42122b43873dd">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8798fd5a3c174f6896993790e49c87c6">
    <domeo:sets rdf:resource="urn:pddi:uuid:927acb84-d563-41db-8572-347a400d1729"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N59085b1a5069480e9850350d58a2c5c3">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0b6dd150eaa44bbc85e7753adb31a1cb">
    <domeo:sets rdf:resource="urn:pddi:uuid:DDF1BCA3-7919-4801-AE9B-F82800873321"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/091539D9-C38B-4CF5-8573-15E765E5707B">
    <rdfs:label>alprazolam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>1</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N102c8fd8233a40c4a2332586df560953">
    <domeo:sets rdf:resource="urn:pddi:uuid:cbe46642-5c5a-492c-9dbe-04cfe9648a19"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64a06fa0-df56-4ad7-a768-2fc0fca45597">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6d346686-fe95-4079-83a5-0be13cbd2e22"/>
    <domeo:uuid>969655bf-4223-40e4-b850-593a36218402</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd08416142d254613ac92271d309fde8c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5368d0c0e3c94533aa7c10e5f80a886b">
    <domeo:sets rdf:resource="urn:pddi:uuid:8C5843FC-C2EC-4D50-8F5B-6C27A25DAAA9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N69b5d1ec41bb4b60aa763b62231d0398">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nce7f903107334208b117a2a964353b69">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N626a2e74155b469096609834316af225">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/f15f7eb2-c5dd-4641-8cfb-999f5699fc76">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>metoprolol</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6918</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0F0B55C-92C3-42AC-BA8B-D25B34B24813">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8c94553666654017bff49f7c06c8ba4a">
    <domeo:sets rdf:resource="urn:pddi:uuid:458B4870-C0B1-4D54-895C-15181F6B8B3E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7ad0d27b43eb447f8b3675a08c1a332b">
    <domeo:sets rdf:resource="urn:pddi:uuid:41391B56-0A05-4D34-AA34-21D3B93A0F68"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/F25B20CF-E40D-44C5-A17F-C8B7A6CEB492">
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N05118991901b491f835d02ca4a7d7d30">
    <domeo:sets rdf:resource="urn:pddi:uuid:BB683AC0-8B9D-425E-B8AC-8420C9115DDF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N684fc78be4224f6aa9517e494d3a44c2">
    <domeo:sets rdf:resource="urn:pddi:uuid:98D71E7C-4C30-47DE-980C-D4814F49B1D5"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N17469ec254584c12aafd9c264b733c90">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3506dc73837f4aa585b647f57c923ec2">
    <domeo:sets rdf:resource="urn:pddi:uuid:951D4AB3-DD90-4F43-94EC-A4100FC1584E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne338e2974e774d5db10d74a917b6a0c9">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5ec1faf6688e4d3f90aae0d6301361ff">
    <domeo:sets rdf:resource="urn:pddi:uuid:a8ad0339-4e3f-4626-837e-efbd98802192"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc600044f88ed45079c0146df77a9ce36">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6a7d459043564cc9922117645e455d64">
    <domeo:sets rdf:resource="urn:pddi:uuid:28796307-0af1-4642-b0ca-d729392a1eae"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5b9b9f88b560459498f63183d9a45573">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4aa157f7bea34e66b44e890263f90e5c">
    <domeo:sets rdf:resource="urn:pddi:uuid:aad1fe6f-573a-4a4a-8da9-8f0c2d0a7380"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9103a227e921444280343fbe369ac52c">
    <domeo:sets rdf:resource="urn:pddi:uuid:4dd351b2-54ea-4452-a1d0-9b022b88631a"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncea2d4dace4143bda54c2b0a9a99069d">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7cad7ec25a2b4ecdb3bc2e032aac47e8">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0d0c739a82eb48eeab17a651b9aa17f8">
    <domeo:sets rdf:resource="urn:pddi:uuid:16B26536-147A-4AEA-A64B-EEDD24D7DAEF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N66d7f359c57d4895866c8464dcd00ccc">
    <domeo:sets rdf:resource="urn:pddi:uuid:5952BFEC-E144-479C-A264-FE43D8E0C3A5"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nadffd4f1ad6f40dc97b1205783a82746">
    <domeo:sets rdf:resource="urn:pddi:uuid:b6feb170-170a-46d6-91f0-773967276d84"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc9e15362f0b944e3afed17f9b74b9297">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:67BD1A9B-50CB-4E32-B19C-6BDF2E55F585">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/8A7FAE58-902A-4619-B67B-0F275C7DC452"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2124DCFE-AF88-4C06-8031-3A323FD122BB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na0c65db134684ec883fa2c998d5b495c">
    <domeo:sets rdf:resource="urn:pddi:uuid:2d1d7af3-09a9-46a5-8e5b-f89fd0ae6c87"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N386f9f937a6543d38e27bb638d7077b2">
    <domeo:sets rdf:resource="urn:pddi:uuid:e6ca4c27-ac31-48bf-9529-ab1c8a45c149"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9ccd143939eb4b389f7350a804a22c16">
    <domeo:sets rdf:resource="urn:pddi:uuid:962C8851-3F0C-403D-81E3-DC5CB440336D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb44c22559bbe4639af53769dc05534b2">
    <domeo:sets rdf:resource="urn:pddi:uuid:8D9122CA-5371-485E-9356-3C3274919690"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1051dcc76a1c484fa87d375e42461ead">
    <domeo:sets rdf:resource="urn:pddi:uuid:CBC29AFD-3ED4-44B2-99EB-037E39A9E78B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf09e9e18d3d244ad9e7055402bbc0b42">
    <domeo:sets rdf:resource="urn:pddi:uuid:C365B712-9191-4E7B-B556-6BAB89111E9E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N534459e06bcf4c84b34ed095cd9de8d6">
    <domeo:sets rdf:resource="urn:pddi:uuid:509fcd46-377b-45e6-af8a-410391a2dd48"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2B3C3834-BFFF-4D50-BEAC-DB1B916682B9">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/465D2CB0-5AAF-45A4-8D77-670D95311862"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5EF69470-676F-49C0-B1D0-92CDB64557E1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1ef1cc8585d742eeac5ff9e23ab1ff7f">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5564150b746b4820a785d02b5b9f9bb9">
    <domeo:sets rdf:resource="urn:pddi:uuid:48CDFD2C-A735-46A1-A0B1-5C700E15C5EA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:996619A2-AFDD-4E31-9005-B6E80970C1FC">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D9B002C4-004B-4DA1-9EC8-B7DF51D8A4F6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/633D11ED-8993-4B40-A4F4-AE2C63D3FA61"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne379fea10d634edeba3f16ca8813eade">
    <domeo:sets rdf:resource="urn:pddi:uuid:860D5D85-357C-4060-AC23-A6F12DB1068A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:726D46E7-2558-47B2-A574-723C0898F849">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/6C308BCB-40C4-4A1C-9BF3-78ADB5D8984A"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/73315268-ECC5-4B73-A441-DD362873D3DC"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4c7a6a2f992a437080c1c767a6a61c61">
    <domeo:sets rdf:resource="urn:pddi:uuid:d1f4afd3-c3a0-4041-ab9e-613a83049322"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N33b1d7d23a614ca7a5c213c8506c7a6b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N91e0634072e84764a9df45db4b9a83fa">
    <domeo:sets rdf:resource="urn:pddi:uuid:B494B604-15CA-4998-98A2-CAECAD140675"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc648fc5e78104a38827ab22a69404cf2">
    <domeo:sets rdf:resource="urn:pddi:uuid:a9735a74-fa87-4d86-8714-a17792524aa8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N31d8f16ba591450ab0399c7fd1891fc4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2aece38644434b4bb38c2f4d58fcc10e">
    <domeo:sets rdf:resource="urn:pddi:uuid:77C4CB18-7DEC-4BC6-A16A-D59CC3A7F458"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc29d9de5df504121bd6644dd2dfbba87">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N43d4a438e4fb4798b6cd73b3b55158f5">
    <domeo:sets rdf:resource="urn:pddi:uuid:2437C682-01DF-4B57-BF3E-A737C6426FA2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N46739bce56124b9eac2e491c113a8e6a">
    <domeo:sets rdf:resource="urn:pddi:uuid:95963186-0DDA-48F8-8FD1-8ABA4A5D57D6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N16705a4ebca346e4ab031974d9dd65ec">
    <domeo:sets rdf:resource="urn:pddi:uuid:202B0EFA-3862-41F0-9B1F-F6DE88CDE6AB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N162be5447a5748efa9a9550973596581">
    <domeo:sets rdf:resource="urn:pddi:uuid:7E43A3E2-7BAE-4042-B9EA-CF146721DE2F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne8bd1d6a3d9f488dbd760fd7a691cf09">
    <domeo:sets rdf:resource="urn:pddi:uuid:8754B695-04B4-4CA2-B837-CB0BA450A23B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c3d55034-f27a-4d8e-bc99-f4aa1c00f3fc">
    <domeo:uuid>ea6b664b-596b-4f08-8ba5-d77763d9642a</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6051a8f6-3f18-4805-9613-42cf7bdd7281"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N972b7329faf34e668fafcf7c06bbd90d">
    <domeo:sets rdf:resource="urn:pddi:uuid:b1126b28-f5ef-48a7-91fc-44e5215aa5fc"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N61914bd2f437481ea5c2a9fa8b7ab9f6">
    <domeo:sets rdf:resource="urn:pddi:uuid:80d5c67c-d0a5-418b-968a-68bb762a3e24"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9304f1b3cbdb41b0ab823ef85338b5d6">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na26cf9e758fb493ead2bb28578a1251c">
    <domeo:sets rdf:resource="urn:pddi:uuid:811234aa-4310-481f-a814-75ce1e5eb949"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9f93c4a9afad4d04b0565200aaedc455">
    <domeo:sets rdf:resource="urn:pddi:uuid:99001f4e-5658-4154-80c1-eb368f40e204"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb7679cb9f78241d7beb383a52e6f459b">
    <domeo:sets rdf:resource="urn:pddi:uuid:5703E553-0680-4625-A085-39A6E0C36327"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc3098b71bea64e4ea047948892850079">
    <domeo:sets rdf:resource="urn:pddi:uuid:31F7988B-A343-4386-A6B3-301A3B602FDD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0852A8A4-FD74-4E88-BD1C-F6843FC6A4A2">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/1DB0610E-CF8B-4569-93EA-7477B040E50C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/D62A9890-1032-4015-8785-729A247627D5"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N553ca15df269459b859e5e06166994f3">
    <domeo:sets rdf:resource="urn:pddi:uuid:D8A6394B-01B3-43A1-9780-07287688E420"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N01c6b55f7b7840838f8633df88752cb3">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:258FF08E-C38A-4317-9E56-2529EAA66FAB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3E170858-1634-4C3C-BC77-FEB770B02B60"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/DE83202F-90D8-4503-9E34-F2007C1B2722"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4af3b4bc3ef04f56b309c1f0b1fb1429">
    <domeo:sets rdf:resource="urn:pddi:uuid:629953da-8c05-4179-b781-acd0e222fffe"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/BE33CA4E-F2EB-4423-815D-F0BFA085F26A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>50 to 200</dikbD2R:dose>
    <rdfs:label>Fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/031D367A-CA33-47A6-90B4-7052206A3E15">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N47ced6b5e25349afb2b1d70716e9cd94">
    <domeo:sets rdf:resource="urn:pddi:uuid:C2725CEB-AF84-4C34-9F9B-2055DB44786A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd284c39ece6e449994a2dbe39e3a5820">
    <domeo:sets rdf:resource="urn:pddi:uuid:39724c07-2350-41a6-930a-b629d166d73d"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb3e73c51516c4ccfa8e01d05cc9268b4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nea8341b2258f402b8f5f441962be03c8">
    <domeo:sets rdf:resource="urn:pddi:uuid:40F0C806-D446-4EBB-89B8-392167F4F83E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5001F30A-C0CC-43F1-B7CB-4DB5573E6308">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/3BB75DE6-A3F1-45E5-BF5F-F8D5BC8D56C9"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/90C2CDCB-016A-4EFD-AE0C-2576563D80B4"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbf1366c42b8e4e738f43f4817d45b678">
    <domeo:sets rdf:resource="urn:pddi:uuid:C3239A6E-8969-4843-AED9-751A6C46A15C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb33797ff17e8407b9ef6e41261bf3ea9">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:d7ebf644-59c8-4910-9b1c-734f99863ce6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:d2824b60-f9ad-4ea3-b32d-f90f13a9bc13"/>
    <domeo:uuid>f9ce0bfe-5600-49d7-8774-38aae107c5a9</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N08cec0140ff84942a0c1acf8613dcd07">
    <domeo:sets rdf:resource="urn:pddi:uuid:7ae9c448-e28d-4732-9bf7-269cf9b7c206"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N997c28abeb03449a91fb69ae9bfef287">
    <domeo:sets rdf:resource="urn:pddi:uuid:03EC91C6-1133-4B13-B357-1B3DFE07AA22"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N30c960c734bf46c68ff7d713d2b2b339">
    <domeo:sets rdf:resource="urn:pddi:uuid:AEE7AB83-6F25-49C3-9A31-96DC7750E478"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5f1da3757e60452394d4aed310f55df8">
    <domeo:sets rdf:resource="urn:pddi:uuid:2ca7c011-6a97-4750-b293-78aad27f16ad"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndf6c89045cdb4580b7ce2493530001e9">
    <domeo:sets rdf:resource="urn:pddi:uuid:F4F02943-8BF8-438F-A62E-89E7329BEA30"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N93e6b9fa12cd4ab48f198a14bea4770f">
    <domeo:sets rdf:resource="urn:pddi:uuid:4336736A-0EF6-489B-A919-A212779276CC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N41f49a0423514086b6ec1686a4ffe976">
    <domeo:sets rdf:resource="urn:pddi:uuid:d15fb319-49db-4775-8f78-635514434724"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9faef2f374654ac094cc89031662c7ba">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3ab8c197e78247ca807cfd7a0d1baa65">
    <domeo:sets rdf:resource="urn:pddi:uuid:04A4CB48-227D-4161-9C50-3D1693729A05"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N929ca454053145b5b9d8482cab88c540">
    <domeo:sets rdf:resource="urn:pddi:uuid:D5BAA5DD-D9F8-47EC-BD0E-B87F48784868"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N88a729a62030460b8c95a98c991d7a7b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/domeo-tools/export-tool/0171A817-E74F-4DD2-B75B-7C19CD268758">
    <rdfs:label>cimetidine</rdfs:label>
    <dikbD2R:dose>800</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9bc2d5ce-85ea-486d-82a2-e61a794fa2e3">
    <ao:prefix>y clinical effect.  Phenytoin  </ao:prefix>
    <pav:createdOn>2015-09-14 11:03:10 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>When a single oral 30 mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone. In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS: Postmarketing Reports).</ao:exact>
    <domeo:uuid>e56280fe-0c2b-4a6e-abcf-8365cc53fdf3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc64f0f75670e4bd9b852430e56cb47ef">
    <domeo:sets rdf:resource="urn:pddi:uuid:31F40E8C-65EA-4FEF-B949-615B81F92506"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbabd42f0692d452ba95aec8e8d230c00">
    <domeo:sets rdf:resource="urn:pddi:uuid:16020a08-b9b2-4a03-9f15-eb3f2a733e4f"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N64ff6bc308d94f67bbf8862c9755fc61">
    <domeo:sets rdf:resource="urn:pddi:uuid:bad6d0b8-6028-41d0-867a-a665f030262d"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N219d717eeb4f46dab959bc7f88611d8f">
    <domeo:sets rdf:resource="urn:pddi:uuid:0B4038B5-E006-4313-91F5-7CCCE46EA9AA"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N31b2f671ec42420ebea9a1d6c7f7a414">
    <domeo:sets rdf:resource="urn:pddi:uuid:898787C7-20B1-406C-B9DB-39C1B6E3F391"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc3cc2943cbf942599f424b54ab96e636">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb5e7360cd9dc4633aeda64cc59dd6440">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3cdfb965e69c4ee58b4863dfd2fbae19">
    <domeo:sets rdf:resource="urn:pddi:uuid:2953d13d-bf11-4341-8850-095dac3e8c22"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6f8cb1b09354442aa5c3743e99c9d580">
    <domeo:sets rdf:resource="urn:pddi:uuid:8eab6ae3-5bd1-4845-8b79-9eece52cf228"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N218cd82e65f14238a03349daec473c24">
    <domeo:sets rdf:resource="urn:pddi:uuid:cb9558d5-8801-4b03-b913-a3aa0a4d169a"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N81a96b69a18d4b4fbec69f1cdf9dd1c3">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N883b2a40423f4808b42e1b5546499bb9">
    <domeo:sets rdf:resource="urn:pddi:uuid:6FD15A0C-0770-4A9E-AB6F-F3ACF5A86142"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1639de93418b4bc9bbfdccdd54f774a7">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne1fe254d6a2f4e0a8067a4ae31345128">
    <domeo:sets rdf:resource="urn:pddi:uuid:40C952BF-5CC9-4F9E-9A1C-E9430E07F888"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N97a8c69c32584e31aeeb343586388356">
    <domeo:sets rdf:resource="urn:pddi:uuid:6ED09715-10C4-44D3-90C4-3DF330DCCCD5"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N99b84241624148fd96f016f912ece3bc">
    <domeo:sets rdf:resource="urn:pddi:uuid:EDDB83B7-891D-461D-BCF9-7BE2DEB58676"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N97e1080567e54433b59b4c9d50443165">
    <domeo:sets rdf:resource="urn:pddi:uuid:66392DB5-9BCB-40C6-9661-44C5D6504927"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na046a76f2d69456cb35910d64c408488">
    <domeo:sets rdf:resource="urn:pddi:uuid:23D80B4C-79B5-4BC8-8A7D-ECA168B4CA80"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:75FF611E-C9FB-47BB-ADE0-9F787F6E07BB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/A116E1A7-A0EB-4A62-BEA7-68CF500A9BF7"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/AB8EA8A8-CA09-44B8-9394-1378A877BD14"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2DB92658-4E0F-4CD4-A84B-74BC5EA15F3A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/FDFBBDA1-FAD7-4F01-BE07-CB62D83D0B17"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/737FCF99-E840-4209-872F-039C6EF9C37D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndeefe76572cc4d98ae062c16a2f0a5fa">
    <domeo:sets rdf:resource="urn:pddi:uuid:87BE57B5-2BAD-4490-939D-9A43FEFEF37B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N29e7222a488e45df8c004b523fdff983">
    <domeo:sets rdf:resource="urn:pddi:uuid:6CEF2950-8389-4385-89C4-7E31620BC4AC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncc3d13e426b14ca3b120d684c9a72b71">
    <domeo:sets rdf:resource="urn:pddi:uuid:a3b8a024-c1e4-466c-afe7-9e897f0235d9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7543e896860748cab66223683a284d78">
    <domeo:sets rdf:resource="urn:pddi:uuid:150AD41F-E365-4996-9439-3F57B9816BB9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8ee8f0757d334faf82fbd34d92b5fc36">
    <domeo:sets rdf:resource="urn:pddi:uuid:D3401B5F-E88C-4B9B-90A2-F592987F2301"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N41b8846b49b2421aac42849d0a0b48ee">
    <domeo:sets rdf:resource="urn:pddi:uuid:E993C666-D1C6-4612-817D-D7C87B1560EB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N65d7cb095fc046f494a72475fa22ec35">
    <domeo:sets rdf:resource="urn:pddi:uuid:992e1f09-7e0b-47d5-a4c9-94e09c6eb442"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7498068c73ca4d2db16cd003bea68ad5">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Neb348141470d41239d24a734202d46aa">
    <domeo:sets rdf:resource="urn:pddi:uuid:B03E580F-9D80-4F4F-8A09-8D85B5B8A723"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc7fcd7031cd44801b722667f446cefe2">
    <domeo:sets rdf:resource="urn:pddi:uuid:F15FCE0D-03BC-4C50-B4E9-0911A44190F5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:214A2D1B-F711-4199-97CC-E27AB8427FC8">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/B31243FB-9E7F-4F0A-A2E9-77182523168C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/F5DD2146-50E8-4086-AE46-22F41E301BA2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N90685b11e1264d969c4d9a9f5406703e">
    <domeo:sets rdf:resource="urn:pddi:uuid:21fdf362-b6d8-418c-be34-b3037d1e1a37"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na8e44bb815f3429a9c6d827187adc631">
    <domeo:sets rdf:resource="urn:pddi:uuid:DDD031E5-D8DB-4237-8393-8751CD1E6E59"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2ef971c80c3a47049062bef7a4db4e00">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N49851ce4f8d04ae29c8acb56d17edd8a">
    <domeo:sets rdf:resource="urn:pddi:uuid:62CF0CF6-3022-4EDC-BB58-8706F755E604"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7c837b03719745a080bb1eddc6acce3d">
    <domeo:sets rdf:resource="urn:pddi:uuid:439F9211-D925-4ADE-A1F3-FB3A3B2E6737"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1b985d7b6c384a93acbde5a0c1a381da">
    <domeo:sets rdf:resource="urn:pddi:uuid:254ED692-020B-4F68-8746-725D20F675E2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0882d3e076614d74945709238285c66a">
    <domeo:sets rdf:resource="urn:pddi:uuid:282E16BF-4C3D-4E52-A13D-9EF41DD22824"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na55e078f39394ec8983ea14eb026437e">
    <domeo:sets rdf:resource="urn:pddi:uuid:A5B8DE27-AF12-4FB0-BD8C-166677E24BD3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N689d8f8b718540e398509b7cab3931d2">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne0ec3d5ba1a34221b8b9c4439849ceaf">
    <domeo:sets rdf:resource="urn:pddi:uuid:4131B4A8-D97D-4570-9B36-BC1D177DE005"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7d507c9054494213b18d11100832820f">
    <domeo:sets rdf:resource="urn:pddi:uuid:B069E0D9-6E39-4993-8F5C-A90012A6CAF6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8C8F7427-CD63-4D51-88F8-29B985E8FCAE">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/13CF2FF2-163D-401F-824E-E1B3B4AF9DAB"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/45737D8F-9B92-45BB-8734-810D48E4BF13"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbb1bcc5eca0647509648dc49152dcf3f">
    <domeo:sets rdf:resource="urn:pddi:uuid:9B0CFAFA-5356-49EC-AEF1-384F091799E2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N71f8c542a4f0492db5acd17228235a68">
    <domeo:sets rdf:resource="urn:pddi:uuid:D9BAB021-461D-4B75-9894-5A04DF941246"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N648d96e531404f97ac17c1cb47a60924">
    <domeo:sets rdf:resource="urn:pddi:uuid:bda27dfc-23ab-4d3d-ac60-206a714a0f9e"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9794be27a4704735ab428711dd534205">
    <domeo:sets rdf:resource="urn:pddi:uuid:f94a35b5-9c13-4d5e-a1bc-12a69d918843"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N502abc081bb0440b894c09a6330e5485">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4a050cdc035f48159d7798e69ca52f08">
    <domeo:sets rdf:resource="urn:pddi:uuid:7C5A73C6-C165-4198-B7D1-E977772C5F2A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N912271702f784c7d816ae4927609f3ba">
    <domeo:sets rdf:resource="urn:pddi:uuid:C2D8DB93-B0CA-4578-8D63-9A85C6FEC43C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N370e93fbe3ec4f05ba82b078a427efcf">
    <domeo:sets rdf:resource="urn:pddi:uuid:5428bd64-9644-4759-9880-6ba3111a77f6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9c0951bd081141c4bb9391477e717093">
    <domeo:sets rdf:resource="urn:pddi:uuid:464A1097-F8F0-463F-A3BC-A99C3ABC4E8B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7724fb55daef408f8c53feb527d32fd1">
    <domeo:sets rdf:resource="urn:pddi:uuid:58B59744-6B62-4952-879A-503E330A26BF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N68921c562e9d4a5bb1852f3489a0ccd4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc935d78043014c1a81aac8de279c5152">
    <domeo:sets rdf:resource="urn:pddi:uuid:2083b670-5f2b-4cc5-9371-baa94813b6ec"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4963ba5a934641438ebb93aa08d57d35">
    <domeo:sets rdf:resource="urn:pddi:uuid:0c285221-c07a-42eb-851b-dc3ef1f9ea39"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1b190130bf9e455eb7c2fb9b4568d754">
    <domeo:sets rdf:resource="urn:pddi:uuid:CEF16EAB-5AA2-4FE4-B67F-3F67CCC15F78"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N09f1a73a19484844bf5da62d0fcc1b9c">
    <domeo:sets rdf:resource="urn:pddi:uuid:E9A62CA3-EFD9-4609-9A41-F7C56DD6730D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1876eab6e1ec44dd9eabf475a447a016">
    <domeo:sets rdf:resource="urn:pddi:uuid:E11191D4-8147-4A58-8A12-EE7E6B99A5F8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N756c729866874920bc1a5c6038972a63">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndecacff3fb3d42209b0dcffabdd05a63">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc0c59d7c06c94ee18543c176b6240200">
    <domeo:sets rdf:resource="urn:pddi:uuid:66cef0a6-6063-4fce-8f3a-8a33aeae2159"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4804f050699e4211a44c5f6f5cc0a900">
    <domeo:sets rdf:resource="urn:pddi:uuid:90de22fd-85e7-42c4-bc65-3433113412e3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8cad520aa4bd49f4b3ea1e90be5e8082">
    <domeo:sets rdf:resource="urn:pddi:uuid:F665787C-AC4C-42B7-94BC-8B640D83014D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1a619cac6c2c414692d81ad53a8124ba">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E7118659-6CDC-4724-AAB6-3F8DF448BD10">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/E4E84D77-E1E6-434B-9941-AD3E9116E80A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5FE87938-BCF2-40FD-AE17-AE7CFD0B5D7B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncc44e6d26557410184a0f9b0217b4d80">
    <domeo:sets rdf:resource="urn:pddi:uuid:E1D6C6EE-88E8-4378-94F7-A48C80B19F82"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncf4211df3d0c4fe18f607bba0dbae8a7">
    <domeo:sets rdf:resource="urn:pddi:uuid:098F35D9-F94C-45FA-B857-9BDA3662BFEC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbe9751c80c3848c7b02777cbebea42d1">
    <domeo:sets rdf:resource="urn:pddi:uuid:7DB449CA-E59D-4070-9C87-2409B06D1CD0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc57568bb7fc048b3ad7aa879075d9b77">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N54e9a37030b8408fa79e0b8f48494699">
    <domeo:sets rdf:resource="urn:pddi:uuid:8B0C913D-6ACC-4291-BDFE-62A5987AC530"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd21f8eefbb664b4498f17a57565d6b79">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc770c55746a04776bcc04c6a07b0a53b">
    <domeo:sets rdf:resource="urn:pddi:uuid:945A03C5-C85D-4B96-B6EB-1AE94912F4B3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N211f91c0f7a2477fb57263d58239f2c1">
    <domeo:sets rdf:resource="urn:pddi:uuid:1C9ECA4A-5865-4525-A32B-153BFD579AB4"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne701be22eacc44c88197835ce2289b4a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:40D083B5-563C-4F5E-AA62-01F4D689274C">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/2C3D8F7A-CA84-4F66-844F-EF59686D0871"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/EE4EA623-BE83-41AA-B5B1-DA09807C8C8B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne93322c661ae46a6aae9b8c81ce4ae6e">
    <domeo:sets rdf:resource="urn:pddi:uuid:f11f91ea-d728-420a-b7db-a1b3dd281805"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2bd81a0bcbaa4ca99c76b4a588e7ea8a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5104392e30cc462b83fd06fa635716af">
    <domeo:sets rdf:resource="urn:pddi:uuid:82E3243F-7C87-4AD8-827F-7C4BE42771A9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfd43138db7bc40e488cab205433253a2">
    <domeo:sets rdf:resource="urn:pddi:uuid:159C40A3-2CEB-484F-9396-A5DFFE3954D0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N160a748bcdd840a4ab8c65c66d2a8066">
    <domeo:sets rdf:resource="urn:pddi:uuid:d84db147-31a5-4a31-a6a2-7e80181e39dc"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N75e2e0afc0a34dd9b557fdc99ccce6ac">
    <domeo:sets rdf:resource="urn:pddi:uuid:52163f37-15af-4a25-ad7f-6d0a6cea1dee"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7c8d474ac6354527b1d2c3cf27a584c6">
    <domeo:sets rdf:resource="urn:pddi:uuid:a451459c-3a3b-42a1-a95b-8a99bb4e9421"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N21ef4c95c94141c290a67e0c6a736a19">
    <domeo:sets rdf:resource="urn:pddi:uuid:5487AE94-E404-4EC8-BDB1-2C08F2FE239E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0e786c44136e48b0847a2dda851d5104">
    <domeo:sets rdf:resource="urn:pddi:uuid:393844CA-EF25-4606-A97E-C8748D50293C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc8f1fa1b73484169ab5fe8e11306e1f5">
    <domeo:sets rdf:resource="urn:pddi:uuid:57ab35d3-2cbd-4003-9718-065ef53a744b"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nea9edafc67fd4bd487238248108af8f3">
    <domeo:sets rdf:resource="urn:pddi:uuid:2DC71D50-4C88-4128-9ECC-9BD222F6774F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7ae517bf44cd44afa071a91c36b1b99c">
    <domeo:sets rdf:resource="urn:pddi:uuid:CF763442-9F98-46B3-9D4A-7928FCF835AD"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N64fe80eb524342d18491e601ba189e58">
    <domeo:sets rdf:resource="urn:pddi:uuid:2f27b443-4240-40d2-aebc-5eb8b4b77e59"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:601BFD5F-013B-47DA-8D37-376A25A6B3E6">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/5518CE4F-CD8F-4138-B3F4-FDC829B95F8C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/domeo-tools/export-tool/674458CE-98E3-4A90-BCE8-41C6A57D4D92"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N629d07ad01bf4ebca1c9ada2187b4fc0">
    <domeo:sets rdf:resource="urn:pddi:uuid:dbc81dd2-96e0-4072-bb5a-eccc1b66e935"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N33ed56507b6244ca96f68f122404a953">
    <domeo:sets rdf:resource="urn:pddi:uuid:A68DAC74-FDF9-400A-8275-DC28BD698D4A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N098d8f0bf1e5423f9689daf467e1d721">
    <domeo:sets rdf:resource="urn:pddi:uuid:D372C1A1-12B4-4D25-87A5-3DF2636CBC88"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc9db14ed4d454aa2b1cb2279d5caa798">
    <domeo:sets rdf:resource="urn:pddi:uuid:3DD0FF69-5A98-4348-9A83-00D0D5486439"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd7f616a298254b27a752437b4f888daa">
    <domeo:sets rdf:resource="urn:pddi:uuid:814acb66-664d-4c12-be2f-d59250861ed0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5be64ad9bda4478e938a8b254c32ec53">
    <domeo:sets rdf:resource="urn:pddi:uuid:AE60F2E4-4C0D-47F1-AB91-BF564DE9343C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N89610ded876149b596159c9fff286060">
    <domeo:sets rdf:resource="urn:pddi:uuid:c8dd2661-6d48-4de6-b9bd-1e5ff4843c5f"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2564a8d460f54abe902448bda64f82de">
    <domeo:sets rdf:resource="urn:pddi:uuid:763F8A90-53E7-4FCC-8325-E9AACB11A872"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na1b4a163133d42d096c713623f300889">
    <domeo:sets rdf:resource="urn:pddi:uuid:EFA37061-987D-4F2D-9653-EA3F999481E9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb50e6f8283ca4a70a4db523fc5e6c58a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc848a868a6e24f5992599cc4c07fd577">
    <domeo:sets rdf:resource="urn:pddi:uuid:CF463A6D-9DF0-4906-B521-A3A6566D4C37"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9ebdc72b38c44757b01c59759eba906d">
    <domeo:sets rdf:resource="urn:pddi:uuid:E5102D91-A2DF-46A9-B69F-2D0EB2D43E4C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9204a0cd176d4745b1587a56f6f01d73">
    <domeo:sets rdf:resource="urn:pddi:uuid:FEF277FE-2E3A-4A11-B3BD-D9B61B644DEE"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbe55ae8ce7394498a2a26c48e468aa15">
    <domeo:sets rdf:resource="urn:pddi:uuid:2A79B2EE-D427-4FDB-BB4B-1E0F7A6D3A34"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3c2d97916fba4970b8c9f52dbe2c7950">
    <domeo:sets rdf:resource="urn:pddi:uuid:EA8B9D02-6FF6-41F1-B57E-13B9A76BA42B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncbb152e26da14b6aae06fbc2d5443a51">
    <domeo:sets rdf:resource="urn:pddi:uuid:1195957e-f0f2-4846-80d1-242eb40790fa"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbdaf6ed677334707a0bc314d690648f7">
    <domeo:sets rdf:resource="urn:pddi:uuid:5A456C78-FA0B-4DCA-BDAF-38CC6D11563A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N813a54ce62c541858b26b58b2b245e3f">
    <domeo:sets rdf:resource="urn:pddi:uuid:f75a0488-e9fe-423d-a368-62d4a09b99f5"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9ce2d1cdfa7849c3adc58b2e1dd02bdd">
    <domeo:sets rdf:resource="urn:pddi:uuid:7aed815d-0d6b-47ac-903a-06cca05649de"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0dfbf7824c204dd3a6d6624133f8b3a2">
    <domeo:sets rdf:resource="urn:pddi:uuid:EAB4D6B0-7033-47D1-984F-A7B24C4733ED"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncf32040173e84b7ea394641cc6949052">
    <domeo:sets rdf:resource="urn:pddi:uuid:D0BBF476-9BAB-4930-A220-A2AC9EFDF1E6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4554ea5292c84d9d94fb03a965c7d8be">
    <domeo:sets rdf:resource="urn:pddi:uuid:7c3e5a3e-aeca-4a8e-9d68-ff7647dc16a7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd3da16208b9d405c978cfee8c3fff3e1">
    <domeo:sets rdf:resource="urn:pddi:uuid:AD49C6CE-8DDE-49C2-ADB6-697FC39957A1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1112f010208e4a8d828718ea4ebf11e6">
    <domeo:sets rdf:resource="urn:pddi:uuid:50CEFDCD-023A-4A23-BCF6-9F6B8EECA572"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N092c9442dc8d40a681c66e34c6850423">
    <domeo:sets rdf:resource="urn:pddi:uuid:7DA7E943-210C-4B40-84F2-06D579481838"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf6a2401529d546aa8ea0dccf7b5fc44c">
    <domeo:sets rdf:resource="urn:pddi:uuid:8CD1D4D6-CDC8-43F6-BC59-746BE9D0FD2B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne20323474df847bb897a0a57c9259d43">
    <domeo:sets rdf:resource="urn:pddi:uuid:6fbd3aba-d6a0-45be-90c5-3206e713537a"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N24fdaf4d08574618bcfa99bb9044106d">
    <domeo:sets rdf:resource="urn:pddi:uuid:A757D9A2-ECC6-4E61-AA56-4604AF6960CD"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7d7e6154c2e846278398cdf4a62edd12">
    <domeo:sets rdf:resource="urn:pddi:uuid:86891B77-F02A-44E8-BC1F-D624CD37D7EF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbf1bd28f73d640d5a658b029ddb3d6a4">
    <domeo:sets rdf:resource="urn:pddi:uuid:875a9659-1e7c-441d-8aa9-333100c8c1a0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5b0507ee56c8413aaf328934ac19d39e">
    <domeo:sets rdf:resource="urn:pddi:uuid:2C087E38-767E-48CC-8619-6D6235E8E09B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2ddaf4e87814430ab90c90e10788b93d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N29ac1be0cfad4229b60b52c6a886e2a5">
    <domeo:sets rdf:resource="urn:pddi:uuid:00D5E0CF-2682-4CBD-9DED-38CA8C1BA3B6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nae870788c3ec48c4b7f3612f45399291">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc19ddecb4cf64c5783f38c64d8d793da">
    <domeo:sets rdf:resource="urn:pddi:uuid:a4a42b82-ca0e-49d8-989d-d0b3b52e65ee"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb75ab700bfa24b3e86da150af687d61d">
    <domeo:sets rdf:resource="urn:pddi:uuid:58b84ef2-c9c5-4ba2-a78d-440a1cda1a48"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N32a0b7e59b9e4151bd38210f47a12936">
    <domeo:sets rdf:resource="urn:pddi:uuid:da68f7ea-ebbe-4bb3-b465-829acc2b9c48"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N59c3e13c781244ea8d55dc9d837dbe4f">
    <domeo:sets rdf:resource="urn:pddi:uuid:24A22D5F-649F-4B53-8523-F116DEF6E2E8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndbe8a9b0a5304a93a1c482910c13d1bb">
    <domeo:sets rdf:resource="urn:pddi:uuid:48f140e0-21bc-4490-8bc8-1d129166ebe7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N12887919935c483eae639dc18b72cd27">
    <domeo:sets rdf:resource="urn:pddi:uuid:AEE7C1E9-FD2A-420E-A7C5-AFFBE49B20E6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc367044a1f834099918d4c5d538adfbf">
    <domeo:sets rdf:resource="urn:pddi:uuid:C1040D1B-64AE-4624-AB46-B17C156B61A6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1aba95f6dae842328c05f223dc80380a">
    <domeo:sets rdf:resource="urn:pddi:uuid:47AF6767-AA39-43B3-BD4C-B03E8D8316DB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N295380945fd0404ebad96d5447a9fb42">
    <domeo:sets rdf:resource="urn:pddi:uuid:79A0AA33-EE91-47D1-96A1-777A4F572DEE"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0fb51740f5ea48838bd95447490a7e12">
    <domeo:sets rdf:resource="urn:pddi:uuid:2EFD3C06-AD9D-4B20-983D-F9E7BF78C62C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Neba3c12d8d0344d588f3a198cd0ea22c">
    <domeo:sets rdf:resource="urn:pddi:uuid:D1F4782D-8D61-4989-8449-4BE95C800E70"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5e47d1ff7a1349599cb92dc6cca55b3f">
    <domeo:sets rdf:resource="urn:pddi:uuid:8CBFBAB4-EBD4-4864-8822-7D4ADCEC9EDA"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb7b0ca2535d9462dbb7d30d7e611c157">
    <domeo:sets rdf:resource="urn:pddi:uuid:A38C9832-E37C-497A-8410-123D736CEBF8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9ef7cffb10cb4a17b53cf13dbda0ccd4">
    <domeo:sets rdf:resource="urn:pddi:uuid:e9818f5e-9bbd-41ec-98cc-7daad01aec97"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N769a2170f4394352bdb5ec2e95e1e95b">
    <domeo:sets rdf:resource="urn:pddi:uuid:591D3D6B-1CE7-4F46-B6F1-B58E2AD5A4A7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncdde6d3c28eb470284ff8329b76f1af2">
    <domeo:sets rdf:resource="urn:pddi:uuid:0e91e84c-9589-4471-843d-8e4b18171f9a"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6692032c607b431b86249597aeabf517">
    <domeo:sets rdf:resource="urn:pddi:uuid:EB346943-C7DC-4644-A6CF-19C93F13EB74"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N47db844d1ae44ed9933dddf0fb754b35">
    <domeo:sets rdf:resource="urn:pddi:uuid:3c2c8aad-c3a7-4446-af25-d5eac5bb0f0f"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N712566e019d844629181eefa9fc69d30">
    <domeo:sets rdf:resource="urn:pddi:uuid:5923A030-CB73-463E-B299-4AB7FFAD4823"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N652baea59cb2445e991212ba1c92900a">
    <domeo:sets rdf:resource="urn:pddi:uuid:8A0FFA5E-4E5A-4CCE-A649-3D8521FFC2EF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5afbfb2a31074fd78067f743f2709abc">
    <domeo:sets rdf:resource="urn:pddi:uuid:4DA5AC1A-6B23-4C8E-B169-F07C285ACB2A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfd7da4378d1140f4967518fe4332c92a">
    <domeo:sets rdf:resource="urn:pddi:uuid:EED083AC-6E5A-452D-AB8A-5EFF6F32E0C8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0621e9b3272e429cbc13553e54db2fa4">
    <domeo:sets rdf:resource="urn:pddi:uuid:0B146568-3326-4771-B5D1-7F61850DF044"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7bc2d25aff7d43409bd91ecfa2a53daf">
    <domeo:sets rdf:resource="urn:pddi:uuid:9636E79E-1972-493F-94A2-66EF26CED855"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0ad8d340a467402eaed9bb9ded6ee41b">
    <domeo:sets rdf:resource="urn:pddi:uuid:C54E6622-AA86-4D40-A887-092EA65F0BC2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N80a29a24576147f084ec24ef542622a1">
    <domeo:sets rdf:resource="urn:pddi:uuid:5BFFF98F-C336-4970-8D87-CB9011228EC5"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6c0ffd917c9843aab10317ec2a0eb48a">
    <domeo:sets rdf:resource="urn:pddi:uuid:90D400C1-885B-49C4-B0C7-DA180752721F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N039915a3407745cc94e2422d826c600c">
    <domeo:sets rdf:resource="urn:pddi:uuid:A48ED874-922D-46FD-9450-226F361E4A85"/>
  </rdf:Description>
</rdf:RDF>
